<SEC-DOCUMENT>0001397702-24-000015.txt : 20240228
<SEC-HEADER>0001397702-24-000015.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228162621
ACCESSION NUMBER:		0001397702-24-000015
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silk Road Medical Inc
		CENTRAL INDEX KEY:			0001397702
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				208777622
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38847
		FILM NUMBER:		24695844

	BUSINESS ADDRESS:	
		STREET 1:		1213 INNSBRUCK DR.
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94089-2918
		BUSINESS PHONE:		6505669060

	MAIL ADDRESS:	
		STREET 1:		1213 INNSBRUCK DR.
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94089-2918
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>silk-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:silk="http://silkroadmed.com/20231231" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <head>
    <title>silk-20231231x10k</title>
    <meta http-equiv="Content-Type" content="text/html"/></head>
  <body xml:lang="en-US">
    <div style="display:none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="ct-nonNumeric-3f4135f7-dc2b-4427-a8fa-fcd69218e321" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="ct-nonNumeric-91e9fcc1-cec5-4ec2-a101-60eff0e7862f" contextRef="Duration_1_1_2023_To_12_31_2023">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="ct-nonNumeric-afb1181f-bd0f-4a14-b3db-532ff894ea69" contextRef="Duration_1_1_2023_To_12_31_2023">0001397702</ix:nonNumeric><ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="ct-nonNumeric-aef27b65-cf7b-4cc7-b3da-deb310ab56d2" contextRef="Duration_1_1_2023_To_12_31_2023">Yes</ix:nonNumeric><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="ct-nonNumeric-345f206a-af04-4574-9199-1a58b605bd88" contextRef="Duration_1_1_2023_To_12_31_2023">Yes</ix:nonNumeric><ix:nonNumeric name="dei:EntityVoluntaryFilers" id="ct-nonNumeric-ed693c40-c884-4f7c-b718-eef6f8cd52b9" contextRef="Duration_1_1_2023_To_12_31_2023">No</ix:nonNumeric><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="ct-nonNumeric-c940220e-b236-4523-a334-4ad39b637ffa" contextRef="Duration_1_1_2023_To_12_31_2023">Yes</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-5d95aa1c-7eb9-4f49-8dc4-aea9daebaaab" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-a637edb1-7f74-4201-a99b-726573bfe3e9" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_12_31_2023" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-3bf04cf1-1a9a-405d-aa3f-bedeb093e2ab" name="us-gaap:DeferredTaxAssetsNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-75d41ec1-bd07-4439-8d82-3e992d798b22" name="us-gaap:DeferredTaxAssetsNet" contextRef="As_Of_12_31_2023" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-4a367e19-bd2b-4833-a2ee-41da1810dd33" contextRef="As_Of_12_31_2022">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-ea9efef9-505d-4191-897c-64e4a2fceb36" contextRef="As_Of_12_31_2023">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-24d00192-026d-4075-a91f-bdd0fa580324" contextRef="As_Of_12_31_2022">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-18ad6fb4-b92c-4419-9e27-7f511e1beb87" contextRef="As_Of_12_31_2023">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-7adaddd6-e390-4787-853b-b3d3af6f96a6" contextRef="As_Of_12_31_2022">http://fasb.org/us-gaap/2023#Liabilities</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-3f9f30e3-cce1-4745-9a9e-9d186b53fb29" contextRef="As_Of_12_31_2023">http://fasb.org/us-gaap/2023#Liabilities</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-dd16a680-3f25-4cca-8f06-df833283191e" contextRef="As_Of_12_31_2022">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="ct-nonNumeric-80d6598d-c247-4749-a960-856924837d92" contextRef="As_Of_12_31_2023">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-2cfee51e-ab0e-4f50-aac2-b407cda5d91f" name="us-gaap:PreferredStockValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-d65a29aa-c14e-4d87-b47f-02ec4e8f510e" name="us-gaap:PreferredStockValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="silk-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2007_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:BenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:BenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:BenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2023_To_11_30_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_srt_StatementScenarioAxis_silk_UnderwritersOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:UnderwritersOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_31_2023_To_5_31_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-31</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PledgingPurposeAxis_us-gaap_LetterOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilitySubfacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredRevolvingCreditFacilitySubfacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredRevolvingCreditFacilityAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_HeadquartersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">silk:HeadquartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">silk:AdditionalOfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_27_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">silk:IndexRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:PerformanceStockUnitsOverperformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:PerformanceStockUnitsOverperformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2023_To_11_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:Espp2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">silk:IndexRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">silk:IndexRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:Espp2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredRevolvingCreditFacilityAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit15"><xbrli:measure>silk:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit14"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit13"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit12"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit1"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
    <div class="headerContainer"></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="_Hlk126781700" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">UNITED STATES</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SECURITIES AND EXCHANGE COMMISSION </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Washington, D.C. 20549</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">______________________________</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 15pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 15pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">FORM </span><ix:nonNumeric name="dei:DocumentType" id="ct-nonNumeric-0d3604eb-27ee-4b68-bc35-bdd0b9a10683" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 15pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10-K</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 15pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Mark One)</span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 97.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.24in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:DocumentAnnualReport" id="ct-nonNumeric-6fad6067-ec3a-4be7-8abc-95d56e1f8897" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:boolballotbox"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9746;</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 97.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For the fiscal year ended </span><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="ct-nonNumeric-0828b7c1-d154-49c2-a03a-896f7bd906d6" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:datemonthdayen"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="ct-nonNumeric-ad223540-056e-4621-a1d8-4930e0c56c43" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:datemonthdayyearen" continuedAt="ct-nonNumeric-ad223540-056e-4621-a1d8-4930e0c56c43-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31</span></ix:nonNumeric></ix:nonNumeric><ix:continuation id="ct-nonNumeric-ad223540-056e-4621-a1d8-4930e0c56c43-continuation-0" continuedAt="ct-nonNumeric-ad223540-056e-4621-a1d8-4930e0c56c43-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, </span></ix:continuation><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="ct-nonNumeric-5046205c-3ce3-4237-8e8d-d4d6b7d5e928" contextRef="Duration_1_1_2023_To_12_31_2023"><ix:continuation id="ct-nonNumeric-ad223540-056e-4621-a1d8-4930e0c56c43-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></ix:continuation></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">OR</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 97.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.25in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="ct-nonNumeric-f57c9ce7-deb8-4b8d-8eb9-648c110cda52" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:boolballotbox"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 97.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Commission File Number &#160;&#160;</span><ix:nonNumeric name="dei:EntityFileNumber" id="ct-nonNumeric-e1e56ee8-457d-441e-aeab-ad9041716110" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">001-38847</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">______________________________</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 15pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityRegistrantName" id="ct-nonNumeric-891e1de5-ea4d-4b4c-a124-ee1693d775b5" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 15pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SILK ROAD MEDICAL, INC.</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Exact name of registrant as specified in its charter) </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">______________________________</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="ct-nonNumeric-311e5e23-dcc3-4ac8-afc0-89e9c489fb78" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:stateprovnameen"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Delaware</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="ct-nonNumeric-a241acbe-bb48-4aa4-8f4b-a17a42800785" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">20-8777622</span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">State or other jurisdiction of</span><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">incorporation or organization</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 33.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(I.R.S. Employer</span><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Identification No.)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="ct-nonNumeric-e2d167db-83bd-4f38-9bbe-879d1bb3381b" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">1213 Innsbruck Dr.</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="ct-nonNumeric-5c21be81-58fb-48a5-924f-cdcb8b37ec52" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sunnyvale</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="ct-nonNumeric-e440fca8-5560-4908-9b85-58b3193e79c5" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CA</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="ct-nonNumeric-cd84ac79-0fd1-4bf0-b38e-70dfcd470820" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">94089</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Address of registrant&#8217;s principal executive offices) (Zip Code)</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Registrant&#8217;s telephone number, including area code: (</span><ix:nonNumeric name="dei:CityAreaCode" id="ct-nonNumeric-60c51588-dc2a-4579-806c-15dd0d4b4f64" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">408</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">) </span><ix:nonNumeric name="dei:LocalPhoneNumber" id="ct-nonNumeric-1bdcb93f-832c-4237-8557-db398c549294" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">720-9002</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">______________________________</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Securities registered pursuant to Section 12(b) of the Act:</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 26.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Title of each class</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 26.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Trading Symbol(s)</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Name of each exchange on which registered</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="ct-nonNumeric-f63af8ee-af3f-4335-9917-4fd4205a0f4f" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 26.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="ct-nonNumeric-1efb1325-7770-4a38-9dd1-2f1b87a7bdfb" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SILK</span></ix:nonNumeric></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 36.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="ct-nonNumeric-d451d1ed-0681-4c73-8369-39b3a56262fc" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:exchnameen"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Nasdaq</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Stock Market LLC</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Securities registered pursuant to Section 12(g) of the Act:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">None</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 6.250in;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Yes&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-c940220e-b236-4523-a334-4ad39b637ffa;">&#9746;</span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160; No&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></p><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 6.250in;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Yes&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ed693c40-c884-4f7c-b718-eef6f8cd52b9;">&#9746;</span></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-aef27b65-cf7b-4cc7-b3da-deb310ab56d2;">&#9746;</span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   No&#160;&#160;</span></p><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-345f206a-af04-4574-9199-1a58b605bd88;">&#9746;</span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 47.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:EntityFilerCategory" id="ct-nonNumeric-632b9be8-2c16-443a-a313-991f94521c9b" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:entityfilercategoryen"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Large accelerated filer</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9746;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 47.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accelerated filer</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Non-accelerated filer</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 47.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Smaller&#160;reporting&#160;company</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:EntitySmallBusiness" id="ct-nonNumeric-2c5f7dd0-a69d-40d3-89d2-f35a9fdaf886" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:boolballotbox"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Emerging growth company</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="ct-nonNumeric-112d6883-c055-4127-83a8-b6d8d1dc77c3" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:boolballotbox"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 47.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 23.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 3pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) Exchange Act.&#160;&#160;</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></p><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" id="ct-nonNumeric-4c248e9d-9ca9-4e0c-b8e7-d803c0af237c" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:boolballotbox"><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9746;</span></ix:nonNumeric></p><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" id="ct-nonNumeric-f39a3e83-fdbd-4b4b-b423-03735204a10a" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:boolballotbox"><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></ix:nonNumeric></p><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#167;240.10D-1(b). </span><span style="white-space:pre-wrap; color: #000000;font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span></p><p dir="ltr" style="font-family: Segoe UI Symbol;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicat</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">e by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  </span><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9744;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> No  </span><ix:nonNumeric name="dei:EntityShellCompany" id="ct-nonNumeric-5736e00c-6957-4184-8916-907e18b3bea9" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Segoe UI Symbol;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#9746;</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d1b6a537-88bb-4629-9f71-de292aa28cdd" name="dei:EntityPublicFloat" contextRef="As_Of_6_30_2023" unitRef="Unit12" decimals="-8" format="ixt:numdotdecimal" scale="9">1.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion as of June 30, 2023 based on the closing sale price of the registrant&#8217;s common stock on the Nasdaq Global Select Market on such date. Solely for purposes of this disclosure, shares of common stock held by executive officers and directors of the registrant as of such date have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: 3pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of February 23, 2024, the number of outstanding shares of the registrant's common stock, par value $0.001 per share, was </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da98ee7f-9b44-467a-b499-245de699c002" name="dei:EntityCommonStockSharesOutstanding" contextRef="As_Of_2_23_2024" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">39,174,619</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><ix:nonNumeric name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ct-nonNumeric-264efae9-54d9-40d9-b6f2-c6b3833f2f0e" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Portions of the definitive proxy statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, are incorporated by reference into Part III of this report where indicated. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 14pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span id="Section2" style="text-decoration: none;"></span><span id="TableofContents" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 14pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TABLE OF CONTENTS</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 14pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 14pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Page</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="#Section3" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Part I</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section4" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 1.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section4" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Business</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section5" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 1A.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section5" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Risk Factors</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section6" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 1B.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section6" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Unresolved Staff Comments</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Cybersecurity" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 1C</span></a><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Cybersecurity" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Cybersecurity</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section7" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 2. </span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section7" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Properties</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section8" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 3.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section8" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Legal Proceedings</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section9" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 4.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section9" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Mine Safety Disclosures</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="#Section10" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Part II</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section11" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 5.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section11" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section12" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 6.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section12" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">[Reserved]</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">79</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section13" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 7.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section13" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">80</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section14" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 7A.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section14" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">88</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section15" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 8.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section15" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Financial Statements and Supplementary Data</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section37" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 9.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section37" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">116</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section38" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 9A.</span></a><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section38" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Controls and Procedures</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">116</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section39" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 9B.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section39" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Other Information</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">117</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item9C" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 9C.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Item9C" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">117</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="#PartIII" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Part III</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section41" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 10.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section41" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">118</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section42" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 11.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section42" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Executive Compensation</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">118</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section43" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 12.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section43" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">118</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section44" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 13.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section44" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">118</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section45" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 14.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section45" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Principal Accountant Fees and Services</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">118</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="#Section46" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Part IV</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section47" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 15.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section47" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">119</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section49" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Item 16.</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section49" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form 10-K Summary</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">122</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 79.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section50" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Signatures</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">123</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As used in this report, references to &#8220;Silk Road Medical,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us,&#8221; unless the context otherwise requires, refer to Silk Road Medical, Inc.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8220;Silk Road Medical,&#8221; the &#8220;Silk Road Medical&#8221; logo, &#8220;TCAR,&#8221; &#8220;ENROUTE,&#8221; the &#8220;ENROUTE&#8221; logo, &#8220;ENHANCE,&#8221; &#8220;Enflate&#8221; and our other registered or common law trade names, trademarks or service marks appearing in this Annual Report on Form 10-K are our property. Trade names, trademarks and service marks of other companies appearing in this Annual Report on Form 10-K are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies unless otherwise stated. Solely for convenience, the trademarks and tradenames referred to in this Annual Report on Form 10-K appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations, prospects, and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of the federal securities laws and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, or the use of future dates.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These forward-looking statements include, but are not limited to, statements about the following subjects:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our goal to establish transcarotid artery revascularization, or TCAR, as the standard of care for the treatment of carotid artery disease;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our 2024 strategic priorities to grow, strengthen and diversify our business;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our plans to conduct further clinical trials and anticipated enrollment, clinical sites, completion, results and timing thereof;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our plans and expected timeline related to our products, including timing of commercial launch, or developing new products, to address additional indications or to obtain regulatory approvals or clearances or otherwise;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the expected use of our products by physicians, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">including market awareness, acceptance and adoption of our products, and anticipated increased utilization of our products and market penetration</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our expectations regarding the number of procedures that will be performed with our products, the number of physicians we expect to train, and the number of our sales territories;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to obtain, maintain and expand regulatory approvals and clearances for our current products and any new products we create;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the expected growth of our business and our organization;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our expectations regarding government and third-party payer coverage and reimbursement and the anticipated effect of such decisions;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to manage our recent Chief Executive Officer transition and retain and recruit key personnel, including the continued expansion of our sales and marketing infrastructure, and the anticipated timing and effect of such actions;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to obtain an adequate supply of materials, components and finished goods for our products from our third-party suppliers, most of whom are single-source suppliers;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to manufacture sufficient quantities of our products with sufficient quality and the sufficiency of our current manufacturing capabilities;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to obtain and maintain intellectual property protection for our products and our business;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to expand our business into new geographic markets and the anticipated timing thereof, including in Japan and China;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our compliance with extensive Nasdaq and U.S Securities and Exchange Commission, or SEC, requirements and government laws, rules and regulations both in the United States and internationally;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our expectations regarding operating trends, future financial performance and expense management and </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our estimates of our future expenses, ongoing losses, future revenue, including per procedure revenue and the effect thereon of new products, gross margins, operating leverage, capital requirements and our need for, or ability to obtain, additional financing;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">1</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to identify and develop new and planned products and/or acquire new products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 11.35pt;margin-left: 0.50in;margin-right: 0.03in;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our experience with inflationary and price pressures </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and increased labor costs and labor and staffing shortages</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">; </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">developments and projections relating to our market opportunity and penetration, competitors or our industry; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.094in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our intended use of net proceeds from our public offerings.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K to conform these statements to actual results or to changes in our expectations. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SEC as exhibits to this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">2</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span id="Section3" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART I</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="_Hlk125743101" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section4" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1. Business</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk158231938" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Overview</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a medical device company focused on reducing the risk of stroke and its devastating impact. We believe a key to stroke prevention is minimally-invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke. Our business is focused on a relatively new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using our portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk. We have obtained U.S. Food and Drug Administration, or FDA, approvals, secured specific Medicare reimbursement coverage, and commercialize products engineered and indicated specifically for transcarotid use, in patients who require carotid revascularization and who meet certain treatment criteria. </span><span id="_Hlk94602744" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the second quarter of 2022, we announced FDA </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">label and Medicare coverage expansions for the use of TCAR in standard surgical risk patients in the TCAR Surveillance Project, or TSP</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Effective October 11, 2023, the U.S. Centers for Medicare and Medicaid Services, or CMS, published the final decision memo for National Coverage Determination, or NCD, 20.7 expanding coverage for CAS, including TCAR, under indication B4 for both high risk and standard surgical risk patients. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR remains covered within the TSP as well as outside of the TSP under the revised NCD 20.7. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, more t</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">han 85,000 TC</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">AR procedures have been performed globally, including more than 25,000 in the United States during 2023. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Carotid artery disease is the progressive buildup of plaque causing narrowing of the arteries in the front of the neck, which supply blood flow to the brain. Plaque can embolize, or break away from the arterial wall, and travel toward the brain and interrupt critical blood supply, leading to an ischemic stroke. Carotid artery disease is one of the leading causes of stroke, and stroke is one of the most catastrophic, debilitating, and costly conditions worldwide. We believe the best way to mitigate the mortality, morbidity and cost burden of stroke is to prevent strokes in the first place. Clinical evidence has demonstrated that with proper diagnosis and treatment, stroke due to carotid artery disease is mostly preventable. </span><span id="_Hlk94602776" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe there were approximately 4.4 million people with carotid artery disease in the United States in 2022, with an estimated 440,000 diagnoses in 2022, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and existing treatment options have substantial safety and effectiveness limitations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The main goal of treating carotid artery disease is to prevent a future stroke. Unfortunately, one of the main complications of existing treatments for carotid artery disease is causing a stroke, along with other procedure-related adverse events. When intervention beyond medical management is warranted, the current standard of care for reduction in stroke risk is an invasive carotid revascularization procedure called carotid endarterectomy, or CEA. To perform a CEA, a physician makes a large incision in the neck, cuts the carotid artery open, and then removes the plaque from inside the vessel. CEA was first performed in 1953, and while generally effective at reducing stroke risk in the long term, large randomized clinical trials have demonstrated that CEA is associated with a significant risk of adverse events, including cranial nerve injury, heart attack, wound complications, and, in some cases, even stroke and death. These risks are elevated in certain patient populations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk96540338" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To address the invasiveness of CEA, transfemoral carotid artery stenting, or CAS, was developed in the 1990s. The CAS procedure uses minimally-invasive catheters traveling from a puncture site in the groin to place a stent in the carotid artery in the neck to restrain the plaque and prevent embolization that could cause a stroke. While both CEA and CAS have been clinically demonstrated to reduce long-term stroke risk, randomized clinical trials and other studies have shown that CAS, relative to CEA, often results in an almost two-fold increase in stroke within 30 days following treatment, which we believe is due to inadequate protection of the brain. </span><span id="_Hlk94602979" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accordingly, to date, CEA has remained the standard of care.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Therefore, we believe reducing the rate of morbidity and mortality of CEA is an unmet clinical need that continues to persist.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR is a minimally-invasive procedure intended to address the morbidity of CEA and the 30-day stroke risk of CAS while maintaining a reduction in long-term stroke risk beyond the first 30 days. TCAR starts with a small incision in the neck slightly above the collarbone, otherwise known as transcarotid access, through which our ENROUTE&#174; Transcarotid Stent System, or ENROUTE stent, is placed during a period of temporary high-rate blood flow reversal that is enabled by our ENROUTE&#174; Transcarotid Neuroprotection System, or ENROUTE NPS. Blood flow reversal directs embolic debris that could cause a stroke away from the brain, while the stent braces the plaque and prevents embolization to afford a </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">3</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">reduction in long-term stoke risk. We believe that by meeting the standard of brain protection and reduction in 30-day and long-term stroke risk afforded by CEA, while providing benefits commensurate with an endovascular, minimally-invasive approach, TCAR could become the preferred alternative for carotid revascularization. Additionally, we believe that as our technology becomes more widely adopted, TCAR may become a compelling alternative for patients who are treated with medical management alone each year.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk94603082" style="text-decoration: none;"></span><span id="_Hlk96540597" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Based on the estimated</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 440,000 ne</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">w carotid artery disease diagnoses that occurred in the United States in 2022, we believe a total annual U.S. market opportunity of approximatel</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">y $3.1 </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">billion exists for our portfolio of TCAR products. We estimate that there were approximately </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">172,000 ca</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">rotid revascularization procedures performed in 2022, which we estimate to represent a market conversion opportunity of</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> approximately $1.2 </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">billion. More than&#160;25,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR procedures were performed in 2023 in the United States using our products, representing approximately</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 5.7% </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of annual diagnoses of carotid artery disease.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk94603408" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The safety, effectiveness and clinical advantages of TCAR have been demonstrated in multiple clinical trials, post-market studies and registries that have been published in over 300 TCAR publications to date, representing outcomes in tens of thousands of patients. The results of our U.S. pivotal trial, ROADSTER, reflect the lowest reported 30-day stroke rate for any prospective, multicenter clinical trial of carotid stenting of which we are aware. Our ROADSTER 2 post-approval study was completed in 2019 and showed a 30-day stroke rate of 0.6% in the primary analysis population. Additionally, data on real-world outcomes of TCAR relative to CEA and CAS have continued to accrue through the ongoing TCAR Surveillance Project, which is an ongoing open-ended registry sponsored by the Society for Vascular Surgery through the Vascular Quality Initiative, or VQI.</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> In a VQI study published in the </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Journal of the American Medical Association</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in December 2019, a propensity matched analysis of 3,286 high surgical risk patients in each cohort showed in-hospital stroke or death was significantly lower for TCAR at 1.6% versus 3.1% for CAS, p &lt; 0.001. The statistically significant difference favoring TCAR persisted through 30 days and 1 year. In a VQI study published in the </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Annals of Surgery</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in September 2020, a propensity matched analysis of 6,384 high surgical risk patients in each cohort demonstrated significant reduction in the risk of in-hospital myocardial infarction and cranial nerve injury after TCAR compared to CEA (0.5% vs. 0.9%, p = 0.005; 0.4% vs. 2.7%, p &lt; 0.001, respectively), with no differences in the rates of in-hospital stroke/death (1.6% TCAR and 1.6% CEA). </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In a more recent analysis of both high risk and standard risk surgical risk patients, a 2022 VQI study by Zhang GQ, et al published in the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Journal of Vascular Surgery</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, compared outcomes (composite of stroke, death and myocardial infarction) using a multivariate logistic regression analysis analyzing TCAR procedures using the predicate device, TF-CAS using distal filters and CEA procedures from 2015-2020. Within the high risk patient cohort of 10,903 TCAR vs. 7,967 CEA vs. 9,896 TF-CAS procedures, TCAR demonstrated significantly lower odds of 30-day stroke, death and stroke/death and myocardial infarction for TCAR compared to both CEA and TF-CAS. Within the standard risk cohort of 4,694 TCAR vs. 33,720 CEA vs. 7,351 TF-CAS procedures, TCAR and CEA showed equivalent odds of 30-day stroke, death, and stroke/death, whereas TFCAS was associated with significantly higher risk for these endpoints. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2023, an analysis of the National Inpatient Sample database, which is the largest all-payor inpatient database for ~35 million hospitalizations nationwide, was published by Ramsay IA, et al in the journal </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Operative Neurosurgery</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and demonstrated the risk of stroke with TCAR was significantly lower compared to CEA.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR is reimbursed based on established Current Procedural Technology, or CPT, codes and International Classification of Diseases, or ICD-10, codes related to carotid artery disease and carotid artery stenting. Our ENROUTE NPS is currently the only FDA-cleared transcarotid neuroprotection device. CMS is the primary payer for carotid revascularization procedures as carotid artery disease is most often a disease of the elderly, and we estimate Medicare covers approximately 75% of patients treated. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We began commercializing our products in the United States in late 2015. Our revenue increased to</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> $177.1 </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">million for the year ended December 31, 2023 compared to $138.6 million for the year ended December 31, 2022, representing growth of&#160;28%. Our net losses were $55.7 million and $55.0 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, our accumulated deficit was $399.5&#160;million and $343.7 million, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk125817677" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our Product Portfolio</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR is enabled by our proprietary portfolio of TCAR products designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque. In addition to enabling the safety and effectiveness of TCAR, our proprietary products are specifically designed to enable a short learning curve, consistent ease of use and physician comfort. Our products are also currently the only devices cleared and approved by the FDA specifically for transcarotid use.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">4</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our current product portfolio consists of the following five single-use components:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 21.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 26.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 51.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 1.25in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 21.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ENROUTE Transcarotid Neuroprotection System</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 26.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="silk-20231231x10kg001.jpg" style="width: 1.707793in; height: 0.4002647in" alt="Picture 1"/></span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 51.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Used to directly access the common carotid artery and establish temporary blood flow reversal</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Embolic debris is captured and filtered, returning filtered blood to the femoral vein</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allows for flow modulation enabling lesion imaging and patient tolerability</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Only FDA-cleared transcarotid neuroprotection system </span></p></td></tr><tr style="height: 1.06in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 21.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ENROUTE Transcarotid Stent System</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 26.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="silk-20231231x10kg002.jpg" style="width: 1.389611in; height: 0.9429505in" alt="Picture 2"/></span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 51.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cylindrical and tapered configurations with optimized cell design and auto-conforming technology </span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Designed for transcarotid access, improving the accuracy and ergonomics of the TCAR procedure </span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Only FDA-approved transcarotid stent system optimized for the TCAR procedure</span></p></td></tr><tr style="height: 0.58in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 21.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ENHANCE Transcarotid Peripheral Access Kit</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 26.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="silk-20231231x10kg003.jpg" style="width: 1.652778in; height: 0.1544444in" alt="Image 1027"/></span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 51.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Used to gain initial access to the common carotid artery </span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Only access kit specifically designed for use in the common carotid artery</span></p></td></tr><tr style="height: 0.88in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 21.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ENROUTE 0.014&#8221; Guidewire</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 26.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="silk-20231231x10kg004.jpg" style="width: 0.9610389in; height: 0.2962599in" alt="Picture 3"/></span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 51.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Designed for precise and atraumatic vessel navigation and target lesion crossing for delivery of interventional devices</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short working length and proprietary tip designed for the TCAR procedure</span></p></td></tr><tr style="height: 1.17in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 21.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ENROUTE Enflate Transcarotid RX Balloon</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Dilation Catheter</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 26.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="silk-20231231x10kg005.jpg" style="width: 1.113683in; height: 0.7328642in" alt="Picture 7"/></span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 51.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Only transcarotid rapid exchange balloon on the market and only specialty balloon designed for the TCAR procedure</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short working length for transcarotid access and sizes optimized for use with the ENROUTE stent system</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Highly visible radiopaque markers for accurate positioning</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the second quarter of 2023, we received 510(K) clearance for our next generation neuroprotection system, or ENROUTE NPS PLUS, which is designed to support additional ease-of-use and further minimize the risk for complications. We are planning for the upcoming launch of our ENROUTE NPS PLUS in the first half of 2024. We also received PMA approval for tapered configurations of our ENROUTE stent in the second quarter of 2023, which will provide greater choice for physicians to address the diversity of patient specific anatomy. We initiated a limited market release in the first quarter of 2024 with a full market release planned in the first half of 2024.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk125743562" style="text-decoration: none;"></span><span id="_Hlk94609944" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Clinical Data</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The safety, effectiveness and clinical advantages of TCAR have been demonstrated in multiple clinical trials, post-market studies and registries that have been published in over 300 TCAR publications to date. Our first-in-human trial, the PROOF Study, was initiated as a feasibility study to assess the safety and performance of the ENROUTE NPS and later was expanded to support CE marking of the ENROUTE NPS. Data from the PROOF Study were also used to support FDA approval of the investigational device exemption, or IDE, for the ROADSTER Study. Data from the pivotal cohort of the ROADSTER Study supported FDA 510(k) clearance of the ENROUTE NPS, and a subset of the data supported pre-market, or PMA, approval of the ENROUTE stent. We have completed a post-market approval study, ROADSTER 2, which was designed to evaluate the outcomes in TCAR procedures using the ENROUTE stent used in conjunction with the ENROUTE NPS in broader, &#8220;real</span><span style="white-space:pre-wrap; font-family: Cambria Math;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8209;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">world&#8221; use among 692 patients that were enrolled. In May 2022, FDA granted approval for an expanded label indication of the ENROUTE stent allowing for treatment of patients at standard surgical risk, in addition to patients at high surgical risk. This approval was obtained by submitting a retrospective matched analysis of 5,066 standard risk TCAR patients with 15,198 CEA patients in a 1:3 ratio from VQI&#8217;s TCAR Surveillance Project and CEA registries, both sponsored by the Society for Vascular Surgery. Data on TCAR outcomes also continues to accrue through TSP, an ongoing real</span><span style="white-space:pre-wrap; font-family: Cambria Math;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8209;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">world, open-ended regis</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">try. The VQI stated that &gt; </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">60,000</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> TCAR procedures have been submitted to the registry as of December 31, 2023</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">5</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">Summary of Key Clinical Trials</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="7" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 57.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Clinical Trials</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PROOF</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ROADSTER</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ROADSTER 2</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ROADSTER 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TCAR Surveillance Project</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Study Type </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">First in Human</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Pivotal IDE Study</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Post-Approval Study</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Post-Approval Study</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Real world observation </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CE Marking</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">DW-MRI Sub-Study</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Patients </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75 pivotal</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">67 Lead-in</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">692</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Up to 400</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Open Ended</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">56 DW-MRI Sub-Study</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">141 Pivotal</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">with a minimum of 315 per protocol patients</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">78 Continued</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Access</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">52 Stent Sub-</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Study</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Profile </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">High Surgical Risk</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and Standard Surgical Risk</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">High Surgical Risk</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">High Surgical Risk</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Standard Surgical Risk</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">High Surgical Risk and Standard Surgical Risk</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Status </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Complete</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Complete</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Complete</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Enrolling</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ongoing - &gt; 60,000 TCAR cases as of December 31, 2023, per VQI</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Carotid Stent Systems Used </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CE Marked Carotid Stents, including the Cordis Precise Stent</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA Approved Carotid Stents, including the Cordis Precise Stent</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ENROUTE Transcarotid Stent System</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ENROUTE Transcarotid Stent System</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 1.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 23.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ENROUTE Transcarotid Stent System</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk125744553" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">Summary of TCAR Clinical Trial Outcomes </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PROOF</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Pooled ROADSTER</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ROADSTER 2</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Intention to Treat Population</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Intention to Treat Population</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Per-protocol</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Intention to Treat Population</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Per-protocol</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stroke at 30 days</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All stroke </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.3&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.4&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.9&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.6&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All stroke and death </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.3&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.3&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.5&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.3&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.8&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Other adverse events at 30 days</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Myocardial infarction </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.0&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.4&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.0&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.9&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.9&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cranial nerve injury* </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.7&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.40</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(Acute)</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cranial nerve injury </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.7&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.0&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.9 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%**</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(persisting at 6 months)</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Procedural information</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Mean procedure time (mins) </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73.2&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74.8&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74.6</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 24.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Mean length of stay </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(days)</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.7&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NR</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*Only tabulated for Intention to Treat Population.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">**Evaluated at 90 days.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">PROOF First-in-human Clinical Trial</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our first-in-human trial, the PROOF Study, was a single-arm trial conducted at one trial site in Europe from 2009 to 2012. The PROOF Study was initiated as a feasibility study to assess the safety and performance of the ENROUTE NPS in a limited number of patients, initially enrolling 10 patients. The PROOF Study was later expanded to 75 patients to collect the clinical data necessary to support the original CE marking of the ENROUTE NPS. The results from the PROOF </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">6</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Study demonstrated TCAR was technically feasible and resulted in a minor stroke incidence of 1.3% within 30 days (zero major strokes), which was significantly lower than that reported for CAS in prior clinical trials. A sub-study of 56 patients who underwent pre- and post-procedure diffusion-weighted magnetic resonance image scanning, or DW-MRI, demonstrated only 18% of the sub-study population presented with ipsilateral new white lesions. This was comparable to CEA results in prior clinical trials and significantly less than that reported in prior CAS trials. Data from the PROOF Study were also used to support FDA approval of the IDE for the ROADSTER Study.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Pivotal ROADSTER Clinical Trial </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our pivotal trial, the ROADSTER Study, was a single-arm trial conducted at 17 sites across the United States and one site in Europe from 2012 to 2014. The design of the ROADSTER Study, which was used to support FDA 510(k) clearance of the ENROUTE NPS, was largely based upon predicate embolic prevention studies and followed the relevant FDA guidance published in 2008. In the pivotal phase, the ROADSTER study enrolled 141 patients that were classified as being at high surgical risk. The primary endpoint of the ROADSTER Study was a hierarchical composite of stroke, death or myocardial infarction within 30 days.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Among the intention-to-treat, study population, which included patients treated despite major protocol deviations, the primary endpoint event rate at 30 days was 3.5%, comprised of two strokes, two deaths, and one myocardial infarction. Of note, in the per protocol analysis, which included only patients who met all study eligibility criteria, the primary endpoint event rate was 2.9%, comprised of one stroke, two deaths, and one myocardial infarction. The data from the intention-to-treat analysis supported FDA 510(k) clearance of the ENROUTE NPS.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A continued access phase of the ROADSTER Study was conducted during the time that the 510(k) premarket notification for the ENROUTE NPS was under review by FDA. This phase enrolled an additional 78 patients with the same primary and secondary endpoints and similar results as the pivotal phase of the ROADSTER Study. The ENROUTE NPS was 510(k) cleared by the FDA in February&#160;2015.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Following a pre-submission interaction with the FDA, the FDA permitted data from a sub-analysis of 52 patients in the ROADSTER Study who were treated with the Cordis Precise Pro RX Carotid Stent System to be used, in conjunction with existing data from Cordis on CAS clinical trials performed with the Cordis Precise Pro RX Stent System, or Precise stent, to support our pre-market approval application for the ENROUTE stent. The ENROUTE stent system and the Precise stent system share the same design for the stent implant itself, and differ only in the design of the delivery system. Based on this data, the pre-market approval application for the ENROUTE stent was approved in May 2015.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also initiated a separate sub-study of patients treated on a PP basis in the ROADSTER pivotal and continued access cohorts to assess the longer-term rate of ipsilateral stroke beyond 30 days. This sub-analysis, which consisted of 164 patients including 112 from the pivotal phase and 52 from the continued access phase, provided insight into the ability of TCAR to limit stroke incidence in longer-term follow-up. At one-year follow-up, the ipsilateral stroke rate was 0.6% beyond 30 days. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">ROADSTER 2 U.S. Post-Market Approval Study</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The ROADSTER 2 Post-Market Approval Study was a condition of PMA approval for the ENROUTE stent. The study evaluated the outcomes in TCAR using the ENROUTE stent in conjunction with the ENROUTE NPS in broader, &#8220;real world&#8221; use. Similar to the sub-analysis from the ROADSTER Study that led to PMA approval of the ENROUTE stent, the primary endpoint, was the rate of procedural success at 30 days in high surgical risk patients with a three-year minimum life expectancy in the PP study population.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The ROADSTER 2 study enrolled 692 patients at 42 sites, of which 632 patients were included in the PP analysis. Among the operating physicians in the study, 62% of the participating patients were treated by physicians who did not participate in the pivotal ROADSTER Study. Enrollment commenced in 2015 and was completed, along with the final 30-day follow-up assessments in 2019.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The primary endpoint of ROADSTER 2 was successfully met with a procedural success rate of 97.9%, which compared favorably to the rate of procedural success (98.1%) in the ROADSTER Sub-Study population. Data from a </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">7</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">subset of ROADSTER 2 subjects (n=155) were analyzed to assess the incidence of ipsilateral stroke from day 31 through day 365 post-procedure. The ipsilateral stroke rate at one-year follow-up was 0% beyond 30 days.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The Society for Vascular Surgery&#8217;s TCAR Surveillance Project</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The TCAR Surveillance Project was implemented in September 2016 as an initiative of the Society for Vascular Surgery Patient Safety Organization. The TCAR Surveillance Project is an ongoing, open-ended registry that was designed to monitor the safety and effectiveness of transcarotid stents placed directly into the internal carotid artery while reversing blood flow. It is intended to compare TCAR with CEA in centers that participate in the Society for Vascular Surgery VQI. The TCAR Surveillance Project was reviewed by the FDA and deemed to be a scientifically valid extension study of TCAR, thereby allowing CMS to provide coverage within the parameters of the existing National Coverage Determination (NCD 20.7). The Society for Vascular Surgery VQI is designed to improve the quality, safety, effectiveness and cost of vascular health care by collecting and exchanging information, and is available to all providers of vascular health care and their respective institutions participating in the registry. Because data from transfemoral CAS and CEA procedures are also collected in their respective registries within the Society for Vascular Surgery VQI, comparisons of TCAR to transfemoral CAS or CEA can also be made.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Eligible patients must meet the inclusion criteria specified for the TCAR Surveillance Project. This means patients must have had their TCAR procedure performed using any FDA-cleared transcarotid proximal embolic protection device utilizing flow reversal, such as our ENROUTE NPS, and any FDA-approved transcarotid stent, such as our ENROUTE stent</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To date, the ENROUTE NPS is the only such device cleared and approved by the FDA.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Additionally, patients had to be at high surgical risk. Following FDA&#8217;s approval expanding the indication for the ENROUTE stent to standard surgical risk patients, CMS announced expanded coverage for standard risk patients entered in TSP in June 2022. As a result,</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR procedures performed for either high surgical risk or standard surgical risk patients who are entered into TSP are eligible for reimbursement by Medicare if the patients meet the additional requirements set forth above. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk96541041" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Society for Vascular Surgery VQI has reported that 778 centers have contributed more than 60,000 TCAR procedures to the CAS VQI registry as of December 31, 2023. Over time, it is expected that physicians and academic researchers will continue to query the database and produce publications in peer review journals, and present data at medical conferences, regarding the safety and effectiveness of TCAR in real world use.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2023, CMS revised the NCD to cover carotid artery stenting, including TCAR, in both high and standard surgical risk patients, following a request to re-open the NCD from a group of physicians labeled the Multispecialty Carotid Alliance, or MSCA, in June 2022. In their review and as suggested by the MSCA, CMS considered evidence published from the ACT I, CREST (long-term results), SPACE-2, and ACST-2 randomized controlled trials of CAS versus CEA, amongst other datasets. In addition, CMS reviewed multiple publications supporting TCAR including the ROADSTER and ROADSTER 2 studies, and large real-world evidence, or RWE, published datasets from the TCAR Surveillance Project within the VQI, including propensity-matched comparisons to each of CEA and CAS. Under the recent NCD, TCAR remains covered within the TSP while expanding TCAR coverage outside of the TSP, which opens up the potential for some new opportunities in hospitals that previously chose not to participate in the TSP. The revised coverage determination stipulates that such procedures must include documented shared decision-making with the patient prior to treatment, independent neurological assessments, imaging requirements and the maintenance of facility and physician standards. While these requirements are new for carotid artery stenting, they do not apply to procedures done under the auspices of the TSP.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">TCAR Surveillance Project: TCAR vs. CAS</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In a study published in the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Journal of the American Medical Association</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in December 2019, TCAR was compared to CAS in a propensity score matched analysis with 3,286 pairs. TCAR was associated with a lower risk of in-hospital stroke or death (1.6% vs 3.1%; P &lt; .001), stroke (1.3% vs 2.4%; P = .001), and death (0.4% vs 1.0%; P = .008). As expected with two minimally invasive procedures, there was no statistically significant difference in the risk of perioperative MI between the two cohorts (0.2% for TCAR vs. 0.3% for TFCAS; P = .47). At 1 year using Kaplan-Meier life-table estimation, TCAR was associated with a lower risk of ipsilateral stroke or death (5.1% vs 9.6%; hazard ratio, 0.52 [95%CI, 0.41 to 0.66]; P &lt; .001). TFCAS was associated with more radiation (median fluoroscopy time, 5 minutes [interquartile range {IQR}, 3 to 7] vs 16 minutes [IQR, 11 to 23]; P &lt; .001) and more contrast usage (median contrast used, 30 mL [IQR, 20 to 45] vs 80 mL [IQR, 55 to 122]; P &lt; .001).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">TCAR Surveillance Project: TCAR vs. CEA</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In a study published in the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Annals of Surgery</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in September 2020, TCAR was compared to CEA in propensity score matched high surgical risk patients who underwent TCAR or CEA for carotid artery stenosis (2016-2019). Propensity </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">8</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">scores were calculated based on baseline clinical variables and used to match patients in the two treatment groups (n=6,384 each). The primary endpoint was the combined outcome of perioperative stroke and/or death. No significant differences were observed between TCAR and CEA in terms of in-hospital stroke/death [TCAR,1.6% vs. CEA,1.6%, P=.945], stroke [1.4% vs. 1.4%, P=.881], or death [0.4% vs. 0.3%, P=.662]. Compared to CEA, TCAR was associated with lower rates of in-hospital myocardial infarction [0.5% vs. 0.9%, P=.005], cranial nerve injury [0.4% vs. 2.7%, P&lt;.001], and post-procedural hypertension [13% vs.18.8%, P&lt;.001]. They were also less likely to stay in the hospital for more than one day [26.4% vs. 30.1%, P&lt;.001]. No significant interaction was observed between procedure and symptomatic status in predicting postoperative outcomes. At one year, the incidence of ipsilateral stroke or death was similar between the two groups [HR (95%CI): 1.09 (0.87-1.36), P=.44]. This propensity-score matched analysis demonstrated significant reduction in the risk of postoperative myocardial infarction and cranial nerve injury after TCAR compared to CEA, with no differences in the rates of stroke/death. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In a more recent analysis of both high risk and standard surgical risk patients, a 2022 VQI study by Zhang GQ, et al published in the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Journal of Vascular Surgery</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, compared outcomes (composite of stroke, death and myocardial infarction) using a multivariate logistic regression analysis analyzing TCAR procedures using the predicate device, TF-CAS using distal filters and CEA procedures from 2015-2020. Within the high risk patient cohort of 10,903 TCAR vs. 7,967 CEA vs. 9,896 TF-CAS procedures, TCAR demonstrated significantly lower odds of 30-day stroke, death and stroke/death and myocardial infarction for TCAR compared to both CEA and TF-CAS. Within the standard risk cohort of 4,694 TCAR vs. 33,720 CEA vs. 7,351 TF-CAS procedures, TCAR and CEA showed equivalent odds of 30-day stroke, death, and stroke/death, whereas TFCAS was associated with significantly higher risk for these endpoints. In 2023, an analysis of the National Inpatient Sample database, which is the largest all-payor inpatient database for ~35 million hospitalizations nationwide, was published by Ramsay IA, et al in the journal </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Operative Neurosurgery</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and queried data from 2015-2019, demonstrating the risk of stroke with TCAR was significantly lower compared to CEA with multivariate analysis (OR 0.47 (95% CI, 0.25-0.87), P = .017) and after propensity-matched analysis (OR 0.50 (95% CI, 0.25-0.97), P = .042).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">TCAR Surveillance Project: Learning Curve</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In a study published in the </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Journal of the American College of Surgeons</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in January 2020, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Kashyap, et al, examined the learning curve of TCAR performed by surgeons participating in the TCAR Surveillance Project. The authors reviewed 3,456 TCAR procedures performed by 417 unique practitioners at 178 centers. Patients were grouped into four levels based upon the physicians&#8217; experience with TCAR at the time of procedure: novice (1-5 cases), intermediate (6-20 cases), advanced (20-30 cases) and expert (&gt;30 cases). Of the patients analyzed, 41% of patients were treated by novice physicians, 40% of patients were treated by intermediate physicians, 9% of patients were treated by advanced physicians and 10% of patients were treated by expert physicians. There was no significant difference in the baseline characteristics by surgeon case experience with three exceptions; expert physicians were more likely to treat patients with moderate or severe congestive heart failure, novice and intermediate physicians were more likely to treat patients with prior CEA or CAS, and advanced and expert physicians were more likely to treat patients with CMS medical high-risk criteria. There was a statistically significant reduction in operative time (novice 81.7 mins, expert 59.6 mins; p&lt;.001) and flow reversal time (novice 12.2 mins, expert 9.7 mins; p&lt;.001) over the four levels. There was a decrease in fluoroscopy time and contrast usage up to the advanced level. Bleeding complications were significantly less frequent in the advanced and expert groups of physicians. There was no difference in the incidence of cranial nerve injury across the groups of physicians. Expert physicians were more likely to use local anesthesia compared to the other three categories of physicians. There was no difference in the technical failure rate across the four categories of physicians. The rate of composite stroke, stroke alone and death did not differ between the categories. The authors noted that TCAR novices can achieve the same clinical outcomes as expert practitioners, while in comparison, CAS requires more than 50 cases to achieve proficiency.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Ongoing TCAR Studies</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 106.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">ROADSTER 3 U.S. Post-Market Approval Study</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk126609329" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2022, we announced FDA approval of a label expansion for the ENROUTE stent for use in standard surgical risk patients. In June 2022, we announced that CMS, through collaboration with the Society for Vascular Surgery&#8217;s Patient Safety Organization and their VQI has expanded coverage for TCAR to include standard surgical risk patients within the VQI&#8217;s TCAR Surveillance Project. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As a condition of FDA approval for such label expansion, we are conducting a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">prospective, multi-center, single-arm </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">post-approval study, ROADSTER 3, to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">evaluate on-label usage of the ENROUTE stent and the ENROUTE NPS for the treatment of patients at standard risk for adverse events from carotid endarterectomy who require carotid revascularization and who are eligible for treatment with these devices. The targeted enrollment in ROADSTER 3 is at least 315 patients treated per protocol at up to 60 U.S. sites. The primary endpoint is a hierarchical composite of major adverse events defined as any death, stroke or myocardial infarction within 30 days of the index procedure, plus ipsilateral stroke within 31 days to 365 days of the TCAR procedure. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk125746801" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">9</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Our Commercial Strategy</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe vascular surgeons represent the specialty most frequently responsible for managing the care of and receiving referrals for patients with carotid artery disease and are skilled in endovascular procedures. Our sales, marketing, professional education and medical affairs efforts are focused on driving adoption and supporting their practice development by offering them an innovative, safe, effective and minimally-invasive alternative for treating carotid artery disease.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk126678363" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We market and sell our products in the United States through a direct sales organization consisting o</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">f sales management, sales representatives, known as area managers, and clinical support specialists, known as therapy developme</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">nt specialists.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The area managers are typically complemented by one therapy development specialist in each territory. Our sales professionals have substantial experience launching and establishing new disruptive therapies and converting open surgical procedures to minimally-invasive alternatives. We primarily market our products directly to vascular surgeons, their staffs, operating room managers and hospital administrators. We also market to other specialists with experience in CEA and/or CAS with the appropriate skill set for TCAR, including neurosurgeons, cardiothoracic surgeons and non-surgical interventionalists in radiology, neuroradiology and cardiology.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our area managers are responsible for developing territory business plans, targeting and opening new accounts, promoting the benefits of TCAR and our products, and driving adoption and penetration of TCAR. Together with the therapy development specialist, they also support the training and proper use of our TCAR portfolio of products and provide clinically consultative support for patient selection, pre-procedure planning, procedure support, and post-procedure care. As we continue to grow the size of our U.S. sales organization, with a focus on increasing adoption of TCAR by existing customers and expanding our current customer base, we expect to focus on adding a strategic mix of area managers and therapy development specialists. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our highly specialized area managers and therapy development specialists, along with other key employees, receive in-depth training and develop a thorough understanding of carotid artery disease, patient selection, imaging interpretation, procedure planning, reimbursement and regulatory policies to meaningfully support our customers and maintain compliance. Our extensive training and continuous education program consists of foundational training, procedure observation, and sales skills development. Our personnel are selected based on their focus on patient outcomes and delivering a positive customer experience in addition to their technical and clinical aptitude.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, we support our sales organization with marketing and market and practice development initiatives. We plan to continue to expand and enhance our marketing and analytics capabilities to support our growing commercial organization and customer base.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk126678392" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">While we do not currently sell our products in markets outside the United States, we are pursuing regulatory clearances in Japan and China. In Japan, we received Shonin approval for the ENROUTE NPS and the ENROUTE stent in the fourth quarter of 2022. During the fourth quarter of 2023, we entered into an exclusive distribution agreement for our products in Japan and we submitted our updated reimbursement application during the first quarter of 2024. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, in the first quarter of 2023, we received approval from China&#8217;s National Medical Products Administration, or NMPA, for our ENROUTE NPS. In the first quarter of 2024, we received NMPA approval for our ENROUTE stent, and we also entered into an exclusive distribution agreement for our products in China. In both geographies, we are conducting regulatory activities to support future clearance of our next-generation ENROUTE NPS PLUS that was cleared in the U.S. in the second quarter of 2023. Our next steps include</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> assessing the reimbursement process and our pathway and timeline to launch.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk125812357" style="text-decoration: none;"></span><span id="_Hlk94611128" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Professional Education </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are focused on developing strong relationships with our customers and devote significant resources to training and educating physicians in the use of TCAR and our associated products. Our Office of Medical Affairs leads our physician education and training programs in addition to disseminating the scientific information and clinical data supporting TCAR. The Office of Medical Affairs also leads compliance activities.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our practice is to require physicians to complete a training program before performing TCAR, which is also a regulatory requirement derived from the PMA approval of the ENROUTE stent. To facilitate training, we have developed a robust training course including clinical and procedural details as well as hands-on workshops designed to provide the highest potential for successful outcomes. We conduct physician training courses in large group, in-person formats as well as virtual and small groups. We also provide training through physician proctors on an as needed basis. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we have trained and certified over 2,800 physicians in the United States.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">10</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We offer a series of training programs for fellows and our objective is to support them in being certified to perform TCAR upon graduation from their fellowship. TCAR is now offered in most of the teaching institutions where fellows train in the United States. TCAR is also now included as part of the examination required for board certification in vascular surgery. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk94611455" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Coverage and Reimbursement</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk96541384" style="text-decoration: none;"></span><span id="_Hlk158903029" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CMS covers carotid artery angioplasty and stenting, including TCAR, under NCD 20.7. Since September 2016, TCAR was primarily covered under NCD 20.7 indication B3, as an FDA-approved post-approval study </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sponsored by the </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ociety for Vascular Surgery&#8217;s</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> VQI</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">T</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CAR </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">urveillance </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">P</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">roject</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. For providers participating in the VQI</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TSP, </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NCD 20.7 cover</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">patients at high surgical risk for CEA who are either symptomatic with </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8805;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50% stenosis or asymptomatic with </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8805;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">80% stenosis, and effective May 31, 2022, CMS expanded coverage in the VQI TSP to include the standard surgical risk population. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For providers not participating in the VQI TSP, TCAR was </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">previously </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">only covered under NCD 20.7 indication B4 for patients at high risk for CEA and </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">who had</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> symptomatic carotid artery stenosis &gt;70%. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Following a request to re-open the NCD from a group of physicians labeled the MSCA in June 2022, and effective October 11, 2023,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CMS published the final decision memo for NCD 20.7 expanding coverage for CAS, including TCAR, under indication B4 for both high risk and standard surgical risk patients. TCAR continues to be covered under NCD 20.7 for percutaneous transluminal angioplasty, or PTA, according to these indications:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.75in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">B3 &#8211; Concurrent with Carotid Stent Placement in FDA-Approved Post-Approval Studies (e.g., VQI TSP)</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0.75in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">B4 &#8211; Concurrent with Carotid Stent Placement</span></p><div style="padding-left: 0;text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: #DDD9C3;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #DDD9C3;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #DDD9C3;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 38.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #DDD9C3;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Indications</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">B3. VQI TSP* </span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(no change)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 38.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">B4. Carotid Stent Placement </span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Updated 10/11/2023)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">B4. Carotid Stent Placement (Original thru 10/10/2023)</span></p></td></tr><tr><td colspan="3" style="background: #DBE5F1;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 77.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Clinical Criteria</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #DBE5F1;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Surgical Risk Factor</span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 58.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Standard Risk &amp; High Risk</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">High Risk</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Symptom Status &amp; Degree of Stenosis</span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 58.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Symptomatic &amp; &#8805;50% stenosis</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asymptomatic &amp; &#8805;70% stenosis</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Symptomatic &amp; &#8805;70% stenosis</span></p></td></tr><tr><td colspan="3" style="background: #DBE5F1;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 77.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Additional Criteria</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #DBE5F1;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facility Requirements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facility standards and approval</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facility and physician standards for carotid stent program</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CMS facility approval and certification</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Registry or Data Collection</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Registry participation (VQI-TSP)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not required for coverage</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Data collection</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurological Assessments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not specified</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pre &amp; post-op neurological assessments by a neurologist or NIHSS certified HCP</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not specified</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Imaging Guidelines</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not specified</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Duplex US and CTA/MRA or</span></p><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Duplex US and DSA when non-invasive imaging is inconclusive or CTA/MRA are contraindicated</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not specified</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shared Decision Making</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not specified</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shared decision-making with patients about CEA, CAS (including TCAR), and OMT before treatment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 20.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.10in;margin-right: 0;margin-top: 0;text-indent: -0.10in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.100in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not specified</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Medicare coverage for VQI TSP is based on the study protocol (clinicaltrials.gov (NCT02850588)). </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the revised NCD 20.7, placement of an FDA-approved carotid stent with an FDA-approved or cleared embolic protection device in patients with symptomatic carotid artery stenosis &#8805;50% and in patients with asymptomatic carotid artery stenosis &#8805;70% are covered under the following conditions: </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurological assessment must be performed by a neurologist or NIH stroke scale (NIHSS) certified health professional before and after CAS.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">First-line evaluation of carotid artery stenosis must use duplex ultrasound.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Computed-tomography angiography (CTA) or magnetic resonance angiography (MRA), if not contraindicated, must be used to confirm degree of stenosis, and provide information about the aortic arch, and extra and intra-cranial circulation.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">11</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(4)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intra-arterial digital subtraction (catheter) angiography may be used only when there is significant discrepancy between non-invasive imaging results or contraindicated for CTA or MRA.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prior to furnishing CAS, the practitioner must engage in a shared decision-making interaction with the beneficiary, which must include:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion of all treatment options for carotid stenosis, including CEA, CAS (which includes TCAR), and optimal medical therapy (OMT).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Explanation of risks and benefits for each option specific to the beneficiary&#8217;s clinical condition.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Integration of clinical guidelines (e.g., patient co-morbidities and concomitant treatments).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(4)</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion and incorporation of beneficiary&#8217;s personal preferences and priorities in choosing a treatment plan. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facilities must establish and maintain institutional and physician standards to support a dedicated carotid stent program. However, CMS facility approval or certification is not required. The Medicare Administrative Contractors will have discretion to make carotid artery stenting coverage determinations not addressed in NCD 20.7. As a result of the expansion of coverage in NCD 20.7 and CMS&#8217;s stated goals for broader patient access, we believe there could be rising interest and awareness in minimally invasive carotid stenting procedures including TCAR.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR, like CAS, is only reimbursed by Medicare as an inpatient procedure and therefore reimbursed to hospitals under the Medicare Severity Diagnosis Related Group, or MS-DRG, system.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are three key aspects of reimbursement in the United States: coding, coverage and payment.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Coding</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> refers to distinct numeric and alphanumeric billing codes that are used by healthcare providers to report the provision of medical procedures and the use of supplies for specific patients to payers. CPT codes are published by the American Medical Association and are used to report medical services and procedures performed by or under the direction of physicians. Medicare pays physicians for services based on submission of a claim using one or more specific CPT codes. Physician payment for procedures may vary according to site of service. Hospitals are reimbursed for inpatient procedures based on Medicare Severity Diagnosis Related Group, or MS-DRG classifications derived from ICD-10-CM diagnosis and ICD-10-PCS codes that describe the patient&#8217;s diagnoses and procedure(s) performed during the hospital stay. MS-DRGs closely calibrate payment for groups of services based on the severity of a patient&#8217;s illness. One single MS-DRG payment is intended to cover all hospital costs associated with treating an individual during his or her hospital stay, except for physician charges associated with performing medical procedures, which are reimbursed through CPT codes and payments.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Payment</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> refers to the amount paid to providers for specific procedures and supplies. Payment is generally determined by the specific CPT and billing code. In addition, there may be separate numeric codes, under which the billing code is classified, to establish a payment amount.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Coverage</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> refers to decisions made by individual payers as to whether or not to pay for a specific procedure and related supplies and if so, under what conditions, including specific diagnoses and clinical indications.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Coding for Physicians</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2014, the Society for Vascular Surgery helped to guide an editorial change by the American Medical Association to CPT 37215 to be inclusive of TCAR. The Category I CPT code for TCAR, effective January 1, 2015, is CPT 37215: Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; with distal embolic protection. Published CMS guidance confirms that reverse flow embolic protection systems, such as our ENROUTE NPS, qualify as distal embolic protection under this code. This code has a 90-day global period. Coverage and payment for CPT code 37215 is only available from CMS in the inpatient setting, subject to the terms of the National Coverage Determination Manual Section 20.7, and facilities must establish and maintain institutional and physician standards to support a dedicated carotid stent program. Hospitals participating in the VQI are considered to meet CMS&#8217;s minimum facility standards.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Coding for Hospitals</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are a number of appropriate ICD-10-CM diagnosis codes that describe occlusions and stenosis of carotid arteries for asymptomatic patients as well as cerebral infarction due to embolus and thrombus of carotid arteries for </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">12</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">symptomatic patients, which establish medical necessity. As of October 1, 2020, the proper ICD-10-PCS procedure codes for TCAR includes a code for carotid stenting [e.g. 037(H/J/K/L)3(D/E/F/G)Z] and a code for extracorporeal reverse flow neuroprotection [e.g. X2(H/J) 336]. Based on the ICD 10 diagnosis and procedure codes, TCAR inpatient admissions are assigned to MS-DRG 034 when the patient presents with major complications or co-morbidities, or MCC, 035 when the patient presents with a complication or co-morbidity, or CC, or 036 for patients without complications or co-morbidities.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Payment for Physicians</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The 2024 national average physician professional fee payment for CPT code 37215 is approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">951</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. We believe physicians feel this level of payment represents a reasonable amount for TCAR. CEA procedures are reimbursed under CPT code 35301, for which the 2024 national average physician professional fee payment is $1,084.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Payment for Hospitals</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Medicare national unadjusted 2024 hospital inpatient payment amounts for MS-DRGs 034, 035 and 036 are </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$27,316, $16,100 and $12,660,</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> respectively.&#160;Based on prior procedure volumes </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">assigned to MS-DRGs</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, we estimate that the weighted average payment amount across MS-DRGs 034, 035 and 036 is $15,785 in 2024. These MS DRG payments are intended to cover all hospital costs associated with treating an individual during his or her hospital stay, except for physician charges associated with performing medical procedures. We believe that facilities feel this level of payment represents a reasonable amount for the treatment of patients with TCAR. CEA procedures are reimbursed under MS-DRGs 037, 038 and 039. The national unadjusted 2024 payment amounts for MS-DRGs 037, 038 and 039 to be $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23,635, $11,202 and $7,989,</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> respectively.&#160;Based on prior procedure volumes, we estimate that the weighted average payment amount across these three Extracranial Procedure MS-DRGs to be $10,726. The base payment amounts for MS-DRGs may vary greatly by individual acute-care hospital for several reasons including but not limited to geographic, teaching status, case-mix index, and use of electronic health record systems.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk125809722" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Research, Development and Clinical Programs</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our research and development activities encompass basic research, clinical research and product development. Our engineering team has mechanical engineering, project management, materials science, and prototyping expertise. In addition, our clinical research organization has trial design, project management, data management and other clinical study operational expertise.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our research and development efforts are currently focused on improving and expanding our portfolio of TCAR products and their labeled indications for use to further improve and simplify the treatment experience for a broad base of patients and physicians. We have worked together with vascular surgeons and other physicians to develop our products. The objective of our research and development program is to leverage our engineering capabilities, clinical and regulatory organizations, and unique insights into treatment of carotid artery disease to continue to lead the TCAR category.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk125811147" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our clinical research activities are currently focused on our recently closed feasibility study in acute ischemic stroke, NITE-1, as well as completing enrollment </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in ROADSTER 3, our post-approval study for TCAR in standard surgical risk patients. NITE-1 results, as of the date of an abstract submission to the International Stroke Conference, were included in a poster presentation in early February 2024. Final results will be submitted in a manuscript later this year.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also have a broad intellectual property platform addressing the transcarotid approach and, in the future, we intend to leverage our expertise to develop new products targeting market opportunities and disease states that could benefit from the physiologic and engineering advantages made possible by our transcarotid approach, including in the heart, aortic arch and brain. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the fiscal years ended December 31, 2023, 2022 and 2021, our research, development and clinical expenses were $41.3 million, $36.4 million and $27.1 million, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Seasonality</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our revenue has fluctuated and we expect to continue to fluctuate from quarter-to-quarter due to a variety of factors, including seasonality and number of selling days. With respect to seasonality, our first quarter revenue may be harmed by adverse weather and the resetting of annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures. Holiday and summer vacations by healthcare providers and/or patients may adversely affect procedure volumes that in turn affect hospital ordering patterns. In addition, we have also experienced moderate procedure volumes during major medical conferences when significant portions of our customer base are attending the conferences.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">13</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk125814717" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Competition</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR is a relatively new procedure category and as such the basis of competition for our products is with respect to alternative carotid revascularization procedures. We are positioning TCAR as an alternative to the existing procedures CEA and CAS, and therefore compete primarily with manufacturers of medical devices used in those procedures.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The major manufacturers of products, such as patches and shunts, used in connection with CEA include LeMaitre Vascular, Inc., Getinge AB, Baxter International Inc., Terumo Medical Corporation, W. L. Gore &amp; Associates, Inc. and Edwards Lifesciences Corporation. Many of these companies are large public companies or divisions of publicly-traded companies and have several competitive advantages, including established relationships with vascular surgeons who commonly perform the CEA procedure, significantly greater name recognition and significantly greater sales and marketing resources.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Companies with actively marketed FDA-approved stents and embolic protection devices for use with CAS procedures or which could potentially be used in TCAR include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, and Cordis Corporation. Other companies have approved devices not currently marketed in the U.S., including W. L. Gore &amp; Associates, Inc., Terumo Medical Corporation, Contego Medical Inc. and InspireMD, Inc. Additionally, some companies have stents and other products in ongoing IDE or planned IDE trials in the U.S., including Terumo Medical Corporation, Contego Medical Inc. and InspireMD, Inc. Preliminary results from Contego Medical Inc.&#8217;s PERFORMANCE II and InspireMD, Inc.&#8217;s C-Guardians studies were presented at the Vascular InterVentional Advances, or VIVA, conference in November 2023. Contego Medical Inc. and InspireMD, Inc. have also announced plans to develop products for TCAR. Many of these companies have several competitive advantages including the following: more established sales and marketing programs and networks, larger portfolio of products, longer operating histories, established relationships with healthcare professionals and greater name recognition.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Some competitors market other endovascular products that can be used in CAS and TCAR, such as peripheral access kits, guidewires, stents, balloons and sheaths. Such companies include but are not limited to Abbott Laboratories, Boston Scientific Corporation, Cordis Corporation, Medtronic plc and Cook Medical Inc.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to competing for market share for TCAR, we also compete against these companies for personnel, including qualified personnel that are necessary to grow our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe the principal competitive factors in our market include the following:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patient outcomes and adverse event rates;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patient experience;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acceptance by treating physicians and referral sources;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Physician learning curve;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ease-of-use and reliability;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patient recovery time and level of discomfort;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Economic benefits and cost savings;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Price;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Availability and amount of reimbursement; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Strength of clinical evidence.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also compete against manufacturers of medications used for medical management of carotid artery disease, including aspirin and statins. Many such companies are large public companies or divisions of publicly-traded companies and have several competitive advantages including the following: established treatment patterns where drugs are generally first-line therapy and invasive procedures or surgery are considered later; established relationships with general practitioners who commonly prescribe such medications; significantly greater name recognition; and significantly greater sales and marketing resources.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">14</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk94611670" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Intellectual Property</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We actively seek to protect the intellectual property and proprietary technology that we believe is important to our business, which includes seeking and maintaining patents covering our technology and products, proprietary processes and any other inventions that are commercially or strategically important to the development of our business. We also rely upon trademarks to build and maintain the integrity of our brand, and we seek to protect the confidentiality of trade secrets that may be important to the development of our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To protect our proprietary rights, we rely on a combination of trademark, copyright, patent, trade secret and other intellectual property laws, employment, confidentiality and invention assignment agreements, and protective contractual provisions with our employees, contractors, consultants, suppliers, partners and other third parties.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we o</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">wned 179 patents globally, of which 78 were issued U.S. patents and 101 were patents outside of the United States. Our patents expire between November 2024 and July 2039. Our material patents, their jurisdiction, expiration</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> date and the product to which they relate, are listed in the table below:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Jurisdiction</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Patent No.</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Expiration Date</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Related Product</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,002,728</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12/2/2025</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,343,089</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6/22/2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Stent System</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,157,760</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9/3/2030</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,784,355</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/7/2029</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,740,834</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/6/2029</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,011,364</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4/10/2031</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,833,555</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10/26/2029</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">US</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,238,853</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/16/2039</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Europe</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,173,425</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/18/2028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">France</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,173,425</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/18/2028</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Germany</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,173,425</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/18/2028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Italy</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,173,425</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/18/2028</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Great Britain</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,173,425</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/18/2028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Japan</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,290,290</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/18/2028</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Japan</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,693,661</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/18/2028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 33.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Neuroprotection System</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we h</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ad 96 pending patent applications globally, including 41 in the United States and 55 outside the United States.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk94611948" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we had trademark registrations for &#8220;Silk Road Medical,&#8221; the &#8220;Silk Road Medical&#8221; logo, &#8220;TCAR,&#8221; &#8220;Enroute&#8221; and the &#8220;Enroute&#8221; logo and &#8220;Enhance&#8221; in the United States, and various other countries. Including these trademark registrations, our trademark portfolio contained 101 trademark registrations/applications.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also seek to maintain certain intellectual property and proprietary know-how as trade secrets, and generally require our partners to execute non-disclosure agreements prior to any substantive discussions or disclosures of our technology or business plans. Our trade secrets include proprietary account analytics, user training methods, and operational processes. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk94620664" style="text-decoration: none;"></span><span id="_Hlk125815130" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Manufacturing and Supply </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk94622587" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently manufacture the ENROUTE NPS and ENROUTE NPS PLUS, or our ENROUTE NPS products, at our facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of approximately 35,000 square feet of space for our production and distribution operations, including manufacturing, quality control and storage. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe our combined facilities will be sufficient to meet our manufacturing needs for at least the next five years</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk94620732" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our manufacturing and distribution operations are subject to regulatory requirements of the FDA&#8217;s Quality System Regulation, or QSR, for medical devices sold in the United States, set forth in 21 CFR part 820. Our quality system is also certified as demonstrating compliance to ISO 13485:2016. In July 2022, we voluntarily requested the cancellation of our CE Mark certifications for business reasons but will continue to work with our Registrar to maintain ISO 13485:2016 certifications of our quality system for both our Sunnyvale and Plymouth facilities. We may seek new CE Mark certifications in the future. We are also subject to applicable local regulations relating to the environment, waste management and health and safety matters, including measures relating to the release, use, storage, treatment, </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">15</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">transportation, discharge, disposal, sale, labeling, collection, recycling, treatment and remediation of hazardous substances.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA monitors compliance with the QSR through periodic inspections of our facilities. Our suppliers&#8217; facilities are also subject to FDA regulations, including the QSR, and unannounced inspections by the FDA and other similar regulatory authorities. Our Registrar for ISO 13485:2016, British Standards Institute, or BSI, monitors compliance to the standard&#8217;s requirements through annually scheduled audits of our manufacturing facilities.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have been an FDA registered medical device establishment and California licensed medical device manufacturer since 2011. We completed the initial FDA registration of our Plymouth, Minnesota facility in May 2022.</span><span style="white-space:pre-wrap; color: #FF0000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA has conducted a total of five establishment inspections of our manufacturing facility in Sunnyvale, California. The most recent inspection in 2023 concluded with no actions indicated. The FDA conducted an initial facility inspection in our Plymouth, Minnesota location in January 2024 and a one-observation Form 483 Notice of Observation was issued pertaining to a singular piece of production equipment in relation to calibration and preventive maintenance. In response, we initiated a Corrective and Preventive Action, or CAPA, to address the 483. We believe that we are in compliance, in all material respects, with all applicable FDA requirements, including the QSR.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since obtaining ISO 13485 certification in 2011 for the Sunnyvale facility, BSI has conducted scheduled surveillance audits annually, recertification audits every third year, and periodic audits since the initial certification period. The most recent recertification audit for Sunnyvale was conducted in September 2023 and no major non-conformities were identified. The initial ISO 13485:2016 certification of the Plymouth facility was completed in November 2023, with no major non-conformities identified. We are no longer subject to unannounced audits since our CE Mark certifications have been canceled. We believe that we are in compliance, in all material respects, with all ISO 13485 requirements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk94622264" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Manufacturing of the materials and components of the ENROUTE NPS products are provided by approved suppliers, some of which are single-source suppliers of key components, sub-assemblies and materials. We purchase finished transcarotid access kits, guidewires, balloons and stents through contract manufacturers. Cordis is our contract manufacturer and currently the sole source supplier for the ENROUTE stent. We typically maintain several months&#8217; worth of ENROUTE stents in inventory, and we estimate that it would take up to two years or more to qualify a second source supplier for our ENROUTE stent. The suppliers for our ENROUTE NPS products and our other product lines are evaluated, qualified and approved through a stringent supplier management program, which includes various evaluations, assessments, qualifications, validations, testing and inspection to ensure the supplier can meet acceptable quality requirements. We ensure a strict change control policy with our key suppliers to ensure that no component or process changes are made without our prior approval.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Order quantities and lead times for components purchased from suppliers are based on our forecasts derived from historical demand and anticipated future demand. Lead times for components may vary depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components, sub-assemblies and materials. We typically stock several months of supply for components and raw materials to mitigate any supply delays or disruptions. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Considering ongoing global supply chain constraints, we are working with all our suppliers on additional orders and forecasting to mitigate any potential supply issues. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We perform assembly, testing, inspection and final product release activities for the ENROUTE NPS. Finished ENROUTE NPS devices are ethylene oxide sterilized at a qualified supplier.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cordis License Agreement</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In December 2010, we entered into a license agreement with Cordis, which agreement was amended in May 2023 (as amended, the Cordis License Agreement). Pursuant to the Cordis License Agreement, Cordis granted us a worldwide, non-exclusive, perpetual, royalty-bearing license to certain of its intellectual property related to the PRECISE carotid stent, or the Licensed IP, for transcervical treatment of carotid artery disease with an intravascular stent for certain applications for accessing blood vessels through the neck and cervical area. Cordis may not license the Licensed IP in our licensed field of use to any other third party during the term of the Cordis License Agreement.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Cordis License Agreement requires us to work exclusively with either Cordis or Confluent Medical Technologies, Inc. (f/k/a Nitinol Devices and Components, Inc.), or Confluent, for the development, manufacture and supply of the licensed products. If either Cordis or Confluent cannot continue to manufacture or supply the licensed products, we can seek a third-party manufacturer with the prior written consent of Cordis.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have the right to assign or transfer the Cordis License Agreement to an entity that succeeds all or substantially all of our equity or assets. The Cordis License Agreement may be terminated by either party in the event of uncured material </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">16</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">breach by the other party that remains uncured for 60 days (or 30 days for payment related breaches), or bankruptcy of the other party.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cordis Supply Agreement </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2011, we entered into a supply agreement with Cordis and have since entered into several amendments, most recently in May 2023 (as amended, the Cordis Supply Agreement). Pursuant to the Cordis Supply Agreement, Cordis has assisted in the development of a transcarotid stent delivery system according to our specifications with a PRECISE carotid stent implant, or ENROUTE stent and has supplied the ENROUTE stent through preclinical and clinical trials. Cordis has agreed to supply the ENROUTE stent for our commercial sale through February 19, 2029 and has agreed to engage in good faith negotiations to extend its supply commitment beyond that date. Cordis has the exclusive right to manufacture and supply the current generation of the ENROUTE stent during the term of the Cordis Supply Agreement. If Cordis is not able to supply the ENROUTE stent, upon our election, Cordis shall permit Confluent or a third-party manufacturer to provide supply of the ENROUTE stent, provided that Cordis retains the right to manufacture and supply the ENROUTE stent to us to the extent it is able to do so. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Cordis Supply Agreement requires a specified minimum volume purchase commitment from us from July 2023 through February 2029 based on the actual units purchased during the prior year period from July 1 through June 30, with the unit purchase price dependent upon annual volume during the same prior year period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Cordis Supply Agreement will continue in full force and effect until the earlier to occur of (i) termination of the Cordis License Agreement; (ii) our election if and when Cordis approves another manufacturer; (iii) mutual written termination; or (iv) termination pursuant to the terms therein. The Cordis Supply Agreement may be terminated by either party in the event of uncured material breach by the other party that remains uncured for 30 days, or bankruptcy of the other party.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk125819059" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Government Regulation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">United States Food &amp; Drug Administration</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products and operations are subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, as well as other federal and state regulatory bodies in the United States. The laws and regulations govern, among other things, product design and development, pre-clinical and clinical testing, manufacturing, packaging, labeling, storage, record keeping and reporting, clearance or approval, marketing, distribution, promotion, import and export, and post-marketing surveillance.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the United States will require either a premarket notification to the FDA requesting permission for commercial distribution under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act, or FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a PMA application. In some cases, where no predicate device exists, Class II devices may come to market through the de novo authorization process. The 510(k) clearance, de novo authorization, and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees, unless an exemption is available.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Device Classification</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the FDCA, medical devices are classified into one of three classes-Class&#160;I, Class&#160;II or Class&#160;III-depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class&#160;I devices, also called Class&#160;I reserved devices, also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class&#160;I products are exempt from the premarket notification requirements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Class&#160;II devices are those that are subject to the General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class&#160;II devices are subject to premarket </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">17</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">review and clearance by the FDA. Premarket review and clearance by the FDA for Class&#160;II devices is accomplished through the 510(k) premarket notification process.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Class&#160;III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class&#160;III devices cannot be reasonably assured solely by the General Controls and Special Controls described above. Therefore, these devices are subject to the PMA application process, which is generally more costly and time consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a new medical device does not qualify for the 510(k) premarket notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk and requires PMA or that general controls would be inadequate to control the risks and special controls cannot be developed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The Investigational Device Process</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an IDE application. Some types of studies deemed to present &#8220;non-significant risk&#8221; are deemed to have an approved IDE once certain requirements are addressed and Institutional Review Board. or IRB, approval is obtained. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of subjects. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate IRBs at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and effectiveness, even if the trial meets its intended success criteria.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA&#8217;s good clinical practice regulations for institutional review board approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable, or, even if the intended safety and effectiveness success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The 510(k) Clearance Process</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent,&#8221; as defined in the statute, to a legally marketed predicate device.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">18</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. The Medical Device User Fee Amendments sets a performance goal of 90 days for FDA review of a 510(k) submission, but the review time can be delayed if FDA raises questions or requests additional information during the review process. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. A manufacturer can also submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application or de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">More recently, in September 2019, the FDA finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list of device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The De Novo Process</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Medical devices that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. De novo classification requests are also subject to the payment of user fees. Under FDASIA, the FDA is required to make a decision within 120 days following receipt of the de novo request, but the process may take significantly longer. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. If the </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">19</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA grants the de novo request, the device may be legally marketed in the United States. However, the FDA may reject the request if it identifies a legally marketed predicate device that would be appropriate for a 510(k) notification or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and/or special controls cannot be developed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Once a device receives a de novo classification as a Class II device, any modification that could significantly affect its safety or efficacy, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, another de novo request or even PMA approval.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The PMA Approval Process</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA, by statute and by regulation, has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an applicant fails to respond to an FDA request for information (e.g., major deficiency letter) within a total of 360 days. Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years, but may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The device may not be shown safe or effective to the FDA&#8217;s satisfaction;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The manufacturing process or facilities may not meet applicable requirements; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in FDA approval policies or adoption of new regulations may require additional data.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data is available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also require post-market surveillance for certain devices cleared under a 510(k) notification, such as implants or life-supporting </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">20</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">or life-sustaining devices used outside a device user facility. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Japan Pharmaceuticals and Medical Devices Agency</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Japan maintains a regulatory framework, similar to that described for the United States, under its Pharmaceutical and Medical Device Act, or PMD Act. The PMD Act covers regulations on pharmaceuticals, medical devices, and cosmetics and is governed by the Ministry of Health, Labor, and Welfare, or MHLW, which has the authority to (1) issue marketing licenses, (2) issue Marketing Authorization Holder licenses, and (3) issue Foreign Manufacturer Registration, or FMR, licenses, among its other responsibilities in policies and administrative measures. Within the MHLW, the Pharmaceuticals and Medical Devices Agency, or PMDA, performs the technical management and review of medical devices including, but not limited to, (1) review, examination, analysis, and approval recommendations, (2) Quality Management Systems, Good Laboratory Practice, and Good Clinical Practice inspections, and (3) collection and analysis of Post Market Surveillance data. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our portfolio in Japan is subject to the PMD Act regulatory framework. Like the FDCA regulatory framework, medical devices must be classified into one of four classes - Class I, Class II, Class III, or Class IV - depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. Our devices are classified as Class IV, Specially Controlled Medical Devices, with a regulatory pathway that requires MHLW approval (Shonin pathway). </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the Shonin regulatory pathway, the PMDA may conduct audits to verify compliance with Good Clinical Practice, Documentation Reliability, and Quality Management System standards and/or regulations, in addition to inspections of the manufacturing facility and processes. Often, in the case of novel device approvals, the PMDA may require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the PMDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are several additional pre-requisites that are required of medical device manufacturers to obtain approval for market authorization in Japan. These include the appointment of a Marketing Authorization Holder in Japan and the acquisition of an FMR. Only a Marketing Authorization Holder, or MAH, a Japanese domestic medical device manufacturer, or a Designated Marketing Authorization Holder, or DMAH, a designee by an overseas medical device manufacturer, may import and sell medical products to the Japanese market. Additional duties of the MAH/DMAH include, but may not be limited to, the following:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facilitating PMDA product registration, managing product license modifications, and maintaining product approvals;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Managing product quality and safety to ensure that manufacturing sites comply with Japan&#8217;s Quality Management System requirements;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Managing product storage in the Japanese market;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Administering product release to distributors in the Japanese market; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Managing post-market surveillance in the Japanese market. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the PMDA evaluation of a Shonin application is favorable, MHLW may then issue the applicant a license for the product. This product license does not have an expiration date, however, the FMR and QMS conformity certificate expires every five years and requires renewal to keep the product in compliance on the Japanese market.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">China National Medical Products Administration</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">China maintains a regulatory framework for medical devices directed by State Decree No. 739, &#8220;The Regulations on the Supervision and Administration of Medical Devices&#8221;. State Decree No. 739 outlines regulations on the following elements, (1) General Provisions, (2) Medical Device Product Registration and Filing, (3) Medical Device Production, (4) Operation and Use of Medical Devices, (5) Handling of Adverse Events and Recall of Medical Devices, (6) Supervision and Inspection, and (7) Legal Liability. The Chinese NMPA is charged with the administration of these regulations and coordinates its supervision with other governmental bodies, (i.e., Center for Medical Device Evaluation, Center for Medical </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">21</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Device Standardization), to ensure that devices registered, imported/exported, manufactured, sold, or used in the Chinese market are safe and effective.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our portfolio in China is subject to the State Decree No. 739 framework. Manufacturers of medical devices must classify those devices into one of three categories - Class I, Class II, or Class III - depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. Our devices are classified as Class III, a higher-risk device category requiring special measures to be strictly controlled and managed to ensure safety and effectiveness and which are subject to product registration.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the regulatory framework in China, manufacturers must demonstrate the following in order to successfully gain approval for a medical device:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Appoint a Legal Agent in China;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Obtain foreign market approval, (typically either FDA clearance/approval or EU certificate);</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Obtain certification of a Quality Management System (typically ISO 13485 certification);</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepare Chinese specific Product Technical Requirements (PTR); and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Perform successful Type Testing of the product per established PTR.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The legal agent in China is a domestic representative (or service) who acts as an interface with the Chinese regulatory bodies in both pre-market and post-market phases of any medical device distributed in China. Often, a distributor serves as both the domestic distributor and the legal agent if that distributor has the appropriate Chinese licensing to do so. Additional duties of the legal agent include, but may not be limited to, the following:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Performs product registration/filing for overseas manufacturers;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Performs domestic post market surveillance duties, (e.g., Adverse Event reporting, recall coordination, customer compliant collection, etc.);</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Assists NMPA with inspection and quality evaluation of overseas manufacturers; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Manages and monitors medical device importation, sales, and distribution in China.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the NMPA evaluation of the medical device filing is favorable, the applicant is issued a license for the product. This product license has a five (5) year expiration period and must be renewed prior to license expiry for the product to continue to be imported, sold, or distributed in China.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Pervasive and Continuing Regulation </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">After a device is placed on the market, numerous regulatory requirements continue to apply. These include:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA, NMPA, and PMDA QSR, which require manufacturers, including their suppliers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Medical device reporting, or MDR, regulations, which require that manufacturers report to the FDA, NMPA, and/or PMDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Medical device</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> recalls, wh</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ich require that manufacturers report to the FDA, NMPA, and PMDA any recall of a medical device, provided the recall was initiated to either reduce a risk to health posed by the device, or to remedy a violation of the FDCA, State Decree No. 47, or PMD Act caused by the device that may present a risk to health; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">22</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk126323394" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have registered with the FDA as a medical device manufacturer and a specification developer</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and have obtained a manufacturing license from the California Department of Public Health, or CDPH. The FDA and CDPH have broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of CDPH to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of our suppliers. Additionally, our Registrar, BSI, regularly inspects our manufacturing, design and operational facilities to ensure ongoing ISO&#160;13485 compliance. Further, in February 2024, the FDA issued a final rule replacing the QSR with the Quality Management System Regulation, or QMSR, which incorporates by reference the quality management system requirements of ISO 13485:2016. The FDA has stated that the standards contained in ISO 13485:216 are substantially similar to those set forth in the existing QSR. This final rule does not go into effect until February 2026. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We maintain a Foreign Manufacturer Registration with Japan&#8217;s MHLW which requires assessment of the quality system by PMDA on an ongoing basis. We also maintain a DMAH in the Japanese market that has been appropriately recognized by MHLW, which oversees quality management and operations in the Japanese market for our products licensed in Japan. Similarly, we maintain a legal agent in the Chinese market that has been appropriately recognized by NMPA, which oversees quality management and operations in the Chinese market for our products licensed in China.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, NMPA, or PMDA, which may include any of the following sanctions:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Warning letters, fines, injunctions, consent decrees and civil penalties;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Repair, replacement, refunds, recall or seizure of our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating restrictions, partial suspension or total shutdown of production;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Refusing our requests for submissions, including 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products, or license modifications;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Withdrawing 510(k) clearance or premarket approvals that have already been granted; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Criminal prosecution.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk94622929" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Compliance</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our compliance organization is designed to support our growing organization through an effective Corporate Compliance Program based on our legal and regulatory environment. Our compliance and ethics programs support our key business objectives, identify legal and ethical behavior boundaries through our code of conduct, and establish a system to inform leadership. Primary responsibilities of our compliance organization are as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Healthcare compliance program development and implementation;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Existing program evaluation through risk assessment and internal audits;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Compliance issue investigation and remediation;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate compliance training and education; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">HIPAA privacy training.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk126160481" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Health Insurance Portability and Accountability Act</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, established federal protection for the privacy and security of health information. Under HIPAA, the Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information used or disclosed by &#8220;Covered Entities,&#8221; including healthcare providers and their Business Associates. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. The privacy </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">23</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">regulations protect medical records and other protected health information by limiting their use and release, giving patients the right to access their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security policies and procedures. HIPAA requires Covered Entities to execute Business Associate Agreements with their Business Associates and subcontractors, who provide services to Covered Entities and who need access to protected health information. In addition, companies that would not otherwise be subject to HIPAA may become contractually obligated to follow HIPAA requirements through agreements with Covered Entities and Business Associates, and some of our customers may require us to agree to these provisions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, HIPAA and other federal privacy regulations, such as Section 5 of the Federal Trade Commission Act, there are a number of state laws regarding the privacy and security of health information and personal data that apply to us. The compliance requirements of these laws, including additional breach reporting requirements, and the penalties for violation vary widely, and new privacy and security laws in this area are evolving. Requirements of these laws and penalties for violations vary widely.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we or our operations are found to be in violation of HIPAA, HITECH, or their implementing regulations, we may be subject to penalties, including civil and criminal penalties, fines, and exclusion from participation in federal or state healthcare programs, and the curtailment or restructuring of our operations. HITECH increased the civil and criminal penalties that may be imposed against Covered Entities, their Business Associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">U.S. Federal, State and Foreign Fraud and Abuse Laws</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal and state governments have enacted, and actively enforce, a number of laws to address fraud and abuse in federal healthcare programs. Our business is subject to compliance with these laws.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Anti-Kickback Statutes</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including, for example, gifts, certain discounts, the furnishing of free supplies, equipment or services, credit arrangements, payment of cash and waivers of payments. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered businesses, the statute has been violated. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties per violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines and imprisonment. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid. In addition, some kickback allegations have been claimed to violate the Federal False Claims Act.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Office of Inspector General, or OIG, of the HHS has issued a series of regulations known as &#8220;safe harbors.&#8221; These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is per se illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy an applicable safe harbor may result in increased scrutiny by government enforcement authorities such as OIG.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of recipients for healthcare products or services reimbursed by any source, not only government healthcare programs, and may apply to payments made directly by the patient.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Government officials have focused their enforcement efforts on the marketing of healthcare services and products, among other activities, and recently have brought cases against companies, and certain individual sales, marketing and executive personnel, for allegedly offering unlawful inducements to potential or existing customers in an attempt to procure their business.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">24</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Federal False Claims Act</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal False Claims Act, or FCA, imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">qui tam</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> provisions of the FCA allow a private individual to bring actions on behalf of the federal government alleging that the defendant has violated the FCA and to share in any monetary recovery. In addition, various states have enacted false claims laws analogous to the FCA, and many of these state laws apply where a claim is submitted to any third-party payer and not only a federal healthcare program.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">When an entity is determined to have violated the FCA, it may be required to pay up to three times the actual damages sustained by the government, plus civil fines and penalties for each false claim, subject to adjustment for inflation. As part of any settlement, the government may require the entity to enter into a corporate integrity agreement, which imposes certain compliance, certification and reporting obligations. There are many potential bases for liability under the FCA. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The federal government has used the FCA to assert liability on the basis of kickbacks, or in instances in which manufacturers have provided billing or coding advice to providers that the government considered to be inaccurate. In these cases, the manufacturer faces liability for &#8220;causing&#8221; a false claim. In addition, the federal government has prosecuted companies under the FCA in connection with off-label promotion of products. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products and the sale and marketing of our products may be subject to scrutiny under these laws.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Civil Monetary Penalties</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Civil Monetary Penalty Act of 1981 imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Open Payments</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Physician Payments Sunshine Act, known as &#8220;Open Payments&#8221; and enacted as part of the Affordable Care Act, requires </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Failure to submit required information on time may result in civil monetary penalties with additional amounts for knowingly failing to submit payment information. We are subject to Open Payments and the information we disclose may lead to greater scrutiny, which may result in modifications to established practices and additional costs. Additionally, similar reporting requirements have also been enacted on the state level domestically, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with healthcare professionals.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Foreign Corrupt Practices Act</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, if any, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">International Laws</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outside of the United States, we are subject to medical device laws and other applicable laws in countries where we operate or commercialize our medical devices. In addition to medical device laws, various countries have adopted anti-</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">25</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">bribery laws providing for severe consequences in the form of criminal penalties and significant fines for individuals or companies committing a bribery offense. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For instance, in the United Kingdom, under the U.K. Bribery Act 2010, a bribery occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the U.K. Bribery Act 2010. An individual found in violation of the U.K. Bribery Act 2010, faces imprisonment of up to ten years. In addition, the individual can be subject to an unlimited fine, as can commercial organizations for failure to prevent bribery.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There are also international privacy laws that impose restrictions on the access, use, and disclosure of health information. All of these laws may impact our business. Our failure to comply with these privacy laws or significant changes in the laws restricting our ability to obtain required patient information could significantly impact our business and our future business plans.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk125819364" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">U.S. Centers for Medicare and Medicaid Services</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Medicare is a federal program administered by the U.S. Centers for Medicare and Medicaid Services through fiscal intermediaries and carriers. Available to individuals age 65 or over, and certain other individuals, the Medicare program provides, among other things, healthcare benefits that cover, within prescribed limits, the major costs of most medically necessary care for such individuals, subject to certain deductibles and copayments.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CMS has established guidelines for the coverage and reimbursement of certain products and procedures by Medicare. In general, in order to be reimbursed by Medicare, a healthcare procedure furnished to a Medicare beneficiary must be reasonable and necessary for the diagnosis or treatment of an illness or injury, or to improve the functioning of a malformed body part. The methodology for determining coverage status and the amount of Medicare reimbursement varies based upon, among other factors, the setting in which a Medicare beneficiary received healthcare products and services. Any changes in federal legislation, regulations and policy affecting CMS coverage and reimbursement relative to the procedure using our products could have a material effect on our performance.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CMS also administers the Medicaid program, a cooperative federal/state program that provides medical assistance benefits to qualifying low income and medically needy persons. State participation in Medicaid is optional, and each state is given discretion in developing and administering its own Medicaid program, subject to certain federal requirements pertaining to payment levels, eligibility criteria and minimum categories of services. The coverage, method and level of reimbursement vary from state to state and is subject to each state&#8217;s budget restraints. Changes to the availability of coverage, method or level of reimbursement for TCAR may affect future revenue negatively if reimbursement amounts are decreased or discontinued.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All CMS programs are subject to statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings, interpretations of policy, intermediary determinations, and government funding restrictions, all of which may materially increase or decrease the rate of program payments to healthcare facilities and other healthcare providers, including those paid for TCAR.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">United States Health Reform</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Changes in healthcare policy could increase our costs, decrease our revenue and impact sales of and reimbursement for our current and future products. The ACA substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payers and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The implementation of the Affordable Care Act in the United States, for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">26</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">significantly. The Affordable Care Act also provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research, and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, the Affordable Care Act has expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. We do not yet know the full impact that the Affordable Care Act will have on our business. There have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect additional challenges and amendments </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in the future. It is unclear how efforts to repeal and replace the ACA will impact the healthcare industry or our business operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2032, unless Congress takes additional action. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payers to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the rates we will be able to charge for our current and future products or the amounts of reimbursement available for our current and future products from governmental agencies or third-party payers. Current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Human Capital</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our mission is to help deliver brighter patient outcomes - one procedure at a time. We recognize that our employees are key to our ability to achieve this mission and believe our employees have been and will continue to be a primary reason for our growth and success.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Recognizing the importance of our human capital, our board of directors, through the compensation committee, retains direct oversight of our human capital and oversees and reviews our culture, policies, and strategies related to human capital management, including with respect to diversity and inclusion initiatives, pay equity, talent, recruitment and development, performance management and employee engagement.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a certified Great Place to Work,</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> which certification is the only recognition based entirely on what employees report about their workplace experience. 97% of our employees say Silk Road Medical is a great place to work, compared to 57% of employees at a typical U.S.-based company, according to a Great Place To Work</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2023 Global Employee Engagement Study. We take pride in our company culture to ensure a sense of support and family among our employees.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our Cartwheel Culture: Building and Supporting Human Capital </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We understand the commitment our employees make to our company, and we take our commitment to them very seriously. Consistent with this commitment, we strive to create a work environment in which everyone is empowered to develop, to contribute, and to thrive. We strongly believe our corporate culture is the operating system that powers the company. We talk about it, obsess over it, and have even given it a name &#8211; Cartwheel Culture. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Cartwheel Culture is uniquely ours, and it&#8217;s one we love and nurture every day. Our Cartwheel Culture provides a shared set of beliefs that drives everyday behaviors. These include: </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#9642;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Courage: We think big. We act boldly. We take on new challenges. We challenge ourselves and our colleagues to try new things that are difficult. We take smart risks. We explore new ideas and do things differently. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#9642;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Focus on Core Strength: We unleash our strengths and shore up weaknesses in our company, in every department and in each member of our company. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#9642;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Flexibility: We view opportunities and challenges from all angles&#8230;even upside down. We explore all possibilities and are both willing and able to respond to changing circumstances and expectations. We make it a priority to listen and understand other people&#8217;s ideas and viewpoints. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">27</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#9642;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lend a Hand: We actively support each other to achieve our common goal. Teamwork Matters. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#9642;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Persistence: We believe that innovation comes from persistence and learning from our mistakes. We are persistent in the pursuit of our goals and believe that it&#8217;s better to try and sometimes fail than to sit tight and fail for sure. We learn from the mistakes we make and move forward. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Code of Business Conduct and Business Ethics</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All employees are expected to conduct business with the highest standards of business ethics. Each employee receives and agrees to follow our Code of Business Conduct and Ethics. Our Code of Business Conduct and Ethics does more than just codify rules of conduct - it is the very foundation by which we conduct business every day. The Code of Business Conduct and Ethics, which also applies to our board members, describes how we put our values into practice, and it explains our commitments, our expectations and provides guidance for our employees and all others who work on our behalf. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our employees receive annual training on our Code of Business Conduct and Ethics. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have an open access policy, signifying that employees are encouraged to discuss any related concerns with management or report concerns anonymously through an Integrity Helpline. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Number of Employees, Tenure and Turnover</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our workforce consists of a highly-skilled, diverse, and engaged team dedicated to the company&#8217;s mission and goals. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we had 474 active employees, all located within the United States, of whom 264 employees were engaged in sales, general and administrative activities, 95 were engaged in research and development activities, and 115 were engaged in manufacturing operations. During 2023, the number of employees increased by 60, or nearly 15%. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None of our employees are represented by a labor union, and we have never experienced any employment-related work stoppages. We consider our relationship with our employees to be good. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, 28% of our employees had been with Silk Road Medical for more than four years. While fluctuations may occur within our workforce from time to time, we track and attempt to manage our attrition rates and also analyze employee departure data so that we can continually improve upon our employee experience. During 2023, our employee turnover rate related to voluntary terminations was approximately 8%, which was 3% lower than the prior year.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Commitment to Diversity, Equity, and Inclusion </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We strive to create an inclusive work environment that represents the diversity in the communities where we live and work, and we are proud of the diversity throughout our entire organization. In late 2022, we formed a Diversity, Equity, and Inclusion (DEI) Council with the mission of fostering an environment that is inclusive and welcoming to all. The Council started work with a climate assessment survey and baseline training to bring awareness, engage employees on the topic of inclusion, and create a common language. The Council&#8217;s work expanded in 2023 with a focus on employee education, cultural awareness, and DEI awareness in our HR and marketing programs.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, women made up approximately 46% of our workforce, including 38% of our senior level leaders and 48% of our total corporate leaders. People of color made up approximately 44% of our workforce, including 21% of our senior level leaders and 27% of our total corporate leaders.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our workforce spans approximately four generations. Baby Boomers make up about 10% of our workforce, GenX makes up about 46% of our workforce, Millennials make up about 38% of our workforce, and GenZ makes up about 6% of our workforce.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that it is important to have a balanced and diverse board of directors and are committed to building and maintaining director diversity with members who bring a range of expertise, perspectives, experiences, and personal characteristics pertaining to age, race, gender, and ethnicity. As of December 31, 2023, our board of directors, which consisted of eight members, included two female directors and two directors who self-identify as an underrepresented minority.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, we actively recruit candidates from a variety of backgrounds and work to ensure a fair interview and selection process. We are also active in building a diverse pipeline of candidates through our Summer @ the Road internship program. We have partnered with organizations such as East Side Prep in East Palo Alto, California, and diversity groups at several universities from which we recruit students. In 2023, we had 13 interns with 77% being people of color and 67% of engineering interns being women. Five interns accepted full-time jobs starting in 2024. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">28</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Commitment to Creating a Safe, Healthy, and Secure Work Environment </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are committed to providing a safe, healthy and secure work environment for all employees and visitors. Safety is extremely important to the company.&#160;We have developed and implemented several health and safety programs throughout our facilities with employees&#8217; safety in mind. These programs include an Injury and Illness Prevention/AWAIR Program, an Emergency Action Plan, an Ergonomic Program, an Exposure Control Plan, a Hazard Communication Program, a Hazardous Waste Management Program, and other specialized safety programs. We support these programs and allot time for safety training. In addition, any employee working in a hospital operating room is required to wear a dosimetry badge that monitors occupational radiation exposure to ensure compliance with annual limits. Our Employee Safety Committee reviews performance monthly to discuss trends and risks, as well as opportunities for improvement. We have in place an Employee Emergency Response Team comprised of volunteers trained in First Aid, CPR, AED operation and site-specific emergency procedures. We are proud of our safety record. During 2023, our total recordable injury rate was 1.1, which is below the average for the medical device manufacturing industry. The total recordable injury rate is a standard metric comparing recordable injury rate per 100 employees.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Commitment to Competitive and Fair Compensation </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We place a focus on attracting and retaining talented and experienced individuals to manage and support our operations and </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">believe that employees should be compensated fairly for their contributions to the company. To ensure we pay our employees competitively, annual benchmarking is completed on all positions throughout the company and we use external benchmarking surveys to guide our assessment of compensation competitiveness. Our compensation program consists of three primary components: base salary, annual bonus targets (non-sales), commission plans (sales), and equity. We also offer all eligible employees the option to participate in our Employee Stock Purchase Plan or ESPP. Participants in the ESPP may purchase our common stock at a 15% discount to market price. We believe our ESPP plan, along with our new hire equity grants and refresh equity grants, helps to build an ownership mindset amongst our participating employees.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Commitment to the Health and Wellbeing of our Employees</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">One of our top priorities is to maintain the health and well-being of our employees and their families. We offer a comprehensive health and wellness program with a variety of options for eligible employees. Health benefits include three medical plans, dental, and vision insurance. The company covers 90% of health care premiums on behalf of our employees. Financial wellness benefits include life and disability insurance, flexible spending accounts, a health savings account with generous employer funding, a 401(k)-retirement savings program with a company match, paid time off for employees in non-exempt positions, flexible time away for employees in exempt positions, and 160 hours of child bonding pay. Additional wellness discounts and perks are offered through our health carriers. Well-being offerings include an employee assistance program, a fitness benefit of $50 a month to be used toward the fitness method of choice, a company wellness app with fitness challenges and monetary incentives, and flexible work arrangements for positions that can be performed remotely from one of our primary work locations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Commitment to Learning and Development; Succession Planning</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that the professional development of our employees is a critical element to the success of our company. We have invested in a robust learning and development program that provides employees at all levels of the company opportunities to build and grow their skills in their current roles and prepare them for future roles in the company. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have an extensive training and development program in place for our salesforce that includes a robust clinical training continuum for our therapy development specialists, area managers, and area directors. Upon hire, these employees attend a training program that includes intensive clinical/practical application training the observation of live TCAR cases, followed by intermediate training with advanced clinical education. Employees in these roles also attend regular continuing education courses on clinical topics to ensure their knowledge is current.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also actively support the professional education of employees throughout the organization, with a special focus on leadership development. We've both internally developed and thoughtfully sourced respected external programming to provide intrapersonal development as well as classes to support key professional skill sets for daily tasks, including software tools and applications. Development opportunities are thoughtfully scheduled and promoted to reach all employees with in-person classes in both physical sites and virtual class opportunities to serve the field-based employee population.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On an annual basis, our leadership team participates in talent planning exercises to identify organizational priorities, potential successors, and development needs. This practice enables us to identify the resources and skill sets needed to </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">29</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">meet our growth objectives. Our board of directors also conducts an annual talent management review, focusing on the development of talent, diversity, and succession planning for critical positions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Employee Engagement</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We provide all employees with the opportunity to share their opinions and feedback on our culture through an engagement survey that is generally performed every year. Results of the engagement survey are measured and analyzed to enhance the employee experience, promote employee retention, drive change, and leverage the overall success of our organization. Our strong employee response was indicative of our engagement, with 82% of employees participating in the most recent survey.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Commitment to Corporate Philanthropy </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Through our corporate philanthropy program, Lend a Hand, we are committed to supporting social causes and educational initiatives that help build stronger and healthier communities. Over the years, we have been involved in a variety of projects, including holiday gift drives, school backpack drives, the hand-making and donation of blankets to a local rehabilitation and healthcare center near our Sunnyvale, California headquarters, participation in the Stroke Awareness Foundation&#8217;s Fight Stroke Walk, and building bikes for underprivileged children. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Additional Information</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additional information about our human capital and people, including our culture; employee health and safety; diversity, equity and inclusion; talent attraction, retention and development; employee wellness; and community involvement and engagement, is included in our most recent Corporate Responsibility Report, which is available under the Corporate Governance section on our website. Information contained or referenced on our website is not incorporated by reference and does not form a part of this Annual Report on Form 10-K.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Corporate Information</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We were incorporated in Delaware on March 21, 2007 as Silk Road Medical, Inc. Our principal executive offices are located at 1213 Innsbruck Drive, Sunnyvale, California 94089, and our telephone number is (408) 720-9002. Our website address is </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">www.silkroadmed.com</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.  </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Available Information</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We file electronically with the SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make available on our investor relations website at https://investors.silkroadmed.com/, free of charge, copies of these reports and other information as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that information we post on social media channels could be deemed to be material information. The information on, or that may be accessed through, our website and social media channels is not incorporated by reference into this Annual Report on Form 10-K and should not be considered a part of this Annual Report on Form 10-K.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span id="Section5" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1A. Risk Factors</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition, results of operations and future growth prospects. Our business could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations and future prospects. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes. Please also see &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Summary of Principal Risk Factors</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">30</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following risks and uncertainties are among the most significant we face. However, the risks and uncertainties identified in this subsection are not the only ones we face and are qualified in their entirety by reference to all of the risk factors as further described in this Item 1A.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Business</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have a history of net losses, and we expect to incur operating losses in the future and we may not be able to achieve or sustain profitability.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on, and currently sell products to enable, TCAR, which is our only product offering.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business is dependent upon the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">total market opportunity for TCAR and our ability to penetrate it through continued adoption of TCAR by hospitals and physicians.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adoption of TCAR depends upon positive clinical data and medical society recommendations, and negative clinical data or medical society recommendations would adversely affect our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Global supply chain constraints and constrained labor markets have resulted and could continue to result in the inability of our suppliers to deliver finished goods, components, sub-assemblies or materials to us on a timely basis or at all.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on Cordis to supply the ENROUTE stent, and if Cordis fails to supply the ENROUTE stent in sufficient quantities or at all, it will have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General macroeconomic factors, including inflation, price pressures and recessionary pressures, could increase our manufacturing costs and operating expenses or lower demand for our TCAR products and have a material adverse impact on our financial condition and results of operations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we are not able to obtain or maintain adequate levels of third-party coverage and reimbursement for the procedures using our products, if third parties rescind or modify their coverage, or if patients are left with significant out-of-pocket costs, it would have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we fail to comply with our obligations in our intellectual property license from Cordis, we could lose license rights that are important to our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR involves surgical risks and is contraindicated in certain patients, which may limit adoption.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We face manufacturing risks that could adversely affect our ability to manufacture products, reduce our gross margins and negatively affect our business and operating results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We depend on a limited number of single-source suppliers to manufacture our components, sub-assemblies, materials and products, including Cordis, which makes us vulnerable to supply shortages and price fluctuations that could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We face risks related to health epidemics and other outbreaks, such as possible resurgences of COVID-19 and the spread of new variants, which may negatively impact our business and operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The market for our products is highly competitive. If our competitors are able to develop or market carotid artery disease treatments that are safer, more effective or gain greater acceptance in the marketplace than any products we develop, our commercial opportunities will be reduced or eliminated.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are highly dependent upon our sales personnel. In addition, during 2023, we expanded our sales and marketing infrastructure, including the number of sales personnel and sales territories, to help us drive and </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">31</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">support revenue growth. These changes naturally result in some sales disruption, which disruption adversely affected our revenue in various periods throughout 2023 and may continue to adversely affect our revenue through the first half of 2024.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our actual operating results have differed in the past, and in the future may differ, significantly from our guidance, which has caused, and could continue to cause, the market price of our common stock to decline.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our failure to manage the transition associated with our Chief Executive Officer, retain our existing senior management team, or continue to attract qualified new personnel could have a material adverse effect on our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 9pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Intellectual Property</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our success depends on our ability to obtain, maintain and protect our intellectual property rights.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 5.600in;">Risks Related to Government Regulation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Healthcare policy changes, including legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products have in the past and could in the future be subject to product recalls that could harm our reputation or increase the probability of inspection by, or additional scrutiny from, the FDA or other relevant regulatory bodies.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in the CMS fee schedules </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and other reimbursement requirements, such as those in revised NCD 20.7, may affect our hospital customers and thereby harm our revenue and operating results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Business</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have a history of net losses, and we expect to incur operating losses in the future and we may not be able to achieve or sustain profitability.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have incurred net losses since our inception in March 2007. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the year ended December 31, 2023, we had a net loss of $55.7 million </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and we expect to continue to incur additional losses in the future. As of December 31, 2023, we had an accumulated deficit of $399.5 million. To date, we have financed our operations primarily through equity and debt financings and from sales of our portfolio of TCAR products. The losses and accumulated deficit have primarily been due to the substantial investments we have made to develop our products, as well as for costs related to general research and development, including clinical and regulatory initiatives to obtain marketing approval, sales and marketing efforts, investments in manufacturing and distribution capacity, and other infrastructure improvements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the next several years, we expect to continue to devote a substantial amount of our resources to increase adoption of TCAR using our products, expand commercialization efforts in the United States and select international markets, improve and expand reimbursement for TCAR, conduct clinical studies, and develop additional products. No assurance can be provided that our strategic initiatives will be successful or lead us to profitability. In addition, as a public company, we incur significant legal, accounting, director and officer liability insurance and other expenses, all of which continue to increase.</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to generate sufficient revenue from our existing products or from any of our products in development, to transition to profitability and generate consistent positive cash flows, is uncertain. Accordingly, we expect to continue to incur operating losses for the foreseeable future and we cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will sustain profitability. Our failure to achieve and sustain profitability in the future or within a timeline expected by investors will make it more difficult to finance our business and accomplish our strategic objectives, which would have a material adverse effect on our business, financial condition and results of operations and cause the market price of our common stock to decline.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">While we believe we will continue to grow our revenues, we may be unable to sustain our historical revenue growth.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our revenue from sales of our TCAR products has grown in each of the fiscal years since we began commercialization in 2015 and we believe it will continue to grow. Historically, we have experienced significant revenue growth but we may not achieve similar growth rates in future periods. You should not rely on our operating results for any </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">32</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">prior quarterly or annual period as an indication of our future operating performance. Our ability to increase our revenue in future periods at our historical growth rates, or at all, will depend primarily on our ability to increase sales of our TCAR products, which, in turn, will depend in part on our success in growing our customer base and reorders from those customers. We may not be able to generate, sustain or increase revenue from our TCAR products on a quarterly or annual basis. If we cannot achieve or sustain revenue growth for an extended period, our operating results may be adversely affected and our stock price may decline. In addition, a significant amount of our operating expenses are relatively fixed due to our manufacturing, research and development, and sales and general administrative efforts. Any failure to adjust spending quickly enough to compensate for a shortfall relative to our anticipated revenue could magnify the adverse impact of such shortfalls on our results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We rely on, and currently sell products to enable, TCAR, which is our only product offering.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To date, all of our revenue has been derived, and we expect it to continue to be derived in the near term, from sales of our products that enable TCAR. TCAR is a relatively new treatment option for certain patients diagnosed with carotid artery disease and, as a result, physician awareness of TCAR and our products, and experience with TCAR and our products, is limited. A number of factors that are outside of our control may contribute to fluctuations in our financial results, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Physician experience and hospital demand for our products and the extent of adoption of TCAR, including the rate at which physicians recommend our products and TCAR to their patients;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Failure of our products that enable TCAR to significantly penetrate the target markets;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delays in, or failure to supply product, component and material deliveries by our third-party suppliers;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Positive or negative media coverage, or public, patient and/or physician perception, of our products and TCAR or competing products and procedures;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any product quality, recall, safety or effectiveness concerns that arise regarding our products or TCAR;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unanticipated delays in product development or product launches;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to maintain our current or obtain further regulatory clearances or approvals;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adequate levels of third-party coverage and reimbursement for the procedures using our products; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Introduction of new products, procedures or drugs for treating carotid artery disease that compete with our products and the TCAR procedure, including without limitation, the approval or substitution of other stents that could be used in TCAR procedures and the effect of competing products on the average selling prices of our products,</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and changes in reimbursement for our products and competing products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">It is therefore difficult to predict our future financial performance and growth, and such forecasts are inherently limited and subject to a number of uncertainties. If our assumptions regarding the market opportunity for TCAR or the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, because we devote substantially all of our resources to our products that enable TCAR and rely on our products and the adoption of TCAR as our sole source of revenue, any factors that negatively impact our products or TCAR, or result in a decrease in sales of products, could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our business is dependent upon the </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">total market opportunity for TCAR and our ability to penetrate it through continued adoption of TCAR by hospitals and physicians.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our future growth and profitability largely depend on </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the total market opportunity for TCAR, the determination of which is inherently imprecise, and our ability to penetrate it, which is largely dependent upon our ability to increase physician awareness and adoption of TCAR and on the willingness of physicians to recommend the procedure to more of their patients. While we are confident in our estimate of the annual total addressable market for our TCAR products, especially since it is based on a number of internal and third-party estimates, it may prove to be incorrect. If the actual number of patients who would benefit from our products and the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. With respect to our ability to </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">33</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">penetrate this market opportunity, physicians may not use our products unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our products provide a safe and effective treatment alternative for carotid artery disease. Even if we are able to raise awareness and increase adoption of TCAR among physicians, physicians tend to be slow in changing their medical treatment practices and may be hesitant to select our products or TCAR for recommendation to patients for a variety of reasons, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Long-standing relationships with competing companies and distributors that sell other products, such as stents and embolic protection devices for CAS;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Competitive response and negative selling efforts from providers of alternative carotid revascularization products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Perceived liability risk generally associated with the use of new products and procedures;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lack or perceived lack of sufficient clinical evidence, including long-term data or a randomized controlled trial, supporting clinical benefits;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lack of experience with TCAR as a treatment alternative to CEA;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Familiarity and experience with CEA, and reluctance to change to or use new products and procedures; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Time commitment and skill development that may be required to gain familiarity and proficiency with TCAR and our products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">While we believe the revised </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NCD 20.7 for Percutaneous Transluminal Angioplasty </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">will lead to benefit carotid artery disease awareness in general and help grow the overall carotid intervention market, which would be a potential positive for all carotid interventions, including TCAR, no assurance can be provided that this will prove true. In addition, while we believe the higher associated procedural stroke risk for transfemoral carotid artery stenting and steep learning curve will continue to limit the pool of eligible patients and skilled interventionalists, thereby limiting the growth potential for transfemoral CAS in the near term, no assurance can be provided that this will prove true either. During CMS review of the clinical literature and as suggested by the Multispecialty Carotid Alliance, or MSCA, CMS considered evidence published from the ACT I, CREST (long-term results), SPACE-2 and ACST-2 randomized controlled trials of CAS versus CEA, amongst other datasets. As well, in November 2023, preliminary results of newer CAS technologies in the PERFORMANCE II and C-Guardians IDE studies were presented at the late-breaking trials session Vascular InterVentional Advances, or VIVA, conference. Physicians may find these data compelling and may be more willing to try the newer transfemoral CAS products at the expense of our TCAR procedure, especially in the near term and as a result of revised NCD 20.7. Accordingly, </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">it is possible that </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we may experience increased future competition from </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">stents and embolic protection devices for CAS</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> based on the revised NCD 20.7,</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> which could adversely affect our revenue, other financial results and business</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Physicians play a significant role in determining the course of a patient&#8217;s treatment for carotid artery disease and, as a result, the type of treatment that will be recommended or provided to a patient. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This is particularly true in light of the new requirement in revised NCD 20.7 which requires a practitioner to engage in a shared </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">decision-making interaction with the beneficiary prior to furnishing CAS. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We focus our sales, marketing and education efforts primarily on vascular surgeons, and aim to educate referring physicians such as internal medicine specialties, cardiologists, radiologists, neurologists, and general practitioners regarding the patient population that would benefit from TCAR. However, we cannot assure you that we will achieve broad education or market acceptance among these practitioners. For example, if diagnosing physicians who serve as the primary point of contact for patients are not made aware of TCAR, they may not refer patients to physicians for treatment using our products, and those patients may instead not seek treatment at all or may be treated with alternative procedures. In addition, some physicians may choose to utilize TCAR on only a subset of their total patient population or may not adopt TCAR at all. If a physician experiences an adverse event in one or more of their TCAR patients or elects to convert TCAR to CEA mid-procedure, they may not continue offering and performing TCAR at the same rate or at all. Further, TCAR may not fit into the workstreams of certain physicians. If we are not able to effectively demonstrate that TCAR is beneficial in a broad range of patients, adoption of TCAR will be limited and may not occur as rapidly as we anticipate, which would have a material adverse effect on our business, financial condition and results of operations. We cannot assure you that TCAR or our products will achieve broad market acceptance among hospitals and physicians. Any failure of TCAR or our products to satisfy demand or to achieve meaningful market acceptance and penetration will harm our future prospects and have a material adverse effect on our business, financial condition and results of operations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, the medical device industry&#8217;s relationship with physicians is under increasing scrutiny by the Health and Human Services Office of the Inspector General, or OIG, the Department of Justice, or DOJ, state attorneys general, and other foreign and domestic government agencies. Our failure to comply with laws, rules and regulations governing our </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">34</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general or other government agencies, could significantly harm our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In most cases, before physicians can use our products for the first time, our products must be approved for use by a hospital&#8217;s new product or value analysis committee, or the staff of a hospital or health system. Following such approval, we may be required to enter into a purchase contract. Such approvals or requirements to enter into a purchase contract could deter or delay the use of our products by physicians. We cannot provide assurance that our efforts to obtain such approvals, enter into purchase contracts, or generate adoption will be successful or increase the use of our products, and if we are not successful, it could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, if patient receptivity toward TCAR becomes less favorable in the future, this shift could negatively impact market acceptance of TCAR. Any negative change due to patient receptivity could also be compounded by patients reporting to physicians or other patients through word-of-mouth or social media.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Finally, the total market opportunity for TCAR could decrease if glucagon-like peptide (GLP-1) agonists are prescribed more broadly and result in less cardiovascular disease including carotid artery disease and overall fewer strokes over the long term.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span id="_Hlk149155474" style="text-decoration: none;"></span><span id="_Hlk133497518" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Adoption of TCAR depends upon positive clinical data and medical society recommendations, and negative clinical data or medical society recommendations would adversely affect our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The rate of adoption of TCAR and sales of our products that facilitate the procedure is heavily influenced by clinical data. Although the Society for Vascular Surgery&#8217;s Vascular Quality Initiative contains real world data retrospectively comparing carotid revascularization procedures including TCAR, we have not conducted a randomized clinical trial of TCAR or head-to-head clinical trials to prospectively compare TCAR to the procedures historically available to patients, such as CEA or CAS, which may limit the adoption of TCAR. Additionally, the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis 2, or CREST-2, clinical trial currently funded by the National Institutes of Health, is ongoing and is designed to compare the effectiveness of each of CEA and CAS, in parallel randomized trials, with best medical therapy alone in standard surgical risk asymptomatic patients with carotid artery disease. The CEA trial completed enrollment in the fourth quarter of 2023. We project the CAS trial to complete enrollment later in 2024 followed by a mean follow-up period of four years. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The national principal investigators have stated that results will not be published until 2026. After the follow-up period post final enrollment, the trial could conclude that medical management alone achieves the same or better therapeutic results as CEA and/or CAS, which could have an adverse impact on the adoption of TCAR. Finally, our competitors and third parties may also conduct clinical trials of our products without our participation. Unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us, our competitors or third parties, the interpretation of our or other clinical data or findings of new or more frequent adverse events, could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span id="_Hlk149155805" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As physicians are influenced by guidelines issued by physician organizations, such as the Society for Vascular Surgery, the rate of adoption of TCAR and sales of our products that facilitate the procedure are also influenced by medical society recommendations. We believe the Society for Vascular Surgery&#8217;s Clinical Practice Guidelines, or SVS Guidelines, are of importance to the broader market acceptance of TCAR. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The revised SVS Guidelines on the management of carotid artery disease were published in June 2021. Like previous versions of the guidelines, the revised SVS Guidelines generally discuss CAS, and embolic protection methods, including flow reversal. The revised SVS Guidelines do state that</span><span style="white-space:pre-wrap; color: #818181;font-family: Calibri-Bold;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR is preferred over CEA and CAS in anatomically or physiologically high surgical risk patients, whether symptomatic or asymptomatic. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If subsequent versions of the SVS Guidelines do not recommend TCAR, or if the Society for Vascular Surgery issues a negative or more limited statement regarding TCAR, physicians may not adopt or continue to use TCAR or our products at the same rate or at all, which would have a material adverse effect on our business, financial condition and results of operations. Additionally, if key opinion leaders who currently support TCAR cease to recommend TCAR or our products, our business, financial condition and results of operations will be adversely affected. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Adoption of TCAR depends upon appropriate physician training, and inadequate training may lead to adverse patient outcomes, adversely affect adoption of TCAR and adversely affect our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The success of TCAR depends in part on the skill of the physician performing the procedure and on our customers&#8217; adherence to appropriate patient selection and proper techniques provided in training sessions conducted by our training faculty. For example, we train our customers to ensure correct use of our ENROUTE NPS and proper deployment of our ENROUTE stent. However, physicians rely on their previous medical training and experience when performing TCAR, and we cannot guarantee that all such physicians will have the necessary surgical and endovascular skills to perform the procedure. While we mandate physician attendance at our TCAR training program or training with proctors, we do not control which physicians perform TCAR or how much training they receive. Physicians who have not completed our </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">35</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">training sessions may nonetheless attempt to perform TCAR. If physicians perform TCAR in a manner that is inconsistent with its labeled indications, with components that are not our products or without adhering to or completing our training sessions, their patient outcomes may not be consistent with the outcomes achieved in our and other clinical trials, studies or registries of TCAR. This result may negatively impact the perception of patient benefit and safety and limit adoption of TCAR and our products that facilitate the procedure, which would have a material adverse effect on our business, financial condition and results of operations. Additionally, hospitals and physician organizations may adopt physician credentialing guidelines requiring TCAR training that is more extensive than our training program. If physicians conclude that we do not provide adequate TCAR training, they may be less likely to adopt TCAR and our products, which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Global supply chain constraints and constrained labor markets have resulted and could continue to result in the inability of our suppliers to deliver finished goods, components, sub-assemblies or materials to us on a timely basis or at all, which would adversely affect our business, financial condition and results of operations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may not be able to maintain an adequate supply of the components, sub-assemblies and materials that are used to manufacture our TCAR products as well as to support our research and development activities for new products. F</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">or example, certain liners and shrink tubing components used in both the ENROUTE stent and the ENROUTE NPS have been in short supply and delivery of these materials have been delayed from time to time, which could result in manufacturing delays for our TCAR products.&#160;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In particular, we are concerned with the ability of a critical supplier of certain polymer tubing materials used in our products to provide us and our third party manufacturer these polymer tubing materials on a timely basis. If this supplier is unable to provide these polymer tubing materials on a timely basis, it could result in TCAR product delays to our customers, which, in turn, would adversely affect our results of operations. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Similarly, we rely on Lake Region Medical for our supply of guidewires, Nordson Medical for our balloon catheters, and Galt Medical for our transcarotid access kits, which have also been in short supply from time to time.</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> If there were a shortage of supply, the cost of components, sub-assemblies and materials may increase </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">or we may need to pay a premium to obtain sufficient supply, either of which could</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> harm our ability to provide our product</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s on a cost-effective basis or at all, or we may experience delays in providing our TCAR products to our customers. We also may experience delays in and increased costs for our research and development programs and clinical trials due to the inability to obtain the necessary materials to advance these programs and trials. In connection with any supply shortages, reliable and cost-effective replacement sources may not be available on short notice or at all, and this may force us to increase prices and face a corresponding decrease in demand for our TCAR products, or force us to absorb these increased costs. Our suppliers may also be impacted by supply or labor shortages which may delay or impact the availability of the components, sub-assemblies and materials needed to manufacture our TCAR products. In the event that any of our suppliers experience supply or labor shortages, delays, or were to reduce, or discontinue, production of our key product components, sub-assemblies or the materials used in our TCAR products, developing alternate sources of supply for these items would be time consuming, difficult and costly. If we or one of our suppliers were to experience a supply shortage with our components, sub-assemblies and the materials or labor necessary to manufacture our TCAR products our reputation in the market, demand for our TCAR products and our operating results may be significantly and adversely affected and new products may be delayed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We rely on Cordis to supply the ENROUTE stent, and if Cordis fails to supply the ENROUTE stent in sufficient quantities or at all, it will have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on Cordis to manufacture the ENROUTE stent pursuant to a supply agreement, and as such, Cordis is our sole supplier of this product. While we strive to maintain an inventory of several months&#8217; worth of ENROUTE stents to guard against potential shortfalls in supply, no assurance can be provided that this strategy will be sufficient. If we were to experience a shortfall or issue with the supply of ENROUTE stents by Cordis, we estimate that it would take up to two years or more to find an alternative supplier for our ENROUTE stent and multiple years to identify and seek approval for a different carotid stent. In addition, Cordis currently manufactures the ENROUTE stent at a facility in Juarez, Mexico. This facility has previously and in the future could become subject to a COVID-19 or other outbreak which would cause Cordis to temporarily shut down manufacturing operations, which would in turn present risk to the ongoing supply of our stents used in TCAR procedures. If Cordis&#8217;s ability to manufacture the ENROUTE stent is interrupted as a result or for any other reason, including, for example, its inability to obtain necessary or sufficient components or products from other third parties, or if Cordis experiences a product recall, cash flow or liquidity issues or breaches its supply agreement with us, we may not have a sufficient number of stents for delivery to support TCAR procedures. Any shortfall in the supply of ENROUTE stents may result in lower adoption rates for TCAR, fewer TCAR procedures being performed generally, and a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">General macroeconomic factors, including inflation, price pressures, and recessionary risks, could increase our manufacturing costs and operating expenses or lower demand for our TCAR products and have a material adverse impact on our financial condition and results of operations. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">36</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The risk of a sustained economic downturn or recession and other macroeconomic factors could adversely affect customer demand for our TCAR products, or otherwise have an adverse impact on our results of operations and financial condition. We continuously monitor the effects of inflationary factors, such as increases in our cost of goods sold and selling and operating expenses, which may adversely affect our results of operations. Specifically, we are experiencing inflationary and price pressures and increased labor costs and labor and staffing shortages, affecting the cost of the components for our TCAR products and the wages that we pay our employees, as well as the wages our vendors pay their employees, due to challenging labor market conditions.&#160;Competitive, macroeconomic and regulatory conditions restrict our ability to fully recover, such as increased costs through price increases, higher costs of acquired goods and services resulting from inflation, other drivers of cost increases or reduced demand for TCAR products.&#160;We may be unable to pass these increased costs along to our customers or fully offset the impact of persistent inflation or a recession. Our inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations or cause us to need to obtain additional capital earlier than anticipated. General macroeconomic factors also may affect our customers, vendors and suppliers and their ability to pay us or continue to supply us products and services, which could also adversely affect our results of operations or financial condition.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="_Hlk133497979" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are not able to obtain or maintain adequate levels of third-party coverage and reimbursement for the procedures using our products, if third parties rescind or modify their coverage, or if patients are left with significant out-of-pocket costs, it would have a material adverse effect on our business, financial condition and results of operations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR is currently covered under certain circumstances for certain patients by the Centers for Medicare and Medicaid Services, or CMS, under a National Coverage Determination, and has been covered by some commercial payers, independent networks and other entities not governed by the National Coverage Determination. In the United States, we derive our revenue from sales to hospitals and medical centers, which typically bill all or a portion of the costs and fees associated with our products to various third-party payers, including Medicare, Medicaid, Veterans&#8217; Administration, private commercial insurance companies, health maintenance organizations and other healthcare-related organizations, and then bill patients for any applicable deductibles or co-payments. For example, our contracts are with the hospitals and medical centers that purchase our products for use with TCAR and not with the commercial payers. As a result, access to adequate coverage and reimbursement for our products by third-party payers is essential to the acceptance of our products by our customers.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">However, in the United States, there is no uniform policy of coverage and reimbursement for medical device products and services among third-party payers, so coverage and reimbursement can differ significantly from payer to payer, and each coverage decision and level of reimbursement is independent. As a result, third-party reimbursement may not be available or adequate for our products, and there is no guarantee that we will be able to maintain our current levels of coverage or reimbursement or be able to expand coverage to other insurance carriers. Further, payers continually review new technologies for possible coverage and can, without notice, deny or limit coverage for products and procedures or delay coverage approval until further clinical data are available. As a result, the coverage determination, technology assessment, and coverage reconsideration processes are often time-consuming and costly processes that may require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained. If third-party reimbursement is not available or adequate for TCAR procedures using our products, or if there is any decline in the amount that payers are willing to reimburse our customers for TCAR, new customers may not adopt, or may reduce their rate of adoption of, our products and we could experience additional pricing pressure, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Products for carotid stenting including our TCAR products are covered for Medicare beneficiaries under certain circumstances under NCD 20.7 for Percutaneous Transluminal Angioplasty. Coverage for non-Medicare patients depends upon commercial and other payer policies.</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Medicare program is administered by CMS and the Medicare Administrative Contractors, or MACs, which make determinations regarding Medicare hospital and physician coverage and payment. CMS reimburses hospital inpatient services based on Medicare Severity Diagnosis Related Groups, or MS-DRGs. All CAS, TCAR and CEA procedures are currently paid only as Medicare inpatient procedures. CMS&#8217;s policy focus on hospital price transparency, site (e.g. inpatient, outpatient, ambulatory surgery center and office) neutral payments and MS-DRG refinements may place additional downward pressure on future hospital inpatient payments. Medicare payments to physicians are based on a Resource Based Relative Value System. CMS&#8217;s policy changes to adjust or reallocate reimbursement between primary care services and specialty services may result in reductions in the payment rate for procedures involving our products. As a result of any reductions in payments to hospitals and physicians for TCAR procedures, TCAR utilization may decline, which would have a material adverse effect on our business, financial condition and results of operations. Additionally, patients may elect to reduce or defer out-of-pocket costs during times of economic uncertainty or periods of legislative change. If hospital, physician and/or patient demand for TCAR, and thus our products that facilitate the procedure, are adversely affected by third-party reimbursement policies and decisions, it will have a material adverse effect on our business, financial condition and results of operations.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">37</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CMS released the final decision update to NCD 20.7, expanding the Medicare coverage of carotid artery stenting.</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> CMS determined that coverage of percutaneous transluminal angioplasty, or PTA, of the carotid artery concurrent with stenting is reasonable and necessary with the placement of a FDA approved carotid stent with a FDA-approved or cleared embolic protection device, for Medicare beneficiaries in patients with symptomatic carotid artery stenosis &#8805;50% and in patients with asymptomatic carotid artery stenosis &#8805;70% under the following conditions: </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurological assessment must be performed by a neurologist or NIH stroke scale (NIHSS) certified health professional before and after CAS.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">First-line evaluation of carotid artery stenosis must use duplex ultrasound.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Computed-tomography angiography (CTA) or magnetic resonance angiography (MRA), if not contraindicated, must be used to confirm degree of stenosis, and provide information about the aortic arch, and extra and intra-cranial circulation.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(4)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intra-arterial digital subtraction (catheter) angiography may be used only when there is significant discrepancy between non-invasive imaging results or contraindicated for CTA or MRA.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prior to furnishing CAS, the practitioner must engage in a shared decision-making interaction with the beneficiary. The shared decision-making interaction must include:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion of all treatment options for carotid stenosis including, carotid endarterectomy (CEA), CAS (which includes TCAR), and optimal medical therapy (OMT).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Explanation of risks and benefits for each option specific to the beneficiary&#8217;s clinical condition.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Integration of clinical guidelines (e.g., patient co-morbidities and concomitant treatments).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(4)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion and incorporation of beneficiary&#8217;s personal preferences and priorities in choosing a treatment plan. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facilities must establish and maintain institutional and physician standards to support a dedicated carotid stent program. However, CMS facility approval or certification is not required. The Medicare Administrative Contractors will have discretion to make carotid artery stenting coverage determinations not addressed in NCD 20.7. While we believe the revised NCD 20.7 will benefit carotid artery disease awareness in general and help grow the overall carotid intervention market, which would be a potential positive for all carotid interventions, including TCAR, no assurance can be provided that this will prove true. In addition, while we believe the higher associated procedural stroke risk for transfemoral carotid artery stenting and steep learning curve will continue to limit the pool of eligible patients and skilled interventionalists, thereby limiting the growth potential for transfemoral CAS in the near term, no assurance can be provided that this will prove true either.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Internationally, reimbursement systems in foreign markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country basis. In certain international markets, a product must be approved for reimbursement before it can be approved for sale in that country. Additionally, many international markets have government-managed healthcare systems that control reimbursement for products and procedures. In most markets there are both private insurance systems and government-managed systems. If sufficient levels of coverage and reimbursement are not available for TCAR or our current or future products, in either the United States or internationally, the demand for our products and our revenues will be adversely affected.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, when payers combine their operations, the combined company may elect to reimburse for TCAR at the lowest rate paid by any of the participants in the consolidation or use its increased size to negotiate reduced rates. If one of the payers participating in the consolidation does not reimburse for TCAR at all, the combined company may elect not to reimburse for TCAR, which would adversely impact our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we fail to comply with our obligations in our intellectual property license from Cordis, we could lose license rights that are important to our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a party to a license agreement with Cordis, under which Cordis has granted us a worldwide, non-exclusive, perpetual, royalty-bearing license, without the right to sublicense, to certain of its intellectual property related to the PRECISE&#174; carotid stent for transcervical treatment of carotid artery disease with an intravascular stent for certain applications for accessing blood vessels through the neck and cervical area. Our license agreement with Cordis imposes, and we expect that any future license agreements will impose, certain diligence, royalty, and other obligations on us. If we fail to comply with these obligations, our licensors, including Cordis, may have the right to reduce the scope of our rights or terminate these agreements, in which event we may not be able to develop and market any product that is covered by these agreements. Termination of this license for failure to comply with such obligations or for other reasons, or reduction, elimination or expiration of our licensed rights under it or any other license or agreement, may result in our having to negotiate new or reinstated licenses on less favorable terms or our not having sufficient intellectual property rights to operate our business or cause us to enter into new licenses for different stents. The occurrence of such events could materially harm our business and financial condition.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">38</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors, including Cordis, to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. In some cases we do not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span id="_Hlk133498804" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">TCAR involves surgical risks and is contraindicated in certain patients, which may limit adoption.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risks of TCAR using our products include the risks that are common to surgical and endovascular procedures, including perforation, dissection, embolization, bleeding, infection, nerve injury and restenosis. Endovascular procedures occurring in the carotid arteries also include the additional risks of stroke, heart attack and death. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risks of using our products in TCAR include risks that are common to surgical and endovascular procedures and are detailed in the FDA-approved and FDA-cleared labeling. Major adverse events associated with all carotid interventions include stroke, heart attack and death. These risks may prevent widespread market adoption in the absence of adequate physician training on our products and in appropriate patient selection.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our current products are contraindicated, and therefore should not be used, in certain patients. Our ENROUTE NPS is contraindicated in patients in whom antiplatelet and/or anticoagulation therapy is contraindicated; patients with uncorrected bleeding disorders; patients with severe disease of the ipsilateral common carotid artery; and patients with uncontrollable intolerance to flow reversal. Our ENROUTE stent is contraindicated in patients in whom antiplatelet and/or anticoagulation therapy is contraindicated; patients in whom the ENROUTE NPS is unable to be placed; patients with uncorrected bleeding disorders; patients with known allergies to nitinol; and patients with lesions in the ostium of the common carotid artery. Our ENHANCE peripheral access kit is contraindicated in patients with a known or suspected obstruction in the vessel. Our ENROUTE guidewire is contraindicated in patients judged not acceptable for percutaneous intervention. Our ENROUTE Enflate RX Balloon Dilatation Catheter is contraindicated for use in coronary arteries. Generally, further contraindications include, but may not be limited to: patients with highly calcified lesions resistant to PTA; patients with a target lesion with a large amount of adjacent acute or sub-acute thrombus; patients with uncorrected bleeding disorders; and patients that have not been anti-coagulated. Additionally, patients who lack at least five centimeters of common carotid artery free of significant disease are not indicated for our ENROUTE NPS.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We face manufacturing risks that could adversely affect our ability to manufacture products, reduce our gross margins and negatively affect our business and operating results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business strategy depends on our ability to manufacture, and our contract manufacturers&#8217; ability to manufacture, our current and future products in sufficient quantities and on a timely basis to meet customer demand, while adhering to product quality standards, complying with regulatory quality system requirements and managing manufacturing costs. We have facilities located in Sunnyvale, California, and in Plymouth, Minnesota, where we currently assemble and package certain of our products, and inspect, release and ship all of our products. If our or our manufacturing partners&#8217; facilities suffers damage, or a force majeure event, this could materially impact our ability to operate.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are also subject to numerous other risks relating to our manufacturing capabilities, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Quality and reliability of components, sub-assemblies and materials that we source from third-party suppliers, who are required to meet our quality specifications, the majority of which are our single-source suppliers for the products they supply;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our or our manufacturing partners&#8217; inability to secure components, sub-assemblies and materials in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our or our manufacturing partners&#8217; inability to maintain compliance with quality system requirements or pass regulatory quality inspections;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our or our manufacturing partners&#8217; failure to develop products in a timely manner or to required specifications or to increase production capacity or volumes to meet demand;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our or our manufacturing partners&#8217; inability to design or modify production processes to enable us to produce future products efficiently or implement changes in current products in response to design or regulatory requirements; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternative suppliers for components in a timely manner.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">39</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As demand for our products increases, we will have to invest additional resources to purchase components, sub-assemblies and materials, hire and train employees, and enhance our manufacturing processes. If we or our manufacturing partners fail to increase our production capacity efficiently, we may not be able to fill customer orders on a timely basis, our sales may not increase in line with our expectations, and our operating margins could fluctuate or decline. In addition, although we expect some of our products in development to share product features, components, sub-assemblies and materials with our existing products, the manufacture of these products may require modification of our or our manufacturing partners&#8217; current production processes or unique production processes, the hiring of specialized employees, the identification of new suppliers for specific components, sub-assemblies and materials or the development of new manufacturing technologies. It may not be possible for us or our manufacturing partners to manufacture these products at a cost or in quantities sufficient to make these products commercially viable or to maintain current gross margins, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We depend on a limited number of single-source suppliers to manufacture our components, sub-assemblies, materials and products, including Cordis, which makes us vulnerable to supply shortages and price fluctuations that could have a material adverse effect on our business, financial condition and results of operations</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on single-source suppliers for the components, sub-assemblies and materials for our products, such as our ENROUTE stent and for certain key components, sub-assemblies and materials for our ENROUTE NPS</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> In addition</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, we rely on Lake Region Medical to supply our guidewires, Nordson Medical for our balloon catheters, and Galt Medical for our transcarotid access kits. These components, sub-assemblies and materials are critical and there are relatively few alternative sources of supply. We have not qualified or obtained necessary regulatory approvals for additional suppliers for most of these components, sub-assemblies and materials, and we do not carry a significant inventory for some of these items. While we believe that alternative sources of supply may be available, we cannot be certain whether they will be available if and when we need them, or that any alternative suppliers would be able to provide the quantity and quality of components and materials that we would need to manufacture our products if our existing suppliers were unable to satisfy our supply requirements. To utilize other supply sources, we would need to identify and qualify new suppliers to our quality standards and obtain any additional regulatory approvals required to change suppliers, which could result in manufacturing delays and increase our expenses. Our manufacturing partners, including Cordis, rely on single-source suppliers as well, and are subject to the foregoing risks.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our and our manufacturing partners&#8217; dependence on third-party suppliers subjects us to a number of risks that could impact our ability to manufacture our products and harm our business, financial condition and results of operations, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interruption of supply resulting from modifications to, or discontinuation of, a supplier&#8217;s operations;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delays in product shipments resulting from uncorrected defects, reliability issues or a supplier&#8217;s failure to produce components that consistently meet our quality specifications;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inability to obtain adequate supply in a timely manner or on commercially reasonable terms due to global supply chain constraints or other factors;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Difficulty identifying and qualifying alternative suppliers for components in a timely manner;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inability of suppliers to comply with applicable provisions of the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA&#8217;s Quality System Regulation, or QSR, or other applicable laws or regulations enforced by the FDA and other state and applicable regulatory authorities;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inability to adequately ensure the quality of products and components manufactured by third parties;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Production delays related to the evaluation and testing of products and components from alternative suppliers and corresponding regulatory qualifications;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delays in delivery by our suppliers due to changes in demand from us or their other customers;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delays or inability of suppliers to provide products and components due to cash flow or liquidity issues; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An outbreak of disease or similar public health threat, such as the ongoing threat of new COVID-19 variants, particularly as it may impact our supply chain.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">40</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we require our third-party suppliers to supply us with components that meet our specifications and comply with applicable provisions of the QSR and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to ensure the components meet our requirements, there is a risk that our suppliers will not always act consistent with our best interests, and may not always supply components that meet our requirements or supply components in a timely manner. For example, in the first quarter of 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by Cordis. Our decision to recall these lots was based on complaints we received about tips detaching from the stent delivery system as well as internal testing that we conducted. We determined the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification. Recalls like this one could cause the supply of our TCAR products to customers to be interrupted, us to incur additional expenses, have to purchase replacement products, negative publicity or damage to our reputation, any of which could cause our results of operations to be adversely impacted.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We face risks related to health pandemics, epidemics and other outbreaks, such as COVID-19 and its variants, which may negatively impact our business and operations</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business has been in the past and in the future could be adversely impacted by the effects of health pandemics, epidemics and other outbreaks, such as COVID-19 and its variants, including through:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Postponement of TCAR procedures by physicians or their patients in response or the diversion of resources to treat patients with conditions deemed higher priority;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Hospital staffing shortages which may result in fewer diagnoses and a lower number of TCAR procedures performed;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restrictions on hospital capacity, or other resource constraints, such as the availability of contrast dye, that may cause problems for hospitals scheduling or rescheduling TCAR procedures;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Limitations in hospital or employee resources that would otherwise be focused on performing TCAR procedures;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients who may be reluctant to visit their physicians at their offices or in hospitals;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Physicians not performing as many diagnostic tests for their patients and closures, staffing shortages, or reduced hours of the labs where these tests are performed, which may translate into fewer than expected TCAR procedures being performed throughout various periods of the pandemic;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delays in enrollment in our clinical trials, including our ROADSTER 3 trial, which is related to our standard surgical risk post-approval study;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Governmental mandates which may impact our personnel and personnel at third-party manufacturing facilities, and the availability or cost of materials, which could disrupt our supply chain and/or reduce our margins;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delays in necessary interactions with local regulators, ethics committees and other third parties and contractors due to limitations in employee resources or forced furlough of government employees;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unavailability of key personnel or large groups of our employees due to an outbreak;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intermittent travel restrictions and restrictive hospital policies impacting our sales professionals and therapy development specialists who support them;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Competition for operating room and hybrid operating rooms within hospitals that are resource constrained or have dedicated certain resources only to outbreak patients;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The spread of new virus variants and varying infection and related hospitalization rates which increase the volatility and uncertainty in the expected number of TCAR procedures and demand for our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Hospitals cancelling and deferring elective surgeries, which reduces their revenue and impacts their financial results, which could result in pricing pressure on our products as they seek cost savings;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">41</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Hospitals having issues with cash flow or ceasing doing business due to the impact of the pandemic on their operations, which could reduce the number of hospitals where TCAR is performed and adversely affect our ability to collect amounts due to us and our revenue as a result;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The effect of an outbreak on our anticipated international expansion or regulatory approvals in some countries;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Hospitals restricting or limiting access for non-patients, including our sales professionals and therapy development specialists, or our sales personnel choosing not to enter hospitals, which could negatively impact our access to physicians and their staff.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on suppliers, vendors, outsourcing partners, consultants, alliance partners and other third parties to research, develop, manufacture and commercialize our products and manage certain parts of our business. Using these third parties poses a number of risks, such as: (i) they may not perform to our standards or legal requirements; (ii) they may not produce reliable results; (iii) they may not perform in a timely manner; (iv) they may not maintain confidentiality of our proprietary information; (v) disputes may arise with respect to ownership of rights to technology developed with our partners; and (vi) disagreements could cause delays in, or termination of, the research, development or commercialization of our products or result in litigation or arbitration. Moreover, some third parties are located in markets subject to political and social risk, corruption, violence, infrastructure problems and natural disasters, in addition to country-specific privacy and data security risk given current legal and regulatory environments. Failure of third parties to meet their contractual, regulatory, and other obligations may materially affect our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions, but keep limited components, sub-assemblies, materials and finished products on hand. To ensure adequate inventory supply and manage our operations with our manufacturing partners and suppliers, we forecast anticipated materials requirements and demand for our products in order to predict inventory needs and then place orders with our suppliers based on these predictions. Our ability to accurately forecast demand for our products would be negatively affected by many factors, including our rapid growth, product recalls, pandemics, failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products, our failure to accurately forecast customer acceptance of new products, changes to hospital capacity, staffing, procedure and protocol changes, unanticipated changes in general market conditions or regulatory matters, weakening of economic conditions or consumer confidence and the realization of other risks as described in this section.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs. Conversely, if we underestimate customer demand for our products or our own requirements for components, sub-assemblies and materials, our manufacturing partners and suppliers may not be able to deliver components, sub-assemblies and materials to meet our requirements. If we do not have adequate supply of components, sub-assemblies and materials there may be interruptions, delays or cancellations of deliveries of our TCAR products to our customers, any of which would damage our reputation, customer relationships and business. In addition, several components, sub-assemblies and materials incorporated into our products require lengthy order lead times, and additional supplies or materials may not be available when required on terms that are acceptable to us or our manufacturing partners, or at all, and our manufacturing partners and suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, any of which could have an adverse effect on our ability to meet customer demand for our products and our results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our quarterly and annual results of operations, including our revenue, net income or net loss and cash flow, may vary significantly in the future, and period-to-period comparisons of our operating results may not be meaningful. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Fluctuations in quarterly and annual results may decrease the value of our common stock. Because our quarterly results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business and should only be relied upon as one factor in determining how our business is performing.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">42</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our actual operating results </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">have differed in the past, and in the future may differ, significantly from our guidance and/or analyst expectations, which has caused in the past and could again cause in the future the market price of our common stock to decline.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, we release guidance regarding our future performance, such as our anticipated annual revenue, that represents our management&#8217;s estimates as of the date of release. This guidance, which consists of forward-looking statements, is prepared by our management and is qualified by, and subject to, the assumptions and the other information contained or referred to in the release. Our guidance is not prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants, and neither any independent registered public accounting firm nor any other independent expert or outside party compiles, examines or reviews the guidance and, accordingly, no such person expresses any opinion or any other form of assurance with respect thereto.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our guidance is based upon a number of assumptions and estimates that, while presented with numerical specificity, is inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. We generally state possible outcomes as high and low ranges which are intended to provide a sensitivity analysis as variables are changed but are not intended to represent that actual results could not fall outside of these ranges. The principal reason that we release this data is to provide a basis for our management to discuss our business outlook with analysts and investors. Analysts and others also publish financial projections or forecasts from time to time. We do not accept any responsibility for any projections or reports published by any such persons.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions of the guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Actual results will vary from the guidance and the variations may be material. Investors should also recognize that the reliability of any forecasted financial data will diminish the farther in the future that the data are forecast. In light of the foregoing, investors are urged to put the guidance in context and not to place undue reliance on it.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any failure to successfully implement our operating strategy or the occurrence of any of the events or circumstances set forth in this Annual Report on Form 10-K could result in the actual operating results being different than our guidance, and such differences may be adverse and material. The failure to achieve such guidance has in the past disappointed and in the future could disappoint investors and analysts and cause the market price of our common stock to decline. While we do not provide quarterly revenue guidance, we lowered our annual revenue guidance in connection with the release of our preliminary third quarter 2023 revenue results in October 2023, which contributed to a significant decrease in our stock price, which has decreased from a 52-week high of $58.04 on January 13, 2023 to a 52-week low of $6.08 on October 26, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have a limited total addressable market based on our current labeling restrictions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The total addressable market for TCAR is limited by a number of factors. The safety and effectiveness of certain products for TCAR has not been established for certain patients. For example, the FDA-cleared labeling for the ENROUTE NPS states that patients should have at least five centimeters of common carotid artery free of significant disease for initial access to the artery and positioning of the ENROUTE NPS sheath. In addition, per the FDA-approved labeling for the ENROUTE stent, TCAR is limited to certain threshold degrees of stenosis depending on symptom and surgical risk status. In addition, physicians may choose to perform CEA in patients with certain anatomical characteristics, including heavily calcified carotid arteries, calcified lesions or severe vessel tortuosity. Finally, current labeling for our products includes contraindications for certain patients, thus further reducing our total addressable market.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Expanding the addressable market for TCAR is dependent upon reimbursement expansion initiatives, </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">favorable data from any post-approval study we or other researchers conduct, and obtaining and maintaining coverage and adequate reimbursement for any new product approvals.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2022, we announced FDA approval of a label expansion for the ENROUTE stent for use in standard surgical risk patients. In June 2022, we </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announced that CMS, through collaboration with the Society for Vascular Surgery&#8217;s Patient Safety Organization and their VQI, has expanded coverage for TCAR to include standard surgical risk patients within the VQI&#8217;s TCAR Surveillance Project. As a condition of FDA approval for such label expansion, we are conducting and currently enrolling patients in a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">prospective, multi-center, single-arm </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">post-approval study, ROADSTER 3, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to assess real-world treatment of standard surgical risk patients with carotid artery disease using TCAR</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the ROADSTER 3 study or other studies conducted by independent researchers or organizations, or complaints or other reports from our customers or patients, reveal a higher rate of adverse events or other unexpected safety or efficacy concerns, FDA may restrict or withdraw the label expansion approval. Any future report or publication raising any material safety or efficacy concerns regarding any of our approved products or approved uses may cause CMS or other payors to modify or restrict their coverage and reimbursement policies for our products and related procedures. If any of these events were to occur, or if </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">43</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we fail to demonstrate continued safety and efficacy for our approved products and their indications, it may have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in public health insurance coverage and government reimbursement rates for the TCAR procedures using our products could affect the adoption of our products and our future revenue</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal government is considering ways to change, and has changed, the manner in which healthcare services are paid for in the United States. Individual states may also enact legislation that impacts Medicaid payments to hospitals and physicians. In addition, CMS establishes Medicare payment levels for hospitals and physicians on an annual basis, which can increase or decrease payment to such entities. Internationally, medical reimbursement systems vary significantly from country to country, with some countries limiting medical centers&#8217; spending through fixed budgets, regardless of levels of patient treatment, and other countries requiring application for, and approval of, government or third-party reimbursement. Even if we succeed in bringing our products to market in foreign countries, uncertainties regarding future healthcare policy, legislation and regulation, as well as private market practices, could affect our ability to sell our products in commercially acceptable quantities at acceptable prices.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and profitability.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In an effort to reduce costs, many hospitals in the United States have become members of Group Purchasing Organizations, or GPOs, and Integrated Delivery Networks, or IDNs. GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer these negotiated prices to affiliated hospitals and other members. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups reduces market prices for our products and/or require administrative fees, thereby reducing our revenue and/or margins.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#8217; notice. Accordingly, the members of such groups may choose to purchase alternative products due to the price or quality offered by other companies, which could result in a decline in our revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not be able to achieve or maintain satisfactory pricing and margins for our products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for our products or maintain prices at the levels we have historically achieved. Any decline in the amount that payers reimburse our customers for TCAR could make it difficult for customers to continue using, or to adopt, our products and could create additional pricing pressure for us. In addition, the introduction of competitive stents that could be used in TCAR procedures and other products could also put pressure on the pricing of our products. If we are forced to lower the price we charge for our products, our gross margins will decrease, which will adversely affect our ability to invest in and grow our business. If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode. We will continue to be subject to significant pricing pressure, which could harm our business and results of operations. Also, our use of distributors in non-U.S. countries may adversely impact our gross margins.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are required to vacate a facility, we may be unable to produce the products we manufacture or we may experience delays in production or an increase in costs, which could adversely affect our results of operations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently maintain a portion of our manufacturing, warehouse, research and development and non-field-based sales, general and administrative operations in a building located in Sunnyvale, California, which is situated on or near earthquake fault lines. We have redundant manufacturing for our ENROUTE NPS at our Plymouth, Minnesota facility. Should either of our facilities be significantly damaged or destroyed by natural or man-made disasters, such as earthquakes, fires, tornados or other events, including climate change-related severe weather or disasters, it could take extensive time to relocate or rebuild, during which time our employees may seek other positions and our research and development would cease or be delayed. While we maintain property and business interruption insurance, such insurance has limits and would only cover the cost of rebuilding and relocating and lost revenue, but not general damage, losses caused by earthquakes, losses we may suffer due to our products being replaced by competitors&#8217; products or loss in value </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">44</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">due to associated decreases in our stock price. The inability to perform our research and development activities, combined with our limited inventory of materials and components and manufactured products, may cause physicians to discontinue using our products or harm our reputation, and we may be unable to reestablish relationships with such physicians in the future. Consequently, a catastrophic event at our facilities could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, we rely on our manufacturing partners to supply certain of our products, and our partners are subject to similar risks with respect to their facilities. If our manufacturing partners&#8217; facilities are damaged or destroyed and their ability to supply products to us is limited, it could negatively affect our reputation, physician relationships and TCAR adoption, all of which could have a material adverse effect on our business, financial condition and results of operations. Several of our products are sterilized at a particular third-party facility, with limited alternate facilities. If an event occurs that results in damage to or closure of one or more of such facilities, we may be unable to sterilize such products at the previous levels or at all. Because of the time required to approve and license a sterilization facility, a third party may not be available on a timely basis to replace capacity in the event sterilization capacity is lost.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we fail in our sales training initiatives, to increase or improve our sales and marketing capabilities or to develop broad brand awareness, our growth will be impeded and our business will suffer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently rely on our direct sales force to sell our products in targeted geographic regions in the U.S., and any failure to continue to hire, train, maintain, motivate and grow our direct sales force could harm our business. Our operating results are directly dependent upon the sales and marketing efforts of our employees. If our direct sales force fails to adequately promote, market and sell our products, our revenue may suffer. The members of our direct sales force are highly trained and possess substantial technical and clinical expertise, which we believe is critical in driving adoption of TCAR. The members of our U.S. sales force are at-will employees. The loss of these personnel to competitors or otherwise could materially harm our business. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical and clinical expertise and qualifications, or if we are unable to successfully instill such technical and clinical expertise in replacement personnel, our revenues and results of operations could be materially harmed. Because the competition for qualified sales personnel is high, we cannot assure you we will be able to hire and retain sales personnel on favorable or commercially reasonable terms, if at all. Failure to hire or retain qualified sales personnel would prevent us from expanding our business and generating revenue. If we are unable to expand our sales and marketing capabilities, we may not be able to effectively commercialize our products, which could have an adverse impact on our business. In addition, the hiring and training of new sales personnel takes time and could adversely affect our revenue and financial results for a particular period, as could changes in our sales territories and sales structure. In addition, we have expanded our sales and marketing infrastructure, including number of sales personnel and sales territories, to help us drive and support revenue growth and we intend to continue this expansion. These changes naturally result in some sales disruption, which disruption adversely affected our revenue in various periods throughout 2023 </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and may continue to adversely affect our revenue through the first half of 2024.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In order to generate future growth, we plan to continue to expand and leverage our sales, marketing, and medical affairs infrastructure to increase our trained physician and hospital customer base and our business. Identifying and recruiting qualified sales, marketing and medical affairs personnel and training them on TCAR, on applicable federal and state laws and regulations, and on our internal policies and procedures requires significant time, expense and attention. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There is significant competition for direct sales personnel with strong sales skills and clinical knowledge and it often takes several months or more before a sales representative is fully trained and productive. Our business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products. In addition, the loss of key sales personnel could impact our physician and customer relationships and future ability to sell to certain accounts covered by such personnel. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time or timely reduce fixed costs, could have a material adverse effect on our business, financial condition and results of operations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, our medical affairs department may not train physicians at a rate sufficient to expand our physician base in a manner consistent with our business plan. Our ability to increase our customer base and achieve broader market acceptance of our products will depend to a significant extent on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. Our business may be harmed if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our brand is critical to achieving broad acceptance of our products and penetrating new accounts. Brand promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of our products.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">45</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The market for our products is highly competitive. If our competitors are able to develop or market carotid artery disease treatments or products that are safer, more effective or gain greater acceptance in the marketplace, than any products we develop, our commercial opportunities will be reduced or eliminated.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our industry is highly competitive, subject to change and significantly affected by new product introductions and other activities of industry participants. Competition in our industry has increased with new technologies and market entrants seeking approvals for carotid disease treatment indications in the U.S. CEA has historically been performed by vascular surgeons as the primary surgical solution for carotid artery disease. The major manufacturers of products, such as patches and shunts, used in connection with CEA include LeMaitre Vascular, Inc., Getinge AB, Baxter International Inc., Terumo Medical Corporation, W.L.Gore and Associates, Inc. and Edwards Lifesciences Corporation. Some competitors market products for use in CAS, such as peripheral access kits, stents, distal and proximal embolic protection devices, guidewires, balloons and sheaths. Such companies include Abbott Laboratories, Boston Scientific Corporation, Cook Medical Inc., Cordis Corporation, Medtronic plc, Terumo Medical Corporation, W.L. Gore and Associates, Inc., Contego Medical Inc. and InspireMD, Inc. Preliminary results from Contego Medical Inc.&#8217;s PERFORMANCE II and InspireMD, Inc.&#8217;s C-Guardians IDE studies were presented at the VIVA conference in November 2023. Abbott Laboratories, Contego Medical Inc. and InspireMD, Inc. have also announced plans to develop products for TCAR. These technologies, other products that are in ongoing clinical trials, new drugs or additional indications for existing drugs could demonstrate better safety, effectiveness, clinical results, lower costs or greater physician and patient acceptance. In addition, physicians may choose to use other company stents and not our ENROUTE stent in connection with TCAR procedures, including a recently approved stent by Abbott Laboratories, or may choose to use products not labeled for TCAR in an off label fashion and competitive companies may promote their CAS products for off-label use in TCAR.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We compete, or may compete in the future, against other companies which have longer operating histories, more established products and greater resources, which may prevent us from achieving significant market penetration or improved operating results. These companies enjoy several competitive advantages, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Greater financial and human capital resources;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Significantly greater name recognition;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Established relationships with vascular surgeons and other treating specialties, referring physicians, customers and third-party payers;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additional lines of products, and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Established sales, marketing and worldwide distribution networks.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because of the size of the market opportunity for the treatment of carotid artery disease, we believe potential competitors have historically dedicated and will continue to dedicate significant resources to aggressively promote their products or develop new products. New treatment options may be developed that could compete more effectively with our products due to the prevalence of carotid artery disease and the extensive research efforts and technological progress that exist within the market. This is particularly true in light of the revised</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> NCD </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.7 &#8211; Percutaneous Transluminal Angioplasty, which expanded reimbursement coverage of transfemoral carotid artery stenting into asymptomatic and standard surgical risk patients and could lead to increased future competition for our TCAR products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our ability to compete depends on our ability to innovate successfully and deliver any new products in a timely manner.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The market for our products is competitive, dynamic, and marked by rapid and substantial technological development and product innovation. New entrants or existing competitors could attempt to develop and introduce products that compete directly with ours. Demand for our products and future related products could be diminished by equivalent or superior products and technologies offered by competitors. If we are unable to innovate successfully, our products could become obsolete and our revenue would decline as our customers purchase our competitors&#8217; products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Developing products is expensive and time-consuming and could divert management&#8217;s attention away from our core TCAR products. However, if we are unsuccessful in developing and commercializing new products, our ability to increase our revenue may be impaired. Even if we are successful in developing additional products, the success of any new product offering or enhancements to existing products will depend on several factors, including our ability to:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">properly identify and anticipate physician and patient needs;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">46</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">develop and introduce new products or product enhancements in a timely but controlled manner;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">avoid infringing upon the intellectual property rights of third-parties;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical trials;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtain the necessary regulatory clearances or approvals for new products or product enhancements;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">be fully FDA-compliant with marketing of new devices or modified products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide adequate training to potential users of our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtain adequate coverage and reimbursement for our customers performing procedures using our products; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">develop an effective and dedicated sales and marketing team for any new products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are currently focused on improving existing products for TCAR, developing new products for TCAR, and developing new products for other disease states beyond carotid artery disease. For example, following receipt of 510(k) clearance from the FDA in September 2022, we initiated a limited market release of our ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter in the fourth quarter of 2022 and a full market release during the second quarter of 2023.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> In addition, we received PMA approval for tapered configurations of our ENROUTE stent in June 2023 and initiated a</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> limited market release in the first quarter of 2024</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">with a full market release planned in the first half of 2024. If we are unable to continue to develop new products, applications or features due to constraints, such as insufficient cash resources, high employee turnover, inability to hire personnel with sufficient technical skills or a lack of other research and development resources, we may not be able to maintain our competitive position compared to other companies. Furthermore, many of our competitors devote a considerably greater amount of funds to their research and development programs than we do, and those that do not may be acquired by larger companies that would allocate greater resources to research and development programs. Our failure or inability to devote adequate research and development resources or compete effectively with the research and development programs of our competitors could harm our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any significant delays in our product launches may significantly impede our ability to enter or compete in a given market and may reduce the sales that we are able to generate from these products. We may experience delays in any phase of a product development, including during research and development, clinical trials, regulatory review, manufacturing and marketing. Delays in product introductions could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, the launch of new products if not timed correctly and if not controlled properly may result in an adverse impact on sales of such new products, as well as sales of our TCAR products. In addition, our new products may not carry the same margins as our current TCAR products, which could adversely affect our gross margins.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Defects or failures associated with our products could lead to additional recalls, safety alerts or litigation, as well as significant costs and negative publicity.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business is subject to significant risks associated with the manufacture, distribution and use of medical devices that are placed inside the human body, including the risk that patients may be severely injured by or even die from the misuse or malfunction of our products caused by design flaws or manufacturing defects. In addition, component failures, design defects, off-label uses or inadequate disclosure of product-related information could also result in an unsafe condition or the injury or death of a patient. These problems could lead to a recall or market withdrawal of, or issuance of a safety alert relating to, our products and could result in significant costs, negative publicity and adverse competitive pressure. For example, in the first quarter of 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by Cordis. The circumstances giving rise to recalls are unpredictable, and any recalls of existing or future products increase the probability of inspection by, or additional scrutiny from, the FDA and could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We provide a limited warranty that our products are free of material defects and conform to specifications, and offer to repair, replace or refund the purchase price of defective products. As a result, we bear the risk of potential warranty claims on our products. In the event that we attempt to recover some or all of the expenses associated with a warranty claim against us from our suppliers or vendors, we may not be successful in claiming recovery under any warranty or indemnity provided to us by such suppliers or vendors and any recovery from such vendor or supplier may not be adequate.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The medical device industry has historically been subject to extensive litigation over product liability claims. Operating in the area of the neck with the brain as the end organ is dangerous and presents risks of adverse events such as bleeding, arterial dissection, cranial nerve injury, myocardial infarction, stroke and death, which subject us to a greater risk </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">47</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of being involved in litigation than companies with products used in less critical areas of the body. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury or death, even if due to physician error. In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, hospitals, physicians or others purchasing or using our products, even if our products were not the actual cause of such injury or death. We may choose to settle any claims to avoid fault and complication not due to failure of our products. An adverse outcome involving one of our products could result in reduced market acceptance and demand for all of our products, and could harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of regulatory reviews of our premarket notifications or applications for marketing. Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we carry product liability insurance in the United States and in other countries in which we conduct business, including for clinical trials and product marketing, we can give no assurance that such coverage will be available or adequate to satisfy any claims. Product liability insurance is expensive, subject to significant deductibles and exclusions, and may not be available on acceptable terms, if at all. If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations. Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management&#8217;s attention from our business and might result in adverse publicity, which could result in reduced acceptance of our products in the market, product recalls or market withdrawals.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are required to file adverse event reports under Medical Device Reporting, or MDR, regulations with the FDA, which reports are publicly available on the FDA&#8217;s website. We are required to file MDRs if our products may have caused or contributed to a serious injury or death or malfunctioned in a way that could likely cause or contribute to a serious injury or death if it were to recur. Any such MDR that reports a significant adverse event could result in negative publicity, which could harm our reputation and future sales.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The failure of TCAR to meet patient expectations or the occurrence of adverse events from TCAR could impair our financial performance.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our future success depends upon patients having an experience with TCAR that meets their expectations in order to increase physician demand for our products as a result of positive feedback, social media and word-of-mouth. Patients may be dissatisfied if their expectations of the procedure and results, among other things, are not met. Despite what we believe to be the safety profile of our products, patients may experience adverse events such as arterial restenosis or dissection, cranial nerve injury, wound complications, transient ischemic attacks, stroke, heart attack, and death. If the results of TCAR do not meet the expectations of patients, or they experience adverse events, it could discourage patients from referring TCAR to others. For example, although we have not received any reports of strokes, deaths or other long-term patient sequelae from the tip detachments that triggered our recent recall, if there were to be patient injury, dissatisfied patients may express negative opinions through social media or we may otherwise suffer reputational damage or become subject to product liability lawsuits. Any failure to meet patient expectations and any resulting negative publicity or lawsuits could harm our reputation and future sales.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our failure to manage the transition associated with our Chief Executive Officer, retain our existing senior management team, or continue to attract and retain qualified new personnel could have a material adverse effect on our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our success depends largely on the continued services of key members of our executive management team and others in key management positions. For example, the services of our new Chief Executive Officer, or CEO, Charles S. McKhann, our Chief Financial Officer and Chief Operating Officer, Lucas W. Buchanan, and our Chief Commercial Officer, Andrew S. Davis, are essential to driving adoption of our products and revenue growth, executing on our corporate strategy and ensuring the continued operations and integrity of financial reporting within our company. Mr. McKhann became CEO on November 2, 2023 succeeding Erica J. Rogers, who retired after having served as CEO and on our board of directors for over 11 years. Our failure to manage this CEO change and transition, retain our existing senior management team, or continue to attract and retain qualified new personnel could have a material adverse effect on our business. In addition, the CEO transition and any related uncertainty regarding our future business direction may be disruptive to our business and our relationships with employees and customers. Additionally, the departure of Ms. Rogers as our former CEO resulted in a loss of institutional knowledge and there can be no assurances that we will be able to mitigate that loss through our transitional consulting arrangement with her. If we are unable to execute an orderly transition, our business may be adversely affected. Furthermore, the success of our business is dependent on the </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">48</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">continuation of an experienced and talented management team. If we were to lose the benefit of the experience, efforts, and abilities of any of our key executives or members of senior management, our business could be adversely affected. While we implemented retention packages for our key executives and employees during 2023, any of our employees may terminate their employment with us at any time and the recent significant decline in the value of long term incentives could also negatively impact our ability to retain key employees. We do not currently maintain key person life insurance policies on any of our employees. If we lose one or more key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, our research and development programs, and sales efforts depend on our ability to attract and retain highly skilled engineers and sales professionals. We may not be able to attract or retain qualified engineers and sales professionals in the future due to the competition for qualified personnel. We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than we do. When we hire employees from competitors or other companies, their former employers have previously and may in the future attempt to assert that these employees or we have breached legal obligations, which may result in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees, particularly in the San Francisco Bay Area, often consider the value of the stock awards they receive in connection with their employment along with salary, benefits and other factors. If the perceived benefits of our stock awards decline, either because we are a public company, the significant drop in our stock price during 2023 or for other reasons, it may harm our ability to recruit and retain highly skilled employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The use, misuse or off-label use of our products may result in injuries that lead to product liability suits, which could be costly to our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The ENROUTE stent has been approved by the FDA for the treatment of patients who require carotid revascularization and meet certain treatment parameters. If physicians expand the patient population in which they elect to use our products that is outside of the intended use approved by the FDA, then the use, misuse, or off-label use of our products may result in outcomes and adverse events including stroke, myocardial infarction and death, potentially leading to product liability claims. However, we cannot prevent a physician from using our products for off-label applications or using components or products that are not our products when performing TCAR. In addition, we cannot guarantee that physicians are trained by us or their peers prior to utilizing our products. Complications resulting from the use of our products off-label or use by physicians who have not been trained appropriately, or at all, may expose us to product liability claims and harm our reputation. Moreover, if the FDA determines that our promotional materials or physician training, including our paid consultants&#8217; educational materials, constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to enforcement action, including warning letters, untitled letters, fines, penalties, or seizures. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines and/or other penalties against companies for alleged improper promotion and has investigated, prosecuted, and/or enjoined several companies from engaging in off-label promotion.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, if our products are defectively designed, manufactured or labeled, contain defective components or are misused, we may become subject to costly litigation initiated by physicians, hospitals or patients. Product liability claims are especially prevalent in the medical device industry and could harm our reputation, divert management&#8217;s attention from our core business, be expensive to defend and may result in sizable damage awards against us. Although we maintain product liability insurance, we may not have sufficient insurance coverage for future product liability claims. We may not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. Any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation, significantly increase our expenses, and reduce product sales. Product liability claims could cause us to incur significant legal fees and deductibles and claims in excess of our insurance coverage would be paid out of cash reserves, harming our financial condition and operating results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our past growth has provided, and our future growth may create, challenges to our organization. The number of our employees has increased significantly during the past several years and in the future, we expect to hire and train new personnel as we continue to grow and expand our operations. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any growth that we experience in the future will require us to expand our sales, general and administrative personnel, manufacturing and distribution operations, and facilities and information technology, or IT, and infrastructure. In addition to the need to scale our organization, future growth will </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">49</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. Rapid expansion in personnel could mean that less experienced people manufacture, market and sell our products, which could result in inefficiencies and unanticipated costs, reduced quality and disruptions to our operations. In addition, rapid and significant growth may strain our administrative and operational infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As demand for our products or any of our future products increases, we will need to continue to scale our capacity, expand customer service, billing and systems processes and enhance our internal quality assurance program. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs or inability to meet increased demand. If we encounter difficulty meeting market demand, quality standards or physician expectations, our reputation could be harmed and our business could suffer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may need substantial additional funding and may not be able to raise capital when needed, which could force us to delay, reduce or eliminate our product development programs and commercialization efforts.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that our cash and cash equivalents and investments, together with our expected revenue, will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months. However, we have based these estimates on assumptions that may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect. Our future funding requirements will depend on many factors, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The degree and rate of market acceptance of TCAR and our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The total market opportunity for our products and our ability to penetrate and capture market share from other competing products and technologies;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to continue to grow our revenues and maintain pricing and gross margins, especially in light of increased competition or investor perception thereof;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The effect of competing technologies and products on our business, operating results and prospects, or other adverse market developments;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The scope and timing of investment in and the future success of our sales force, marketing initiatives and physician training programs; </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The scope, rate of progress and cost of our research and development activities, current or future clinical studies and additional regulatory clearances or approvals; </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The scope and timing of investment in acute ischemic stroke and other neurovascular and cardiac products we may develop;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The rate at which we expand internationally and our ability to launch and sell our products successfully in such markets;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Whether we acquire third-party companies, products or technologies;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restructuring, refinancing or repayment of debt;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The costs associated with any future product recall that may occur;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The costs of attaining, defending and enforcing our intellectual property rights;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The emergence of competing technologies or other adverse market developments; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The impact of health pandemics, epidemics and other outbreaks, such as COVID-19 and its variants, on our business and operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may seek to raise additional capital through equity offerings or debt financings and such additional financing may not be available to us on acceptable terms, or at all. In addition, any additional equity or debt financing that we raise may </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">50</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">contain terms that are not favorable to us or our stockholders. For example, if we raise funds by issuing equity or equity-linked securities, the issuance of such securities could result in dilution to our stockholders. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, the terms of debt securities issued or borrowings could impose significant restrictions on our operations including restrictive covenants, such as limitations on our ability to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, and other operating restrictions that could adversely affect our ability to conduct our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms, such as relinquishment or licensing of certain technologies or products that we otherwise would seek to develop or commercialize ourselves, or reserve for future potential arrangements when we might otherwise be able to achieve more favorable terms. In addition, we may be forced to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to us.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we are unable to obtain adequate financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products. If this were to occur, our ability to grow and support our business and to respond to market challenges could be significantly limited, which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we had an aggregate of approximately $75.0&#160;million in principal outstanding under our Loan Agreement with Oxford Finance. We must make significant interest-only monthly payments under the Loan Agreement, and the term loans outstanding under the Loan Agreement will begin to amortize in equal monthly installments beginning in July 2026 (unless we elect to extend the interest-only period by another year), which will divert resources from other activities. Our obligations under the Loan Agreement are collateralized by substantially all of our assets and we are subject to customary affirmative and negative covenants, including covenants limiting our ability and the ability of our subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type. The covenants related to the Loan Agreement, as well as any future financing agreements into which we may enter, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies. While we have not previously breached and are not currently in breach of these or any other covenants contained in our Loan Agreement, there can be no guarantee that we will not breach these covenants in the future. Our ability to comply with these covenants may be affected by events beyond our control, and future breaches of any of these covenants could result in a default under the Loan Agreement. If not waived, future defaults could cause all of the outstanding indebtedness under the Loan Agreement to become immediately due and payable, termination of commitments to extend further credit, a 5% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement. If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, our assets could be foreclosed upon and we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business as a going concern.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Adverse developments with respect to the stability of financial institutions we do business with, or unstable banking, credit and/or capital market conditions generally, or the perception thereof, could adversely affect our ability to access cash, obtain additional financing, restructure or refinance our indebtedness, or meet our liquidity and debt service requirements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure could materially and adversely affect our liquidity, financial condition, results of operations, business and stock price. Last year&#8217;s closures of Silicon Valley Bank, Signature Bank and First Republic Bank and their placement into receivership with the Federal Deposit Insurance Corporation, or FDIC, has created bank-specific and broader financial institution liquidity risk and concerns. Although the Department of the Treasury, the Federal Reserve, and the FDIC jointly released a statement that depositors at Silicon Valley Bank and Signature Bank would have access to their funds, even those in excess of the standard FDIC insurance limits, and such access to date by us to our cash and cash equivalents held at SVB has been uninterrupted, future adverse developments with respect to specific financial institutions or the broader </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">51</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">financial services industry may lead to market-wide liquidity shortages. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, a portion of our cash and cash equivalents was maintained with SVB and exceeded federally insured limits. Substantially all of our cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. As of the issuance date of this Annual Report on Form 10-K, we have not experienced any losses on our deposits and all of our cash deposited with SVB has been accessible to us, although no assurance can be provided that we will not experience any future losses on our deposits or access to our cash equivalents and investments. As of December 31, 2023, our cash equivalents and investments are invested in highly rated money market funds, U.S. treasury bills, U.S. government securities, commercial paper, corporate bonds/notes, and agency bonds/notes. Uncertain financial markets, or a U.S. sovereign default or threat thereof, could result in a tightening in the credit markets, a reduced level of liquidity in many financial markets, and extreme volatility in fixed income and credit markets. The credit ratings of securities in our investments could deteriorate and may have an adverse impact on the carrying value of these investments. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any such failure may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank or lender that has failed or is otherwise distressed or if other banks and financial institutions enter receivership or become insolvent in the future, we may experience delays or other issues in accessing our cash and meeting our financial obligations. In addition, any future unstable banking, credit and/or capital market conditions could also adversely affect our ability to obtain additional financing, restructure or refinance our indebtedness, if needed, or meet our liquidity and debt service requirements or the ability of our suppliers, vendors, customers and others in which we do business to do any of the foregoing with respect to their respective businesses.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may acquire other companies or technologies, or enter into license agreements, distribution arrangements or strategic partnerships, which could fail to result in a commercial product or generate sales, divert our management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we currently have no agreements or commitments to complete any such transactions, we may in the future seek to acquire, license or invest in businesses, products or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities. We could also seek to enter into distribution arrangements or strategic partnerships with third parties that we believe could increase our revenue or offer other commercial benefits. However, we cannot assure you that we would be able to successfully complete any acquisition, license agreement or distribution agreement we choose to pursue, or that we would be able to successfully integrate any business or product or technology in a cost-effective and non-disruptive manner. Similarly, we cannot guarantee that we would derive benefits from any distribution arrangement or other strategic partnership. The pursuit of potential acquisition, license or partnering opportunities may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable transactions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or strategic partners, or be successful in entering into an agreement with any particular target or partner, or obtain the expected benefits of any acquisition, license, investment or other strategic partnership arrangement.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies. We may not be able to successfully integrate any acquired personnel, operations and technologies, or effectively manage the combined business following an acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results. In addition, if an acquired business, product or technology fails to meet our expectations, our operating results, business and financial condition may suffer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span id="_Hlk133502198" style="text-decoration: none;"></span><span id="_Hlk155599440" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our ability to utilize our net operating loss carryforwards may be limited. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we had U.S. federal and state net operating loss carryforwards, or NOLs, of $332.0&#160;million and $288.6 million, respectively. Our U.S. federal NOLs arising in tax years ending on or before December 31, 2017 are subject to expiration and will begin to expire in 2027 (U.S. federal NOLs, and certain state NOLs, arising in tax years ending after December 31, 2017 are not subject to expiration) and our state NOLs will begin to expire in 2024. We may use these NOLs to offset taxable income for U.S. federal and state income tax purposes. However, Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, and similar state provisions may limit the NOLs we may use in any year for U.S. federal and state income tax purposes in the event of certain changes in ownership of our company. An ownership change pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. We completed a 382 study of our historic ownership changes through December 31, 2023 and determined there are limitations on the use of our loss and credit carryforwards. In addition, future issuances or sales of our stock, including certain transactions involving our stock that are outside of our control, could result in future ownership changes. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">52</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ownership changes that have occurred in the past or that may occur in the future could result in the imposition of an annual limit on the amount of pre-ownership change NOLs and other tax attributes we can use to reduce our taxable income or income tax liability, potentially increasing and accelerating our liability for income taxes, and also potentially causing those tax attributes to expire unused. Any limitation on using NOLs could, depending on the extent of such limitation and the NOLs previously used, result in our retaining less cash after payment of U.S. federal and state income taxes during any year in which we have taxable income, rather than losses, than we would be entitled to retain if such NOLs were available as an offset against such income for U.S. federal and state income tax reporting purposes, which could adversely impact our operating results. Furthermore, U.S. federal NOLs arising in tax years beginning after December 31, 2017 may only be used to offset 80% of our taxable income. This change may require us to pay U.S. federal income taxes in future years despite generating a loss for U.S. federal income tax purposes in prior years. Limitations under state law may differ.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or our customers or patients, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the ordinary course of our business, we may become exposed to, or collect, store, or otherwise process sensitive data, including procedure-based information and legally-protected health information, credit card, and other financial information, insurance information, and other potentially personally identifiable information. We also store and process sensitive intellectual property and other proprietary business information. We rely on IT systems, networks and services, including internet sites, data hosting and processing facilities and tools, physical security systems and other hardware, software and technical applications and platforms, some of which are managed, hosted, provided and/or used by third parties or their vendors, to assist in conducting our business, and they also face numerous security threats. The ever-increasing use and evolution of technology, including cloud-based computing and artificial intelligence, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third party providers' systems, portable media or storage devices.</span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we take measures designed to protect sensitive information from unauthorized access or disclosure, our IT and infrastructure, and that of our technology partners and third parties on which we rely, may be vulnerable to breakdown or other damage or interruption from service interruptions, system malfunctions, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches and incidents from inadvertent or intentional actions by employees and/or other third parties, or from cyber-attacks by malicious third parties (including supply chain cyber-attacks or the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise system infrastructure or lead to the loss, destruction, alteration, prevention of access to, disclosure, or dissemination of, or damage or unauthorized access to, our data (including trade secrets or other confidential information, intellectual property, proprietary business information, and personal information) or data that is processed or maintained on our behalf, or other assets. Although the aggregate impact on our operations and financial condition has not been material to date, we have been the target of events of this nature and expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and becoming more prevalent in the industry. We and the third parties on which we rely may be more susceptible to security breaches and other security incidents due to many of our employees and employees of our third-party service providers working remotely for some portion of time. Also, Russia&#8217;s war with Ukraine may subject us and third-party service providers to heightened risks of cybersecurity incidents and security and privacy breaches, including attacks that could materially disrupt our research and development programs or other aspects of our operations. We continue to invest in leading-edge cybersecurity solutions, highly-qualified and certified security personnel and managed security services with respect to our data and IT in an effort to reduce these risks and continue to monitor our systems on an ongoing basis for any current or potential threats. There can be no assurance, however, that our efforts will prevent breakdowns or breaches to, or incidents or compromises impacting, our third-party providers&#8217; databases, systems, or other IT or infrastructure.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any system or other IT failure, accident or security breach or incident that causes interruptions in our own or in our third-party service providers&#8217; operations, or results in data loss, corruption, or unavailability, could result in a material disruption of our research and development programs or other aspects of our operations. In addition, if any disruption or security breach or incident results in loss, destruction, alteration, or unavailability of, or damage or unauthorized access to, our data or applications or unauthorized access to, disclosure, dissemination or other processing of confidential or proprietary information that we or our third-party service providers process, including personal information, we may incur liability as a result, our research and development programs and competitive position may be adversely affected. Any such disruption, failure or security breach or incident could also cause us to incur additional costs to respond to and otherwise address such disruption, failure or security breach or incident. In the event of any such disruption, failure or security breach or incident, or any perception that one has occurred, we could be exposed to claims, demands, and litigation from private parties, and governmental investigations and other proceedings and we could be subject to significant fines or penalties. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As a result of a new SEC rule on cybersecurity disclosure, we are required to disclose, on a </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">53</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">current basis pursuant to new Item 1.05 of SEC Form 8-K, any cybersecurity incident that we determine to be material and describe the material aspects of the nature, scope, and timing of the incident, as well as the material impact or reasonably likely material impact of the incident on us, including our financial condition and results of operations. We incur significant costs in an effort to detect and prevent security breaches and incidents, and no assurance can be provided that we will be successful in this regard.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach or incident. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, our IT systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems. This enables us to keep pace with continuing changes in information processing technology, evolving legal and regulatory standards, the increasing need to protect patient and customer information, changes in the techniques used to obtain unauthorized access to data and information systems, and the IT needs associated with our evolving products. There can be no assurance that our efforts (including, but not limited to, consolidating, protecting, upgrading, and expanding our systems and capabilities, continuing to build security into the design of our products, and developing new systems to keep pace with continuing changes in information processing technology, including, but not limited to, generative artificial intelligence platforms) will be successful or that additional systems issues will not arise in the future.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have no experience selling our products outside of the United States and may be unsuccessful in achieving adoption of our products and revenue growth outside of the United States in a timely manner or at all. In addition, </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">as international expansion of our business occurs, it will expose us to market, regulatory, political, operational, financial, legal and economic risks associated with doing business outside of the United States.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our long-term strategy is to sell our products outside the United States and increase our international presence. In furtherance of this strategy, we have taken actions to sell our products initially in Japan and China, including but not limited to, securing required regulatory approvals, working towards obtaining reimbursement for our products, and entering into </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">distribution agreements with distributors to sell our products in Japan and China, once we commercially launch our products in those countries. Our future sales in Japan and China, as well as any other country, however, are dependent upon our ability to obtain adequate reimbursement for our products in those countries. If we do not obtain adequate reimbursement for our products in Japan or China or any other country, we may not be successful in selling our products in those countries. In addition, we have no experience selling our products outside the United States and therefore we may be unsuccessful in achieving adoption of our products and revenue growth outside of the United States in a timely manner or at all. Furthermore, d</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">oing </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">business internationally involves a number of risks, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Difficulties in staffing and managing our international operations and increases in infrastructure costs including legal, tax, accounting and information technology;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reduced or varied protection for or enforcing or defending our intellectual property rights in some countries; </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Obtaining regulatory clearance where required for our products in various countries;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Requirements to maintain data and the processing of that data on servers located within such countries;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Complexities associated with </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtaining and maintaining adequate reimbursement for our products and managing multiple payer reimbursement regimes, government payers or patient self-pay systems;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Difficulties in finding effective and adequately training and managing international distributors;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Difficulties in penetrating markets in which our competitors&#8217; products or alternative procedures that do not use our products are more established;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Training of third parties on our products and the procedures in which they are used;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Limits on our ability to penetrate international markets if we are required to manufacture our products locally;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">54</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial risks, such as longer payment cycles, difficulty collecting accounts receivable, foreign tax laws and complexities of foreign value-added tax systems, the effect of local and regional financial pressures on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unexpected changes in tariffs, trade barriers and regulatory requirements;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The imposition of additional U.S. and foreign governmental controls or regulations; new or enhanced trade restrictions and restrictions on the activities of foreign agents, representatives, and distributors; withdrawal from or revision to international trade agreements and the imposition or increases in import and export licensing and other compliance requirements, customs duties and tariffs, import and export quotas and other trade restrictions, license obligations, and other non-tariff barriers to trade;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restrictions on the site-of-service for use of our products and the economics related thereto for physicians, providers and payers;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Fluctuations in our operating performance based on our geographic mix of sales;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transportation delays and interruptions;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Natural disasters, political and economic instability, including wars, terrorism, political unrest, outbreak of disease, boycotts, curtailment of trade and other market restrictions; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Regulatory and compliance risks that relate to maintaining accurate information and control over activities subject to regulation under the United States Foreign Corrupt Practices Act of 1977, or FCPA, U.K. Bribery Act of 2010 and comparable laws and regulations in other countries.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any of these factors could significantly harm our future international expansion and operations and, consequently, have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, pursuant to the terms of our existing intellectual property license and supply agreement with Cordis, there are certain restrictions on our ability to sell the ENROUTE stent through select direct competitors of Cordis. If we are unable to locate international distributors that are not select direct competitors to Cordis, to market and sell our ENROUTE stent, our ability to expand our business internationally may be harmed, which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">In anticipation of our international expansion into Japan and China, we recently entered into exclusive distribution agreements with distributors to sell our products in these countries. Exclusive distribution arrangements, however, involve risk and these distributors and any future distributor we engage may not effectively distribute our products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our future sales in Japan and China, once we obtain reimbursement and launch our products in those countries, will depend in large part on the distributors with whom we have entered into exclusive distribution agreements in those countries. While we believe we have selected experienced and qualified distributors in these countries, we will be completely dependent on their efforts to market and sell our products in these countries, and we will be unable to control their efforts completely. In addition, we are unable to ensure that our distributors will comply with all applicable laws regarding the marketing and sale of our products. If our distributors fail to effectively market and sell our products, or comply with all applicable laws, our operating results and business may suffer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws and any investigation, and the outcome of any investigation, by government agencies of possible violations by us of the FCPA could have a material adverse effect on our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FCPA and similar worldwide anti-bribery laws prohibit companies and their intermediaries from corruptly providing any benefits to government officials for the purpose of obtaining or retaining business. We recently completed the process of further enhancing policies and procedures with the intent to help ensure compliance with these laws. In the future, we may operate in parts of the world that have experienced governmental corruption to some degree. Moreover, because of the significant role government entities play in the regulation of many foreign healthcare markets, we may be exposed to heightened FCPA and similar risks arising from our efforts to seek regulatory approval of and reimbursement for our products in such countries. We cannot assure you that our internal control policies and procedures will protect us from improper acts committed by our employees or agents. Violations of these laws, or allegations of such violations, would </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">55</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">significantly disrupt our business and have a material adverse effect on our business, financial condition and results of operations. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are exposed to the risk of fraud or other misconduct by our employees, collaborators, vendors, principal investigators, consultants, independent contractors, and commercial partners. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with governmental laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. While we are unaware of any current matters, we are unable to predict whether we will be subject to actions under the FCPA or a similar state law, or the impact of such actions. Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations, which could have a material adverse effect on our business and financial condition. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Intellectual Property</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties&#8217; trade secrets. Additionally, our products include components that we purchase from vendors, and may include design components that are outside of our direct control. Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use product names. Moreover, in recent years, individuals and groups that are non-practicing entities have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments. Vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third-party&#8217;s patent or trademark or of misappropriating a third-party&#8217;s trade secret.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since some patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our products. Competitors may also contest our patents, if issued, by showing the patent examiner that the invention was not novel or was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees and consultants and any other partners or collaborators who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Further, if patents, trademarks, or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from selling our products, license fees, damages and the payment of attorney fees and court costs. In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. Although patent, trademark, trade secret, and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses on satisfactory terms, if at all. If we do not obtain necessary licenses, we may not be able to redesign our products to avoid infringement.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">56</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office, or USPTO, may be necessary to determine priority with respect to our patents, patent applications, trademarks or trademark applications. We may also become involved in other proceedings, such as reexamination, inter parties review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing our products or using product names, which would have a significant adverse impact on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, we may file lawsuits or initiate other proceedings to protect or enforce our patents, trademarks or other intellectual property rights, which could be expensive, time consuming and unsuccessful. Competitors may infringe our issued patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Furthermore, even if our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business&#160;caused by the infringer&#8217;s competition in the market. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our success depends on our ability to obtain, maintain and protect our intellectual property rights.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In order to remain competitive, we must develop, maintain and protect the proprietary aspects of our brands, technologies and data. We rely on a combination of contractual provisions, confidentiality procedures and patent, copyright, trademark, trade secret and other intellectual property laws to protect the proprietary aspects of our brands, technologies and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success depends, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining and maintaining other intellectual property rights. We may not be able to obtain or maintain intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. In addition, our trade secrets, data and know-how could be subject to unauthorized use, misappropriation, or disclosure to unauthorized parties, despite our efforts to enter into confidentiality agreements with our employees, consultants, clients and other vendors who have access to such information, and could otherwise become known or be independently discovered by third parties. Our intellectual property, including trademarks, could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our products, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Failure to obtain and maintain intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our trademarks, data, technology and other intellectual property and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely, in part, on our ability to obtain, maintain, expand, enforce, and defend the scope of our intellectual property portfolio or other proprietary rights, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights. The process of applying for and obtaining a patent is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. In addition, the issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. Issued patents may be challenged, narrowed, invalidated or circumvented. Decisions by courts and governmental patent agencies may introduce uncertainty in the enforceability or scope of patents owned by or licensed to us. Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own products and practicing our own </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">57</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">technology. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid, unenforceable or not infringed; competitors may then be able to market products and use manufacturing and analytical processes that are substantially similar to ours. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The term of individual patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a nonprovisional patent application in the applicable country. We cannot assure that patents will be issued from any of our pending applications or that, if patents are issued, they will be of sufficient scope or strength to provide meaningful protection for our technology. Notwithstanding the scope of the patent protection available to us, a competitor could develop treatment methods or devices that are not covered by our patents. Furthermore, numerous U.S. and foreign-issued patents and patent applications owned by third parties exist in the fields in which we are developing products. Because patent applications can take many years to issue, there may be applications unknown to us, which applications may later result in issued patents that our existing or future products or technologies may be alleged to infringe.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry. In the future, we may need to engage in litigation to enforce patents issued or licensed to us, to protect our trade secrets or know-how, to defend against claims of infringement of the rights of others or to determine the scope and validity of the proprietary rights of others. Litigation could be costly and could divert our attention from other functions and responsibilities. Furthermore, even if our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market.&#8221;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adverse determinations in litigation could subject us to significant liabilities to third parties, could require us to seek licenses from third parties or could prevent us from manufacturing, selling or using the product, any of which could severely harm our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information that is not patentable or that we elect not to patent. However, trade secrets can be difficult to protect and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others upon the commencement of their relationship with us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions. These contracts may not provide meaningful protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors. Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. In addition, the laws of many foreign countries may not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition. A third party could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology. Our competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our products, brand and business. The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our products and harm our business, the value of our investment in research and development or acquisitions could be reduced and third parties might make claims against us related to </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">58</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">losses of their confidential or proprietary information. Any of the foregoing could materially and adversely affect our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Further, it is possible that others will independently develop the same or similar technology or otherwise obtain access to our unpatented technology, and in such cases we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology similar to ours or competing technologies, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products, we may not be able to stop a competitor from marketing products that are the same as or similar to our products, which would have a material adverse effect on our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A company may attempt to commercialize competing products utilizing our proprietary design, trademarks or tradenames in foreign countries where we do not have sufficient patent protection and where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Filing, prosecuting and defending patents or trademarks on our current and future products in all countries throughout the world would be prohibitively expensive. The requirements for patentability and trademarking may differ in certain countries, particularly developing countries. The laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from utilizing our inventions and trademarks in all countries outside the United States. Competitors may use our technologies or trademarks in jurisdictions where we have not obtained patent or trademark protection to develop or market their own products and further, may export otherwise infringing products to territories where we have patent and trademark protection, but enforcement on infringing activities is inadequate. These products or trademarks may compete with our products or trademarks, and our patents, trademarks or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trademarks and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents and trademarks or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent and trademarks rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents and trademarks at risk of being invalidated or interpreted narrowly and our patent or trademark applications at risk, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">59</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information, of these former employers or competitors.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An inability to incorporate technologies or features that are important or essential to our products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our products. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which could have an adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Further, the Leahy-Smith Act created new procedures to challenge the validity of issued patents in the United States, including post-grant review and inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent with an effective filing date of March 16, 2013 or later, a petition for post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for inter partes review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior to March 16, 2013. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with an effective filing date of March 16, 2013 or later. Post-grant </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">60</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">review proceedings can be brought on any ground of invalidity, whereas inter partes review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we, our licensors or collaborators will be successful in defending the patent, which would result in a loss of the challenged patent right to us.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on trademarks, service marks, tradenames and brand names to distinguish our products from the products of our competitors, and have registered or applied to register these trademarks. We cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands and managing through regulatory implications such as relabeling. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In other cases, our competitors may associate our marks, such as TCAR, with their products and infringe upon our intellectual property as a result. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Government Regulation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. In March 2010, the Affordable Care Act was enacted in the United States, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect our business, the Affordable Care Act:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expanded the eligibility criteria for Medicaid programs.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The taxes imposed by the Affordable Care Act and the expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased sale of our products and, lower reimbursement by payers for our products, all of which may have a material adverse effect on our business, financial condition and results of operations. Since its enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the Affordable Care Act. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">61</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the constitutionality of the ACA. It is unclear how the other healthcare reform measures of the Biden administration or future litigation will impact the ACA or our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2032, unless additional Congressional action is taken.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, enacted on April&#160;16, 2015, repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments which began in 2019 that are based on various performance measures and physicians&#8217; participation in alternative payment models such as accountable care organizations. It is unclear what effect new quality and payment programs, such as MACRA, may have on our business, financial condition, results of operations or cash flows.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect additional state and federal healthcare policies and reform measures to be adopted in the future. Any of these could make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained. They could result in reduced demand for our products or result in additional pricing pressure.&#160;Any such reforms could have a material adverse effect on our industry generally and on our customers. Any changes of, or uncertainty with respect to, future coverage or reimbursement rates could affect demand for our products, which in turn could impact our ability to successfully commercialize our products and could have an adverse material effect on our business, financial condition and results of operations.&#160;Changes and reforms in Japan and China and other countries where we may decide to commercialize could have similar effects.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Effective October 11, 2023, CMS published the final decision memo for NCD 20.7 expanding coverage for CAS, including TCAR, under indication B4 for both high risk and standard surgical risk patients. The revised NCD 20.7 does not impact existing TCAR coverage under indication B3 for FDA-approved post-approval studies such as the VQI TSP. CMS determined that coverage of percutaneous transluminal angioplasty, or PTA, of the carotid artery concurrent with stenting, including TCAR, under indication B4 is reasonable and necessary with the placement of an FDA-approved carotid stent and with an FDA-approved or cleared embolic protection device, in patients with symptomatic carotid artery stenosis &#8805;50% and in patients with asymptomatic carotid artery stenosis &#8805;70% under the following conditions: </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurological assessment must be performed by a neurologist or NIH stroke scale (NIHSS) certified health professional before and after CAS.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">First-line evaluation of carotid artery stenosis must use duplex ultrasound.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Computed-tomography angiography (CTA) or magnetic resonance angiography (MRA), if not contraindicated, must be used to confirm degree of stenosis, and provide information about the aortic arch, and extra and intra-cranial circulation.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(4)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intra-arterial digital subtraction (catheter) angiography may be used only when there is significant discrepancy between non-invasive imaging results or contraindicated for CTA or MRA.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prior to furnishing CAS, the practitioner must engage in a shared decision-making interaction with the beneficiary, which must include:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion of all treatment options for carotid stenosis, including CEA, CAS (which includes TCAR), and optimal medical therapy (OMT).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Explanation of risks and benefits for each option specific to the beneficiary&#8217;s clinical condition.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Integration of clinical guidelines (e.g., patient co-morbidities and concomitant treatments).</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(4)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion and incorporation of beneficiary&#8217;s personal preferences and priorities in choosing a treatment plan. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facilities must establish and maintain institutional and physician standards to support a dedicated carotid stent program. However, CMS facility approval or certification is not required. The Medicare Administrative Contractors will have discretion to make carotid artery stenting coverage determinations not addressed in NCD 20.7. As a result of the expansion of coverage in NCD 20.7 and CMS&#8217;s stated goals for broader patient access, we believe there could be rising interest and awareness in minimally invasive carotid stenting procedures including TCAR.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">62</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our products have in the past and could in the future be subject to product recalls that could harm our reputation or increase the probability of inspection by, or additional scrutiny from, the FDA or other relevant regulatory bodies.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture. A government mandated or voluntary recall by us has occurred, and could occur again in the future, as a result of component failures, manufacturing errors or design or labeling defects. In January 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System. Additional recalls of our products would divert managerial attention, be expensive, harm our reputation with customers, result in additional scrutiny from the FDA or other relevant regulatory bodies and harm our financial condition and results of operations. Additional recall announcements could also negatively affect our stock price.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in the CMS fee schedules may affect our hospital customers and thereby harm our revenue and operating results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Government payers, such as Centers for Medicare and Medicaid Services as well as insurers, have increased their efforts to control the cost, utilization and delivery of healthcare services. From time to time, the U.S. Congress has considered and implemented changes in the CMS fee schedules in conjunction with budgetary legislation. Reductions of reimbursement by Medicare or Medicaid for procedures that use our products or changes in policy regarding coverage of these procedures, such as adding requirements for payment, or prior authorizations, may be implemented from time to time. Reductions in the reimbursement rates and changes in payment policies of other third-party payers may occur as well. Similar changes in the past have resulted in reduced payments for procedures that use medical device products as well as added costs and have added more complex regulatory and administrative requirements. Further changes in federal, state, local and third-party payer regulations or policies may have a material adverse impact on the demand for our products and on our business. Actions by agencies regulating insurance or changes in other laws, regulations, or policies may also have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we fail to comply with broad-based healthcare and other governmental regulations, we could face substantial fines and penalties and our business, results of operations and financial condition could be adversely affected.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The products we offer are highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely in the future. Our arrangements with physicians, hospitals and medical centers will expose us to broadly applicable fraud and abuse and other laws and regulations that may restrict the financial arrangements and relationships through which we market, sell and distribute our products. Our employees, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. Federal and state healthcare laws and regulations that may affect our ability to conduct business, include, without limitation:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Federal and state laws and regulations regarding billing and claims payment applicable to TCAR and regulatory agencies enforcing those laws and regulations;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA prohibitions against the advertisement, promotion and labeling of our products for off-label uses, or uses outside the specific indications approved by the FDA;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal Anti-Kickback Statute, which broadly prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the CMS programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties per violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines and imprisonment. Similarly, violations can result in mandatory exclusion from participation in government healthcare programs, including Medicare and Medicaid;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government. These laws can apply to manufacturers who provide inaccurate information on coverage, </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">63</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">coding, and reimbursement of their products to persons who bill third-party payers. Private individuals can bring False Claims Act &#8220;qui tam&#8221; actions, on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making, or causing to be made, false statements relating to healthcare matters;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FCPA, the U.K. Bribery Act of 2010, and other local anti-corruption laws that apply to our international activities;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal Physician Payment Sunshine Act, or Open Payments, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or Affordable Care Act, and its implementing regulations, which requires applicable manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value made to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. Applicable manufacturers are required to submit annual reports to CMS. Our failure to submit required information on time may result in civil monetary penalties with additional amounts for &#8220;knowing failures&#8221;, for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; HIPAA also created criminal liability for knowingly and willfully falsifying or concealing a material fact or making a materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Failure to comply with the HIPAA privacy and security standards when applicable can result in civil monetary penalties, and, in certain circumstances, criminal penalties including fines and/or imprisonment. State attorneys general can also bring a civil action to enjoin a HIPAA violation or to obtain statutory damages on behalf of residents of his or her state.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers or patients; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers, foreign and state laws, including the E.U. General Data Protection Regulation, or GDPR, governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers. Analogous foreign law equivalents are more fully described in the section titled &#8220;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Business&#8212;Government Regulation.&#8221;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities, such as stock-option compensation paid to physicians, could be subject to challenge under one or more of such laws. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. We may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">64</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The growth of our business and sales organization and our planned expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages, fines, imprisonment, for individuals, exclusion from participation in government programs, such as Medicare and Medicaid, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject to tax laws, regulations, and policies of the several taxing jurisdictions. Changes in tax laws, as well as other factors, could cause us to experience fluctuations in our tax obligations and effective tax rates and otherwise adversely affect our tax positions and/or our tax liabilities. For example, in August 2022 the United States enacted a 1% excise tax on stock buybacks and a 15% alternative minimum tax on adjusted financial statement income for certain large corporations as part of the Inflation Reduction Act of 2022. Further, many countries, and organizations such as the Organization for Economic Cooperation and Development have proposed implementing changes to existing tax laws, including a proposed 15% global minimum tax. Any of these developments or changes in federal, state, or international tax laws or tax rulings could adversely affect our effective tax rate and our operating results. There can be no assurance that our effective tax rates, tax payments, or tax credits and incentives will not be adversely affected by these or other developments or changes in law.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we fail to obtain and maintain necessary regulatory clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our products are subject to extensive regulation by the FDA in the United States and by regulatory agencies in other countries where we do business. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product design, development and manufacture;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Laboratory, preclinical and clinical testing, labeling, packaging, storage and distribution;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Premarketing clearance or approval;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Record keeping;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product marketing, promotion and advertising, sales and distribution; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Before a new medical device, or a new intended use for an existing product, can be marketed in the United States, a company must first submit and receive either 510(k) clearance pursuant to Section 510(k) of the Food, Drug and Cosmetic Act, or the FDCA, or approval of a premarket approval, or PMA, application from the FDA, unless an exemption applies. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In many cases, the process of obtaining PMA approval, which was required for the ENROUTE stent, is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, in order to clear the proposed device for marketing. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based on extensive data, including technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices for which the 510(k) process cannot be used and that are deemed to pose the greatest risk. Modifications to </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">65</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">products that are approved through a PMA application generally need prior FDA approval of a PMA supplement. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k), or such modification may put the device into class III and require PMA approval. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but may last longer. The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory approvals or clearances would have a material adverse effect on our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In September 2019, the FDA issued revised final guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a list of device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. For example, the FDA issued a final rule in February 2024 replacing the QSR with the QMSR, which incorporates by reference the quality management system requirements of ISO 13485:2016. The FDA has stated that the standards contained in ISO 13485:216 are substantially similar to those set forth in the existing QSR. This final rule does not go into effect until February 2026. Any new statutes, regulations, or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance or approval for, manufacture, market, or distribute our products. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be promulgated that could prevent, limit, or delay regulatory clearance or approval of our product candidates. If the Supreme Court reverses or curtails the </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Chevron </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">doctrine, which gives deference to regulatory agencies in litigation against FDA and other agencies, more companies may bring lawsuits against FDA to challenge longstanding decisions and policies of FDA, which could undermine FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt FDA&#8217;s normal operations, which could delay FDA&#8217;s review of our marketing applications. We cannot determine what effect changes in regulations, statutes, legal interpretation, or policies, when and if promulgated, enacted, or adopted may have on our business in the future. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are safe or effective for their intended uses;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The disagreement of the FDA or the applicable foreign regulatory body with the design, conduct or implementation of our clinical trials or the analyses or interpretation of data from pre-clinical studies or clinical trials;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">66</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The applicable regulatory authority may identify significant deficiencies in our manufacturing processes, facilities or analytical methods or those of our third-party contract manufacturers;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA or foreign regulatory authorities may audit our clinical trial data and conclude that the data is not sufficiently reliable to support approval or clearance.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Similarly, regulators may determine that our financial relationships with our principal investigators resulted in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself. Even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Moreover, the FDA, PMDA, and NMPA strictly regulate the labeling, promotion and advertising of our products, including comparative and superiority claims vis a vis competitors&#8217; products, that may be made about products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As a condition of approving a PMA application, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For example, as a condition of the FDA approval for the label expansion for ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy, in September 2022, we announced the enrollment of the first patient in ROADSTER 3, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our prospective, multi-center, single-arm study to assess real-world treatment of standard surgical risk patients with carotid artery disease using TCAR</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Failure to conduct the post-approval study in compliance with applicable regulations or to timely complete required post-approval studies or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm our business. As discussed above, findings of meaningfully higher rates of adverse events or any unexpected safety or efficacy concerns related to our approval products in such post-approval study or any other independent studies or reports can result in FDA withdrawal or restriction of our PMA approval, which can have a material adverse effect on our business prospects, reputation, and market acceptance of our products.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, we are required to investigate all product complaints we receive, and timely file reports with the FDA, including MDRs that require that we report to regulatory authorities if our products may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur.&#160;If these reports are not submitted in a timely manner, regulators may impose sanctions and we may be subject to product liability or regulatory enforcement actions, including warning letters, untitled letters, fines, civil penalties, recalls, seizures, operating restrictions, denial of requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products, withdrawal of current 510(k) clearances or premarket approvals and narrowing of approved or cleared product labeling, all of which could harm our business. In addition, the FDA may provide notice of and conduct additional inspections, such as &#8220;for cause&#8221; inspections, of our business, sites and facilities as part of its review process. </span><span id="_Hlk133503671" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have a robust post-market surveillance and complaint handling system which provides for timely communication between our field employees and customers and our internal Quality Assurance team. Information regarding our products and user and patient experiences is reviewed and, where appropriate, regulatory authorities are notified. Adverse events and device malfunctions are reported in the United States to the FDA and publicly listed in the Manufacturer and User Facility Device Experience (MAUDE) database.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we initiate a correction or removal action for our products to reduce a significant risk to health posed by our products, we would be required to submit a publicly available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall which could lead to an additional inspection by, or increased scrutiny from, the FDA, other international regulatory agencies and our customers regarding the quality and safety of our products. Furthermore, the submission of these reports could be used by competitors against us and cause physicians to delay or cancel prescriptions, which could harm our reputation. For example, in the first quarter of 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by Cordis. Recalls like this one could cause the supply of our TCAR products to customers </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">67</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to be interrupted, us to incur additional expenses, negative publicity or damage to our reputation, any of which could cause our results of operations to be adversely impacted.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA and the Federal Trade Commission, or FTC, also regulate the advertising, promotion and labeling of our products to ensure that the claims we make are consistent with our regulatory clearances and approvals, that there is adequate and reasonable scientific data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including adverse publicity, warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA and state authorities have broad investigation and enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizure of our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating restrictions, partial suspension or total shutdown of production;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denial of our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Withdrawal of 510(k) clearance or premarket approvals that have already been granted; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Criminal prosecution.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If any of these events were to occur, our business and financial condition could be harmed. In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our products. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are subject to United States and certain foreign laws and regulations relating to export and import controls, sanctions, embargoes, anti-corruption, and anti-money laundering. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which would harm our business. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject to export control and import laws and regulations, including the United States Export Administration Regulations, United States Customs regulations, various economic and trade sanctions regulations administered by the United States Treasury Department&#8217;s Office of Foreign Assets Controls, the United States Foreign Corrupt Practices Act of 1977, as amended (FCPA), the United States domestic bribery statute contained in 18 U.S.C. &#167; 201, the United States Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. International trade, tariff, and import/export laws and regulations may require us to obtain licenses or permits in order to complete certain activities necessary for the research, manufacture, and development of our product candidates. Moreover, we expect such laws and regulations, along with associated guidance and interpretations, to evolve over time in ways that may impact various aspects of our business. The process for obtaining any necessary licenses or permits may be lengthy and time-consuming, and if we are not able to obtain any such licenses or permits in a timely manner, we may experience delays in our ability to manufacture, develop, and commercialize our product candidates.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, collaborators, and other third parties from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell products, if any, for which we receive regulatory approval outside the United States, to conduct clinical trials, or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. In the ordinary course of our business, we may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We may be held liable for the corrupt or other illegal activities of our employees, agents, contractors, collaborators, and other third parties, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">68</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. The U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers&#8217; ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation. If we are unable to obtain or use services from existing service providers or become unable to export or sell our products to any of our customers or service providers, our business, liquidity, financial condition, and/or results of operations would be materially and adversely affected.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our clinical trials may fail to demonstrate competent and reliable evidence of the safety and effectiveness of our products, which would prevent or delay commercialization of our products in development.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may be required to conduct clinical studies that demonstrate competent and reliable evidence that our products are safe and effective before we can commercialize our products. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our products for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our products. Even if regulatory approval is secured for any of our products, the terms of such approval may limit the scope and use of our products, which may also limit their commercial potential. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but not limited to, the following:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients do not enroll in clinical trials at the rate expected;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients do not comply with trial protocols;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patient follow-up is not at the rate expected;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients experience adverse events;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients die during a clinical trial, even though their death may not be related to the products that are part of the trial;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Device malfunctions occur with unexpected frequency or potential adverse consequences;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Side effects or device malfunctions of similar products already in the market that change the FDA&#8217;s view toward approval of new or similar PMAs or result in the imposition of new requirements or testing;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Institutional review boards and third-party clinical investigators may delay or reject the trial protocol;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other FDA or IRB requirements;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Third-party investigators are disqualified by the FDA;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records, and reports of sponsors of clinical investigations;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">69</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Third-party clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results unreliable, or the company or investigators fail to disclose such interests;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in government regulations or administrative actions;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; or</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA concludes that our trial design is unreliable or inadequate to demonstrate safety and effectiveness.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span id="_Hlk133503999" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Material modifications to our products may require new 510(k) clearances, premarket approval, or other international regulatory submissions, or may require us to recall or cease marketing our products until new clearances or approvals are obtained.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Material modifications to the intended use or technological characteristics of our products may require new 510(k) clearances, premarket approvals, or other international regulatory submissions prior to implementing the modifications, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Furthermore, changes to our manufacturing facility or supplier of components used in our products may require prior FDA approval of a PMA supplement or may require international regulatory activity. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance; however, the FDA can review a manufacturer&#8217;s decision. Any modification to an FDA cleared or approved device that would significantly affect its safety or effectiveness or that would constitute a major change in its intended use would require a new 510(k) clearance or approval of a PMA supplement. Similar requirements for approval of significant changes are in place in international markets. We may not be able to obtain additional 510(k) clearances, premarket approvals, or international approvals for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all. Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. We have made modifications to our products in the past that we believe do not require additional clearances or approvals, and we may make additional modifications in the future. If the FDA, PMDA, or NMPA disagree and require new clearances or approvals for any of these modifications, we may be required to recall and to stop selling or marketing our products as modified, which could harm our operating results and require us to redesign our products. In these circumstances, we may be subject to significant enforcement actions. In July 2022, we voluntarily requested the cancellation of our CE Mark certifications for business reasons but will continue to work with our Certification Body to maintain ISO 13485:2016 certification of our quality system. The CE Certificates were cancelled, effective August 23, 2022, but the ISO 13485:2016 certification remains in effect. We may seek new CE Mark certifications in the future.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we, or our suppliers, fail to comply with the FDA&#8217;s QSR, our manufacturing or distribution operations could be delayed or shut down and our revenue could suffer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our manufacturing and design processes and those of our third-party component suppliers are required to comply with the QSR, which cover procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our products. We are also subject to similar state requirements and licenses, and to ongoing ISO 13485 compliance in our operations. The FDA issued a final rule in February 2024 replacing the QSR with the QMSR, which incorporates by reference the quality management system requirements of ISO 13485:2016. The FDA has stated that the standards contained in ISO 13485:216 are substantially similar to those set forth in the existing QSR. This final rule does not go into effect until February 2026. In addition, we must engage in extensive recordkeeping and reporting and must make available our facilities and records for periodic unannounced inspections by governmental agencies, including the FDA and state authorities. If we fail a regulatory inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take timely and adequate corrective action in response to an adverse regulatory inspection could result in, among other things, a shutdown of our manufacturing or product distribution operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would cause our business to suffer. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our products and cause our revenue to decline.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are registered with the FDA as a medical device specifications developer, manufacturer and complaint file establishment. The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of the California Department of Public Health, or CDPH, to determine our compliance with the QSR and other regulations at both our design and manufacturing facilities, and these </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">70</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">inspections may include the manufacturing facilities of our suppliers. These inspections may be initiated as a result of concerns regarding the safety of our products or the components thereof. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA conducted an initial facility inspection in our Plymouth, Minnesota location in January 2024 and a</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> one-observation Form 483 Notice of Observation was issued pertaining to a singular piece of production equipment in relation to calibration and preventive maintenance. In response, we initiated a Corrective and Preventive Action, or CAPA, to address the 483.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We can provide no assurance that we will continue to remain in material compliance with the QSR. If the FDA or CDPH inspect any of our facilities and discover compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings. Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a delay at our manufacturing facility, we may be unable to produce our products, which would harm our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Inadequate funding for the FDA, the SEC, the CMS and other government agencies as a result of a U.S. federal government shutdown could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in the past as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Disruptions at the FDA and other agencies may also slow the time necessary for new products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Environmental, social and corporate governance, or ESG matters, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders on ESG matters including climate change, energy and water use, plastic waste and other sustainability concerns. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices, including rules related to climate change and climate-related disclosures, continue to grow. For example, in 2022, the SEC published a proposed rule that would require companies to provide significantly expanded climate-related disclosures, and in October 2023, the State of California adopted broad climate reporting laws that will require certain businesses to report on greenhouse gas (GHG) emissions and climate-related financial risk. Compliance with these climate-related disclosures may result in significant costs and operational impacts and impose increased oversight obligations on our board of directors and management.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our ESG practices fail to meet regulatory requirements or investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, diversity in our employee base or on our board of directors, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation, brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with us. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changing customer and consumer preferences or increased regulatory requirements may result in increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with these demands or requirements could cause us to incur additional manufacturing, operating or product development costs. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we do not adapt to or comply with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors may reconsider their capital investment in our company, and </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">71</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">customers and consumers may choose to stop purchasing our products, which could have a material adverse effect on our reputation, business or financial condition. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Compliance with environmental laws and regulations could be expensive, and failure to comply with these laws and regulations could subject us to significant liability.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our research and development and manufacturing operations involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive and noncompliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and operating results.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">New climate-related reporting rules in California and other jurisdictions could require significant time, attention, and resources from management, and could also lead to increased costs and liabilities.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2022, the SEC proposed new rules that would require public companies to disclose extensive climate-related information in their registration statements and periodic reports. The proposed rules would mandate disclosures related to climate-related risks and their impacts, GHG emissions, and climate-related financial statement metrics. In October 2023, the State of California adopted the Climate Corporate Data Accountability Act and the Climate-Related Financial Risk Act. These broad climate reporting laws that would require certain businesses doing business in California to report on GHG emissions and climate-related financial risks.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As a company that files periodic reports with the SEC and that has operations in California, we may fall under the jurisdiction of these new laws, which impose rigorous reporting obligations regarding our GHG climate-related financial risks and extensive requirements for the disclosure of GHG emissions. Compliance with these climate-related disclosure rules will require substantial time and attention of management and financial resources. We must develop robust systems, processes, and controls for assessing and reporting our climate-related financial risks, as well as ensuring transparency and accuracy in our disclosures.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Ownership of Our Common Stock</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The market price of our common stock in the past has been and may continue to be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The market price of our common stock in the past has been and may continue to be highly volatile and may fluctuate substantially due to many factors, including, without limitation:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Estimates and recommendations regarding our business, prospects and the value of our common stock by securities analysts, the loss of analyst coverage or our failure to achieve analysts&#8217; estimates,</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> which failure to achieve analysts&#8217; consensus estimates occurred with both our first quarter 2023 and third quarter 2023 financial results;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Perceptions by securities analysts and other investors regarding our business, prospects and the value of our common stock, including without limitation, the total market opportunity for our products, our ability to penetrate the market, the effect of the revised NCD 20.7 and the effect on our business and results of operations, including without limitation pricing, of competitive stents and products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Quarterly variations in our or our competitors&#8217; results of operations;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Periodic fluctuations in our revenue, which could be due in part to the way in which we recognize revenue and other factors, such as pricing and the effect of stocking orders if we sell to international distributors;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The financial and business projections we may provide to the public, any changes in these projections or our failure to meet these projections, which occurred when we revised downward our annual revenue guidance in October 2023;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">72</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General market conditions and other factors unrelated to our operating performance or the operating performance of our competitors, including deteriorating market conditions due to investor concerns regarding inflation, interest rate and economic policies, supply chain issues, the impact of GLP-1 usage, geopolitical tensions including the war between Russia and Ukraine, the war between Israel and Hamas and changes in China-Taiwan relations;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in reimbursement by current or potential payers, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">including CMS&#8217;s final decision on NCD 20.7, Percutaneous Transluminal Angioplasty, that provides coverage for CAS including TCAR</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating performance and stock market valuations of other technology companies generally, or those in the medical device industry in particular;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Actual or anticipated changes in regulatory oversight of our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The results of our clinical trials </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">as well as studies and registries conducted by others using our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The results of clinical trials that study competing carotid interventions or medical management of carotid artery disease;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The loss of key personnel, including changes in our board of directors and management, such as the recent retirement of our prior CEO and appointment of a new CEO;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product recalls, backorders or other problems associated with our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to obtain required approvals and reimbursement coverage for our products internationally and successfully launch and sell our products in such markets;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Legislation or regulation of our market;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lawsuits threatened or filed against us, including litigation by current or former employees alleging wrongful termination, sexual harassment, whistleblower or other claims;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The announcement of new products or product enhancements by us or our competitors;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Announced or completed acquisitions of businesses or technologies by us or our competitors;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Announcements related to patents issued to us or our competitors and related litigation;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Developments in our industry; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other risks and uncertainties described in this report.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, in the past, stockholders have instituted securities class action litigation following periods of market volatility, </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">especially significant drops in stock price like we have recently experienced. Such litigation could subject us to substantial costs, divert resources and the attention of management from our business and harm our business, results of operations, financial condition and reputation. These factors may materially and adversely affect the market price of our common stock.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are obligated to maintain proper and effective internal control over financial reporting and any failure to maintain the adequacy of our internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, to furnish a report by management on the effectiveness of our internal control over financial reporting in our Annual Report on Form 10-K each year. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. We are also required to comply with, among other requirements, the auditor attestation requirements of Section 404 in our Annual Report on Form 10-K each year. If we have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered public accounting firm.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">73</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our compliance with Section 404 requires that we incur substantial accounting expense and expend significant management efforts. We have engaged outside consultants who function in the capacity of an internal audit group, and we plan to continue to hire additional consultants, accounting and financial staff with appropriate public company experience and technical accounting knowledge as we maintain the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our ordinary shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy our current and any future material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Anti-takeover provisions in our restated certificate of incorporation and amended and restated bylaws, and Delaware law, could discourage a change in control of our company or a change in our management.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our restated certificate of incorporation and amended and restated bylaws contain provisions that might enable our management to resist a takeover. These provisions include, among others:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Advance notice requirements applicable to stockholders for matters to be brought before a meeting of stockholders and requirements as to the form and content of a stockholders&#8217; notice;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A supermajority stockholder vote requirement for amending certain provisions of our restated certificate of incorporation and amended and restated bylaws;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A requirement that the authorized number of directors may be changed only by resolution of the board of directors;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowing all vacancies, including newly created directorships, to be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, except as otherwise required by law;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A requirement that our stockholders may only take action at annual or special meetings of our stockholders and not by written consent;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Limiting the forum to Delaware for certain litigation against us; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Limiting the persons that can call special meetings of our stockholders to our board of directors, the chairperson of our board of directors, the chief executive officer or the president, in the absence of a chief executive officer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These provisions might discourage, delay or prevent a change in control of our company or a change in our management. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; abilities to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action arising pursuant to any </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">74</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provision of the Delaware General Corporation Law or our amended restated certificate of incorporation or bylaws (as either may be amended from time to time), or (4)&#160;any action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware or federal court located within the State of Delaware if the Court of Chancery does not have jurisdiction, in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act against any person in connection with any offering of our securities, including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant. With respect to the Securities Exchange Act of 1934, or Exchange Act, only claims brought derivatively under the Exchange Act would be subject to the forum selection clause described above. The enforceability of similar choice of forum provisions in other companies' certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation and bylaws to be inapplicable or unenforceable in such action. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation and bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and operating results. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our business or the value of our common stock could be negatively affected as a result of actions by activist stockholders. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We value constructive input from our stockholders, and our board of directors and management team are committed to acting in the best interests of our stockholders. However, stockholders may from time to time engage in proxy solicitations, advance stockholder proposals or otherwise attempt to effect changes or acquire control over the Company. Responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, disrupting our operations and diverting the attention of our board of directors and senior management from the pursuit of business strategies. In addition, perceived uncertainties as to our future direction, strategy or leadership created as a consequence of activist stockholder initiatives may result in the loss of potential business opportunities, harm our ability to attract new investors, customers, employees, and joint venture partners, and cause our stock price to experience periods of volatility or stagnation. The recent significant drop in our stock price makes us particularly vulnerable to activist investors at this time.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 9pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our common stock.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have never paid cash dividends and do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects for future earnings and other factors our board of directors may deem relevant. In addition, our loan agreement limits our ability to, among other things, pay dividends or make other distributions or payments on account of our common stock, in each case subject to certain exceptions. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our common stock price appreciates and you then sell our common stock.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section6" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1B. Unresolved Staff Comments</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Cybersecurity" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1C. Cybersecurity</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Background</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cybersecurity, compliance, data privacy, and data protection are essential to our business. In the ordinary course of business, we collect and store certain confidential information, such as the specifications of our products, information about our employees, customers, contractors, vendors, and suppliers, and information about TCAR procedures, which in some instances may include identifiable patient information. To safeguard this information, we have implemented a cybersecurity defense-in-depth approach leveraging the Center for Internet Security, Inc. (CIS) Critical Security Controls (CSC) framework designed to identify, meet, and defeat dangerous cyber attacks in order to protect confidential information, mitigate data compromise and breaches, and provide IT resiliency. The CIS CSC framework defines five </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">75</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">critical areas to build robust cybersecurity defense posture. We have developed and maintain a collection of policies and procedures to implement and support this cybersecurity framework.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Role of Management and Board Oversight</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our cybersecurity team is comprised of individuals with experience in cybersecurity who hold cybersecurity-specific credentials and certifications. The team members belong to relevant professional organizations and receive continuing education and certification to stay abreast of emerging trends and cybersecurity best practices.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.30in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have established a Technology Steering Committee, or TSC, containing members of our senior management team to provide governance and strategic direction for managing cyber risks, maintaining IT regulatory compliance, and optimizing technology initiatives for alignment with our company goals and objectives. The TSC convenes quarterly, and meetings include updates on cybersecurity matters provided by the cybersecurity leader.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our board of directors has delegated to the audit committee, which is comprised of entirely independent directors, the responsibility to oversee our cybersecurity programs and cyber-related risks. Specifically, audit committee delegation under its formal written charter includes the responsibility to oversee the integrity of our IT systems, processes and data, and review and assessment with management (i) the adequacy of controls and security for our IT systems, processes and data, and (ii) our contingency plans in the event of a breakdown or security breach affecting our IT systems.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The cybersecurity team reports to our Chief Accounting Officer, which in turn reports to our Chief Financial Officer. Both officers regularly attend audit committee meetings where cybersecurity is discussed and the audit committee is updated on security risks and key initiatives at least twice per year by the senior management team. The TSC is responsible for providing cybersecurity risk management oversight and approving the budget to fund our IT and cybersecurity programs. An important purpose of these management updates is to inform the audit committee of any potential risks and remediation tactics related to our cybersecurity posture, IT systems, and data privacy.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Consultants and Advisors</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We engage with a range of external experts, including cybersecurity assessors, consultants, auditors, and legal counsel in evaluating and testing our risk management systems. This enables us to leverage specialized knowledge and insights, ensuring our cybersecurity strategies and processes remain current.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have engaged a managed security services company to provide 24x7x365 monitoring to detect cyber threats and support us in containing and responding to cyber threats. The services provided by the managed security services company include monitoring for and updating us regarding emerging cybersecurity threats, real-time monitoring of our firewalls and other security controls, and support for the development and execution of our Incident Response Plan. The managed security services company performs monthly vulnerability scanning and generates reports. Our cybersecurity team has access to dashboards providing status updates on the managed security services company&#8217;s cybersecurity-related activity, meets regularly with the managed security services company&#8217;s staff, and receives regular reporting from the managed security services company.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also receive and participate in other third-party cybersecurity assessments, such as: quarterly vulnerability scanning as part of our PCI DSS compliance requirements, annual network assessments, annual penetration testing, and vulnerability scans as part of our cyber insurance underwriting process.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, we engage specialized consultants and third-party managed service providers on a project-specific basis to assist us with projects that will improve our IT infrastructure, strengthen our security posture, and improve our cyber readiness.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cybersecurity Strategy and Risk Management</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have integrated cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are an integral part of our decision-making processes at every level. Our cybersecurity program is designed for assessing, identifying and managing material risks from cybersecurity threats to the confidentiality, integrity, and availability of our assets and information. Risk management is embedded into our IT processes and we continuously monitor risk by evaluating emerging threats and vulnerabilities.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have established security controls based on the CIS CSC framework. Key components of our cybersecurity program include, but are not limited to, asset management, encryption, data loss prevention technology, access controls, </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">76</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">multi-factor authentication, vulnerability management, independent penetration testing, email and web gateway protection, multi-faceted backup and data recovery solutions, anti-malware, firewalls, IDS and IPS, auditing and monitoring, regular policy updates, security awareness training, anti-phishing campaigns, and third-party risk management. We also subscribe to third-party threat intelligence tools and services that support monitoring, analyzing, and responding to emerging risks and threats.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have established an Incident Response Plan and a Security Operations Center to manage any cyber incident. We have retained a third-party incident response firm to support incident detection, management, and mitigation. We also maintain appropriate levels of cyber insurance. We implement processes to oversee and manage the risks associated with third-party service providers. We conduct security assessments of critical third-party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes ongoing assessments by our Information Security team. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">At least annually, we conduct information security awareness training for all employees. In addition, we have retained a third-party vendor to provide regular online awareness training modules for our employees. Each module contains a video extract followed by a short quiz.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To date, we have not experienced any material security incidents or data breaches as a result of a compromise of our information systems and are not aware of any cybersecurity incidents that have had a material impact or are reasonably likely to materially affect our business strategy, operating results, or financial condition.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section7" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 2. Properties</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently lease approximately 31,000 square feet for our corporate headquarters and manufacturing facility located in Sunnyvale, California under a lease agreement which terminates in October 2027. We have an additional option to extend the lease term for a period of five&#160;years. The </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">option must be exercised no more than 12&#160;months and no less than nine months prior to the expiration of the applicable term.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also lease approximately 82,000 square feet of office and manufacturing space located in Plymouth, Minnesota under a lease agreement which terminates in November 2029. We have the option to extend the lease term for two additional five-year periods. The option must be exercised no more than 12&#160;months and no less than nine months prior to the expiration of the applicable term. We believe our two facilities meet our current and future anticipated needs. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section8" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 3. Legal Proceedings</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject to litigation and other legal actions from time to time arising in the ordinary course of business, including intellectual property, products liability, breach of contract, commercial, employment, and other similar claims which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. In the opinion of management, the outcome of these and any other pending legal matters will not have a material adverse effect on our financial condition, results of operations or cash flows.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section9" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 4. Mine Safety Disclosures</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span id="Section10" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART II</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section11" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Market Information</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;SILK,&#8221; and began trading on April 4, 2019. Prior to that date, there was no public trading market for our common stock.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Holders of Record</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of January 31, 2024, there were approximately </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">54 </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">stockholders of record of our common stock. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">77</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Dividends</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have never declared or paid, and do not anticipate declaring or paying, any cash dividends on any of our capital stock. We do not anticipate paying any dividends in the foreseeable future, and we currently intend to retain all available funds and any future earnings for use in the operation of our business, to finance the growth and development of our business and for future repayment of debt. Future determinations as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing conditions, including our operating results, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, our term loan agreement limits our ability to pay dividends or make other distributions or payments on account of our common stock, in each case subject to certain exceptions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Recent Sales of Unregistered Securities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We did not sell any unregistered shares of our common stock or other equity securities of ours during the quarter ended December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Issuer Purchases of Equity Securities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We did not purchase any shares of our common stock or other equity securities of ours during the quarter ended December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Performance Graph</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following graph illustrates a comparison of the total cumulative stockholder return on our common stock with the total return for (i) the Nasdaq Composite Index (U.S.) and (ii) the Nasdaq U.S. Benchmark Medical Equipment TR Index for the period from April 4, 2019 (the first day of trading of our common stock), through December 31, 2023. The graph assumes an investment of $100 in our common stock at market close on April 4, 2019 and the reinvestment of dividends, if any. The comparisons in the table are not intended to forecast or be indicative of possible future performance of our common stock. This graph shall not be deemed &#8220;soliciting material&#8221; or be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the "Securities Act"), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="silk-20231231x10kg006.jpg" style="width: 7.300071in; height: 4.01519in" alt="A graph showing the number of companies&#10;&#10;Description automatically generated with medium confidence"/></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">78</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.38in;"><td style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">$100 investment in stock or index</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Apr. 4, 2019</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Jun. 30, 2019</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sep. 30, 2019</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Dec. 31, 2019</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Mar. 31, 2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Jun. 30, 2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sep. 30, 2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Dec. 31, 2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Mar. 31, 2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Jun. 30, 2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sep. 30, 2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Dec. 31, 2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Mar. 31, 2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Jun. 30, 2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sep. 30, 2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Dec. 31, 2022</span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Mar. 31, 2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Jun. 30, 2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sep. 30, 2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 3.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Dec. 31, 2023</span></p></td></tr><tr style="height: 0.25in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Silk Road Medical, Inc. (SILK) </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">134</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">112</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">87</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">116</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">186</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">174</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">140</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">132</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">152</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">118</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">114</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">124</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">146</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34</span></p></td></tr><tr style="height: 0.23in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Nasdaq Composite </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">102</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">102</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">115</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">99</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">129</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">144</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">166</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">171</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">188</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">187</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">203</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">185</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">144</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">138</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">137</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">160</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">181</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">174</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">198</span></p></td></tr><tr style="height: 0.49in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Nasdaq US Benchmark Medical Equipment TR</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">105</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">117</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">96</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">112</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">130</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">144</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">145</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">162</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">171</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">179</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">163</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">135</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">130</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">145</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">148</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">153</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">137</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">151</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section12" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 6. [Reserved]</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section13" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">79</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 7. Management&#8217;s Discussion And Analysis Of Financial Condition And Results Of Operations</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; beginning on page 1.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">This section of this Annual Report on Form 10-K generally discusses 2023 and 2022 items and year-to-year comparisons between 2023 and 2022. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 that are not included in this Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="_Hlk125819665" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Overview</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a medical device company focused on reducing the risk of stroke and its devastating impact. We believe a key to stroke prevention is minimally-invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke. We have pioneered a relatively new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care. </span><span id="_Hlk95345490" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We manufacture and sell in the United States our portfolio of TCAR products, which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We began commercializing our products in the United States in late 2015. Our products are currently the only devices cleared and approved by the FDA specifically for transcarotid use. </span><span id="_Hlk125746517" style="text-decoration: none;"></span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the second quarter of 2022, we announced FDA </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">label and Medicare coverage expansions for the use of TCAR in standard surgical risk patients</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TCAR is reimbursed based on established CPT codes and ICD-10 codes related to carotid stenting that track to MS-DRG classifications. We expanded our product portfolio with the full market release of our ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter in the second quarter of 2023. Also in the second quarter of 2023, we received 510(k) clearance for our next generation neuroprotection system, or ENROUTE NPS PLUS, which is designed to support additional ease-of-use and further minimize the risk for complications. We are planning for the upcoming launch of our ENROUTE NPS PLUS in the first half of 2024. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also received PMA approval for tapered configurations of our ENROUTE stent in the second quarter of 2023,</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">which provides greater choice for physicians to address the diversity of patient specific anatomy. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We initiated a limited market release in the first quarter of 2024 with a full market release planned in the first half of 2024. As of December 31, 2023, more than 85,000 TCAR procedures have been performed globally, including more than 25,000 in the United States during 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Products for CAS, including our TCAR products, are covered for Medicare beneficiaries under certain circumstances under the Centers for Medicare and Medicaid Services, or CMS&#8217;s, National Coverage Decision, or NCD, 20.7 for Percutaneous Transluminal Angioplasty. In January 2023, the CMS initiated a national coverage analysis of NCD 20.7. A final decision memo was released on October 11, 2023. In the final decision memo, CMS determined that coverage of percutaneous transluminal angioplasty, or PTA, of the carotid artery concurrent with stenting is reasonable and necessary with the placement of an FDA approved carotid stent with an FDA-approved or cleared embolic protection device, for Medicare beneficiaries in patients with symptomatic carotid artery stenosis &#8805;50% and in patients with asymptomatic carotid artery stenosis &#8805;70% under the following conditions: </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurological assessment must be performed by a neurologist or NIH stroke scale (NIHSS) certified health professional before and after CAS;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">First-line evaluation of carotid artery stenosis must use duplex ultrasound;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Computed-tomography angiography (CTA) or magnetic resonance angiography (MRA), if not contraindicated, must be used to confirm degree of stenosis, and provide information about the aortic arch, and extra and intra-cranial circulation; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intra-arterial digital subtraction (catheter) angiography may be used only when there is significant discrepancy between non-invasive imaging results or contraindicated for CTA or MRA.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">80</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prior to furnishing CAS, the practitioner must engage in a shared decision-making interaction with the beneficiary, which must include:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion of all treatment options for carotid stenosis, including CEA, CAS (which includes TCAR), and optimal medical therapy (OMT);</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Explanation of risks and benefits for each option specific to the beneficiary&#8217;s clinical condition;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Integration of clinical guidelines (e.g., patient co-morbidities and concomitant treatments); and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61607;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Discussion and incorporation of beneficiary&#8217;s personal preferences and priorities in choosing a treatment plan. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Facilities must establish and maintain institutional and physician standards to support a dedicated carotid stent program. However, CMS facility approval or certification is not required. The Medicare Administrative Contractors will have discretion to make carotid artery stenting coverage determinations not addressed in NCD 20.7. As a result of the expansion of coverage in NCD 20.7 and CMS&#8217;s stated goals for broader patient access, we believe there could be rising interest and awareness in minimally invasive carotid stenting procedures including TCAR.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We designed our U.S. commercial strategy and built our direct sales force with a particular focus on vascular surgery practices. Vascular surgeons are skilled in endovascular procedures, and our sales and marketing efforts are focused on driving adoption and supporting their practice development by offering them an innovative, safe, effective and minimally-invasive alternative for treating carotid artery disease. We also market to other specialists with experience in CEA or CAS with the appropriate skill set for TCAR, including neurosurgeons, cardiothoracic surgeons and non-surgical interventionalists in radiology, neuroradiology and cardiology. We also work on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders. We consider the hospitals and medical centers where the procedure is performed to be our customers, as they typically are responsible for purchasing our products. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our sales and marketing efforts are focused on leveraging our broad commercial footprint to drive utilization across our trained physician base. This includes onboarding and training new sales, sales management, and other field professionals to expand and align our territories and increase touch points with our customers. During 2023, we expanded our sales and marketing infrastructure, including a number of sales personnel and sales territories, to help us drive and support revenue growth. These changes naturally result in some sales disruption, which disruption adversely affected our revenue in various periods throughout 2023 and may continue to adversely affect our revenue through the first half of 2024.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">While we do not currently sell our products in markets outside the United States, we have obtained some and are pursuing additional regulatory approvals and commercial partners for selling certain of our products in Japan and China. In Japan, we received Shonin approval for the ENROUTE NPS and the ENROUTE stent in the fourth quarter of 2022, and we submitted for Shonin approval for the ENROUTE NPS PLUS in the second quarter of 2023. During the fourth quarter of 2023, we entered into a distribution agreement for our products in Japan, and are pursuing next steps including assessing the reimbursement process and our pathway and timeline to launch in Japan. In China, in the first quarter of 2023, we received approval from China&#8217;s NMPA for our ENROUTE NPS. During the first quarter of 2024 we received approval from China&#8217;s NMPA for our ENROUTE stent, and we also entered into a distribution agreement for our products in China. We expect to submit our ENROUTE NPS PLUS for NMPA approval during the first quarter of 2024.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We manufacture and distribute the ENROUTE NPS and ENROUTE NPS PLUS at our facilities in Sunnyvale, California, and Plymouth, Minnesota using components and sub-assemblies manufactured both in-house and by third party manufacturers and suppliers. We believe our combined facilities will be sufficient to meet our manufacturing needs for at least the next five years. We purchase our other products, including our ENROUTE stent and ENROUTE Enflate product, from third-party contract manufacturers. Many of our third-party manufacturers and outside vendors are currently single-source suppliers. We remain concerned with the ability of a critical supplier of certain polymer tubing materials, and related components used in our products to provide us and our third party manufacturer these polymer tubing materials on a timely basis. If this supplier is unable to provide these polymer tubing materials on a timely basis, it could result in TCAR product delays to our customer. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Components of our Results of Operations</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Revenue</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently derive all of our revenue from the sale of our portfolio of TCAR products to hospitals and medical centers in the United States. Each of our products is purchased individually, and the majority of our revenue is derived from sales of the ENROUTE NPS and the ENROUTE stent. No single customer accounted for 10% or more of our revenue during </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">81</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the years ended December 31, 2023 and 2022.&#160;K</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ey performance indicators that drive our revenue include the number of procedures, the number of active sales territories, the number of trained physicians certified to perform TCAR, the number of hospital accounts that perform our procedures, the number of procedures per physician or hospital account, revenue per procedure, introduction of new products, product mix and average selling prices for our products. We expect our revenue to continue to increase in the future through increased adoption of TCAR and as a result of the introduction of new products and international expansion. However, any decreases in our key performance indicators could have a negative impact on our future revenue, as could other factors, such as price pressures, increased labor costs, labor and staffing shortages, hospital capacity and patient behavior caused by COVID-19 or as a result of general macroeconomic factors, and increased competition. In addition, we have expanded our sales and marketing infrastructure</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, including a number of sales personnel and sales territories, to help us drive and support revenue growth and we intend to continue this expansion. These changes naturally result in some sales disruption, which disruption adversely affected our revenue in various periods throughout 2023, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we expect this may continue to adversely affect our revenue through the first half of 2024.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our revenue has fluctuated and we expect to continue to fluctuate from quarter-to-quarter due to a variety of factors, including seasonality and number of selling days. With respect to seasonality, our first quarter revenue may be harmed by adverse weather and the resetting of annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures. Holiday and summer vacations by healthcare providers and/or patients may adversely affect procedure volumes that in turn affect hospital ordering patterns. In addition, we have also experienced moderate procedure volumes during major medical conferences when significant portions of our customer base are attending the conferences.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cost of Goods Sold and Gross Margin</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently manufacture the ENROUTE NPS and ENROUTE NPS PLUS at our facilities in California and Minnesota. We purchase our other products from third-party manufacturers. Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, direct labor, manufacturing overhead, scrap, product rework, reserves for excess, obsolete and non-sellable inventories, as well as distribution-related expenses. Overhead costs include the cost of quality control, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs, such as those incurred for shipping our products and royalties related to the sale of our ENROUTE stent. We expense all inventory provisions as cost of goods sold. We record adjustments to our inventory valuation for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions. We expect cost of goods sold to increase in absolute dollars to the extent more of our products are sold.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, including primarily average selling prices, product sales mix, production and ordering volumes, manufacturing costs, product yields, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">replacement of expired product, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">headcount, and cost-reduction strategies. We expect our gross margin to increase over the long-term as our production and ordering volumes increase and as we spread the fixed portion of our overhead costs over a larger number of units produced, potentially offset by inflationary pressures and investments in additional operational infrastructure in both our California and Minnesota facilities. Specifically, we have and may continue to experience inflationary and price pressures and increased labor costs and labor and staffing shortages affecting the cost of the components for our TCAR products and the wages that we pay our employees, as well as the wages our vendors pay their employees, due to challenging labor market conditions. We began commercial production at our Plymouth, Minnesota facility during the third quarter of 2022; with two manufacturing facilities, we expect our gross margin to continue to be slightly lower in the short term. We intend to use our design, engineering and manufacturing know-how and capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and have a positive long-term impact on our gross margin. However, our gross margin could fluctuate from quarter to quarter as we introduce new products, execute certain manufacturing engineering projects, adopt new manufacturing processes and technologies, and expand our distribution operations and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">infrastructure to support our planned long-term growth and risk mitigation. In addition, possible resurgences of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">COVID-19 and new virus variants may negatively impact our gross margin in the near term due to unfavorable production variances as a result of lower production and lower demand.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research and Development Expenses</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development, or R&amp;D, expenses consist primarily of engineering, product development, clinical studies to develop and support our products, regulatory expenses, medical affairs, and other costs associated with products and technologies that are in development. These expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">82</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">facility overhead expenses, in each case related to R&amp;D programs. Additionally, R&amp;D expenses include costs associated with our clinical studies, including clinical trial design, clinical trial site initiation and study costs, data management, related travel expenses and the cost of products used for clinical trials, internal and external costs associated with our regulatory compliance and quality assurance functions and overhead costs. We expect R&amp;D expenses as a percentage of revenue to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial and other related activities. In addition, possible resurgences of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">COVID-19 and new virus variants may impact our product development efforts and clinical and regulatory matters for the foreseeable future. COVID-19 has impacted enrollment in clinical trials across the medical device industry and may affect any new trials we decide to pursue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Selling, General and Administrative Expenses</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Selling, general and administrative, or SG&amp;A, expenses consist primarily of compensation for personnel, including stock-based compensation, related to selling and marketing functions, physician education programs, commercial operations and analytics, reimbursement, finance, information technology and human resource functions. Other SG&amp;A expenses include sales commissions, training, travel expenses, promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees (including legal, audit and tax fees), insurance costs, general corporate expenses and allocated facilities-related expenses. We expect SG&amp;A expenses to continue to increase in absolute dollars as we expand our infrastructure to both drive and support anticipated growth in revenue and as we expand our presence. In addition, we plan to continue exploring sales and marketing expansion opportunities in international geographies. While we expect SG&amp;A expenses to increase, we expect SG&amp;A expenses as a percentage of revenue to decrease over time due to anticipated increased revenue.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span id="_Hlk95347004" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Interest Income (Expense), net</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest income (expense), net consists primarily of cash interest expense incurred on our outstanding indebtedness and non-cash interest expense related to the accretion of closing fees and amortization of debt discount and issuance costs associated with our debt agreements. Our interest expense is offset by interest income earned on our cash, cash equivalents and investments.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Results of Operations:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(in thousands, except percentages)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Change</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">% Change</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 177,134</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 138,638</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 38,496</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">28%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of goods sold</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 50,048</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 37,876</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 12,172</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">32%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gross profit</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 127,086</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 100,762</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 26,324</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating expenses:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 41,324</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 36,449</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 4,875</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Selling, general and administrative</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 145,033</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 116,317</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 28,716</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 186,357</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 152,766</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 33,591</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss from operations</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (59,271)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (52,004)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (7,267)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest income (expense), net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 3,086</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (2,571)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 5,657</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">220%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss on debt extinguishment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (245)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 245</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other income (expense), net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 442</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (190)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 632</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (55,743)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (55,010)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (733)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1%</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Comparison of Years Ended December 31, 2023 and 2022</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Revenue. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Revenue increased </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$38.5&#160;million, or&#160;28%, to $177.1&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">million during the year ended December&#160;31, 2023, compared to $138.6 million during the year ended December&#160;31, 2022. The increase in revenue was attributable to an increase in the number of products sold as physicians performed more TCAR procedures and as we expanded our sales territories, increased the number of new accounts, and trained more physicians in TCAR. </span><span id="_Hlk95999777" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although revenue increased as compared with the prior year period, it was impacted by the natural sales disruption resulting from the expansion of our sales and marketing infrastructure during 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 92.9%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.21in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Cost of Goods Sold and Gross Margin. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Cost of goods sold increased $12.2</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, or&#160;32%, to $50.0&#160;million during the year ended December&#160;31, 2023, compared to $37.9&#160;million during the yea</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">r ended December&#160;31, 2022. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This increase </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">83</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 92.9%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.21in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">was attributable to the increase in the number of products sold</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Gross margin for the year ended December&#160;31, 2023 decreased to</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;72</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, compared to 73% for the year ended December&#160;31, 2022</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The decrease in gross margin during 2023 was driven by unfavorable production variances, as a result of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">production rework being completed in the first quarter of 2023, and also by higher manufacturing costs associated with labor and materials and having two manufacturing facilities compared to one facility for most of the prior year period. Gross margin for 2022 was adversely affected by COVID-19 related production issues in the first quarter of 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 92.9%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.10in;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Research and Development Expenses.  </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">R&amp;D expenses increased</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> $4.9&#160;million, or 13%, to $41.3 million during the year ended December&#160;31, 2023, compared to $36.4&#160;million during the year ended December&#160;31, 2022. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This was driven primarily by growth in personnel and investment in new and ongoing R&amp;D programs and specifically by an increase of $4.3 million in personnel-related expenses, including stock-based compensation, as a result of increased headcount, an increase of $0.8 million in clinical and regulatory expenses, and an increase of $0.4 million related to product development materials. This increase was partially offset by a decrease in outside services fees.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 93.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.10in;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 93.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.10in;margin-top: 0;text-indent: 0.23in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Selling, General and Administrative Expenses. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> SG&amp;A expenses increased $28.7&#160;million</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, or&#160;25%, to </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$145.0&#160;million during the year ended December&#160;31, 2023, compared to $116.3&#160;million during the year ended December&#160;31, 2022</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. This increase was primarily due to the continued expansion of our sales team and commercial efforts, compared to the prior year period. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">More specifically, the increase is attributable to an increase of $24.8 million in payroll and personnel-related expenses, an increase of $1.5 million in consulting and professional fees, a net increase of $1.2 million in physician training and travel-related costs, an increase of $0.7 million in software-related costs, and an increase of $0.5 million in the allocated costs of facilities and other related expenses. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Personnel-related expenses included stock-based compensation expense of $29.6&#160;million and $18.6&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 95.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.04in;margin-top: 0;text-indent: 0.23in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Interest Income (Expense), Net. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Interest income (expense), net increased $5.7 million, or 220%, to income of $3.1 million during the year ended December 31, 2023, compared to an expense of $2.6 million during the year ended December 31, 2022. The increase in net interest income was attributable to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">higher average balances and higher weighted average interest rates on our cash, cash equivalents and investments, partially offset by both the increased interest rate and increased amount of borrowings outstanding under our loan agreement as a result of our May 2022 refinancing of our debt obligation as compared with the prior period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other Income (Expense), Net. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Other income (expense), net increased to income of $0.4 million during the year ended December 31, 2023, compared to an expense of $0.2 million during the year ended December 31, 2022. The increase in net other income was attributable to $0.6 million in other income received under a government grant and job creation fund, partially offset by losses on the disposal of property and equipment during the year.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Liquidity and Capital Resources</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Sources of Liquidity</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To date, our principal sources of liquidity have been net proceeds from sales of our common stock in public offerings, private sales of our equity securities, and debt financings, as well as revenue from product sales, which we expect to be our primary source of future liquidity, and to a lesser extent, proceeds from stock option exercises and employee stock purchase plan purchases. As of&#160;December 31, 2023, we had cash, cash equivalents and</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> investments of $190.9 million,</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> $75.0 million outstanding principal in term loans, an additional $125.0 million in available but unused term loans, and $25.0 million in availability under a revolving credit facility available under a loan agreement, as described in more detail below.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2022, we completed an underwritten public offering of approximately 2.7 million shares of our common stock at a public offering price of $43.00 per share, resulting in net proceeds of approximately $109.0 million.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect to continue to devote a substantial amount of our capital resources to expand commercialization efforts and increase adoption of TCAR using our products, conduct clinical studies and expand our clinical evidence base, and develop additional products. We also plan to continue exploring the future sale of our products in select international geographies. In addition, as a public company, we incur significant legal, accounting, director and officer liability insurance, exchange listing and SEC compliance, investor relations and other expenses, all of which continue to increase. Because of these and other factors, we expect to continue to incur substantial net losses and negative cash flows from operations for the foreseeable future.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe our existing cash, cash equivalents and investments, together with our expected revenue, will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months from the issuance date of the financial statements contained in this report.</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Our future funding requirements will depend on many factors, including:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">84</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The degree and rate of market acceptance of TCAR and our products;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The total market opportunity for our products and our ability to penetrate and capture market share from other competing products and technologies;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to continue to grow our revenues and maintain pricing and gross margins, especially in light of increased competition or investor perception thereof;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The effect of competing technologies and products on our business, operating results and prospects, or other adverse market developments;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The scope and timing of investment in and the future success of our sales force, marketing initiatives and physician training programs;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The scope, rate of progress and cost of our research and development activities, current or future clinical studies and additional regulatory clearances or approvals;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The scope and timing of investment in acute ischemic stroke and other neurovascular and cardiac products we may develop;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The rate at which we expand internationally and our ability to launch and sell our products successfully in such markets;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Whether we acquire third-party companies, products or technologies;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restructuring, refinancing or repayment of debt;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The costs associated with any future product recall that may occur;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The costs of attaining, defending and enforcing our intellectual property rights; and</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The impact of health pandemics, epidemics and other outbreaks, such as COVID-19 and its variants, on our business and operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Loan Agreement</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On May 27, 2022, we entered into a Loan and Security Agreement, or Loan Agreement, with Oxford Finance LLC and its agent, or Oxford Finance, which provides for </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a $225.0 million loan facility, comprised of a $25.0 million secured revolving credit facility and a $200.0 million secured term loan facility. W</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">e concurrently drew down $75.0&#160;million under the term loan facility and used a portion of the proceeds to pay off outstanding amounts under and terminate our prior loan agreement with Stifel Bank.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The term loans are available in three tranches. Upon our request, the revolving credit facility will be increased from $25.0 million to $50.0 million. The revolving loans are available subject to a borrowing base equal to 85% of eligible receivables plus 50% of eligible inventory, up to the lesser of 40% of the borrowing base or $10.0 million in the case of eligible inventory. As of December 31, 2023, there were no amounts outstanding under the $25.0 million secured revolving credit facility.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The term loans and any revolving loans mature on May 1, 2027. The principal amount of outstanding term loans are required to be repaid in equal monthly installments beginning on July 1, 2026. Since we achieved a specified consolidated trailing twelve-month revenue target, we have the option to extend the first amortization date for the term loans to July 1, 2027, which option must be exercised no earlier than June 30, 2023 and no later than 30 days prior to July 1, 2026. To date, we have not exercised this option. If we exercise this option, then the maturity date for both the revolving loans and the term loans will be May 1, 2028. The principal amount of outstanding revolving loans, together with accrued and unpaid interest, is due on the maturity date.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any revolving loans under the Loan Agreement accrue interest at the greater of 1-month Secured Overnight Financing Rate, or SOFR, or the Index Rate, and 0.85%, plus a margin of 3.00%. The term loans accrue interest at the greater of the Index Rate and 0.85%, plus a margin of 5.00%. The Index Rate is capped at 2.50% for purposes of the Loan Agreement. Interest on both revolving loans and term loans is payable monthly in arrears. As of December 31, 2023, the aggregate outstanding principal balance under the term loan facility was $75.0 million with the variable interest rate capped at the maximum rate of 7.50%, and no amounts were outstanding under the revolving credit facility of the Loan Agreement. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The term loan may not be reborrowed once repaid, but we may prepay the term loan at any time in full, or in </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">85</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">part in increments of $10.0 million. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are required to pay a prepayment fee of 3.0% for prepayments of term loans made in the first year after closing, 2.0% for prepayments of term loans made in the second year after closing, 1.0% for prepayments of term loans made in the third year after closing and no prepayment fees thereafter. Upon the earlier of prepayment or maturity of the term loans, we are required to pay a fee of 5.0% of the aggregate original principal amount of the funded term loans, which fee increases to 6.75% if we exercise our option to extend the amortization date and maturity date. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are also obligated to pay other customary fees for a loan facility of this size and type. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our obligations under the Loan Agreement are secured by substantially all of our assets. The Loan Agreement requires that we maintain </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consolidated trailing twelve-month revenues of at least 75% of the outstanding principal amount of the term loans, measured as of the last day of each fiscal quarter; or if the revenue target is not achieved, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we must have maintained unrestricted cash and cash equivalents (net of outstanding revolving loans) subject to control agreements in favor of Oxford Finance equal to at least 50% of the outstanding principal amount of the term loans</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting our ability and the ability of our subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of our obligations under the Loan Agreement, the termination of the lender&#8217;s commitments, a 5% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, the aggregate outstanding principal balance under the Loan Agreement was</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75.0</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> mil</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">lion and the variable interest rate was 7.5%. As of December 31, 2023, we were in compliance with all covenants under the term loan agreement.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Material Cash Requirements</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our material cash requirements include our outstanding term loan under the Loan Agreement, operating leases and non-cancellable purchase commitments. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, we had principal, interest and fees commitments of $95.9 million under the Loan Agreement, of which $5.9 million in interest and fees is expected to be paid within the next 12 months. Our operating lease commitments consist of our lease obligations for our facilities in Sunnyvale, California and Plymouth, Minnesota. Our total operating lease commitments as of December 31, 2023 are approximately $10.8 million, of which $2.0 million is expected to be paid within the next 12 months.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have non-cancellable purchase commitments primarily related to our ENROUTE stent, as described under &#8220;Cordis Supply Agreement&#8221; below and other inventory components of approximately $14.4 million within the next 12 months.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cordis License Agreement</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have paid Cordis a one-time license execution fee and are obligated to pay royalties to Cordis on a calendar quarter basis during the term of the Cordis License Agreement, calculated based on net sales of the licensed products we sell during the preceding quarterly period. The license granted under Cordis License Agreement shall remain in full force and effect unless terminated by mutual agreement between us and Cordis.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cordis Supply Agreement </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are obligated under the Cordis Supply Agreement to purchase a minimum volume of the ENROUTE stent annually. This obligation is binding during the term of the Cordis Supply Agreement.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">86</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash Flows</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes our cash flows for each of the periods presented below:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="10" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash (used in) provided by:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating activities </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (32,014)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (32,581)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (38,935)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Investing activities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (7,176)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (162,068)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 72,644</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financing activities </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 3,887</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 139,699</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 6,978</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 49.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net increase (decrease) in cash, cash equivalents and restricted cash </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (35,303)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (54,950)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 40,687</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Cash Used in Operating Activities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities for the year ended December 31, 2023 was $32.0 million, consisting primarily of a net loss of $55.7 million and an increase in net operating assets of $13.9 million, partially offset by non-cash charges of $37.6 million. The change in net operating assets was primarily due to increases in accounts receivable, due to an increase in sales, in inventories, to support the growth of our operations, prepaid expenses and other current assets, and an increase in accounts payable and accrued liabilities due to the timing of payments and the growth of our operations and accrued payroll and related expenses. The non-cash charges primarily consisted of stock-based compensation, as well as depreciation and amortization, accretion of discounts on investments, amortization of right-of-use assets, non-cash interest expense, provision for excess and obsolete inventories, and a loss on the disposal of property and equipment. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities for the year ended December 31, 2022 was $32.6 million, consisting primarily of a net loss of $55.0 million and an increase in net operating assets of $6.0 million, partially offset by non-cash charges of $28.4 million. The increase in net operating assets was primarily due to increases in accounts receivable due to an increase in sales and in inventories to support the growth of our operations and a decrease in other liabilities due to the timing of payments. These changes were partially offset by increases in accounts payable and accrued liabilities, due to the timing of payments and the growth of our operations and accrued payroll and related expenses. The non-cash charges primarily consisted of stock-based compensation, as well as depreciation and amortization, amortization of right-of-use assets, non-cash interest expense, accretion of discounts on investments, loss on debt extinguishment and a loss on the disposal of property and equipment. We recognized a loss on debt extinguishment of $0.2 million in connection with the early termination of our prior term loan agreement with Stifel Bank.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Cash Provided by (Used in) Investing Activities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 96.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.18in;margin-top: 0;text-indent: 0.23in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in investing activities in the year ended December 31, 2023 was $7.2 million, which consisted of purchases of investments of $175.0 million and purchases of property and equipment of $1.5 million, partially offset by proceeds from maturities of investments of $169.3 million.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 96.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.18in;margin-top: 0;text-indent: 0.23in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in investing activities in the year ended December 31, 2022 was $162.1 million, which consisted of purchases of investments of $168.2 million and purchases of property and equipment of $5.0 million, partially offset by proceeds from maturities of investments of $11.1 million.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Cash Provided by Financing Activities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 96.7%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.25in;margin-top: 0;text-indent: 0.23in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities in the year ended December 31, 2023 was $3.9 million, which reflects proceeds from stock option exercises and purchases under our employee stock purchase plan.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities in the year ended December 31, 2022 was $139.7 million, which reflects net proceeds of $109.0 million from our October 2022 public offering and net proceeds of $73.9 million from the issuance of debt, partially offset by repayment of debt of $49.0 million and proceeds from stock option exercises and purchases under our employee stock purchase plan of $5.8 million.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Critical Accounting Policies and Estimates</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">87</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">While our significant accounting policies are more fully described in Note&#160;2 of our audited financial statements included in this Annual Report on Form 10-K, we believe the following discussion addresses our most critical accounting policy, which is most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Revenue Recognition</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our revenue is generated from the sale of our products to hospitals and medical centers in the United States through direct sales representatives and is primarily comprised of product revenue net of returns, administration fees and sales rebates. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of our products to customers, either upon shipment of the product or delivery of the product to the customer under our standard terms and conditions.&#160;Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the goods. We accept product returns at our discretion or if the product is defective as manufactured. We establish estimated provisions for returns based on historical experience and consideration of other factors that we believe could significantly impact our expected returns.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Recently Issued Accounting Pronouncements </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See Note 3 to our financial statements included elsewhere in this Annual Report on Form 10-K for new accounting pronouncements not yet adopted as of the date of this Annual Report on Form 10-K.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section14" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate sensitivities, credit risk, foreign currency exchange rate sensitivity and inflation risk.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Interest Rate Risk</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our exposure to market risk is principally confined to our cash, cash equivalents and investments and our outstanding variable-rate term debt, capped at the maximum rate of 7.50%.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We had cash, cash equivalents and investments of $190.9&#160;million as of December 31, 2023, which consisted of bank deposits, money market funds, U.S. government securities, U.S. treasury bills, commercial paper, corporate bonds/notes, and agency bonds/notes. The primary objectives of our investment activities are the preservation of capital and support of our liquidity requirements. We place our cash, cash equivalents, and investments with high-quality financial institutions and have established investment guidelines relative to diversification and maturities designed to maintain safety and liquidity. Our investments are exposed to market risk due to fluctuations in interest rates, which may affect our income and the fair market value of our investments. If interest rates rise, the market value of our investments may decline, which could result in a realized loss if we sell an investment before its scheduled maturity.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. A hypothetical 10% change in interest rates would not have a material impact on the value of our cash and cash equivalents or our investments as of December 31, 2023. While we believe our cash, cash equivalents, and investments do not contain excessive risk, we cannot provide absolute assurance that, in the future, our investments will not be subject to adverse changes in market value.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are also subject to interest rate risk from variable interest rates applicable to borrowings under our Loan Agreement in light of the variable interest rates thereunder. Any revolving loans under the Loan Agreement accrue interest at the greater of 1-month SOFR, or the Index Rate, and 0.85%, plus a margin of 3.00%. The term loans accrue interest at the greater of the Index Rate and 0.85%, plus a margin of 5.00%. The Index Rate is capped at 2.50% for purposes of the Loan Agreement. As of December 31, 2023, the aggregate outstanding principal balance under the term loan facility was $75,000,000 with the variable interest rate capped at the maximum rate of 7.50% and no amounts were outstanding under the revolving credit facility.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">88</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Credit Risk</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023 and 2022, a portion of our cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of our cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. On March 10, 2023, SVB was shut down and placed under receivership with the Federal Deposit Insurance Corporation, or FDIC, by the California Department of Financial Protection and Innovation. On March 26, 2023, the FDIC announced it had entered into a purchase and assumption agreement with First Citizens Bank &amp; Trust Company under which all of SVB&#8217;s deposits were assumed. As of the issuance date of the financial statements included in this report, we have not experienced any losses on our deposits and all of our cash deposited with SVB has been accessible to us. Given the continued potential instability of financial institutions, we cannot provide assurance that we will not experience losses on these deposits.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, our cash equivalents and investments are invested in highly rated money market funds, U.S. treasury bills, U.S. government securities, commercial paper, corporate bonds/notes, and agency bonds/notes. Uncertain financial markets, or a U.S. sovereign default or threat thereof, could result in a tightening in the credit markets, a reduced level of liquidity in many financial markets, and extreme volatility in fixed income and credit markets. The credit ratings of securities in our investments could deteriorate and may have an adverse impact on the carrying value of these investments.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our accounts receivable primarily relate to revenue from the sale of our products to hospitals and medical centers in the United States. No customer represented 10% or more of our accounts receivable as of December 31, 2023 or 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Foreign Currency Risk</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business is conducted primarily in U.S. dollars. Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our results of operations, financial position or cash flows.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Inflation Risk</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Macroeconomic challenges in the global economy have contributed to a rising inflationary trend and impacted our cost of goods sold and selling and operating expenses, which we expect to continue into the foreseeable future. If our costs become subject to prolonged, significant inflationary pressures, we may not be able to fully offset such higher costs through price increases, which would have an adverse effect on our ability to maintain or increase our gross margin. Our inability or failure to do so could harm our business, financial condition or results of operations.</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section15" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">89</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 8. Financial Statements and Supplementary Data</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span id="Section16" style="text-decoration: none;"></span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Page(s)</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section17" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;"> (PCAOB ID </span><ix:nonNumeric name="dei:AuditorFirmId" id="ct-nonNumeric-dbdb8bdb-4728-4617-a5cc-3ef229539c4e" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">238</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">91</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Financial Statements:</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.13in;margin-right: 0;margin-top: 0;"><a href="#Section18" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Balance Sheets as of December 31, 2023 and December 31, 2022</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">93</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.13in;margin-right: 0;margin-top: 0;"><a href="#Section19" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, December 31, 2022 and December 31, 2021</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">94</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.13in;margin-right: 0;margin-top: 0;"><a href="#Section20" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Statements of Stockholders' Equity for the years ended December 31, 2023, December 31, 2022 and December 31, 2021</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">95</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.13in;margin-right: 0;margin-top: 0;"><a href="#Section21" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Statements of Cash Flows for the years ended December 31, 2023, December 31, 2022 and December 31, 2021</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">96</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 93.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section22" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Notes to Financial Statements</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">97</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">90</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 115.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Section17" style="text-decoration: none;"></span><span id="eXC_Paragraph_9" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Report of Independent Registered Public Accounting Firm</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Paragraph_5" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 10pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="eXC_Paragraph_10" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the Board of Directors and Stockholders of Silk Road Medical, Inc.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 10pt;"><span id="eXC_Paragraph_11" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p dir="ltr" style="font-family: Georgia;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="eXC_Paragraph_12" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have audited the accompanying balance sheets of Silk Road Medical, Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for each of the three years in the period ended December 31, 2023, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2023 appearing under Item 15(b) (collectively referred to as the &#8220;financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Internal Control - Integrated Framework </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Internal Control - Integrated Framework </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(2013) issued by the COSO. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 10pt;"><span id="eXC_Paragraph_16" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Basis for Opinions</span></p><p dir="ltr" style="font-family: Georgia;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Paragraph_13" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 10pt;"><span id="eXC_Paragraph_21" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Definition and Limitations of Internal Control over Financial Reporting</span></p><p dir="ltr" style="font-family: Georgia;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="eXC_Paragraph_22" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">91</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 10pt;"><span id="eXC_Paragraph_25" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Critical Audit Matters</span></p><p dir="ltr" style="font-family: Georgia;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Paragraph_4" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Revenue recognition </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As described in Note 2 to the financial statements, the Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer. The Company&#8217;s total revenue was $177.1 million for the year ended December 31, 2023. Revenue is measured as the amount of consideration management expects to receive in exchange for transferring the goods. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The principal consideration for our determination that performing procedures relating to revenue recognition is a critical audit matter is the significant audit effort in performing procedures related to the accuracy and occurrence of revenue transactions. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process, including controls over the recording of product sales upon shipment of the product or delivery of the product to the customer. These procedures also included, among others, (i) testing revenue transactions by evaluating the settlement of invoices and credit memos, ii) evaluating credit memos issued during the year, iii) tracing transactions not settled to a detailed listing of accounts receivable; iv) confirming a sample of outstanding customer invoice balances at year end and, for confirmations not returned, obtaining and inspecting source documents, including purchase orders, invoices, sales contracts, proof of delivery, and subsequent cash receipts, where applicable, and v) testing the completeness and accuracy of data provided by management. </span></p><p dir="ltr" style="font-family: Georgia;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 10pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ </span><ix:nonNumeric name="dei:AuditorName" id="ct-nonNumeric-63e5b38c-a5a5-471b-ac4c-56a069ae7855" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="dei:AuditorLocation" id="ct-nonNumeric-cb1e355c-3f95-4414-a9f4-0eab408ab67c" contextRef="Duration_1_1_2023_To_12_31_2023"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Minneapolis, Minnesota</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have served as the Co</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">mpany&#8217;s auditor si</span><span style="white-space:pre-wrap; color: #0D0D0D;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">nce 2013.</span><span style="white-space:pre-wrap; color: #0D0D0D;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">92</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Silk Road Medical, Inc.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance Sheets</span><span id="Section18" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(in thousands, except share and per share data)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current assets:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8a01f8fe-8d64-4aec-a765-7fba6b951669" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,210</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b154d7a1-f492-422f-8906-d669b9cfeb3f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,358</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term investments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-979d7000-c090-44fc-b015-72a5904d1cd4" name="us-gaap:ShortTermInvestments" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">161,264</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a5864c82-0797-4098-8f57-eabce967855e" name="us-gaap:ShortTermInvestments" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">158,316</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts receivable, net of allowances of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-001c33bd-de74-419b-b29e-2fb0f1240d70" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b8556836-f4b4-41cc-bbd9-eecd97da3a6e" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2023 and December 31, 2022, respectively</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8ec3ee82-a5f5-4196-94f8-e2d20220eccb" name="us-gaap:AccountsReceivableNetCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">23,573</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fc69540a-9be5-420e-86cd-81b565afa416" name="us-gaap:AccountsReceivableNetCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,007</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventories</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b2a4c56f-1a70-4862-91a8-8bc43853a77b" name="us-gaap:InventoryNet" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,876</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-64a6a187-a40a-4ada-a6dd-d4a6bc52a485" name="us-gaap:InventoryNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,293</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other current assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-95aca519-2028-4d02-9e71-7fad40ebcbe0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,912</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6df1c26b-d983-42ca-84b5-66c8eac618c6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,924</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-57dc7265-65ad-44d9-8fd2-be18a04d7653" name="us-gaap:AssetsCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">240,835</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b7c7a46f-a34c-402a-9318-f7c297f62996" name="us-gaap:AssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">254,898</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Long-term investments</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da4f6640-5c09-4164-9bba-875f49b60967" name="us-gaap:LongTermInvestments" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,456</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-17f41c34-b677-4478-ab37-783f06eeb4bc" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,114</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-80f9e379-ad1f-449d-a796-33b462a1eae4" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,372</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted cash</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7e100489-4c54-4ab8-b01a-e7936671a101" name="us-gaap:RestrictedCashNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">155</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other non-current assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f02e1a9e-9eae-4f4a-9051-0a69c8b9a6e3" name="us-gaap:OtherAssetsNoncurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,904</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-11945113-48c2-4b8b-924c-596b0c7166cd" name="us-gaap:OtherAssetsNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,260</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-79ed036a-6cf0-4d8d-9e7e-3b9fb7191522" name="us-gaap:Assets" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">265,309</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fa80caf6-2b5e-43e4-ad65-7a836aa8d10f" name="us-gaap:Assets" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">269,685</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Liabilities and stockholders' equity</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current liabilities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a5c45f17-390b-4252-925b-7be66a1c053a" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,676</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e1f38124-fb63-4cdd-b9a4-f90a0ee2c2e8" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,523</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued liabilities </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af51e4d7-74f1-43e2-908f-c14eaff0c80a" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,607</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-46d69562-caa9-4018-a8b6-e8d78c63ce3e" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">21,965</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd2271c3-71e6-49ec-a4fc-5799d9ec3e50" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">30,283</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d60f01f2-5a89-40fd-9574-c488ff99ca80" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,488</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Long-term debt</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5cdf34d3-f08d-41a1-bc88-ff47f5f571e7" name="us-gaap:LongTermDebtNoncurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">75,626</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-77dc75f0-7ca4-4425-96d5-3e469859fe5c" name="us-gaap:LongTermDebtNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">74,596</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb2e071d-7e27-49fb-acac-9ff7d6deab87" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,249</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4736b69c-34b4-4272-804a-006ed507d677" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,726</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ef9dc0ab-3e37-4f96-b88e-42dec3540838" name="us-gaap:Liabilities" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">114,158</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b622fff6-6c4a-42bd-948b-77c783ad1bdb" name="us-gaap:Liabilities" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">105,810</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commitments and contingencies (Note 7)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a637edb1-7f74-4201-a99b-726573bfe3e9;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-5d95aa1c-7eb9-4f49-8dc4-aea9daebaaab;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stockholders' equity:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Preferred stock, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b6f97c6f-bf0b-4440-9e22-e5f231de404c" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2022" unitRef="Unit14" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-0013cd6c-93bf-4f47-af6c-cc8fb690d51b" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2023" unitRef="Unit14" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares authorized: </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-45dd4530-4ee0-43f2-91c9-d3116e1a67dc" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-7f209ef9-340c-4704-ab3d-aca432eed82b" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2023 and 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares issued and outstanding: </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-332e647f-8317-4302-aab5-26e0ab07d432" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-a1aa765b-80c3-4703-826a-d57d1453f4da" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-dd7949bc-e93f-43ef-8406-960073a98719" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-55bd66d7-e026-4c2e-a6c8-8a666deebd4f" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2023 and 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-d65a29aa-c14e-4d87-b47f-02ec4e8f510e;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2cfee51e-ab0e-4f50-aac2-b407cda5d91f;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b201076-689d-40fc-b951-d4fd790dafae" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2022" unitRef="Unit14" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-a22d7ec7-33ab-41c8-9dd1-19c579b25d32" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2023" unitRef="Unit14" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares authorized: </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ef0f8c2f-346d-4152-afb6-ba6b0720b1c9" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-38d775ce-6e33-496d-96b4-225bf0bab13d" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2023 and 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares issued and outstanding:</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5681b80e-6694-422f-be34-5bd6a2b91523" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-6ee1dcf9-dc94-4f1f-98fd-de93f85bb342" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">39,165,481</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c7f422e2-2979-4c0b-9833-e5b0ece38573" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-13a0ef29-5ed4-45e1-9174-81b9464fe788" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">38,355,972</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2023 and 2022, respectively</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b354d0a3-e08d-4354-840c-03f0d0a3537f" name="us-gaap:CommonStockValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">39</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-de74bf65-8584-43ab-9a61-86c69d97bcc5" name="us-gaap:CommonStockValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">38</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additional paid-in capital</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ddb7b14-8fe0-4548-a1ee-c580da77c2a5" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">550,495</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f35d4a97-4d54-49ce-9a71-07c453d89365" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">507,715</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated other comprehensive income (loss)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d1ba76d9-709d-499e-a762-0ddc700a600c" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">72</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-62b0fb90-9ebc-4d12-8fc5-2ff02e35f117" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">166</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated deficit</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a3f2343-d00e-4f40-b5b0-ee29a91256f6" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">399,455</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b1cf982b-e28d-4451-854d-0a942a06ecbe" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">343,712</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stockholders' equity</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9dbba149-dd94-4dc6-984b-cc350667ca82" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">151,151</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e34129e6-03d7-46a1-a99a-93b1fbee2833" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">163,875</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 67.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities and stockholders' equity </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1e6faf5e-f8de-4c3f-b014-307c29684f27" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">265,309</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-82c25e71-4ec7-4bc0-b19d-2176ee68a59b" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">269,685</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying notes are an integral part of these financial statements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">93</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Silk Road Medical, Inc.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Statements of Operations and Comprehensive Loss</span><span id="Section19" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(in thousands, except share and per share data)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a163ea4a-9203-4a2d-8146-ce824b8c0fb8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">177,134</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d69a3144-90c4-4848-b6d7-4ce9031a75ce" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">138,638</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9044c1be-b212-460f-8ba7-d35a81ef7e36" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">101,475</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of goods sold</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd715232-ff84-482e-9526-4211d78a005b" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">50,048</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bf0dcba0-eefc-44c4-adb1-3add833e4700" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">37,876</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0786c3db-5cf1-4841-8680-2994309320a0" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25,446</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gross profit</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3134c32d-ccb5-4606-99ed-ef3c79b540e1" name="us-gaap:GrossProfit" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">127,086</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2463a5b6-4d20-4f74-9490-9161212d006c" name="us-gaap:GrossProfit" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">100,762</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-484e89d5-fc73-47ef-a60e-22850f04564d" name="us-gaap:GrossProfit" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">76,029</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating expenses:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ebb2f3b2-db7e-4c80-ad85-7cd16d874eaf" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">41,324</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-95100842-225e-4569-97e3-ff7c042fdef8" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">36,449</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4f53c027-56c2-46a4-a390-7242cf56379e" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">27,110</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Selling, general and administrative</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5c2d0976-17a1-42e2-a221-c4775064c579" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">145,033</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5aa4d36c-9fce-4402-83d6-cfbc132577c3" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">116,317</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-548cb99e-9e3c-4b3f-911a-fb9f66c822f7" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">96,387</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-03bb73a5-8bc5-4564-9171-c8331888bf88" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">186,357</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4669b1f8-d563-4b17-b57d-4eb8da8ed7ab" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">152,766</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4922bb95-1a03-4777-810d-f82bc8102d5d" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">123,497</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss from operations</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-534c6f09-89c7-468d-94ac-95ee58aba03e" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">59,271</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-517160e1-d51f-4d9d-b086-c6957b773531" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">52,004</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c9bc691-8d2f-427c-ae06-24c15211ebba" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">47,468</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest income</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-756709f1-b29d-4c7d-b507-250b1cbf2d8f" name="us-gaap:InvestmentIncomeInterest" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,957</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a611d87-b533-4b01-a5a4-082909bdf72d" name="us-gaap:InvestmentIncomeInterest" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,527</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ad3bfb2-236c-4768-b366-32a4e929cd7c" name="us-gaap:InvestmentIncomeInterest" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">198</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest expense</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f3d645ff-a683-4d5f-b11d-ae44685c247d" name="us-gaap:InterestExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,871</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e90c210-5a64-4985-b52b-1ff3a61c5e8c" name="us-gaap:InterestExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,098</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-94401612-209d-4804-a5a8-72206fff9b01" name="us-gaap:InterestExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,518</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss on debt extinguishment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-528f4df0-f828-4633-aadb-c691af82ec4f" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">245</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other income (expense), net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2a6e67c4-3390-49f8-9cf0-2a7cc9c78fea" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">442</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f826539a-951c-4163-ab00-d3d362f02609" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">190</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-034c559d-0a05-45b5-aadb-b9d30fc5dacc" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">23</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7228b14f-497a-4178-8816-259d396e3f31" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,743</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b613f71a-0d8a-4fc3-8aee-79cc47931f2f" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,010</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1df67c56-b8d0-4c53-ad58-ce30e06e3bdf" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other comprehensive income (loss):</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unrealized gain (loss) on investments, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b7a3964b-6a05-42a1-8e39-f4dff89dad2b" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">238</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7de5e483-1f17-453f-8ce5-068e7e39ffa3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">166</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e3b6f479-7286-42b3-9042-70baec7ed2ab" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">39</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other comprehensive income (loss)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-53f44826-ee84-4468-b475-199eb8680ba5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">238</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-83c4b1bb-50ee-4957-9c9d-0d6beed4ea0d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">166</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-86c4b723-5a71-4058-a84e-5ac56d3d463c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">39</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Comprehensive loss </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fb75652f-dab5-45cc-8b80-432a33cf34d8" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,505</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56f06b08-f9ca-4f99-a96f-5e68dd728a0a" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,176</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6554b639-02c1-4acf-b46f-8849cff14ad6" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,850</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-befdb4c7-105e-40ad-a579-d14e7d80cb99" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-"><ix:nonFraction id="ct-nonFraction-f1962dd7-4c98-433f-a9f2-c35da2435486" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-">1.44</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3299564-65db-4c02-b75b-f61b52899c61" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-"><ix:nonFraction id="ct-nonFraction-b19676c0-5518-4935-b0ad-15a8d6786725" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-">1.54</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4bce0bd3-c6d0-44c2-9768-e89694b1e246" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-"><ix:nonFraction id="ct-nonFraction-f61a8ad2-a992-4c36-aa40-c39b6bc3807f" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-">1.44</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average common shares used to compute net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ba6b661-7daf-4a35-a52c-f2123c87a234" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-18dfbd5f-edfe-4322-89b2-e20a90b86441" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">38,804,343</ix:nonFraction></ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e5dfd4bb-d4c0-40e6-9721-06a417963d5a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-10d1b442-8306-459c-9255-fa10567f2652" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">35,775,672</ix:nonFraction></ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e3fabcda-d32f-450c-abd4-f7a271af85d2" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-4104a2b0-ac5a-4b68-b100-faac10bd19dc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">34,635,358</ix:nonFraction></ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying notes are an integral part of these financial statements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">94</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Silk Road Medical, Inc.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Statements of Stockholders&#8217; Equity</span><span id="Section20" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(in thousands, except share data)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated Other</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Common Stock</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Additional</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Comprehensive</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Paid-in Capital</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Deficit</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Income (Loss)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances at December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50999f6f-50cd-4c0f-80cd-ad3c32476ad7" name="us-gaap:SharesOutstanding" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">34,249,649</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c2db16c4-0490-4f33-bcc0-775f0922e47d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">34</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca753ac4-b573-40c7-9749-9eca3909f304" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">346,318</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-68cb9f74-480f-4e95-b9d4-bc91e67d28e1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">238,891</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-07d63988-30c9-4c57-a5c7-ade3be23f568" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">39</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4e0b9dae-21c9-4dff-b3f6-c941cb84e623" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">107,500</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercise of stock options</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bffe753f-618a-4275-bebd-9f22f8b673f6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">643,507</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b6f5526a-e8ad-4d0a-b8cf-fdd832478c91" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f25c359e-136e-4acf-83e9-4548b2439893" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,841</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c729ba19-e3ae-4bb2-be41-fb77d1c0be78" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,842</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock upon vesting of restricted stock units</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-17046b1e-eafe-4833-9342-1c558cdc957a" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">34,964</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock under employee stock purchase plan</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2fa51ab5-e076-4eff-bcbb-fcd6beadd7c2" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">52,776</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3415a0cd-b917-43b4-954c-2e306c42d776" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,104</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9ad665a0-9f09-40f6-a15e-7f91a1d3eb4e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,104</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e49995e8-62a5-4195-ac0c-6ee1c36f0ebb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,612</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2eb955b8-a2dc-49bd-bcf3-d6c0dd094e46" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,612</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Disgorgement of short-swing profits, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dc40ce2b-f6b3-4383-84d1-def6d246bfbb" name="silk:DisgorgementOfStockholderSShortSwingProfits" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">32</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7c6d0bff-f592-427c-abf5-034846b982ec" name="silk:DisgorgementOfStockholderSShortSwingProfits" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">32</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5ca14ff4-66ba-4cd2-bdfa-8c08da96768b" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e0c71ae2-4020-4efe-b49d-09650f85f790" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in unrealized loss on investments, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad5dc879-3eae-412e-892b-071bb0f660ed" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">39</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e60e32d8-3ff4-4318-97e1-113ecacb5095" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">39</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances at December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6f1a71b-0131-4582-97ae-b5c71ba60375" name="us-gaap:SharesOutstanding" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">34,980,896</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e8085cca-9119-46cd-bf43-055ecc275356" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">35</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-73755160-2863-4cab-9a3d-e4a7d7535ba5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">367,907</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08be4825-a9d5-4e8d-aa78-3294f3701611" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">288,702</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c47b218-6f49-49f9-b1e8-859fe36a34b2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">79,240</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock in connection with public offering, net of underwriting discount, commissions and offering costs of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-454dc3ac-25d1-4553-a5f1-b7b3c6e37f63" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,008</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c8aa534f-8dda-4338-98cb-a6b486a9e111" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,674,419</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5ca4a94e-a23d-49b8-8458-206c60a7ed5d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e65f2949-f936-4777-a68d-e410f1e279b0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">108,989</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-646381c9-9a48-4e7a-b69b-8fe416d060e9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">108,992</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercise of stock options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-48c0a9f6-f009-4725-9256-7bc577906d00" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">453,199</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e230b2bf-d2bb-4cf4-a202-127a589538bb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,364</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c153e756-c2e6-411d-b94a-d391d98bd15e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,364</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock upon vesting of restricted stock units</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-724252b9-a1b3-4cc0-af3e-573a9e980b7b" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">148,239</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock under employee stock purchase plan</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a89d073-2903-4859-9bbb-ddcf1f6c4427" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">99,219</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e940fc17-1a86-420e-90dd-bee3bb8b6827" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,432</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1b0696d0-abcf-4bff-aca9-26370bd74b78" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,432</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-761410fd-7433-4198-aa63-ee8d4af577cf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25,023</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7e0e24ae-f5f3-4545-b746-01d660a0886f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25,023</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4252c9b8-efc0-4351-84e0-411b4c788d20" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,010</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7dbe2ffa-9e78-40cf-bf77-a078924dfa38" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,010</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in unrealized loss on investments, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c146c3b8-7801-496c-a6ff-3e1919d70e4c" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">166</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2bdfe8dc-20e9-4ed6-9924-b60ec8284f7c" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">166</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances at December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7a85f4e-067d-4a5e-b756-d70e1a3319ee" name="us-gaap:SharesOutstanding" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">38,355,972</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-02532738-9c61-44bc-a240-66a1d35693ca" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">38</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-426abf27-7deb-4ed0-9e14-cb934e4bc182" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">507,715</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9265a4f0-f455-4df7-aa0a-0cb8f8877dc6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">343,712</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32ba48ab-5561-4ffa-9827-583540dd00e5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">166</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2131420-a742-41c6-a69b-860d9a605e66" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">163,875</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercise of stock options</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ddb1e7c1-8b1d-4e2a-a819-94c5a81e47e3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">199,642</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca4b9e88-c3d7-477d-b26a-691a6a19eb70" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,486</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d703615a-b052-48e3-a5f3-bbe4b97a5c09" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,486</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock upon vesting of restricted stock units</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98066ad7-ebcd-40fc-a439-9b6f6925d70a" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">410,085</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aec91df0-212b-4b9c-a613-f32307d1ef79" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-953e29d7-7a46-4e9e-84e8-73c91a36b4e8" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock under employee stock purchase plan</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9ad39b51-b2ac-455e-bf24-ec3a03088d19" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">199,782</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b886b86b-f4da-4370-9b3a-b85397b2ce19" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,401</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1b128eb2-e451-4ffd-a23b-933ef27d330c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,401</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6d1dffea-ab66-4add-859b-7d909fa24bf8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">38,893</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2abdd448-7c6d-43c6-9b2e-0697a15111d6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">38,893</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6311a34-bfdb-491c-8276-a43cea7de454" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,743</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9b157b13-1f27-46ff-befa-ae601c8e4dee" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,743</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in unrealized gain on investments, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b8b93078-91f9-4e36-8b98-94fb53b5f591" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">238</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fc74620f-c4ac-4da2-a117-00fcf00866a1" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">238</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 36.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-348a66e5-3724-4f27-9edf-f8cd298329f5" name="us-gaap:SharesOutstanding" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">39,165,481</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84406667-eb28-4ffe-885a-d15e8f505172" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">39</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-23b45301-2ecb-4b11-b34e-4eeaa3060c18" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">550,495</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1edc28a-082a-43c6-b750-06b385b8162c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">399,455</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f136b8f8-5466-44c0-a598-92ed26a82227" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">72</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e707152a-da36-4053-8bf8-001b095a81a6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">151,151</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying notes are an integral part of these financial statements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">95</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Silk Road Medical, Inc.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Statements of Cash Flows</span><span id="Section21" style="text-decoration: none;"></span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(in thousands)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from operating activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-68fea53a-1096-4e32-a7df-8b0cad630a6a" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,743</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-06dec6fd-0b10-41c3-a79b-5daf0db5ec86" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,010</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c22a703-bbb5-4da7-aa9d-319ff12d5f9b" name="us-gaap:ProfitLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation and amortization expense</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-03692fd6-3b62-406d-885f-be3fa512f3b2" name="us-gaap:OtherDepreciationAndAmortization" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,696</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fce627e6-9061-47e8-b2ef-580819ae4ca1" name="us-gaap:OtherDepreciationAndAmortization" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,127</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-64b3efb2-f35f-4a5d-a8ff-f50e03e7c529" name="us-gaap:OtherDepreciationAndAmortization" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,032</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-00bee32c-c3f3-42e5-b2d0-e24cd0104389" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">38,893</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ec586112-b257-4af3-8914-c8256d102e9e" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25,023</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b0b40b16-47f1-4515-8b59-6c56b6487b68" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,612</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of premiums (accretion of discounts) on investments, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dcba9e98-2d5a-40df-84e0-7130afcd0985" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,497</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-754a1f64-a761-4294-8614-3672e37d7f68" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,419</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2eb83f85-a93f-4aa4-abc3-be32281cccb8" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">577</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of debt discount and debt issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2346ddd8-fe4d-4ba7-9f0a-48e774105548" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">232</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e2c5cb49-6dec-4535-a931-e817bc9644d3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">218</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c364071-f203-4621-83d4-bfc3ca1ab516" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">158</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of right-of-use asset</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d68639b-830f-4bbd-8e1b-82fd980734fe" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,096</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9b4cd153-2952-4329-a537-8f49db3228f0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,041</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-27f74847-1394-4b91-8d2a-e5d2c609874b" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">887</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Non-cash interest expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0defb280-94fa-42b0-865b-c95c5a135c49" name="us-gaap:PaidInKindInterest" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">819</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2de2d356-da50-48f8-8fb3-cd419422a74e" name="us-gaap:PaidInKindInterest" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,037</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss on extinguishment of debt</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-44003d09-e59a-491f-aa3b-7f476c924e1e" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">245</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Loss on disposal of property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d51eb86d-daa1-4c4e-9f15-42bd4c4be680" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">160</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a1d5e56e-aec1-4e18-a67e-b2784290b78c" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">180</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-36f65fac-1559-4bcc-bc05-3d19f9c09e3f" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for (recovery of) doubtful accounts receivable</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97f80814-3843-44d6-bdc5-fd5b80d0d70c" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">45</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37ab3a93-bc34-4d44-bdbf-2c00c8633c49" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-486cf2a9-1e10-42c9-8a01-dade8f61e83a" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for excess and obsolete inventories</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-77704097-1822-4d58-9300-fa80dcb761c2" name="us-gaap:InventoryWriteDown" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">198</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b7775505-28b3-4195-a298-3f309cdddaa4" name="us-gaap:InventoryWriteDown" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ec90e726-bd91-48fb-90bb-45c600fec09c" name="us-gaap:InventoryWriteDown" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">77</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in operating assets and liabilities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts receivable</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ccc9de45-c915-46e2-9640-8f41dfbe26e6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,610</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d8bdfc0-2a52-497e-a437-eb1b45f694ef" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,172</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d594fb6c-348c-411c-a46e-087083d04661" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,769</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventories</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-508f5e89-fa2b-41b8-8ee2-6c1d0e46d39d" name="us-gaap:IncreaseDecreaseInInventories" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,781</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5e608bf0-0504-42c4-b975-2b028bf8d667" name="us-gaap:IncreaseDecreaseInInventories" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,447</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6a8e74b-0432-4588-b373-1ff5ad662a15" name="us-gaap:IncreaseDecreaseInInventories" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,563</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other current assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2f8fc79c-1f6b-4894-a895-8092dc881d94" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,988</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84371899-b61b-4aeb-a892-734ff4f71c74" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">525</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2be55b8a-9f8b-430f-a5d2-68dffb310902" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">772</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fdab76bd-a0db-44f2-bddd-b92d9e94e1dc" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">236</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e18c5344-caf6-4ea0-96cf-b3e8481e5e61" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">27</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42f337fb-ccc9-47f6-90b5-04014b4d4288" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">117</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d013e2c8-c0ac-4f96-a81a-7f944c00e95e" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,063</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-86e307cd-4b78-4b5a-bb38-0ced5089eabd" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">967</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-07644f44-eec6-45ff-9e7a-eaf25aa3554d" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,159</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-59110115-295e-430b-ba4a-3007d42a1761" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,854</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f8e2be49-e40a-45ea-82aa-c02922e00f75" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,868</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56ea61d0-be4f-4021-8c15-24ff0ebe1fe7" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,418</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d8397726-1397-40e4-9e85-f7f934f836b4" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,215</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3595c1c1-be47-448d-8073-bd6f3fbbd760" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">690</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7182305a-0fd4-4faf-af2f-a20d82ce7710" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">520</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-724b4490-dadf-40f7-a141-9af77fc0b563" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,014</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-437230f3-aef7-4a33-9136-c19a119d7aa7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,581</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d42029aa-9b62-4cf8-a5f1-10e85ed4f4a4" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">38,935</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from investing activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchases of property and equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9ded64f-53b9-4fe4-a8b9-eca7b2cb1ab2" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,507</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e3c8edc6-fc7a-45b4-93f1-603dbf03db03" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,005</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d2890a68-27cd-40a1-84a4-c370fbe3c82e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,758</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from sale of property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f185dc8f-8e46-4b41-8628-b6d0d3b25f85" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchases of investments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50b066b4-25c9-4ac5-a671-156ab6691196" name="us-gaap:PaymentsToAcquireInvestments" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">174,969</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e991da6b-403f-4448-a2b9-0f465d198e6f" name="us-gaap:PaymentsToAcquireInvestments" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">168,163</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from maturity of investments</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85aa03b8-6361-4b6a-94d2-04e2c8e86a64" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">169,300</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-587d4ec4-fa8e-4bd9-b5bb-d5739028b023" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c45e2108-0cc0-4dfd-b243-e2937c250080" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">77,400</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by (used in) investing activities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6cedcdd3-2324-4c8b-875c-80c357d335f9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">7,176</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-055509ab-eeba-4568-a268-754c73b8229a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">162,068</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-22166f62-5921-40b5-8c4f-572afbfdbc3a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">72,644</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from financing activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5eafa089-da6e-4dc1-b4a7-78ac0a199770" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">108,992</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from long-term debt, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-067c8c47-4e28-4dac-88ac-3a3a32ccaa72" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73,911</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from issuance of common stock</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d937812c-3e33-4551-8203-df62aedd7a2f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,887</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7054d4f-9c7c-4c47-a750-a7f319e38bd6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,796</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3560e473-c05e-43ae-afa8-3f08a9ad2264" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,946</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Principal repayment of long-term debt</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b255c1af-d45a-4be4-8f21-f5adf4146800" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">49,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from disgorgement of short-swing profits, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b15459fb-db6b-4cd2-9958-000e61d0761c" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">32</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-422f6a87-1614-48f4-8ab1-e86a077c3f14" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,887</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6874fbc3-48b5-407c-a519-414664c92c69" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">139,699</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-996d906c-a13e-4794-afa8-5099049a8b9a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,978</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net change in cash, cash equivalents and restricted cash</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-06203175-dd77-49f3-92fc-443cb422bcad" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">35,303</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6fd26d30-4187-42bc-bdab-92dee073bf18" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">54,950</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-563fa0c2-0385-4e34-9ed0-6945478952f0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">40,687</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cbb7684e-49f7-47c2-a341-dad6c9fa5c42" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,513</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7f9c0f38-9523-4ecb-87ec-aa9a83971ce0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">110,463</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3a542af6-5746-483e-b9eb-c94d5669da2c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">69,776</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash, cash equivalents and restricted cash, end of year</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4cb9e7d4-e9bc-4c47-ade8-0bcc87fedd0f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,210</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea2d8cfa-49d1-41ac-bbc4-211004a83392" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,513</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f062ffb-e481-4e34-903b-b052f1e81122" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">110,463</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Supplemental disclosure of cash flow information</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for interest</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0cd8ffba-fe8d-4378-8213-dadcf7af7913" name="us-gaap:InterestPaidNet" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,821</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ce413c12-80a2-4d2d-8d96-262c3b9d8fa9" name="us-gaap:InterestPaidNet" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,843</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b928082c-a47b-4fa5-a57d-0fa9b834db5b" name="us-gaap:InterestPaidNet" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,360</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Noncash investing and financing activities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable and accrued liabilities for purchases of property and equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-302274b0-0727-4689-9375-da82380e7d02" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">67</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-301fea03-b7b6-4864-b172-8879093365a4" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">117</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3b2a9706-0ac6-451f-a861-3296da26dd4c" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,138</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Right-of-use asset obtained in exchange for lease obligation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2eac5241-0e4c-4969-bfc6-fecdb5f033f8" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9e3e3b65-bda1-48bc-af06-1baa409fc867" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">903</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6b6e21a-a19d-4217-bc93-1e788b324dca" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,307</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying notes are an integral part of these financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">96</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section22" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ct-nonNumeric-c01dc991-1962-4f19-80d2-587478d66e86" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-c01dc991-1962-4f19-80d2-587478d66e86-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">1.&#160;&#160;&#160;&#160;Formation and Business of the Company </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-c01dc991-1962-4f19-80d2-587478d66e86-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">The Company</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Silk Road Medical, Inc., or the Company, was incorporated in the state of Delaware on March&#160;21,&#160;2007.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company, has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke. The Company's portfolio of products enable a procedure referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles. The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company commercialized its products in the United States beginning in</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> late 2015. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Liquidity</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of December&#160;31, 2023, the Company had an accumulated deficit of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c5c480d-af0e-4bcb-941f-76c150e0b5bf" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" sign="-">399,455,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company expects to incur losses for the foreseeable future. The Company</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> believes tha</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t its cash and cash equivalents and available-for-sale securities of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-62962a53-b4d2-4376-9819-8bfbdb8b842b" name="silk:CashCashEquivalentsAndAvailableForSaleInvestments" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">190,930,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> as of December&#160;31, 2023, as well as its expected revenues will provide sufficient funds to allow the Company to fund its planned current operations for the next 12 months from the issuance of these financial statements. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Public Offering</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2022, the Company completed an underwritten public offering of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2184c9a8-d856-4903-97eb-43e6c89b7d4a" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_10_1_2022_To_10_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,674,419</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of its common stock at a public offering price of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b64b87a9-bdd2-4c1d-bef8-b8920e466844" name="us-gaap:SaleOfStockPricePerShare" contextRef="As_Of_10_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">43.00</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. The shares include the full exercise of the underwriters&#8217; option to purchase an additional </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-536b21f6-4f7d-4a19-8cbb-4b26dae08206" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_10_1_2022_To_10_31_2022_srt_StatementScenarioAxis_silk_UnderwritersOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">348,837</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares pursuant to the underwriting agreement. The Company received cash proceeds of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f1fa4a6-785e-4a2b-ac20-b757c60e1022" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="Duration_10_1_2022_To_10_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">108,992,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> after deducting underwriting discounts and commissions of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f4557db-dc08-4797-b536-4962bec56207" name="silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" contextRef="Duration_10_1_2022_To_10_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">5,750,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and expenses of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cf8abd6e-c0c0-43f1-89ca-505e98f8b63f" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="Duration_10_1_2022_To_10_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">258,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section23" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-0" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ct-nonNumeric-5738e872-c7b2-416c-9985-e8ef50594ad2" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-5738e872-c7b2-416c-9985-e8ef50594ad2-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis of Preparation</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-5738e872-c7b2-416c-9985-e8ef50594ad2-continuation-0" continuedAt="ct-nonNumeric-5738e872-c7b2-416c-9985-e8ef50594ad2-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-5738e872-c7b2-416c-9985-e8ef50594ad2-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="ct-nonNumeric-52409ac7-fc5a-4ab2-babf-18c5c455ff2d" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-52409ac7-fc5a-4ab2-babf-18c5c455ff2d-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-52409ac7-fc5a-4ab2-babf-18c5c455ff2d-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ct-nonNumeric-486052a5-4189-4d5c-a15d-54c8b33a4700" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-486052a5-4189-4d5c-a15d-54c8b33a4700-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-486052a5-4189-4d5c-a15d-54c8b33a4700-continuation-0" continuedAt="ct-nonNumeric-486052a5-4189-4d5c-a15d-54c8b33a4700-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-486052a5-4189-4d5c-a15d-54c8b33a4700-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2023 and 2022. The carrying amounts of certain of the Company&#8217;s financial instruments, which include accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments. Management believes that its debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value. </span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash, Cash Equivalents and Restricted Cash</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe-continuation-0" continuedAt="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are recorded at fair value, based on quoted market prices. As of </span></p></ix:continuation></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">97</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-1" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-2"><div><ix:continuation id="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe-continuation-1" continuedAt="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe-continuation-2"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December&#160;31, 2023 and 2022, the Company&#8217;s cash equivalents were entirely comprised of investments in money market funds.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ct-nonNumeric-f15a373b-0151-49de-a4d0-3b075f11067e" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-63a99401-0cea-41a5-bef8-7cd756682166" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,210</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fe935585-6cb6-4b77-b353-6ee67e2ae2d4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,358</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted cash </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8c03c604-609b-4bcc-9302-1327040b4413" name="us-gaap:RestrictedCashNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">155</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash, cash equivalents and restricted cash </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5db1aca5-166f-4200-980a-c499d3bfbcc4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,210</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b4e8841-bf8d-4908-a018-9e13db4fe29c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,513</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe-continuation-2"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company had </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e40c6885-3ad2-4da9-a7ff-a575e96de3ef" name="us-gaap:RestrictedCashNoncurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted cash as of December 31, 2023. Restricted cash as of December&#160;31, 2022 consisted of a letter of credit of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-684114aa-20f4-4aca-861b-bead9de46b66" name="us-gaap:RestrictedCashNoncurrent" contextRef="As_Of_12_31_2022_us-gaap_PledgingPurposeAxis_us-gaap_LetterOfCreditMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">155,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> representing collateral for the Company&#8217;s facility lease in California. </span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" id="ct-nonNumeric-f52d5d30-d4eb-42ce-bfa2-a92e3589e2ac" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-f52d5d30-d4eb-42ce-bfa2-a92e3589e2ac-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Investments</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-f52d5d30-d4eb-42ce-bfa2-a92e3589e2ac-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term and long-term investments consist of debt securities classified as available-for-sale. Short-term investments have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss). Realized gains and losses are included in earnings and are der</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ived based on the specific-identification method for determining the costs of investments sold and were insignificant for the years ended December 31, 2023, 2022 and 2021. Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. The Company evaluates the securities in an unrealized loss position for expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, current economic conditions and credit ratings. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company did </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-14c303de-dbf7-4431-bf9c-3099754ab2e9" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-6be0c5c0-d216-44b8-8039-5ef4662c67df" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-992c49ca-7892-4d72-a243-cc300eaac53f" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t recognize any credit losses on its available-for-sale securities during the years ended December 31, 2023, 2022 or 2021 and there were no impairment charges for unrealized losses in the periods presented.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a-continuation-0" continuedAt="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, U.S. government securities, U.S. treasury bills, agency bonds/notes, and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2023, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023 and December&#160;31, 2022, a portion of the Company&#8217;s cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of the Company&#8217;s cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. On March 10, 2023, SVB was shut down and placed under receivership with the Federal Deposit Insurance Corporation, or FDIC, by the California Department of Financial Protection and Innovation. On March 26, 2023, the FDIC announced it had entered into a purchase and assumption agreement with First Citizens Bank &amp; Trust Company under which all of SVB&#8217;s deposits were assumed. As of the issuance date of these financial statements, the Company has not experienced any losses on its deposits and all of the Company&#8217;s cash deposited with SVB has been accessible to the Company.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s accounts receivable are due from a variety of hospitals and medical centers in the United States. As of December&#160;31, 2023 and 2022, no customer represented 10% or more of the Company&#8217;s accounts receivable. For the years ended December&#160;31, 2023, 2022 and 2021, there were no customers that represented 10% or more of revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">98</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-2" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-3"><div><ix:continuation id="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a-continuation-1" continuedAt="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a-continuation-2"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its commercial products in-house. Certain of the Company&#8217;s finished goods,  components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in finished goods, component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, competition, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a-continuation-2"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies. In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ct-nonNumeric-0f252899-5a7c-4637-83d5-ebbb658c91f3" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-0f252899-5a7c-4637-83d5-ebbb658c91f3-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accounts Receivable</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-0f252899-5a7c-4637-83d5-ebbb658c91f3-continuation-0" continuedAt="ct-nonNumeric-0f252899-5a7c-4637-83d5-ebbb658c91f3-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-0f252899-5a7c-4637-83d5-ebbb658c91f3-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company estimates allowances for expected credit losses. Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#8217; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. These specific allowances are reevaluated and adjusted as additional information is received that impacts the amount reserved. During the years ended December 31, 2023, 2022 and 2021, the Company did not experience any material credit-related losses.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" id="ct-nonNumeric-c775eb07-1148-4b67-938f-3d4454dc57ba" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-c775eb07-1148-4b67-938f-3d4454dc57ba-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inventories</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-c775eb07-1148-4b67-938f-3d4454dc57ba-continuation-0" continuedAt="ct-nonNumeric-c775eb07-1148-4b67-938f-3d4454dc57ba-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-c775eb07-1148-4b67-938f-3d4454dc57ba-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate. The Company&#8217;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements. The estimate of excess quantities is judgmental and primarily dependent on the Company&#8217;s estimates of future demand for a particular product. If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ct-nonNumeric-e1ecb903-1556-46ec-8dd2-beb28ef9c6f8" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-e1ecb903-1556-46ec-8dd2-beb28ef9c6f8-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Property and Equipment</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-e1ecb903-1556-46ec-8dd2-beb28ef9c6f8-continuation-0" continuedAt="ct-nonNumeric-e1ecb903-1556-46ec-8dd2-beb28ef9c6f8-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-e1ecb903-1556-46ec-8dd2-beb28ef9c6f8-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are recorded at cost less accumulated depreciation or amortization. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-66e4bc74-f742-46aa-8b80-6c3c31595686" contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-f89343eb-e0f7-4e97-9295-e60b7bc3900c" contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">99</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-3" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-4"><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ct-nonNumeric-c17cd862-e768-4f28-9e64-1663597cc6b4" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-c17cd862-e768-4f28-9e64-1663597cc6b4-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Impairment of Long-Lived Assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-c17cd862-e768-4f28-9e64-1663597cc6b4-continuation-0" continuedAt="ct-nonNumeric-c17cd862-e768-4f28-9e64-1663597cc6b4-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-c17cd862-e768-4f28-9e64-1663597cc6b4-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value. The Company did </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c115c9da-fbb3-4925-9216-4570bfa6c650" name="us-gaap:AssetImpairmentCharges" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-429c85a1-4929-4698-bd62-244972b52c82" name="us-gaap:AssetImpairmentCharges" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-1b7fee94-4673-4d67-a0b8-abd08ca28a32" name="us-gaap:AssetImpairmentCharges" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t record any impairment of long-lived assets during the years ended December&#160;31, 2023, 2022 and 2021.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="ct-nonNumeric-90fcb880-3bc8-41e0-8913-625178e1ab0a" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-90fcb880-3bc8-41e0-8913-625178e1ab0a-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Leases</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-90fcb880-3bc8-41e0-8913-625178e1ab0a-continuation-0" continuedAt="ct-nonNumeric-90fcb880-3bc8-41e0-8913-625178e1ab0a-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-90fcb880-3bc8-41e0-8913-625178e1ab0a-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for its leasing arrangements in accordance with Accounting Standards Codification, or ASC 842, &#8220;Leases.&#8221; The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset. The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain. Variable lease costs represent payments that are dependent on usage, a rate or index. Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred. The Company elected to account for contracts that contain lease and non-lease components as a single component, consistent with its historical practice. The Company does not have any finance leases.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ct-nonNumeric-4ac7d6e7-06b1-4a57-b977-063d08746273" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-4ac7d6e7-06b1-4a57-b977-063d08746273-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Revenue Recognition</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-4ac7d6e7-06b1-4a57-b977-063d08746273-continuation-0" continuedAt="ct-nonNumeric-4ac7d6e7-06b1-4a57-b977-063d08746273-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives and is primarily comprised of product revenue net of returns, administration fees and sales rebates. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer.&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it. Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title. The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Administration fees and sales rebates are accounted for as a reduction in revenue, calculated based on the terms agreed to with the customer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023 and 2022, the Company recorded $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ec5035d-0f71-4476-9fc2-6d8b92363886" name="us-gaap:UnbilledReceivablesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">227,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4d4f7b5f-b3f6-4319-90a1-ede753b50c28" name="us-gaap:UnbilledReceivablesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">148,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Costs associated with product sales, which include commissions and royalties, are expensed when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160;Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the statements of operations and comprehensive loss.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accepts product returns at its discretion or if the product is defective as manufactured. The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the balance sheet.&#160;The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods </span></p></ix:continuation></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">100</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-4" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-5"><div><ix:continuation id="ct-nonNumeric-4ac7d6e7-06b1-4a57-b977-063d08746273-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sold. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" id="ct-nonNumeric-888c9d43-8aa5-464b-8472-1704f694717d" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-888c9d43-8aa5-464b-8472-1704f694717d-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cost of Goods Sold</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-888c9d43-8aa5-464b-8472-1704f694717d-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its portfolio of TCAR products at its California and Minnesota facilities and purchases other products from third party manufacturers. Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, manufacturing overhead costs, direct labor, scrap, product rework, reserves for excess, obsolete and non-sellable inventories as well as logistics-related expenses. A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs. These overhead costs include the cost of quality control, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company entered into the lease for its additional facility in Minnesota in May 2021 and did not begin commercial production of the ENROUTE Neuroprotection System until the third quarter of 2022. During this time, the Company experienced additional overhead expenses related to its investment in the start-up phase of its manufacturing capacity expansion, which were recorded as a period expense. </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ct-nonNumeric-e0ea2ef0-f197-48db-a77c-3cd0f5a4465e" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-e0ea2ef0-f197-48db-a77c-3cd0f5a4465e-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Research and Development</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-e0ea2ef0-f197-48db-a77c-3cd0f5a4465e-continuation-0" continuedAt="ct-nonNumeric-e0ea2ef0-f197-48db-a77c-3cd0f5a4465e-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#8217;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development. Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses. Additionally, clinical studies include costs associated with clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Clinical Trials</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-e0ea2ef0-f197-48db-a77c-3cd0f5a4465e-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accrues and expenses costs for its clinical trial activities performed by third parties, including any clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:AdvertisingCostsPolicyTextBlock" id="ct-nonNumeric-45194000-3c56-4411-98d3-69849a46d345" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-45194000-3c56-4411-98d3-69849a46d345-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Advertising Costs</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-45194000-3c56-4411-98d3-69849a46d345-continuation-0" continuedAt="ct-nonNumeric-45194000-3c56-4411-98d3-69849a46d345-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-45194000-3c56-4411-98d3-69849a46d345-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company expenses advertising costs as incurred. Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items. Advertising costs of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0343db5b-823a-4fed-94c3-296ebdec7a88" name="us-gaap:AdvertisingExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">461,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ab787038-c5d4-416d-a749-10b530ece226" name="us-gaap:AdvertisingExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">347,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-613af11b-a1e5-4190-8608-3eebd4408e32" name="us-gaap:AdvertisingExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">221,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> were expensed during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ct-nonNumeric-203a9d2d-5343-4eb9-a2c9-401633263014" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-203a9d2d-5343-4eb9-a2c9-401633263014-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Foreign Currency</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-203a9d2d-5343-4eb9-a2c9-401633263014-continuation-0" continuedAt="ct-nonNumeric-203a9d2d-5343-4eb9-a2c9-401633263014-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-203a9d2d-5343-4eb9-a2c9-401633263014-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net. The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2023, 2022 and 2021.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock&#8211;Based Compensation</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7-continuation-0" continuedAt="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board, or FASB, ASC 718,&#160;&#8220;Compensation-Stock Compensation.&#8221; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units, performance stock units, and shares issued under its employee stock purchase plan. ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model. The fair value of stock options is recognized over the period during which an optionee is required to provide services in </span></p></ix:continuation></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">101</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-5" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-6"><div><ix:continuation id="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7-continuation-1" continuedAt="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7-continuation-2"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis. The Company accounts for option forfeitures as they occur.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant. These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for performance stock units with market-based conditions at their fair value on the date of the award using the Monte Carlo simulation model. These costs are recognized over the requisite service period, which is usually the vesting period, regardless of the likelihood of achievement of the market-based performance criteria.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7-continuation-2"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for its employee stock purchase plan based on the </span><span id="_Hlk157943524" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">estimated fair value on the first day of the offering period </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">using an option pricing model for each purchase period. These costs are recognized on a straight-line basis over the offering period.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="ct-nonNumeric-a409f090-b5c8-4c02-ae4f-713e9ed9bdb3" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-a409f090-b5c8-4c02-ae4f-713e9ed9bdb3-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-a409f090-b5c8-4c02-ae4f-713e9ed9bdb3-continuation-0" continuedAt="ct-nonNumeric-a409f090-b5c8-4c02-ae4f-713e9ed9bdb3-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-a409f090-b5c8-4c02-ae4f-713e9ed9bdb3-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company also follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes.&#8221; ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-93c32e1b-062e-4830-a792-dccbcedc251e" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> liability related to uncertain tax positions is recorded on the financial statements. It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ct-nonNumeric-1ddd3cd4-35c6-48cb-8061-d49b3da2584f" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-1ddd3cd4-35c6-48cb-8061-d49b3da2584f-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Comprehensive Loss</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-1ddd3cd4-35c6-48cb-8061-d49b3da2584f-continuation-0" continuedAt="ct-nonNumeric-1ddd3cd4-35c6-48cb-8061-d49b3da2584f-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-1ddd3cd4-35c6-48cb-8061-d49b3da2584f-continuation-1"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale. For the years ended </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December&#160;31, 2023, 2022 and 2021</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive loss. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets as a component of stockholders' equity. </span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="ct-nonNumeric-f174a5b6-3858-45a6-b335-241b21fb5f52" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-f174a5b6-3858-45a6-b335-241b21fb5f52-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-f174a5b6-3858-45a6-b335-241b21fb5f52-continuation-0" continuedAt="ct-nonNumeric-f174a5b6-3858-45a6-b335-241b21fb5f52-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and performance stock units are considered to be potentially dilutive securities. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share was determined as follows (in thousands, except share and per share data):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ct-nonNumeric-6e84a853-77ac-4786-b95b-9c694988fe9f" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-88a3d94c-5b3f-4880-86ae-0a6654af4be6" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,743</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-907d0c93-62ee-4d07-8117-29d31f211eb8" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,010</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c7154c3d-a32e-4106-886a-b63f7aee4f37" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average common stock outstanding used to compute net loss per share, basic and diluted </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-07840930-6a30-4960-88f4-b43424ffd1e6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-8b091b81-d6b5-4e6d-86bd-6a2f1c3155da" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">38,804,343</ix:nonFraction></ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e28c7507-cada-44ca-b1e2-3cf92e23488d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-cbb6f996-a8ae-49dc-907e-cce49b900e8d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">35,775,672</ix:nonFraction></ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-423d1bbf-f6d4-49e4-a268-cb042e7cd5a9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-a352e428-58b3-48a5-91c4-332b9e582af9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">34,635,358</ix:nonFraction></ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5b67ebf6-772b-4fd5-8279-cc0821ff2662" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-"><ix:nonFraction id="ct-nonFraction-749b7d16-2756-403b-8466-ec33a499224c" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-">1.44</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c8c1d24a-1671-4bd5-90a1-5f49e7bb3f71" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-"><ix:nonFraction id="ct-nonFraction-c8a01688-5fbc-4135-b388-c7a75aae7cb1" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-">1.54</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be0d3451-048a-44a2-9e78-2361195ed2de" name="us-gaap:EarningsPerShareBasic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-"><ix:nonFraction id="ct-nonFraction-d6819db4-6389-4957-a08d-434aeda13b64" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" sign="-">1.44</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">102</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-6" continuedAt="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-7"><ix:continuation id="ct-nonNumeric-f174a5b6-3858-45a6-b335-241b21fb5f52-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ct-nonNumeric-6c5e1f12-5d1d-4c4a-8087-9be55e3ebf0f" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock options </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-729741ef-a377-4183-bc64-92e3375089a1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">3,632,684</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d4d49296-23a3-4987-acb0-f029d77d67a8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">3,839,858</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-951d60dd-ef00-49bc-9bff-4d92b29c54d3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">3,780,939</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted stock units and performance stock units</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-10bf222c-1cfd-4acc-a7ae-3e8f6d919275" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">3,536,197</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-03368f05-845b-4b3c-80bc-e5d138962509" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">1,329,824</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb806a83-0fdf-4323-84aa-04b6a10ec0d4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">530,274</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5834183a-e518-4d7d-9dfc-f486fa400c9c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">7,168,881</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42946ef6-8f37-4367-ba0e-5cba598d2365" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">5,169,682</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-15927554-28b9-4949-824b-39158aba05e9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">4,311,213</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ct-nonNumeric-dd1fc03e-b3a5-4ffc-8663-4aa3699cf434" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-dd1fc03e-b3a5-4ffc-8663-4aa3699cf434-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Segment and Geographical Information</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-dd1fc03e-b3a5-4ffc-8663-4aa3699cf434-continuation-0" continuedAt="ct-nonNumeric-dd1fc03e-b3a5-4ffc-8663-4aa3699cf434-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-dd1fc03e-b3a5-4ffc-8663-4aa3699cf434-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company operates and manages its business as </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cef8a22a-c014-45ca-8035-169f50b0f724" name="us-gaap:NumberOfOperatingSegments" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit15" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-ff9f1092-9101-47ab-9e28-31bb9ae1d824" name="us-gaap:NumberOfReportableSegments" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit15" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reportable and operating segment. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Primarily all of the Company&#8217;s long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment. All of the Company&#8217;s revenue was in the United State</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s for the years ended December&#160;31, 2023, 2022 and 2021, based on the shipping location of the external customer.</span></ix:continuation></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d-continuation-7"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section24" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="ct-nonNumeric-bcb0b1c7-df3a-4fb7-8498-01d484ad2303" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-bcb0b1c7-df3a-4fb7-8498-01d484ad2303-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">3.&#160;&#160;&#160;&#160;Recent Accounting Pronouncements</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-bcb0b1c7-df3a-4fb7-8498-01d484ad2303-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Recently Issued Accounting Standards</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segments expenses. ASU 2023-07 became effective for the Company on January 1, 2024. The Company does not believe that the adoption of this new guidance will have a material impact on its segment reporting disclosures. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09, which enhances income tax disclosure requirements by requiring specified categories and greater disaggregation within the rate reconciliation table, disclosure of income taxes paid by jurisdiction, and providing clarification on uncertain tax positions and related financial statement impacts. ASU 2023-09 is effective for the Company on January 1, 2025 with early adoption permitted. The Company is currently evaluating the impact of adoption of this new guidance on its income tax disclosures.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section25" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">4.&#160;&#160;&#160;&#160;Fair Value Measurements</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72-continuation-0" continuedAt="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 &#8211; quoted prices in active markets are identical assets and liabilities;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 &#8211; observable inputs other than quoted prices in active markets for identical assets and liabilities;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 &#8211; unobservable inputs.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company&#8217;s</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> investments</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> are classified within Level 1 of the fair value hierarchy include money market funds valued using quoted market prices and U.S. treasury bills valued using broker or dealer quotations with reasonable levels of price transparency. Investments classified within Level 2 include commercial paper, which are valued using model-based valuation techniques, and corporate bonds/notes, U.S. government securities and agency bonds/notes, which are valued based upon quoted market prices for similar instruments in active markets or quoted prices for identical or similar </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">103</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72-continuation-1" continuedAt="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72-continuation-2"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">instruments in markets that are not active for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following tables set forth by level within the fair value hierarchy the Company&#8217;s assets that are reported at fair value as of December&#160;31, 2023 and 2022 using the inputs defined above (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ct-nonNumeric-626e2557-a3aa-4f2b-b7d2-79e94aa404f8" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-626e2557-a3aa-4f2b-b7d2-79e94aa404f8-continuation-0"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-626e2557-a3aa-4f2b-b7d2-79e94aa404f8-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d39cf893-6563-4ca2-8c94-e665cf96f36d" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,483</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9bcdcccf-be74-4bf8-923e-3d379c1e3b54" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,483</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-70ba2d2a-2c0b-4f8e-9759-a62c317581b5" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,899</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-524238ee-45c0-4879-a4b7-7cf36afd2514" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,899</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e09ec75b-e0d9-45b7-836a-15bf48248cbe" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">33,150</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-49ff0d6e-ca47-4268-9c9c-054f94f01069" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">33,150</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8334f8ad-3fd1-493c-ac06-7eb56e0ac644" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">39,438</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32b9b822-4cb0-4032-a17f-fd49fe7af20d" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">39,438</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a3be0527-6d71-4e4c-b6e8-4d94fad4c4a9" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,556</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-61bad5d4-24a4-4fe5-a06d-e40e9345224d" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,556</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-023d808a-5087-4445-84cc-1e7989d0cfa4" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">68,677</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b5a56dbf-d118-4656-b7a0-dffc5157db72" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">68,677</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-528a6c40-9d75-4a2c-889c-e596a69d94c6" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31,382</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d2ff667-132f-4bfa-ba46-e6294572274a" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">158,821</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f786a2e-5536-4724-8c75-08a843cde262" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190,203</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-245b8b3a-53eb-4dcb-a1d3-d85789766da7" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,158</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c425871e-b4ea-4310-a214-ac5bb313566c" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,158</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37911340-3688-4b6f-b9d0-007999a7b21e" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,776</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e84882ad-bd31-41db-bb38-c9ab4e86e53e" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,776</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98532d04-f231-42ce-8d71-b4dee657bc3c" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">48,875</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6e9276e6-9e53-4ce3-a16d-c88c5e984836" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">48,875</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-952d4edc-cef3-4474-b644-d0c528d6099c" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,515</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8bc19f8d-354c-49dc-bb63-f2d75d514645" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,515</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bb2bbf0d-d243-4504-971f-193c76acfac0" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">83,270</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7240522e-6751-4bb6-83ba-66c60a7c4cb4" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">83,270</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-421d2e79-ea84-4b90-937d-8e01f09f12f2" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,996</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e896a2e2-82ef-4945-a5d7-de591fa7eb4c" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,996</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency notes</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c133feca-3c78-4bf7-878d-3a3c03a9ce0c" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,884</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e5ea3236-ff5f-4140-9092-2b1ecf208cd7" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,884</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-83a9a050-8ac5-4e8b-8f73-2af1a0465ffb" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">74,934</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e23eda9e-ed95-49a5-9fab-a0d0a15121aa" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">138,540</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-15fcc812-7a32-4b12-9c46-a58546c4bec8" name="us-gaap:AssetsFairValueDisclosure" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">213,474</ix:nonFraction></span></p></td></tr></table></div></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were no transfers between fair value hierarchy levels during the years ended December&#160;31, 2023, 2022, and 2021.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72-continuation-2"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section26" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">5.&#160;&#160;&#160;&#160;Balance Sheet Components</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-0" continuedAt="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Investments</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The fair value of the Company's available-for-sale investments as of December&#160;31, 2023 and 2022 are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="ct-nonNumeric-563170c8-c58a-4b5f-9190-1befd35165a1" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-563170c8-c58a-4b5f-9190-1befd35165a1-continuation-0"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-563170c8-c58a-4b5f-9190-1befd35165a1-continuation-0" continuedAt="ct-nonNumeric-563170c8-c58a-4b5f-9190-1befd35165a1-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross Unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized Cost</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gains</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Losses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85ddd0ff-7c0e-44c4-b3c1-1803202e2c20" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,483</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0981bc1f-8703-4f09-b94b-e92daa7f3851" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,483</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0620bcab-2e07-4ee3-b4fe-8ac75030dd79" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,896</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-612fc508-1c2c-4be0-bf58-d5ce2bd2e7f4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f34912e9-909a-45cf-9c47-17bee481bc1b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,899</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-43aeb3b9-5e0f-44a7-9a55-8ff1f13be5be" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">33,160</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a200c88-bc9b-44a4-a5cc-8388a874ac98" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4838e68d-11fb-4030-9893-4921c9021965" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f04033c5-6d99-4a7d-814f-069d0d76d291" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">33,150</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-763b3f44-70d6-4f83-9be9-87c98cfbb19d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">39,398</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-26a8b9d5-8282-49c4-98dc-96d31238c952" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c2b969bb-a825-432b-a1e1-93958cda540a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-28ebc4fc-6191-41a3-a7b5-479861048abe" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">39,438</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-58f10aae-9b52-4523-a1a7-7ed786a866c0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,501</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d882715a-a319-421a-9287-fdce049f9380" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a67c9333-3f79-49fb-9ab6-95e6cd97f0e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,556</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ec3ad026-2734-4e0f-bd1d-cc1606ad4a15" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">68,693</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-07ad6ada-2bbc-431e-92b7-4d5160d319f7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">27</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b49ed640-e9fc-438c-ba3e-432a11bc649d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">43</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85117a3a-2def-469e-9984-430e8276bc9a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">68,677</ix:nonFraction></span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8488bff8-80ab-4647-a3df-a008cc226f05" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190,131</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-92ebf6af-6c26-407f-b999-c536b3137c52" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">145</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7b88a86d-4a0c-4876-a2bc-99a445a223aa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-92dfc8b3-3d6a-4251-8db7-6e3ae50bd0b3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190,203</ix:nonFraction></span></p></td></tr><tr style="height: 0.19in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Classified as:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash equivalents </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da00b1e4-bd48-4b16-a7c5-c941dcc7a1e1" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,483</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term investments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1adf5aca-8bbc-46d0-8f25-7df2203328b1" name="us-gaap:ShortTermInvestments" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">161,264</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Long-term investments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96249b6b-d1bb-464b-91c2-4c9200dd3716" name="us-gaap:LongTermInvestments" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,456</ix:nonFraction></span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-67879fa5-748c-4d49-b049-a9569d61c60a" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190,203</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">104</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-1" continuedAt="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-2"><div><ix:continuation id="ct-nonNumeric-563170c8-c58a-4b5f-9190-1befd35165a1-continuation-1"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross Unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized Cost</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gains</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Losses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c6e0a6a-41e8-4134-857b-3f47507859e8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,158</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d3875fb6-d4ce-44d8-b1b0-fdfe229bf83e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,158</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e0c2af6-0dee-45be-a639-1a5d7c3019c9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,772</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-602f6491-3d10-4c20-8c68-3a2d6a5327d9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b30b408-84dd-4894-aee9-d5a7c30c971f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,776</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3b2b311c-e732-4093-b2ce-36bb2c059a90" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">48,875</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b3afe93-8ace-420f-a7ab-4bf218802289" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">48,875</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ec4be13-ec85-4ac5-a689-34430beab8de" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,528</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-59e99a65-beeb-4186-9499-ed9c99423119" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-22e61833-1eee-4f57-9b92-5db82139ec07" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,515</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-631d9dbb-9d7e-4fec-a6fb-febe7cfc3afd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">83,432</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c4f77a8c-6ff3-43c8-aa53-f0feb95412a0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4d0866f7-ebdc-46a2-96c5-f9729f0204ac" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">164</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-86640f8e-9412-43cc-a7be-feda415d386e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">83,270</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a89e5317-fa88-4ee4-941c-b7a78538f108" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea59a8c5-982e-4b2e-ae1c-8308065c29a2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d433fa1-1d02-4f03-b569-ec2cdda1064c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,996</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency notes</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f321f927-252e-47d1-97bb-83de4c1e7ccb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,876</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f341bd01-4c2c-46ff-8d3e-ec49b1c9a35a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04521197-342e-4b08-82b1-9e82f1d9a4e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,884</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-78eb640a-8cb2-4338-974b-4eb717e97499" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">213,641</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-467dbc4e-6a08-43bc-8e59-638d3784f177" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d09ac577-a370-4f60-9509-903479924d78" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">181</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9e7d1a1e-d293-4dab-93d2-0faa67c349c6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">213,474</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Classified as:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1fffc3a0-ad50-458b-90ce-44ddce5da069" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">55,158</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term investments </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9bce6e88-e06a-4bcb-b6d1-13d1c33cc703" name="us-gaap:ShortTermInvestments" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">158,316</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff774692-a264-48d9-a94c-cc8bf4adfafb" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">213,474</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the fair value of the Company&#8217;s cash equivalents, and available-for-sale investments classified by maturity as of December&#160;31, 2023 and 2022 (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="ct-nonNumeric-6e883a0d-600d-4519-b90d-70257487367c" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.36in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts maturing within one year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-047df09f-657d-4c97-b100-32e4e6bc9847" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">180,747</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2a5df89-f4f3-4bec-a49a-d1d76d9da807" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">213,474</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts maturing after one year through two years </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-536477ae-779e-4d5b-8f10-c1bd198b1218" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,456</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6ff9ef2e-eb15-4ef5-a418-68f3b0cb05a2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190,203</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ee12530b-5cb6-493a-9797-e498c15ab959" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">213,474</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Available-for-sale investments held as of December 31, 2023 had a weighted average days to maturity of </span><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="ct-nonNumeric-99fc91e1-90ce-4ce3-bfde-e20c8a339e92" contextRef="As_Of_12_31_2023" format="ixt-sec:durday"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">163</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> days.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2023 and 2022 (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="ct-nonNumeric-d0a985fe-967f-4f0b-987c-5dfc5bd2b8cb" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Less than 12 months</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Less than 12 months</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Unrealized Loss</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Unrealized Loss</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9681ed4c-39ff-44e1-b651-bfd675d857a1" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">21,842</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9105ae0f-1f73-4afc-b763-51371d4e98d4" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-59119c32-3f87-4045-9c0b-186634145a96" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,490</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-642df3f5-b77b-4da3-a4f3-fb87b1fa7e9e" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8e9ca0a2-d23d-4c7f-b02c-926277f42306" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,684</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7134bcb7-322a-45fa-9a4b-37c4eaffe3c3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25efaba6-3dbb-4c46-864f-cbe8a41c58c8" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73,329</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f8aeb32e-80b2-4611-9c83-b8547a215941" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">164</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e6e5ddbe-18f8-448d-9640-bc7a1b82c03f" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,994</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0073cbe9-09b3-4e81-9c3d-b93e0228ed9f" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-09c320c6-50d8-4574-a37f-43714c4255ec" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">48,964</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3a54bbf-4c3a-4ad8-9d54-ac5cfebc9c25" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">43</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9660ade-b8d1-4dc6-bc87-2a5e33364d6d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">90,490</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a96146dc-6982-4ef9-8567-f4347d6b8b24" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-57ad6d51-cc19-4769-8c1c-63825da67f33" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">76,813</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08add11b-7be1-4c1f-95d5-81504d059a9a" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">181</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be8d921a-da6e-41c0-a48a-3cd4fa2a2230" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-333ad2b6-04a2-49d4-bd79-46b55c73d4b9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> available-for-sale investments in an unrealized loss position greater than twelve months as of December 31, 2023 and 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inventories</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Components of inventories were as follows (in thousands): </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ct-nonNumeric-851e68b9-d86d-489f-b2ca-c96601a66274" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Raw materials</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5f56f1ea-a538-4931-8df5-f3ba0865d4e1" name="us-gaap:InventoryRawMaterials" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,512</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5a9bccb1-f76b-49e7-a358-73bd0fc51e94" name="us-gaap:InventoryRawMaterials" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,913</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Finished products</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af31b588-a78a-48c2-8e48-7b6a6fae0a67" name="us-gaap:InventoryFinishedGoods" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">23,364</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f34b356-5da1-415a-88a7-ecb098b994ea" name="us-gaap:InventoryFinishedGoods" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,380</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total inventories</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-46f1b4fe-e2b5-44f0-9c5a-4fa98dadd4b7" name="us-gaap:InventoryGross" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,876</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-abe90338-e777-4ff9-8785-9266bc61cacd" name="us-gaap:InventoryGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">19,293</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023 and 2022, there were </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c1310ae-7a0f-4692-81ec-a6660b300e14" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-c06a9cee-0ca5-432e-b36e-dbb3ede8b8cb" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> work-in-process inventories. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">105</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-2" continuedAt="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-3"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Property and Equipment, Net</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ct-nonNumeric-3db1c9ce-6f02-4bd3-975d-00722e6a8ccf" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and fixtures</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2d977c19-2caf-40c6-98d5-fa50fa5e73b9" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,052</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c2f4699-9e46-4349-a241-dd2d7739bfd4" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,822</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-41ac25bc-c2e3-4c96-8c15-1b5d72298958" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,776</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-63fb6359-4e39-4a1d-9a37-f6daef549bfc" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,046</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Software</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a64f898f-e6e7-44f2-ae79-b848872a1143" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">296</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-102d402c-12e0-40ed-8008-b60d91b87fb3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">296</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasehold improvements</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-adcfbd9c-8a5d-434c-ad8e-071348ba57d8" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,561</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-424115fa-b00f-435d-a09f-09c49100e96f" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,246</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a5241457-6301-4700-83da-78fbaad2fdd4" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,685</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-41d34c0b-5415-4b74-96ad-900c793620d0" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,410</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Accumulated depreciation </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3fa6711-0e3b-40fe-9352-8531369d9efb" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,907</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6ca7a825-7120-4b8c-a2db-f491e0eb2fe1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,355</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add:  Construction-in-progress</span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5ea13a96-de71-4fb7-808e-74d6751b18c6" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">336</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-527576b1-2176-4f14-a310-43a116b878cf" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">317</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total property and equipment, net</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb82c492-a349-4c0f-9096-e06f3e79ed58" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,114</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b454c52-5679-4b41-acc8-ccb8ae7d2d80" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,372</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation and amortization expense was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e363c294-c342-4091-b5d5-ebc758615e64" name="us-gaap:Depreciation" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">2,696,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-23d6c90a-8cee-4c86-908d-d5599358bd35" name="us-gaap:Depreciation" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">2,127,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c165b47e-278a-4276-a43a-c97bdfec6d0b" name="us-gaap:Depreciation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">1,032,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accrued Liabilities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued liabilities consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ct-nonNumeric-95b0dfb9-b184-4472-a575-ec5f34155cdb" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued payroll and related expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8d5cc949-5205-4501-b704-7b664fa49b2a" name="us-gaap:AccruedSalariesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,113</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9644f3d7-7417-4179-b953-118ee685cb73" name="us-gaap:AccruedSalariesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,216</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9df298ae-8d69-4c18-90e2-2f005456188a" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,703</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ffce4c68-b6bc-46cb-a8b4-9ce656a006a9" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,844</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued travel expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1efaf639-6d86-43c6-93f7-d4f419c4f171" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">944</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16aed67e-3c6d-4876-85cf-1708c63a2121" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">775</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued interest payable</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-45350e0a-f448-4f99-ad9d-3942beef9645" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">517</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c01b6daa-4b73-47fd-ba02-1b39d88ada31" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">519</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for sales returns</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-01662ba6-dffe-44f1-94c0-f76b0f750fbe" name="silk:AccruedTravelExpensesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">500</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-823bf571-5658-4d53-97a3-4256513c70d0" name="silk:AccruedTravelExpensesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">540</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued royalty expense</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-006ace88-126e-4710-9ae2-b9a9e64903b0" name="silk:ProvisionsForSalesReturns" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">405</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9862a51-2dd0-4e6e-958d-e3880400a394" name="silk:ProvisionsForSalesReturns" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">973</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued administration fees and sales rebates</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6734e8b5-cf9c-43cd-95f7-68f4351fb6da" name="silk:AccruedAdministrationFeesAndSalesRebates" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">405</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8fc990e2-1627-446e-bb19-2ba540859b98" name="silk:AccruedAdministrationFeesAndSalesRebates" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">338</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued professional services</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-817f4174-ed8c-428c-ad76-2fa1b976832e" name="us-gaap:InterestPayableCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">326</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea251e1b-67ef-404a-9a48-20467479d5f9" name="us-gaap:InterestPayableCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">781</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued clinical expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2b0cbf99-44d8-406c-aa8f-dbe35192b509" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">256</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2d5afe8-5373-4526-9d23-83a83a3ee503" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">249</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred revenue</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-801fdf60-c89b-4c90-aaaf-677b174d3dcf" name="silk:AccruedClinicalExpensesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">143</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-09709b30-c41f-4872-a282-47c0783161a5" name="silk:AccruedClinicalExpensesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">253</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued other expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d789c83a-d116-42de-a695-6fbe8333c92f" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,295</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4d647963-4194-4fe8-9e6c-f939fc6f5a9d" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">477</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total accrued liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d2f50db-8afe-41bd-a862-25fa3b1a14ed" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,607</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fe7fe197-ef0d-4e5d-b775-be0f950afc2b" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">21,965</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777-continuation-3"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section27" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">6.&#160;&#160;&#160;&#160;Long-term Debt</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-0" continuedAt="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stifel Bank</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2020, the Company entered into a Loan and Security Agreement with Stifel Bank which provided for a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-24157294-6fb4-4cfb-be5f-bfa80ff5f8e6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> loan facility, comprised of a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0ca3637f-a0f2-4665-922e-f345b56e7f33" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured revolving credit facility, with a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-53f54dc7-fa65-4e17-9c34-4a0313cf88c9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilitySubfacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> subfacility for the issuance of letters of credit and other ancillary banking services, and a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3ce1b0e2-90d3-4e78-8bf0-7be3bbb397ae" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured term loan facility, provided that amounts outstanding under both facilities may not exceed an aggregate principal amount of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af2318d5-d6d8-4781-ace3-032ffeda0f6f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at any time. Interest under the revolving credit facility was the greater of a) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e418b2fe-9a15-4beb-87e4-daa93e114b47" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% above the "Prime Rate" as published by </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">The Wall Street Journal</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or b) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-46f2c81e-1681-4a8b-874a-78e1333e9da1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">4.75</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. Interest under the term loan facility was the greater of a) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f628f3f-faf3-4a0d-8545-a207309c34d8" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.75</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% above the "Prime Rate" as published by </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">The Wall Street Journal</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or b) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3d817d9a-3c72-4b54-a7c1-7b3a75d4ec1b" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">4.75</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The Company drew down $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-10c12e15-3ac9-4c84-bcb1-01f2ca298293" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">49,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> under the term loan facility in October 2020. Concurrent with the Loan and Security Agreement, the Company entered in a Success Fee Agreement in October 2020 with Stifel Bank, which requires that the Company pay Stifel Bank the lesser of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e34fed12-7b17-4d0d-bc9a-af1a0acc35b8" name="silk:DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.75</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the original principal amount of all credit extensions made under the Loan and Security Agreement or $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eb239e0a-de52-4b8d-8915-44f5786e44dc" name="silk:DebtInstrumentCovenantLiquidityEventPaymentAmount" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">375,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in the event the Company completes a Liquidity Event (liquidation, merger, sale of the Company or change in control). </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">106</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-1" continuedAt="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-2"><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On May 27, 2022, in connection with the consummation of the Loan and Security Agreement with Oxford Finance, as noted below, the Company repaid all amounts outstanding under the term loan with Stifel Bank. The Success Fee Agreement obligation of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7b8137b-3836-44e2-84b0-a9e635ecce81" name="us-gaap:DebtInstrumentFeeAmount" contextRef="As_Of_5_27_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">367,500</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> survives the Stifel Bank debt repayment and terminates on October 29, 2025. The Company has determined the probability of a Liquidity Event to be remote and accordingly, has not recognized a liability as of December 31, 2023 and 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Oxford Finance</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2022, the Company entered into a Loan and Security Agreement, or Loan Agreement, with Oxford Finance LLC and its agents, or Oxford Finance, which provides for </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c287ff1c-7cce-4141-8a92-d02d3e96b96f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">225,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> loan facility, comprised of a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-99f9ddf2-8934-4e76-a634-f543369eefd0" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">25,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured revolving credit facility and a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9426a078-4411-4d76-a945-feaf5b8a5532" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured term loan facility. The term loans are available in three tranches. The first $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b4bcdce-0b8d-4c9c-a12d-33a4c7810589" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">75,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> tranche of term loans was available at closing in May 2022. A second tranche of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff486294-5341-420e-b918-278e78399c9e" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">75,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of term loans is available through December 31, 2024. A third tranche of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-997a33fd-0741-400e-b94b-c6304a0bb851" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> would be available through December 31, 2024 so long as, at the time of draw, the Company has consolidated trailing 12-month revenues equal to at least </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-43c6b724-50b6-479b-a6a6-9d02977d34fa" name="silk:DebtCovenantRevenueCovenant" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">90</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the sum of the outstanding term loans plus the amount of any requested third tranche term loans. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Upon request of the Company, the revolving credit facility will be increased from $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fca29310-193f-4d11-8919-70758d49b374" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">25,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6e018455-545f-4635-a9a2-806ebc02e084" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The revolving loans are available subject to a borrowing base equal to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c7670a0f-5eab-4bb6-9ade-16f82c76001f" name="silk:PercentOfBorrowingBaseOfEligibleReceivables" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">85</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of eligible receivables plus </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1173eebd-c9e6-4548-a94f-6b556a3ad210" name="silk:PercentOfEligibleInventory" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">50</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of eligible inventory, up to the lesser of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25d9c544-c60f-46d3-ae09-75d10e2e3a0b" name="silk:PercentOfBorrowingBaseInCaseEligibleInventory" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">40</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the borrowing base or $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fbe9ed3f-3739-49d9-813d-976414d6b663" name="silk:BorrowingBaseAmountInCaseEligibleInventory" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, in the case of eligible inventory. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The revolving loans and the term loans mature on </span><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="ct-nonNumeric-82610ffe-01e1-43b9-ae23-8240ae9f9122" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">May 1, 2027</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The principal amount of outstanding revolving loans, together with accrued and unpaid interest, is due on the maturity date. The term loans begin to amortize in equal monthly installments beginning on July 1, 2026. As the Company achieved a specified </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consolidated trailing twelve-month revenue target, it has </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the option to extend the first amortization date for the term loans to July 1, 2027. Such election may be made </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no earlier than June 30, 2023 and no later than thirty (30) days prior to July 1, 2026. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the Company exercises this option, then the maturity date for both the revolving loans and the term loans will be May 1, 2028.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The revolving loans accrue interest at the greater of 1-month Secured Overnight Financing Rate (SOFR), or the Index Rate, and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fa2832e4-d565-49c0-8837-bf27c9b63e75" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.85</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, plus a margin of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eadbca54-294b-42e8-8dfe-dc3fb751e990" name="silk:DebtInstrumentMarginRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">3.00</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The term loans accrue interest at the greater of the Index Rate and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c2165ea9-219e-45f5-98c6-a981ef25c9c1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">0.85</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, plus a margin of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-438b6f07-c918-4ef0-9e51-caea1f7e95f8" name="silk:DebtInstrumentMarginRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">5.00</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The Index Rate is capped at </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-77cc7da9-63ff-444a-9ea3-faf2015d2a87" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">2.50</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for purposes of the Loan Agreement. Interest on both revolving loans and term loans is payable monthly in arrears. The Company may borrow, prepay and reborrow revolving loans, without premium or penalty. The term loans once repaid or prepaid may not be reborrowed. Term loans may be prepaid in full, or in part in increments of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-22c057cb-303a-4d3c-ae9e-1021493738b6" name="silk:TermLoanPrepaidInIncrements" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company is required to pay a prepayment fee of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-93518dce-c7dd-41fa-8d0c-742bd4026e28" name="silk:PercentageOfPrepaymentFees" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">3.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for prepayments of term loans made in the first year after closing, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cc1e5bd3-8eca-40c7-adab-59550b227af6" name="silk:PercentageOfPrepaymentFeesInSecondYear" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">2.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for prepayments of term loans made in the second year after closing, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c6477f4f-de06-41ec-9f63-be1ca8d3d1f7" name="silk:PercentageOfPrepaymentFeesInThirdYear" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">1.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for prepayments of term loans made in the third year after closing and no prepayment fees thereafter. Upon the earlier of prepayment or maturity of the term loans, the Company is required to pay a fee of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2fc07b02-8ab3-4d22-a869-08a1dadc0e70" name="silk:PercentAggregateOriginalPrincipalAmount" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">5.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the aggregate original principal amount of the funded term loans, which fee increases to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6ef2fc4a-8ec6-4fa0-8e46-de6347e7a804" name="silk:PercentAggregateOriginalPrincipalAmount" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">6.75</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% if the Company exercises its option to extend the amortization date and maturity date. The Company is also obligated to pay other customary fees for a loan facility of this size and type.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Also in May 2022, the Company borrowed the first $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9b5ba34b-8712-48af-9396-c12924ca2840" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">75,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> tranche of the term loan and used a portion of the proceeds to pay off and terminate the prior term loan agreement with Stifel Bank totaling $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5ed17ec3-c1fb-4274-9bc6-67615b343d67" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">49,181,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, which included a final interest payment of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7576dcea-df21-4597-b13a-99b25638115b" name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">181,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company recognized a loss on debt extinguishment of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-19bbb080-61f3-4976-906e-8de1930c4c1c" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">245,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in connection with the early termination of its prior term loan agreement with Stifel Bank. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Obligations under the Loan Agreement are secured by substantially all of the Company's assets. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Loan Agreement requires the Company to maintain consolidated trailing twelve-month revenues of at least </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b1a163c5-6b3d-4cd1-bcac-6a11ad7e5cce" name="silk:DebtCovenantRevenueCovenant" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">75</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding principal amount of the term loans, measured as of the last day of each fiscal quarter; or if the revenue target is not achieved, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Company must have maintained unrestricted cash and cash equivalents (net of outstanding revolving loans) subject to control agreements in favor of Oxford Finance equal to at least </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cfe09f02-cd19-43d7-9f34-a6e08ebaa7ca" name="silk:DebtInstrumentCovenantMaximumBorrowingThreshold" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding principal amount of the term loans</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting the Company's ability and the ability of the Company's subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of the Company&#8217;s obligations under the Loan Agreement, the termination of the lender&#8217;s commitments, a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3ffe620-7673-4c4d-ae7c-5e89917d0a58" name="silk:PercentageOfPrepaymentFees" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.</span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">107</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-2" continuedAt="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-3"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, the aggregate outstanding principal balance under the term loan facility was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b41f4573-aeee-433e-ac49-aca6b20cdb44" name="us-gaap:LineOfCredit" contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">75,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> with the variable interest rate capped at the maximum rate of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5c993d44-1ad5-4726-ae8a-e3febff0d4e1" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">7.50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and no amounts were outstanding under the revolving credit facility of the Loan Agreement</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. As of December 31, 2023, the Company was in compliance with all applicable financial covenants.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Future payments under the Oxford Finance term loan agreement as of December 31, 2023 are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="ct-nonNumeric-ff0ade50-3507-4b5e-aee8-d685161eb1f3" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ending December 31:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6cdcdc2f-970f-46bb-a16c-3795fa0d829a" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,719</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f878372-cda2-42b9-adfc-c65652a72a70" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,703</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ba9dca1e-a006-4de8-8d5a-b7cdfb4fb25f" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">45,699</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2027</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f0c08bb0-2286-4d45-96d4-90c43847cc5e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">34,517</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9b02b4a5-9636-48eb-8dad-ea9bd9597ba7" name="silk:LongTermDebtGrossBeforeAccretionOfClosingFees" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">91,638</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add: Accretion of closing fees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-51d005b7-b054-4487-b965-283437562297" name="silk:AccretionOfClosingCosts" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,329</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f18127cb-f24f-4eec-b131-e870023ee88b" name="silk:LongTermDebtGrossAfterAccretionOfClosingFees" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">92,967</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Amount representing interest</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bc0f34d5-fd94-42cd-9345-77d74d09bfba" name="silk:LongTermDebtUnpaidInterest" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">16,638</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Amount representing debt discount and debt issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-93a103c5-a88b-47e9-a890-a46d96c97bc5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">703</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Present value of minimum payments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a80479cf-a663-4582-b88b-9c210bc13c64" name="us-gaap:LongTermDebt" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">75,626</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c-continuation-3"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section28" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">7.&#160;&#160;&#160;&#160;Commitments and Contingencies</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7-continuation-0" continuedAt="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Operating Lease and Rights-of-Use</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s operating lease obligation at its corporate headquarters in California consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2027. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2023, the Company extended the lease term for an additional </span><ix:nonNumeric name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="ct-nonNumeric-e18abce8-d3be-44b4-a7b0-7a1198c5ee27" contextRef="As_Of_5_31_2023" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three years</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and recorded an additional $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d4165da9-d5a8-4bf7-8e4e-d0743139219a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="Duration_5_31_2023_To_5_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">2,504,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> right-of-use asset and lease liability from the remeasurement. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of </span><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ct-nonNumeric-621d40fa-6606-41ad-9a90-1f89aec6605d" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_HeadquartersMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five year</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s non-cancelable operating lease obligation at its facility in Minnesota consists of additional office, laboratory and manufacturing space and expires in November 2029. The lease agreement includes a renewal provision allowing the Company to extend this lease for two additional </span><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ct-nonNumeric-27d5a463-d1d3-4d34-b073-a79e8aaec8bf" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five year</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> terms.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance sheet information as of December&#160;31, 2023 and 2022 consists of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="silk:AssetsAndLiabilitiesLesseeTableTextBlock" id="ct-nonNumeric-527e3fe3-4af9-4f3e-bac1-7a602cc2df7b" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Operating Lease:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use asset in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-dd16a680-3f25-4cca-8f06-df833283191e;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-80d6598d-c247-4749-a960-856924837d92;">other non-current assets</span></span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9de3bc70-05a1-44f0-967e-c32d3752d102" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,489</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-553c88af-2c8a-4ed0-b66b-7d4d7d74b1ec" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,081</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-4a367e19-bd2b-4833-a2ee-41da1810dd33;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ea9efef9-505d-4191-897c-64e4a2fceb36;">accrued liabilities </span></span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b9685ef7-aeae-42eb-b715-632759c2a85e" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,703</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-596a9254-a9a9-434c-926f-cac57f47c4c9" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,844</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-24d00192-026d-4075-a91f-bdd0fa580324;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-18ad6fb4-b92c-4419-9e27-7f511e1beb87;">other liabilities </span></span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-91e8cc67-4883-469e-90c2-8fe0006aa4a5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,304</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5074026e-7cde-43c2-9b66-dbe1f56ac78b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,998</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating lease </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-7adaddd6-e390-4787-853b-b3d3af6f96a6;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-3f9f30e3-cce1-4745-9a9e-9d186b53fb29;">liabilities</span></span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1787d31e-015f-4165-9b35-5f5af3492429" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,007</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-74d20c2a-aebc-47f1-b80c-d8d4f64c81b0" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,842</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the Company's operating lease payments as of December&#160;31, 2023 (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ct-nonNumeric-e8fa9705-1bb0-48aa-8cf7-051531e8ca32" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.19in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ending December 31:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b7767911-8f01-4b7b-b451-0f6ff0cff46f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,991</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-27aebe1c-d9e2-4e25-a63d-0690591df3a9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,130</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d0bf1fb-c06b-48af-8efb-61d50746f21a" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,255</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2027</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a968053-4cc1-46db-bff5-6a8a2771f0d0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,068</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-07e67a8c-aa2e-4045-9a37-b07c0cd0ee2e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,233</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Thereafter</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9336715c-f096-4a70-81a7-3ba9d73cb31f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,158</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total lease payments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b889535b-1b10-4a1b-8673-da47759e371a" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,835</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-44661f2e-114e-45dc-b9cc-dc58e17ed944" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,828</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Present value of lease liabilities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-743f4044-e48a-4a9b-8297-6da867dc6ff7" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,007</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">108</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7-continuation-1" continuedAt="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7-continuation-2"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Purchase Obligations</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. As of December&#160;31, 2023, the Company had non-cancellable purchase obligations to suppliers of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db4d310f-cab6-4244-9d3a-313d811fc69b" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">15,660,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, the Company has minimum purchase commitments under its amended supply agreement with Cordis from July 2024 through February 2029 which require a specified minimum volume commitment based on the actual units purchased during the prior year period from July 1 through June 30, with the unit purchase price dependent upon annual volume during the same prior year period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Indemnification</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the normal course of business, the Company enters into contracts and agreements with suppliers and other parties that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director or officer is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director or officer may be subject to any proceeding arising out of acts or omissions of such director or officer in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9ca7486a-c5e5-4317-a222-b07c609097ac" name="silk:IndemnificationObligationsLiabilityRecognized" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t recognized any liabilities relating to these obligations as of December&#160;31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Contingencies </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7-continuation-2"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows. From time to time, the Company may pursue litigation to assert its legal rights and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8126a362-9981-4657-8c9a-1bec79e0c130" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-4d72c503-b722-4981-bf10-b32ccd2b05ee" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> contingent liabilities requiring accrual as of December&#160;31, 2023 and 2022.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section29" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span id="Section30" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ct-nonNumeric-b7afcf8b-5ff9-4813-8691-1e08b3de4ce1" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-b7afcf8b-5ff9-4813-8691-1e08b3de4ce1-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">8.&#160;&#160;&#160;&#160;Stockholders&#8217; Equity</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-b7afcf8b-5ff9-4813-8691-1e08b3de4ce1-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Preferred Stock</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, the Company&#8217;s restated certificate of incorporation authorizes the Company to issue up to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b4d4287-1353-4a82-a06e-4db202bba16d" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of preferred stock with $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3097fe1-af44-453d-96b8-9aa3ee40ffcc" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2023" unitRef="Unit14" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value per share, of which no shares were issued and outstanding.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Common Stock</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, the Company&#8217;s restated certificate of incorporation authorizes the Company to issue up to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-861296b0-e9af-4e11-940b-728e6da4700d" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock with $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d8931998-93da-4a12-ab63-89f6b5e4ded6" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2023" unitRef="Unit14" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value per share, of which </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8cdaa8b8-707e-4204-b42a-9975361075c1" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-fb8b3e07-dd29-4479-a357-8e0c353b7a4e" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">39,165,481</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares were issued and outstanding. The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. As of December 31, 2023, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9cf3dc01-b26e-4070-9be9-87efae631a9c" name="us-gaap:DividendsCommonStock" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> dividends have been declared to date. Each share of common stock is entitled to one vote.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023 and 2022, the Company had reserved common stock for future issuances as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="silk:ScheduleOfCommonStockReserveForFutureIssuances" id="ct-nonNumeric-80c5a898-65aa-4ea8-add0-170d994fbdab" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="3" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding stock options and equity awards</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-680b1b24-2682-45ac-a251-1928d55244fd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">7,168,881</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f5ac8f7c-f39d-4b49-a4de-0b0b7a081c69" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">5,169,682</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for grants of future stock options and equity awards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ef199ea0-6070-4bcb-ac07-cbb6268e00c1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">532,627</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-47aa19dd-732a-4518-819b-52aba0e0bf3e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,209,072</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for Performance Stock Units for overperformance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f789abf-7559-4a66-b68b-572601877794" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">809,225</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0add89e2-9f9b-42f8-a9b0-e9d38493ba67" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">207,468</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for employee stock purchase plan</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37718fcf-39bf-4b69-9918-0326495952bf" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,356,463</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e89bd1c0-7138-4ea1-abcb-08d012f4b0ad" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,172,686</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total common stock reserved for future issuance</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ce9eaf2f-8778-42f0-a3b1-17e07225343b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">9,867,196</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cfbb77b0-d829-4ea9-b972-a82920f67c48" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">8,758,908</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section31" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">109</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">9.&#160;&#160;&#160;&#160;Stock-Based Compensation Plans</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-0" continuedAt="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2019, the Company's Board of Directors [and stockholders] approved the 2019 Equity Incentive Plan, or 2019 Plan, effective immediately prior to the Company&#8217;s IPO. The 2019 Plan replaced the prior 2007 Stock Option Plan, or 2007 Plan, and the NeuroCo 2015 Equity Incentive Plan, which the Company assumed in connection with its acquisition of NeuroCo in December 2018, with respect to future grants. The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants. A total of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6753d297-e693-4a7d-be39-124d1c39ddef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="As_Of_12_31_2007_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,317,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock were initially reserved for issuance pursuant to the 2019 Plan. In addition, the shares reserved for issuance under the 2019 Plan also include shares reserved but not issued under the prior 2007 Plan, plus any share awards granted under the 2007 Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. In addition, the number of shares available for issuance under the 2019 Plan also include an annual increase on the first day of each fiscal year, equal to the lesser of (i) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7f92b412-8b79-4897-ba86-9b9cef7b5356" name="silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares; (ii) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af27e224-f29c-4a47-afc8-d13d52794e57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">4.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors. As of December&#160;31, 2023, the Company has reserved </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fb37e98b-b060-49d6-a252-efb2df4a1e3a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">7,952,134</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock for issuance under the 2019 Plan.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A summary of the shares available for issuance under the 2019 Plan is as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="ct-nonNumeric-721614d2-227e-40ca-8798-48ac29ac698d" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Shares</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2b56d8f2-6676-4e20-a1e0-7c2ee76a5474" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,790,687</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2aa094a4-31e0-457d-bd39-aa37884948af" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,369,985</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d0c107e8-36a3-4633-8a06-6a9fb4015bc1" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">847,080</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d646efe3-32fa-43fd-81a1-1328939f7349" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">163,620</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-24cdb4b1-26c9-43d3-9f94-4d7b231a84d0" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,477,212</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b30595ba-c914-4e49-a7d5-c08f635c4f22" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,399,235</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for Performance Stock Units for overperformance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-57c0706a-47b5-4513-9fd1-2d901011197a" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal" sign="-">207,468</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c4dcd589-eba3-4f4e-bfdd-226b4286498f" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,600,996</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4e22c34a-bc27-473c-8fbf-0912da566e3d" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">141,089</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d85ed1f4-610c-42da-a4d3-8a45838bf147" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,209,072</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9627bcbc-4dff-4d3e-bff2-d4ec497b97d9" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,534,238</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for Performance Stock Units for overperformance</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-955e5c2d-3560-4928-b710-a93f36ae3976" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">601,757</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e54b1d12-b0d5-4335-868a-2948e5885ce7" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,893,796</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9946a424-61c9-4d24-87eb-3eb41f0d6957" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">284,870</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-813d95a2-65b0-4500-9f18-1129c0cfb22f" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">532,627</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The exercise price of Incentive Stock Options and Non-Statutory Stock Options shall not be less than </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3ccf25fd-784b-4f31-8a8f-fe0e3bee73bb" name="silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50769c29-179e-42d8-a622-931631eb4c69" name="silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">85</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, respectively, of the estimated fair value of the shares on the date of grant as determined by the Board of Directors. The exercise price of options granted to a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-44871c22-f358-46b3-90f2-5d433329556f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">10</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% stockholder shall not be less than </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b982aada-64e0-473c-a89b-bc1454b77cf5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">110</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors. To date, options have a term of ten years and generally vest over </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-a2abe759-ec29-451b-9154-a3ba94204835" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> from the date of grant.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock option activity under the Company&#8217;s 2007 Stock Option Plan, 2015 Equity Incentive Plan and 2019 Plan is set forth below</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="ct-nonNumeric-3f6b910e-5f25-4860-88d8-2228c18af539" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-3f6b910e-5f25-4860-88d8-2228c18af539-continuation-0"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="9" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options Outstanding</span></p></td></tr><tr style="height: 1.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Exercise Price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Remaining Contractual Term (in Years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Aggregate Intrinsic Value (in thousands)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6eec236e-efe3-44d5-811e-18310cf770ff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">4,237,828</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08aa6775-6e6f-4993-b26a-443ec5e51c9b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2020" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">16.56</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-66e38af3-0751-49f4-9fa5-689899259c74" contextRef="Duration_1_1_2020_To_12_31_2020" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.38</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ef60fdd-b333-40c4-9ba4-3b69359c74e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">197,407</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be5d907a-450b-4d8b-8926-5de40eef80ab" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">323,057</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e2ffeada-9f82-40f8-9347-22f2ce449bf5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">53.94</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eed74c08-47c0-432e-bef2-ca36fb9228b0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">643,507</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-54b39a22-dc84-41ac-a9d4-ecf944f26f0a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">7.49</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8e3e2310-0353-40f9-8fdc-c9a22b74217b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">136,439</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-21d4ab65-9a56-4f7b-a036-49fec527e30a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">40.30</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f69021fb-4bce-4606-b905-8723f1e579e3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">3,780,939</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e12c0856-889c-4538-b583-799990da2ba6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">20.45</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-b3ef24e3-e543-49d7-a51b-2ae303912252" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.71</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1c634beb-153d-4dcb-9d14-8d4f0723aa2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">91,900</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ed51506b-8a00-4397-888a-dc2e576cc5ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">587,015</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7c0d6371-499c-4bf6-aa5e-34e2e1e1aaf5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">37.69</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">110</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-1" continuedAt="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-2"><div><ix:continuation id="ct-nonNumeric-3f6b910e-5f25-4860-88d8-2228c18af539-continuation-0"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d5a6c307-8dd6-4dc7-a77e-7cfa1d849a94" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">453,199</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f909709c-4bc2-4cb0-9fac-461ee5583c88" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">7.42</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-587b0228-fd62-4f93-9d46-4dcbc6134c30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">74,897</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db6ad32e-f4eb-4ca4-8a0b-f50924f006fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">41.16</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-863c3f44-74e0-46fe-aceb-420533ca550d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">3,839,858</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f0b18789-604d-4a0c-ba69-7ae3493e8527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">24.22</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-8af71e66-79f4-4b62-b8e7-f473abfec244" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.41</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-78714ea3-947c-4f1d-b096-84baf2c90f95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">112,755</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85466df8-b54c-4248-a574-be4030ba9f81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">19,898</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cdd32176-c566-43d1-b55f-1ba779671810" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">33.57</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-331e38f3-fc12-45e9-a2f9-8a84791aed67" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">199,642</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6f452a9-ee09-4977-9615-9ac4f32a3292" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">7.44</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-271be3b6-7418-467f-a0e7-5a395aed7ffd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">27,430</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d2df73d1-9c83-4194-800e-960c03a57c85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">47.09</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a4d152f6-6b50-4bf3-8b74-1a16ce4b0c72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">3,632,684</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96555e25-a8fa-45d8-a40f-3693ca941d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">25.02</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-5970578e-afe2-446a-98ed-e7b88c5089b4" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.52</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e683539-a093-4aa9-9352-435099f6d493" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,942</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and exercisable at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7b0747fc-6363-4149-a685-db64b31baac5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">3,184,646</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b43d449-5f40-48b8-800f-bf2b00fe77da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="As_Of_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">22.62</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ct-nonNumeric-024d2e46-0703-4b1c-9feb-7cc310cc1c3e" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.19</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f3249287-deb2-4815-9d47-4182bc63f606" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,942</ix:nonFraction></span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and expected to vest at December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aed99fd3-4167-4cc5-84c6-c4127266ab39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="As_Of_12_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">3,632,684</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-66393283-ee46-4483-ab40-414200f47457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">25.02</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ct-nonNumeric-8f56a5db-4b2d-40cc-ae08-c67176926e29" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.52</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dcabfb7b-58f9-4144-880f-1ff1a13d2009" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,942</ix:nonFraction></span></p></td></tr></table></div></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cea4620f-ca7a-4417-b7c0-902ea3d5dc74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">7,857,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-47da6877-76e6-4f10-a481-8c4776959be6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">17,575,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7966cf5a-0b85-490e-9bfc-171d8b1ae6a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">29,355,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a206334e-5f08-40ca-a828-63a6734ffaa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">17.67</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ba093325-2810-413a-82b9-ab9a97b7e8bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">37.69</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0ea55dd-e21c-423d-8936-7019bd1da72c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">23.83</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, respectively. The total fair value of options vested during the years ended December&#160;31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-72057ab2-c225-47c4-bb27-d18c9c1aae8b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">9,207,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d8f1dcf6-b9ec-4830-ad88-681c4e4b7ed5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">9,816,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-11579048-17bf-4b1e-adf9-48d1dc63cdaf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">9,076,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively, based on the grant date fair value.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Restricted Stock Units </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, the Company began awarding restricted stock units, or RSUs, under the 2019 Plan. RSUs generally vest and are settled in shares of common stock over </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-ceaa849e-73d4-4b73-a227-92b2c6803f5e" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in annual equal increments. The total award date fair value of awards provided during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1afdac3d-5e3d-4e6d-af44-7d59413ae86b" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">46,939,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-74588f7c-a7f1-4796-84f6-e279a615c55d" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">30,486,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7257802-e534-4abe-b23d-bd2d59f83040" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">28,110,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively. The total fair value of awards vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d9633f05-4bcb-4399-a2ba-28d20ea58a1a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">13,203,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-52f85901-3056-46a1-81c0-6dd5644fb90c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">6,135,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7b8fc1bc-ae88-4ae1-9823-d08f09e235e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">1,893,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively. The fair value of RSUs is based on the closing price of the Company&#8217;s common stock on the date of award. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A summary of RSU activity for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ct-nonNumeric-0e3feb2d-fc1a-444c-bac6-61e440a7e38d" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Restricted Stock Units</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Grant Date Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f529edd7-e8bd-4e29-8ade-91291ca7d93c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">68,396</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6075c6b9-e322-476e-bb74-9a8b40671efc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">46.16</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f357db83-e401-489b-a9ac-85dc798129ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">524,023</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-40dd7232-eea0-4685-b6e9-3d84bbda14a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">53.64</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-46d3de3a-e16a-4210-9494-73fee0dab375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">34,964</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6de458c3-d6e9-43cf-a477-f351bfa387e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">49.95</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8d345e0e-637c-42f7-a0e2-c78dbb2c3a9f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">27,181</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e754da56-8a74-45b1-8c64-5ea87c6eef08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">51.99</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-30b44e1d-cb2c-490d-89ad-74d75f04ba15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">530,274</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9333afda-ca22-41c8-bf30-cbd333ab6385" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">53.01</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e063815c-4908-4066-abe8-32b748ac7ab9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">806,513</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-62f87d1c-a7ef-4bdb-84d9-38699a8cc4ce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">37.80</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5dc56968-3885-443d-9ba3-01d60cd0500e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">148,239</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-797c2a76-4de8-4402-b6c0-a501b15b3206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">52.14</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7035400c-823f-4cad-9858-a62c93333596" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">66,192</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aa199148-9882-48da-99ff-135058834258" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">44.38</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-09213bf1-7258-44ae-8660-7c1ea015fdd4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,122,356</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f4c49aac-715f-42d1-a144-4f55429fdadf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">42.70</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-66c94a42-c03d-47b7-85ca-5ceae9294cc4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,162,465</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d7ed368c-126c-4365-b08f-0e10bc89586b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">21.71</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5ddf7ad7-1b8a-4c85-922e-d42a3bcf8021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">410,085</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fbc4f8b1-3779-4bbc-8d3e-ec52bc8d745a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">43.44</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-260c3a0f-bc5e-4459-916e-a387825f6c8e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">147,764</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4f2eddda-d97d-40e7-9b07-18736bee7585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">41.23</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f389f577-dc2e-4fbb-bb50-98f2d0882e6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,726,972</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aa097e09-f0b3-488a-ad7e-a15e1c48874e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">26.02</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected to vest at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-66c64840-4b42-4eca-aea4-74ff00f856b4" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,726,972</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f6202a64-ff7d-4e59-af80-004dca91da62" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">26.02</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">111</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-2" continuedAt="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-3"><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Performance Stock Units</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2022, the Company began awarding performance stock units, or PSUs, under the 2019 Plan to certain executive officers and key employees. PSUs generally vest at the end of a </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-06125f65-d4d4-49cb-b0ae-51630f893f6b" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> service period, subject to continued service to the Company. The total number of shares of common stock to be issued upon vesting and settlement of the PSUs will be determined based on the total stockholder return, or TSR, of the Company&#8217;s common stock price relative to a group of Benchmark Companies over a </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-79702ec9-7a3d-4387-bf66-7e761223609a" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> performance period and range from </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13cb3f03-f3be-4aa7-a519-36105c465409" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ed677fdf-d4f8-462e-b47b-4f7b0627a502" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">200</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target value of shares awarded, depending on the Company&#8217;s performance against the targeted Benchmark Companies. The total award date fair value of awards provided during the years ended December 31, 2023 and 2022 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7494d7a9-f234-4142-8960-35136515b87c" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">14,950,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1bd591c2-a8af-460d-8160-16abdbe6100a" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">16,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There was no PSU activity for the year ended December 31, 2021. A summary of PSU activity for the years ended December 31, 2023 and 2022 is as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ct-nonNumeric-7237b2fb-8ae6-4eaf-a2cc-d0eba03c40d6" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Performance Stock Units</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Grant Date Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb22cb2b-8ce3-4cbd-a6a5-9e0b486b73cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">207,468</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d978959-968a-4aa6-b7bb-35d6d599621a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">77.12</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c185cd5-d4f0-46dc-b9d3-43def4fd0af2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">207,468</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd3d715f-0540-40ed-992d-5eb5e7c518e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">77.12</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-622f4601-6690-4ce7-b55e-7221719076ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">711,433</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6a5e6ab-8b57-4f83-a687-c2b00c03cc7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">21.01</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-61ac2678-2fa3-4981-a520-f6025a10a790" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">109,676</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b6c1b0b2-c669-4924-a44c-d32cddc35cb0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">76.66</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f62018d-e13d-4433-b571-a35e194e7f68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">809,225</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7c9c789d-e473-4201-a3d7-7d7549cbad9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">27.86</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected to vest at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c68bc8bf-9663-481d-bc7b-c4a367c59c1c" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">809,225</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81a8b1e1-aea8-4dfc-bf56-a0b71271687d" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal">27.86</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The shares expected to vest as of December 31, 2023 reflects PSUs awards performance and vesting at </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5f3227d4-1855-453a-842a-8a51d5fcefc6" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target value of shares granted.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019 Employee Stock Purchase Plan</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2019, the Company's Board of Directors [and stockholders] adopted the 2019 Employee Stock Purchase Plan, or the ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions. A total of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e2afcd0-a054-4c09-b22d-b40a118c7063" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="As_Of_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">434,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock were initially reserved for issuance and is increased on the first day of each fiscal year by an amount equal to the lesser of (i)&#160;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1de23a67-f113-450a-bf5c-2b5a5ad8ae2d" name="silk:AdditionalCommonStockCapitalSharesReservedForFutureIssuance" contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares (ii)&#160;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a18a3fe8-de69-4c82-a16a-3a756d2b3682" name="silk:PercentOfOutstandingShares" contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">1.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors. The price of the common stock purchased will be the lower of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b9afd7ed-5924-49c7-abc8-cbfb12f61d51" name="silk:FairMarketValueOfCommonStock" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal" scale="-2">85</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. The ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a63717dc-4521-4bfc-af58-bf39337f3af4" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">465,952</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock have been issued to employees participating in the ESPP and </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d41904a-40d2-4908-b24e-b69dc3671292" name="silk:CommonStockCapitalSharesAvailableForFutureIssuance" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,356,463</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares were available for future issuance under the ESPP.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock-Based Compensation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company estimated the fair value of stock options using the Black&#8211;Scholes option pricing model. The fair value of stock options is being amortized on a straight&#8211;line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following assumptions for the years ended December&#160;31, 2023, 2022 and 2021:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ct-nonNumeric-e958400c-9962-4181-aad6-78ec626e78ed" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term (in years)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-ae2835f6-96b7-422c-a55e-25437198e76b" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-68a1bfbb-9384-4cef-8a7f-f7bb689c0ee5" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-fecae585-67c7-45a9-84a9-dccdd280bfc1" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.25</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-98a52ed4-b79a-4c5a-ae36-a10831e3d747" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-03fb3fde-8e8d-4808-9ae1-2a6afe03dcf3" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.25</span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5da287dd-3ddd-4fc3-89b1-c78196d564b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">55.1</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bf533f60-0cfd-4faa-97a0-77d7f3ec98e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">48.2</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8cc45432-9971-4b82-bff9-136d0f41e51e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">51.4</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da15d3a2-af60-4df2-b0df-8b816de55f70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">45.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eefb147e-8d57-4ea0-93d5-a9f0d0f2c454" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">50.4</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85cfebad-fcdd-476b-9921-fa71b6883ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">3.94</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9a2f176e-5d22-4291-8a79-e95289c8ba77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">1.60</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e5a900b4-0aaa-4842-a8c7-c7d70f9b6ae6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">3.84</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bf4f7585-01c9-45bb-935c-4a0a88821633" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0.41</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-baab46b0-7c80-4b08-93e9-83b3ecaca0eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">1.08</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">112</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-3" continuedAt="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-4"><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The fair value of the underlying common stock is based on the closing price of the Company's common stock on The Nasdaq Global Select Market on the date of grant. The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the &#8220;simplified method,&#8221; whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected stock price volatility assumption was determined by supplementing its historical stock trading volatility with the historical volatilities for industry peers, as the Company does not have sufficient trading history for the Company&#8217;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the&#160;Company&#8217;s common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the&#160;Company&#8217;s stock options. The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has elected to recognize forfeitures of share-based payment awards as they occur.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2022, the Company awarded an aggregate of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56c3b2be-c5c9-4e81-a8ec-41fb9bff7930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">207,468</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> PSUs to certain executive officers that vest at the end of a </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-552e4818-2ff0-4241-a26b-651184e38dca" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> service period based on the TSR of the Company&#8217;s common stock price relative to a group of Benchmark Companies measured over three performance periods. The Company estimated the fair value of the PSUs using the Monte Carlo simulation model, which is being amortized over the requisite service period of the awards. The fair value of the PSUs was estimated using the following assumptions for the year ended December 31, 2022: peer companies volatility of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5e653dab-80f3-4359-92a5-d15c132cafc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">59.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, Company volatility of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0f96b74-2ef0-4f7f-8c7b-a4f01a4623d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">60.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, risk-free interest rate of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-06a271ed-3bdf-4fd1-bebf-41d1c98e285d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">4.09</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%-</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e8da16ab-202f-4548-b1a4-5d9a2ba257fd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">4.20</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, correlation with index of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-168645dd-46e6-4039-82eb-66717bcba427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0.41</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and dividend yield of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-52f10938-c687-437a-9ba2-78bad6547f1c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2023, the Company awarded an aggregate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8329c4d6-04c4-467a-a5cb-8862559c4b2d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">99,350</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> PSUs, assuming target performance. Up to one-third of the target award can be earned and vested at the end of the first and second annual measurement periods based on the total stockholder return, or TSR, of the Company&#8217;s common stock price relative to a group of peer companies, and up to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4267dae5-3bd2-42ae-b316-8a9b24c1846d" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" contextRef="Duration_3_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">200</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target award at the end of the </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-912ca1ee-b3b4-42e4-9578-f52ea1746562" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> performance measurement period. The fair value of the PSUs was estimated using the Monte Carlo simulation model and the following assumptions for the year ended December 31, 2023: peer companies volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bca93028-2549-46c3-840f-f4c4374af8cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">62.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, Company volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-65e24219-2fdd-44a3-81ba-9e8f277324fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">61.2</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, risk-free interest rate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4be54b55-b2a3-44f6-86a0-4246dbe1c4e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">4.58</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, correlation with index of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13aefb6c-4163-4526-8d4a-37baa3caaeb4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0.38</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and dividend yield of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-54691960-7ccf-454b-bb0a-12a1c9bf4afd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2023, the Company awarded an aggregate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c4d83dd-7397-41cf-8f73-b1974d394f0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">612,083</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> PSUs, assuming target performance. Up to one-third of the target award can be earned and vested at the end of the first and second annual measurement periods based on the total stockholder return, or TSR, of the Company&#8217;s common stock price relative to a group of peer companies, and up to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e4fa9f55-d040-42a5-9ab6-7ebda7a30dfe" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" contextRef="Duration_11_1_2023_To_11_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">200</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target award at the end of the </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-d5a3b8b5-f486-49f5-95a6-4c8753454a2c" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> performance measurement period. The fair value of the PSUs was estimated using the Monte Carlo simulation model and the following assumptions for the year ended December 31, 2023: peer companies volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8754e4a2-81d1-4983-bbba-04d5f624055f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">56.9</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, Company volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2f26a118-ec50-4251-9cee-142c15f1f7f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">71.1</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, risk-free interest rate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3f2a913a-fada-4ac7-b2e1-36dd8df3be75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">4.72</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, correlation with index of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e58b9383-b652-4d6a-92d4-1865634e44dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0.35</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and dividend yield of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bdaa3806-d270-4b4a-bc5c-844130d5fecc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The fair value of the shares to be issued under the Company&#8217;s ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2023, 2022 and 2021:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ct-nonNumeric-6b763ced-cfc2-4209-8361-1ed429299f76" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term (in years)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-9b4e6280-1402-4995-b527-ad690cbb67c8" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-4f0c321f-8b8f-45a0-abb9-51681150ec60" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-cf845e55-51c0-4a6f-bd36-ec5471937e1e" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85ad4f56-4ba6-424f-a215-354ea95eb701" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">47.4</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d1aead01-ce3f-431b-a483-8b02b41eab7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">119.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca1d35a4-2644-43cb-9c52-9a08b5bc2455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">51.6</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a79bd967-ce28-468e-8715-2bfb8aa15525" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">74.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12896de1-0888-448a-b608-a3c549b2162c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">46.9</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f2a2ee58-06ee-4c57-a79d-fbe935a843ff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal" scale="-2">51.6</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-40336891-aab4-4c52-aad6-a4f218ba4b4e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">4.64</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-162c2fcf-4c71-4dc6-b7db-0a4b83acb59b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">5.43</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3ac1227d-83f2-4eef-b632-f89a6e0b5fad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0.07</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-66e5167f-6c80-4a7a-909b-b6017beb2ca7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">4.64</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-05ffc660-ed02-479d-b6f8-e56353b05c23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0.03</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f4886a6-45f1-4402-bd57-6b5fd319b283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember" unitRef="Unit13" decimals="4" format="ixt:numdotdecimal" scale="-2">0.10</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ct-nonNumeric-873d581e-e0f0-43b4-8fb8-221e9b3c8e09" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of goods sold</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f68f586d-e6c3-4f5f-bcb6-e33135f71c5c" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,671</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bbd0db54-538a-4898-8d04-32ef04d03c9c" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,138</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-666d25b0-7a91-4e1e-b424-ac42e2f525e7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">635</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-374a86b9-0b1e-4ccf-bf2c-5e61114eabbf" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,589</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8c8928dc-9b84-4078-baa5-10505b986a33" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,240</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f943a6c4-be4e-4088-8b42-f17ba1f11370" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,909</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Selling, general and administrative expenses</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-70ad5bef-cac8-4d96-841d-fe26cd6acf4d" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29,633</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cdfba206-9108-4cbf-8de9-c77ddebdffc5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,645</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6843e5d6-1b00-4a45-bdd0-e6d35d7d2bf5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,068</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-61630d9b-0b76-4546-9a72-921e00ac1d1f" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">38,893</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4812b2a6-60f7-4c50-bfd6-90ff8b187fdc" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25,023</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4292f2b0-9a38-4413-84dc-28d6732cff63" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,612</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, there was total unrecognized compensation costs of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84358a81-5d36-43fe-aa09-8367e6a561b5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">5,645,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> related to stock options expected to be recognized over a period of approximately </span><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ct-nonNumeric-f479b8ef-5f59-48e6-b78c-f06afa38051e" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.63</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, a total of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-851c3023-dd7b-412f-be8b-38fd12c274ee" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">73,195,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of unrecognized compensation costs related to unvested RSUs and PSUs expected to be recognized over a period of approximately </span><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ct-nonNumeric-61173ca4-e355-47fd-9ba0-ce1ea0a01b99" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.76</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">113</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-4" continuedAt="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-5"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">years and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81fbc471-a556-4543-a013-bbe4a70d3023" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">679,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of unrecognized compensation costs related to the ESPP, which the Company will recognize over </span><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ct-nonNumeric-3f9fe6e3-6f4b-4732-91a2-df69a813b94d" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.38</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107-continuation-5"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section32" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10.&#160;&#160;&#160;&#160;Income Taxes</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59-continuation-0" continuedAt="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of income before taxes are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ct-nonNumeric-66e5eabf-e185-4576-9d59-a894c7328464" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">United States </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-01e16cad-8b1f-4417-8cdc-c6b259a66f87" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,743</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c5e68650-31ba-4ad4-9992-cb3d16494be3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,010</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f021c01-0d30-4309-b0ca-0ada393502fb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">International </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss before income taxes</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-231cf901-c33b-4996-ba57-676a18bba2cd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,743</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-997a0b23-cd56-4217-bd7a-60253593e89a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">55,010</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81c28fbd-5888-4410-b33b-c8c3825c908c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">49,811</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ct-nonNumeric-e5ae3f1a-f9be-40af-bee9-d7360ab0e9da" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tax at federal statutory rate </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d315302f-6884-49a7-af9c-9a4ac136b146" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">11,706</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db83de5e-d35f-40fc-bac7-989fba463d67" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">11,552</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f545a44a-bf37-4be4-a7a6-1fce956e1e1b" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">10,460</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">State taxes, net of federal benefit </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-893d4447-74c0-4d8e-ac9c-55f9ae93f737" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">2,311</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-838a73ee-9c09-4563-a5f9-c718b2e444f0" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">2,206</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6bc3b6e2-c98a-47dd-a37f-381b1b49c3da" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,852</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Permanent differences </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-03bb1f3e-5baf-4ab0-b823-3e161b036a26" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">392</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d78fa115-3132-4f9c-8ba7-733d01df52bd" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">2,893</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c6b2afbb-071a-4673-968a-5f4bf40fd6a2" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">5,224</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in valuation allowance </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c65c2025-d0db-419c-a54d-56693dddcb4a" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,549</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-855c6856-bc5b-42b7-ad78-c9ca43c37500" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">18,237</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6c0e3341-c976-4f2a-8074-02fca0a95e22" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,918</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Limitation of compensation deduction under IRS Sec.162(m)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fff19dd7-dff4-4404-9604-e48f0381ba35" name="silk:LimitationOfCompensationDeduction" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,320</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-720c5e15-7646-4b88-83c6-92d5dc4ff445" name="silk:LimitationOfCompensationDeduction" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General business credits </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1cd0a5e3-829b-46e9-b4f5-549d1cdb2bf1" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,536</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c798ec07-9966-4bb3-9646-fe733bcc6e6e" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,166</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c9f0a262-d358-4466-954c-67288a3512e8" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">852</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ecb71f8a-5f23-412b-ba5a-e74252543a72" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">119</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4e02f9f0-32cb-4df8-8354-7452398f71da" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">401</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-efd7c533-6a2c-4055-8e27-33e04a019a74" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">490</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for income taxes </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3279cba1-b010-4140-b485-69389b649730" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">43</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-51918975-8188-48bd-8c5b-deae49401dc5" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">29</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ba9cf39-abb2-459a-817c-36feb1774b9d" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company's provision for income taxes amounts are not significant and are included within other income (expense) on the statements of operations and comprehensive loss.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2023 and 2022 consist of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ct-nonNumeric-affee236-bb91-4fcc-9314-38de9561f8e8" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Net operating loss carryforwards </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f5167d6-4a71-4809-b329-0cd2c00ebc3c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">85,945</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8abd7878-7608-4c95-bfa6-382a30ded928" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">82,768</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Research and development credits </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85d7ce7d-d441-42e4-bb72-a4399e098879" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,753</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-df23db9f-59ef-47ab-9c88-54ae9be0e5e8" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,898</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Capitalized start-up costs/Intangibles </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-600631cc-e871-4622-a6b8-9b29019237e5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Section 174 R&amp;D capitalization</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e479d294-e7b7-44be-bb52-db5745843af2" name="silk:DeferredTaxAssetsSection174" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,892</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-767377cf-59fa-4435-8203-487e9e5cc5cc" name="silk:DeferredTaxAssetsSection174" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,816</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Accruals and reserves </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-247d489d-68ac-48aa-a5dd-5f8f53e676fe" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,775</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-204cfa65-fe88-4196-a488-a3b424cf98c4" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,820</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Stock-based compensation </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-930aed77-b8b3-42d0-90be-a10c48bc4086" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,353</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1e6ef399-3753-4e51-a20c-c45533350e69" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,209</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Operating lease liability </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8ba3bfeb-20e8-4b10-8371-d4d2e4ebd63b" name="silk:DeferredTaxAssetsOperatingLeaseLiability" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,272</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08d218a3-1d7e-4eb0-a049-765c02458925" name="silk:DeferredTaxAssetsOperatingLeaseLiability" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,973</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Interest limitation </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd394c60-fa2f-489e-91db-8d457479e7a1" name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,114</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-777b5501-14b7-4cab-bbf8-0b0994faf9bd" name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,013</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax assets </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6879d677-9a17-4a27-8de6-5723b2dc0081" name="us-gaap:DeferredTaxAssetsGross" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">126,104</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2105bd1c-9473-4a89-bc4d-835c1ed954c8" name="us-gaap:DeferredTaxAssetsGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">114,498</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Valuation allowance </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-141deb45-0cee-453c-a430-0e0e34cad4c4" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">122,993</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fe490476-eb43-4686-a6ac-5e9f5ef3a959" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">111,444</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax liabilities: </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Operating lease asset </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d3bc2e6b-e8b3-495b-98ea-e934442df85f" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,636</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b787baed-2c54-4eb8-b0af-f861cf884e91" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,278</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-22ea8f1d-c9e7-4b40-b32e-85b55b28a915" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,475</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c16e98af-d62d-4e2e-a312-6c1b5d260237" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,776</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax liabilities </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f149c42a-0be7-44d3-940b-8ff0d418c58f" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,111</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-448e3bbf-038c-48ac-9159-8e5c99c90fbf" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,054</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax assets </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-75d41ec1-bd07-4439-8d82-3e992d798b22;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-3bf04cf1-1a9a-405d-aa3f-bedeb093e2ab;">&#8212;</span></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management believes it is more likely than not that the deferred tax assets will not be realized; accordingly, a valuation allowance has been established on U.S. net deferred tax assets. The valuation allowance increased $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c8d4005-f525-4901-9abd-4164cf1d6822" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">11,549,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37cc7d52-b53a-4f37-ad53-dd9b375de808" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">18,237,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3d27c22d-f0cf-4335-8788-883045857a09" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">17,918,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">114</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59-continuation-1" continuedAt="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59-continuation-2"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, the Company had net operating loss carryforwards of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ce528388-ff49-464d-91d2-aa08e9eca24b" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">331,957,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12ad4383-8807-4a41-a555-fedf38ac03a9" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">288,608,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards begin to expire in 2027 and 2024, respectively. Federal NOL carryforwards generated in tax years beginning in 2018 are not subject to expiration. Federal NOLs that arose on or after January 1, 2018 can be carried forward indefinitely against future income, but can only be used to offset a maximum of 80% of the Company's federal taxable income in any year.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law. Federal tax legislation enacted in December 2017, commonly known as the Tax Cuts and Jobs Act, contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company&#8217;s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The Company may have previously experienced, and may in the future experience, one or more Section 382 &#8220;ownership changes,&#8221; including in connection with the Company&#8217;s initial public offering. If so, the Company may lose some or all of the tax benefits of its NOLs and tax credits. The extent of such limitations for prior years, if any, has not yet been formally determined.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Tax Cuts and Jobs Act, research and development expenditures are no longer fully deductible and are required to be capitalized and amortized under Section 174 of the Internal Revenue Code in tax years beginning on or after January 1, 2022. The capitalized research expenses must be amortized over five years for research performed in the U.S. and 15 years for research performed outside the U.S. The mandatory capitalization requirement increased the Company&#8217;s deferred tax assets, which were fully offset by a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">At December&#160;31, 2023, the Company had $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6276304f-2300-4535-9ea1-422139ac1039" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">10,122,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-750e09da-a75f-4978-86b1-c90a509cdc6e" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">5,869,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of federal and state research and development credit carryforwards, respectively, on a tax return basis. If not utilized, the federal credits will expire beginning in 2027. The California research and development credits can be carried forward indefinitely.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, the Company had $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f30c4aef-698d-422a-8c7c-300c676eab4c" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">4,364,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of unrecognized tax benefits. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits would increase or decrease within twelve months of the year ended December&#160;31, 2023. If recognized, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ba9c6171-dc5b-487e-83aa-83ce585ec02e" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> would affect the effective tax rate.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. There was </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a0c8f96-2f4d-46de-ba37-981f4b35015e" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-bcf21559-cc0b-435c-8787-08e0093da94a" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-0af40b03-7029-432f-ba51-393d27acbee9" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> such expense recorded during the years ended December&#160;31, 2023, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A reconciliation of the unrecognized tax benefits from January 1, 2021 to December&#160;31, 2023 is as follows (in thousands)</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" id="ct-nonNumeric-4acfcaad-cc73-452a-b848-104b40183fd9" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance at the beginning of year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3914a14b-42f9-4d0c-b58e-c293302db994" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,788</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7a2fbc9f-bbe8-40f3-b4d6-08b074397059" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,314</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1dafb477-1021-4cb7-886f-6ce7ce3cfd6f" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,019</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increases related to current years&#8217; tax positions </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-216c4b0a-d597-47ca-bc12-5b5613bb2042" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">571</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-424f2b8a-0d20-4344-a247-402914793532" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">474</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2d7d8ac3-dc37-403b-99d2-c8d8526c5153" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">704</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increases related to prior years&#8217; tax positions </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-406b53db-5b21-434c-9faa-2ff2cb5d631e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-10e503fa-8d48-4e27-874e-61ff2c5d797a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">591</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance at end of year </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4661f511-cab4-4aae-94d9-9fe65b19324e" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,364</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d365ebd3-2346-48a3-af5f-57c35b333167" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,788</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bbdb82c8-740a-4f7c-ac30-45553c39d9d6" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,314</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59-continuation-2"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception. As a result of the Company&#8217;s net operating loss carryforwards, all of its tax years are subject to federal and state tax examination.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section33" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section34" style="text-decoration: none;"></span><ix:nonNumeric name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock" id="ct-nonNumeric-aed51992-1837-4cda-9a1a-bc3f5d7b3fdd" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-aed51992-1837-4cda-9a1a-bc3f5d7b3fdd-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">11.&#160;&#160;&#160;&#160;401(k) Plan</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-aed51992-1837-4cda-9a1a-bc3f5d7b3fdd-continuation-0" continuedAt="ct-nonNumeric-aed51992-1837-4cda-9a1a-bc3f5d7b3fdd-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code, or the IRC, under which participants may contribute up to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-56391d84-562a-4dd5-bea9-fa2d4415ff1f" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">90</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of their eligible compensation, subject to maximum deferral limits specified by the IRC. The Company may make a discretionary matching contribution to the 401(k)&#160;plan and may make a discretionary employer contribution to each eligible employee each year. Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e470a5a3-313f-44bb-b642-4d6c7303c79f" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">50</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the first </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6ace74cf-0482-4b50-9373-a14fc8e4f807" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" scale="-2">5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of compensation deferred to the 401(k) plan and at 50% of the first 6% of compensation deferred effective January 1, 2022. The Company's matching contributions were $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-26aac1b3-99d5-4d35-90a7-7ae909910eba" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="Duration_1_1_2023_To_12_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">2,256,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84b05dad-2e5e-4a51-a291-6e8474e084fb" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">1,872,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dd7702fb-d3fb-4d94-a235-813465344709" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">1,313,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-aed51992-1837-4cda-9a1a-bc3f5d7b3fdd-continuation-1"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><a id="Section35" style="text-decoration: none;"></a><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">115</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><a id="Section36" style="text-decoration: none;"></a><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section37" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section38" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 9A. Controls and Procedures</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Evaluation of Disclosure Controls and Procedures</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, refers to controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to a company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the framework in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Internal Control-Integrated Framework</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on that evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2023 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which i</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s included in Part II, Item 8 under the caption &#8220;Report of Independent Registered Public Accounting Firm&#8221; of this Annual Report on Form 10-K</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Changes in Internal Control over Financial Reporting</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">116</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inherent Limitations on Effectiveness of Controls </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting can also be circumvented by collusion or improper management override of the controls. Projections of any evaluation of controls effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or deterioration in the degree of compliance with policies or procedures.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section39" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 9B. Other Information</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended December 31, 2023, none of our directors or &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) </span><ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" id="ct-nonNumeric-301e8bb2-2ac1-4d1f-b2dc-fd54d93e0022" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">adopted</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or </span><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" id="ct-nonNumeric-57a2aa29-727b-40db-aaa3-8a9cd9730321" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">terminated</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;</span><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" id="ct-nonNumeric-73972a75-54e2-470f-afff-ba00a20dbe30" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">non-Rule</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" id="ct-nonNumeric-a318069e-b1ed-4dd5-91ff-72fdd038f6ae" contextRef="Duration_1_1_2023_To_12_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10b5-1</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> trading arrangement,&#8221; as each term is defined in Item 408(a) of SEC Regulation S-K.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Arial,Bold;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0000FF;font-family: Arial,Bold;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span id="Item9C" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">117</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART III</span><span id="PartIII" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section41" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 10. Directors, Executive Officers and Corporate Governance</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required in response to this item is incorporated herein by reference to the information contained under the captions entitled &#8220;Proposal No. 1 Election of Directors&#8212;Information about Director Nominees,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Corporate Governance&#8221; in our definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the fourth quarter of 2023, we did not make any material changes to the procedures by which stockholders may recommend nominees to our board of directors, as described in our definitive proxy statement for our 2023 Annual Meeting of Stockholders.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section42" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 11. Executive Compensation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required in response to this item is incorporated herein by reference to the information contained under the captions entitled &#8220;Executive Compensation,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation Committee Report&#8221; and &#8220;Director Compensation&#8221; in our definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023.</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section43" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required in response to this item is incorporated herein by reference to the information contained under the caption entitled &#8220;Stock Ownership&#8221; in our definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section44" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required in response to this item is incorporated herein by reference to the information contained under the captions entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Corporate Governance&#8212;Director Independence&#8221; in our definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section45" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 14. Principal Accountant Fees and Services</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required in response to this item is incorporated herein by reference to the information contained under the captions entitled &#8220;Proposal No. 3: Ratification of Appointment of Independent Registered Public Accounting Firm&#8212;Audit, Audit-Related, Tax, and Other Fees&#8221; and &#8220;Proposal No. 3: Ratification of Appointment of Independent Registered Public Accounting Firm&#8212;Pre-Approval Policies and Procedures&#8221; in our definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">118</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART IV</span><span id="Section40" style="text-decoration: none;"></span><span id="Section46" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Section47" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item&#160;15.&#160;&#160;Exhibits and Financial Statement Schedule</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.50in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">(a)</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Financial Statements.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The financial statements included in "Index to Financial Statements" in Part II, Item 8 are filed as part of this Annual Report on Form 10-K.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.50in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">(b)</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Financial Statement Schedule.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><ix:nonNumeric name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="ct-nonNumeric-9cdb6fe6-9e2f-4e22-a769-6ab3a2c3d2ab" contextRef="Duration_1_1_2023_To_12_31_2023" escape="true" continuedAt="ct-nonNumeric-9cdb6fe6-9e2f-4e22-a769-6ab3a2c3d2ab-continuation-0"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. The table below presents Schedule II, Valuation and Qualifying Accounts, detailing the activity of the allowance for credit losses for the years ended December 31, 2023, 2022 and 2021 (in thousands):</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-9cdb6fe6-9e2f-4e22-a769-6ab3a2c3d2ab-continuation-0"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Description</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at Beginning of Year</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Charged to Expenses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Write Offs</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at </span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">End of Year</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for credit losses:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f41c4c8a-9ca5-4197-b5a5-d379dd3eab3c" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5314f935-e015-488e-8a85-03f80a868e12" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">45</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e52c219-5ef5-4c28-b99d-3fa73364dabf" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb934ea4-9375-4174-94a4-e51d30a06d89" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d0f55797-ac7c-4b74-ba0e-25d556d2d78a" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a108508c-f617-4841-9f9d-7b44f41ce2d1" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">3</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2f8f8578-8a31-48af-9ff1-a00ca69165e3" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31, 2021</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e224e05-3dbf-42b9-8a47-5717052f59f7" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="As_Of_12_31_2020_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85395378-d5f2-48d4-b240-bd46af6eb990" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b39fbe87-9505-4e05-8633-5ccf825113a9" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8910146a-22d5-473b-bcaa-9a4fb8c01dbf" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6</ix:nonFraction></span></p></td></tr></table></div></ix:continuation><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.50in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">(c)</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibits.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following exhibits are incorporated herein by reference or are filed or furnished with this Annual Report on Form 10-K as indicated below:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span id="Section48" style="text-decoration: none;"></span><span id="_Hlk96614126" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit Description</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SEC File No.</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filing</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filed/Furnished</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Herewith</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex3_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Restated Certificate of Incorporation of Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.2</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000017/silk-20230309xex3_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Bylaws of Silk Road Medical, Inc. effective as of March 15, 2023</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/15/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit41followons-.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Specimen Common Stock Certificate of Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.2</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit43followons-.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Stockholders Agreement dated July 7, 2017 among Silk Road Medical, Inc. and certain stockholders</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.3</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.3</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex4_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Description of Silk Road Medical, Inc. securities registered pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Indemnification Agreement between Silk Road Medical, Inc. and each non-employee director and executive officer</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit102followons.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Silk Road Medical, Inc. 2007 Stock Plan, as amended, and related form agreements</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.3+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit103followons.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Silk Road Medical, Inc. 2019 Employee Stock Purchase Plan</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.3</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.4+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit104followons.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Silk Road Medical, Inc. Executive Incentive Compensation Plan</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.4</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.5+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex10_5.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Silk Road Medical, Inc. 2019 Equity Incentive Plan</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.6+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex10_6.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Silk Road Medical, Inc. 2019 Equity Incentive Plan Stock Option Agreement</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.7+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000061/silk-20231102xex10_5.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Silk Road Medical, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Agreement</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.5</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11/2/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.8+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000036/silk-20230331xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Silk Road Medical, Inc. 2019 Equity Incentive Plan Performance Stock Unit Agreement</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/9/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.9+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex10_9.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Employment Agreement between Silk Road Medical, Inc. and each executive officer</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.10+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000061/silk-20231102xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Employment Offer Letter Agreement dated October 30, 2023 between Silk Road Medical, Inc. and Charles McKhann</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11/2/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.11+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000061/silk-20231102xex10_7.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Executive Retirement and Transition Agreement effective as of November 2, 2023 between Silk Road Medical, Inc. and Erica J. Rogers</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.7</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11/2/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.12+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000061/silk-20231102xex10_8.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consulting Agreement effective as of November 2, 2023 between Silk Road Medical, Inc. and Erica J. Rogers</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.8</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11/2/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.13+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1013followon.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Confirmatory Employment Letter effective as of March 21, 2019 between Silk Road Medical, Inc. and Erica Rogers</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.13</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.14+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1014followon.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Confirmatory Employment Letter effective as of March 21, 2019 between Silk Road Medical, Inc. and Lucas Buchanan</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.14</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="8" style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 100.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">119</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td colspan="8" style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 100.0%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: none;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit Number</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: none;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit Description</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: none;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: none;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SEC File</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">No.</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: none;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: none;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filing</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: none;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filed/Furnished</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Herewith</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.15+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1016followon.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Confirmatory Employment Letter effective as of March 21, 2019 between Silk Road Medical, Inc. and Andrew Davis</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.16</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.16+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000012/silk-20221231xex10_17.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Confirmatory Employment Letter dated June 29, 2022 between Silk Road Medical, Inc. and Kevin Klemz</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.17</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2/28/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.17+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1015followon.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Confirmatory Employment Letter effective as of March 21, 2019 between Silk Road Medical, Inc. and Richard Ruedy</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.15</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.18+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000054/silk-20230915xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Letter Agreement dated September 15, 2023 between Silk Road Medical, Inc. and Andrew Davis</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9/15/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.19+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000061/silk-20231102xex10_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Change in Control and Severance Agreement effective as of November 2, 2023 between Silk Road Medical, Inc. and Charles McKhann</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.3</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11/2/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.20+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000051/silk-20230630xex10_4.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Change in Control and Severance Agreement effective as of June 22, 2022 between Silk Road Medical, Inc. and Erica Rogers</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.4</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/8/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.21+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000051/silk-20230630xex10_5.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Change in Control and Severance Agreement effective as of June 22, 2022 between Silk Road Medical, Inc. and Lucas Buchanan</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.5</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/8/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.22+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000051/silk-20230630xex10_6.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Change in Control and Severance Agreement effective as of June 22, 2022 between Silk Road Medical, Inc. and Andrew Davis</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.6</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/8/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.23+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000012/silk-20221231xex10_22.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Change in Control and Severance Agreement effective as of August 15, 2022 between Silk Road Medical, Inc. and Kevin Klemz</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.22</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2/28/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.24+</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1019followon.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Change in Control and Severance Agreement effective as of March 21, 2019 between Silk Road Medical, Inc. and Richard Ruedy</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.19</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.25#</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit106followons.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Supply Agreement effective as of October 21, 2011 between Silk Road Medical, Inc. and Cordis Corporation, as amended by the Amendment dated March 12, 2012, the Second Amendment to the Supply Agreement dated July 12, 2012, the Third Amendment to the Supply Agreement dated April 19, 2013 and the Fourth Amendment to the Supply Agreement dated April 9, 2018</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.6</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.26</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#8224;</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000036/silk-20230331xex10_4.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Fifth Amendment to Supply Agreement entered into as of May 8, 2023 between Cordis US Corp., as successor to Cordis Corporation, and Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.4</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/9/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.27#</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit107followons.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">License Agreement effective as of December 17, 2010 between Silk Road Medical, Inc. and Cordis Corporation</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.7</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.28</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#8224;</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000036/silk-20230331xex10_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">First Amendment to License Agreement entered into as of May 8, 2023 between Cordis US Corp., as successor to Cordis Corporation, and Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.3</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/9/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.29</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit108followons.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Quality Assurance Agreement effective as of May 4, 2015 among Silk Road Medical, Inc. and Lake Region Medical and affiliates</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.8</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.30#</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit109followons.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Manufacturing and Supply Agreement entered into as of January 10, 2018 between Silk Road Medical, Inc. and Galt Medical Corporation</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.9</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.31</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#8224;</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770222000027/silk-20220331xex10_14.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">IP License Agreement dated and effective as of May 12, 2016 between Silk Road Medical, Inc. and Route 92 Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.14</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/10/2022</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.32</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#8224;</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770222000027/silk-20220331xex10_15.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">IP Assignment and License Agreement dated and effective as of May 12, 2016 between Silk Road Medical, Inc. and Route 92 Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.15</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/10/2022</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.33</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#8224;</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770222000032/silk-20220527xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Loan and Security Agreement dated as of May 27, 2022 between Silk Road Medical, Inc. and Oxford Finance, LLC</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/31/2022</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.34</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770222000045/silk-20220630xex10_17.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">First Amendment to Loan and Security Agreement entered into as of June 13, 2022 and effective as of May 27, 2022 between Silk Road Medical, Inc. and Oxford Finance, LLC</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.17</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/9/2022</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.35</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1011followon.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Lease Agreement dated as of November 30, 2017 between Hanover Properties Ltd. and Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">333-233044</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.11</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2019</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.36</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex10_36.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">First Amendment to Lease dated as of August 27, 2018 between Hanover Properties Ltd. and Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.37</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770223000036/silk-20230331xex10_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Second Amendment to Lease dated as of May 3, 2023 between Hanover Properties Ltd. and Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/9/2023</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.38</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770221000054/silk-20210630xex10_23.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Lease Agreement effective as of May 12, 2021 between ARHC UHPTHMN01 LLC and Silk Road Medical, Inc.</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.23</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/6/2021</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.39</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770222000045/silk-20220630xex10_18.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">First Amendment to Lease Agreement entered into as of June 30, 2022 between Silk Road Medical, Inc. and Parkers Lake Medtech LLC</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.18</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/9/2022</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.40</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1397702/000139770222000067/silk-20220930xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Second Amendment to Lease Agreement entered into as of September 15, 2022 between Silk Road Medical, Inc. and Parkers Lake Medtech LLC</span></a><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">001-38847</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11/9/2022</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23.1</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex23_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consent of Independent Registered Public Accounting Firm</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24.1</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Section50" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Power of Attorney, reference is made to the Signatures page to this Form 10-K</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">31.1</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex31_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="6" style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">120</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td colspan="8" style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 100.0%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit Number</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 51.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit Description</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SEC File </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">No.</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filing</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filed/Furnished</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Herewith</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">31.2</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex31_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">32.1</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex32_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">**</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">97.1</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="silk-20231231xex97_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Silk Road Medical, Inc. Clawback Policy</span></a></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.INS</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Instance Document</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.SCH</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Schema Document</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.CAL</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.DEF</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.LAB</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Label Linkbase Document</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.PRE</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 7.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">104</span></p></td><td colspan="2" style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 51.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 6.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: bottom;width: 8.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: solid windowtext 1.0pt;border-right: solid windowtext 1.0pt;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 5.4pt;padding-right: 5.4pt;padding-top: 0;vertical-align: top;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">*</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Filed herewith.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">**</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furnished herewith. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This certification is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Silk Road Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">+</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicates a management contract or compensatory plan or arrangement.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8224;</span><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><span style="white-space:pre-wrap; margin: 0 0 0 0.25in;padding: 0 0 0 0;">&#160;</span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">#</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a grant of confidential treatment. The omitted information has been filed separately with the SEC.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.50in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">121</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 16. Form 10-K Summary</span><span id="Section49" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">122</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;"/><div class="headerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><a href="#TableofContents" style="text-decoration: none;"><span style="white-space:pre-wrap; white-space:pre-wrap; color: #0000FF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Table of Contents</span></a></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span id="Section50" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SIGNATURES</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:right"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: 0;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SILK ROAD MEDICAL, INC.</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">By:</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Charles S. McKhann</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Charles S. McKhann</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Chief Executive Officer</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">By:</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Lucas W. Buchanan</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lucas W. Buchanan</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 78.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 24.5pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 231.85pt;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Chief Operating Officer and Chief Financial Officer</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span id="Power_of_Attorney" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">POWER OF ATTORNEY</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Charles S. McKhann, Lucas W. Buchanan and Kevin M. Klemz, and each of them acting individually, as such person&#8217;s true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for such person and in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated: </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.19in;"><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Signature</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Title</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Charles S. McKhann</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chief Executive Officer and Director</span><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Executive Officer)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Charles S. McKhann</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Lucas W. Buchanan</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chief Operating Officer and Chief Financial Officer</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Financial Officer)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lucas W. Buchanan</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> /s/ Mhairi L. Jones</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vice President, Finance and Chief Accounting Officer</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Mhairi L. Jones</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Accounting Officer)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Rick D. Anderson</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Rick D. Anderson</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.14in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Kevin J. Ballinger</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Kevin J. Ballinger</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Tanisha V. Carino</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr style="height: 0.13in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tanisha V. Carino</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Tony M. Chou</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tony M. Chou, M.D.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Jack W. Lasersohn</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chair of the Board of Directors</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Jack W. Lasersohn</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Elizabeth H. Weatherman</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Elizabeth H. Weatherman</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 52.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid windowtext 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Donald J. Zurbay</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 52.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0.08in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td rowspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: middle;width: 16.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2024</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 25.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 9.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Donald J. Zurbay</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div class="footerContainer"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">123</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>silk-20231231xex3_1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:18:41 PM-->
<html>
	<head>
		<title>
			Exhibit 3.1
		</title>
	</head>
	<body><div style="margin-left:67pt;margin-right:40pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-weight:bold;">Exhibit 3.1</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:67pt;margin-right:40pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:92.20%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:07.80%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:92.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 48pt">
						<font style="font-size:48pt;border-bottom-style:solid;border-bottom-width:2pt;height:100%;text-indent:0pt;">Delaware</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:07.80%;padding:0pt 6.5pt">
					<p style="margin:0.05pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Calibri;font-size:10pt;">Page</font><font style="display: inline;font-family:Calibri;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:10pt;">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:92.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 16pt">
						<font style="display: inline;font-size:16pt;">The First State</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:07.80%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:2.45pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 55.6pt 0pt 23pt;line-height:200%;text-indent:31.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">I,</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">JEFFREY</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">W.</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">BULLOCK,</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">SECRETARY</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">OF</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">STATE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">OF</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">THE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">STATE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">OF DELAWARE,</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">DO</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">HEREBY</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">CERTIFY</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">THE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">ATTACHED</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">IS</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">A</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">TRUE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">AND</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">CORRECT COPY</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">OF</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">THE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">RESTATED</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">CERTIFICATE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">OF</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&#x201C;SILK</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">ROAD</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">MEDICAL,</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">INC.&#x201D;, FILED</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">IN</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">THIS</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">OFFICE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">ON</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">THE</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">EIGHTH</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">DAY</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">OF</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">DECEMBER,</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">A.D.</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;">2023, AT 2:20 O`CLOCK P.M.</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Courier New;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;"><img src="silk-20231231xex3_1g001.jpg" style="width: 2.385118in; height: 0.9998753in" alt="Picture 1"></font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:100.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;"><img src="silk-20231231xex3_1g002.jpg" style="width: 1.176936in; height: 1.156106in" alt="Picture 1"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">4319923</font><font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:11pt;">8100</font></p>
				</td>
				<td valign="middle" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">Authentication:</font><font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:11pt;">204774397</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">SR#</font><font style="display: inline;font-family:Calibri;font-size:11pt;"> 20234173677</font></p>
				</td>
				<td valign="middle" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-family:Calibri;font-size:11pt;">Date:</font><font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:11pt;">12-10-</font><font style="display: inline;font-family:Calibri;font-size:11pt;">23</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-family:Calibri;font-size:9pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-family:Calibri;font-size:9pt;">You</font><font style="display: inline;font-family:Calibri;font-size:9pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:9pt;">may</font><font style="display: inline;font-family:Calibri;font-size:9pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:9pt;">verify</font><font style="display: inline;font-family:Calibri;font-size:9pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:9pt;">this</font><font style="display: inline;font-family:Calibri;font-size:9pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:9pt;">certificate</font><font style="display: inline;font-family:Calibri;font-size:9pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:9pt;">online</font><font style="display: inline;font-family:Calibri;font-size:9pt;">&nbsp;</font><font style="display: inline;font-family:Calibri;font-size:9pt;">at</font><font style="display: inline;font-family:Calibri;font-size:9pt;"> corp.delaware.gov/authver.shtml</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:0pt;line-height:11.9pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt 32.05pt 0pt 434.65pt;line-height:105%;text-indent: -0.7pt;text-align:right;font-family:Times New Roman;font-size: 9pt">

			<font style="display: inline;color:#0A0A0A;font-size:9pt;">St</font><font style="display: inline;color:#28262F;font-size:9pt;">a</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">t</font><font style="display: inline;color:#28262F;font-size:9pt;">e</font><font style="display: inline;color:#28262F;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">of</font><font style="display: inline;color:#28262F;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">D</font><font style="display: inline;color:#28262F;font-size:9pt;">e</font><font style="display: inline;color:#0E0F2D;font-size:9pt;">l</font><font style="display: inline;color:#28262F;font-size:9pt;">awa</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">r</font><font style="display: inline;color:#28262F;font-size:9pt;">e</font>

		</p>

		<p style="margin:0pt 32.05pt 0pt 434.65pt;line-height:105%;text-indent: -0.7pt;text-align:right;font-family:Times New Roman;font-size: 9pt">

			<font style="display: inline;color:#28262F;font-size:9pt;">Sec</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">r</font><font style="display: inline;color:#28262F;font-size:9pt;">e</font><font style="display: inline;color:#424146;font-size:9pt;">t</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">a</font><font style="display: inline;color:#28262F;font-size:9pt;">ry</font><font style="display: inline;color:#28262F;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#212D4B;font-size:9pt;">o</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">f</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">S</font><font style="display: inline;color:#212D4B;font-size:9pt;">t</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">ate</font>

		</p>

		<p style="margin:0pt 32.05pt 0pt 434.65pt;line-height:105%;text-indent: -0.7pt;text-align:right;font-family:Times New Roman;font-size: 9pt">

			<font style="display: inline;color:#0A0A0A;font-size:9pt;">Di</font><font style="display: inline;color:#28262F;font-size:9pt;">v</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">i</font><font style="display: inline;color:#28262F;font-size:9pt;">s</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">i</font><font style="display: inline;color:#28262F;font-size:9pt;">o</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">n</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">o</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">f</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">Cor</font><font style="display: inline;color:#28262F;font-size:9pt;">po</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">r</font><font style="display: inline;color:#28262F;font-size:9pt;">a</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">ti</font><font style="display: inline;color:#28262F;font-size:9pt;">o</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">n</font><font style="display: inline;color:#28262F;font-size:9pt;">s</font>

		</p>

		<p style="margin:0pt 13.95pt 0pt 417.95pt;line-height:105%;text-align:right;font-family:Times New Roman;font-size: 9pt">

			<font style="display: inline;color:#0A0A0A;font-size:9pt;">D</font><font style="display: inline;color:#28262F;font-size:9pt;">e</font><font style="display: inline;color:#0E0F2D;font-size:9pt;">li</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">v</font><font style="display: inline;color:#28262F;font-size:9pt;">e</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">r</font><font style="display: inline;color:#28262F;font-size:9pt;">e</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">d</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">02</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">:</font><font style="display: inline;color:#28262F;font-size:9pt;">20</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">PM1</font><font style="display: inline;color:#28262F;font-size:9pt;">2</font><font style="display: inline;color:#85808E;font-size:9pt;">/</font><font style="display: inline;color:#212D4B;font-size:9pt;">0</font><font style="display: inline;color:#28262F;font-size:9pt;">8</font><font style="display: inline;color:#85808E;font-size:9pt;">/</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">2</font><font style="display: inline;color:#28262F;font-size:9pt;">023</font>

		</p>

		<p style="margin:0pt 13.95pt 0pt 417.95pt;line-height:105%;text-align:right;font-family:Times New Roman;font-size: 9pt">

			<font style="display: inline;color:#28262F;font-size:9pt;">F</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">ILED</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">0</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">2</font><font style="display: inline;color:#28262F;font-size:9pt;">:</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">2</font><font style="display: inline;color:#28262F;font-size:9pt;">0P</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">M12</font><font style="display: inline;color:#85808E;font-size:9pt;">/</font><font style="display: inline;color:#28262F;font-size:9pt;">0</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">8</font><font style="display: inline;color:#72727B;font-size:9pt;">/</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">2</font><font style="display: inline;color:#212D4B;font-size:9pt;">0</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">23</font>

		</p>

		<p style="margin:0pt 13.95pt 0pt 0pt;line-height:105%;text-align:right;font-family:Times New Roman;font-size: 9pt">

			<font style="display: inline;color:#28262F;font-size:9pt;">S</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">R</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">2023</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">4</font><font style="display: inline;color:#212D4B;font-size:9pt;">1</font><font style="display: inline;color:#424146;font-size:9pt;">7</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">3</font><font style="display: inline;color:#28262F;font-size:9pt;">6</font><font style="display: inline;color:#424146;font-size:9pt;">77</font><font style="display: inline;color:#424146;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">-</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">F</font><font style="display: inline;color:#0E0F2D;font-size:9pt;">il</font><font style="display: inline;color:#28262F;font-size:9pt;">eNu</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">mber</font><font style="display: inline;color:#0A0A0A;font-size:9pt;">&nbsp;</font><font style="display: inline;color:#28262F;font-size:9pt;">43</font><font style="display: inline;color:#0E0F2D;font-size:9pt;">1</font><font style="display: inline;color:#28262F;font-size:9pt;">9923</font>

		</p>

</div>
		<p style="margin:0pt;line-height:11.9pt;text-align:center;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">RESTATED</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">CERTIFICATE</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">OF</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">INCORPORATION</font>
		</p>
		<p style="margin:0.7pt 31.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">OF</font>
		</p>
		<p style="margin:1.2pt 27.45pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">SILK</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">ROAD</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">MEDICAL,</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">INC.</font>
		</p>
		<p style="margin:12.35pt 204.7pt 0pt 177.25pt;line-height:103.75%;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">Pursuant</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">to</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">Section</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">245</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">of</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">the General Corporation Law of the State of Delaware</font>
		</p>
		<p style="margin:12.05pt 33.65pt 0pt 6.05pt;text-indent:35.75pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">Silk</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">RoadMedical,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Inc.,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">a</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">organized and</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">existing under</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">and</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">by</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">virtue</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">provisions </font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">General</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Corporation Law</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">State</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Delaware</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">(</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">"</font><font style="display: inline;color:#0A0A0A;text-decoration:underline;">General</font><font style="display: inline;color:#0A0A0A;text-decoration:underline;">&nbsp;</font><font style="display: inline;color:#0A0A0A;text-decoration:underline;">Corporation</font><font style="display: inline;color:#0A0A0A;text-decoration:underline;">&nbsp;</font><font style="display: inline;color:#0A0A0A;text-decoration:underline;">Law</font><font style="display: inline;color:#0A0A0A;">"),</font>
		</p>
		<p style="margin:11.7pt 0pt 0pt 41.6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">DOES</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">HEREBY</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">CERTIFY:</font>
		</p>
		<p style="margin:11.8pt 32.9pt 0pt 5.5pt;line-height:100.83%;text-indent:36.1pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">FIRST:</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">That the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">name of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">this corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">is</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Silk</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Road</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Medical,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Inc.</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">(the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">"</font><font style="display: inline;color:#0A0A0A;text-decoration:underline;">Corporation</font><font style="display: inline;color:#0A0A0A;">"),</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">and</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">that the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">filed</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">a</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Certificate oflncorporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">pursuant to the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">General</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Law</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">on</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">March 21, </font><font style="display: inline;color:#0A0A0A;">2007, under the name Silk Road Medical, Inc., which Certificate of Incorporation was amended </font><font style="display: inline;color:#0A0A0A;">subsequent</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">thereto</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">by</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Amended</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">and</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Restated</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Certificate</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Incorporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">filed</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">pursuant</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">to</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">General </font><font style="display: inline;color:#0A0A0A;">Corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Law</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">on</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">April</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">8,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">2019,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Certificate</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Amendment</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">thereto</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">filed</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">pursuant</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">to</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">General </font><font style="display: inline;color:#0A0A0A;">Corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Law</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">on</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">June</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">21</font><font style="display: inline;color:#28262F;">,</font><font style="display: inline;color:#28262F;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">2021,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">and</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Certificate</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Amendment</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">thereto</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">filed</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">pursuant to</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">General </font><font style="display: inline;color:#0A0A0A;">Corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Law</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">on</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">June</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">21,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">2023.</font>
		</p>
		<p style="margin:11.7pt 32.8pt 0pt 6pt;text-indent:35.75pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">SECOND:</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">That the Corporation's Restated Certificate of Incorporation only restates and integrates and does not further amend the provisions of the Corporation's Amended and Restated Certificate of Incorporation, as amended or supplemented through June 21, 2023, and there is no discrepancy between those provisions in the Corporation's Amended and Restated Certificate of Incorporation, as amended or supplemented through June 21, 2023, and the pro</font><font style="display: inline;color:#28262F;">v</font><font style="display: inline;color:#0A0A0A;">isions of the Corporation's Restated Certificate oflncorporation.</font>
		</p>
		<p style="margin:11.7pt 32.8pt 0pt 5.85pt;line-height:100.83%;text-indent:36.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">THIRD: That the Board of Directors duly adopted resolutions approving the restatement and integration of the Corporation's Amended and Restated Certificate of Incorporation, as amended or supplemented</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">through June</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">21,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">2023, pursuant to</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Section 245</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">General Corporation Law</font><font style="display: inline;color:#28262F;">, &nbsp;</font><font style="display: inline;color:#0A0A0A;">declaring said restatement and integration to be advisable and in the best interests of the Corporation and its stockholders, which resolution setting forth the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">proposed restatement and integration is</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">as</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">follows:</font>
		</p>
		<p style="margin:11.85pt 32.45pt 0pt 41.95pt;line-height:100.83%;text-indent:35.7pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">RESOLVED</font><font style="display: inline;color:#28262F;">, &nbsp;</font><font style="display: inline;color:#0A0A0A;">that the Amended and Restated Certificate</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">oflncorporation,</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">as amended</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">or </font><font style="display: inline;color:#0A0A0A;">supplemented through June</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">21, 2023, of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the Corporation be</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">restated in its entirety to read </font><font style="display: inline;color:#28262F;">a</font><font style="display: inline;color:#0A0A0A;">s &nbsp;</font><font style="display: inline;color:#0A0A0A;">follows:</font>
		</p>
		<p style="margin:0.4pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 27.15pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">ARTICL</font><font style="display: inline;font-weight:bold;color:#28262F;font-size:11.5pt;">E</font><font style="display: inline;font-weight:bold;color:#28262F;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">I</font>
		</p>
		<p style="margin:0.1pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 0pt 0pt 42.2pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">The</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">name</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">is</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Silk</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Road</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Medical</font><font style="display: inline;color:#28262F;">,</font><font style="display: inline;color:#28262F;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Inc.</font>
		</p>
		<p style="margin:0.95pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 26.7pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">ARTICLE</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;color:#0A0A0A;font-size:11.5pt;">II</font>
		</p>
		<p style="margin:0.8pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 32.9pt 0pt 6pt;text-indent:36.15pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#0A0A0A;">The address</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the </font><font style="display: inline;color:#28262F;">C</font><font style="display: inline;color:#0A0A0A;">orporation</font><font style="display: inline;color:#28262F;">'</font><font style="display: inline;color:#0A0A0A;">s registered office in</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">the</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">State of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Delaware is</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">1209</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Or</font><font style="display: inline;color:#28262F;">a</font><font style="display: inline;color:#0A0A0A;">nge</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Street</font><font style="display: inline;color:#28262F;">, &nbsp;</font><font style="display: inline;color:#0A0A0A;">City of</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Wilmington, County of New Castle</font><font style="display: inline;color:#28262F;">, &nbsp;</font><font style="display: inline;color:#0A0A0A;">Delaware</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">1</font><font style="display: inline;color:#28262F;">9</font><font style="display: inline;color:#0A0A0A;">801.</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">The name of the Corporation's registered </font><font style="display: inline;color:#0A0A0A;">agent</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">at</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">such</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">address</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">is</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">The</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Corporation</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Trust</font><font style="display: inline;color:#0A0A0A;">&nbsp;</font><font style="display: inline;color:#0A0A0A;">Company.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:3.4pt 26.1pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;">1</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3.4pt 26.1pt 0pt 0pt;text-align:center;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;font-weight:bold;font-size:11.5pt;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">III</font>
		</p>
		<p style="margin:0.85pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 42.75pt 0pt 6pt;text-indent:36.15pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">purpose of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">this</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">corporation is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">engage in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">any</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">lawful act or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">activity</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">which corporations may</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">be organized under</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Delaware General Corporation Law, as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">same</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">exists or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">may</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">hereafter be amended from time to time.</font>
		</p>
		<p style="margin:0.55pt 26.3pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">IV</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100.83%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.65pt 0pt 0pt;">
				<font style="margin:0pt 32.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;line-height:100.83%;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.1pt 0pt 0pt;"> 4.1</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Authorized Capital</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">total</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">all</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">classes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">capital</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Corporation is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">authorized to issue is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">One Hundred and Five Million (I</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">05,000,000) shares, consisting of One</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Hundred</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Million</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(100,000,000)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Common</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">par</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">$0.00</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">I</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">per</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">share (the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Common Stock"), </font><font style="display: inline;font-size:12pt;color:#000000;">and Five Million (5,000,000) shares of Preferred Stock, par value $0.001 per share (the </font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Preferred Stock").</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.95pt 0pt 0pt;">
				<font style="margin:0pt 32.95pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.25pt 0pt 0pt;"> 4.2</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Increase or Decrease in Authorized Capital Stock.</font><font style="display: inline;font-size:12pt;color:#000000;"> The number of authorized shares of Preferred Stock or Common Stock may be increased or decreased (but not below the number of shares thereof</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">then</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">outstanding) by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">affirmative vote of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">majority in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">voting power</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation entitled to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">vote generally in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">election of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">directors, irrespective of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto), voting together as a single class, without</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">separate vote of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">class</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">classes the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">authorized shares of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which are being increased or decreased, unless a vote by any holders of one or more series of Preferred Stock is required</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by the express terms of any series of Preferred Stock as provided for or fixed pursuant to the provisions of Section 4.4 of this Article IV.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:42pt;"><p style="width:42pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 26.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;"> 4.3</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Common</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:13.6pt 32.55pt 0pt 0pt;">
				<font style="margin:13.6pt 32.55pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.35pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">The holders of shares of Common Stock shall be entitled to one vote for each</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">share on each matter properly submitted to the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares of Common</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">are</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entitled</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">tovote.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Except as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">otherwise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">required</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">law</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">certificate</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">incorporation (this </font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Certificate of Incorporation" </font><font style="display: inline;font-size:12pt;color:#000000;">which term, as used herein, shall mean the certificate of incorporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation, as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amended from time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">including the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terms of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any certificate of designations</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock), and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">subject to the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rights of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock, at any annual or special meeting of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares of Common</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock shall have the right to vote for the election of directors and on all other matters properly submitted to a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">vote of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the stockholders; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entitled to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">vote</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amendment to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this Certificate ofincorporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that relates</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">solely to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the terms, number of shares, powers, designations, preferences, or relative participating, optional or other special rights</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(including, without limitation,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">voting rights),</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">qualifications,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">limitations or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">restrictions thereon, of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one more other such series, to vote thereon pursuant to this Certificate of Incorporation (including, without limitation, by any certificate of designations</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">relating to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock) or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">pursuant to the DGCL.</font></p></td></tr></table></div>
		<p style="margin:0.55pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.9pt 0pt 0pt;">
				<font style="margin:0pt 32.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.3pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Subject to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rights of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock, the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares of Common Stock shall be entitled to receive such dividends and other distributions (payable in cash, property</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">capital stock of the Corporation)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">when, as and if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">declared thereon</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by the Board of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Board</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">of</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">Directors")</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">from</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">out</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">assets</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">funds</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:3.95pt 0pt 0pt 6.05pt;text-indent: -0.05pt;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3.95pt 0pt 0pt 6.05pt;text-indent: -0.05pt;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">Corporation</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">legally available therefor and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shall</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">share equally on a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">per</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">share basis in such dividends and </font><font style="display: inline;">distributions.</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.15pt 32.45pt 0pt 0pt;">
				<font style="margin:0.15pt 32.45pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.35pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">In the event of any voluntary or involuntary liquidation, dissolution or winding- up</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation, after</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">payment or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provision for payment of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the debts and other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">liabilities of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">subject</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rights</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">thereof,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Common</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entitled</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">receive</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">all</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">remaining</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">assets</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">available for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">distribution</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders, ratably in proportion</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Common Stock held by them.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:42pt;"><p style="width:42pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 26.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 4.4</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Preferred</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock.</font></p></td></tr></table></div>
		<p style="margin:0.2pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.85pt 0pt 0pt;">
				<font style="margin:0pt 32.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.35pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock may be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">issued from</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to time in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">one or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">more</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">authorized, subject to limitations prescribed by law, to fix by resolution or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">resolutions and to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">set forth in a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">certification of designations filed pursuant to the DGCL the powers, designations, preferences and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">relative,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">participation,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">optional or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rights, if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">qualifications,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">limitations</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">restrictions thereof,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">wholly</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">unissued</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">series</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">including without limitation authority to fix by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">resolution or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">resolutions the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">dividend rights, dividend rate,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">conversion rights, voting rights, rights and terms of redemption (including, without limitation, sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</font></p></td></tr></table></div>
		<p style="margin:0.3pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.75pt 0pt 0pt;">
				<font style="margin:0pt 32.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.35pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Board of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors is further</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">authorized to increase (but not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">above the total</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">authorized</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">class)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">decrease</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(but</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">below</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such series then outstanding) the number of shares of any series, the number of which was fixed by it, subsequent</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to the issuance of shares of such series then outstanding, subject to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the powers, preferences and rights, and the qualifications, limitations and restrictions thereof stated in the Certificate of Incorporation or the resolution of the Board of Directors originally fixing the number of shares of such series. If the number of shares of any series is so decreased, then the shares constituting such decrease shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">resume the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">status which</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">they</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">had</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">prior</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">adoption of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">resolution originally fixing the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number of shares of such series.</font></p></td></tr></table></div>
		<p style="margin:0.6pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 27.2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">V</font>
		</p>
		<p style="margin:0.85pt 0pt 0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:35pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 33.05pt 0pt 0pt;">
				<font style="margin:0pt 33.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.2pt 0pt 0pt;"> 5.1</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">General Powers.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">business</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">affairs</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation shall be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">managed by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">under the direction of the Board of Directors.</font></p></td></tr></table></div>
		<p style="margin:0.1pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 26.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;"> 5.2</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Number</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">ofDirectors:</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Election:</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Term.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="line-height:100.83%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:13.6pt 32.9pt 0pt 0pt;">
				<font style="margin:13.6pt 32.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;line-height:100.83%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.25pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Subject to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rights of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the election of directors, the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number of directors that constitutes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entire Board of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors shall be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fixed solely by resolution of the Board of Directors.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:13.75pt 32.2pt 0pt 0pt;">
				<font style="margin:13.75pt 32.2pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.2pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Subject to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the rights of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the election of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">directors, effective upon the closing date (the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Effective</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">Date") </font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the initial sale of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares of</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:3.95pt 32.9pt 0pt 5.85pt;text-indent:0.15pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3.95pt 32.9pt 0pt 5.85pt;text-indent:0.15pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">common stock in the Corporation's initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, the directors of the Corporation were divided into three</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">classes as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">nearly equal</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">size</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">as is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">practicable, designated Class I,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Class II and Class III.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The term of office of the initial Class I</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">directors shall expire at the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">first regularly-scheduled</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">annual meeting of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the stockholders</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">following the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Effective Date,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">term of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">office</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">initial</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Class II</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">directors shall</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">expire at the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">second annual meeting of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders following the Effective Date</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">term of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">office of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the initial</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Class</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">III</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">directors</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shall</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">expire</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">at</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">third</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">annual</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">meeting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">following</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Effective Date. At each annual meeting of stockholders, commencing with the first regularly-scheduled annual meeting of stockholders following the Effective Date, each of the successors elected to replace the directors of a Class whose term shall have expired at</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">such annual meeting shall be elected to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">hold office until</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the third</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">annual meeting next</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">succeeding his</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">her</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">election and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">until his</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">her respective</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">successor shall</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">have been</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">duly</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">elected</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">qualified. Subject to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">rights</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">ofholders of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">any</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">series</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Preferred Stock with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">respect</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">election of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">directors, if</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">number of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">directors that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">constitutes</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Board</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Directors is changed, any newly created directorships or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">decrease in directorships shall be so</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">apportioned by the Board of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Directors among the classes as to make all</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">classes</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">as nearly equal in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">number as is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">practicable, provided that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">no</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">decrease in the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">number of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">directors constituting the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Board of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Directors shall</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shorten the term of any incumbent</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">director.</font>
		</p>
		<p style="margin:0.45pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 32.9pt 0pt 5.85pt;text-indent:72.2pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Notwithstanding the foregoing, at the 2022 annual meeting of the stockholders, the successors of the directors whose terms expire at that meeting shall be</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">elected for a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">term expiring at the 2023 annual meeting of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">at the 2023 annual meeting of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">successors of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">directors</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">whose terms</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">expire at</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">meeting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shall be</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">elected for</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">term</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">expiring at the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2024</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">annual meeting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders; and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">at</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">each</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">annual</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">meeting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Corporation thereafter, the directors shall be elected for terms expiring at the next succeeding annual meeting of the stockholders, with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">each director to hold office until his or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">her</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">successor</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shall</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">have</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">been</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">duly</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">elected</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">qualified and, commencing</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">with the 2024 annual meeting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders, the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">classification of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Board</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of Directors shall cease.</font>
		</p>
		<p style="margin:0.15pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.9pt 0pt 0pt;">
				<font style="margin:0pt 32.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Notwithstanding the foregoing provisions of this Section 5.2, and subject to the rights of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of any series of Preferred Stock with respect to the election of directors, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal.</font></p></td></tr></table></div>
		<p style="margin:0.25pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.9pt 0pt 0pt;">
				<font style="margin:0pt 32.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:35pt;">
			<p style="line-height:100.83%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12.05pt 33.05pt 0pt 0pt;">
				<font style="margin:12.05pt 33.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;line-height:100.83%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 5.3</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Removal.</font><font style="display: inline;font-size:12pt;color:#000000;"> Subject to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the rights of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock with respect to the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">election of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">directors, a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">director may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">removed from</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">office in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">manner</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provided in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Section 14l(k) </font><font style="display: inline;font-size:12pt;color:#000000;">oftheDGCL.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:35pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:11.6pt 32.95pt 0pt 0pt;">
				<font style="margin:11.6pt 32.95pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.1pt 0pt 0pt;"> 5.4</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Vacancies and</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Newly Created Directorships.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rights of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of any series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">election</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">directors,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">except as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">otherwise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provided in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">DGCL, vacancies occurring on the Board of Directors for any reason and newly created directorships resulting from an increase in the authorized number of directors may be filled only by vote of a majority of the remaining members of the Board of Directors, although less than a quorum, or by a sole remaining director, at any meeting of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Board of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors. A</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">person so</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">elected by the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Board of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors to fill a vacancy</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">newly created</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">directorship shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">hold office</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">until the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">next election of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">class</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which such</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:3.95pt 30.1pt 0pt 6pt;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3.95pt 30.1pt 0pt 6pt;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">director shall have been assigned</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">by the Board of Directors</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and until</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">his or her</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">successor shall</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">be duly elected and qualified.</font>
		</p>
		<p style="margin:0.6pt 26.15pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">VI</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 30.1pt 0pt 5.05pt;line-height:101.67%;text-indent:37.15pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">In</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">furtherance</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">not</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in limitation</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of the powers</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">conferred</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">by</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">statute,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the Board</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of Directors 1s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">expressly authorized to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">adopt, amend or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">repeal the Bylaws of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Corporation.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 26.15pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">VII</font>
		</p>
		<p style="margin:0.85pt 0pt 0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 37.75pt 0pt 0pt;">
				<font style="margin:0pt 37.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 7.1</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">No Action by</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Written Consent of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stockholders.</font><font style="display: inline;font-size:12pt;color:#000000;"> Except as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">otherwise expressly provided by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the terms of any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock permitting the holders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such series of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Preferred Stock to act by written consent, any action required or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">permitted to be taken by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders of the Corporation must be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">effected at a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">duly called annual or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">special meeting of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the stockholders</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">effected by written consent in lieu of a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">meeting.</font></p></td></tr></table></div>
		<p style="margin:0.15pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.55pt 0pt 0pt;">
				<font style="margin:0pt 32.55pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21.4pt 0pt 0pt;"> 7.2</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Special Meetings.</font><font style="display: inline;font-size:12pt;color:#000000;"> Except as otherwise expressly provided by the terms of any series of Preferred Stock permitting the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holders of such series of Preferred Stock to call a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">special meeting of the holders</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of such series, special meetings of stockholders of the Corporation may be called only by the Board of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors, the chairperson of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Board of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors, the chief executive officer</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the president (in the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">absence of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">chief</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">executive</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officer), and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">ability of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">call</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">special meeting is hereby specifically denied. The Board of Directors may cancel, postpone or reschedule any previously scheduled special meeting at any time, before or after the notice for such meeting has been sent to the </font><font style="display: inline;font-size:12pt;color:#000000;">stockholders.</font></p></td></tr></table></div>
		<p style="margin:0.25pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100.83%;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 33.55pt 0pt 0pt;">
				<font style="margin:0pt 33.55pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;line-height:100.83%;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.05pt 0pt 0pt;"> 7.3</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Advance Notice.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Advance notice of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholder nominations for the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">election of directors and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">business to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">brought by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders before any meeting of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation shall be given in the manner provided in the Bylaws of the Corporation.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:13.4pt 32.85pt 0pt 0pt;">
				<font style="margin:13.4pt 32.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.3pt 0pt 0pt;"> 7.4</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exclusive Jurisdiction.</font><font style="display: inline;font-size:12pt;color:#000000;"> Unless the Corporation consents in writing to the selection of an alternative</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">forum, the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Court of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Chancery of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">State</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Delaware (or,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Court of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Chancery does not have</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">jurisdiction,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">federal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">district</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">court</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">District</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">ofDelaware) shall,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fullest</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">extent</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">permitted by law, be the sole and exclusive forum for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">derivative action or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">proceeding brought on behalf of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(ii)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">action</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">asserting a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">claim</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">breach of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">afiduciary</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">duty</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">owed</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">director,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officer or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">employee</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation's stockholders,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(iii)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any action arising pursuant to any provision of the DGCL or this Certificate oflncorporation or the Corporation's bylaws</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">either</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amended from</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time), or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(iv)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">action</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">asserting a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">claim</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">governed by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the internal affairs</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">doctrine, except for, as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">each</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">through (iv)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">above, any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">claim as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to which such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within ten (I</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">0) days following</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">determination),</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">vested in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exclusive jurisdiction of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">court</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">forum</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">than such court, or for which such court does not have subject matter jurisdiction. Any person or entity purchasing</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">otherwise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acquiring</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">interest</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">capital</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">deemed to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have notice of and consented to the provisions of this Section 7.4.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:3.4pt 27pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3.4pt 27pt 0pt 0pt;text-align:center;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;font-weight:bold;font-size:11.5pt;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;">VIII</font>
		</p>
		<p style="margin:0.85pt 0pt 0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.95pt 0pt 0pt;">
				<font style="margin:0pt 32.95pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21.95pt 0pt 0pt;"> 8.1</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Limitation of Personal Liability.</font><font style="display: inline;font-size:12pt;color:#000000;"> To the fullest extent permitted by the DGCL, as it presently exists or may hereafter be amended from time to time, a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">director or officer of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation shall not be personally liable to the Corporation or its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">monetary damages for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">breach of fiduciary duty as a director or officer. If the DGCL is amended to authorize corporate action further eliminating</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">limiting</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">personal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">liability</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">directors</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officers,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">then</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">liability</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">director</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so </font><font style="display: inline;font-size:12pt;color:#000000;">amended.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:13.75pt 32.75pt 0pt 0pt;">
				<font style="margin:13.75pt 32.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.25pt 0pt 0pt;"> 8.2</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Indemnification.</font><font style="display: inline;font-size:12pt;color:#000000;"> The Corporation shall indemnify, to the fullest extent permitted by applicable</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">law,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">director</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officer</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation who</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">was</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">party or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">threatened to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">investigative (a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Proceeding")</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">reason of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fact that he</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">she is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">was a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">director, officer, employee or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">agent of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation or is or was serving at the request of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">including</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">service</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">employee</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">benefit</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">plans,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">against</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">expenses</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(including</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">attorneys' fees),</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">judgments, fines</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amounts paid</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">settlement actually</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">reasonably incurred</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">person</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in connection with any such Proceeding. The Corporation shall be required to indemnify a person in connection</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Proceeding initiated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">person only</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Proceeding was</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">authorized</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Board of Directors.</font></p></td></tr></table></div>
		<p style="margin:0.35pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 33.15pt 0pt 6pt;text-indent:36.15pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The Corporation shall have the power to indemnify, to the extent permitted by the DGCL, as it presently</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">exists</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">may</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">hereafter</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">be</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">amended</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">from</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">time</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">time,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">any</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">employee</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">agent</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Corporation who was or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">party or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">threatened</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to be made a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">party</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">any</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Proceeding</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by reason</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">fact</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">he or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">she</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">was</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">director,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">officer,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">employee or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">agent of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Corporation or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">was</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">serving</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">at</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys' fees),</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">judgments, fines and amounts paid in settlement actually and reasonably incurred by such</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">person in connection with any such Proceeding.</font>
		</p>
		<p style="margin:0.2pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 33.2pt 0pt 6pt;text-indent:36.1pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Any</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">repeal</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">amendment</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">this</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Article</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">VIII</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">stockholders</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Corporation</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">changes in law, or the adoption of any other provision of this Certificate of Incorporation inconsistent with this Article VIII will, unless otherwise required by law, be prospective only (except to the extent such amendment</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">change</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">law</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">permits the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Corporation to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">further</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">limit</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">eliminate</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">liability</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">directors or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">officers)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">shall</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">not</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">adversely</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">affect any</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">right or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">protection</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">director</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">officer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Corporation existing at the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">time</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">such repeal or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">amendment</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">adoption of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">such inconsistent</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">provision with</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">respect to acts or omissions occurring prior to such repeal or amendment or adoption of such inconsistent </font><font style="display: inline;color:#000000;">provision.</font>
		</p>
		<p style="margin:0.7pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 26.3pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">IX</font>
		</p>
		<p style="margin:0.8pt 0pt 0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 32.1pt 0pt 0pt;">
				<font style="margin:0.05pt 32.1pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.05pt 0pt 0pt;"> 9.1</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Certain</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Acknowledgment.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">In</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">recognition and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">anticipation that (i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">certain current or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">former directors, principals, officers,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">employees and/or other representatives</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">consultants or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">advisors to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the stockholders may serve, whether during or after the period in which the stockholders own stock of the Corporation,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">directors,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officers</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">agents</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">("Associated</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">Directors")</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(ii)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:3.95pt 32.85pt 0pt 5.85pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3.95pt 32.85pt 0pt 5.85pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">stockholders and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">their</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">respective Affiliates may now engage and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">may continue to engage in the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">same</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or similar</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">activities</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">related</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">lines of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">business as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">those in which</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Corporation, directly</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">indirectly, may engage and/or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">other</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">business activities that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">overlap with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">compete with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">those in which the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Corporation or any of its</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Affiliates, directly or indirectly, may engage or propose to engage, the provisions of this Article</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">IX</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">are</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">set</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">forth</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">regulate and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">define</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">conduct</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">certain</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">affairs</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Corporation with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">respect to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">certain classes</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">categories of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">business opportunities as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">they</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">may involve any of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">stockholders, the Associated Directors or their respective Affiliates and the powers, rights, duties and liabilities of the Corporation</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and its directors, officers and stockholders</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in connection therewith.</font>
		</p>
		<p style="margin:0.2pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.85pt 0pt 0pt;">
				<font style="margin:0pt 32.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.05pt 0pt 0pt;"> 9.2</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Competition and</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Corporate Opportunities;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Renouncement.</font><font style="display: inline;font-size:12pt;color:#000000;"> None</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders or any of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">their</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respective Affiliates or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(ii) any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Associated Director (including any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Associated Director who serves as a director or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officer of the Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in both</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">his or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">her director and officer</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">capacities)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">his or her Affiliates (the Persons (as defined below) identified in (i) and (ii) above being referred to, collectively, as </font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Identified Persons" </font><font style="display: inline;font-size:12pt;color:#000000;">and, individually, as an </font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">"Identified</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:11.5pt;color:#000000;">Person") </font><font style="display: inline;font-size:12pt;color:#000000;">shall, to the fullest extent permitted by law, have any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">duty to refrain from directly or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">indirectly (1) engaging in the same or similar</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">business</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">activities</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">lines</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">business</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Affiliates</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">now</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">engages or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">proposes to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">engage or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(2)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">otherwise competing with the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Affiliates, and,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the fullest extent permitted by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">law,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">no</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Identified Person shall be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">liable to the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Affiliate</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">breach</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fiduciary duty</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">solely</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">reason of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fact</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such Identified Person engages in any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such activities.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">To the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fullest extent permitted by law, the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation hereby</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">renounces any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">interest or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">expectancy in,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">right to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">offered</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">opportunity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">participate in,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any business</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">opportunity that may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">corporate opportunity for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Identified</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Person and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or any of its Affiliates, except as provided in Section 9.3 of this Article IX.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Section 9.3 of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this Article IX,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in the event that any Identified Person acquires knowledge of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">potential transaction or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other business</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">opportunity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">corporate</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">opportunity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">itself,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">herself or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">himself</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Affiliates, such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Identified Person shall,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fullest extent permitted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">law,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">no</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">duty</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to communicate or offer such transaction or other business opportunity to the Corporation or any of its Affiliates and, to the fullest extent permitted by law, shall not be liable to the Corporation or its stockholders or to any Affiliate of the Corporation for breach of any fiduciary duty as a stockholder, director or officer of the Corporation solely by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">reason of the fact that such Identified Person pursues or acquires such corporate opportunity for itself, herself or himself, or offers or directs such corporate opportunity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">another</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Person or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">does</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">communicate information regarding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">corporate</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">opportunity to the Corporation.</font></p></td></tr></table></div>
		<p style="margin:0.55pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.8pt 0pt 0pt;">
				<font style="margin:0pt 32.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.1pt 0pt 0pt;"> 9.3</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Allocation of Corporate Opportunities</font><font style="display: inline;font-size:12pt;color:#000000;">. Notwithstanding the foregoing provision of this Article </font><font style="display: inline;font-weight:bold;color:#000000;">IX, </font><font style="display: inline;font-size:12pt;color:#000000;">the Corporation does not renounce its interest in any corporate opportunity offered to any Associated Director (including any Associated Director who serves as a director or officer of the Corporation) if such opportunity is expressly offered to such person solely in his or her capacity as a director or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officer</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation, and the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provisions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Section 9.2 of this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Article </font><font style="display: inline;font-weight:bold;color:#000000;">IX </font><font style="display: inline;font-size:12pt;color:#000000;">shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not apply to any such corporate opportunity.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3.95pt 32.65pt 0pt 0pt;">
				<font style="margin:3.95pt 32.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.1pt 0pt 0pt;"> 9.4</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Certain Matters Deemed Not Corporate</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Opportunities</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">In</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">addition to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">notwithstanding the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">foregoing provisions of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Article IX, a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">potential corporate opportunity shall not be deemed to be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a corporate opportunity for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">it is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">business opportunity that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">neither financially or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">legally able,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">nor</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">contractually permitted, to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">undertake, (ii) from its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">nature, is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the line of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation's business or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">ofno</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">practical</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">advantage to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(iii) is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">one</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in which the Corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">has no interest or reasonable expectancy.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:42pt;"><p style="width:42pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 26.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 9.5</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Certain</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Definitions.</font></p></td></tr></table></div>
		<p style="margin:0.15pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32pt 0pt 0pt;">
				<font style="margin:0pt 32pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.05pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">For</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">purposes of this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Article IX, (i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">"Affiliate" </font><font style="display: inline;font-size:12pt;color:#000000;">shall mean (a) in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">each of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholders,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any Person that, directly or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">indirectly, is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">controlled by such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stockholder, controls such stockholder or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">common control with such stockholder and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shall include any principal, member, director, manager, partner, stockholder, officer, employee or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other representative</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of any of the foregoing (other than the Corporation and any entity that is controlled by the Corporation), (b) in respect of a Associated Director, any Person that, directly or indirectly, is controlled by such Associated Director (other than the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation and any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entity that is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">controlled by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation) and (c)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Corporation, any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Person that, directly or indirectly, is controlled by the Corporation; and (ii) </font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">"Person" </font><font style="display: inline;font-size:12pt;color:#000000;">shall mean any individual, corporation, general or limited partnership, limited liability company, joint venture, trust, association</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or any other entity.</font></p></td></tr></table></div>
		<p style="margin:0.4pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 30.75pt 0pt 0pt;">
				<font style="margin:0.05pt 30.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.05pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">For purposes of this Article IX, </font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">"control," </font><font style="display: inline;font-size:12pt;color:#000000;">including the terms </font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">"controlling," "controlled by"</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">"under</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">common control with,"</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">possession, directly or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">indirectly,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the power to direct or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">cause the direction of the management and policies of a person, whether through the ownership</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">voting</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock, by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">contract, or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">otherwise.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">A</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">person who is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">owner</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of20%</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">more</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">voting power of the outstanding voting stock of a corporation, partnership, unincorporated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">association or other entity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shall be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">presumed to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">control of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such entity, in the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">absence of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">proof by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">preponderance</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the evidence to the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">contrary.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Notwithstanding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the foregoing, a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">presumption of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">control shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not apply where such person holds voting</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock, in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">good</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">faith, as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">agent,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">bank, broker,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">nominee, custodian or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">trustee for one or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">more owners who do</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not individually</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or as a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">group have control of such entity.</font></p></td></tr></table></div>
		<p style="margin:0.1pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100.83%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 32.85pt 0pt 0pt;">
				<font style="margin:0pt 32.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;line-height:100.83%;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 9.6</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Notice of this Article.</font><font style="display: inline;font-size:12pt;color:#000000;"> To the fullest extent permitted by law, any Person purchasing or otherwise acquiring any interest in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">capital</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Corporation shall be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">deemed</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have notice of and to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have consented to the provisions of this Article IX.</font></p></td></tr></table></div>
		<p style="margin:11.6pt 26.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">ARTICLE</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;color:#000000;">X</font>
		</p>
		<p style="margin:0.15pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 32.95pt 0pt 5.8pt;text-indent:36.35pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation (including, without limitation, any rights, preferences or other designations of Preferred Stock), in the manner now or hereafter prescribed by this Certificate of Incorporation</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">DGCL;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">all</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">rights,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">preferences</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">privileges</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">herein</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">conferred</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">upon</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">stockholders by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">pursuant</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">this</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Certificate ofincorporation in its</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">present form</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">as</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">hereafter amended are</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">granted subject to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the right reserved in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">this Article X. Notwithstanding</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">any other provision of this Certificate of Incorporation,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">addition to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">any</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">other</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">vote that may</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">be</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">required by law or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the terms of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">any series of Preferred Stock, the affirmative vote of the holders of at least 66&#xBD;% of the voting power of all then outstanding</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">shares</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">capital</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">stock</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Corporation</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">entitled</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">vote</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">generally</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">election</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">directors, voting</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">together as</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">single</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">class,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">shall be</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">required to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">amend, alter</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">repeal, or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">adopt any</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">provision as</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">part of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">this</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Certificate</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Incorporation</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">inconsistent</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">with</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">purpose</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">intent</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Article</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">V,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Article</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">VI,</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:3.4pt 30.1pt 0pt 6.05pt;line-height:103.75%;text-indent: -0.05pt;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3.4pt 30.1pt 0pt 6.05pt;line-height:103.75%;text-indent: -0.05pt;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;font-size:11.5pt;">Article VII</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">or</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">this</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">Article X</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">(including, without limitation, any</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">such Article as</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">renumbered as</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">a</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">result of any</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">amendment, alteration, change, repeal or adoption of any other</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">Article).</font>
		</p>
		<p style="margin:0.75pt 0pt 0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 13.95pt 0pt 22.05pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-style:italic;font-size:11.5pt;">[Remainder</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">of</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">page</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">intentionally</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">left</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">blank;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">signature</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">page</font><font style="display: inline;font-style:italic;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:11.5pt;">follows]</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:48pt;margin-right:20pt;">
		<p style="margin:4.85pt 30.1pt 0pt 6.55pt;line-height:115%;text-indent:36.05pt;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:4.85pt 30.1pt 0pt 6.55pt;line-height:115%;text-indent:36.05pt;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;font-size:11.5pt;">IN</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">WITNESS WHEREOF, Silk</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">Road Medical, Inc.</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">has</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">caused this</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">Restated Certificate of Incorporation</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">to</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">be</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">signed by</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">a</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">duly</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">authorized</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">officer</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">of</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">the</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">Corporation</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">on</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">this</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">7</font><font style="display: inline;font-size:9pt;">th</font><font style="display: inline;font-size:9pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">day</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">of</font><font style="display: inline;font-size:11.5pt;">&nbsp;</font><font style="display: inline;font-size:11.5pt;">December</font><font style="display: inline;font-size:11.5pt;"> 2023.</font>
		</p>
		<p style="margin:4.85pt 30.1pt 0pt 6.55pt;line-height:91.67%;text-indent:36.05pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11.5pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:52.88%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.68%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:41.44%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:52.88%;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11.5pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.68%;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11.5pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.44%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11.5pt;">/s/ Kevin M. Klemz</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:52.88%;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11.5pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.68%;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.44%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11.5pt;">Kevin M. Klemz</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:52.88%;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11.5pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.68%;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:41.44%;padding:0pt 6.5pt">
					<p style="margin:8.85pt 0pt 0pt;line-height:12.9pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11.5pt;">Executive Vice President, Chief Legal Officer and Secretary</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">11</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>silk-20231231xex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:18:59 PM-->
<html>
	<head>
		<title>
			Exhibit 4.3 2023
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit 4.3</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:center;color:#000000;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">DESCRIPTION </font><font style="display: inline;font-family:Arial;font-size:10pt;">OF SILK ROAD MEDICAL, INC. </font><font style="display: inline;font-family:Arial;font-size:10pt;">SECURITIES</font><br /><font style="display: inline;font-family:Arial;font-size:10pt;">REGISTERED PURSUANT TO SECTION 12 OF THE </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-align:center;color:#000000;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">SECURITIES</font><font style="display: inline;font-family:Arial;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Arial;font-size:10pt;">EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-size:10pt;">General</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Silk Road Medical, Inc., a Delaware corporation (Silk Road Medical, we, us, and our), has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (Exchange Act): common stock, par value $0.001 per share (common stock). </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the provisions of our Restated Certificate of Incorporation and Amended and Restated Bylaws, which are filed as exhibits to our most recent Annual Report on Form 10-K and are incorporated by reference herein.&nbsp;&nbsp;We encourage you to read our Restated Certificate of Incorporation and Amended and Restated Bylaws and the applicable provisions of the Delaware General Corporation Law (DGCL) for additional information.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-size:10pt;">Authorized Capital Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our authorized capital stock consists of 105,000,000 shares of capital stock, par value $0.001 per share, of which:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">100,000,000 shares are designated as common stock; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">5,000,000 shares are designated as preferred stock</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">The number of authorized shares of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the shares entitled to vote generally in the election of directors, irrespective of Section 242(b)(2) of the DGCL, voting together as a single class, without the separate vote of the holders of the preferred stock as a single class unless otherwise provided for in a certificate of designation of any series of preferred stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-size:10pt;color:#000000;">Common Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Only our common stock is registered under Section 12 of the Exchange Act, and trades on The Nasdaq Global Select Market under the symbol &#x201C;SILK.&#x201D; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Voting Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Each holder of our common stock is entitled to one vote for each share on all matters properly submitted to a vote of the stockholders, including the election of directors. However, except as otherwise required by law, holders of our common stock shall not be entitled to vote on any amendment to our Restated Certificate of Incorporation that relates solely to the terms, number of shares, powers, designations, preferences, or relative participating, optional or other special rights, or to qualifications, limitations or restrictions thereon, of one or more outstanding series of preferred stock. Our stockholders do not have cumulative voting rights in the election of directors. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Except as otherwise provided by law, our Restated Certificate of Incorporation, our Amended and Restated Bylaws or the rules of any applicable stock exchange on which securities are listed, in all matters other than the election of directors, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders. Except as otherwise required by law</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> or</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> our Restated Certificate of Incorporation</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> or</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> Amended and Restated Bylaws, directors shall be elected by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. </font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-family:Arial;font-size:10pt;">Where a separate vote by a class or series or classes or series is required, in all matters other than the election of directors, the affirmative vote of the majority of the voting power of the shares of such class or series or classes or series present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of such class or series or classes or series, except as otherwise provided by law, our Restated Certificate of Incorporation, our Amended and Restated Bylaws or the rules of any applicable stock exchange.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Dividends</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Subject to </font><font style="display: inline;font-family:Arial;font-size:10pt;">preferences</font><font style="display: inline;font-family:Arial;font-size:10pt;"> that may be applicable to any then outstanding convertible preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Liquidation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share </font><font style="display: inline;font-family:Arial;font-size:10pt;">ratably</font><font style="display: inline;font-family:Arial;font-size:10pt;"> in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of convertible preferred stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Rights and Preferences</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Holders of our common </font><font style="display: inline;font-family:Arial;font-size:10pt;">stock</font><font style="display: inline;font-family:Arial;font-size:10pt;"> have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Fully Paid and Nonassessable</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">All of our outstanding shares of common stock are fully paid and nonassessable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-style:normal;font-size:10pt;">Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our board of directors has the authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preferences, sinking fund provisions and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. No shares of preferred stock are outstanding.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Anti-Takeover Effects or Provisions of </font><font style="display: inline;font-family:Arial;font-size:10pt;">the DGCL and o</font><font style="display: inline;font-family:Arial;font-size:10pt;">ur Restated Certificate of Incorporation</font><font style="display: inline;font-family:Arial;font-size:10pt;"> and </font><font style="display: inline;font-family:Arial;font-size:10pt;">Amended and Restated Bylaws </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Some provisions of the DGCL</font><font style="display: inline;font-family:Arial;font-size:10pt;"> and</font><font style="display: inline;font-family:Arial;font-size:10pt;"> our Restated Certificate of Incorporation and Amended and Restated Bylaws could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-size:10pt;"></font><font style="display: inline;font-family:Arial;font-size:10pt;">2</font><font style="display: inline;font-family:Arial;font-size:10pt;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-family:Arial;font-size:10pt;">of our potential ability to negotiate with the proponent of a non-friendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Delaware Anti-Takeover Statute</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Before such date, </font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">the</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested holder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">On or after such date, the business combination is approved by </font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">the</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> board of directors</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> of the corporation</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;"> and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">In general, Section 203 defines business combination to include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Any merger or consolidation involving the corporation and the interested stockholder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">Any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">The receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">In general, Section 203 defines interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation or any entity or person affiliated with or controlling or controlled by such entity or person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Undesignated Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire </font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">our company</font><font style="display: inline;font-family:Arial;font-size:10pt;color:#000000;">. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-size:10pt;"></font><font style="display: inline;font-family:Arial;font-size:10pt;">3</font><font style="display: inline;font-family:Arial;font-size:10pt;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Special Stockholder Meetings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our Restated Certificate of Incorporation and Amended and Restated Bylaws provide that a special meeting of stockholders may be called only by our board of directors, the chairperson of our board of directors, or our Chief Executive Officer or President. This provision might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our common stock to take any action, including the removal of directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our Amended and Restated Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors. Our Amended and Restated Bylaws also specify certain requirements regarding the form and content of a stockholder&#x2019;s notice.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-style:italic;font-size:10pt;">Advance Notice of Stockholder Business at Annual Meetings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">If a stockholder is submitting a stockholder proposal related to the business of the company at an annual meeting, such stockholder must: (i) be a stockholder of record at the time notice is given, (ii) be a stockholder of record on the record date for determination of stockholders entitled to notice of the annual meeting, (iii) be a stockholder of record on the record date for the determination of stockholders entitled to vote at the annual meeting, (iv) be a stockholder of record at the time of the annual meeting, and (v) timely deliver proper written notice to </font><font style="display: inline;font-family:Arial;font-size:10pt;">our Corporate S</font><font style="display: inline;font-family:Arial;font-size:10pt;">ecretary. The business brought before an annual meeting by a stockholder must be a proper matter for stockholder action pursuant to our Amended and Restated Bylaws and applicable law.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">To be in proper written form, a stockholder&#x2019;s notice related to the business of the company must contain the following items (Business Solicitation Statement): (i) a brief description of the business intended to be brought before the annual meeting, (ii) the text of the proposed business (including the text of any resolutions proposed for consideration and, in the event that such proposal or business includes a proposal to amend our Amended and Restated Bylaws, the text of the proposed amendment), (iii) the reasons for conducting such business at the annual meeting, and (iv) any material interest that the stockholder has in such business or any person (a) controlling, directly or indirectly, or acting in concert with such stockholder, (b) who is a beneficial owner of shares of stock of the company owned of record or beneficially by such stockholder and whose behalf the proposal or nomination, as the case may be, is being made, or (c) controlling, controlled by or under common control with such person referred to in the preceding clauses (a) and (b) (Stockholder Associated Person). Furthermore, the notice shall also include: (i) the name and address of the stockholder or Stockholder Associated Person proposing such business, (ii) the class or series and number of shares of the company that are held of record or are beneficially owned by the stockholder or Stockholder Associated Person, (iii) whether and to the extent to which any hedging activities have been entered into by or on behalf of such stockholder or Stockholder Associated Person with respect to our securities, (iv) any proxy, contract, or arrangement pursuant to which the stockholder or any Stockholder Associated Person has a right to vote any of our securities, (v) any dividend rights to our securities owned by the stockholder or Stockholder Associated Person that are separated or separable from the underlying security of the company, (vi) any proportionate interest in our securities that are held by a general or limited partnership, (vii) any performance-related fees that the stockholder or Stockholder Associated Person is entitled to based on the value of our securities, (viii) any agreement, arrangement or understanding among the stockholder, Stockholder Associated Person, or others acting in concert with them in connection with the business proposal, (ix) any significant equity interests held by the stockholder or Stockholder Associated Person in a principal competitor of the company, (x) any interests the stockholder or Stockholder Associated Person has in any contract with the company, its affiliates, or principal competitor, (xi) any information requested by the company in determining whether such proposed item of business is a proper matter for stockholder action, (xii) any material pending or threatened legal proceeding in which the stockholder or Stockholder Associated Person is a party or participant involving the company, (xiii) any material relationship between the stockholder or Stockholder Associated Person with the company </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-size:10pt;"></font><font style="display: inline;font-family:Arial;font-size:10pt;">4</font><font style="display: inline;font-family:Arial;font-size:10pt;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-family:Arial;font-size:10pt;">or its officers, directors, or affiliates, (xiv) names and addresses of other stockholders known by the stockholder proposing such business to support such proposal and their interests in the company, (xv) any information necessary in order to make any filings pursuant to the Exchange Act, (xvi) any other information relating to the stockholder or Stockholder Associated Person or others acting in concert with them that would be required to be disclosed in a proxy statement or other filings required to be made in connection with the Exchange Act, (xvii) a representation that such stockholder is a holder of record of stock of the company when the notice was submitted, is entitled to vote at such meeting and such stockholder intends to appear in person or by proxy at the meeting to propose such business, and (xviii) a representation and undertaking as to whether such party or others acting in concert with the stockholder or Stockholder Associated Person intends to deliver a proxy statement or form of proxy or otherwise solicit proxies from holders of at least the percentage of voting power necessary to approve or adopt the proposal or otherwise solicit proxies from stockholders in support of such proposal.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-style:italic;font-size:10pt;">Advance Notice of Director Nominations at Annual Meetings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">If a stockholder is submitting a nomination in connection with an annual meeting, such stockholder must: (i) be a stockholder of record at the time notice if given, (ii) be a stockholder of record on the record date for the determination of stockholders entitled to notice of the annual meeting, (iii) be a stockholder of record on the record date for the determination of stockholders entitled to vote at the annual meeting, (iv) be a stockholder of record at the time of the annual meeting, and (v) submit the notice in a timely manner to </font><font style="display: inline;font-family:Arial;font-size:10pt;">our Corporate S</font><font style="display: inline;font-family:Arial;font-size:10pt;">ecretary at the principal executive offices of the company. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">To be in proper written form, a stockholder&#x2019;s notice related to director nominations at an annual meeting must contain the following items with respect to each nominee (Nominee Solicitation Statement): (i) the name, age, business address and residence address of the nominee, (ii) the principal occupation or employment of the nominee, (iii) the class and number of shares of the company that are held of record or are beneficially owned by the nominee and any derivative positions held or beneficially held by the nominee, (iv) any other agreement, arrangement or understanding that has been made the effect or intent of which is to create or mitigate loss to, or to manage the risk or benefit of share price changes for, or to increase or decrease the voting power of the nominee with respect to the company&#x2019;s securities, (v) any direct or indirect compensatory, payment, indemnification or other financial agreement, arrangement or understanding that such nominee has, or has had within the past three years, with any person or entity other than the company, in each case in connection with candidacy or service as a director of the company, (vi) a description of any other material relationships between the stockholder giving the notice and any Stockholder Associated Person, on the one hand, and the nominee and such nominee&#x2019;s respective affiliates and associates, or others acting in concert with them, on the other hand, (vii) any other information relating to the nominee that would be required to be disclosed about such nominee if proxies were being solicited for the election or re-election of the nominee as a director, or that is otherwise required by applicable laws, (viii) a written statement executed by the nominee acknowledging and representing that the nominee consents to being named as a nominee and to serving as a director and intends to serve a full term on our board of directors if elected, and (ix) a statement whether such person would be in compliance if elected as a director of the company and will comply with all applicable corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the company. The stockholder giving notice shall include in the Nominee Solicitation Statement information that is similarly required of a Business Solicitation Statement except that references to business shall instead refer to the nominations of directors. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Any person nominated to serve on our board of directors shall furnish to </font><font style="display: inline;font-family:Arial;font-size:10pt;">our Corporate S</font><font style="display: inline;font-family:Arial;font-size:10pt;">ecretary, at the principal executive offices of the company, the following: (i) information required to be set forth in the stockholder&#x2019;s notice of nomination of such person as a director as of a date subsequent to the date on which the notice of such person&#x2019;s nomination was given, (ii) such other information reasonably required by the company to determine the eligibility of such nominee to serve as a director or to service as an independent director or audit committee financial expert of the company under applicable securities laws, (iii) a completed written questionnaire provided by the company disclosing the background, qualifications, stock ownership and independence of such proposed nominee, (iv) a written representation and agreement from such proposed nominee to the company that such nominee (a) is not and, if elected, will not become a party to any agreement, arrangement, or understanding with, and has not given and will not give any </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-size:10pt;"></font><font style="display: inline;font-family:Arial;font-size:10pt;">5</font><font style="display: inline;font-family:Arial;font-size:10pt;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-family:Arial;font-size:10pt;">commitment or assurance to, any person or entity as to how such proposed nominee will act or vote on any issue or question or that would limit or interfere with such proposed nominee&#x2019;s ability to comply with such proposed nominee&#x2019;s fiduciary duties, (b) is not, and will not become a party to, any agreement, arrangement or understanding with any person or entity other than the company with respect to any direct or indirect compensation or reimbursement for service as a director, and (c) will comply with applicable corporate governance, conflict of interest, code of business conduct and ethics, confidentiality and stock ownership and trading policies and guidelines of the company, and (v) such other information that could be material to a reasonable stockholder&#x2019;s understanding of the independence, or lack thereof, or the qualifications of such nominee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-style:italic;font-size:10pt;">Advance Notice of Director Nominations at Special Meetings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">If a stockholder is submitting a nomination in a special meeting of the stockholders at which directors are to be elected or re-elected, such stockholder must: (i) be a stockholder of record at the time notice if given, (ii) be a stockholder of record on the record date for the determination of stockholders entitled to notice of the special meeting, (iii) be a stockholder of record on the record date for the determination of stockholders entitled to vote at the special meeting, (iv) be a stockholder of record at the time of the special meeting, and (v) deliver a timely written notice to </font><font style="display: inline;font-family:Arial;font-size:10pt;">our Corporate S</font><font style="display: inline;font-family:Arial;font-size:10pt;">ecretary at the principal executive offices of the company.&nbsp;&nbsp;A stockholder&#x2019;s notice related to director nominations at a special meeting must contain the same information as requested of a stockholder&#x2019;s notice related to a director nomination at an annual meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Elimination of Stockholder Action by Written Consent</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our Restated Certificate of Incorporation and Amended and Restated Bylaws eliminate the right of stockholders to act by written consent without a meeting. As a result, a holder controlling a majority of our common stock would not be able to amend our Amended and Restated Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Amended and Restated Bylaws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Election and Removal of Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our Restated Certificate of Incorporation and Amended and Restated Bylaws authorize only our board of directors to fill any vacant directorships, including newly created seats, by a vote of a majority of the remaining directors. In addition, the number of directors constituting our board of directors are permitted to be set only by a resolution adopted by our board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">While our board of directors is currently divided into three classes, we are in the process of eliminating our classified board of directors. Commencing with the 2024 annual meeting of our stockholders, the classification of our board of directors will cease. Once our board </font><font style="display: inline;font-family:Arial;font-size:10pt;">of directors </font><font style="display: inline;font-family:Arial;font-size:10pt;">is no longer classified, directors may be removed with or without cause by holder of a majority of the shares then entitled to vote at an election of directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Exclusive Forum</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our Restated Certificate of Incorporation and Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us or any of our directors or officers arising pursuant to any provision of the DGCL, our Restated Certificate of Incorporation, or our Amended and Restated Bylaws, or (4) any other action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware or federal district court located within the State of </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-size:10pt;"></font><font style="display: inline;font-family:Arial;font-size:10pt;">6</font><font style="display: inline;font-family:Arial;font-size:10pt;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-family:Arial;font-size:10pt;">Delaware if the Court of Chancery does not have jurisdiction, in all cases subject to the court&#x2019;s having jurisdiction over indispensable parties named as defendants. Unless we consent in writing to the selection of an alternative forum, the federal district courts shall be the exclusive forum for a complaint asserting a cause of action under the Securities Act. With respect to the Exchange Act, only claims brought derivatively under the Exchange Act would be subject to the forum selection clause described above. The enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in our Restated Certificate of Incorporation and Amended and Restated Bylaws to be inapplicable or unenforceable in such action. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. Any person or entity purchasing or otherwise acquiring any interest in our shares of common stock shall be deemed to have notice of and consented to this exclusive forum provision but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-style:italic;font-size:10pt;">Amendment to Provisions in Our Restated Certificate of Incorporation and Amended and Restated Bylaws</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Except for the provision making it possible for our board of directors to issue preferred stock, the affirmative vote of the holders of at least 66 2/3% of the voting power of our outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class, </font><font style="display: inline;font-family:Arial;font-size:10pt;">is</font><font style="display: inline;font-family:Arial;font-size:10pt;"> required to amend, alter or repeal any provisions in our Restated Certificate of Incorporation that are inconsistent with certain provisions in our Restated Certificate of Incorporation, including those related to the election or removal of directors, amendment to our Restated Certificate of Incorporation, amendment to our Amended and Restated Bylaws, and the prohibition against stockholder action by written consent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">The board of directors may adopt, amend, or repeal our Amended and Restated Bylaws without stockholder approval, subject to the power of our stockholders to adopt, amend, or repeal our Amended and Restated Bylaws by the affirmative vote of the holders of at least 66 2/3% of the voting power of our then outstanding voting stock. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">The provisions of the DGCL</font><font style="display: inline;font-family:Arial;font-size:10pt;"> and</font><font style="display: inline;font-family:Arial;font-size:10pt;"> our Restated Certificate of Incorporation and Amended and Restated Bylaws may have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-size:10pt;">Exchange Listing</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">Our common stock is quoted on The Nasdaq Global Select Market under the symbol &#x201C;SILK.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;font-size:10pt;">Transfer Agent</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-size:10pt;">The transfer agent for our common stock is Equiniti Trust Company</font><font style="display: inline;font-family:Arial;font-size:10pt;">, LLC</font><font style="display: inline;font-family:Arial;font-size:10pt;">. &nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-size:10pt;"></font><font style="display: inline;font-family:Arial;font-size:10pt;">7</font><font style="display: inline;font-family:Arial;font-size:10pt;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>silk-20231231xex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:19:17 PM-->
<html>
	<head>
		<title>
			Exhibit 10.1
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-weight:bold;font-size:11pt;">Exhibit 10.1</font>

		</p>

		<p style="margin:0pt 5.5pt 0pt 0pt;text-align:right;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-indent:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;"><img src="silk-20231231xex10_1g001.jpg" style="width: 2.40625in; height: 0.6141601in" alt="A close-up of a logo&#xA;&#xA;Description automatically generated"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-indent:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">SILK ROAD MEDICAL,</font><font style="display: inline;"> INC</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-weight:bold;text-indent:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">INDEMNIFICATION AGREEMENT</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">This Indemnification Agreement </font><font style="display: inline;">(this &#x201C;Agreement&#x201D;) is dated as of </font><font style="display: inline;">__________________</font><font style="display: inline;">, and is between </font><font style="display: inline;">Silk Road Medical,</font><font style="display: inline;"> Inc.</font><font style="display: inline;">, a Delaware corporation (</font><font style="display: inline;">together with its affiliates and subsidiaries, </font><font style="display: inline;">the &#x201C;Company&#x201D;), and </font><font style="display: inline;">_________________</font><font style="display: inline;"> (&#x201C;Indemnitee&#x201D;).</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:4.5pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">RECITALS</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">A.</font><font style="display: inline;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">Indemnitee&#x2019;s service to the Company substantially benefits the Company.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">B.</font><font style="display: inline;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">Individuals are reluctant to serve as directors or officers of corporations or in certain other capacities unless they are provided with adequate protection through insurance or indemnification against the risks of claims and actions against them arising out of such service.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">C.</font><font style="display: inline;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">Indemnitee does not regard the protection currently provided by applicable law, the Company&#x2019;s governing documents and any insurance as adequate under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">D.</font><font style="display: inline;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">In order to induce Indemnitee to continue to provide services to the Company, it is reasonable, prudent and necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee as permitted by applicable law.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">E.</font><font style="display: inline;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">This Agreement is a supplement to and in furtherance of the indemnification provided in the Company&#x2019;s certificate of incorporation and bylaws, and any resolutions adopted pursuant thereto, and this Agreement shall not be deemed a substitute therefor, nor shall this Agreement be deemed to limit, diminish or abrogate any rights of Indemnitee thereunder.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The parties therefore agree as follows:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 1.</font>
			<a name="_Ref159412671"></a><font style="display: inline;font-weight:bold;color:#000000;">Definitions.</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<a name="_DV_C74"></a><font style="display: inline;color:#000000;">A &nbsp;</font><font style="display: inline;color:#000000;">&#x201C;Change in Control&#x201D; shall</font><font style="display: inline;color:#000000;"> be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</font><a name="_DV_C75"></a></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:116pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 18pt 0pt 0pt;">(i)</font>
			<a name="_DV_C76"></a><font style="display: inline;font-style:italic;color:#000000;">Acquisition of Stock by Third Party.</font><font style="display: inline;color:#000000;"> Any Person (as defined below) becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&#x2019;s then outstanding securities;</font><a name="_DV_C77"></a></p></td></tr></table></div>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 18pt 0pt 0pt;">(ii)</font>
			<a name="_DV_C78"></a><font style="display: inline;font-style:italic;color:#000000;">Change in Board Composition.</font><font style="display: inline;color:#000000;"> During any period of two consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Company&#x2019;s board of directors, and any new directors (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections&nbsp;</font><font style="display: inline;color:#000000;">1(a)(i)</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">1(a)(iii)</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">1(a)(iv)</font><font style="display: inline;color:#000000;">) whose election by the board of directors or nomination for election by the Company&#x2019;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Company&#x2019;s board of directors;</font><a name="_DV_C79"></a></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:112pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 18pt 0pt 0pt;">(iii)</font>
			<a name="_DV_C80"></a><font style="display: inline;font-style:italic;color:#000000;">Corporate Transactions.</font><font style="display: inline;color:#000000;"> The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;</font><a name="_DV_C81"></a></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:112pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 18pt 0pt 0pt;">(iv)</font>
			<a name="_DV_C82"></a><font style="display: inline;font-style:italic;color:#000000;">Liquidation.</font><font style="display: inline;color:#000000;"> The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#x2019;s assets; and</font><a name="_DV_C83"></a></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:113pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 18pt 0pt 0pt;">(v)</font>
			<a name="_DV_C84"></a><font style="display: inline;font-style:italic;color:#000000;">Other Events.</font><font style="display: inline;color:#000000;"> Any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended, whether or not the Company is then subject to such reporting requirement</font><a name="_DV_C85"></a><font style="display: inline;color:#000000;">, except the completion of the</font><font style="display: inline;color:#000000;"> Company&#x2019;s initial public offering </font><font style="display: inline;color:#000000;">shall not be considered a Change in Control</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">For purposes of this Section&nbsp;</font><font style="display: inline;color:#000000;">1(a)</font><font style="display: inline;color:#000000;">, the following terms shall have the following meanings:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:144pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-decoration:none;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (1)</font>
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">&#x201C;Person&#x201D; shall have the meaning as set forth in Sections&nbsp;13(d) and 14(d) of the Securities Exchange Act of 1934, as amended; provided, however, that &#x201C;Person&#x201D; shall exclude (i)&nbsp;the Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii)&nbsp;any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:144pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (2)</font>
			<a name="_DV_C92"></a><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">&#x201C;Beneficial Owner&#x201D; shall have the meaning given to such term in Rule&nbsp;13d-3 under the Securities Exchange Act of 1934, as amended; provided, however, that &#x201C;Beneficial Owner&#x201D; shall exclude any Person otherwise becoming a Beneficial Owner by reason of (i)&nbsp;the stockholders of the Company approving a merger of the Company with another entity or (ii)&nbsp;the Company&#x2019;s board of directors approving a sale of securities by the Company to such Person.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">2</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;color:#000000;">&#x201C;Corporate Status&#x201D; describes the status of a person who is or was a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;color:#000000;">&#x201C;DGCL&#x201D; means the General Corporation Law of the State of Delaware.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;color:#000000;">&#x201C;Disinterested Director&#x201D; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;color:#000000;">&#x201C;Enterprise&#x201D; means the Company and any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 7pt 0pt 0pt;"> (f)</font>
			<font style="display: inline;color:#000000;">&#x201C;Expenses&#x201D; include all reasonable </font><font style="display: inline;color:#000000;">and actually incurred </font><font style="display: inline;color:#000000;">attorneys&#x2019; fees, retainers, court costs, transcript costs, fees and costs of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also include (i)&nbsp;Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond or other appeal bond or their equivalent, and (ii)&nbsp;for purposes of Section&nbsp;</font><font style="display: inline;color:#000000;">12(d)</font><font style="display: inline;color:#000000;">, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#x2019;s rights under this Agreement or under any directors&#x2019; and officers&#x2019; liability insurance policies maintained by the Company. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (g)</font>
			<font style="display: inline;color:#000000;">&#x201C;Independent Counsel&#x201D; means a law firm, or a partner or member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i)&nbsp;the Company or Indemnitee in any matter material to either such party (other than as Independent Counsel with respect to matters concerning Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#x201C;Independent Counsel&#x201D; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#x2019;s rights under this Agreement.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (h)</font>
			<font style="display: inline;color:#000000;">&#x201C;Proceeding&#x201D; means any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, </font><font style="display: inline;color:#000000;">including any appeal therefrom </font><font style="display: inline;color:#000000;">and including without limitation any such Proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be involved as a party, a potential party, a non-party witness or otherwise by reason of (i)&nbsp;the fact that Indemnitee is or was a director or officer of the Company, (ii)&nbsp;any action taken by Indemnitee or any action or inaction on Indemnitee&#x2019;s part </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">3</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">while acting as a director or officer of the Company, or (iii)&nbsp;the fact that he or she is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification or advancement of expenses can be provided under this Agreement.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;color:#000000;">Reference to &#x201C;other enterprises&#x201D; shall include employee benefit plans; references to &#x201C;fines&#x201D; shall include any excise taxes assessed on a person with respect to any employee benefit plan; references to &#x201C;serving at the request of the Company&#x201D; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#x201C;not opposed to the best interests of the Company&#x201D; as referred to in this Agreement</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 2.</font>
			<a name="_Ref159413960"></a><font style="display: inline;font-weight:bold;color:#000000;">Indemnity in Third-Party Proceedings.</font><font style="display: inline;color:#000000;"> The Company shall indemnify Indemnitee in accordance with the provisions of this Section&nbsp;</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;"> if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 3.</font>
			<a name="_Ref159414009"></a><font style="display: inline;font-weight:bold;color:#000000;">Indemnity in Proceedings by or in the Right of the Company.</font><font style="display: inline;color:#000000;"> The Company shall indemnify Indemnitee in accordance with the provisions of this Section&nbsp;</font><font style="display: inline;color:#000000;">3</font><font style="display: inline;color:#000000;"> if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;</font><font style="display: inline;color:#000000;">3</font><font style="display: inline;color:#000000;">, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#x2019;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;</font><font style="display: inline;color:#000000;">3</font><font style="display: inline;color:#000000;"> in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court of Chancery or such other court shall deem proper.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 4.</font>
			<a name="_Ref159414067"></a><font style="display: inline;font-weight:bold;color:#000000;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</font><font style="display: inline;color:#000000;"> To the extent that Indemnitee is a party to or a participant in and is successful (on the merits or otherwise) in defense of any Proceeding or any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">4</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">Indemnitee&#x2019;s behalf in connection therewith.</font><font style="display: inline;color:#000000;"> &nbsp; &nbsp;</font><font style="display: inline;color:#000000;">For purposes of this section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 5.</font>
			<a name="_Ref159414774"></a><a name="_Ref167877878"></a><font style="display: inline;font-weight:bold;color:#000000;">Indemnification for Expenses of a Witness.</font><font style="display: inline;color:#000000;"> To the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified to the extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#x2019;s behalf in connection therewith.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 6.</font>
			<a name="_Ref159414121"></a><font style="display: inline;font-weight:bold;color:#000000;">Additional Indemnification.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<a name="_Ref159414123"></a><font style="display: inline;color:#000000;">Notwithstanding any limitation in Sections&nbsp;</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">3</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">4</font><font style="display: inline;color:#000000;">, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with the Proceeding or any claim, issue or matter therein.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;color:#000000;">For purposes of Section&nbsp;</font><font style="display: inline;color:#000000;">6(a)</font><font style="display: inline;color:#000000;">, the meaning of the </font><font style="display: inline;color:#000000;">phrase &#x201C;to the fullest extent permitted by applicable law&#x201D; shall include, but not be limited to:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:116pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 18pt 0pt 0pt;">(i)</font>
			<font style="display: inline;color:#000000;">the fullest extent permitted by the provision of</font><font style="display: inline;color:#000000;"> the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 18pt 0pt 0pt;">(ii)</font>
			<font style="display: inline;color:#000000;">the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 7.</font>
			<a name="_Ref159414163"></a><font style="display: inline;font-weight:bold;color:#000000;">Exclusions.</font><font style="display: inline;color:#000000;"> Notwithstanding any provision in this Agreement, </font><a name="OLE_LINK22"></a><a name="OLE_LINK23"></a><font style="display: inline;color:#000000;">the Company shall not be obligated under this Agreement to make any indemnity in connection with any Proceeding (or any part of any Proceeding):</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<a name="_Ref165347684"></a><font style="display: inline;color:#000000;">for which payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid</font><font style="display: inline;color:#000000;">, subject to any subrogation rights set forth in Section </font><font style="display: inline;color:#000000;">15</font><font style="display: inline;color:#000000;">;</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<a name="_Ref159414165"></a><a name="_Ref214898104"></a><font style="display: inline;color:#000000;">for an accounting or disgorgement of profits pursuant to Section&nbsp;16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (c)</font>
			<a name="_Ref214898106"></a><font style="display: inline;color:#000000;">for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (</font><font style="display: inline;color:#000000;">the &#x201C;Sarbanes-Oxley </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">5</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">Act&#x201D;), or the payment to the Company of profits arising from the purchase and sale by</font><font style="display: inline;color:#000000;"> Indemnitee of securities in violation of Section&nbsp;306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements);</font><a name="_Ref165347701"></a></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;color:#000000;">any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the</font><font style="display: inline;color:#000000;"> Company&#x2019;s</font><font style="display: inline;color:#000000;"> Board</font><font style="display: inline;color:#000000;"> of Directors (the &#x201C;Board&#x201D;)</font><font style="display: inline;color:#000000;"> or the Compensation Committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section 10D of the</font><font style="display: inline;color:#000000;"> Securities</font><font style="display: inline;color:#000000;"> Exchange Act</font><font style="display: inline;color:#000000;"> of 1934, as amended;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;color:#000000;">initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, agents or other indemnitees, unless (i)&nbsp;the Company&#x2019;s board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii)&nbsp;otherwise authorized in Section&nbsp;</font><font style="display: inline;color:#000000;">12(d)</font><font style="display: inline;color:#000000;"> or (iv)&nbsp;otherwise required by applicable law</font><font style="display: inline;color:#000000;">; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 7pt 0pt 0pt;"> (f)</font>
			<font style="display: inline;color:#000000;">if prohibited by applicable law.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 8.</font>
			<a name="_Ref159414187"></a><a name="_Ref166646463"></a><font style="display: inline;font-weight:bold;color:#000000;">Advances of Expenses.</font><font style="display: inline;color:#000000;"> The Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding</font><font style="display: inline;color:#000000;"> prior to its final disposition</font><font style="display: inline;color:#000000;">, and such advancement shall be made as soon as reasonably practicable, b</font><font style="display: inline;color:#000000;">ut in any event no later than </font><font style="display: inline;color:#000000;">9</font><font style="display: inline;color:#000000;">0</font><font style="display: inline;color:#000000;"> days, after the receipt by the Company of a written statement or statements requesting such advances from time to time (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice). Advances shall be unsecured and interest free and made without regard to Indemnitee&#x2019;s ability to repay such advances. Indemnitee hereby undertakes to repay any advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> and no other form of undertaking shall be required other than the execution of this Agreement</font><font style="display: inline;color:#000000;">. This Section&nbsp;</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;"> shall not apply to the extent advancement is prohibited by law and shall not apply to any Proceeding </font><font style="display: inline;color:#000000;">(or any part of any Proceeding) </font><font style="display: inline;color:#000000;">for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding </font><font style="display: inline;color:#000000;">(or any part of any Proceeding) </font><font style="display: inline;color:#000000;">referenced in Section&nbsp;</font><font style="display: inline;color:#000000;">7(b)</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">7(c)</font><font style="display: inline;color:#000000;"> prior to a determination that Indemnitee is not entitled to be indemnified by the Company</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 8pt 0pt 0pt;"> 9.</font>
			<a name="_Ref159414234"></a><font style="display: inline;font-weight:bold;color:#000000;">Procedures for Notification and Defense of Claim.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<a name="_Ref165690451"></a><font style="display: inline;color:#000000;">Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof. The written notification to the Company shall include, in reasonable detail, a description of the nature of the Proceeding and the facts underlying the Proceeding. The failure by Indemnitee to notify the Company will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">6</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">shall not constitute a wai</font><font style="display: inline;color:#000000;">ver by Indemnitee of any rights</font><font style="display: inline;color:#000000;">, except to the extent that such failure or delay ma</font><font style="display: inline;color:#000000;">terially prejudices the Company</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;color:#000000;">If, at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has directors&#x2019; and officers&#x2019; liability insurance in effect</font><font style="display: inline;color:#000000;"> that may be applicable to the Proceeding</font><font style="display: inline;color:#000000;">, the Company shall give prompt notice of the commencement of the Proceeding to the insurers in accordance with the procedures set forth in the applicable policies. The Company shall thereafter take all commercially-reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;color:#000000;">In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to </font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">assume the defense of such Proceeding</font><font style="display: inline;color:#000000;"> with counsel approved by Indemnitee, which approval shall not be unreasonably withheld</font><font style="display: inline;color:#000000;">, conditioned or delayed</font><font style="display: inline;color:#000000;">, upon the delivery to Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. Notwithstanding the Company&#x2019;s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the fees and expenses of Indemnitee&#x2019;s </font><font style="display: inline;color:#000000;">separate </font><font style="display: inline;color:#000000;">counsel to the extent (i)&nbsp;the employment of</font><font style="display: inline;color:#000000;"> separate</font><font style="display: inline;color:#000000;"> counsel by Indemnitee is authorized by the Company, (ii)&nbsp;counsel for the Company or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense such that Indemnitee needs to be separately represented, </font><font style="display: inline;color:#000000;">(iii</font><font style="display: inline;color:#000000;">)&nbsp;the Company is not financially or legally able to perform its indemnification obligations or (</font><font style="display: inline;color:#000000;">i</font><font style="display: inline;color:#000000;">v)&nbsp;the Company shall not have retained, or shall not continue to retain, counsel to defend such Proceeding. Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee&#x2019;s personal expense. </font><font style="display: inline;color:#000000;">The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Company.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;color:#000000;">Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be reasonably appropriate.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;color:#000000;">The Company shall not be liable to indemnify Indemnitee for any settlement of any Proceeding (or any part thereof) without the Company&#x2019;s prior written consent, which shall not be unreasonably withheld</font><font style="display: inline;color:#000000;">, conditioned or delayed</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 7pt 0pt 0pt;"> (f)</font>
			<font style="display: inline;color:#000000;">The Company shall not settle any Proceeding (or any part thereof) </font><font style="display: inline;color:#000000;">in a manner that imposes any penalty or liability on Indemnitee </font><font style="display: inline;color:#000000;">without Indemnitee&#x2019;s prior written consent, which shall not be unreasonably withheld</font><font style="display: inline;color:#000000;">, conditioned or delayed</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 10.</font>
			<a name="_Ref159414285"></a><a name="_Ref166318187"></a><font style="display: inline;font-weight:bold;color:#000000;">Procedures upon Application for Indemnification.</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<a name="_Ref166318264"></a><a name="_Ref159414289"></a><font style="display: inline;color:#000000;">To obtain indemnification, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">7</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">Proceeding. </font><font style="display: inline;color:#000000;">The Company shall, as soon as reasonably practicable after receipt of such request for indemnification, advise the board of directors that Indemnitee has requested indemnification. </font><font style="display: inline;color:#000000;">Any delay in providing the request will not relieve the Company from its obligations under this Agreement, except to the extent such failure is prejudicial.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<a name="_Ref166318164"></a><font style="display: inline;color:#000000;">Upon written request by Indemnitee for indemnifi</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">cation pursuant to Section&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">10(a)</font><font style="display: inline;color:#000000;">, a determination with respect to Indemnitee&#x2019;s entitlement thereto shall be made</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in the specific </font><font style="display: inline;color:#000000;">c</font><font style="display: inline;color:#000000;">ase (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Company&#x2019;s board of directors, a copy of which shall be delivered to Indemnitee or (ii) if </font><font style="display: inline;color:#000000;">a Change in </font><font style="display: inline;color:#000000;">Control shall not have occurred,</font><font style="display: inline;color:#000000;"> (A)&nbsp;by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#x2019;s board of directors, (B)&nbsp;by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#x2019;s board of directors, (C)&nbsp;if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company&#x2019;s board of directors, a copy of which shall be delivered to Indemnitee or (D)&nbsp;if so directed by the Company&#x2019;s board of directors, by the stockholders of the Company. If it is determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within </font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">thirty</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">days</font><font style="display: inline;color:#000000;"> after such determination. Indemnitee shall cooperate with the person, persons or entity making the determination with respect to Indemnitee&#x2019;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys&#x2019; fees and disbursements) </font><font style="display: inline;color:#000000;">actually and </font><font style="display: inline;color:#000000;">reasonably incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company, to the extent permitted by applicable law.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (c)</font>
			<a name="_Ref159414326"></a><a name="_Ref166571554"></a><font style="display: inline;color:#000000;">In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">10(b)</font><font style="display: inline;color:#000000;">, the Independent Counsel shall be selected as provided in this Section&nbsp;</font><font style="display: inline;color:#000000;">10(c)</font><font style="display: inline;color:#000000;">. If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Company&#x2019;s board of directors, and the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Company&#x2019;s board of directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; </font><font style="display: inline;font-style:italic;color:#000000;">provided</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">however</font><font style="display: inline;color:#000000;">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#x201C;Independent Counsel&#x201D; as defined in Section&nbsp;</font><font style="display: inline;color:#000000;">1</font><font style="display: inline;color:#000000;"> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after the later of (i)&nbsp;submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">10(a)</font><font style="display: inline;color:#000000;"> hereof and (ii)&nbsp;the final disposition of the Proceeding, the parties have not agreed upon an Independent Counsel, either the </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">8</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">Company or Indemnitee may petition </font><font style="display: inline;color:#000000;">the Delaware Court of Chancery</font><font style="display: inline;color:#000000;"> for resolution of any objection which shall have been made by the Company or Indemnitee to the other&#x2019;s selection of Independent Counsel and for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&nbsp;</font><font style="display: inline;color:#000000;">10(b)</font><font style="display: inline;color:#000000;"> hereof. Upon the due commencem</font><font style="display: inline;color:#000000;">ent of any judicial proceeding or arbitration</font><font style="display: inline;color:#000000;"> pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">12(a)</font><font style="display: inline;color:#000000;"> of this Agreement, the Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;color:#000000;">The Company agrees to pay the reasonable fees and expenses of any Independent Counsel.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 11.</font>
			<a name="_Ref159414611"></a><font style="display: inline;font-weight:bold;color:#000000;">Presumptions and Effect of Certain Proceedings.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;color:#000000;">In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption</font><font style="display: inline;color:#000000;"> by clear and convincing evidence</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<a name="_Ref159414607"></a><font style="display: inline;color:#000000;">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="display: inline;font-style:italic;color:#000000;">nolo</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">contendere</font><font style="display: inline;color:#000000;"> or its equivalent, shall not (except as otherwise expressly provide</font><font style="display: inline;color:#000000;">d in this Agreement) of itself </font><font style="display: inline;color:#000000;">adversely affect the right of Indemnitee to indemnific</font><font style="display: inline;color:#000000;">ation or</font><font style="display: inline;color:#000000;"> create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (c)</font>
			<a name="_Ref165368436"></a><font style="display: inline;color:#000000;">For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith to the extent Indemnitee relied in good faith on (i)&nbsp;the records or books of account of the Enterprise, including financial statements, (ii)&nbsp;information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, (iii)&nbsp;the advice of legal counsel for the Enterprise or its board of directors or counsel selected by any committee of the board of directors or (iv)&nbsp;information or records given or reports made to the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert selected with reasonable care by the Enterprise or its board of directors or any committee of the board of directors. The provisions of this Section&nbsp;</font><font style="display: inline;color:#000000;">11(c)</font><font style="display: inline;color:#000000;"> shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnit</font><font style="display: inline;color:#000000;">ee may be deemed to have met any</font><font style="display: inline;color:#000000;"> applicable standard of conduct.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;color:#000000;">Neither the knowledge, actions nor failure to act of any other director, officer, agent or employee of the Enterprise shall be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">9</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 12.</font>
			<a name="_Ref159414463"></a><font style="display: inline;font-weight:bold;color:#000000;">Remedies of Indemnitee.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<a name="_Ref159414472"></a><font style="display: inline;color:#000000;">Subject to Section&nbsp;</font><font style="display: inline;color:#000000;">12(e)</font><font style="display: inline;color:#000000;">, in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">10</font><font style="display: inline;color:#000000;"> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not t</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">imely made pursuant to Section&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">12(d)</font><font style="display: inline;color:#000000;"> of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been made pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">10</font><font style="display: inline;color:#000000;"> of this Agreement within 90 days after the later of the receipt by the Company of the request for indemnification or the final disposition of the Proceeding, (iv)&nbsp;payment of indemnification pursuant to this Agr</font><font style="display: inline;color:#000000;">eement is not made (A)&nbsp;within </font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">thirty</font><font style="display: inline;color:#000000;"> days after a determination has been made that Indemnitee is entitled to indemnification or (B)&nbsp;with respect to indemnification pursuant to Sections&nbsp;</font><font style="display: inline;color:#000000;">4</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">5</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">12(d)</font><font style="display: inline;color:#000000;"> of this Agreement,</font><font style="display: inline;color:#000000;"> within thirty</font><font style="display: inline;color:#000000;"> days after receipt by the Company of a written request therefor, or (v)&nbsp;the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or proceeding designed to deny, or to recover from</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by </font><font style="display: inline;color:#000000;">the Delaware Court of Chancery</font><font style="display: inline;color:#000000;"> of his or her entitlement to such indemnificati</font><font style="display: inline;color:#000000;">on or advancement of Expenses. </font><font style="display: inline;color:#000000;">Alternatively, Indemnitee, at his or her option, may seek an award in arbitration with respect to his or her entitlement to such indemnification or advancement of Expenses, to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Indemnitee shall commence such proceeding seeking an adjudicat</font><font style="display: inline;color:#000000;">ion or an award in arbitration</font><font style="display: inline;color:#000000;"> within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section&nbsp;</font><font style="display: inline;color:#000000;">12(a)</font><font style="display: inline;color:#000000;">. The Company shall not oppose Indemnitee&#x2019;s right to seek any such adjudi</font><font style="display: inline;color:#000000;">cation or award in arbitration</font><font style="display: inline;color:#000000;"> in accordance with this Agreement.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;color:#000000;">Neither (i)&nbsp;the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii)&nbsp;an actual determination by the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. In the event that a determination shall have been made pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">10</font><font style="display: inline;color:#000000;"> of this Agreement that Indemnitee is not entitled to indemnific</font><font style="display: inline;color:#000000;">ation, any judicial proceeding or arbitration</font><font style="display: inline;color:#000000;"> commenced pursuant to this Section&nbsp;</font><font style="display: inline;color:#000000;">12</font><font style="display: inline;color:#000000;"> shall be conducted in all respects as a </font><font style="display: inline;font-style:italic;color:#000000;">de novo</font><font style="display: inline;color:#000000;"> trial, or arbitration,</font><font style="display: inline;color:#000000;"> on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determinati</font><font style="display: inline;color:#000000;">on. In any judicial proceeding or arbitration</font><font style="display: inline;color:#000000;"> commenced pursuant to this Section&nbsp;</font><font style="display: inline;color:#000000;">12</font><font style="display: inline;color:#000000;">, the Company shall, to the fullest extent not prohibited by law, have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">by clear and convincing evidence</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (c)</font>
			<a name="_Ref491275058"></a><font style="display: inline;color:#000000;">To the fullest extent not prohibited by law, the Company shall be precluded from assert</font><font style="display: inline;color:#000000;">ing in any judicial proceeding or arbitration</font><font style="display: inline;color:#000000;"> commenced pursuant to this Section&nbsp;</font><font style="display: inline;color:#000000;">12</font><font style="display: inline;color:#000000;"> that the procedures and presumptions of this Agreement are not valid, binding and enforceable and sha</font><font style="display: inline;color:#000000;">ll stipulate in any such court or before any such arbitrator</font><font style="display: inline;color:#000000;"> that the Company is bound by all the provisions of this Agreement.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">If a determination shall have been made pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">10</font><font style="display: inline;color:#000000;"> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">10</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">determinat</font><font style="display: inline;color:#000000;">ion in any judicial proceeding or arbitration</font><font style="display: inline;color:#000000;"> commenced pursuant to this Section&nbsp;</font><font style="display: inline;color:#000000;">12</font><font style="display: inline;color:#000000;">, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#x2019;s statements not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (d)</font>
			<a name="_Ref165968927"></a><a name="_Ref173582735"></a><a name="OLE_LINK27"></a><a name="_Ref491275383"></a><font style="display: inline;color:#000000;">To the extent not prohibited by law, the Company shall indemnify Indemnitee against all Expenses that are incurred by Indemnitee in connection with any action for indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#x2019; and officers&#x2019; liability insurance policies maintained by the Company to the extent</font><font style="display: inline;color:#000000;"> Indemnitee is successful in such action</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">and, if requested by Indemnitee, shall (as soon as reasonably practicable, b</font><font style="display: inline;color:#000000;">ut in any event no later than </font><font style="display: inline;color:#000000;">9</font><font style="display: inline;color:#000000;">0</font><font style="display: inline;color:#000000;"> days, after receipt by the Company of a written request therefor) advance such Expenses to Indemnitee, subject to the provisions of Section&nbsp;</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (e)</font>
			<a name="_Ref166303026"></a><font style="display: inline;color:#000000;">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification shall be required to be made prior to the final disposition of the Proceeding.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 13.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Contribution.</font><font style="display: inline;color:#000000;"> To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether for Expenses, judgments, fines or amounts paid or to be paid in settlement, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding; and (ii)&nbsp;the relative fault of Indemnitee and the Company (and its other directors, officers, employees and agents) in connection with such events and transactions.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 14.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Non-exclusivity.</font><font style="display: inline;color:#000000;"> The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company&#x2019;s certificate of incorporation or bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company&#x2019;s certificate of incorporation and bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the restrictions expressly set forth herein or therein. Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. Except as expressly set forth herein, the assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 15.</font>
			<a name="_Ref213650499"></a><a name="_Ref491368205"></a><font style="display: inline;font-weight:bold;color:#000000;">Primary Responsibility.</font><font style="display: inline;color:#000000;"> The Company acknowledges that</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to the extent </font><font style="display: inline;color:#000000;">Indemnitee</font><font style="display: inline;color:#000000;"> is serving as a director on the Company&#x2019;s</font><font style="display: inline;color:#000000;"> board of directors at the request or direction of a venture capital</font><font style="display: inline;color:#000000;"> or private equity</font><font style="display: inline;color:#000000;"> fund or entity and/</font><font style="display: inline;color:#000000;"> certain </font><font style="display: inline;color:#000000;">of its </font><font style="display: inline;color:#000000;">affiliates (collectively, </font><font style="display: inline;color:#000000;">the </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">11</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">&#x201C;Secondary Indemnitors&#x201D;)</font><font style="display: inline;color:#000000;">, Indemnity has certain rights to indemnification and advancement of expenses provided by such Secondary Indemnitors</font><font style="display: inline;color:#000000;">. The Company agrees that, as between the Company and the Secondary Indemnitors, the Company is primarily responsible for amounts required to be indemnified or advanced under the Company&#x2019;s certificate of incorporation or bylaws or this Agreement and any obligation of the Secondary Indemnitors to provide indemnification or advancement for the same amounts is secondary </font><font style="display: inline;color:#000000;">to those Company obligations. </font><font style="display: inline;color:#000000;">To the extent not in contravention of any insurance policy or </font><font style="display: inline;color:#000000;">policies providing liability or other insurance for the Company or</font><font style="display: inline;color:#000000;"> any director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or</font><font style="display: inline;color:#000000;"> any other Enterprise, the</font><font style="display: inline;color:#000000;"> Company waives any right of contribution or subrogation against the </font><font style="display: inline;color:#000000;">Secondary Indemnitors </font><font style="display: inline;color:#000000;">with respect to the liabilities for which the Company is primarily responsible under this Section&nbsp;</font><font style="display: inline;color:#000000;">15</font><font style="display: inline;color:#000000;">. In the event of any payment by the </font><font style="display: inline;color:#000000;">Secondary Indemnitors</font><font style="display: inline;color:#000000;"> of amounts otherwise required to be indemnified or advanced by the Company under the Company&#x2019;s certificate of incorporation or bylaws or this Agreement, the </font><font style="display: inline;color:#000000;">Secondary Indemnitors </font><font style="display: inline;color:#000000;">shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee for indemnification or advancement of expenses under the Company&#x2019;s certificate of incorporati</font><font style="display: inline;color:#000000;">on or bylaws or this Agreement </font><font style="display: inline;color:#000000;">or, to the extent such subrogation is unavailable and contribution is found to be the applicable remedy, shall have a right of contribution w</font><font style="display: inline;color:#000000;">ith respect to the amounts paid</font><font style="display: inline;color:#000000;">; &nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">provided, however,</font><font style="display: inline;color:#000000;"> that the foregoing sentence will be deemed void if and to the extent that it would violate any applicable insurance policy. The </font><font style="display: inline;color:#000000;">Secondary Indemnitors</font><font style="display: inline;color:#000000;"> are express third-party beneficiaries of the terms of this Section&nbsp;</font><font style="display: inline;color:#000000;">15</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 16.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">No Duplication of Payments.</font><font style="display: inline;color:#000000;"> The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract, agreement or otherwise</font><font style="display: inline;color:#000000;">, subject to any subrogation right set forth in Section </font><font style="display: inline;color:#000000;">15</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 17.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Insurance.</font><font style="display: inline;color:#000000;"> To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, trustees, general partners, managing members, officers, employees, agents or fiduciaries of the Company or any other Enterprise, Indemnitee shall be covered by such policy or policies to the same extent as the most favorably-insured persons under such policy or policies in a comparable position.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 18.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Subrogation.</font><font style="display: inline;color:#000000;"> In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 19.</font>
			<a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><font style="display: inline;font-weight:bold;color:#000000;">Services to the Company.</font><font style="display: inline;color:#000000;"> Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation or is removed from such position. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">12</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;color:#000000;">any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that any employment with the Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, with or without notice, except as may be otherwise expressly provided in any executed, written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies adopted by the Company&#x2019;s board of directors or, with respect to service as a director or officer of the Company, the Company&#x2019;s certificate of incorporation or bylaws or the DGCL.</font><font style="display: inline;color:#000000;"> No such document shall be subject to any oral modification thereof.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 20.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Duration.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">This Agreement shall continue until and terminate upon the later of (a) ten years after the date that Indemnitee shall have ceased to serve as a director or officer of the Company or as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other Enterprise, as applicable; or (b) one year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement relating thereto.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 21.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Successors.</font><font style="display: inline;color:#000000;"> This Agreement </font><font style="display: inline;color:#000000;">shall be binding upon the Company and its successors and assigns, including any direct or indirect successor</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> by purchase, merger, consolidation or otherwise</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> to all or substantially all of the business or assets of the Company, and shall inure to the benefit of Indemnitee and Indemnitee&#x2019;s heirs,</font><font style="display: inline;color:#000000;"> executors and administrators. </font><font style="display: inline;color:#000000;">The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, by written agreement, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 22.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Severability.</font><font style="display: inline;color:#000000;"> Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company&#x2019;s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (ii)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (iii)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 23.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Enforcement.</font><font style="display: inline;color:#000000;"> The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">13</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 24.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Entire Agreement.</font><font style="display: inline;color:#000000;"> This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; </font><font style="display: inline;font-style:italic;color:#000000;">provided</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;font-style:italic;color:#000000;">however</font><font style="display: inline;color:#000000;">, that this Agreement is a supplement to and in furtherance of the Company&#x2019;s certificate of incorporation and bylaws and applicable law.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 25.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Modification and Waiver.</font><font style="display: inline;color:#000000;"> No supplement, modification or amendment to this Agreement shall be binding unless executed in writing by the parties hereto. No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor shall any waiver constitute a continuing waiver. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 26.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Notices.</font><font style="display: inline;color:#000000;"> All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or ce</font><font style="display: inline;color:#000000;">rtified mail, postage prepaid, </font><font style="display: inline;color:#000000;">sent </font><font style="display: inline;color:#000000;">by electronic mail</font><font style="display: inline;color:#000000;"> or otherwise delivered by hand, messenger or courier service addressed:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;color:#000000;">if to Inde</font><font style="display: inline;color:#000000;">mnitee, to Indemnitee&#x2019;s address</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or electronic mai</font><font style="display: inline;color:#000000;">l address</font><font style="display: inline;color:#000000;"> as shown on the signature page of this Agreement or in the Company&#x2019;s records, as may be updated in accordance with the provisions hereof; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;;padding:0pt 5pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;color:#000000;">if to the Company, to the attention of the Chief Executive Officer or Chief Financial Officer of the Company at </font><font style="display: inline;color:#000000;">1213 Innsbruck Drive, Sunnyvale, CA 94089</font><font style="display: inline;color:#000000;">, or at such other current address as the Company shall have furnished to Indemnitee</font><font style="display: inline;color:#000000;">, with a copy (which shall not constitute notice) to </font><font style="display: inline;color:#000000;">the attention of the Chief </font><font style="display: inline;color:#000000;">Legal</font><font style="display: inline;color:#000000;"> Officer of the Company at </font><font style="display: inline;color:#000000;">14755 27th Avenue North, Plymouth, MN 55447</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i)&nbsp;if delivered by hand, messenger or courier service, when delivered (or if sent </font><font style="display: inline;font-style:italic;color:#000000;">via</font><font style="display: inline;color:#000000;"> a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day af</font><font style="display: inline;color:#000000;">ter deposit with the courier), or</font><font style="display: inline;color:#000000;"> (ii)&nbsp;if sent </font><font style="display: inline;font-style:italic;color:#000000;">via</font><font style="display: inline;color:#000000;"> mail, at</font><font style="display: inline;color:#000000;"> the earlier of its receipt or five days</font><font style="display: inline;color:#000000;"> after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, ad</font><font style="display: inline;color:#000000;">dressed and mailed as aforesaid</font><font style="display: inline;color:#000000;">, or (iii)&nbsp;if sent </font><font style="display: inline;font-style:italic;color:#000000;">via</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">electronic mail, </font><font style="display: inline;color:#000000;">upon</font><font style="display: inline;color:#000000;"> confirmation of delivery</font><font style="display: inline;color:#000000;"> when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on th</font><font style="display: inline;color:#000000;">e recipient&#x2019;s next business day</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 27.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Applicable Law and Consent to Jurisdiction.</font><font style="display: inline;color:#000000;"> This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard </font><font style="display: inline;color:#000000;">to its conflict of laws rules. </font><font style="display: inline;color:#000000;">Except with respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;</font><font style="display: inline;color:#000000;">12(a)</font><font style="display: inline;color:#000000;"> of this Agreement,</font><font style="display: inline;color:#000000;"> the Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">14</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;"><font style="display: inline;color:#000000;">connection with this Agreement, (iii)&nbsp;appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, </font><font style="display: inline;color:#000000;">The Corporation Trust Company, Wilmington</font><font style="display: inline;color:#000000;">, Delaware as its agent in the State of Delaware as such party&#x2019;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 28.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Counterparts.</font><font style="display: inline;color:#000000;"> This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;;padding:0pt 4pt 0pt 0pt;"> 29.</font>
			<font style="display: inline;font-weight:bold;color:#000000;">Captions.</font><font style="display: inline;color:#000000;"> The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<a name="_Hlk149249697"></a><font style="display: inline;color:#000000;">(</font><font style="display: inline;font-style:italic;color:#000000;">Remainder of page intentionally left blank; s</font><font style="display: inline;font-style:italic;color:#000000;">ignature page follows</font><font style="display: inline;color:#000000;">)</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			&nbsp;
		</p></div><div style="margin-left:72pt;margin-right:54pt;">
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-size:11pt;">-</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">15</font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;"></font><font style="font-family:Times New Roman;font-size:12pt;display: inline;font-size:11pt;">-</font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt 5.5pt 0pt 0pt;text-align:right;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">The parties are signing this Indemnification Agreement as of the date stated in the introductory sentence.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;color:#000000;font-size:12pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:42.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:42.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:26.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;">EXECUTIVE</font></p>
				</td>
				<td valign="top" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:26.55pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:26.55pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-indent:0pt;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;">SILK ROAD MEDICAL, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:42.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:42.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Date:____________________________</font></p>
				</td>
				<td valign="top" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:44.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">By:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:42.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Title:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0.5pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 6pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<sub style="display: inline;font-family:Calibri;font-size:18pt;">&#xFEFF;</sub>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;font-style:italic;font-size:11pt;">[Signature Page to Indemnification Agreement]</font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>5
<FILENAME>silk-20231231xex10_36.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:20:32 PM-->
<html>
	<head>
		<title>
			Exhibit 10.36
		</title>
	</head>
	<body><div style="margin-left:57pt;margin-right:57pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit 10.36</font>

		</p>

</div>
		<p style="margin:3.8pt 0.15pt 0pt;text-decoration:none;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">FIRST</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">AMENDMENT</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">TO</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">LEASE</font>
		</p>
		<p style="margin:13.6pt 5.65pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">This First Amendment to Lease, dated as of August </font><font style="display: inline;">27,</font><font style="display: inline;"> 2018, is entered into by and between Hanover Properties, Ltd., a California limited partnership (&#x201C;Landlord&#x201D;), and Silk Road Medical, Inc., a Delaware corporation (&#x201C;Tenant&#x201D;).</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.15pt 0pt 0.1pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;text-decoration:underline;">RECITALS</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24.95pt 0pt 0pt;"> A.</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Landlord</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Tenant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entered</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">into</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">certain</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Lease</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">dated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of November 30, 2017 (the &#x201C;Lease&#x201D;) for those certain premises consisting of approximately 31,268 rentable square feet (the &#x201C;Premises&#x201D;) in the building located at 1213 Innsbruck Drive, Sunnyvale, California.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25.9pt 0pt 0pt;"> B.</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Pursuant to the Lease, Landlord constructed certain improvements to the Premises for Tenant (the &#x201C;Tenant Improvements&#x201D;) and provided Tenant with an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">allowance of $790,700 (the &#x201C;Tenant Improvements Allowance&#x201D;) for the design, permitting and construction of the Tenant Improvements.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Lease also provided</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Tenant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">additional</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">allowance</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">$316,280</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201C;Additional</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Allowance&#x201D;)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">could be utilized by Tenant to pay any Tenant Improvements costs in excess of the Tenant Improvements Allowance, which Additional Allowance would then repaid by Tenant to Landlord as additional rent under the Lease.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25.9pt 0pt 0pt;"> C.</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Landlord and Tenant now desire to amend the Lease to reflect the additional rent which will be due as result of Tenant&#x2019;s election to utilize the entire</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amount of the Additional Allowance.</font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.15pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;text-decoration:underline;color:#000000;">AGREEMENT</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">In</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">consideration</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">mutual</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">covenants</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">set</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">forth</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">herein</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">other</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">valuable consideration, Landlord and Tenant agree to amend the Lease as follows:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 6pt 0pt 0pt;">
				<font style="margin:0pt 6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 1.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Term</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Landlord and Tenant hereby confirm that the term of the Lease commenced on June 13, 2018 (the &#x201C;Commencement Date&#x201D;) and shall expire on October 12, 2024, subject to Tenant&#x2019;s option to further extend the term as provided in Paragraph 45 of the Lease.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 12pt 0pt;">
				<font style="margin:0pt 5.85pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 2.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Base Rent</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Landlord and Tenant acknowledge that the additional rent payable under the Lease pursuant to paragraph 5(c) of the Work Letter Agreement attached as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">EXHIBIT</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">C</font><font style="display: inline;font-size:12pt;color:#000000;"> to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Lease will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">$5,274.96</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">per</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">month</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">based</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">upon</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">74-month amortization schedule.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Accordingly, the schedule of Base Rent set forth in Paragraph 5(a) of the Lease is hereby deleted and replaced with the following:</font></p></td></tr></table></div>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;font-family:Calibri;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:41.76%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.64%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">Months of Term</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">Base Rent</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Jun 13, 2018 &#x2013; Aug 12, 2018</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$0.00/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Aug 13, 2018 &#x2013; Jun 12, 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$82,763.56/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Jun 13, 2019 &#x2013; Jun 12, 2020</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$85,088.22/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Jun 13, 2020 &#x2013; Jun 12, 2021</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$87,482.62/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Jun 13, 2021 &#x2013; Jun 12, 2022</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$89,948.84/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Jun 13, 2022 &#x2013; Jun 12, 2023</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$92,489.06/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Jun 13, 2023 &#x2013; Jun 12, 2024</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$95,105.48/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:41.76%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">Jun 13, 2024 &#x2013; Oct 12, 2024</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.92%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:31.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;">$97,800.40/month</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:20.64%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:57pt;margin-right:57pt;">
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25.95pt 0pt 0pt;"> 3.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">No Further Modifications</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Except as set forth in this First Amendment,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Lease if unmodified and in full force and effect.</font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;text-decoration:underline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;font-family:Calibri;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.36%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.82%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 13pt">
						<font style="font-size:13pt;border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">LANDLORD</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 13pt">
						<font style="font-size:13pt;border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">TENANT</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 13pt">
						<font style="font-size:13pt;border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">Hanover Properties, Ltd.,</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">a California limited partnership</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">Silk Road Medical, Inc.,</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">a Delaware corporation</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">By: The Christensen Company, LLC,</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">By: </font><font style="font-size:12pt;border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">/s/ Erica Rogers</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">General Partner</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">Name: Erica Rogers</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">By: </font><font style="font-size:12pt;border-bottom-style:solid;border-bottom-width:2pt;color:#000000;height:100%;text-indent:0pt;">/s/ Gavin Christensen</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.36%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">Gavin Christensen, Manager</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:04.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;color:#000000;">Title: CEO</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>silk-20231231xex10_5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:19:38 PM-->
<html>
	<head>
		<title>
			Exhibit 10.5 2023
		</title>
	</head>
	<body><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3pt 0pt 0pt 158.4pt;text-align:right;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit </font><font style="display: inline;font-weight:bold;font-size:10pt;">10</font><font style="display: inline;font-weight:bold;font-size:10pt;">.</font><font style="display: inline;font-weight:bold;font-size:10pt;">5</font><font style="display: inline;font-weight:bold;font-size:10pt;"> &nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:3pt 158.25pt 0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:3pt 158.25pt 0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">SILK</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">ROAD</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">MEDICAL,</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INC.</font>
		</p>
		<p style="margin:0pt 158.25pt 0pt 158.35pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">2019</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">EQUITY</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INCENTIVE</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">PLAN</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 13pt">
			<font style="display: inline;font-weight:bold;font-size:13pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:9.05pt 0pt 0pt;">
				<font style="margin:9.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 1.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:9.05pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Purposes</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">the</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">purposes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">are:</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 8.2pt 0pt 0pt;">
				<font style="margin:0pt 8.2pt 0pt 0pt;font-family:Symbol;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 8.2pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">to attract and retain the best available personnel for positions of substantial</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">responsibility,</font></p></td></tr></table></div>
		<p style="margin:0.4pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
				<font style="margin:0.05pt 0pt 0pt;font-family:Symbol;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provide</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">additional</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">incentive</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Employees,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Consultants,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:11.8pt 0pt 0pt;">
				<font style="margin:11.8pt 0pt 0pt;font-family:Symbol;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;border-top:1pt none #D9D9D9;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:11.8pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">promote</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">success</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Company&#x2019;s</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">business.</font></p></td></tr></table></div>
		<p style="margin:12pt 5.75pt 0pt 5.9pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 2.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Definitions</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">As</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">used</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">herein,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">following</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">definitions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">apply:</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Administrator</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means the Board or any of its Committees as will be administering the Plan, in accordance with Section 4 of the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.65pt 0pt 0pt;">
				<font style="margin:0.05pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Applicable</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Laws</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">legal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">regulatory</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">requirements</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">relating</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the administration of equity-based awards and the related issuance of Shares thereunder, including but not limited to U.S. federal and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any non-U.S. country or jurisdiction where Awards are, or will be, granted under the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.55pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.45pt 5.75pt 0pt 0pt;">
				<font style="margin:4.45pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Award</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.65pt 0pt 0pt;">
				<font style="margin:0.05pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Award Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Award Agreement is subject to the terms and conditions of the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
				<font style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (e)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Board</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Board</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Directors</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the </font><font style="display: inline;font-size:12pt;color:#000000;">Company.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (f)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Change</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">in</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Control</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">occurrence</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">following</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">events:</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.7pt 0pt 0pt;">
				<font style="margin:3pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 20pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">A change in the ownership of the Company which occurs on the date that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">one</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">person,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">more</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">than</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">one</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">person</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acting</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">group</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Person</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;),</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acquires</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">ownership</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company; provided, however, that for </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:3pt 5.7pt 0pt 5.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;font-size:12pt;color:#000000;">purposes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">subsection,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(A)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acquisition</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">additional</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">one</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Person,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">who</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control, and (B) if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company&#x2019;s voting stock immediately prior to the change in ownership, the direct or indirect beneficial</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">ownership</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fifty</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">percent</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(50%)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">more</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">total</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">voting</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">power</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Company</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of the ultimate parent entity of the Company, such event will not be considered a Change in Control under this subsection (i). For this purpose, indirect beneficial ownership will include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which own the Company, as the case may be, either directly</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or through</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">one or more subsidiary corporations or other business entities; or</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:111pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">A change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12)-month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (iii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">A change in the ownership of a substantial portion of the Company&#x2019;s assets</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">occurs</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Person</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acquires</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">has</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acquired</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">during</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the twelve (12)-month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of the Company&#x2019;s assets: (A) a transfer to an entity that is controlled by the Company&#x2019;s stockholders immediately after the transfer, or (B)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#x2019;s stock, (2) an entity, fifty percent (50%) or more of the total value or voting power of which is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:4.5pt 5.8pt 0pt 6pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">For purposes of this definition, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.65pt 0pt 5.95pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">unless</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">transaction</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">qualifies</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">as</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">change</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">control</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">event</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">within</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">meaning</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of Section 409A.</font>
		</p>
		<p style="margin:3pt 0pt 0pt 5.9pt;text-indent:108pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Further</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">for</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">avoidance</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">doubt,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">transaction</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">will</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">not</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">constitute</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a Change</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Control</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">if:</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(i)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">its</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">sole</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">purpose</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">change</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">state</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Company&#x2019;s</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">incorporation,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3pt 0pt 0pt 5.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;">(ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (g)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Code</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means the Internal Revenue Code of 1986, as amended.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Reference to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (h)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Committee</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means a committee of Directors or of other individuals</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">satisfying Applicable Laws appointed by the Board, or a duly authorized committee of the Board, in accordance with Section 4 hereof.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (i)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Common</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Common</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;"> Company.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25pt 0pt 0pt;"> (j)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Company</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means Silk Road Medical, Inc., a Delaware corporation, or any successor thereto.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.7pt 0pt 0pt;">
				<font style="margin:0.05pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (k)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Consultant</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means any natural person, including an advisor, engaged by the Company or a Parent or Subsidiary to render bona fide services to such entity, provided the services</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(i)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">are not in connection with the offer or sale of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">securities in a capital-raising transaction, and (ii)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">do not directly promote or maintain a market for the Company&#x2019;s securities, in each case, within the meaning of Form S-8 promulgated under the Securities Act, and provided, further, that a Consultant will include only those persons to whom the issuance of Shares may be registered under Form S-8 promulgated under the Securities Act.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
				<font style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (l)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Director</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">member</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;"> Board.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.5pt 0pt 0pt;">
				<font style="margin:0.05pt 5.5pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21pt 0pt 0pt;"> (m)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Disability</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">total</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">permanent</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">disability</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">defined</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in Section 22(e)(3) of the Code, provided that in the case of Awards other than Incentive Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.</font></p></td></tr></table></div>
		<p style="margin:0.4pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.7pt 0pt 0pt;">
				<font style="margin:0.05pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (n)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Employee</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means any person, including Officers and Directors, employed</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by the Company or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director&#x2019;s fee by the Company will be sufficient to constitute &#x201C;employment&#x201D; by the </font><font style="display: inline;font-size:12pt;color:#000000;">Company.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (o)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exchange</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Act</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Securities</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Exchange</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Act</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">1934,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amended.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (p)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exchange Program</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">selected</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Administrator,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and/or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(iii) the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exercise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">price</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">outstanding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Award</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">increased</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">reduced.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Administrator</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">will</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">determine</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">terms</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">conditions</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">any Exchange Program in its sole discretion.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 14.05pt 0pt 0pt;">
				<font style="margin:0pt 14.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.9pt 0pt 0pt;"> (q)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Fair</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Market</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Value</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Common</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 14.05pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;font-size:12pt;color:#000000;">determined as follows:</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.8pt 0pt 0pt;">
				<font style="margin:4.5pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 20pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">For purposes of any Awards granted on the Registration Date, the Fair Market</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Value will be the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">initial price</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to the public</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as set forth</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in the final prospectus included within the registration statement in Form S-1 filed with the Securities and Exchange Commission for the initial public offering of the Company&#x2019;s Common Stock.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:111pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">For</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">purposes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Awards</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">granted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Fair</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Market Value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">closing</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">sales</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">price</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Common</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">quoted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">established</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exchange or national market system (including without limitation the New York Stock Exchange, NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market of The NASDAQ Stock Market) on which the Common Stock is listed on the date of determination (or the closing bid,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if no sales were reported), as reported in </font><font style="display: inline;font-style:italic;font-size:12pt;color:#000000;">The Wall Street Journal </font><font style="display: inline;font-size:12pt;color:#000000;">or such other source as the Administrator deems reliable.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If the determination date for the Fair Market Value occurs on a non-trading day (i.e., a weekend or holiday), the Fair Market Value will be such price on the immediately preceding trading day, unless otherwise determined by the Administrator. In the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">absence of an established market for the Common Stock, the Fair Market Value thereof will be determined in good faith by the Administrator.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.7pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The determination of fair market value for purposes of tax withholding may be made in the Administrator&#x2019;s discretion subject to Applicable Laws and is not required to be consistent with the determination of Fair Market Value for other purposes.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (r)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Fiscal</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Year</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">fiscal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">year</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Company.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (s)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Incentive Stock Option</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated </font><font style="display: inline;font-size:12pt;color:#000000;">thereunder.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 14.35pt 0pt 0pt;">
				<font style="margin:4.5pt 14.35pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24.9pt 0pt 0pt;"> (t)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Nonstatutory</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terms</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">does</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not qualify or is not intended to qualify as an Incentive Stock Option.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 20.3pt 0pt 0pt;">
				<font style="margin:0.05pt 20.3pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.9pt 0pt 0pt;"> (u)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Officer</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">person</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">who</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">officer</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Company</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">within</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the meaning</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Section</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">16</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Exchange</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Act</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rules</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">regulations</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">promulgated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">thereunder.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (v)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">granted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">pursuant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the </font><font style="display: inline;font-size:12pt;color:#000000;">Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (w)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Outside</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Director</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Director</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">who</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Employee.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 14.75pt 0pt 0pt;">
				<font style="margin:0pt 14.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.9pt 0pt 0pt;"> (x)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Parent</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201C;parent</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">corporation,&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">whether</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">now</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">hereafter</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">existing,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as defined in Section 424(e) of the Code.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;"> (y)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">means</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">holder</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">outstanding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Award.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.75pt 0pt 0pt;">
				<font style="margin:3pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (z)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">&#x201C;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Performance Share</font><font style="display: inline;font-size:12pt;color:#000000;">&#x201D; means an Award denominated in Shares which may be earned in whole or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine pursuant to Section 10.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.7pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">(aa)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;text-decoration:underline;color:#000000;">Performance Unit</font><font style="display: inline;color:#000000;">&#x201D; means an Award which may be earned in whole or in part </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 5.7pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;">upon attainment of performance goals or other vesting criteria as the Administrator may determine and which may be settled for cash, Shares or other securities or a combination of the foregoing pursuant to Section 10.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.7pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(bb)</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Period</font><font style="display: inline;text-decoration:underline;">&nbsp;</font><font style="display: inline;text-decoration:underline;">of</font><font style="display: inline;text-decoration:underline;">&nbsp;</font><font style="display: inline;text-decoration:underline;">Restriction</font><font style="display: inline;">&#x201D; means</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">period during</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">which</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">transfer</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 78pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:18.9pt;"><font style="display: inline;">(cc)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Plan</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">means</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">this</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2019</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Equity</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Incentive</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Plan.</font></font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.75pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(dd)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Registration Date</font><font style="display: inline;">&#x201D; means the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act, with respect to any class of the Company&#x2019;s securities.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.6pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(ee)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Restricted Stock</font><font style="display: inline;">&#x201D; means Shares issued pursuant to a Restricted Stock award under Section 7 of the Plan, or issued pursuant to the early exercise of an Option.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 5.7pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(ff)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Restricted Stock Unit</font><font style="display: inline;">&#x201D; means a bookkeeping entry representing an amount</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">equal to the Fair Market Value of one Share, granted pursuant to Section 8. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.</font>
		</p>
		<p style="margin:0.45pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 5.7pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(gg)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Rule 16b-3</font><font style="display: inline;">&#x201D; means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 78pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:18.9pt;"><font style="display: inline;">(hh)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Section</font><font style="display: inline;text-decoration:underline;">&nbsp;</font><font style="display: inline;text-decoration:underline;">16(b)</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">means</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Section</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">16(b)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Exchange</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Act.</font></font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.7pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(ii)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Section</font><font style="display: inline;text-decoration:underline;">&nbsp;</font><font style="display: inline;text-decoration:underline;">409A</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">means</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Code</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Section</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">409A,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">it</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">has</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">been</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">may</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</font>
		</p>
		<p style="margin:0.4pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 76.05pt 0pt 78pt;line-height:186.67%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(jj)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Securities Act</font><font style="display: inline;">&#x201D; means the Securities Act of 1933, as amended. (kk)</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Service</font><font style="display: inline;text-decoration:underline;">&nbsp;</font><font style="display: inline;text-decoration:underline;">Provider</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">means</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">an</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Employee,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Director</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Consultant.</font>
		</p>
		<p style="margin:0pt 5.6pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(ll)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">Share</font><font style="display: inline;">&#x201D; means a share of the Common Stock, as adjusted in accordance with Section 14 of the Plan.</font>
		</p>
		<p style="margin:0.4pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.65pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(mm) &#x201C;</font><font style="display: inline;text-decoration:underline;">Stock Appreciation Right</font><font style="display: inline;">&#x201D; means an Award, granted alone or in connection with an Option, that pursuant to Section 9 is designated as a Stock Appreciation Right.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.65pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">(nn) &#x201C;</font><font style="display: inline;text-decoration:underline;">Subsidiary</font><font style="display: inline;">&#x201D; means a &#x201C;subsidiary corporation,&#x201D; whether now or hereafter existing, as defined in Section 424(f) of the Code.</font>
		</p>
		<p style="margin:0pt 5.65pt 0pt 6pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 3.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Subject</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">to</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">the </font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock Subject to the Plan</font><font style="display: inline;font-size:12pt;color:#000000;">. Subject to the provisions of Section 14 of the Plan and the automatic increase set forth in Section 3(b) of the Plan, the maximum aggregate number of </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 5.8pt 0pt 5.95pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;font-size:12pt;color:#000000;">Shares that may be issued under the Plan is 2,317,000 Shares, plus (i) any Shares that, as of the date of stockholder approval of this Plan, have been reserved but not issued pursuant to any awards granted under the Company&#x2019;s 2007 Stock Plan (the &#x201C;2007 Plan&#x201D;) and are not subject to any awards granted thereunder, and (ii) any Shares subject to stock options or similar awards granted under the 2007 Plan that, after the date of stockholder approval of this Plan, expire or otherwise terminate without having been exercised in full and Shares issued pursuant to awards granted under the 2007 Plan that, after the date of stockholder approval of this Plan, are forfeited to or repurchased by the Company,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the maximum number</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be added</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Plan</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">pursuant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">clauses (i) and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(ii)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">equal to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">11,260,827 Shares.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Shares</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">may</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">be</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">authorized,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">but</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">unissued,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or reacquired</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Common </font><font style="display: inline;color:#000000;">Stock.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.85pt 0pt 0pt;">
				<font style="margin:4.5pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Automatic Share Reserve Increase</font><font style="display: inline;font-size:12pt;color:#000000;">. Subject to the provisions of Section 14 of the Plan, the number of Shares available for issuance under the Plan will be increased on the first</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">day</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">each</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Fiscal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Year</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">beginning</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">2020</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Fiscal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Year,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amount</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">equal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">least</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(i) 3,000,000 Shares, (ii) four percent (4%) of the outstanding Shares on the last day of the immediately preceding Fiscal Year or (iii) such number of Shares determined by the Board.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.55pt 0pt 0pt;">
				<font style="margin:0pt 5.55pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Lapsed Awards</font><font style="display: inline;font-size:12pt;color:#000000;">. If an Award expires or becomes unexercisable without</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">having been exercised in full, is surrendered pursuant to an Exchange Program, or, with respect to Restricted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Restricted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Units,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Performance</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Units</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Performance</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">forfeited</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or repurchased by the Company due to failure to vest, the unpurchased Shares (or for Awards other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">than Options or Stock Appreciation Rights the forfeited or repurchased Shares), which were subject thereto will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">become available for future grant or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">sale under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Plan (unless the Plan</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">has terminated). With</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Appreciation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Rights,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">only</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">actually</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">issued</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(i.e.,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">net</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares issued) pursuant to a Stock Appreciation Right will cease to be available under the Plan; all remaining Shares under Stock Appreciation Rights will remain available for future grant or sale under the Plan (unless the Plan has terminated).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares that have actually been issued under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares issued pursuant to Awards of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Restricted Stock, Restricted Stock Units, Performance Shares or Performance Units are repurchased by the Company or are forfeited to the Company, such Shares will become available for future grant under the Plan. Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment as provided in Section 14, the maximum number of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate Share number stated in Section 3(a), plus, to the extent allowable under Section 422 of the Code and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan pursuant to Sections 3(b) and 3(c).</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.75pt 0pt 0pt;">
				<font style="margin:3pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Share Reserve</font><font style="display: inline;font-size:12pt;color:#000000;">. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 4.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Administration</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">the</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (a)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Procedure</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 20pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Multiple Administrative Bodies</font><font style="display: inline;font-size:12pt;color:#000000;">. Different Committees with respect to different groups of Service Providers may administer the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:111pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Rule 16b-3</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the requirements for exemption under Rule 16b-3.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> (iii)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Other Administration</font><font style="display: inline;font-size:12pt;color:#000000;">. Other than as provided above, the Plan will be administered by (A) the Board or (B) a Committee, which committee will be constituted to satisfy Applicable Laws.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Powers of the Administrator</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:120pt;"><p style="width:120pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;;"> (i)</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">determine</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Fair</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Market</font><font style="display: inline;font-size:12pt;color:#000000;"> Value;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 12pt 0pt;">
				<font style="margin:0pt 5.6pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;;;padding:0pt 18pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to select the Service Providers to whom Awards may be granted hereunder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 12pt 0pt;">
				<font style="margin:0pt 5.6pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;;;padding:0pt 16pt 0pt 0pt;"> (iii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to determine the number of Shares to be covered by each Award granted hereunder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:120pt;"><p style="width:120pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;;"> (iv)</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">to approve forms of Award Agreements for use under the Plan;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:12pt 5.6pt 12pt 0pt;">
				<font style="margin:12pt 5.6pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;;;padding:0pt 17pt 0pt 0pt;"> (v)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 12pt 0pt;">
				<font style="margin:0pt 5.6pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;;;padding:0pt 16pt 0pt 0pt;"> (vi)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to institute and determine the terms and conditions of an Exchange Program;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 12pt 0pt;">
				<font style="margin:0pt 5.6pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;;;padding:0pt 14pt 0pt 0pt;"> (vii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan</font><font style="display: inline;font-size:12pt;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 12pt 0pt;">
				<font style="margin:0pt 5.6pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;;;padding:0pt 12pt 0pt 0pt;"> (viii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying</font></p></td></tr></table></div></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3pt 0pt 12pt 6pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3pt 0pt 12pt 6pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-size:12pt;">applica</font><font style="display: inline;">ble</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">non-U.S.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">laws</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">qualifying</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">favorable</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">tax</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">treatment</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">under</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">applicable</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">non-U.S. </font><font style="display: inline;">laws;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.65pt 0pt 0pt;">
				<font style="margin:4.5pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;;;padding:0pt 22pt 0pt 0pt;"> (ix)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to modify or amend each Award (subject to Section 19 of the Plan), including but not limited to the discretionary authority to extend the post-termination exercisability period of Awards and to extend the maximum term of an Option (subject to Section 6(b) of the Plan regarding Incentive Stock Options);</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:112pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 20pt 0pt 0pt;"> (x)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to allow Participants to satisfy tax withholding obligations in such manner as prescribed in Section 15 of the Plan;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> (xi)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by the Administrator;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:105pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (xii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant under an Award; and</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:102pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 7.95pt 0pt 0pt;">
				<font style="margin:0pt 7.95pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23.95pt 0pt 0pt;"> (xiii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">to make all other determinations deemed necessary or advisable for administering the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Effect of Administrator&#x2019;s Decision</font><font style="display: inline;font-size:12pt;color:#000000;">. The Administrator&#x2019;s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 5.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Eligibility</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Nonstatutory Stock Options, Stock Appreciation Rights, Restricted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock, Restricted Stock Units, Performance Shares and Performance Units may be granted to Service Providers.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Incentive Stock Options may be granted only to Employees.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 6.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Options</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Limitations</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Each Option will be designated in the Award Agreement as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">either an Incentive Stock Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">dollars ($100,000), such options will be treated as nonstatutory stock options. For purposes of this Section 6(a), incentive stock options will be taken into account in the order in which they were granted.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The fair market value of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shares will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be determined as of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time the option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect to such shares is granted.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Term of Option</font><font style="display: inline;font-size:12pt;color:#000000;">. The term of each Option will be stated in the Award Agreement.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">In the case of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an Incentive Stock Option, the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">term</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will be ten</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(10) years from</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of grant or such shorter term as may be provided in the Award Agreement.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Moreover, in the case of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five (5) years from the date of grant or such shorter term as may be provided in the Award Agreement.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;"> (c)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Option</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exercise</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Price</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">and</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Consideration</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">8</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 8.8pt 0pt 0pt;">
				<font style="margin:0pt 8.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;text-justify:inter-ideograph;;;padding:0pt 19.9pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exercise</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Price</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">per</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">share</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exercise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">price</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">issued pursuant to exercise of an Option will be determined by the Administrator, subject to the following:</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:149pt;"><p style="width:149pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (1)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">In</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">case</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Incentive</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock </font><font style="display: inline;font-size:12pt;color:#000000;">Option</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:180pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> (A)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the voting power</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of </font><font style="display: inline;font-size:12pt;color:#000000;">grant.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:180pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.65pt 0pt 0pt;">
				<font style="margin:4.5pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (B)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">granted to any Employee other than an Employee described in paragraph (A) immediately above, the per Share exercise price will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:144pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (2)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">In the case of a Nonstatutory Stock Option, the per Share exercise price will be no less than one hundred percent (100%) of the Fair Market Value per Share</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on the date of grant.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:144pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.7pt 0pt 0pt;">
				<font style="margin:4.5pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (3)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Notwithstanding the foregoing, Options may be granted with a per Share exercise price</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of less than one hundred percent (100%) of the Fair Market Value per Share on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">grant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">pursuant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">transaction</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">described</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">manner</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">consistent</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with, Section 424(a) of the Code.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:111pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.65pt 0pt 0pt;">
				<font style="margin:0.05pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Waiting Period and Exercise Dates</font><font style="display: inline;font-size:12pt;color:#000000;">. At the time an Option is granted, the Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> (iii)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Form of Consideration</font><font style="display: inline;font-size:12pt;color:#000000;">. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">at</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">grant.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">consideration</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">consist</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entirely</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of:</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(1)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">cash;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(2)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">check;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(3)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">promissory</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">note,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">extent</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">permitted</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Applicable</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Laws,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(4)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">other</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Shares,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">provided</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">such Shares have</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a Fair Market Value on</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided that accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">sole</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">discretion;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(5)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">consideration</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">received</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Company</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">under</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">broker-assisted</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(or other) cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan; (6) by net exercise; (7) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (8) any combination of the foregoing methods of payment.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (d)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exercise</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 20pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Procedure for Exercise; Rights as a Stockholder</font><font style="display: inline;font-size:12pt;color:#000000;">. Any Option granted hereunder</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exercisable</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">according</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terms</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">at</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">times</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font></p></td></tr></table></div></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3pt 5.4pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3pt 5.4pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">conditions as determined by the Administrator and set forth in the Award Agreement.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">An Option</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">may not be exercised for a fraction of a Share.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.6pt 0pt 5.95pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">An Option will be deemed exercised when the Company receives: (i)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a notice</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">exercise</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">such</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">form</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Administrator</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">may</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">specify</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">from</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">time to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">time)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">from</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised (together with applicable withholding taxes). Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse. Until</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Shares</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">are</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">issued</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">evidenced</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">by</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">appropriate</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">entry</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">on</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">books</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Company</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 14 of the Plan.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.7pt 0pt 6pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:111pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.65pt 0pt 0pt;">
				<font style="margin:0.05pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 21pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Termination of Relationship as a Service Provider</font><font style="display: inline;font-size:12pt;color:#000000;">. If a Participant ceases to be a Service Provider, other than upon the Participant&#x2019;s termination as the result of the Participant&#x2019;s</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">death</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or Disability,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may exercise his or her</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three (3) months following the Participant&#x2019;s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by the unvested portion of the Option will revert</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert to the </font><font style="display: inline;font-size:12pt;color:#000000;">Plan.</font></p></td></tr></table></div>
		<p style="margin:0.55pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.6pt 0pt 0pt;">
				<font style="margin:4.5pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;;;padding:0pt 23pt 0pt 0pt;"> (iii)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Disability of Participant</font><font style="display: inline;font-size:12pt;color:#000000;">. If a Participant ceases to be a Service Provider as a result of the Participant&#x2019;s Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following the Participant&#x2019;s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If after termination the Participant does not exercise his or her Option within the time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">specified</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">herein,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terminate,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">covered</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">revert</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to the Plan.</font></p></td></tr></table></div></div><div style="margin-left:54pt;margin-right:54pt;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.6pt 0pt 0pt;">
				<font style="margin:3pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;;;padding:0pt 22pt 0pt 0pt;"> (iv)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Death of Participant</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant dies while a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Service Provider,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Option may be exercised following the Participant&#x2019;s death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in the Award Agreement), by the Participant&#x2019;s designated beneficiary, provided such beneficiary has been designated prior to Participant&#x2019;s death in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant&#x2019;s estate or by the person(s) to whom the Option is transferred pursuant to the Participant&#x2019;s will or in accordance with the laws of descent and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant&#x2019;s death. Unless otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:117pt;"><p style="width:117pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;text-justify:inter-ideograph;;"> (v)</font>
			</p>
		</td><td style="width:6pt;"><p style="width:6pt;width:6pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="text-indent:0pt;margin-left:-31.95pt; padding-right:5.99999999999997pt;"><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Tolling</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Expiration</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:12pt;color:#000000;">A</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant&#x2019;s</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Award</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">also</font></font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">provide</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">that:</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:144pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.65pt 0pt 0pt;">
				<font style="margin:0.05pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 18pt 0pt 0pt;"> (1)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exercise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">following</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">termination</font><font style="display: inline;font-size:12pt;color:#000000;"> of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant&#x2019;s status as a Service Provider (other than upon the Participant&#x2019;s death or Disability) would result in liability under Section 16(b), then the Option will terminate on the earlier of (A) the expiration of the term of the Option set forth in the Award Agreement, or (B) the tenth (10th) day after the last date on which such exercise would result in liability under Section 16(b); or</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:144pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.65pt 0pt 0pt;">
				<font style="margin:0.05pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (2)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">if the exercise of the Option following the termination of the Participant&#x2019;s status as a Service Provider (other than upon the Participant&#x2019;s death or Disability) would be prohibited at any time solely because the issuance of Shares would violate the registration requirements under the Securities Act, then the Option will terminate on the earlier of (A) the expiration of the term of the Option or (B) the expiration of a period of thirty (30)-day period after the termination of the Participant&#x2019;s status as a Service Provider during which the exercise of the Option would not be in violation of such registration requirements.</font></p></td></tr></table></div>
		<p style="margin:0.4pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
				<font style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 7.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Restricted</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.7pt 0pt 0pt;">
				<font style="margin:0.05pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Grant of Restricted Stock</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Restricted Stock Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on such Shares have lapsed.</font></p></td></tr></table></div></div><div style="margin-left:54pt;margin-right:54pt;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;">-11-</font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.75pt 0pt 0pt;">
				<font style="margin:3pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Transferability</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Except as provided in this Section 7 or the Award</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Agreement, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Other Restrictions</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Administrator, in its sole discretion,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may impose</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Removal of Restrictions</font><font style="display: inline;font-size:12pt;color:#000000;">. Except as otherwise provided in this Section 7, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25pt 0pt 0pt;"> (f)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Voting Rights</font><font style="display: inline;font-size:12pt;color:#000000;">. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (g)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Dividends and Other Distributions</font><font style="display: inline;font-size:12pt;color:#000000;">. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were </font><font style="display: inline;font-size:12pt;color:#000000;">paid.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.7pt 0pt 0pt;">
				<font style="margin:4.5pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (h)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Return of Restricted Stock to Company</font><font style="display: inline;font-size:12pt;color:#000000;">. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 8.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Restricted</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Units</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 15.05pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Grant</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Restricted Stock Units may be granted at</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any time and from time to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time as determined by the Administrator. After the Administrator determines that it will grant Restricted Stock Units under the Plan, it will advise the Participant in an Award Agreement of the terms,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">conditions,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">restrictions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">related</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">grant,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">including</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Restricted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock </font><font style="display: inline;font-size:12pt;color:#000000;">U</font><font style="display: inline;font-size:12pt;color:#000000;">ni</font><font style="display: inline;font-size:12pt;color:#000000;">ts</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Vesting Criteria and Other Terms</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the Administrator in its discretion.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Earning Restricted Stock Units</font><font style="display: inline;font-size:12pt;color:#000000;">. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">12</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.7pt 0pt 0pt;">
				<font style="margin:3pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Form and Timing of Payment</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s) determined by the Administrator and set forth in the Award Agreement.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Administrator, in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its sole discretion,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may only settle earned</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Restricted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock Units in cash, Shares, or a combination of both.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Cancellation</font><font style="display: inline;font-size:12pt;color:#000000;">. On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 9.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Appreciation</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Rights</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Grant of Stock Appreciation Rights</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to the terms and conditions of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Plan, a Stock Appreciation Right may be granted to Service Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Number of Shares</font><font style="display: inline;font-size:12pt;color:#000000;">. The Administrator will have complete discretion to determine the number of Stock Appreciation Rights granted to any Service Provider.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exercise Price and Other Terms</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The per share exercise price for the Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to be issued pursuant to exercise of a Stock Appreciation Right will be determined by the Administrator and will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. Otherwise, the Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">granted under the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.7pt 0pt 0pt;">
				<font style="margin:0.05pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stock Appreciation Right Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.7pt 0pt 0pt;">
				<font style="margin:0.05pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Expiration of Stock Appreciation Rights</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">A Stock Appreciation Right granted under the Plan will expire ten (10) years from the date of grant or such shorter term as may be provided in the Award Agreement, as determined by the Administrator, in its sole discretion. Notwithstanding the foregoing, the rules of Section 6(d) relating to exercise also will apply to Stock Appreciation Rights.</font></p></td></tr></table></div>
		<p style="margin:0.4pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.65pt 0pt 0pt;">
				<font style="margin:0.05pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25pt 0pt 0pt;"> (f)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Payment of Stock Appreciation Right Amount</font><font style="display: inline;font-size:12pt;color:#000000;">. Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment from the Company in an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amount determined by multiplying:</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:114pt;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 18.05pt 0pt 0pt;">
				<font style="margin:0pt 18.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;text-justify:inter-ideograph;;;padding:0pt 19.9pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">difference</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">between</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Fair</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Market</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Share</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date of exercise over the exercise price; times</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:115pt;"><p style="width:115pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:0pt;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:left;text-justify:inter-ideograph;;;padding:0pt 22.9pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">number</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">respect</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">which</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Stock</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Appreciation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Right</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is </font><font style="display: inline;color:#000000;">exercised.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">At</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">discretion</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Administrator,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">payment</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">upon</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Stock</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Appreciation</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Right</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">exercise may be in cash, in Shares of equivalent value, or in some combination thereof.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">13</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 10.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Performance</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Units</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">and</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Performance</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Shares</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Grant of Performance Units/Shares</font><font style="display: inline;font-size:12pt;color:#000000;">. Performance Units and Performance Shares may be granted to Service Providers at any time and from time to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete discretion in determining the number of Performance Units and Performance Shares granted to each Participant.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Value of Performance Units/Shares</font><font style="display: inline;font-size:12pt;color:#000000;">. Each Performance Unit will have an initial value that is established by the Administrator on or before the date of grant.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Each</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Performance</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Share will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">initial value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">equal to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Fair</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Market</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Value of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a Share</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on the date</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of </font><font style="display: inline;font-size:12pt;color:#000000;">grant.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.65pt 0pt 0pt;">
				<font style="margin:4.5pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Performance Objectives and Other Terms</font><font style="display: inline;font-size:12pt;color:#000000;">. The Administrator will set performance</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">objectives</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">vesting</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provisions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(including,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">without</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">limitation,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">continued</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">status</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as a Service Provider) in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The time period during which the performance objectives or other vesting provisions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">must be met will be called the &#x201C;Performance Period.&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Each Award of Performance Units/Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will be evidenced by an Award Agreement that will specify the Performance Period, and such other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terms and conditions as the Administrator, in its sole discretion, will determine. The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Earning of Performance Units/Shares</font><font style="display: inline;font-size:12pt;color:#000000;">. After the applicable Performance</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Form and Timing of Payment of Performance Units/Shares</font><font style="display: inline;font-size:12pt;color:#000000;">. Payment of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">earned Performance Units/Shares will be made as soon as practicable after the expiration of the applicable Performance Period. The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25pt 0pt 0pt;"> (f)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Cancellation of Performance Units/Shares</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited to the Company, and again will be available for grant under the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 11.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Outside Director Limitations</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">No Outside Director may be paid, issued or granted, in any Fiscal Year, cash compensation and equity awards (including any Awards issued under this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan) with an aggregate value greater than $500,000, increased to $1,000,000 in the Fiscal Year an Outside</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Director</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">initially</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">becomes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">member</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Board</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">each</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">equity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">award</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">based on its grant date fair value (determined in accordance with U.S. generally accepted accounting principles)). </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">14</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 5.7pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;font-size:12pt;color:#000000;">Any cash compensation paid or Awards granted to an individual for his or her services as an Employee, or for his or her services as a Consultant (other than as an Outside Director), will not count for purposes of the limitation under this Section 11.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 12.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Leaves of Absence/Transfer Between Locations</font><font style="display: inline;font-size:12pt;color:#000000;">. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, or any Subsidiary.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">For purposes of Incentive Stock Options, no such leave</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may exceed three (3) months, unless reemployment upon expiration of such leave is guaranteed by statute or contract.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If reemployment upon expiration of a leave of absence approved by the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Company is not so guaranteed, then six (6) months following the first (1st) day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 13.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Transferability of Awards</font><font style="display: inline;font-size:12pt;color:#000000;">. Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
				<font style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 14.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Adjustments;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Dissolution</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">or</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Liquidation;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Merger</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">or</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Change</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">in</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Control</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.6pt 0pt 0pt;">
				<font style="margin:0.05pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Adjustments</font><font style="display: inline;font-size:12pt;color:#000000;">. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award, and the numerical Share limits in Section 3 of the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.55pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.65pt 0pt 0pt;">
				<font style="margin:4.5pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Dissolution or Liquidation</font><font style="display: inline;font-size:12pt;color:#000000;">. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Change in Control</font><font style="display: inline;font-size:12pt;color:#000000;">. In the event of a merger of the Company with or into another</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">corporation</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">other</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entity</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Change</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Control,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">each</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">outstanding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Award</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">treated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as the Administrator determines subject to the restriction in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the following</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">paragraph, including, without limitation, that each Award be assumed or an equivalent option or right substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. The Administrator will not be required to treat all Awards or Participants similarly in the transaction.</font></p></td></tr></table></div>
		<p style="margin:3pt 5.6pt 0pt 5.95pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">In the event that the successor corporation does not assume or substitute for the Award, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares as to which such Awards would not otherwise be vested </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">15</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:3pt 5.6pt 0pt 5.95pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;">or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, unless specifically provided otherwise under the applicable Award Agreement, a Company policy applicable to the Participant,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or other written agreement between the Participant and the Company, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met. In addition, if an Option or Stock Appreciation Right is not assumed or substituted in the event of a Change in Control, the Administrator will notify the Participant in writing or electronically that the Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right will terminate upon the expiration of such period.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.6pt 0pt 5.9pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">For the purposes of this subsection (c), an Award will be considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or property)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">received in the Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares);</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">provided,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">however,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">if</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">such</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">consideration</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">received</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Change</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Control</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">not</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Option or Stock Appreciation Right</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or upon the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">payout of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Restricted Stock Unit, Performance Unit or Performance Share, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the Change in Control.</font>
		</p>
		<p style="margin:0.45pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.6pt 0pt 5.95pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Notwithstanding</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">anything</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">this</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Section</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">14(c)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">contrary,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">an</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Award</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">vests,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&#x2019;s consent; provided, however, a modification to such performance goals only to reflect the successor corporation&#x2019;s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.7pt 0pt 0pt;">
				<font style="margin:0.05pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Outside Director Awards</font><font style="display: inline;font-size:12pt;color:#000000;">. With respect to Awards granted to an Outside Director, in the event of a Change in Control,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Participant will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such Award, including those Shares which would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, unless specifically provided otherwise under the applicable Award Agreement, a Company policy applicable to the Participant, or other written agreement between the Participant and the Company, all performance goals or other vesting criteria will be deemed</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">achieved at one hundred percent (100%) of target levels and all other terms and conditions met.</font></p></td></tr></table></div></div><div style="margin-left:54pt;margin-right:54pt;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">16</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;"> 15.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Tax</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Withholding Requirements</font><font style="display: inline;font-size:12pt;color:#000000;">. Prior to the delivery of any Shares or cash pursuant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Award</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exercise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">thereof)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">earlier</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">time</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">tax</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">withholding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">obligations</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">are due, the Company will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have the power and the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">right</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy U.S. federal, state, or local taxes, non-U.S. taxes, or other taxes (including the Participant&#x2019;s FICA obligation) required to be withheld with respect to such Award (or exercise thereof).</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.65pt 0pt 0pt;">
				<font style="margin:0pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Withholding Arrangements</font><font style="display: inline;font-size:12pt;color:#000000;">. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">tax</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">withholding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">obligation,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">whole</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">part</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(without</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">limitation)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">paying</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">cash,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(ii)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">electing</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">have</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Company withhold</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">otherwise</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">deliverable</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">cash</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Shares</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">having</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">fair</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">market value not in excess of the maximum statutory amount required to be withheld, or (iii) delivering to the Company already-owned Shares having a fair market value not in excess of the maximum statutory amount required to be withheld. The fair market value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 0pt 0pt;">
				<font style="margin:0pt 5.6pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Compliance With Section 409A</font><font style="display: inline;font-size:12pt;color:#000000;">. Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Section 409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A, except as otherwise determined in the sole discretion of the Administrator. The Plan and each Award Agreement under the Plan is intended to meet the requirements of Section 409A and will be construed and interpreted in accordance with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such intent, except as otherwise determined in the sole discretion of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Administrator.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">To</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">extent that an Award or payment, or the settlement or deferral thereof, is subject to Section 409A the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Section 409A, such that the grant, payment, settlement or deferral will not be subject to the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">additional tax or interest applicable under Section 409A.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">In no event will the Company (or any Parent or Subsidiary of the Company, as applicable) reimburse a Participant for any taxes imposed</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or other costs incurred as a result of Section 409A.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.75pt 0pt 0pt;">
				<font style="margin:0.05pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 16.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">No Effect on Employment or Service</font><font style="display: inline;font-size:12pt;color:#000000;">. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant&#x2019;s relationship as a Service Provider, nor will they interfere in any way with the Participant&#x2019;s right or the right of the Company (or any Parent or Subsidiary of the Company) to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.6pt 12pt 0pt;">
				<font style="margin:0pt 5.6pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 17.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Date of Grant</font><font style="display: inline;font-size:12pt;color:#000000;">. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.</font></p></td></tr></table></div></div><div style="margin-left:54pt;margin-right:54pt;">
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.65pt 0pt 0pt;">
				<font style="margin:3pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 18.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Term of Plan</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to Section 23 of the Plan, the Plan will become effective upon the later to occur of (i) its adoption by the Board or (ii) the business day immediately prior to the Registration Date.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">It will continue in effect for a term of ten (10) years from the date adopted by the Board, unless terminated earlier under Section 19 of the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">17</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 19.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Amendment</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">and</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Termination</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">the</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;"> Plan</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Amendment and Termination</font><font style="display: inline;font-size:12pt;color:#000000;">. The Administrator may at any time amend, alter, suspend or terminate the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stockholder Approval</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Effect of Amendment or Termination</font><font style="display: inline;font-size:12pt;color:#000000;">. No amendment, alteration, suspension or termination of the Plan will materially impair</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the rights of any Participant, unless</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator&#x2019;s ability</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to exercise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the powers granted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to it hereunder with respect</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Awards granted under the Plan prior to the date of such termination.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 20.</font>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Conditions</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Upon</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Issuance</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;"> Shares</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.7pt 0pt 0pt;">
				<font style="margin:0.05pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Legal Compliance</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares will not be issued pursuant to an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such </font><font style="display: inline;font-size:12pt;color:#000000;">compliance.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.65pt 0pt 0pt;">
				<font style="margin:4.5pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Investment Representations</font><font style="display: inline;font-size:12pt;color:#000000;">. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.7pt 0pt 0pt;">
				<font style="margin:0pt 5.7pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 21.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Inability to Obtain Authority</font><font style="display: inline;font-size:12pt;color:#000000;">. The inability of the Company to obtain authority from any regulatory body having jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any U.S. federal or state law, any non-U.S.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">law, or the rules and regulations of the Securities and Exchange Commission, the stock exchange on which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company&#x2019;s counsel to be necessary or advisable for the issuance and sale of any Shares hereunder, will relieve the Company</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification or rule compliance will not have been obtained.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3pt 5.65pt 0pt 0pt;">
				<font style="margin:3pt 5.65pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 22.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Clawback</font><font style="display: inline;font-size:12pt;color:#000000;">. The Administrator may specify in an Award Agreement that the Participant&#x2019;s rights, payments, and/or benefits with respect to an Award will be subject to reduction, cancellation, forfeiture, and/or recoupment upon the occurrence of certain specified events, in addition to any applicable vesting, performance or other conditions and restrictions of an Award. Notwithstanding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provisions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">contrary</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Award</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">granted</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shall be subject to the Company&#x2019;s clawback policy (if any) as may be established and/or amended from time to time. The Board may require a Participant to forfeit or return to and/or reimburse the Company all or a portion of the Award and/or Shares issued under the Award, any amounts paid under the Award, and any payments or proceeds paid or provided upon disposition of the Shares </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">18</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:3pt 5.65pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;font-size:12pt;color:#000000;">issued under the Award, pursuant to the terms of such Company policy or as necessary or appropriate to comply with Applicable Laws.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.75pt 0pt 0pt;">
				<font style="margin:0pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 23.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Stockholder Approval</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Plan will be subject to approval by the stockholders of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Company within twelve (12) months after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable </font><font style="display: inline;font-size:12pt;color:#000000;">Laws.</font></p></td></tr></table></div>
		<p style="margin:4.5pt 158.25pt 0pt 0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font><a name="Silk_Road_Medical___Form_of_Stock_Option"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">19</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>silk-20231231xex10_6.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:19:57 PM-->
<html>
	<head>
		<title>
			Exhibit 10.6 2023
		</title>
	</head>
	<body><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3pt 0pt 0pt 158.4pt;text-align:right;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;font-size:10pt;">Exhibit </font><font style="display: inline;font-weight:bold;font-size:10pt;">10</font><font style="display: inline;font-weight:bold;font-size:10pt;">.</font><font style="display: inline;font-weight:bold;font-size:10pt;">6</font><font style="display: inline;font-weight:bold;font-size:10pt;"> &nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:3pt 158.25pt 0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:4.5pt 158.25pt 0pt 158.2pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<a name="Silk_Road_Medical___Form_of_Stock_Option"></a><font style="display: inline;font-weight:bold;font-size:12pt;">SILK</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">ROAD</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">MEDICAL,</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INC.</font>
		</p>
		<p style="margin:0pt 158.2pt 0pt 158.35pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">2019</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">EQUITY</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INCENTIVE</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">PLAN STOCK OPTION AGREEMENT</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.8pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Unless</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">otherwise</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">defined</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">herein,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">terms</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">defined</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Silk</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Road</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Medical,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Inc. 2019</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Equity Incentive Plan (the &#x201C;Plan&#x201D;) will have the same defined meanings in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the &#x201C;Notice of Grant&#x201D;), the Terms and Conditions of Stock Option Grant attached hereto as </font><font style="display: inline;text-decoration:underline;">Exhibit A</font><font style="display: inline;">, the Exercise Notice attached hereto as </font><font style="display: inline;text-decoration:underline;">Exhibit B</font><font style="display: inline;">, and all other exhibits and appendices attached hereto (all together, the &#x201C;Option </font><font style="display: inline;">Agreement&#x201D;).</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">NOTICE</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">OF</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">STOCK</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">OPTION</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;"> GRANT</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Participant:</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">Address:</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.9pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The undersigned Participant has been granted an Option to purchase Common Stock of Silk Road Medical, Inc. (the &#x201C;Company&#x201D;), subject to the terms and conditions of the Plan and this Option Agreement, as follows:</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:50.4pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:207.00pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Grant</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Number:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:193.50pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:207.00pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Date of Grant:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:193.50pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:207.00pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Vesting Commencement Date:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:193.50pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:207.00pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Number of Shares Granted:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:193.50pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:207.00pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Exercise Price per Share (in U.S. Dollars):</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:193.50pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:207.00pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Total</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Exercise</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Price(in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">U.S.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Dollars):</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:193.50pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:207.00pt;height:18.85pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:13.75pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Type</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of </font><font style="display: inline;">Option:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:193.50pt;height:18.85pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:13.75pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:10pt;">_____&nbsp; </font><font style="display: inline;">Incentive Stock Option</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:207.00pt;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:193.50pt;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:10pt;">_____&nbsp; </font><font style="display: inline;">Nonstatutory Stock Option</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:207.00pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Term/Expiration Date:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:193.50pt;padding:0pt 6.5pt">
					<p style="margin:0.5pt 0pt 0pt;line-height:150%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:4.5pt 95.95pt 0pt 42pt;line-height:186.67%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;text-decoration:underline;">Vesting Schedule</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Subject</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">accelerated</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">vesting</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">as</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">set</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">forth</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">below</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Plan,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">this</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Option</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">will</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">be exercisable, in whole or in part, in accordance with the following schedule:</font>
		</p>
		<p style="margin:0.45pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">[</font><font style="display: inline;color:#000000;">Twenty-five percent (25%) of the Shares subject to the Option shall vest on the one (1) year anniversary</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Vesting</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Commencement</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Date,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">one forty-eighth (1/48th) of the Shares subject</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3.4pt 5.8pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3.4pt 5.8pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;color:#000000;">to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to Participant continuing to be a Service Provider through each such date.]</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 42pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;text-decoration:underline;">Termination</font><font style="display: inline;text-decoration:underline;">&nbsp;</font><font style="display: inline;text-decoration:underline;">Period</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.8pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">This Option will be exercisable for </font><font style="display: inline;color:#000000;">[three (3) months]</font><font style="display: inline;color:#000000;"> after Participant ceases to be a Service Provider, unless such termination is due to Participant&#x2019;s death or Disability, in which case this Option will</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">be exercisable </font><font style="display: inline;color:#000000;">for [twelve (12) months]</font><font style="display: inline;color:#000000;"> after Participant ceases to be a Service Provider. Notwithstanding the foregoing sentence, in no event may this Option be exercised after the Term/Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 14 of the Plan.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.8pt 0pt 5.95pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">By Participant&#x2019;s signature and the signature of the representative of the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Company below, Participant and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan and this Option Agreement, including the Terms and Conditions of Stock Option Grant, attached hereto as </font><font style="display: inline;text-decoration:underline;">Exhibit A</font><font style="display: inline;">, all of which are made a part of this document.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant acknowledges receipt of a copy of the Plan.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant has reviewed the Plan and this Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option Agreement, and fully understands all provisions of the Plan and this Option Agreement.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and the Option Agreement.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant further agrees to notify the Company upon any change in the residence address indicated below.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 13pt">
			<font style="display: inline;font-size:13pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 13pt">
			<font style="display: inline;font-size:13pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 13pt">
			<font style="display: inline;font-size:13pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:5.95pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:228.95pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">PARTICIPANT</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:257.40pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">SILK</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">ROAD</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">MEDICAL,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:228.95pt;border-bottom:1pt solid #000000 ;height:27.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;height:27.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:257.40pt;border-bottom:1pt solid #000000 ;height:27.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:228.95pt;border-top:1pt solid #000000 ;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Signature</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:257.40pt;border-top:1pt solid #000000 ;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Signature</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:228.95pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:257.40pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:228.95pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Print</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Name</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:257.40pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Print</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Name</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:228.95pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:257.40pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:228.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:257.40pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Title</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Address:</font>
		</p>
		<p style="margin:0.25pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;"></font>
		</p>
		<p style="margin:4.5pt 158.25pt 0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">EXHIBIT</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">A</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 51.95pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">TERMS</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">AND</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">CONDITIONS</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">OF</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">STOCK</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">OPTION</font><font style="display: inline;font-weight:bold;font-size:12pt;"> GRANT</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:42pt;"><p style="width:42pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 1.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Grant</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of </font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">The Company hereby grants to the individual (&#x201C;Participant&#x201D;) named in the Notice of Stock Option Grant of this Option Agreement (the &#x201C;Notice of Grant&#x201D;) an option (the &#x201C;Option&#x201D;) to purchase the number of Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the &#x201C;Exercise Price&#x201D;), subject to all of the terms and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">conditions in this Option Agreement and the Plan, which is incorporated herein by this reference. Subject to Section 19(c) of the Plan, in the event of a conflict between the terms and conditions of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terms</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">conditions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Agreement,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terms</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">conditions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan will prevail.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.9pt 0pt 0pt;">
				<font style="margin:4.5pt 5.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">For U.S. taxpayers, the Option will be designated as either an Incentive Stock Option (&#x201C;ISO&#x201D;) or a Nonstatutory Stock Option (&#x201C;NSO&#x201D;).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If designated in the Notice of Grant as an ISO, this Option is intended to qualify as an ISO under Section 422 of the Internal Revenue Code of 1986, as amended (the &#x201C;Code&#x201D;).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">However, if this Option is intended to be an ISO, to the extent that it exceeds the $100,000 rule of Code Section 422(d) it will be treated as an NSO.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Further, if for any reason this Option (or portion thereof) will not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a NSO granted under the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">In no event will the Administrator, the Company or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify for any reason as an ISO.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:78pt;"><p style="width:78pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (c)</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">For</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">non-U.S.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">taxpayers,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">designated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">an</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">NSO.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 2.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Vesting Schedule</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Except as provided in Section </font><a href="#_bookmark0"><font style="display: inline;font-size:12pt;color:#000000;">3</font></a><font style="display: inline;font-size:12pt;color:#000000;">, the Option awarded by this Option Agreement will vest in accordance with the vesting provisions set forth in the Notice of Grant.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares subject to this Option that are scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in accordance with any of the provisions of this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option Agreement, unless Participant will have been continuously a Service Provider from the Date of Grant until the date such vesting occurs.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 3.</font>
			<a name="_bookmark0"></a><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Administrator Discretion</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Option at any time, subject to the terms of the Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If so accelerated, such Option will be considered as having vested</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as of the date specified by the Administrator.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:42pt;"><p style="width:42pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 4.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exercise</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;"> Option</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Right to Exercise</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Option may be exercised only within the term set out in the Notice of Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option Agreement.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3.4pt 5.8pt 0pt 0pt;">
				<font style="margin:3.4pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Method of Exercise</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Option is exercisable by delivery of an exercise notice (the &#x201C;Exercise Notice&#x201D;) in the form attached as </font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exhibit B</font><font style="display: inline;font-size:12pt;color:#000000;"> to the Notice of Grant or in a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">manner and pursuant to such procedures as the Administrator may determine, which will state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised (the &#x201C;Exercised Shares&#x201D;), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Exercise Notice will be completed by Participant and delivered to the Company.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Exercise Notice will be accompanied by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">payment</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">aggregate</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Exercise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Price</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">all</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Exercised</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Tax</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Obligations</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(as defined in Section 6(a)).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Option will be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.9pt 0pt 0pt;">
				<font style="margin:0pt 5.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25.95pt 0pt 0pt;"> 5.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Method of Payment</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Payment of the aggregate Exercise Price will be by any of the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">following, or a combination thereof, at the election of Participant:</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (a)</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">cash</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">U.S. </font><font style="display: inline;font-size:12pt;color:#000000;">dollars;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (b)</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">check</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">designated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">U.S.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">dollars;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.9pt 0pt 0pt;">
				<font style="margin:0pt 5.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.8pt 0pt 0pt;">
				<font style="margin:0.05pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">if Participant is a U.S. employee, surrender of other Shares which have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the Exercised Shares and that are owned free and clear of any liens, claims, encumbrances, or security interests, provided that accepting such Shares, in the sole discretion of the Administrator, will not result in any adverse accounting consequences to the Company.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:42pt;"><p style="width:42pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
				<font style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 6.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Tax</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Obligations</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.8pt 0pt 0pt;">
				<font style="margin:0.05pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Responsibility for Taxes</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant acknowledges that, regardless of any action taken by the Company or, if different, Participant&#x2019;s employer (the &#x201C;Employer&#x201D;) or Parent or Subsidiary to which Participant is providing services (together, the Company, Employer and/or Parent or Subsidiary to which the Participant is providing services, the &#x201C;Service Recipient&#x201D;), the ultimate liability for any tax and/or social insurance liability obligations and requirements in connection with the Option, including, without limitation, (i) all federal, state, and local taxes (including</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Participant&#x2019;s Federal</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Insurance Contributions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Act (FICA)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">obligation)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that are</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">required to be withheld by the Company or the Service Recipient or other payment of tax-related items</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">related to Participant&#x2019;s participation in the Plan and legally applicable to Participant, (ii) the Participant&#x2019;s and, to the extent required by the Company (or Service Recipient), the Company&#x2019;s (or Service Recipient&#x2019;s) fringe benefit tax liability, if any, associated with the grant, vesting, or exercise of the Option or sale of Shares, and (iii)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any other Company (or Service Recipient) taxes the responsibility for which the Participant has, or has agreed to bear, with respect to the Option (or exercise thereof or issuance of Shares thereunder) (collectively, the &#x201C;Tax Obligations&#x201D;), is and remains Participant&#x2019;s responsibility and may exceed the amount actually withheld by the Company</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or the Service Recipient.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant further acknowledges that the Company and/or the Service Recipient</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(A)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">make</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">no</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">representations</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">undertakings</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">regarding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">treatment</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Tax</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3.4pt 5.85pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3.4pt 5.85pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">Obligations in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends or other distributions, and (B) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate Participant&#x2019;s liability for Tax Obligations or achieve any particular tax result.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Further, if Participant is subject to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Tax Obligations in more than one jurisdiction between the Date of Grant and the date</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of any relevant taxable or tax withholding event, as applicable, Participant acknowledges that the Company and/or the Service Recipient (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the applicable taxable event, Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Tax Withholding</font><font style="display: inline;font-size:12pt;color:#000000;">. When the Option is exercised, Participant generally will recognize</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">immediate</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">U.S.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">taxable</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">income</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">U.S.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">taxpayer.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">non-</font></p></td></tr></table></div>
		<p style="margin:0pt 5.8pt 0pt 5.95pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">U.S. taxpayer, Participant will be subject to applicable taxes in his or her jurisdiction.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Pursuant to such procedures as the Administrator may specify from time to time, the Company and/or Service Recipient shall withhold the amount required to be withheld for the payment of Tax Obligations.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The Administrator, in its sole discretion and pursuant to such procedures</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">as it may specify from time to time, may permit Participant to satisfy such Tax Obligations, in whole or in part (without limitation), if permissible by applicable local law, by (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable Shares having a fair market value equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">accounting consequences), (iii) withholding the amount of such Tax Obligations from Participant&#x2019;s wages or other cash compensation paid to Participant by the Company and/or the Service Recipient, (iv)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">delivering to the Company already vested and owned Shares</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">having</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">fair</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">market</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">value</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">equal</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">such</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Tax</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Obligations,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(v)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">selling</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">sufficient</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">number</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of such Shares</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">otherwise deliverable</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to Participant through such</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">means as the Company may determine in its sole discretion (whether through a broker or otherwise) equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial accounting consequences).</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">To the extent determined appropriate by the Company in its discretion, it will have the right (but not the obligation) to satisfy any Tax Obligations by reducing the number of Shares otherwise deliverable to Participant.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Further, if Participant is subject to tax in more than one jurisdiction between the Date of Grant and a date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges and agrees that the Company and/or the Service Recipient (and/or former employer, as applicable) may be required to withhold or account for tax in more than one jurisdiction.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the Option exercise, Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the Shares if such amounts are not delivered at the time of exercise.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (c)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Notice of Disqualifying Disposition of ISO Shares</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">pursuant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">ISO</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">on</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">before</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">later</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(i)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">two</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(2)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">years</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">after</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Date</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3.4pt 5.8pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3.4pt 5.8pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">Grant, or (ii) the date one (1) year after the date of exercise, Participant will immediately notify the Company in writing of such disposition.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant agrees that Participant may be subject to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">income tax withholding by the Company on the compensation income recognized by Participant.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Code Section 409A</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Under Code Section 409A, a stock right (such as the Option) that vests after December 31, 2004 (or that vested on or prior to such date but which was materially modified after October 3, 2004) that was granted with a per share exercise price that is determined by the Internal Revenue Service (the &#x201C;IRS&#x201D;) to be less than the fair market value of an underlying share on the date of grant (a &#x201C;discount option&#x201D;) may be considered &#x201C;deferred compensation.&#x201D;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">A stock right that is a &#x201C;discount option&#x201D; may result in (i) income recognition by the recipient of the stock right prior to the exercise of the stock right, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The &#x201C;discount option&#x201D; may also result in additional state income, penalty and interest tax to the recipient of the stock right. Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the fair market value of a Share on the date of grant in a later examination.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the fair market value of a Share on the date of grant, Participant shall be solely responsible for Participant&#x2019;s costs related to such a </font><font style="display: inline;font-size:12pt;color:#000000;">determination.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 7.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Rights as Stockholder</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book entry form) will have been issued, recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">brokerage account).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">After such issuance, recordation, and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.8pt 0pt 0pt;">
				<font style="margin:0.05pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 27pt 0pt 0pt;"> 8.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">No Guarantee of Continued Service</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER, WHICH</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW IS AT THE WILL OF THE COMPANY (OR THE SERVICE RECIPIENT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">WITH PARTICIPANT&#x2019;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE SERVICE RECIPIENT) TO TERMINATE PARTICIPANT&#x2019;S RELATIONSHIP AS A SERVICE</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">PROVIDER, SUBJECT TO APPLICABLE LAW, WHICH TERMINATION, UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW, MAY BE AT ANY TIME, WITH OR WITHOUT CAUSE.</font></p></td></tr></table></div>
		<p style="margin:0.05pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3.4pt 5.85pt 0pt 0pt;">
				<font style="margin:3.4pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25.95pt 0pt 0pt;"> 9.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Nature of Grant</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">In accepting the Option, Participant acknowledges, understands and agrees that:</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.85pt 0pt 0pt;">
				<font style="margin:4.5pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (a)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past;</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.85pt 0pt 0pt;">
				<font style="margin:0.05pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (b)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">all decisions with respect to future option or other grants, if any, will be at the sole discretion of the Company;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:78pt;"><p style="width:78pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (c)</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">voluntarily</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">participating</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.9pt 0pt 0pt;">
				<font style="margin:0pt 5.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> (d)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">the Option and any Shares acquired under the Plan are not intended to replace any pension rights or compensation;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (e)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">the Option and Shares acquired under the Plan and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.9pt 0pt 0pt;">
				<font style="margin:0pt 5.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> (f)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">the future value of the Shares underlying the Option is unknown, indeterminable, and cannot be predicted with certainty;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (g)</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">underlying</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">do</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">increase</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">value,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">no</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 5.95pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">value;</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;"><p style="width:77pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 25.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> (h)</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exercises</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acquires</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Shares,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 5.95pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Shares</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">may</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">increase</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">decrease</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">value,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">even</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">below</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Exercise</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Price;</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 27pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">for purposes of the Option, Participant&#x2019;s engagement as a Service Provider will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">considered</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terminated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">no</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">longer</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">actively</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">providing</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">services</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Company or any Parent or Subsidiary (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Service</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Provider</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">terms</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant&#x2019;s</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">employment</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">service</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">agreement,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any),</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">unless otherwise expressly provided in this Option Agreement (including by reference in the Notice of Grant to other arrangements or contracts) or determined by the Administrator, (i) Participant&#x2019;s right to vest in the Option under the Plan, if any, will terminate as of such date and will not be extended</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by any notice period (</font><font style="display: inline;font-style:italic;font-size:12pt;color:#000000;">e.g</font><font style="display: inline;font-size:12pt;color:#000000;">., Participant&#x2019;s period of service would not include any contractual notice period or any period of &#x201C;garden leave&#x201D; or similar period mandated under employment laws in the jurisdiction where Participant is a Service Provider or Participant&#x2019;s employment or service agreement, if any, unless Participant is providing bona fide services during such time);</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and (ii) the period (if any) during which Participant may exercise the Option after such termination of Participant&#x2019;s engagement as a Service Provider will commence on the date Participant ceases to actively</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provide</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">services</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">extended</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">notice</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">period</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">mandated</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">employment laws in the jurisdiction where Participant is employed or terms of Participant&#x2019;s engagement agreement, if any; the Administrator shall have the exclusive discretion to determine when Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">no</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">longer actively</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">providing services</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for purposes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of his</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">her</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option grant </font><font style="display: inline;font-size:12pt;color:#000000;">(including</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">whether Participant may still be considered to be providing services while on a leave of absence and consistent with local law);</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 25pt 0pt 0pt;"> (j)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">unless otherwise provided in the Plan or by the Copmpany in its discretion,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Option and the benefits evidenced by this Option Agreement do not create any entitlement to have the </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 5.85pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;font-size:12pt;color:#000000;">Option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and</font></p></td></tr></table></div>
		<p style="margin:0.05pt 0pt 0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:72pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.9pt 0pt 0pt;">
				<font style="margin:4.5pt 5.9pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22.95pt 0pt 0pt;"> (k)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">following</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provisions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">apply</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">only</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">providing</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">services</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">outside the United States:</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6.5pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:4.5pt 5.85pt 0pt 0pt;">
				<font style="margin:4.5pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> (i)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">the Option and the Shares subject to the Option are not part of normal or expected compensation or salary for any purpose;</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 24pt 0pt 0pt;"> (ii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">acknowledges</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">agrees</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">no</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Service</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Recipient</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be liable for any foreign exchange rate fluctuation between Participant&#x2019;s local currency and the United States</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Dollar</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">that</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">affect</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">value</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">amounts</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">due</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">pursuant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to the exercise of the Option or the subsequent sale of any Shares acquired upon exercise; and</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> (iii)</font>
			<font style="display: inline;font-size:12pt;color:#000000;">no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from the termination of Participant&#x2019;s engagement as a Service Provider (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and in consideration of the grant of the Option to which Participant is otherwise not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">entitled, Participant irrevocably agrees</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">never</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to institute any claim against any Service Recipient, waives his or her ability, if any, to bring any such claim, and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">releases</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">each</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Service</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Recipient</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">from</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">claim;</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">if,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">notwithstanding</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">foregoing,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.85pt 0pt 0pt;">
				<font style="margin:0.05pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 10.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">No Advice Regarding Grant</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#x2019;s participation in the Plan, or Participant&#x2019;s acquisition or sale of the underlying Shares.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant is hereby advised to consult with his or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.85pt 0pt 0pt;">
				<font style="margin:0.05pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 11.</font>
			<font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;color:#000000;">Data Privacy</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;color:#000000;">Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant&#x2019;s personal data as described in this Option Agreement and any other Option grant materials by and among, as applicable, the Employer or other Service Recipient, the Company and any Parent or Subsidiary for the exclusive purpose of implementing, administering and managing Participant&#x2019;s participation in the Plan.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3.4pt 5.8pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3.4pt 5.8pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant understands that the Company and the Employer may hold certain personal information about Participant, including, but not limited to, Participant&#x2019;s name, home address</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#x2019;s favor (&#x201C;Data&#x201D;), for the exclusive purpose of implementing, administering and managing the Plan.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.75pt 0pt 5.95pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant understands that Data will be transferred to a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration, and management of the Plan.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipient&#x2019;s country of operation (e.g., the United States) may have different data privacy laws and protections than Participant&#x2019;s country.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purposes of implementing, administering</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">and</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">managing</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant&#x2019;s</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">participation</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">in</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">the</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Plan.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">understands</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">that Data will be held only as long as is necessary to implement, administer and manage Participant&#x2019;s participation in the Plan.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Participant understands that if he or she resides outside the United States, he or she may, at any time, view Data, request additional information about the storage</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">If Participant does not consent, or if Participant</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">later seeks to revoke his or her consent, his or her engagement as a Service Provider and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing Participant&#x2019;s consent is that the Company would not be able to grant Participant Options or other equity awards or administer or maintain such awards.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant&#x2019;s ability to participate in the Plan.</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">For more information on the consequences of Participant&#x2019;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.</font>
		</p>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.75pt 0pt 0pt;">
				<font style="margin:0.05pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 12.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Address for Notices</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Any notice to be given to the Company under the terms of this Option Agreement will be addressed to the Company at Silk Road Medical, Inc., 1213 Innsbruck</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Dr., Sunnyvale, CA 94089, or at such other address as the Company may hereafter designate in </font><font style="display: inline;font-size:12pt;color:#000000;">writing.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;;;padding:0pt 22pt 0pt 0pt;"> 13.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Non-Transferability of Option</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Participant only by Participant.</font></p></td></tr></table></div></div><div style="margin-left:54pt;margin-right:54pt;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:3.4pt 5.8pt 0pt 0pt;">
				<font style="margin:3.4pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;;;padding:0pt 22pt 0pt 0pt;"> 14.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Successors</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">and</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Assigns</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Company</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">may</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">assign</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">its</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rights</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">under</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option Agreement to single or multiple assignees, and this Option Agreement shall inure to the benefit of the successors and assigns of the Company.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to the restrictions on transfer herein set forth, this Option Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The rights and obligations of Participant under this Option Agreement may only be assigned with the prior written consent of the Company.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 15.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Additional Conditions to Issuance of Stock</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If at any time the Company will determine, in its discretion, that the listing, registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal or non-U.S. law, the tax code and related regulations or under the rulings or regulations of the United States Securities and Exchange Commission or any other governmental regulatory body or the clearance, consent or approval of the United States Securities and Exchange Commission or any other governmental regulatory authority is necessary or desirable as a condition to the purchase by, or issuance of Shares, to Participant (or his or her estate) hereunder, such purchase or issuance will not occur unless and until such listing, registration,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">qualification,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">rule</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">compliance,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">clearance,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">consent</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">approval</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">have</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">been</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">completed, effected or obtained free of any conditions not acceptable to the Company.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Subject to the terms of the Option Agreement and the Plan, the Company shall not be required to issue any certificate or certificates for Shares hereunder prior to the lapse of such reasonable period of time following the date of exercise of the Option as the Administrator may establish from time to time for reasons of administrative convenience.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.85pt 0pt 0pt;">
				<font style="margin:0.05pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 16.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Language</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">If Participant has received this Option Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.8pt 0pt 0pt;">
				<font style="margin:0.05pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 17.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Interpretation</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Administrator will have the power to interpret the Plan and this Option Agreement and to adopt such rules for the administration, interpretation and application of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares subject to the Option have vested).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Neither the Administrator nor any person acting on behalf of the Administrator will be personally liable for any action, determination, or interpretation made in good faith with respect to the Plan or this Option </font><font style="display: inline;font-size:12pt;color:#000000;">Agreement.</font></p></td></tr></table></div>
		<p style="margin:0.4pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.85pt 0pt 0pt;">
				<font style="margin:0.05pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 18.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Electronic Delivery and Acceptance</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Company may, in its sole discretion,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">decide to deliver any documents related to the Option awarded under the Plan or future options that may be awarded under the Plan by electronic means or request Participant&#x2019;s consent to participate in the Plan by electronic means.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and maintained by the Company or a third party designated by the Company.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 12pt 0pt;">
				<font style="margin:0pt 5.8pt 12pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;;;padding:0pt 22pt 0pt 0pt;"> 19.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Captions</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Captions</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provided</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">herein</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">are</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">convenience</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">only</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">are</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">serve</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a basis for interpretation or construction of this Option Agreement.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:3.4pt 5.85pt 0pt 0pt;">
				<font style="margin:3.4pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;;;padding:0pt 22pt 0pt 0pt;"> 20.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Agreement Severable</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">In the event that any provision in this Option Agreement will be </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:3.4pt 5.85pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt"><font style="display: inline;font-size:12pt;color:#000000;">held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Option </font><font style="display: inline;font-size:12pt;color:#000000;">Agreement.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 21.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Amendment, Suspension or Termination of the Plan</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">By accepting this Option, Participant expressly warrants that he or she has received an Option under the Plan, and has</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">received, read, and understood a description of the Plan.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 22.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Governing Law and Venue</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Option Agreement will be governed by the laws of California, without giving effect to the conflict of law principles thereof.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">For purposes of litigating any dispute that arises under this Option or this Option Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted in the courts of Santa Clara County, California, or the United States federal courts for the Northern District of California, and no other courts, where this Option is made and/or to be performed.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 22pt 0pt 0pt;"> 23.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Country Addendum</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Notwithstanding any provisions in this Option Agreement, this Option shall be subject to any special terms and conditions set forth in an appendix (if any) to this Option Agreement for any country whose laws are applicable to Participant and this Option (as determined by the Administrator in its sole discretion) (the &#x201C;Country Addendum&#x201D;).</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Moreover, if Participant relocates to one of the countries included in the Country Addendum (if any), the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">reasons.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Country</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Addendum</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">(if</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any)</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">constitutes</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">part</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">this</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;"> Agreement.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.85pt 0pt 0pt;">
				<font style="margin:0.05pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 24.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Modifications to the Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Option Agreement constitutes the entire understanding of the parties on the subjects covered.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant expressly warrants that he or she is not accepting this Option Agreement in reliance on any promises, representations, or inducements other than those contained herein.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Modifications to this Option Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company. Notwithstanding anything to the contrary in the Plan or this Option Agreement, the Company reserves the right to revise this Option Agreement as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Code Section 409A</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or to otherwise avoid imposition of any additional tax or income recognition under Section 409A of the Code in connection with the Option.</font></p></td></tr></table></div>
		<p style="margin:0.4pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0.05pt 5.8pt 0pt 0pt;">
				<font style="margin:0.05pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 23pt 0pt 0pt;"> 25.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">No Waiver</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Either party&#x2019;s failure to enforce any provision or provisions of this Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">shall</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">not</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">in</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">way</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">construed</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">a</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">waiver</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">any</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">such</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provision</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">provisions, nor prevent that party from thereafter enforcing each and every other provision of this Option Agreement.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#x2019;s right to assert all other legal remedies available to it under the circumstances.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;"><p style="width:41pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 26.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Tax</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Consequences</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Participant</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">has</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">reviewed</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">with</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">his</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">or</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">her</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">own</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">tax</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">advisors</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 5.95pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">U.S.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">federal,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">state,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">local</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">non-U.S.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">tax</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">consequences</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">this</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">investment</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">transactions contemplated</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">this</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Option</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Agreement.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">With</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">respect</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">such</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">matters,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Participant</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">relies</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">solely</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">on</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:3.4pt 5.9pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:3.4pt 5.9pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">such advisors and not on any statements or representations of the Company or any of its agents, written or oral.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant understands that Participant (and not the Company) shall be responsible for Participant&#x2019;s own tax liability that may arise as a result of this investment or the transactions contemplated by this Option Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:4.5pt 158.25pt 0pt 158.2pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;"></font><font style="display: inline;">11</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:4.5pt 158.25pt 0pt 158.2pt;text-align:center;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;font-size:12pt;">SILK</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">ROAD</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">MEDICAL,</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INC.</font>
		</p>
		<p style="margin:0pt 158.2pt 0pt 158.35pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">2019</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">EQUITY</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INCENTIVE</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">PLAN STOCK OPTION AGREEMENT COUNTRY ADDENDUM</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 13pt">
			<font style="display: inline;font-weight:bold;font-size:13pt;">&#xFEFF;</font>
		</p>
		<p style="margin:10.85pt 0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">TERMS</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">AND</font><font style="display: inline;"> CONDITIONS</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.8pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">This Country Addendum includes additional terms and conditions that govern the Option granted to Participant</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">under</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Plan</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">if</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">works</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">one</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">countries</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">listed</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">below.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">If</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a citizen or resident of a country (or is considered as such for local law purposes) other than the one in which he or she is currently working or if Participant relocates to another country after receiving the Option, the Company will, in its discretion, determine the extent to which the terms and conditions contained herein will be applicable to Participant.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 5.95pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Certain capitalized terms used but not defined in this Country Addendum shall have the meanings</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">set forth in the Plan, and/or the Stock Option Agreement to which this Country Addendum is </font><font style="display: inline;">attached.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">NOTIFICATIONS</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 5.85pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;"><font style="display: inline;">This Country Addendum also includes notifications relating to exchange control and other issues of which Participant should be aware with respect to his or her participation in the Plan.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The information is based on the exchange control, securities and other laws in effect in the countries listed in this Country Addendum, as of </font></font><font style="display: inline;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;"></font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Such laws are often complex and change frequently.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">As a result, the Company strongly recommends that Participant not rely on the notifications herein as the only source of information relating to the consequences of his or her participation in the Plan because the information may be outdated when Participant exercises the Option or sells Shares acquired under the Plan.</font>
		</p>
		<p style="margin:0.4pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 5.85pt 0pt 5.95pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">In addition, the notifications are general in nature and may not apply to Participant&#x2019;s particular situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant is advised to seek appropriate professional advice as to how the relevant laws in Participant&#x2019;s country may apply to Participant&#x2019;s situation.</font>
		</p>
		<p style="margin:0.45pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0.05pt 5.8pt 0pt 5.95pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Finally, if Participant is a citizen or resident of a country other than the one in which Participant is currently</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">working</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">considered as such</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">local</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">law</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">purposes) or</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">if</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Participant</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">moves to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">another country after the Option is granted, the information contained herein may not be applicable to </font><font style="display: inline;">Participant.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:4.5pt 158.25pt 0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:4.5pt 158.25pt 0pt;text-align:center;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">EXHIBIT</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;text-decoration:underline;">B</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 158.25pt 0pt 158.2pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">SILK</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">ROAD</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">MEDICAL,</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INC.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 158.2pt 0pt 158.35pt;line-height:186.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">2019</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">EQUITY</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">INCENTIVE</font><font style="display: inline;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-size:12pt;">PLAN EXERCISE NOTICE</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 356.6pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Silk</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Road</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Medical,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Inc. 1213 Innsbruck Dr.</font>
		</p>
		<p style="margin:0pt 334.2pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Sunnyvale, CA 94089</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Attention:</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Stock</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Administration</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 13pt">
			<font style="display: inline;font-size:13pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:42pt;"><p style="width:42pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:10.85pt 0pt 0pt;">
				<font style="margin:10.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;"> 1.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:10.85pt 0pt 0pt;">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:89pt;"><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Exercise</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">of</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:190.05pt;text-align:left"><font style="display: inline;font-size:12pt;color:#000000;">Effective</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">today,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:39.6pt;text-align:left"><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;"></font><font style="display: inline;font-size:12pt;color:#000000;">,</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;"></font><font style="display: inline;font-size:12pt;color:#000000;">,</font><font style="display: inline;font-size:12pt;color:#000000;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font></font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:297.5pt;"><font style="display: inline;color:#000000;">undersigned</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(&#x201C;Purchaser&#x201D;)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">hereby</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">elects</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">purchase</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;color:#000000;">shares</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">&#x201C;Shares&#x201D;)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;line-height:12.8pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Common</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Stock</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Silk</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Road</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Medical,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Inc.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">&#x201C;Company&#x201D;)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">under</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">pursuant</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">2019</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Equity</font>
		</p>
		<p style="margin:0pt 0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:363.55pt;"><font style="display: inline;color:#000000;">Incentive</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Plan</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">&#x201C;Plan&#x201D;)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Stock</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Option</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Agreement,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">dated</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">including</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font></font>
		</p>
		<p style="margin:0pt 5.8pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;"><font style="display: inline;color:#000000;">Notice</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Grant,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Terms</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Conditions</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Stock</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Option</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Grant,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">exhibits</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">attached</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">thereto (the &#x201C;Option Agreement&#x201D;).</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The purchase price for the Shares will be $</font></font><font style="display: inline;color:#000000;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">as</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">required by the Option Agreement.</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 2.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Delivery of Payment</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Purchaser herewith delivers to the Company the full purchase price of the Shares and any Tax Obligations (as defined in Section 6(a) of the Option Agreement) to be paid in connection with the exercise of the Option.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 3.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Representations of Purchaser</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Purchaser acknowledges that Purchaser has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">their terms and conditions.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.8pt 0pt 0pt;">
				<font style="margin:0pt 5.8pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 4.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Rights as Stockholder</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Until the issuance (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company) of the Shares, no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to the Option, notwithstanding the exercise of the Option.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The Shares so acquired will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">issued</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Purchaser</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">soon</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">as</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">practicable</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">after</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">exercise</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">No</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">adjustment</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">will</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">be made for a dividend or other right</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">for which the record date is</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">prior</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">to the</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">date of</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">issuance, except as provided in Section 14 of the Plan.</font></p></td></tr></table></div>
		<p style="margin:0.45pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:6pt;"><p style="width:6pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 5.85pt 0pt 0pt;">
				<font style="margin:0pt 5.85pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 26pt 0pt 0pt;"> 5.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Tax Consultation</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Purchaser understands that Purchaser may suffer adverse tax consequences as a result of Purchaser&#x2019;s purchase or disposition of the Shares.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Purchaser represents that Purchaser has consulted with any tax consultants Purchaser deems advisable in connection with the purchase or disposition of the Shares and that Purchaser is not relying on the Company for any tax advice.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:54pt;margin-right:54pt;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;"><p style="width:5pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:3.4pt 5.75pt 0pt 0pt;">
				<font style="margin:3.4pt 5.75pt 0pt 0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:12pt;text-align:justify;text-justify:inter-ideograph;;;padding:0pt 27pt 0pt 0pt;"> 6.</font>
			<font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Entire</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Agreement;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Governing</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;text-decoration:underline;color:#000000;">Law</font><font style="display: inline;font-size:12pt;color:#000000;">.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">The</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Plan</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">and</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Option</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">Agreement</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">are</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">incorporated herein by reference.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Exercise Notice, the Plan and the Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Purchaser with respect to the subject matter hereof, and may not be modified adversely to the Purchaser&#x2019;s interest except by means of a writing signed by the Company and Purchaser.</font><font style="display: inline;font-size:12pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:12pt;color:#000000;">This Option Agreement is governed by the internal substantive laws, but not the choice of law rules, of California.</font></p></td></tr></table></div>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:5.95pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:233.45pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">Submitted</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by:</font></p>
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:252.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">Accepted</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">PURCHASER</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">SILK</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">ROAD</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">MEDICAL,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;border-bottom:1pt solid #000000 ;height:27.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;height:27.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-bottom:1pt solid #000000 ;height:27.90pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;border-top:1pt solid #000000 ;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Signature</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-top:1pt solid #000000 ;height:16.65pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Signature</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Print</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Name</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Print</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Name</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Address</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:10.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;border-bottom:1pt solid #000000 ;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Title</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:233.45pt;border-top:1pt solid #000000 ;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:252.90pt;border-top:1pt solid #000000 ;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:233.45pt;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:22.50pt;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:252.90pt;height:21.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Date Received&nbsp;&nbsp; </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0.4pt 0pt 0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font><a name="Silk_Road_Medical___Form_of_RSU_Agreemen"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:5.83%;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>8
<FILENAME>silk-20231231xex10_9.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:20:15 PM-->
<html>
	<head>
		<title>
			Exhibit 10.9
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11pt;">Exhibit 10.9</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;"><img src="silk-20231231xex10_9g001.jpg" style="width: 2.208333in; height: 0.5636428in" alt="A close-up of a logo&#xA;&#xA;Description automatically generated"></font>
		</p>
		<p style="margin:0pt 0pt 24pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;text-decoration:underline;">EMPLOYMENT</font><font style="display: inline;font-weight:bold;text-decoration:underline;"> AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;text-decoration:underline;">INTRODUCTION</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">This Employment</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Agreement </font><font style="display: inline;">and any addenda or exhibits attached hereto </font><font style="display: inline;">(&#x201C;Agreement&#x201D;) is between </font><font style="display: inline;">Silk Road Medical, Inc.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(&#x201C;</font><font style="display: inline;">Employer</font><font style="display: inline;">&#x201D;) and </font><font style="display: inline;">________________</font><font style="display: inline;"> &nbsp;(</font><font style="display: inline;">&#x201C;Employee&#x201D;</font><font style="display: inline;">, &#x201C;</font><font style="display: inline;">Y</font><font style="display: inline;">ou,&#x201D; or &#x201C;</font><font style="display: inline;">Y</font><font style="display: inline;">our&#x201D;)</font><font style="display: inline;"> (collectively the &#x201C;Parties&#x201D;)</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">This Agreement</font><font style="display: inline;">,</font><font style="display: inline;"> and</font><font style="display: inline;"> any </font><font style="display: inline;color:#000000;">addenda or exhibits, </font><font style="display: inline;">describe important </font><font style="display: inline;">aspects of</font><font style="display: inline;">,</font><font style="display: inline;"> and obligations regarding</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">Y</font><font style="display: inline;">our </font><font style="display: inline;">employment with </font><font style="display: inline;">Employer</font><font style="display: inline;">, including the ownership, protection and nondisclosure</font><font style="display: inline;"> of </font><font style="display: inline;">Employer</font><font style="display: inline;">&#x2019;s </font><font style="display: inline;">trade secrets, confidential information and inventions. This is an enforceable contract which </font><font style="display: inline;">Y</font><font style="display: inline;">ou</font><font style="display: inline;"> must read and sign as a condition of </font><font style="display: inline;">You</font><font style="display: inline;">r</font><font style="display: inline;"> new or continued </font><font style="display: inline;">employment with </font><font style="display: inline;">Employer</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;;font-size: 12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;">Employer</font><font style="display: inline;"> is </font><font style="display: inline;">a medical device company focused on reducing the risk of stroke and </font><font style="display: inline;">it</font><font style="display: inline;">s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">devastating</font><font style="display: inline;"> impact through the use of a new approach for the treatment of carotid </font><font style="display: inline;">artery</font><font style="display: inline;"> disease</font><font style="display: inline;">,</font><font style="display: inline;"> called </font><font style="display: inline;">Trans</font><font style="display: inline;">c</font><font style="display: inline;">arotid</font><font style="display: inline;"> Artery </font><font style="display: inline;">Revascularization</font><font style="display: inline;"> (TCAR)</font><font style="display: inline;">,</font><font style="display: inline;"> and related products</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">Employer</font><font style="display: inline;">&#x2019;s</font><font style="display: inline;"> business is </font><font style="display: inline;">national</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in scope, and </font><font style="display: inline;">Employer</font><font style="display: inline;"> markets and sells its products and services to customers throughout the United States.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">In the course of its business, </font><font style="display: inline;">Employer</font><font style="display: inline;"> has invested in </font><font style="display: inline;">valuable </font><font style="display: inline;">research, design, engineering methodologies and equipment, </font><font style="display: inline;">sales and marketing data,</font><font style="display: inline;"> customer data,</font><font style="display: inline;"> and other sophisticated management and operational procedures designed to enhance product quality and business efficiency</font><font style="display: inline;">, defined in further detail herein as </font><font style="display: inline;">Confidential Information</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and Inventions</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Y</font><font style="display: inline;">ou</font><font style="display: inline;"> and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Employer</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">acknowledge </font><font style="display: inline;">the importance of protecting </font><font style="display: inline;">Employer</font><font style="display: inline;">&#x2019;s</font><font style="display: inline;"> rights with respect to </font><font style="display: inline;">this information without unduly impairing </font><font style="display: inline;">You</font><font style="display: inline;">r ability to pursue employment outside of </font><font style="display: inline;">Employer</font><font style="display: inline;"> in the future should </font><font style="display: inline;">You</font><font style="display: inline;"> so choose. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Therefore, in consideration of and as a condition of Your new or continued employment, and in exchange for Employer&#x2019;s offer of compensation, </font><font style="display: inline;">equity, </font><font style="display: inline;">benefits, promotional opportunities, and access to Employer Confidential Information and Inventions, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows</font><font style="display: inline;">: &nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 1.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Employment-at-Will</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> acknowledge and agree that </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> is on an &#x201C;at-will&#x201D; basis, meaning there is no set term of employment, and either </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> or the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> may terminate </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment relationship at any time, for any reason, with or without prior notice, unless otherwise </font><font style="display: inline;color:#000000;">required</font><font style="display: inline;color:#000000;"> by </font><font style="display: inline;color:#000000;">applicable</font><font style="display: inline;color:#000000;"> law.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> acknowledge that </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> at-will employment cannot be modified unless by written agreement between </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> and the </font><font style="display: inline;color:#000000;">Chief Executive Officer</font><font style="display: inline;color:#000000;"> of the Emp</font><font style="display: inline;color:#000000;">loyer</font><font style="display: inline;color:#000000;"> (&#x201C;CEO&#x201D;)</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> &nbsp;o</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">the CEO&#x2019;s designee</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> further acknowledge that </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> has the right to modify the terms and conditions of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment, including </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> job title, job duties, salary and compensation, and benefits, with or without advanced notice</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> unless otherwise required by applicable law. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;text-decoration:underline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 2.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Job Duties and Avoidance of Conflicts of Interest</font><font style="display: inline;font-weight:bold;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">You agree to devote </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r entire productive time, ability and attention to </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s</font><font style="display: inline;color:#000000;"> business. You agree that while employed by </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> will not directly or indirectly engage in outside ownership, employment, consulting or other activities that, in </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s</font><font style="display: inline;color:#000000;"> exclusive judgment, conflict with </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r employment obligations to </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, unless prior written consent is obtained from an authorized officer of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">.&nbsp;&nbsp;While </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> are employed by </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> are required to give </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> written notice and secure written approval before acting as an owner, employee, consultant to, or providing other activities for, any entity other than </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 3.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Representation of No Restrictions</font><font style="display: inline;color:#000000;">. As a material condition of </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> represent and warrant that </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> are</font><font style="display: inline;color:#000000;"> under no legal obligation to any other company, person or entity which is inconsistent with, or may conflict with, </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> obligations</font><font style="display: inline;color:#000000;"> to Employer</font><font style="display: inline;color:#000000;">, or which might impede </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> ability to fully perform any of </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> duties and responsibilities to </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, including any non-competition</font><font style="display: inline;color:#000000;"> or</font><font style="display: inline;color:#000000;"> non-solicitation agreements</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">You agree that </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> will not use, disclose to </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, or cause </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> to</font><font style="display: inline;color:#000000;"> use, any proprietary information</font><font style="display: inline;color:#000000;">, confidential information</font><font style="display: inline;color:#000000;"> or trade secrets of any former employer or any other person or entity, nor will </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> bring onto the premises of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">transfer to </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s </font><font style="display: inline;color:#000000;">electronic</font><font style="display: inline;color:#000000;"> systems, or otherwise share with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> any </font><font style="display: inline;color:#000000;">proprietary, confidential or trade secret information belonging to any other employer, person or entity unless consented to in writing by such employer, person or entity.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 4.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Compliance with Laws, Policies, and Procedures</font><font style="display: inline;font-weight:bold;color:#000000;">.</font><font style="display: inline;color:#000000;"> &nbsp; &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> agree that </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> will comply with present and future policies and procedures of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, as well as applicable local, state, and federal law, including without limitation</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s Conflict of Interest Guidelines</font><font style="display: inline;color:#000000;"> in place from time to time</font><font style="display: inline;color:#000000;">, polices</font><font style="display: inline;color:#000000;"> prohibiting discrimination</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">harassment </font><font style="display: inline;color:#000000;">and retaliation, </font><font style="display: inline;color:#000000;">and those regarding workplace safety, wage</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and hour</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">requirements</font><font style="display: inline;color:#000000;">, and all other employment </font><font style="display: inline;color:#000000;">practices, and laws governing the use, protection and nondisclosure of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s </font><font style="display: inline;color:#000000;">Confidential Information. </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> further agree to promptly notify </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s </font><font style="display: inline;color:#000000;">Human Resources department </font><font style="display: inline;color:#000000;">or management team</font><font style="display: inline;color:#000000;"> regarding any question or objection </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> may have regarding </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> compliance with state, federal or foreign laws or regulations</font><font style="display: inline;color:#000000;"> or Your compensation, benefits, duties, or employment</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 5.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Commitment to Reporting Non-Compliance</font><font style="display: inline;font-weight:bold;color:#000000;">.</font><font style="display: inline;color:#000000;"> By entering into this Agreement, </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> agree that </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> will promptly notify</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s </font><font style="display: inline;color:#000000;">Human Resources </font><font style="display: inline;color:#000000;">d</font><font style="display: inline;color:#000000;">epartment</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">Compliance Officer </font><font style="display: inline;color:#000000;">if </font><font style="display: inline;color:#000000;">at any time during the course of </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> become aware of or suspect that </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> is not in compliance with any statute, regulation, or any other legal or regulatory standard applicable to any aspect of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s</font><font style="display: inline;color:#000000;"> business. Prompt disclosure and reporting under this Section includes, but is not </font><font style="display: inline;color:#000000;">limited to</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> suspected or alleged violations under the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the False Claims Act, the Anti-Kickback Statute, federal, state, and/or local employment laws related to discrimination, harassment and/or</font><font style="display: inline;color:#000000;"> retaliation, or any other federal, state, local, or international law, statute, or regulation </font><font style="display: inline;color:#000000;">applicable</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s</font><font style="display: inline;color:#000000;"> employees</font><font style="display: inline;color:#000000;"> or former employees, </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">including state</font><font style="display: inline;color:#000000;"> whistleblower</font><font style="display: inline;color:#000000;"> law</font><font style="display: inline;color:#000000;">s.</font><font style="display: inline;color:#000000;"> &nbsp;N</font><font style="display: inline;color:#000000;">othing in this Agreement interferes with</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">right to file a complaint, charge or report with any law enforcement agency</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">any other regulatory body</font><font style="display: inline;color:#000000;"> or agency,</font><font style="display: inline;color:#000000;"> or to participate in any manner in any investigation</font><font style="display: inline;color:#000000;"> initiated by such an agency or regulatory body</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 6.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Protection and Non-Disclosure of </font><font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Employer</font><font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;"> Confidential Information</font><font style="display: inline;font-weight:bold;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> A.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Confidential Information</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">Confidential Information&#x201D;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">means</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">information (including any and all combinations of individual items of information) that </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">has or will develop, acquire, create, compile, discover or own, that has value in or to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s business which is not generally known and which </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">wishes to maintain as confidential. Confidential Information includes both information disclosed by </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">, and information developed or learned by </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> during the course of </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">Confidential Information also includes all information of which the unauthorized disclosure could be detrimental to the interests of Employer, whether or not such information is identified as Confidential Information.&nbsp; </font><font style="display: inline;color:#000000;">By </font><font style="display: inline;color:#000000;">way of </font><font style="display: inline;color:#000000;">example, and without limitation, Confidential Information includes any and all non-public information that relates to the actual or anticipated business and/or products, research or development of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, or to </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or other information regarding the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s products or services and markets therefor, customer lists and customer</font><font style="display: inline;color:#000000;"> information</font><font style="display: inline;color:#000000;"> (including, but not limited to, customers of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> from whom </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> obtained information for use in connection with a possible sale of products and/or services to, or to whom </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> became acquainted with or interacted with regarding the possible sale of products or services while at </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">)</font><font style="display: inline;color:#000000;">, software, developments, inventions, discoveries, ideas, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, financ</font><font style="display: inline;color:#000000;">ial</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">or </font><font style="display: inline;color:#000000;">other business information</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> parts, equipment, or other </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">property. </font><font style="display: inline;color:#000000;">Confidential Information also includes any information that </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> receives from third parties (for example, customers, suppliers, vendors, licensors, licensees, partners, and collaborators) which </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> is required to maintain and treat as confidential or proprietary. </font><font style="display: inline;color:#000000;">Notwithstanding the foregoing, Confidential Information shall not include any such information which: </font><font style="display: inline;color:#000000;">(</font><font style="display: inline;color:#000000;">a) was lawfully known to </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> prior to disclosure; (b) is or becomes known to the public by general publication without violation of any obligation of non-disclosure;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(c) is given to </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> by a third party having a right to do so and without an obligation </font><font style="display: inline;color:#000000;">of confidentiality and non-use; or (d) is required to be disclosed by an order of a court or pursuant to a subpoena or similar writ or order. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> B.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Acknowledgements</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> recognize and acknowledge that during the course of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">will </font><font style="display: inline;color:#000000;">have access to and receive Confidential Information</font><font style="display: inline;color:#000000;"> and t</font><font style="display: inline;color:#000000;">hat such</font><font style="display: inline;color:#000000;"> Confidential Information </font><font style="display: inline;color:#000000;">is valuable, special and essential to the successful and effective conduct of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s</font><font style="display: inline;color:#000000;"> business, and has been developed or acquired by </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> at substantial cost and expense. </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">further acknowledge and agree that the sale or unauthorized use or disclosure of any of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s C</font><font style="display: inline;color:#000000;">onfidential </font><font style="display: inline;color:#000000;">I</font><font style="display: inline;color:#000000;">nformation obtained by </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> during </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> &nbsp;c</font><font style="display: inline;color:#000000;">onstitutes </font><font style="display: inline;color:#000000;">a breach of this Agreement</font><font style="display: inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> C.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Non-Disclosure</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> agree, during </font><font style="display: inline;color:#000000;">the period of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> employment with </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> and at any time </font><font style="display: inline;color:#000000;">after </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r</font><font style="display: inline;color:#000000;"> separation of employment from </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> for any reason</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">to </font><font style="display: inline;color:#000000;">hold </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s Confidential Information in the strictest confidence and take all reasonable precautions to prevent any unauthorized use or disclosure of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> Confidential Information.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">agree </font><font style="display: inline;color:#000000;">not to use or disclose any of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s </font><font style="display: inline;color:#000000;">Confidential Information</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to any person, corporation, firm, company or business entity other than </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">for any reason or purpose whatsoever except as necessary to perform services for </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">as </font><font style="display: inline;color:#000000;">authorized by the prior written consent of </font><font style="display: inline;color:#000000;">the </font><font style="display: inline;color:#000000;">CEO</font><font style="display: inline;color:#000000;">, or another officer of the Company as designated by the </font><font style="display: inline;color:#000000;">CEO</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">or </font><font style="display: inline;color:#000000;">as may be required by court order or applicable law</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">You agree that </font><font style="display: inline;color:#000000;">Employer&#x2019;s</font><font style="display: inline;color:#000000;"> Confidential Information and Employer Property </font><font style="display: inline;color:#000000;">(</font><font style="display: inline;color:#000000;">as defined in Section </font><font style="display: inline;color:#000000;">9)</font><font style="display: inline;color:#000000;"> constitutes the Employer&#x2019;s sole property during and after Your employment with</font><font style="display: inline;color:#000000;"> the Employer and that You will not remove any tangible copies of Confidential Information from the Employer&#x2019;s premises or print tangible copies of any Confidential Information that You accesses electronically from a remote location, nor will You download, upload, or otherwise transfer copies of Confidential Information or Employer property to any external storage media, device or cloud storage, except as necessary to perform Your job duties for the Employer and for Employer&#x2019;s sole benefit. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">When compelled to disclose Confidential Information by court order or applicable</font><font style="display: inline;color:#000000;"> law</font><font style="display: inline;color:#000000;">, prior to disclos</font><font style="display: inline;color:#000000;">ure </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">agree to provide written notice to the </font><font style="display: inline;color:#000000;">CEO</font><font style="display: inline;color:#000000;"> or the </font><font style="display: inline;color:#000000;">Chief Legal Officer</font><font style="display: inline;color:#000000;"> of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">understand that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">unauthorized use or disclosure of </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> Confidential Information during</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment may lead to disciplinary action, up to and including, immediate termination and legal action by the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> D.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">DTSA Notice</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">Pursuant to the Defend Trade Secrets Act of 2016,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">understand that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">may </font><font style="display: inline;color:#000000;">not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a </font><font style="display: inline;color:#000000;">complaint</font><font style="display: inline;color:#000000;"> or other document that is filed in a lawsuit or other proceeding, if such filing is made under seal. In the </font><font style="display: inline;color:#000000;">event </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> file a lawsuit or other proceeding agains</font><font style="display: inline;color:#000000;">t &nbsp;</font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">alleging that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">retaliated against</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">because of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">disclosure,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">may disclose the relevant trade secret to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">attorney and may use the trade secret in the proceeding if (i)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">file any document containing the trade secret under seal, and (ii)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">do not otherwise disclose the trade secret except pursuant to court order</font><font style="display: inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> E.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Exclusions</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">understand that nothing in this Section limits</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">rights to discuss the terms, wages, and working conditions of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment</font><font style="display: inline;color:#000000;">, including </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">regarding </font><font style="display: inline;color:#000000;">unlawful acts in the workplace, such as harassment or discrimination or any other conduct that You have reason to believe is unlawful,</font><font style="display: inline;color:#000000;"> in accordance with applicable law.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">further </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">understand that nothing in this </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">Section or this Agreement</font><font style="display: inline;background-color: #FFFFFF;color:#000000;"> limits or prohibits</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&nbsp;</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">You</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&nbsp;</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">from filing a charge or complaint with, or otherwise communicating or cooperating with or participating in any investigation or proceeding that may be conducted by any federal, state or local </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">government</font><font style="display: inline;background-color: #FFFFFF;color:#000000;"> agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">(&#x201C;</font><font style="display: inline;text-decoration:underline;background-color: #FFFFFF;color:#000000;">Government Agencies</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&#x201D;), including disclosing</font><font style="display: inline;color:#000000;"> documents or other information</font><font style="display: inline;color:#000000;"> as permitted by law, without giving notice to, or receiving authorization from,</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&nbsp;</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">Employer</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">. Notwithstanding, in </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">filing such a complaint or charge</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">,</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&nbsp;</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">You</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&nbsp;</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">agree to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Confidential Information to any parties other than the Government Agencies.</font><font style="display: inline;background-color: #FFFFFF;color:#000000;"> You </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">further understand that</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&nbsp;</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">You</font><font style="display: inline;background-color: #FFFFFF;color:#000000;"> are</font><font style="display: inline;background-color: #FFFFFF;color:#000000;"> not permitted to disclose the </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">Employer</font><font style="display: inline;background-color: #FFFFFF;color:#000000;">&#x2019;s attorney-client privileged communications or attorney work product. </font><a name="_Ref337654076"></a></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font><a name="_cp_blt_1_32"></a><a name="_cp_blt_2_31"></a><a name="_cp_blt_1_34"></a><a name="_cp_blt_2_33"></a><a name="_cp_blt_1_36"></a><a name="_cp_blt_2_35"></a>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 7.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Ownership</font><a name="_Ref204614764"></a><a name="_Ref384043408"></a><font style="display: inline;font-weight:bold;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> A.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Assignment of Inventions</font><font style="display: inline;color:#000000;">. As between</font><font style="display: inline;color:#000000;"> the Employer</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">agree that all right, title, and interest in and to any and all copyrightable material, notes, records, drawings, designs, logos, inventions, improvements, developments, discoveries, ideas and trade secrets conceived, discovered, authored, invented, developed or reduced to practice by me, solely or in collaboration with others, during the period of time</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> are</font><font style="display: inline;color:#000000;"> in the employ of </font><font style="display: inline;color:#000000;">the Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(including during</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">off-duty hours), or with the use of the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s equipment, supplies, facilities, or Confidential Information, and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights relating to the foregoing, except as provided in</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Section</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">(G)</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">below (collectively, &#x201C;</font><font style="display: inline;color:#000000;">Inventions</font><font style="display: inline;color:#000000;">&#x201D;), are the sole property of the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">also agree to promptly make full written disclosure to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;"> of any Inventions, and to deliver and assign and hereby irrevocably assign fully to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">all of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">right, title and interest in and to Inventions.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">agree that this assignment includes a present conveyance to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of ownership of Inventions that are not yet in existence.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">further acknowledge that all original works of authorship that are made by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(solely or jointly with others) within the scope of and during the period of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment with the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and that are protectable by copyright are &#x201C;works made for hire,&#x201D; as that term is defined in the United States Copyright Act.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">understand and agree that the decision whether or not to commercialize or market any Inventions is within the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s sole discretion and for the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s sole benefit, and that no royalty or other consideration will be due to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">as a result of the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s efforts to commercialize or market any such Inventions.</font><a name="26"></a><a name="27"></a><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> B.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Pre-Existing Materials</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">will inform the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, in writing, before incorporating any inventions, discoveries, ideas, original works of authorship, </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or in which</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">have an interest prior to, or separate from,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment with the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, including, without limitation, </font><font style="display: inline;color:#000000;">any Prior Invention(s) as defined by </font><font style="display: inline;color:#000000;">Section</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">(G)</font><font style="display: inline;color:#000000;">, or </font><font style="display: inline;color:#000000;">otherwise utilizing any Prior Invention</font><font style="display: inline;color:#000000;">(s)</font><font style="display: inline;color:#000000;"> in the course of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment with the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">; and the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license (with the right to grant and authorize sublicenses) to make, have made, use, import, offer for sale, </font><a name="_DV_M17"></a><font style="display: inline;color:#000000;">sell</font><a name="_DV_C7"></a><font style="display: inline;color:#000000;">, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such incorporated or utilized Prior Invention</font><font style="display: inline;color:#000000;">(s)</font><font style="display: inline;color:#000000;">, without restriction, including, without limitatio</font><font style="display: inline;color:#000000;">n, as part of, or in connection with, such Invention, and to practice any method related thereto.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">will not incorporate any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by any third party into any Invention without the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s prior written permission.</font><font style="display: inline;color:#000000;"> &nbsp;A</font><font style="display: inline;color:#000000;">ttached hereto</font><a name="_cp_text_1_47"></a><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">as </font><font style="display: inline;text-decoration:underline;color:#000000;">Exhibit </font><a name="_cp_text_1_48"></a><font style="display: inline;text-decoration:underline;color:#000000;">A</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">a list describing all </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">Prior Invention(s) </font><font style="display: inline;color:#000000;">that relate to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s </font><a name="_cp_text_1_50"></a><font style="display: inline;color:#000000;">current or anticipated </font><font style="display: inline;color:#000000;">business, products, or research and development or, if no such list is attached,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">represent and warrant that there are no such </font><font style="display: inline;color:#000000;">Prior Invention(s)</font><font style="display: inline;color:#000000;">. Furthermore,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">represent and warrant that if any </font><font style="display: inline;color:#000000;">Prior Invention(s) </font><font style="display: inline;color:#000000;">are included on </font><font style="display: inline;text-decoration:underline;color:#000000;">Exhibit </font><font style="display: inline;text-decoration:underline;color:#000000;">A</font><font style="display: inline;color:#000000;">, they will not materially affect</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">ability to perform all obligations under this Agreement. </font><a name="_Ref88922495"></a></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> C.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Moral Rights</font><a name="31"></a><a name="32"></a><a name="33"></a><a name="34"></a><a name="35"></a><a name="36"></a><font style="display: inline;color:#000000;">. Any assignment to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of Inventions includes all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout the world that </font><font style="display: inline;color:#000000;">may be known as or referred to as &#x201C;</font><a name="21"></a><font style="display: inline;color:#000000;">moral rights,&#x201D; &#x201C;artist&#x2019;s rights,&#x201D; &#x201C;droit moral,&#x201D; or the like (collectively, &#x201C;</font><a name="22"></a><font style="display: inline;color:#000000;">Moral Rights</font><a name="OLE_LINK17"></a><a name="OLE_LINK18"></a><font style="display: inline;color:#000000;">&#x201D;). To the extent that Moral Rights </font><a name="28"></a><font style="display: inline;color:#000000;">cannot be</font><font style="display: inline;color:#000000;"> assigned under applicable law,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">hereby waive and agree not to enforce any and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent permitted under applicable law</font><a name="_Ref204095621"></a><font style="display: inline;font-style:italic;color:#000000;">.</font><font style="display: inline;font-style:italic;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> D.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Maintenance of Records</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">agree to keep and maintain adequate, current, accurate, and authentic written records of all Inventions made by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(solely or jointly with others) during the term of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment with the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any other format that may be specified by the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">. As between the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">, the records are and will be available to and remain the sole property of the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">at all times.</font><a name="_Ref204591684"></a><a name="_Ref203979988"></a></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> E.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Further Assurances</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">agree to assist the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, or its designee, at the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s expense, in every proper way to secure the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&#x2019;s rights in the Inventions in any and all countries, including the disclosure to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, and all other instruments that the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">shall deem proper or necessary in order to </font><a name="OLE_LINK13"></a><a name="OLE_LINK14"></a><font style="display: inline;color:#000000;">apply for, register, obtain, maintain, defend, and enforce such rights, and</font><font style="display: inline;color:#000000;"> in order to deliver, assign and convey </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to all Inventions, and testifying in a suit or other proceeding relating to such</font><font style="display: inline;color:#000000;"> Inventions.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">further agree that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">obligations under this Section&nbsp;</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">(E)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">shall </font><font style="display: inline;color:#000000;">continue after the termination of this Agreement.</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> F.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Attorney-in-Fact</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">agree that, if the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">is unable because of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">unavailability, mental or physical incapacity, or for any other reason to secure</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">signature with respect to any Inventions, including, without limitation, for the purpose of applying for or pursuing any application for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">in </font><font style="display: inline;color:#000000;">this </font><font style="display: inline;color:#000000;">Section&nbsp;then</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">hereby irrevocably designate and appoint the </font><font style="display: inline;color:#000000;">Employer </font><font style="display: inline;color:#000000;">and its duly authorized</font><font style="display: inline;color:#000000;"> officers and agents as</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">agent and attorney-in-fact, to act for and on</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">behalf to execute and file any papers and oaths, and to do all other lawfully permitted acts with respect to such Inventions to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by me.</font><font style="display: inline;color:#000000;"> This power of attorney shall be deemed coupled with an interest</font><a name="4"></a><font style="display: inline;color:#000000;">, and shall be irrevocable.</font><a name="_Ref88922458"></a><a name="_Ref399259354"></a></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> G.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Exception to Assignments</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><a name="_cp_text_2_71"></a><font style="display: inline;color:#000000;">understand that the provisions of this Agreement requiring assignment of Inventions (as defined under Section</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">(</font><font style="display: inline;color:#000000;">A</font><font style="display: inline;color:#000000;">)</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">above) to the Employer do not apply to any </font><font style="display: inline;color:#000000;">I</font><font style="display: inline;color:#000000;">nvention</font><font style="display: inline;color:#000000;">s which qualif</font><font style="display: inline;color:#000000;">y</font><font style="display: inline;color:#000000;"> under the provisions of California Labor Code Section 2870</font><font style="display: inline;color:#000000;"> and similar state laws</font><font style="display: inline;color:#000000;">, which includes Inventions </font><font style="display: inline;color:#000000;">that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">develo</font><font style="display: inline;color:#1F497D;">p</font><font style="display: inline;color:#000000;"> entirely on</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">own time</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> without using the Employer&#x2019;s equipment, supplies, facilities, or trade secret information</font><font style="display: inline;color:#000000;">, and that do not relate to the business of the Employer or the Employer&#x2019;s actual or reasonably anticipated research or </font><font style="display: inline;color:#000000;">development, or that do not result from any work performed by You for the Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(&#x201C;</font><font style="display: inline;color:#000000;">Prior</font><font style="display: inline;color:#000000;"> Invention</font><font style="display: inline;color:#000000;">(s)</font><font style="display: inline;color:#000000;">&#x201D;)</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">will advise the Employer promptly in writing of any Inventions that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">believe constitute </font><font style="display: inline;color:#000000;">Prior Invention(s)</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">are</font><font style="display: inline;color:#000000;"> not otherwise disclosed on </font><font style="display: inline;text-decoration:underline;color:#000000;">Exhibit </font><font style="display: inline;text-decoration:underline;color:#000000;">A</font><font style="display: inline;color:#000000;"> to permit a determination of ownership by the Employer. Any such disclosure will be received in confidence.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">agree that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">will not incorporate, or permit to be incorporated, any </font><font style="display: inline;color:#000000;">Prior Invention(s) </font><font style="display: inline;color:#000000;">owned by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or in which</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">have an interest into an Employer product, process or service without the Employer&#x2019;s prior written consent. Notwithstanding the foregoing sentence, if, in the course of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment with the </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">incorporate into a</font><font style="display: inline;color:#000000;">n</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Employer </font><font style="display: inline;color:#000000;">product, process or service an </font><font style="display: inline;color:#000000;">Prior Invention(s) </font><font style="display: inline;color:#000000;">owned by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">or in which</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">have an interest,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">hereby grant to the </font><font style="display: inline;color:#000000;">Employer </font><font style="display: inline;color:#000000;">a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual, transferable, sublicensable, worldwide license to reproduce, make derivative works of, distribute, perform, display, import, make, have made, modify, use, sell, offer to sell, and exploit in any other way such </font><font style="display: inline;color:#000000;">Prior Invention(s) </font><font style="display: inline;color:#000000;">as part of or in connection with such product, process or service, and to practice any method related thereto</font><font style="display: inline;text-transform:uppercase;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 8.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Restrictions</font><font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;"> on</font><font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;"> Solicitation</font><font style="display: inline;font-weight:bold;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">In order to protect Employer&#x2019;s critical business interests, including but not limited to those with respect to Confidential Information, customer</font><font style="display: inline;color:#000000;"> relationships</font><font style="display: inline;color:#000000;">, employee</font><font style="display: inline;color:#000000;"> relationships</font><font style="display: inline;color:#000000;">, and vendor relationships, and Employer&#x2019;s </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">investment in its products, services, technology, business planning, sales and marketing programs, and business strategies and plans,</font><font style="display: inline;color:#000000;"> as well as its critical relationships with its sales personnel,</font><font style="display: inline;color:#000000;"> &nbsp;Y</font><font style="display: inline;color:#000000;">ou agree</font><font style="display: inline;color:#000000;"> that You will not, directly or indirectly, either on Your own behalf or on behalf of </font><font style="display: inline;color:#000000;">any other person or entity</font><font style="display: inline;color:#000000;">: &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> A.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;color:#000000;">A</font><font style="display: inline;color:#000000;">ttempt to persuade or solicit any person who is an employee</font><font style="display: inline;color:#000000;">, consultant or contractor </font><font style="display: inline;color:#000000;">of</font><font style="display: inline;color:#000000;"> Employer to terminate or reduce their relationship with the Employer</font><font style="display: inline;color:#000000;"> during Your employment with Employer, and for a period of two (2) years after termination of Your employment with Employer for any reason</font><font style="display: inline;color:#000000;">;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> B.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;color:#000000;">A</font><font style="display: inline;color:#000000;">ttempt to persuade or solicit any </font><font style="display: inline;color:#000000;">actual or prospective </font><font style="display: inline;color:#000000;">C</font><font style="display: inline;color:#000000;">ustomer</font><font style="display: inline;color:#000000;">, as defined herein, to terminate or </font><font style="display: inline;color:#000000;">reduce their relationship with the Employer</font><font style="display: inline;color:#000000;"> during Your employment with Employer and for a period of one (1) year after termination of Your employment with Employer for any </font><font style="display: inline;color:#000000;">reason. </font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">Customer</font><font style="display: inline;color:#000000;">&#x201D;</font><font style="display: inline;color:#000000;"> is defined as </font><font style="display: inline;color:#000000;">any person or entity, including but not limited to health care providers and facilities, to whom or to which You sold, negotiated the sales, </font><font style="display: inline;color:#000000;">supported,</font><font style="display: inline;color:#000000;"> marketed</font><font style="display: inline;color:#000000;"> or promoted products or services on behalf of Employer during the </font><font style="display: inline;color:#000000;">prior </font><font style="display: inline;color:#000000;">one (1) year in which You were employed by Employer</font><font style="display: inline;color:#000000;">, regardless of whether that Customer purchased Employer products from You or the Employer</font><font style="display: inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">You acknowledge that the Employer&#x2019;s offer of consideration set forth in this Agreement is expressly conditioned upon </font><font style="display: inline;color:#000000;">Your</font><font style="display: inline;color:#000000;"> agreement to be bound by the restrictions set forth in this Section 8 and the other terms and conditions of this Agreement, and that it constitutes sufficient, independent, </font><font style="display: inline;color:#000000;">mutually agreed</font><font style="display: inline;color:#000000;"> upon consideration to support the restrictions in this Section 8. You also agree that the foregoing restrictions are reasonable and necessary to protect Employer and do not deprive You of the opportunity to suitably support You or Your family with other employment opportunities after Your employment with Employer ends. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">During the </font><font style="display: inline;color:#000000;">restrictive periods</font><font style="display: inline;color:#000000;"> set forth in this Section </font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">, You will inform any new employer, prior to accepting employment or providing consulting services, of the existence of this Agreement and provide such employer with a copy of this Agreement </font><font style="display: inline;color:#000000;">any addenda or exhibits</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 9.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Return of </font><font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Employer </font><font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Property</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> &nbsp; &nbsp;</font><font style="display: inline;color:#000000;">Upon </font><font style="display: inline;color:#000000;">separation </font><font style="display: inline;color:#000000;">from </font><font style="display: inline;color:#000000;">employment with the Employer for any reason, or </font><font style="display: inline;color:#000000;">at any earlier time as </font><font style="display: inline;color:#000000;">the Employer</font><font style="display: inline;color:#000000;"> may request,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">shall </font><font style="display: inline;color:#000000;">immediately return to Employer any and all </font><font style="display: inline;color:#000000;">Employer Property in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">possession or control</font><font style="display: inline;color:#000000;"> and shall not keep any copies of such Employer Property in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">possession</font><font style="display: inline;color:#000000;">, in physical or electronic format</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">&#x201C;Employer Property&#x201D; </font><font style="display: inline;color:#000000;">means Confidential Information, including Employer equipment such as computer servers, messaging and email systems or accounts, </font><font style="display: inline;color:#000000;">applications</font><font style="display: inline;color:#000000;"> for computers or mobile devices, web-based services (including cloud-based information storage accounts</font><font style="display: inline;color:#000000;">), </font><font style="display: inline;color:#000000;">smart phones, tablets, e-readers, telephone equipment, and other electronic media devices, all tangible embodiments of the Inventions, all electronically stored information and passwords to access such information, Employer credit cards, records, data, notes, notebooks, reports, files, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">8</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">materials, photographs, charts, any other documents and property, and reproductions of any of the foregoing items including, without limitation, those records maintained pursuant to </font><font style="display: inline;color:#000000;">Section </font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">(D)</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Notwithstanding</font><font style="display: inline;color:#000000;"> the foregoing,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">understand that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> are</font><font style="display: inline;color:#000000;"> allowed to keep a co</font><font style="display: inline;color:#000000;">py of the </font><font style="display: inline;color:#000000;">personnel records relating to</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">personal </font><font style="display: inline;color:#000000;">employment. After returning such Employer Property, </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> agree to </font><font style="display: inline;color:#000000;">permanently delete from any electronic media in </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r possession, custody, or control any and all copies of such Employer Property. </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> also agree to provide </font><font style="display: inline;color:#000000;">Employer</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">with </font><font style="display: inline;color:#000000;">a list of any documents that </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> created or are otherwise aware that are password-protected and the password(s) necessary to access such password-protected documents.</font><font style="display: inline;color:#000000;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 54pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:bold;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> 10.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-weight:bold;text-decoration:underline;color:#000000;">Miscellaneous</font><font style="display: inline;font-weight:bold;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;background-color:yellow;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> A.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Applicable Law; Consent to Jurisdiction</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">In the interest of facilitating the consistent interpretation of this Agreement, and in the interest of judicial efficiency and economy, if Your primary work location is Minnesota or any state other than California, this Agreement shall be governed by the laws of the State of Minnesota, without regard to any conflicts of law rules, unless otherwise required by the law of the state of Your primary work location. Accordingly, </font><font style="display: inline;color:#000000;">You </font><font style="display: inline;color:#000000;">consent to personal and exclusive jurisdiction and venue in the state and federal courts located in Hennepin County, State of Minnesota. If Your primary work location is California, this Agreement shall be governed by the law</font><font style="display: inline;color:#000000;">s</font><font style="display: inline;color:#000000;"> of the State of California, without regard to any conflicts of law rules, and </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> agree to submit to personal jurisdiction in the state and federal courts in the State of California, and that any such action must be venued exclusively in Santa Clara County.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;background-color:yellow;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> B.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Remedies</font><font style="display: inline;color:#000000;">. In the event of a breach or threatened breach by </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> of any provision of this Agreement</font><font style="display: inline;color:#000000;"> or its </font><font style="display: inline;color:#000000;">addenda or e</font><font style="display: inline;color:#000000;">xhibits</font><font style="display: inline;color:#000000;">, the Employer shall be entitled to an injunction restraining </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">from such breach or threatened breach, without the necessity of posting a bond. Nothing contained herein shall be construed to prohibit the Employer from pursuing any other remedies available to it for such breach or threatened breach, including recovery of damages from </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">. Moreover, if the Employer prevails against </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">, in whole or in part, in any action to enforce any provision of this </font><font style="display: inline;color:#000000;">Agreement</font><font style="display: inline;color:#000000;"> or its </font><font style="display: inline;color:#000000;">addenda or exhibits</font><font style="display: inline;color:#000000;">, whether for injunctive relief or damages or both, then in addition to whatever injunctive relief or damages may be awarded, the Employer shall be entitled to its costs incurred in the successful pursuit of such action or portion thereof, including reasonable attorneys&#x2019; fees. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> C.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Assignability</font><font style="display: inline;color:#000000;">. This Agreement will be binding upon</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">heirs, executors, assigns, administrators, and other legal representatives, and will be for the benefit of the Employer, its successors, and its assigns. Notwithstanding anything to the contrary herein, the Employer may assign this Agreement and its rights and obligations under this Agreement to </font><font style="display: inline;color:#000000;">any successor to all, or substantially all, of the Employer&#x2019;s relevant assets, whether by merger, consolidation, reorganization, reincorporation, sale of assets or stock, or otherwise. For the avoidance of doubt, the Employer&#x2019;s </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

</div></td></tr></table><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td><p style="margin:0pt 0pt 0pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;;font-size: 12pt;"><font style="display: inline;color:#000000;">successors and assigns are authorized to enforce the Employer&#x2019;s rights under this Agreement</font><font style="display: inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> D.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Entire Agreement</font><font style="display: inline;color:#000000;">. This Agreement, together with the </font><font style="display: inline;color:#000000;">any addenda</font><font style="display: inline;color:#000000;"> or exhibits</font><font style="display: inline;color:#000000;"> attached hereto</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> sets forth the entire agreement and understanding between the Employer and </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">with respect to the subject matter herein and supersedes all prior written and oral agreements, discussions, or representations between us, including, but not limited to, any representations made during</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">hiring process</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;"> You </font><font style="display: inline;color:#000000;">represent and warrant that</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;"> are</font><font style="display: inline;color:#000000;"> not relying on any statement or representation not contained in this Agreement. Any subsequent change or changes in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">duties, salary, compensation, conditions or any other terms of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment will not affect the validity or scope of this Agreement.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> E.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Headings</font><font style="display: inline;color:#000000;">. Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> F.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Severability</font><font style="display: inline;color:#000000;">. If a court or other body of competent jurisdiction finds any provision of this Agreement, or portion thereof,</font><font style="display: inline;color:#000000;"> including but not limited to Section 10(A),</font><font style="display: inline;color:#000000;"> to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible so as to </font><font style="display: inline;color:#000000;">affect</font><font style="display: inline;color:#000000;"> the intent of the Parties, and the remainder of this Agreement will continue in full force and effect.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> G.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Modification, Waiver. </font><font style="display: inline;color:#000000;">No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in a writing signed by the </font><font style="display: inline;color:#000000;">CEO</font><font style="display: inline;color:#000000;">, or another officer of the Company as designated by the </font><font style="display: inline;color:#000000;">CEO</font><font style="display: inline;color:#000000;">, and </font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">No waiver of any provision of this Agreement shall be valid unless </font><font style="display: inline;color:#000000;">t</font><font style="display: inline;color:#000000;">he same is in writing and signed by the part</font><font style="display: inline;color:#000000;">y</font><font style="display: inline;color:#000000;"> against whom it is sought to be enforced. </font><font style="display: inline;color:#000000;">Waiver by the Employer of a breach of any provision of this Agreement will not operate as a waiver of any other or subsequent breach.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> H.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Survivorship. </font><font style="display: inline;color:#000000;">The rights and obligations of the Parties to this Agreement will survive termination of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">You</font><font style="display: inline;color:#000000;">r &nbsp;</font><font style="display: inline;color:#000000;">employment with the Employer.</font><a name="_Hlk97213906"></a></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
				<font style="margin:0pt;font-weight:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman;font-size:12pt;;"> I.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Counterparts</font><font style="display: inline;color:#000000;">. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.&nbsp;&nbsp;This Agreement may be executed by facsimile or e-mail of a PDF file, which shall have the same force and effect as original signatures.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;color:#000000;">[Remainder of page intentionally left blank</font><font style="display: inline;font-style:italic;color:#000000;">; signature page to follow</font><font style="display: inline;font-style:italic;color:#000000;">]</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">By signing below, the Parties acknowledge that they have read, understand, and agree to be bound b</font><font style="display: inline;">y</font><font style="display: inline;"> the terms of this Agreement: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;color:#000000;font-size:12pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:43.32%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:08.66%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:48.02%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:43.32%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;">EMPLOYEE</font><font style="display: inline;">:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:08.66%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.02%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;">SILK ROAD MEDICAL, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:43.32%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:08.66%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.02%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:43.32%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:08.66%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.02%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">By:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:43.32%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Date:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:08.66%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:48.02%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Title:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			&nbsp;
		</p></div><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<a name="a0d0r4c9e1"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">11</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;text-decoration:underline;">EXHIBIT </font><font style="display: inline;font-weight:bold;text-decoration:underline;">A</font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">LIST OF PRIOR INVENTIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">AND ORIGINAL WORKS OF AUTHORSHIP</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:33.34%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Title</font></p>
				</td>
				<td valign="bottom" style="width:33.34%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Date</font></p>
				</td>
				<td valign="bottom" style="width:33.34%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Identifying Number or Brief Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:33.34%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:33.34%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:33.34%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:252pt 0pt 12pt;line-height:115%;font-family:Times New Roman;font-size: 12pt">
			<a name="_Hlk530335673"></a><font style="display: inline;">Inventions or improvements&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________(please type &#x201C;yes&#x201D; or &#x201C;no&#x201D;)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Additional Sheets Attached&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______(please type &#x201C;yes&#x201D; or &#x201C;no&#x201D;)</font>
		</p>
		<p style="margin:30pt 0pt 0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:214pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:34pt;text-align:left"><font style="display: inline;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt 0pt 6.5pt;height:1.00pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:42.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt 0pt 6.5pt;height:1.00pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt 0pt 6.5pt;height:1.00pt">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.26%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:42.30%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.42%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.26%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:42.30%;border-top:1pt solid #000000 ;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Signature</font></p>
				</td>
				<td valign="top" style="width:14.42%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.26%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:42.30%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.42%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.26%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:42.30%;border-top:1pt solid #000000 ;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Name of Employee (typed or printed)</font></p>
				</td>
				<td valign="top" style="width:14.42%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.26%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:42.30%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.42%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.26%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:42.30%;border-top:1pt solid #000000 ;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Date</font></p>
				</td>
				<td valign="top" style="width:14.42%;padding:0pt 6.5pt 0pt 6.5pt;">
					<p style="margin:3pt 0pt;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:214pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:34pt;text-align:left"><font style="display: inline;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:19.6pt;text-align:left"><font style="display: inline;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font><font style="display: inline;"></font></font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:432pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font><font style="display: inline;"></font></font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;">A-</font><font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>silk-20231231xex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:20:48 PM-->
<html>
	<head>
		<title>
			Exhibit 23.1
		</title>
	</head>
	<body><div style="margin-left:64pt;margin-right:64pt;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;">Exhibit 23.1</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:24pt 0pt;line-height:100%;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Georgia;color:#000000;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Georgia;color:#000000;">We hereby consent to the incorporation by reference in the Registration Statement</font><font style="display: inline;font-family:Georgia;">s</font><font style="display: inline;font-family:Georgia;color:#000000;"> on Form S-3 (No. 333-271945) and S-8 (Nos. 333-263157, 333-253739, 333-236841, 333-230778, and 333-270123) of </font><font style="display: inline;font-family:Georgia;">Silk Road Medical, Inc.</font><font style="display: inline;font-family:Georgia;font-weight:bold;color:#FF0000;">&nbsp;</font><font style="display: inline;font-family:Georgia;color:#000000;">of our report dated </font><font style="display: inline;font-family:Georgia;">February 28, 2024</font><font style="display: inline;font-family:Georgia;color:#000000;"> relating to the financial </font><font style="display: inline;font-family:Georgia;">statements, financial statement schedule, and </font><font style="display: inline;font-family:Georgia;color:#000000;">the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<a name="_2et92p0"></a><font style="display: inline;font-family:Georgia;color:#000000;">/s/ PricewaterhouseCoopers LLP</font><br /><font style="display: inline;font-family:Georgia;color:#000000;"></font><font style="display: inline;font-family:Georgia;">Minneapolis</font><font style="display: inline;font-family:Georgia;">, &nbsp;</font><font style="display: inline;font-family:Georgia;">Minnesota</font><br /><font style="display: inline;font-family:Georgia;"></font><font style="display: inline;font-family:Georgia;">February 28</font><font style="display: inline;font-family:Georgia;">, &nbsp;</font><font style="display: inline;font-family:Georgia;">202</font><font style="display: inline;font-family:Georgia;">4</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Arial;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>silk-20231231xex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:21:05 PM-->
<html>
	<head>
		<title>
			Exhibit 31.1
		</title>
	</head>
	<body><div style="margin-left:36pt;margin-right:36pt;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">Exhibit 31.1</font>

		</p>

		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Calibri;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">CERTIFICATION OF </font><font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">PRINCIPAL</font><font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;"> EXECUTIVE OFFICER</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Pursuant to</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Securities Exchange Act Rules 13a-14(a) and 15d-14(a),</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">As Adopted Pursuant to</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Section 302 of the Sarbanes-Oxley Act of 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">I, </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Charles S. McKhann</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, certify that:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Silk Road Medical, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">a.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">b.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">c.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">d.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">T</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">he registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">a.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">b.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:180.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:143.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:143.95pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">/s/ </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Charles</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">S</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">McKhann</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:143.95pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:216.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Charles</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">S</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">McKhann</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:143.95pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:216.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:143.95pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:216.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;height:4.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:143.95pt;height:4.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:216.00pt;height:4.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:143.95pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:216.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Date: </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">February 28</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">202</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">4</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>silk-20231231xex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:21:20 PM-->
<html>
	<head>
		<title>
			Exhibit 31.2
		</title>
	</head>
	<body><div style="margin-left:36pt;margin-right:36pt;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">Exhibit 31.2</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">CERTIFICATION OF </font><font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">PRINCIPAL</font><font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;"> FINANCIAL OFFICER</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Pursuant to</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Securities Exchange Act Rules 13a-14(a) and 15d-14(a),</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">As Adopted Pursuant to</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Section 302 of the Sarbanes-Oxley Act of 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">I, Lucas W. Buchanan, certify that:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Silk Road Medical, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">a.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">b.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">c.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">d.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;color:#000000;font-family:Calibri;font-size:10pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">a.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:72pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">b.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:180.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:130.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:229.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font><a name="_Hlk73451502"></a></p>
				</td>
				<td valign="top" style="width:130.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:229.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">/s/ Lucas W. Buchanan</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:130.45pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:229.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Lucas W. Buchanan</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:130.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:229.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Chief </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Operating Officer and Chief </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:130.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:229.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">(Principal Financial Officer)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:130.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:229.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:180.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:130.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:229.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Date:</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">February 28</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">202</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">4</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>silk-20231231xex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:21:36 PM-->
<html>
	<head>
		<title>
			Exhibit 32.1
		</title>
	</head>
	<body><div style="margin-left:50pt;margin-right:50pt;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 10pt">

			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">Exhibit 32.1</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">PURSUANT TO</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">18 U.S.C. SECTION 1350,</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">AS ADOPTED PURSUANT TO</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">In connection with the Annual Report of Silk Road Medical, Inc. (the &#x201C;Company&#x201D;) on Form 10-K for the fiscal year ended December 31, </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">202</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">3</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Charles S. McKhann, as Chief Executive Officer of the Company, and Lucas W. Buchanan, as Chief </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Operating Officer and Chief </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Financial Officer of the Company, each hereby certifies</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, pursuant to </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Section 906 of the Sarbanes-Oxley Act of 2022 (</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">18 U.S.C. Section 1350</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">)</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, tha</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">t</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;"> to the best of our knowledge</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">1.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">The Report, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">2.</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:169.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.60pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.40pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">/s/ </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Charles S</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">McKhann</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.60pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.40pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Charles</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">S</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">McKhann</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.60pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.40pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.60pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.40pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.60pt;height:4.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.40pt;height:4.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;height:4.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.60pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.40pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Date: </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">February 28</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">202</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">4</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:169.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">/s/ Lucas W. Buchanan</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.50pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.50pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Lucas W. Buchanan</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Chief </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Operating Officer and Chief </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">(Principal Financial Officer)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:169.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:109.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:232.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">Date: </font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">February 28</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">202</font><font style="display: inline;font-family:Arial;color:#000000;font-size:10pt;">4</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>13
<FILENAME>silk-20231231xex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 23.3.2.2-->
<!--Created on: 2/28/2024 1:21:53 PM-->
<html>
	<head>
		<title>
			Exhibit 97.1
		</title>
	</head>
	<body><div style="margin-left:90pt;margin-right:90pt;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11pt;">Exhibit 97.1</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;"><img src="silk-20231231xex97_1g001.jpg" style="width: 2.437195in; height: 0.7499059in" alt="A grey and orange logo&#xA;&#xA;Description automatically generated"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">SILK ROAD MEDICAL, INC.</font>
		</p>
		<p style="margin:0pt 0pt 24pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">CLAWBACK</font><font style="display: inline;font-weight:bold;"> POLICY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;vertical-align:top;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Th</font><font style="display: inline;">is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Silk Road Medical, Inc. Clawback </font><font style="display: inline;">Policy (th</font><font style="display: inline;">is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;font-weight:bold;">Policy</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">) &nbsp;</font><font style="display: inline;">w</font><font style="display: inline;">as </font><font style="display: inline;">approved</font><font style="display: inline;"> effective</font><font style="display: inline;"> as of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">October 2</font><font style="display: inline;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2023</font><font style="display: inline;"> (the &#x201C;</font><font style="display: inline;font-weight:bold;">Effective Date</font><font style="display: inline;">&#x201D;)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">by the</font><font style="display: inline;"> Compensation Committee</font><font style="display: inline;"> (the &#x201C;</font><font style="display: inline;font-weight:bold;">Committee</font><font style="display: inline;">&#x201D;)</font><font style="display: inline;"> of the</font><font style="display: inline;"> Board of Directors </font><font style="display: inline;">(the &#x201C;</font><font style="display: inline;font-weight:bold;">Board</font><font style="display: inline;">&#x201D;) </font><font style="display: inline;">of </font><font style="display: inline;">Silk Road Medical, Inc. </font><font style="display: inline;">(the </font><font style="display: inline;">&#x201C;</font><font style="display: inline;font-weight:bold;">Company</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">). </font><font style="display: inline;">This Policy is adopted pursuant to and intended to comply with</font><font style="display: inline;"> Rule 5608 (Recovery of Erroneously Awarded Compensation) of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The Nasdaq Stock Market LL</font><font style="display: inline;">C</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(&#x201C;</font><font style="display: inline;font-weight:bold;">Nasdaq</font><font style="display: inline;">&#x201D;) </font><font style="display: inline;">so long as the Company&#x2019;s securities are listed on </font><font style="display: inline;">Nasdaq</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;vertical-align:top;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Purpose</font><font style="display: inline;font-weight:bold;"> and Policy Statement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;vertical-align:top;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The Company </font><font style="display: inline;">is committed to conducting business with integrity in accordance with high ethical standards and in compliance with all applicable laws, rules and regulations.&nbsp;&nbsp;This includes the Company&#x2019;s commitment to comply with all laws, rules and regulations applicable to the presentation of the Company&#x2019;s financial information to the public and to the recovery of erroneously awarded </font><font style="display: inline;">incentive-based </font><font style="display: inline;">compensation.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;vertical-align:top;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">As a result, the </font><font style="display: inline;">Committee</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">has adopted this </font><font style="display: inline;">Policy to provide that</font><font style="display: inline;">, in the event the Company is </font><font style="display: inline;">required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period</font><font style="display: inline;"> &nbsp;(</font><font style="display: inline;">each, as applicable, </font><font style="display: inline;">a &nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;font-weight:bold;">Restatement</font><font style="display: inline;">&#x201D;)</font><font style="display: inline;">, the </font><font style="display: inline;">Company will recover </font><font style="display: inline;">reasonably promptly the amount of any </font><font style="display: inline;">&#x201C;e</font><font style="display: inline;">rroneously awarded </font><font style="display: inline;">c</font><font style="display: inline;">ompensation</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x201C;</font><font style="display: inline;">received</font><font style="display: inline;">&#x201D;</font><font style="display: inline;"> by</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a</font><font style="display: inline;">n &#x201C;executive officer,&#x201D; in each case as</font><font style="display: inline;"> such terms are</font><font style="display: inline;"> defined in this Policy</font><font style="display: inline;">, if and to the extent required by </font><font style="display: inline;">any federal or state law, rule or regulation, or rule, regulation, policy or listing standard of the Securities and Exchange Commission </font><font style="display: inline;">(&#x201C;</font><font style="display: inline;font-weight:bold;">SEC</font><font style="display: inline;">&#x201D;) </font><font style="display: inline;">or any securities exchange on which the Company&#x2019;s securities are listed</font><font style="display: inline;">, including without limitation, </font><font style="display: inline;">Nasdaq Rule 5608 (Recovery of Erroneously Awarded Compensation)</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">In the event of any change in any federal or state law, rule or regulation, or rule, regulation, policy or listing standard of the </font><font style="display: inline;">SEC </font><font style="display: inline;">or any securities exchange on which the Company&#x2019;s securities are listed after the Effective Date, which requires the Company to recover compensation from a</font><font style="display: inline;">n executive officer</font><font style="display: inline;">, the </font><font style="display: inline;">Company</font><font style="display: inline;"> will seek recovery under this Policy to the extent required by such laws, rules, regulations or listing standards.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;font-size:12pt;"></font><font style="display: inline;font-weight:bold;font-size:12pt;">Administration</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The </font><font style="display: inline;">Committee</font><font style="display: inline;"> has</font><font style="display: inline;"> full power, authority, and sole and exclusive discretion to reasonably construe, interpret and administer this Policy.</font><font style="display: inline;"> The Committee will</font><font style="display: inline;"> &nbsp;i</font><font style="display: inline;">nterpret this Policy consistent with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Nasdaq Rule 5608 (Recovery of Erroneously Awarded Compensation) </font><font style="display: inline;">and any guidance issued thereunder</font><font style="display: inline;">, the rules and regulations of the </font><font style="display: inline;">SEC</font><font style="display: inline;">,</font><font style="display: inline;"> and any other applicable laws, rules or regulations governing the mandatory recovery of compensation</font><font style="display: inline;">, as such laws, rules or regulations may change, be interpreted or evolve from time to time</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">All determinations and decisions made by the </font><font style="display: inline;">Committee</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">will be made in its reasonable discretion and will </font><font style="display: inline;">be final, conclusive and binding on all </font><font style="display: inline;">affected individuals.&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The term &#x201C;</font><font style="display: inline;font-weight:bold;">Committee</font><font style="display: inline;">&#x201D; as used in this Policy means the Compensation Committee of the Board, or in the absence of such a committee, a majority of the &#x201C;independent directors&#x201D; (</font><font style="display: inline;">as defined under </font><font style="display: inline;">Nasdaq Rule 5605(a)(2)</font><font style="display: inline;">) serving on the Board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Applicability </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">This Policy applies to all &#x201C;incentive-based compensation&#x201D; &#x201C;received&#x201D; by a person</font><font style="display: inline;">, in each case as such terms are defined in this Policy</font><font style="display: inline;">:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">After beginning service as an </font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">executive officer</font><font style="display: inline;color:#000000;">,&#x201D; as such term is defined in this Policy</font><font style="display: inline;color:#000000;">, and w</font><font style="display: inline;color:#000000;">ho served </font><font style="display: inline;color:#000000;">as an executive officer </font><font style="display: inline;color:#000000;">at any time </font><font style="display: inline;color:#000000;">during the performance period for th</font><font style="display: inline;color:#000000;">at</font><font style="display: inline;color:#000000;"> incentive-based compensation</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">While the Company has a class of securities listed on </font><font style="display: inline;color:#000000;">Nasdaq</font><font style="display: inline;color:#000000;"> or another national securities exchange or a national securities association; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">During the </font><font style="display: inline;color:#000000;">three completed fiscal years immediately preceding the date </font><font style="display: inline;color:#000000;">that </font><font style="display: inline;color:#000000;">the Company is required to prepare </font><font style="display: inline;color:#000000;">the R</font><font style="display: inline;color:#000000;">estatement</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">plus </font><font style="display: inline;color:#000000;">any transition period </font><font style="display: inline;color:#000000;">(</font><font style="display: inline;color:#000000;">that results from a change in the Company&#x2019;s fiscal year</font><font style="display: inline;color:#000000;">)</font><font style="display: inline;color:#000000;"> within or immediately following those three completed fiscal years</font><font style="display: inline;color:#000000;">; provided, however, that </font><font style="display: inline;color:#000000;">a transition period between the last day of the Company&#x2019;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months would be deemed a completed fiscal year</font><font style="display: inline;color:#000000;">; and provided, further, that the Company&#x2019;s obligation to recover erroneously awarded compensation is not dependent on if or when the restated financial statements are filed</font><font style="display: inline;color:#000000;">.&nbsp; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">For purpose of determining the relevant recovery period, the date that the Company is required to prepare a Restatement is the earlier to occur of: (i) the date the Company&#x2019;s Board, a committee of the Board or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement; or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Restatement.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;font-weight:bold;"></font><font style="display: inline;font-weight:bold;">Executive Officers Covered by Policy&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">T</font><font style="display: inline;">his Policy covers the Company&#x2019;s current and former executive officers who received erroneously awarded c</font><font style="display: inline;">ompensation</font><font style="display: inline;"> regardless of whether the executive officer committed misconduct or contributed to the error.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The term &#x201C;</font><font style="display: inline;font-weight:bold;">executive officer</font><font style="display: inline;">&#x201D; as used in this Policy </font><font style="display: inline;">means</font><font style="display: inline;"> the Company&#x2019;s</font><font style="display: inline;">:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">p</font><font style="display: inline;color:#000000;">resident</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">principal financial officer</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">principal accounting officer (or if there is no such accounting officer, the controller)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">any vice-president of the Company in charge of a principal business unit, division or function (such as sales, administration or finance)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">any other officer who performs a policy-making function</font><font style="display: inline;color:#000000;">;</font><font style="display: inline;color:#000000;"> or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">any other person who performs similar policy-making functions for the Company and executive officers of the Company&#x2019;s parents or subsidiaries if such individuals perform such policy-making functions for the Company.</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Policy-making function is not intended to include policy-making functions that are not significant. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified by the Company pursuant to Item 401(b) of SEC Regulation S-K.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Authority and Obligation</font><font style="display: inline;font-weight:bold;color:#000000;"> to Recover </font><font style="display: inline;font-weight:bold;color:#000000;">Erroneously Awarded</font><font style="display: inline;font-weight:bold;color:#000000;"> Compensation</font><font style="display: inline;font-weight:bold;color:#000000;">; Exceptions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">In the event </font><font style="display: inline;color:#000000;">of a Restatement, </font><font style="display: inline;color:#000000;">the </font><font style="display: inline;color:#000000;">Company</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">must</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">reasonably promptly </font><font style="display: inline;color:#000000;">recover</font><font style="display: inline;color:#000000;"> any &#x201C;erroneously awarded compensation</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&#x201D; as such term is defined in this Policy</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> in compliance with this Policy, except to the extent one of the three conditions below is met and the Committee has made a determination that recovery would be impracticable.</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">The d</font><font style="display: inline;color:#000000;">irect expense paid to </font><font style="display: inline;color:#000000;">a &nbsp;</font><font style="display: inline;color:#000000;">third part</font><font style="display: inline;color:#000000;">y</font><font style="display: inline;color:#000000;"> to assist in enforcing this Policy would exceed the amount to be recovered and the Company has made a reasonable attempt to recover</font><font style="display: inline;color:#000000;"> any amount of erroneously awarded compensation, has documented such reasonable attempt(s) to recover and provided that documentation to </font><font style="display: inline;color:#000000;">Nasdaq</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">R</font><font style="display: inline;color:#000000;">ecovery would violate home country law </font><font style="display: inline;color:#000000;">where </font><font style="display: inline;color:#000000;">that </font><font style="display: inline;color:#000000;">law </font><font style="display: inline;color:#000000;">was adopted prior to November 28, 2022 and the Company </font><font style="display: inline;color:#000000;">has obtained an opinion </font><font style="display: inline;color:#000000;">of home country counsel</font><font style="display: inline;color:#000000;">, acceptable to </font><font style="display: inline;color:#000000;">Nasdaq</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> that </font><font style="display: inline;color:#000000;">recovery would result in such a violation and has provided such opinion to </font><font style="display: inline;color:#000000;">Nasdaq</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:12pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">Re</font><font style="display: inline;color:#000000;">covery would likely cause an otherwise tax-qualified retirement plan</font><font style="display: inline;color:#000000;">, under which benefits are broadly available to employees of the Company,</font><font style="display: inline;color:#000000;"> to fail to meet the requirements of </font><font style="display: inline;color:#000000;">Section 401(a)(13) or 411(a) of </font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;"> U.S.</font><font style="display: inline;color:#000000;"> Internal Revenue Code</font><font style="display: inline;color:#000000;"> and regulations thereunder</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Erroneously Awarded </font><font style="display: inline;font-weight:bold;color:#000000;">Compensation </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The term &#x201C;</font><font style="display: inline;font-weight:bold;color:#000000;">erroneously awarded compensation</font><font style="display: inline;color:#000000;">&#x201D; as used in this Policy means that </font><font style="display: inline;color:#000000;">amount of </font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">incentive-based c</font><font style="display: inline;color:#000000;">ompensation</font><font style="display: inline;color:#000000;">&#x201D;</font><font style="display: inline;color:#000000;"> received that exceeds the amount of </font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">incentive-based compensation</font><font style="display: inline;color:#000000;">&#x201D;</font><font style="display: inline;color:#000000;"> that otherwise would have been received had it been determined based on the restated amounts, and must be computed without regard to any taxes paid. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">For incentive-based compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in a Restatement</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">the amount must be based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the incentive-based compensation was received</font><font style="display: inline;color:#000000;">; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">th</font><font style="display: inline;color:#000000;">e Company </font><font style="display: inline;color:#000000;">must</font><font style="display: inline;color:#000000;"> maintain documentation of the determination of that reasonable estimate and provide such documentation to </font><font style="display: inline;color:#000000;">Nasdaq</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The term &#x201C;</font><font style="display: inline;font-weight:bold;color:#000000;">incentive-based compensation</font><font style="display: inline;color:#000000;">&#x201D; as used in this Policy means any </font><font style="display: inline;color:#000000;">compensation that is granted, earned or vested based wholly or in part upon the attainment o</font><font style="display: inline;color:#000000;">f</font><font style="display: inline;color:#000000;"> a financial reporting measure</font><font style="display: inline;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The term &#x201C;</font><font style="display: inline;font-weight:bold;color:#000000;">financial reporting measures</font><font style="display: inline;color:#000000;">&#x201D; as used in this Policy means </font><font style="display: inline;color:#000000;">measures that are determined and presented in accordance with the accounting principl</font><font style="display: inline;color:#000000;">e</font><font style="display: inline;color:#000000;">s used in preparing the Company&#x2019;s financial statements</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> and any measure</font><font style="display: inline;color:#000000;">s that are</font><font style="display: inline;color:#000000;"> derived wholly or in part from such measure</font><font style="display: inline;color:#000000;">s.&nbsp;&nbsp;Financial reporting measures include, </font><font style="display: inline;color:#000000;">without limitation,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">stock price and total shareholder return</font><font style="display: inline;color:#000000;">, and may include non-GAAP financial measures.&nbsp;&nbsp;A financial reporting measure need not be presented within the Company&#x2019;s financial statements or included in an SEC filing to constitute a financial reporting measure for this purpose.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Incentive</font><font style="display: inline;color:#000000;">-based c</font><font style="display: inline;color:#000000;">ompensation is deemed &#x201C;</font><font style="display: inline;font-weight:bold;color:#000000;">received</font><font style="display: inline;color:#000000;">&#x201D; &nbsp;</font><font style="display: inline;color:#000000;">as such term is used in this Policy </font><font style="display: inline;color:#000000;">by </font><font style="display: inline;color:#000000;">an e</font><font style="display: inline;color:#000000;">xecutive</font><font style="display: inline;color:#000000;"> officer</font><font style="display: inline;color:#000000;"> in the Company&#x2019;s fiscal period during which the financial reporting measure specified in the </font><font style="display: inline;color:#000000;">incentive-based </font><font style="display: inline;color:#000000;">compensation award is attained, even if the payment or grant of the </font><font style="display: inline;color:#000000;">incentive-based </font><font style="display: inline;color:#000000;">compensation occurs after the end of that period</font><font style="display: inline;color:#000000;">.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Notwithstanding the generality of the foregoing, &#x201C;incentive-based compensation&#x201D; is intended to be interpreted and construed broadly and includes with respect to any plan that takes into account incentive-based compensation (other than a tax-qualified plan) any amount contributed to a notional account based on erroneously awarded compensation and any earnings accrued to date on that notional account. Such plans include</font><font style="display: inline;color:#000000;"> without limitation</font><font style="display: inline;color:#000000;"> long-term disability plans, life insurance plans, supplemental executive retirement p</font><font style="display: inline;color:#000000;">l</font><font style="display: inline;color:#000000;">ans and other compensation, if it is based on incentive-based compensation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">For clarity and the avoidance of doubt, </font><font style="display: inline;">&#x201C;i</font><font style="display: inline;">ncentive</font><font style="display: inline;">-based c</font><font style="display: inline;">ompensation</font><font style="display: inline;">&#x201D;</font><font style="display: inline;"> does not include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">b</font><font style="display: inline;color:#000000;">ase salary</font><font style="display: inline;color:#000000;"> (other than any base salary increase earned wholly or in part based on the attainment of a financial reporting measure, which increase is subject to recovery as incentive-based compensation hereunder);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">b</font><font style="display: inline;color:#000000;">onuses paid solely at the discretion of the </font><font style="display: inline;color:#000000;">C</font><font style="display: inline;color:#000000;">ommittee or Board that are not paid from a &#x201C;bonus pool&#x201D; that is determined by satisfying a financial reporting measure performance goal;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">b</font><font style="display: inline;color:#000000;">onuses paid solely upon satisfying one or more subjective standards </font><font style="display: inline;color:#000000;">(e.g. demonstrated leadership) </font><font style="display: inline;color:#000000;">and/or completion of a specified employment period;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">n</font><font style="display: inline;color:#000000;">on-equity incentive plan awards earned solely upon satisfying one or more strategic measures (e.g., consummating a merger or divestiture), or operational measures (e.g., completion of a project); and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">e</font><font style="display: inline;color:#000000;">quity awards for which the grant is not contingent upon achieving any financial</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">reporting measure performance goal</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> and vesting is contingent solely upon completion</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of a specified employment period and/or attaining one or more non</font><font style="display: inline;color:#000000;">-</font><font style="display: inline;color:#000000;">financial reporting</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">measures</font><font style="display: inline;color:#000000;">.&nbsp; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Method of Recovery</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">The </font><font style="display: inline;color:#000000;">Committee</font><font style="display: inline;color:#000000;"> will determine, in its reasonable discretion, the method for recovering </font><font style="display: inline;color:#000000;">i</font><font style="display: inline;color:#000000;">ncentive</font><font style="display: inline;color:#000000;">-based c</font><font style="display: inline;color:#000000;">ompensation hereunder, which may include, without limitation, any one or more of the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">requiring reimbursement of cash </font><font style="display: inline;color:#000000;">i</font><font style="display: inline;color:#000000;">ncentive</font><font style="display: inline;color:#000000;">-based c</font><font style="display: inline;color:#000000;">ompensation previously paid;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">adjusting or withholding from unpaid compensation</font><font style="display: inline;color:#000000;">, deferred compensation</font><font style="display: inline;color:#000000;"> or other set-off;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">cancelling or setting-off against planned future grants of equity-based awards; and/or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display: inline;color:#000000;">any other method </font><font style="display: inline;color:#000000;">required or </font><font style="display: inline;color:#000000;">authorized by applicable law or contract.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Enforceability</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">In addition to the adoption of this Policy, the Company will take steps to </font><font style="display: inline;">implement</font><font style="display: inline;"> an agreement to this Policy by all current and future executive officers</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">In furtherance of the foregoing, e</font><font style="display: inline;">ach executive officer subject to this Policy is required to sign and return to the Company the Acknowledgement Form attached hereto as </font><font style="display: inline;font-weight:bold;">Exhibit A</font><font style="display: inline;"> pursuant to which such executive officer will agree to be bound by the terms and comply with this Policy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Policy </font><font style="display: inline;font-weight:bold;">Not Exclusive </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Any recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company pursuant to the terms of any </font><font style="display: inline;">other clawback or recovery policy or any </font><font style="display: inline;">similar policy in any employment agreement, incentive or equity compensation plan or award or other agreement and any other legal rights or remedies available to the Company. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Notwithstanding the generality of the foregoing, to the extent that the requirements under the provisions of Section 304 of the Sarbanes-Oxley Act of 2002 are broader than the provisions in this Policy, the provisions of such law will apply to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">No Indemnification</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The Company will not indemnify or agree to indemnify any </font><font style="display: inline;">e</font><font style="display: inline;">xecutive</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">o</font><font style="display: inline;">fficer</font><font style="display: inline;"> or former executive officer</font><font style="display: inline;"> against the loss of erroneously awarded compensation nor will the Company pay or agree to pay any insurance premium to cover the loss of erroneously awarded compensation.&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Effective Date</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Th</font><font style="display: inline;">is Policy is effective as of the E</font><font style="display: inline;">ffective </font><font style="display: inline;">D</font><font style="display: inline;">ate and appl</font><font style="display: inline;">ies t</font><font style="display: inline;">o all </font><font style="display: inline;">i</font><font style="display: inline;">ncentive</font><font style="display: inline;">-based c</font><font style="display: inline;">ompensation </font><font style="display: inline;">received by </font><font style="display: inline;">the Company&#x2019;s current and former </font><font style="display: inline;">executive officers on or after the Effective Date. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Required Disclosures</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The</font><font style="display: inline;"> Company will </font><font style="display: inline;">file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including the disclosure required by the applicable SEC filings and will </font><font style="display: inline;">provide </font><font style="display: inline;">all </font><font style="display: inline;">required SEC and other disclosures regarding this Policy and in the event of a Restatement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Amendment</font><font style="display: inline;font-weight:bold;"> and Termination</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">The </font><font style="display: inline;">Committee</font><font style="display: inline;"> may amend, modify or terminate this Policy in whole or in part at any time in its sole discretion and may adopt such rules and procedures that it deems necessary or appropriate to implement this Policy or to comply</font><font style="display: inline;"> with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Nasdaq Rule 5608 (Recovery of Erroneously Awarded Compensation)</font><font style="display: inline;"> and any other </font><font style="display: inline;">applicable laws</font><font style="display: inline;">, rules</font><font style="display: inline;"> and regulations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Successors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">This Policy shall be binding and enforceable against all </font><font style="display: inline;">current and former </font><font style="display: inline;">e</font><font style="display: inline;">xecutive </font><font style="display: inline;">o</font><font style="display: inline;">fficers</font><font style="display: inline;"> of the Company</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and their </font><font style="display: inline;">respective </font><font style="display: inline;">beneficiaries, heirs, executors, administrators</font><font style="display: inline;">,</font><font style="display: inline;"> or other legal representatives.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">* * * * * *</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Adopted by the </font><font style="display: inline;">Compensation Committee</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">of the </font><font style="display: inline;">Board of Directors of </font><font style="display: inline;">Silk Road Medical, Inc.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">on</font><font style="display: inline;"> November 3</font><font style="display: inline;">, 2023</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt -121.5pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;"><img src="silk-20231231xex97_1g001.jpg" style="width: 2.437195in; height: 0.7499059in" alt="A grey and orange logo&#xA;&#xA;Description automatically generated"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">SILK ROAD MEDICAL, INC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">CLAWBACK POLICY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">ACKNOWLEDGEMENT FORM</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:3.25pt 5.75pt 12pt 0pt;punctuation-wrap:hanging;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">By signing below, the undersigned acknowledges and confirms that the undersigned has received and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">reviewed</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">copy</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the </font><font style="display: inline;">Silk Road Medical, Inc.</font><font style="display: inline;"> Clawback Policy</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">(the</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;font-weight:bold;color:#000000;">Policy</font><font style="display: inline;color:#000000;">&#x201D;).</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 5.75pt 12pt 0pt;punctuation-wrap:hanging;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">By</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">signing</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">this</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Acknowledgement</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Form,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">undersigned</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">acknowledges</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">agrees</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the undersigned</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">will</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">continue</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">be</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">subject</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Policy</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Policy</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">will</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">apply</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">both during</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">after</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">undersigned&#x2019;s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">employment</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">with</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Silk Road Medical, Inc. </font><font style="display: inline;">and its direct and indirect subsidiaries.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 5.75pt 12pt 0pt;punctuation-wrap:hanging;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Further,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">by</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">signing below,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">undersigned</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">agrees</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">abide</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">by</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">terms</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Policy,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">including,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">without</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">limitation, by</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">returning</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">any</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">erroneously</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">awarded</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">compensation (as defined in the Policy)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">to</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Silk Road Medical, Inc. and its direct and indirect subsidiaries </font><font style="display: inline;">to the extent required by, and in a manner permitted by, the Policy.</font>
		</p>
		<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.92%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.58%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:37.50%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.92%;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.58%;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Signature:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:37.50%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.92%;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.58%;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:37.50%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.92%;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.58%;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">Date:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:37.50%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0.2pt 0pt 6pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:2.5pt 36pt 6pt 0pt;punctuation-wrap:hanging;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:214pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;"></font><font style="display: inline;">8</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>silk-20231231x10kg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231x10kg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>silk-20231231x10kg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231x10kg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ />6D8,>
M>])YC>OZ4UOOM]:2@!_F/Z_I1YC^OZ4RB@!_F/Z_I1YC>M,HH ?YC^OZ4>8W
MK3** '^8WK1YC^M,HH ?YC>OZ4>8WK^E,HH ?YC>OZ4>8WK^E,HH ?YC^OZ4
M>8_K^E,HH ?YC^OZ4>8_K^E,HH ?YC>M'F/Z_I3** '^8_K^E'F/Z_I3** '
M^8_K^E'F/Z_I4=% $GF/Z_I1YC^OZ5'10!)YC^M*CL7 )J*GQ?ZP4 (WWV^M
M-I7^^WUIM "T4E% "T4E% "T4E% "T4E+0 44E% "T4E% "T4E+0 44E% "T
M4E% "T4E% "T4E% "T4E% !3XO\ 6"F4^+_6"@!K_?;ZTVE?_6-]:;0 M%%%
M !1244 .I*2B@!U%)10 M%)10 M%)10 M%)10 M)110 9HHI* %HI*6@ HI*
M* %HI** %S3XO]:M1U)#_K5H 8_^L;ZFDJI/JMA%/(CW<2LK$$%NAS41UO3!
M_P OL7YT^5]B/:0[E^BLXZ[I8ZWT7ZTT^(=)'6^B_(_X4^278/:P[HTZ*R_^
M$DT<?\OR?]\M_A3#XHT4 YOTXZ_(W^%')+L+VM/^9?>:]+6-_P )3H?_ $$8
M_P#OEO\ "E_X2C0\9_M.#\211R2[![6G_,C8HK"?QAH*'!U&(G..#1#XPT2>
M4QQW8+ 9/3_&CDEO8:JP;LF;M%9/_"1Z80?+G#L!P@(R?IDU -=,TJ;9+>*)
MP2#NWL<<8X/7Z9J7H6;M+6%_:"L$5K_>2""$8(3UY!'Z=:CDNE>.-!J(Z,'8
MOWY Q2NAV9T/:F/+'&-TDB*,XRS 5@"YLMX;[22RJRE/,R)&QT()[<?G3O-L
M4,9C-ONVE2=P/T[_ ,Z+H1L"]MS.(%D#2$9PO/ZU/6+#>6D;Q 31* >6+ #/
M?IWYK0&H69/%S$?HPHN@L6J2JG]J6''^F0<G ^<<FIQ<0GD31_\ ?0H33"Q+
M25'YT/\ SUC_ .^A1Y\/_/:/_OL4P)**C\Z+M(G_ 'T*7S(_^>B?]]"@!]%,
M#H>CJ?QI_6@ J2'_ %RU'@^AI\(/G+0!Q.I?#?2[_5+N[DNKL//,\K ., LQ
M)QQ[U4/PLTG_ )^[O_OL?X5WLG^M?_>--S5^TGW,?J])_91P?_"K-*_Y^KK_
M +Z'^%(?A7I1_P"7FX_,?X5WF:6G[6?</J]+^5'!?\*KTL?\O,__ ([_ (4G
M_"K-+'_+>4_55_PKOJ*7M)=QJC370X0?#'3EZ2M_WR*D3X<:?&<AL_[R UV]
M&:7/+N/V4.QR \"V:C&R _6W3_"IH_!EK$<K' #[6Z#^E=31FDY-E*$5T.</
MAE%1@@B4D8R(E%58O#DMNZX<,J]/E''&.*ZZDP*11R\6ESQO&Q5 RD\A!T]*
M?%ILJ+&'VLRDX(C'?K72;11L%%@.;339515(0D<@^4, ^O7K3ET^4*H/E;@<
M[A%CGUZ]:Z$H/2D\L46 PXM/D$D/^K*J<LOE@ ^^.>:OM89?*QQ#_MF*NA .
MU/%*P&6NF*&SY%ODG)_=+_A5@6F/^6<(_P"V8J[FC-"20%06K?W(\?[@IXM(
M1_R[P_\ ?L?X58S29I@0_9X^T47_ 'P*7R$_YYQ_]\"I*,T 1^2O]Q!_P$5$
M]C!)]^&-OJM6:* *7]E6?_/K#_WS5FQL;>"[1XX8U89P57VJ2I;?_7K^/\J
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123V^R,9RV]3C@^AHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>silk-20231231x10kg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231x10kg003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1"  B 6P# 2(  A$! Q$!_\0
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944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>silk-20231231x10kg004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231x10kg004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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01-K9#-CT-/HH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>silk-20231231x10kg005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231x10kg005.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBD+!1DF@!::SJHR3BLW4=;L].@>:>>.*-?O.[!0/J37G-_X[U/Q!<-
M9^%[1I1T:\E4A$SW /\ 7TZ&HG4C'<ER2._UCQ-I^CVS3W=S'%&/XF/4]<#U
M/'05QC?&/2 Y"V>HN <!EA7!]^6S3-(^'37=TNH:_<R:C=GG]X?W:<YP!Z9S
MQP,'I7=QZ)!%$D:(JJJA54#  ':I_>2\OQ%[S\C6HHHK4L**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **0D <U4N-0BAXSEO04 7*3(]:
MQCJ-Q+GRX\#&02>M1%[V3'SX/<8_KF@#=,B#JPJ-KF)>K"L9H74&6><K&H);
M<W 'N>*YG4_%>G0S&WTR!K^ZSMR&/E DD?CSCIQSUK.I5A35YLTI49U7:"N=
M?>Z[;6D3.\BA5ZDG@5QU]XSN+^1H-'MWN&'!DVD(N?7\?I^-9MKH>HZS/'/J
MLA9-P(MP2HVX&>G3ICL<YZ\UV^C^&[>PA0!!P,=/Q_F3^=8*5:KLN5?B=#A1
MH[OFE^'_  3C8/ LVOWB7FO3SW!7[D&_$:@CG@=\]QC.!7?Z=H=II\*QPPI&
MB]%10 /P%:21J@PH I]=$*<8+0Y)/FDY6W$50HP!2T458@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBHY)DB7+$4 257N+R*!2685G7&IR2M
MY=NA8GOVJ*.T+N'F)=_3/ H >]U<7;$("D8ZL>*2.T0=B[=V:K.T#KV[5DZM
MXHTO1,BZFW2XX@BY?MV[=<\XI2E&"O)V*A"4W:*N:I$<2%G8!0,D]@*YS5O&
MVEZ>JI:$7T[C*I X*X]V&>WIFL7[;K/B>1G>)K+3QPJ@9)Y(/)QD]?ICIZRZ
M?H]EHJ,P59)LY5V&2HXXSW.1G.!UZ"L'4G5BG1V?5FZIPI2:K;KHBC<0:[XC
MQ)JLXM+7J($&!T(Z=3R!U/0\&M?2=,M;;BT@X!VAFZL?<^G3./;ZTBF:^D^4
M-LS@D?RKK-*TT01JS@9QP/2G3P\(/F>LN[%4Q,YKE6D>R+&GV(A3>_+GJ:T*
M.E%;G.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444$XZT %(S
M!1DG%5+G4(K=>6&?2LMI[F]<;?ECSW[T 7;K5$3*1_,_8"J7DSW;9G)"G^$'
M_/O5BWLHX1D_>[D]33[BYAM(&EED2&)!\SNP 'XFC;<-]$*D*1+@ #V%5=1U
M:QTFW\Z]N$@3L"?F;Z#J>O:N5O/&=UJ-P;/PY:-.YX-S(IVKS@D#VRIR?Q%1
M6/A-9)3?:]</=W3\E"W XQ@D>GMTP.:YGB'-\M%7\^AU+#*"YJSMY=1LOB+7
M/$<K0:+ ;.TSAKF0?/C.,^@X.>.>#@U)IWABRTT_:+QOM=TPRS2<KDCGKU[]
M?7I6\TD<,''EV\ SC P/4X%8<US->2LEH&= >7/ %$<,F^:J^9_A]P3Q+2Y:
M2Y5^/WEVYU&/:Y>94VC(!R2WL*R[83ZI/QE8<\OZ^P]36I8>'/-??.#,W^T,
M(/H.I['G\1756>E1P8) )^G2NDY2MI6EK$BL4V@?=7T_^O6T  ,"@  8%+0
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M% $G2JES?Q6Z_>^;L*S;O56?*P]/6J*@NY9R>?4\F@"S+=3W;XY"^@/\Z?#
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0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>silk-20231231x10kg006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231x10kg006.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ -#X6_"W
MP;XC^'&DZMJVC?:+Z?SO,E^U3)NVS.HX5P!P .!77_\ "DOAY_T+W_D[<?\
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M^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\
MXY7H%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE>@44 >?_
M /"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY7H%% 'G_ /PI+X>?]"]_
MY.W'_P <H_X4E\//^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\
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M5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\
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M*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\
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M_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\ PI+X>?\
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M^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\
MXY7H%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE>@44 >?_
M /"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY7H%% 'G_ /PI+X>?]"]_
MY.W'_P <H_X4E\//^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\
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M5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\
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M*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\
MH7O_ "=N/_CE>@44 ?,'QS\$^'?!W]@_V!I_V/[5]H\[]]))NV^7M^^QQC<>
MGK170?M-?\RM_P!O?_M&B@#O_@E_R2'0O^WC_P!'R5Z!7G_P2_Y)#H7_ &\?
M^CY*] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBN2U/XG^"M(NFMKSQ#:+,
MIVLL>Z7:?0[ <4 =;16=HVOZ3XAM#=:1J%O>P@X9H7SM/H1U!^M:- !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#!".A[9(S47Q_B2?P9ID;CY6U2)3]"K UU'Q.C2/X6:_&B*J)9$*H'  QC%
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M&*UB^%FA?9 NUX2TA7O(6.[/OG(_"N=MTBA_:7NA9A5\S1PUV%[MD8S[XV4
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M$TO4M=T#4-,%]<R6[138W1!,9?& 2.?0=*IWGQEN=,5+[4?!&M6FBNP"WTH
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MO,\J)M!+8QP?8"NMHH *YOQ[X8E\8^#;W0H;E+9[DQD2NI8+M=6Z#_=KI**
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M+%M\QF5E 0#A5 (X^M;EIX,FMOBCJ'B\WD;0W5FML+<(=RD;><Y_V?UKKZ*
M.1\9>#IO%&J>';R*\2W&DWHNG5D+>8,KP/3I6KXLT1_$GA34M&CF6![R Q"1
MER%SWQ6S10!E>&M)?0?#&F:2\JS/9VR0F11@,5&,XK5HHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** / /VFO\ F5O^WO\ ]HT4?M-?\RM_V]_^T:* ._\ @E_R
M2'0O^WC_ -'R5Z!7G_P2_P"20Z%_V\?^CY*] H **** "BBB@ HHHH ****
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M2ABY)P0P.%P,=0/QKTB#16T+X)ZY9IKXUNT^Q7#VMPHX6,H<(#N.0,'^6.*
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MC))ZH/S-<[>>(?"WBGXE:W)X]U4Q:5I<WV;3]/\ WGEN02&<[!UXS[[O08H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS8OC9 N@BR?2-3;Q8L7E'3_LK9,V,;O]W//K7KM% '$_"KPK=>$_ \%K?_\
M(0N9&NKE?[KMCY?J !GWS7;444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '@'[37_,K?\ ;W_[1HH_::_YE;_M[_\
M:-% '?\ P2_Y)#H7_;Q_Z/DKT"O/_@E_R2'0O^WC_P!'R5Z!0 4444 %%%%
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M[9QV;VYTF[-JS,X;S#SR...E<WX)\4>*(_'.I>#O%DEK=74%L+J"\MDV!T)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#P#]IK_F5O^WO_P!HT4?M-?\ ,K?]O?\ [1HH [_X)?\ )(="_P"W
MC_T?)7H%>?\ P2_Y)#H7_;Q_Z/DKT"@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M59KU'RY^][=CR<GIO?%RQ'B#X5:N+&1)VA"W"F-@P.Q@6Z?[.ZJ?_"A_ ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /VFO\
MF5O^WO\ ]HT4?M-?\RM_V]_^T:* ._\ @E_R2'0O^WC_ -'R5Z!7G_P2_P"2
M0Z%_V\?^CY*] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNL6-KXY\/VME8W\@BAOK*;>D3GHKY)_/CVS0!ZA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\
MH!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ
M-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P#
M=/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9
M_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC
M&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\
MXNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P"
MD?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?]
M /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_
M (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\
MA0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/
M_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)
M\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!Y
MS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/
M_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\
M^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT
M3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_
M (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?
M^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_
MY]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C
M0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?
M_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8
M_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\
MH!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ
M-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P#
M=/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9
M_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC
M&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\
MXNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P"
MD?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?]
M /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_
M (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\
MA0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/
M_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)
M\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!Y
MS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/
M_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\
M^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT
M3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_
M (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?
M^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_
MY]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C
M0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?
M_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8
M_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\
MH!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ
M-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P#
M=/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9
M_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC
M&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\
MXNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P"
MD?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?]
M /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_
M (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\
MA0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/
M_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)
M\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!Y
MS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/
M_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\
M^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT
M3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_
M (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?
M^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_
MY]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C
M0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?
M_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8
M_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\
MH!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ
M-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P#
M=/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9
M_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC
M&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\
MXNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P"
MD?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?]
M /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_
M (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\
MA0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/
M_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)
M\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!Y
MS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/
M_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\
M^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT
M3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_
M (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?
M^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_
MY]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C
M0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?
M_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8
M_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\
MH!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ
M-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P#
M=/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9
M_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC
M&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\
MXNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P"
MD?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?]
M /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_
M (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\
MA0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/
M_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)
M\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!Y
MS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/
M_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\
M^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT
M3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_
M (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?
M^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_
MY]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C
M0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?
M_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8
M_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\
MH!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ
M-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P#
M=/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9
M_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC
M&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\
MXNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P"
MD?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?]
M /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_
M (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\
MA0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/
M_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)
M\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!Y
MS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/
M_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\
M^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!YS_PT
M3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_
M (1C0/\ H!Z9_P" D?\ A0!YS_PT3X,_Y]=8_P# =/\ XNC_ (:)\&?\^NL?
M^ Z?_%UZ-_PC&@?] /3/_ 2/_"C_ (1C0/\ H!Z9_P" D?\ A0!A>"_B;X?\
M=W5S:Z3]KCN+=!(T=S$%)7.,C!(ZD?G795X9\+X8K?X[>-H8(TBB03*B(H55
M'G+P .E>YT %%%% '@'[37_,K?\ ;W_[1HH_::_YE;_M[_\ :-% '?\ P2_Y
M)#H7_;Q_Z/DKT"O/_@E_R2'0O^WC_P!'R5Z!0!4U+2[#6+-K/4K."\MF(8Q3
MQAU)'0X-8O\ PKSP9_T*VC_^ :?X5TM% &;I/A[1M!\[^R-*L[#SMOF_9H5C
MWXSC.!SC)_.L_4_ 7A36+PWFH>'[">X+;FD:(!F/^UCK^-=%10!!:6=KI]K'
M:V=O%;V\8PD42!54>P%9FM^$O#_B1D;6-(M;QX^%>1/F ]-PYQ[5M44 4M,T
MG3M%LQ::98V]G;@Y\N",(,^O'>DCT;3(=7FU:/3[9-1F4)+=+$!(Z@  %NI&
M%'Y"KU% &=K&@:3XAM1;:OIUO>P@Y59D#;3Z@]0?I4>B^&M$\.Q-'H^EVMDK
M_?,,8!;ZGJ?QK5HH K7^G66JV;VFH6D-U;/]Z*9 ZG\#67HO@SPWX=G,^D:+
M9VDQ&/-2/Y\>FX\XK=HH **** "O.=3_ .2SZ/\ 7_VVN*]&KSG4_P#DL^C_
M %_]MKB@#T:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#P_P"&O_)?/'/_ &V_]'+7N%>'_#7_
M )+YXY_[;?\ HY:]PH **** / /VFO\ F5O^WO\ ]HT4?M-?\RM_V]_^T:*
M._\ @E_R2'0O^WC_ -'R5Z!7G_P2_P"20Z%_V\?^CY*] H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O.=3_Y+/H_U_P#;:XKT:O.=3_Y+/H_U_P#;
M:XH ]&HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#H8-2_[Z'^%;U% &#_ ,(]=_\ 0P:E_P!]#_"C_A'KO_H8-2_[Z'^%;U%
M&#_PCUW_ -#!J7_?0_PH_P"$>N_^A@U+_OH?X5O44 8/_"/7?_0P:E_WT/\
M"C_A'KO_ *&#4O\ OH?X5O44 8/_  CUW_T,&I?]]#_"C_A'KO\ Z&#4O^^A
M_A6]10!@_P#"/7?_ $,&I?\ ?0_PH_X1Z[_Z&#4O^^A_A6]10!@_\(]=_P#0
MP:E_WT/\*/\ A'KO_H8-2_[Z'^%;U% &#_PCUW_T,&I?]]#_  H_X1Z[_P"A
M@U+_ +Z'^%;U% &#_P (]=_]#!J7_?0_PH_X1Z[_ .A@U+_OH?X5O44 8/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M5_$WXD'2O.T/1Y"+XC;/.O\ RR![#_:]^U>%,S.Q9B68G))/)KVCXW0:)'!:
M3%0-:D.%V=3&.I;^0_\ K5XM7MX-15).*/H\!&"HIQ5KG<_#_P"(-SX3NQ:W
M3--I4K?/'U,1_O+_ %%?0.F:YI6LQ[].U"VNAC)$4@)'U'45\ZZ7\,O$VL:(
MNJ6EK'Y;G]W%))LD<?WAGC'U(K)O_"_B+1"9KO2KVV$9SYHC.U?^!#C]:SK4
M*5:6DK,QKX:A7G>,DI'UA17RSI?CWQ1I##[+K-RR_P!R9O-7\FSC\*[#3/CC
MJT# :GIMK=1^L+&)OZC]!7+/ 55MJ<<\LK1^&S/=J*\ZTSXS^&;U@EXMU8,?
MXI(]Z_FN3^E=AIOB;0]88+I^JVEPYZ(DHW?]\]:YIT:D/B1QSH58?%%HU:**
M*S,@HKF[[QSH6G>(X-#N+L+=2CEOX(SV5CV)KI,Y&15.,HVNMRI0E%)M;A11
M14DA1110 4444 %%%% !1110 445CZKXIT31=RWVHPQR*.8@=S_]\CFANQ=.
MG.I+E@KOR-BBO+-6^,*!632-/);M+<G _P"^1_C7"ZMXQU_6V(N]0E$9X\J(
M[$_(=?QS6;JI'LX?(,55UG[J\]_N/;]6\9Z!HN];K48C,G!AB.]\^F!T/UQ7
M@6NW\>J:]?W\*LL=Q.TBA^H!/>M32? GB'6&4Q:>\,+<^;<?NUQZ\\G\ :QM
M3L)-+U2ZL)75Y+>0QLR]"0<<5E.3:U/H,LP6%PLY1I3YIVU*E/BE>&9)8F*2
M(P96'4$=#3*O:(BR:]IR.H96NH@RD9!&X5![$VE%MFD/'/B<  :S<\>I!_I2
M_P#"=>)_^@S<_I_A7O!\/:*3DZ38_P#@.O\ A1_PCNB_] BQ_P# =/\ "MO9
MR[GR7]M8+_GPOP_R/"D\?>*4&!K$Q^JJ?YBG?\+!\5?]!B3_ +]I_P#$U[B?
M#>AL<G1[ _\ ;NG^%)_PC.@_] ;3_P#P&3_"CV<NX?VS@?\ H'7W+_(\17XB
M>*T.1J[_ (PQG^:T_P#X63XM_P"@M_Y+1?\ Q->U'POH##!T73S_ -NR?X4W
M_A%/#W_0#T[_ ,!D_P *.27<7]KY>]\.ONB?.$\\ES<2W$S;I97+NV,9).2>
M*CJ]K,:1:[J$<:*D:7,BJJC  #' %4:Q/KH-.*:+%C93:C?P65NH::=Q&@)P
M,GWKTS2?@\VX/J^H@+WBM1_[,?\ "N&\'_\ (XZ/_P!?<?\ .OI"M:<4]6?.
MY[F&(PTXTZ3M=?,P=)\&:!HJ@VNG1-(.?-F'F/GZGI^&*WJ**V22V/D:E6I5
MES5&V_,****9F%%13W$%K$9;B:.&,=7D8*!^)K U'QYX;T^WD?\ M:VFD525
MCB?>6/IQFIE.,?B9$JD(?$[&U%J-I-J,]A',INH$5Y(^X#9Q_*K5?.VA>,+B
MR\<?VW<.2MS(1<#_ &"?Z<?E7T':W5O>VZW%K/'-"XRKQL&!_$5CA\0JJ9AA
M<5&NGY$U%%%=!U!6'K/A#0]=4F\L(_-//G1C8^?J.OXYK<HI-)[FE.K.E+FI
MMI^1Y%K/P@N8R\FCWJS)U$-Q\K?3<.#^0KA;S3-:\.7*M<V]U8R@X6097/T8
M<'\#7TO3)H8KB)HIHTDC;JCJ"#^!J'270]O#<08B"Y:R4U]S_KY'RO1117.?
M;G5_#;_D?],_[:_^BGKZ KYY\ 74%EXXTV>YE2*(%U+N< $QL!^I%?0U;TMC
MXKB1/ZU%_P!W]6%%%%:GSP4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 97B36O^$>\/W6J?9_M'D;/W6_9NW,%ZX/KGI7G_\ PN?_ *@'_DY_]A73
M?$R>*/P)?Q/*BR2F,1J6 +D2*3@=^!FO ZQJ3:>A]3DF6X;$X=SK1N[]VM++
MLSU;_A<__4 _\G/_ +"NJ\%^-/\ A+_MW_$O^R?9?+_Y;>9NW;O]D8QM_6OG
M^NR\!>,;7PFU^+JVFF6Z\O!B(^7;N]?]ZIC4=]6=F/R3#K#R>'I^_I;5]U?=
M]CWFBN+L_BEX9N>)9[BU/_3:$G_T'-;-OXP\.W./*UFSY[/*$_GBMU)/J?*5
M,%B:?Q4VODS;HID4T5Q&)(94D0]&1@0?Q%/IG*U;<***JZAJ5EI5M]HO[F.W
MA+!=\AP,GM^E XQ<G:*NRU16#_PFOAK_ *#5I_WW1_PFOAK_ *#5I_WW2NC?
MZK7_ )']S-ZBN9OO'_AJQLVG&I1W!'"Q0?,S'Z=OJ:\U\0_%'5M4WP:</L%J
MW&5.96'^]V_#\ZES2.O"Y1BL0](V7=Z'JFO>+='\.HWVVZ7SP,BWC^:0_AV^
MIQ7E?B'XHZMJF^#3A]@M6XRIS*P_WNWX?G7/:-X:UKQ-<%K.VDE5F^>XD.$!
M[Y8]3],FO4?#WPKTS3MD^JO]ON <[,8B'X=6_'CVJ+SGL>S]7R[+=:SYY]O^
M!LOF>7:-X:UKQ-<%K.VDE5F^>XD.$![Y8]3],FO4?#WPKTS3MD^JO]ON <[,
M8B'X=6_'CVKO8HHX(EBBC6.-1A548 'L*?51II;GG8S/,17]VG[D?+?[_P#(
MKM86;P) ]I T,?W(VC!5?H.U1?V/IG_0.L_^_"_X5=HK2QXZJ36S*7]CZ9_T
M#K/_ +\+_A5B"W@MH_+MX8XDSG;&H49^@J6B@3G)JS84444$GA_PU_Y+YXY_
M[;?^CEKW"O#_ (:_\E\\<_\ ;;_T<M>X4 %%%% '@'[37_,K?]O?_M&BC]IK
M_F5O^WO_ -HT4 =_\$O^20Z%_P!O'_H^2O0*\_\ @E_R2'0O^WC_ -'R5Z!0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %><ZG_ ,EGT?Z_^VUQ7HU>
M<ZG_ ,EGT?Z_^VUQ0!Z-1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5#6=7M="TBYU*]?;
M! FX^K'L![D\5?KY[^*_C3^WM7_LFRDSIUDY#$=)9>A/T'0?C6^'HNK.W0Z<
M+AW7J<O3J<GJ^IZEXR\3O<LC2W5W*$AA4YVCHJ#_ #[U[?H_PET&TL-,^W0F
M:]MCYDSAOEE<]B.Z@]/I6'\'O!?V>#_A);^+$LHVV:,/NKW?\>@]L^M>NUT8
MK$6?LZ>B1UXW%-2]E2=DA%544*JA5 P !P*6BBN \LQ]2\*:!JZL+[2+.8MU
M?R@K_P#?0P?UKCM1^"GARZ5C937EDY^[A_,4?@W)_.O2:*TA6J0^%FT,15A\
M,F>#:C\#];MPS6&H6=V!T5P8F/\ ,?K7':AX(\4:5N:ZT6\54Y+QIYBCWRN1
M7U5173''U%OJ=<,SK+XK,^4M-\8^(]'<&SUB\CV\;'D+K_WRV1^E=,/C-XI-
MC+;O]C:1T*B<1$.I]1@XS^%>[:AH&CZJ&%_IEI<ENIDA4G\^M?/WC?0-,TGQ
MA?V-C;>5;1E"B;V.,QJQZG/4FKEC*#5YP_+_ (!Z."5+'U'#D2:5]?Z\SBI9
MI9IFFED9Y7;<SL<DGUS7L7PS^)F!#H6NS>B6UTY_)6_H:\Q^Q6__ #S_ /'C
M2K:0*P81C(.1DDU-7'X>K'E:?X?YGK5\HE6ARRM_7R/K*BN<\.>--!U_2UN+
M.[B@\M0)()F"-%[$'M[CBK<OBOP_ 2)-:L1CKB=3_(UQ23B[2/C/85;\JB_N
M-BBN9F^(7A6#.[5XV/I'&[?R%95Q\6?#L1Q$E[/[I$ /U(J.:/<WAEV+GM3?
MW'=T5YI-\8]/7_4Z5<O_ +\BK_C6=<_&2Z;_ (]='AC]#+,7_D!2]I$Z89)C
MI?8M\U_F2^,?B#KFA^*[W3K,V_V>'9MWQ9/**QYSZDUA_P#"UO$O]ZT_[\__
M %ZY?7-8GU[6+C4[I(TFGV[EC!"C"A1C)/85GU@YN^C/KL/E>&C1BJE-<R2O
MIUMJ=Q_PM;Q+_>M/^_/_ ->NFU;XP6D8>/2;"29^BRSG:OUVCD_I7D->I:3\
M'Y"RR:OJ"JO>*V&3_P!]'_"JC*;V.7'83+*'+.M%+>R77;L<AJ_CKQ#K/RS7
M[PQ?\\K?]VOXXY/XFHM*\'Z_K95[73Y?+?GSI?D3'KD]?PS7MVD>#- T4 VN
MGQM*.?-F'F/^9Z?ABM^J5-OXF>;4S^G1CR82FDO/_)?YGEFD_!Y%(?5]1+_]
M,K88'_?1_P *[O2?"NB:(J_8=/A1Q_RU8;W_ .^CS6Q16BBEL>+B,QQ6(_B3
M=NVR"BBBJ.(**9YL?G>3O7S=N[9GG'3./2GT %%%% !114%U>VMC%YMW<PV\
M?]Z5PH_,T7L#=MR>BN:N_'_A:R!\S6('([0AI,_]\@USMW\9-%B+"UL;R<CH
M6VH#^I/Z5C+$4H[R,)XJC#>2.\;2M.=BS:?:LS'))A4DG\JXK2O$>BZEXYO=
M#&G6/D(NV"3R5^9U^\.GY?2N3U7XPZI>0R0V5A;VB.I7<SF1QGN#P/TKSR&Y
MGM[E;F&:2.=6W+(C$,#ZYKCK8V-UR?,XZ^;-2C[*3MU/J1-,T^)UDCL;5'4Y
M#+"H(/UQ52\\3Z%8,5NM7LHV'53,"P_ <U\XM>:QK$OE-<7U[(W\&]Y"?PYK
M1M? OBB\QY6BW0S_ ,]0(_\ T(BG]=E+X($RS.K4^"#?XGKU]\5/"]GQ%<SW
M;>D$)_FV!6!=_&FV4$66C2N>S33!<?@ ?YU@V?P>U^90US<65MGJI<NP_(8_
M6M^Q^"]HASJ&KS2_[,$03]3G^5'/BY[*W]>8O:8ZILK?UYG.W7Q>\1SY$*6=
MN#TV1%B/^^B:Y^^\;>)=08F?6;H _P ,3>6/R7 KV*T^%GA6U(+VDMRP_P">
MTS?R&!70VOA[1K$#[+I5E$1T*P*#^>*/JV(G\<P^IXJ?QS/F^#3=:UIO,AM+
MZ]/]\(S_ *U7U#3;S2KG[-?0-!. &,;8R >F?2OJDY"'8 2!P"<"O&=4^%OB
MG5M3N+^XN]-,L[ES^^?C/;[E8UL&XI<MVS"OE\H17)>3/,JMV&J7^ER^;87D
M]L^<YB<KGZ^M=M_PIWQ'_P _.F_]_7_^(K6\.?#'6])UF&XO1I5U9GY9X79F
MW(>N 4QGTK&.&JW6C1SPPE?F6C1GZ/\ &#5[5E35+:*]BZ%U'ER?7C@_E7?Z
M/\2?#>KJ%:\^Q3'CR[H;/_'ON_K69K'PCT2]#OITLUA,>0 ?,C_(\_K7G^L?
M##Q'I67AMUOX?[]L<D?53S^6:Z^;%4=_>7]?,[N;&T-US+[_ /@GT CK(BNC
M!E89!!R"*6OF+3]=USP[<E+2\N;1XVPT+9V@^A0\?F*[O1OC)=18CUBP2=?^
M>MN=K?BIX/YBM:>.IRTEH;4LRI2TGH>Q45SNC^.?#NMA%MM1CCF?CR9_W;Y]
M.>"?H3715UQE&2O%W.^$XS5XNYY5_P *8_ZC_P#Y)_\ V='_  IC_J/_ /DG
M_P#9UZK4,5U!/--%%*KR0,%E4'E"1D _@12]G$]?^W,?_P _/PC_ )'@OBSP
M)J'A?;-O^UV+<?:$3;M/HPR<?G6SX(^(TNE^7INL.TME]V.<\M#]?5?U%>R2
MPQW$+PS1K)&XVLCC((]"*\;\;_#F32_,U+1T:6R^])!U:'W'JOZBH<7%WB>K
MA<QHYA3^K8W?H_ZV?X,]DAFCN(4FAD62)U#*ZG(8'N*?7@7@[QU>>&9A;S;K
MC36/S0YY3W7_  Z&O<M-U*SU:QCO+&=9H''#*>GL?0^U7&:D>/F&6U<%/76+
MV?\ 74MT4459YH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 444$@#)X H **Y'7/B-H.C QQS
M_;;@<>7;G('U;H/UKS37?B5KNL!XH)!86S'[D!^<CW?K^6*B51(]7"9-BL3K
M;E7=_P!7/7];\6:+H"M]NO4$P&1 GS2'\!T_'%>:ZY\6]0NBT6CVZVD6,>;(
M \A^@Z#]:Y/1_"VN>(Y0]G:2/&[?-<2G:GN2QZ_ADUZ3H?PDL+8"76+AKN3.
M?*B)2,?4]3^E1><MCUOJN69?K7ESR[?\#_,\FN)K_4WFN[B2XN3& 9)7);:"
M<#)[#)Q52OIF?P_I5QI$FE/8Q+8R8W0QYC!P01]W!Z@5C?\ "MO"7_0)_P#)
MF7_XJDZ3-J7$F'2M*#7:UMOO1\_UU/@_P8_BY+[R[Y;9K7R\!H]P?=N]QC&W
MWZUZO_PK;PE_T"?_ "9E_P#BJUM%\-Z1X>\_^R[3[/Y^WS/WCONVYQ]XGU-"
MI.^I&*XBIRI-4$U+HVEW]7T/*KGX0ZY&"8+NRFQT!9E)_3'ZUB7/P^\4VI.[
M29' [Q.KY_(YKZ%HJW2B>?3XBQ<?B2?R_P CYFFTS6=)/F2V=]:8_C,;)^M3
M6OBK7[-@8-8O5QV,I8?D<BOI.J5QI&FW?_'QI]K+G^_"I_F*GV3Z,Z5Q#":M
M6HI_UYH\4M_BEXH@QYES!/\ ]=(%'_H.*B\1?$"_\2Z,-/O+2W3$JR"2+<.@
M(Q@D^M>KW?P^\+WA+/I4<;'O"S1_H#C]*X3Q[X%TCP[H2ZA8-<"0SK'M=PRX
M()],]J4HS2W.G"8W+*U:*A2Y97TT6_R9YK11161],;&A>&-6\13;-/M2Z!MK
MS-PB?4_T'->I^'OA7IFG;)]5?[?< YV8Q$/PZM^/'M47P>_Y%Z__ .OO_P!D
M6O1:WA!6N?&9OFN)5:5"#Y4NV[^8R**.")8HHUCC4855& !["GT45J?.7N%%
M%% !1110 4444 %%%% 'A_PU_P"2^>.?^VW_ *.6O<*\/^&O_)?/'/\ VV_]
M'+7N% !1110!X!^TU_S*W_;W_P"T:*/VFO\ F5O^WO\ ]HT4 =_\$O\ DD.A
M?]O'_H^2O0*\_P#@E_R2'0O^WC_T?)7H% !1110 4444 %%%% !1110 4444
M %%%% !1110 5YSJ?_)9]'^O_MM<5Z-7G.I_\EGT?Z_^VUQ0!Z-1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3_P+2@#>HK!_MC6_^A;D_P# M*/[8UO_ *%N3_P+2@#>HK!_MC6_^A;D_P#
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M;:>(]2N/'=_H$GAZYAT^VA62/568^7,Q5#M VXR"Q'WC]TUTE% 'DNM6VK>
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MT8Q;2;?J?-+JJR,JMN4$@-CK[TVO3?\ A2^I_P#05M/^^&H_X4OJ?_05M/\
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M.#Z<&HJ?">QD4%/&)25U9G*?\)5XA_Z#FI?^!3_XT?\ "5>(?^@YJ7_@4_\
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M9F_^+I1\,_" ((TG!'0_:9O_ (NNLHJ/8TOY5]Q'U>C_ "+[D-1!'&J+G:H
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MFG_1]<NR/[LS>:/R?-6]7^)GB?6M)?3KJ[C$,G^L:*,(SCT)':OH:Z\,:#?
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M-;T<1.D]-CIP^*J4'[NW8^:_!?Q)U/PHZ6TI:\TO/S0.WS)[H>WTZ?3K7O\
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M9-G[)K%Q%Z>;"K_R*T<N,CL[_<')CX[._P!Q9'Q<\-W0"W>G7F#_ 'HD<?\
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MRT;1791BOT/%M7^%5SI6DW5^=5BE6WB:0IY1!.!G'6O/:^GM8T_^UM&O-/\
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MZO?IY'IGB7Q]I6BZ<D]I>6M[,\JKY<,RN0N?F)P>.,_CBM>+Q5H$T*2#6M/
M=0P#7* CZC-?,;,6.:>C@#!KECC;U'?86$Q."K8^5*=3EI_9D]-?/M<^J[:Y
MM[RW6>UGBGA?.V2)PRG!P<$<=:EKDOAG+')X!TY4=6*&4, <E3YC'!]."#^-
M=;7H1=U<WK0C"K*,'=)M)]PHHHIF04444 %%%% !1110 4444 %5KZ_M-,M'
MNKVXC@@3J[G _P#UUR_BGXAZ9X?#VUN5O+\9'E(WRQG_ &C_ $'/TKQW5=;U
MCQ5J*&ZDDN)7;;%!&#M'LJC_ /76<JB6Q[6 R6MB??J>[#\7Z?YG8>*OBE<W
MOF6>A!K>W.5:Y8?O''^S_='Z_2N%M]+U74P\]M87EV-WSR10M)\WN0.M>B>%
M?A4T@2\\0$JI&5M$;G_@;#I]!^=;7CGQQ8^"-.73-+BA&H,G[J%% 6$?WB/Z
M=Z*=&=:5CU5F&&PC6'P,.9]7_P 'K^1XM=PRV$Y@O8GMI@,F.92C#\#4'GP_
M\]4_[Z%9\TMSJ=U/=74SRSR$L\CG)9C5[PK>:?IWB>QN]4MVGM8I S(OKV)'
M< \X]J[5@*3<HJ=W'<Z5G2;G%).4=T>Y_#'P<N@::^J7<?\ Q,;X;L,I!BCZ
MA>>A/4_AZ5WU<%K/Q9T'3P%L5EU"4C/[OY$'L6/] :\VUOXD>(M:5HA<BSMR
M?]7:_*<>[=3^=>;6QM.+U=V?G^,S6G*I*<G=OL>V:SXLT/0 PU"_B24#/DJ=
MTA_X".?SKS?6_C'<R@QZ+9+ O_/:X^9OP4<#\2:XO1_".O\ B)UDL[&5XG/-
MQ+\J>YW'K^&:]&T3X.6<.)-:O&N6_P">,&43\6ZG]*YO:XBM\"LCS_;XO$?P
MURK^NO\ D>87-_K?B>_"S37=_<.<K&,M^2C@?@*ZO1/A+K6H*LNHR1Z=$3]U
MOGD(^@X'XG\*]GT[2-.TB 0Z?90VR 8_=I@GZGJ?QJ[5PP,;WJ.[-:>6QOS5
M7=G@GB7X?W]KJAMM$TF^GM8E -P_)E;N1TX[5C_\(-XH_P"@)=_]\U])T4Y8
M"#=[CEEE*3O=H^=]+\+>+M*U.WO[?1KL2P.''R]?:OH.VE:>UBE>)HG= S1O
MU4D=#4M%;T*"HW29TX;#*A=1=[A1116YTA1110 4444 %%%% !1110 4444
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M:UX>@RO+W%F@Z>K(/3U7\JXSP-X]OO!][M.ZXTV5LS6^>G^TGH?Y]^Q'2/\
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MR?:O>M'^%OAFPTB*TO+"*]GQF6>3.YF[XQT'H*[%;6W2Y>Y2")9Y  \@0!F
MZ GJ:EKHK8N=2R6AUXC'5*MDM#B9OA+X-E)*Z8\1/]RYD_JQJC+\%_"LGW&O
MX_\ =G!_F#7HE%9+$55]IF"Q59?:?WGE5S\"]'?_ (]=6OHC_P!-%1_Y 5ER
M_ >8?ZGQ!&WIOM2O\G->TT5:Q=9?:-%CL0OM?D>$2_ S6A_JM4L'_P!X.O\
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M7SS\5OAWI?A+X>_VAY]SJ.LW%[$MQJ%W(6D?Y7R!_=&1[G@<FOH>O)_VAO\
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M5ES^*?$%R29M:OVSV^T,!^0.*]B7X2>&EZF\;ZRC_"I!\*?# '^KNC_VV_\
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M/[-L/^?*V_[]+_A0!4_X231?^@G;?]]T?\))HO\ T$[;_ONK?]FV'_/E;?\
M?I?\*/[-L/\ GRMO^_2_X4 5/^$DT7_H)VW_ 'W1_P ))HO_ $$[;_ONK?\
M9MA_SY6W_?I?\*/[-L/^?*V_[]+_ (4 5/\ A)-%_P"@G;?]]T?\))HO_03M
MO^^ZM_V;8?\ /E;?]^E_PH_LVP_Y\K;_ +]+_A0!4_X231?^@G;?]]T?\))H
MO_03MO\ ONK?]FV'_/E;?]^E_P */[-L/^?*V_[]+_A0!4_X231?^@G;?]]T
M?\))HO\ T$[;_ONK?]FV'_/E;?\ ?I?\*/[-L/\ GRMO^_2_X4 5/^$DT7_H
M)VW_ 'W1_P ))HO_ $$[;_ONK?\ 9MA_SY6W_?I?\*/[-L/^?*V_[]+_ (4
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M 'W1_P ))HO_ $$[;_ONK?\ 9MA_SY6W_?I?\*/[-L/^?*V_[]+_ (4 5/\
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M-L/^?*V_[]+_ (4?V;8?\^5M_P!^E_PJ#,J?\))HO_03MO\ ONC_ (231?\
MH)VW_?=6_P"S;#_GRMO^_2_X4?V;8?\ /E;?]^E_PH J?\))HO\ T$[;_ONC
M_A)-%_Z"=M_WW5O^S;#_ )\K;_OTO^%']FV'_/E;?]^E_P * *G_  DFB_\
M03MO^^Z/^$DT7_H)VW_?=6_[-L/^?*V_[]+_ (4?V;8?\^5M_P!^E_PH J?\
M))HO_03MO^^Z/^$DT7_H)VW_ 'W5O^S;#_GRMO\ OTO^%']FV'_/E;?]^E_P
MH J?\))HO_03MO\ ONC_ (231?\ H)VW_?=6_P"S;#_GRMO^_2_X4?V;8?\
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MV;8?\^5M_P!^E_PH J?\))HO_03MO^^Z/^$DT7_H)VW_ 'W5O^S;#_GRMO\
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M:'JWBG5&M]-MI;EP0"Q^[&O0;B> *@TNTU+6=1BL+"-IKB4X50H_,^@KZ?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#_ (:_\E\\<_\
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MG76445G.;F^:1G.<IR<I/4****D@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+4K2Y8M]JG"7!D&<8#$= 01@5V-U;0WMG-:7""2">-HY$/\ $I&"/RKR_2_
M_C[P9%/IOA/7-'FT=Y6D@BU2.3?!N.< J#G^1/.!F@#'T+21X=^+?BKPIHA=
M-+OM*:X%L&RL4A4 8ST^\<>Q'I6]\ IDD^&,40^_#=S(X]#D'^1%;?@7P)+X
M:NM0UC5[\:EK^I-FYN@NU57LB#L/RZ#@8K%?P+XN\-:_J5YX'U;3(K#4I?/F
ML=21RL<AZLA4'^G8'.!0!!?H;G]I72_+Y^RZ.[RX/3.\#/\ WT*]6KB/ _@:
M[T'4M2U_7M034?$&HG$LZ*0D:#&$0'MP/3@ 8XK333?$@\>2ZB^K1'PZ;?8E
MAM^<28'S9V_7OWH XCP.#:?';QU:RY$LR1S(#W7@_P#LXJ7X[(;G0M L4YFN
M=8B2-0>3PP_J*V?%_@?5KWQ+:>*O"NIP:?K<$1@E%RI,-Q'V#8!/Z'MTQ5/3
MO GB/5_%MCX@\<:G871TX$V5CIZN(4?^^=P!)_P'/&* *-BIMOVEM4\TX^UZ
M.C19/4#8#C_ODU8^/DJI\,)HC]^:[A1!ZG.?Y UL>./ ]YKNIZ;K^@:@FG>(
M-.)$4TBDQRH<Y1P.W)['J>/3'3P)XM\3:]IM[XYU;39;'3I/.BL--1PDD@Z,
MY8#^O<#&30!Z)I4#VNCV-O("'BMXT;/J% -6Z** ,S4+/5;B=6L=56UC"X*&
MW5\GUR:\^U"WOU^)FFVSWP?4&/[N[\H )^YF/W.A^4,/^!9[5ZI7G.I_\EGT
M?Z_^VUQ0!THTOQ'GGQ$F/^O-*?\ V9XA_P"AA3_P"3_&MZB@#!_LSQ#_ -#"
MG_@$G^-']F>(?^AA3_P"3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3
M_&MZB@#!_LSQ#_T,*?\ @$G^-']F>(?^AA3_ , D_P :WJ* ,'^S/$/_ $,*
M?^ 2?XT?V9XA_P"AA3_P"3_&MZB@#!_LSQ#_ -#"G_@$G^-']F>(?^AA3_P"
M3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\
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M3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\
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M3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\
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M3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\
M@$G^-']F>(?^AA3_ , D_P :WJ* ,'^S/$/_ $,*?^ 2?XT?V9XA_P"AA3_P
M"3_&MZB@#!_LSQ#_ -#"G_@$G^-']F>(?^AA3_P"3_&MZB@#!_LSQ#_T,*?^
M 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\ @$G^-']F>(?^AA3_ , D
M_P :WJ* ,'^S/$/_ $,*?^ 2?XT?V9XA_P"AA3_P"3_&MZB@#!_LSQ#_ -#"
MG_@$G^-']F>(?^AA3_P"3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3
M_&MZB@#!_LSQ#_T,*?\ @$G^-']F>(?^AA3_ , D_P :WJ* ,'^S/$/_ $,*
M?^ 2?XT?V9XA_P"AA3_P"3_&MZB@#!_LSQ#_ -#"G_@$G^-']F>(?^AA3_P"
M3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\
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M3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\
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M3_&MZB@#!_LSQ#_T,*?^ 2?XT?V9XA_Z&%/_  "3_&MZB@#!_LSQ#_T,*?\
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M*?\ @$G^-']F>(?^AA3_ , D_P :W5974,I!4C((/!I: ,'^S/$/_0PI_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P_P"&O_)?
M/'/_ &V_]'+7N%>'_#7_ )+YXY_[;?\ HY:]PH **** / /VFO\ F5O^WO\
M]HT4?M-?\RM_V]_^T:* ._\ @E_R2'0O^WC_ -'R5Z!7G_P2_P"20Z%_V\?^
MCY*] H **** "BBB@ KRB'7/&/Q!\1:O#X9U>#0]$TN8VOVHVRSR7,HZX#<
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M[_OBX_\ C% 'H%%>?_\ "?:]_P!"9??]\7'_ ,8H_P"$^U[_ *$R^_[XN/\
MXQ0!WLLL<$3RRN$C099F. !2QR)+&LD;!D8 JPZ$&O.;[QGKE_8SVC^$;^-9
MD*%Q%<,5SWQY(S^=/M?&VNVEI#;KX/OG6) @8Q7 S@8SCR>* /1:*\__ .$^
MU[_H3+[_ +XN/_C%'_"?:]_T)E]_WQ<?_&* /0**\_\ ^$^U[_H3+[_OBX_^
M,4?\)]KW_0F7W_?%Q_\ &* /0**\_P#^$^U[_H3+[_OBX_\ C%'_  GVO?\
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M"L%PV2O;_4CKZT >FT5Y_P#\)]KW_0F7W_?%Q_\ &*/^$^U[_H3+[_OBX_\
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MQ<?_ !BC_A/M>_Z$R^_[XN/_ (Q0!Z!17G__  GVO?\ 0F7W_?%Q_P#&*/\
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M#T"BO/\ _A/M>_Z$R^_[XN/_ (Q1_P )]KW_ $)E]_WQ<?\ QB@#T"BO/_\
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ME]_WQ<?_ !B@#T"BO/\ _A/M>_Z$R^_[XN/_ (Q1_P )]KW_ $)E]_WQ<?\
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MV'T'[DY^O% 'IM%>?_\ "?:]_P!"9??]\7'_ ,8H_P"$^U[_ *$R^_[XN/\
MXQ0!Z!17G_\ PGVO?]"9??\ ?%Q_\8H_X3[7O^A,OO\ OBX_^,4 >@45Y_\
M\)]KW_0F7W_?%Q_\8H_X3[7O^A,OO^^+C_XQ0!Z!17G_ /PGVO?]"9??]\7'
M_P 8H_X3[7O^A,OO^^+C_P",4 =W%<PSO(L4JNT3;'"G.T^AJ6O,K'Q7K>GS
MWDJ>$]0D-U,9F!@N%V'T'[DY^O%7?^$^U[_H3+[_ +XN/_C% 'H%%>?_ /"?
M:]_T)E]_WQ<?_&*/^$^U[_H3+[_OBX_^,4 >@45Y_P#\)]KW_0F7W_?%Q_\
M&*/^$^U[_H3+[_OBX_\ C% 'H%%>?_\ "?:]_P!"9??]\7'_ ,8H_P"$^U[_
M *$R^_[XN/\ XQ0!Z!44%S#<AS!*L@1BC%3G##J/K7"?\)]KW_0F7W_?%Q_\
M8JEIOBO6],CG1/">H3>=.TY+07"[2W;_ %)SCUH ]-HKS_\ X3[7O^A,OO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_=3*VR2)CQ\K>_IR#Z4 9/Q5\.V.O^ ]1DN1LN+"%[NVG!PT;H">#Z'&#_\
M6%:?@#5;K6_ .B:C>[C<S6JF1FZL1QN_'&?QKBHO@]JDP33=5\=:K>^'T/\
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M2?[HF<#\@,?A0!=LOAEX9AU+5-1U"QCU6\U"=I9);]!*44]$4'@ #C(YKD/
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MSIGQ/L=;U?\ X1?Q+X?O]#N-0C*11WRX6<-QMS@8)Y XQVSF@##T#P%?^/\
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MFHO#_A_3?#&C0:5I5N(;:$<?WF/=F/<GUK3H **** "BBB@ HHHH **** /
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MZ7#Y5K ,+GEF)ZLQ[DGO5K3K"#2]-MK"U#B"VC6*,.Y8[0,#)/)JS0 4444
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M/;*$-YH[FXVC&_!8 GW^5?RKI/&GP[T3QDT5Q.TECJT0_P!'O[9MLJXZ9_O
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M]U%R=H_SQ3?A[X*N?#%K=:AJ]]+>Z[J;"6]E+DH#V51TXSU_+ KM: "BBB@
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MMZ@=2"<=<=<6/%NB:EJ7]E?$SP2K+JPMDDFM"/\ CZA*@[2!U8 XQW &.0*
M$\3_  UN_#5T?%/PZ+66H0Y:?34),-RG<!?7_9Z>F"!2:CJ2_$KP):>*_#Z&
M#Q'H4WGK 1EDD49DB/<JPZ>O XYKK?!?Q&T/QG8J8)UM=11?](L9F DC(ZXS
M]X>X_''2N5\"FVF^,WC"YT%@^BO#'Y\D1S$USQG:>A/W^GJ: .L"Z-\5/AX@
MEW?8=1B4N$8;X74@D XZJP]/T-;VBZ+I_A[28-,TRV2WM8%VJBCKZDGN3W-/
MTS2;#1[9K?3K6*VA>5Y66-< NQRQ_/\ PJY0 4444 %%<[XT\60>#O#[:C)
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MR1#A7.[9(HSU^4Y&<$>QH V]=^$'A#5]*6VM=,ATRYA3%O=V:['1AT+8^_\
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M.'7:.Y(4CD<&NC\'?$K1O&-W<:?!%=V.IVX)DLKV/9( .I')SU^OM6+K/_%
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MV:UOB)X.U3QLVD:=!?I9:5#<&XNY5SYVY1\FSMW;GMP:S),_#_XG+(,IX?\
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MTC*/1=Q./PJOX \(7N@#4M7UN>.XU[6)1-=O$/DC ^[&OL,G_(KM* "BBB@
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M1^!;'X5T] !1110 445Y3KIU+Q]\2;_PC#K%WI6CZ1!'+=FS;9+<.X! #=E
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M@!0,  =*6BB@ HHHH *P_&'AJW\7>%;_ $2X8(+A/DDQ]QP<JWX$#\,UN44
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M^Z[("1^->?:/\,[]M<M=5\7>)KG7Y+%M]G Z>7%&_P#?(SR?\\UZ-0 4444
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MQ?W'4J.BJ.=J]/R'H!0!T=MI.FV4[SVFGVL$S_?DBA56;ZD#FKE%% !1110
M4444 86K>%;#6/$6BZW<M(;C26D:!-WR$NN.1Z@@$'VKDO'W@&\GU!/%_A"3
M['XDM?F95X6\4=58="V..>O0]B/2J* ..\!>/++QQIDL<D7V75K;]W?6$@PR
M-T) /)4G\NAJUX/\!:%X(AN4TFW(DN)"\DTAW/C/"9_NCT_&MJWT?3;34KK4
M;>Q@BO;H*)YT0!Y,=,FKM !1110 4444 %>.^)?MWPL\>S^+;6WDN/#6L,JZ
MI%'R8)>T@'N3G\6'&17L517-M!>6TMM<PI-!*I22.1<JP/4$4 5;2[TSQ'HR
MW%O)#?:==Q\'[R2*>""/T(->:?#6U&@>.O&'@B,BYT>V,=U;J_S"+S "4.>O
M# ?\!/K4[_"*^T:^FE\%>+;W0[6<YDLV7SHP?5<G^>3[UUO@SP79^#K"=(KB
M:]O[M_-O+ZX.9)W]3[<G YZF@#=M-.L; ,+.SM[8-RWDQ*F?R%6:** "BBB@
M HHHH \:U.>[^$7CZZU9HY)O".NS![C;S]DG/5L?F?<<=5%>K$:9XDT,C,-]
MIM[#C@[DD1A4]]8VNIV,UE?6\=Q;3*4DBD&0P->9?\*CU31KB9/!_C._T?3Y
MSE[-U\U4)ZE#D8_G[T 'PB$FF:GXN\(>8UQIVD7H^RLYW863=E/PV_F37J,-
MO!;J5@ACB4G)"*%!_*L+P?X0L/!NDM9VDDL\TSF:ZNISF2>0]68_T_\ UUT-
M !1110 4444 %%%% !371)$9)$5T88*L,@TZB@"&VM+:SC\NUMXH$)R5B0*/
MTJ:BB@ HHHH **** ,&S\)Z?9>+M4\2*9'O-1ACAD5SE45!CY?0$!<C_ &?>
MO._$7A[5/AAK<WB[PC"TVC3'=JNDK]U1U,B#L!_X[],@>Q4A 8$$ @C!![T
M<MYF@_%'P)-'#.9=.OX]CE<!XG!!P1V92 ?_ *U:^@:!IOAG1X-*TJW6&UA'
M [L>[,>Y/K4^F:5I^C6GV73;.&TM][/Y<*!1N8Y)XJY0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!X!^TU_S*W_;W_[1HH_::_YE;_M[
M_P#:-% '?_!+_DD.A?\ ;Q_Z/DKT"O/_ ()?\DAT+_MX_P#1\E>@4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M-?\RM_V]_^T:*/
MVFO^96_[>_\ VC10!W_P2_Y)#H7_ &\?^CY*] KS_P""7_)(="_[>/\ T?)7
MH% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@'[37_,K
M?]O?_M&BC]IK_F5O^WO_ -HT4 =_\$O^20Z%_P!O'_H^2O0*\_\ @E_R2'0O
M^WC_ -'R5Z!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!X!^TU_S*W_;W_[1HH_::_YE;_M[_P#:-% '?_!+_DD.A?\ ;Q_Z/DKT"O/_
M ()?\DAT+_MX_P#1\E>@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 > ?M-?\RM_V]_^T:*/VFO^96_[>_\ VC10!W_P2_Y)#H7_ &\?
M^CY*] KS_P""7_)(="_[>/\ T?)7H% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% '@'[37_,K?]O?_M&BC]IK_F5O^WO_ -HT4 =_\$O^
M20Z%_P!O'_H^2O0*\_\ @E_R2'0O^WC_ -'R5Z!0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X!^TU_S*W_;W_[1HH_::_YE;_M[_P#:
M-% '?_!+_DD.A?\ ;Q_Z/DKT"O/_ ()?\DAT+_MX_P#1\E>@4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M-?\RM_V]_^T:*/VFO^
M96_[>_\ VC10!W_P2_Y)#H7_ &\?^CY*] KS_P""7_)(="_[>/\ T?)7H% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@'[37_,K?]O?
M_M&BC]IK_F5O^WO_ -HT4 =_\$O^20Z%_P!O'_H^2O0*\_\ @E_R2'0O^WC_
M -'R5Z!0 4444 %%%% !1110 4444 %%%% !15#4;R[MY+>&RMH9YIBW$TYB
M4 #)Y"L<_A5?[1XB_P"@5I?_ (,I/_C% &O161]H\1?] K2__!E)_P#&*/M'
MB+_H%:7_ .#*3_XQ0!KT5D?:/$7_ $"M+_\ !E)_\8H^T>(O^@5I?_@RD_\
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M7_0*TO\ \&4G_P 8H^T>(O\ H%:7_P"#*3_XQ0!KT5D?:/$7_0*TO_P92?\
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MT>(O^@5I?_@RD_\ C% &O161]H\1?] K2_\ P92?_&*/M'B+_H%:7_X,I/\
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M61]H\1?] K2__!E)_P#&*/M'B+_H%:7_ .#*3_XQ0!KT5D?:/$7_ $"M+_\
M!E)_\8H^T>(O^@5I?_@RD_\ C% &O161]H\1?] K2_\ P92?_&*/M'B+_H%:
M7_X,I/\ XQ0!KT5D?:/$7_0*TO\ \&4G_P 8H^T>(O\ H%:7_P"#*3_XQ0!K
MT5D?:/$7_0*TO_P92?\ QBC[1XB_Z!6E_P#@RD_^,4 :]%9'VCQ%_P! K2__
M  92?_&*/M'B+_H%:7_X,I/_ (Q0!KT5D?:/$7_0*TO_ ,&4G_QBC[1XB_Z!
M6E_^#*3_ .,4 :]%9'VCQ%_T"M+_ /!E)_\ &*/M'B+_ *!6E_\ @RD_^,4
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MQ0!KT5D?:/$7_0*TO_P92?\ QBC[1XB_Z!6E_P#@RD_^,4 :]%9'VCQ%_P!
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M*\;\-?&NWM])2#Q!;7<UW'\HGMD4^8/5@6&#].M;'_"\?#/_ #XZM_WYC_\
MCE2\+53M8B6"KIVY3TRBO,_^%X^&?^?'5O\ OS'_ /'*MZ;\8_#&HWT5J4OK
M4R,%62XB4)D],E6.*3PU5:\I+PE=*_*SK]>U_3/#.D3:IJURMO:Q8!8\DD]
M!U)/H*\Z_P"%X0NANX?!OB.72QR;Q;;Y<>OI_P"/5=^-.AZEJ_A>PN-.LC?_
M -G7R74UH!GS8P#D8[]>GH32:-\</!=_$D5W/-I,X 5H+N$@*?3<N1CZXK Y
MSL?#'BK2/%^DC4='N?-AW;'5EVO&W]UAV-4]'\;66M-KXAM;J/\ L65HIO,5
M1YA4,24P>GRGKBJW@[PGH>D:GJNOZ#J#W%OK+B5HXY$:!2"3E-H]SWK'\/>*
MK_Q%!X\M;R*V2/3)IK>$PH5++M?EN3D\>U &M:?$?3+SX=S>-$M+L6,08F%@
MOFG:^T]\=?>NDTC4HM9T:RU.!'2*[A29%?&X!AD X[\UX?H?_)JNH?[LW_H^
MNI_X3O\ X1KP!X7TK2;;^T?$=]I\"VEDO./D'SOZ*/PSCV) !ZI6?KFKPZ#H
M5]JUQ'))#9PM,Z1XW$*,D#/&:;H*ZPND0'7I;6346&Z46L96-#_=&22<>O>L
MGXC_ /)-?$?_ &#YO_030!R,/QST^YA6:#PGXEEB<95X[165A[$-6EHOQF\-
MZKJ\.E75MJ6DWDS!(UU"W"!V)P ""<?CBLKX=?$;PAI/P]T6PO\ 7K6"Z@M]
MLD3DY4Y/!XKG_BMXDT7XA1:1X>\*/_:>L->*ZS01MB%<$$EL<#D$XZ;<F@#W
MFBN,\=^-V\&V>G6EI:'4=:U&3R+.W+;=[< LWMDC\ZYK4M?^*GA6P_MW6++0
MM0TZ,;[NTLMZRP)W()XX[_>_+F@#UBBN(\0?$6"P\#V'B'1[*749-39([* #
M&7;L^.F""#[\>]<]JNH?%[1-(EUVY/AN>&WC\Z>QB60,J 98 GJ0/]KMWH ]
M8HKD(_B!8?\ "LD\:W$31VYMO-,(/._.W8#_ +_&:YBPU[XJW^FQ^)8],T7^
MSI%\Z/2B7^T/%U&&Z;B.1D_AVH [3PCXPLO&-K?7%E;W$*V=TUJXF !++C)&
M">.:Z%FVH6/89KR7X W N_#.N7(4H)M6DD"GJ,JIQ7K$O^ID_P!TT <+X'^+
M.B>/-5GTZPM;VVGBA\[_ $D( RY .-K'GD5WM?*7@('PU9^&/&D;;(1JTNG7
MQ/3RW5<$_3+G\!7O_P 3=>/A_P  :G<1%OM4Z?9;95^\TDGRC'N,D_A0!5\(
M_%'1O&?B*^T;3;>[#VB,YGD"^7(JL%RN"3SG/2NXKPKX7:$OAGXQZKHX4*UM
MHL DQT,A2%G/_?1-=+<^-/%GBSQ)J&C^!;:PAM--D\JZU/4-Q4R=U0#Z'L?P
MXR >H45YUX;\:Z_:^,%\(^-+2RAU">(RV5Y9L?*N0.HP>AX/ITZ=,IXF\:Z_
M<^,SX.\&6MG)J,,0FO+R\)\JW4X(&!U."OKUZ>@!TGB?QA9>%KK2+>[M[B5M
M4NA:Q&(#"L<<MDCCGM3I_%MI!XXM?"K6UR;NXMC<K, /+"C/!.<Y^7TKQ[QM
MJ/BL>*?!ND>*[2R,\>JQS07UB6\J==R@C#<AAQGZBO2;SQ5?P?&'3O#"Q6QL
M;C3VN'<H?-##=P&SC' [4 =Q17FFL^-_$>L>,;KPKX'M+)IK%0;[4+XL8H2?
MX0!W[=^<\<9J30?%_B?3?&D'A3QE:6;37<1DL]0L PBDP.58'H>#Z<XXYS0!
MZ/17F,OBKQMXJ\0:II_A"TT^QL--E,$M_J2N3+(.R*.WX'C'3.*?X9\9>*+7
MQZ/!OC"VL#=3V[7%K=V.X+(!DX(/L&[#I0!U-MXPLKKQU>>$TM[@7EI;+<O*
M0/+*G;P.<Y^8=JZ*O*M(_P"3D=?_ .P3'_*.O5: "N<'C*Q/CYO"'V>X^VBU
M^U>=A?+V^G7.?PKHZ\F3_DYN3_L"_P!10!ZS17E>O_$'Q1:_$VZ\(Z'I=I>R
M-;(]L9<J(V(!9Y&S]T#/ P>G-1IXR\<^$O%FDZ7XSMM*N=/U6;R(;S3]P\MR
M0 #G'3(X(_'B@#UBBN!\:^.-4T[Q#8^%?"^GPWNO7D9E)N"1%;Q\_,V.O0]^
MW?(%9;>*_'/@[6=-A\8V^EWVEZA,(!>::'!MW/3<&QD?AT!Y[4 >I445Q.H?
M%/P]I][);;;RX,;%6>"-2N1UP2PS2;2W-Z&&K5VU2BW8[:FR2)%&TDCJD: L
MS,<  =237 _\+?\ #_\ SYZG_P!^H_\ XNJNI_%;0KS2KRUCM-1$DT#QJ6C3
M )4@9^?WJ>>/<ZXY3C'))TV=K_PD_A__ *#NF?\ @7'_ (T?\)/X?_Z#NF?^
M!<?^-?--%9^U9[_^K-+_ )^/[D?5$,T5Q"DT$B2Q.-R.C!E8>H(ZT^O+M!^*
M&B:7H%A83VNH-+;P+&Y2-"I(';+BM'_A;_A__GSU/_OU'_\ %UHIQ/!GE&+4
MVHTVT>@51UK5(M$T2]U6='>&TA:9UCQN(49(&>]<<OQ>\/,P!M=24'^(Q)@?
MD]:?C*^M]2^%VN7EI()()M-F9''<;35*2>QRU\'7PZ3JP:N3^"O&^E>.]'?4
M-,\V/RY#'+!, 'C/;."1@CD4[QKXRLO VA+JU_;W$\+3+#L@"ELD$YY(&.*\
M,\,QW7PVTWPSXYLP\FBZG"+?5X1D[#N(#C\LCW!'\5=S\?+F"]^%=K=6TJRP
M37L,D<BG(92CD$4SF/6XW$L22 $!E##/O7%:E\4=#TOQY!X2FCN6NY7CC:=%
M7RHW<956.<Y/';O73SZA!I7A]]0NFVV]M;>=(?\ 95<FO!K/PK>>)_A+XC\6
MS(T>KW]\=5MF!.X+"3@#OT,F/PH ^B:XOQ=\3-%\(W\>F20W>H:K* R65E'O
M?!Z$^G\_:M+P-XD3Q9X,TW5PRF6:(+.!_#*O#C';D'\"*\PO]2E^&/Q<UK7]
M<TRZN]*UA5$%_!'O,/3*\],8QC.< $9H Z.Q^->EB_AM/$&AZOH!F.(YKZ B
M,_4\$?7&*Z[QAXNLO!OAUM;O(9KBW#HFVWVECNZ$9(&/QKF+SQ-\/_BEHLOA
M\ZU#NN<;$<>5*K Y!3>/O?3/>LKXRZ:FC?!2+3(II9H[22WA624@NP7@$X &
M: 'K\>M)(#?\(QXBV'G<+9#QZ_>KL/"/Q#\/>-1(FE7+BZB7=):W";)4'KCH
M1]":VM#_ .0!IO\ UZQ?^@BO*/BK80^%_''A3QCIRBWN)+T6MYY8QYJG'7WV
M[P?7CTH ]FKB-"^*&AZ_XTN_#%K'<I=6YD59I HCE*'#!2#D]STZ UH_$'Q(
MOA3P/JFJB39.D1CM_4RM\JX^A.?H#7CVI>%KCP1\-O"'BVWB8ZGI=R+N]/1F
M2<@E6^GRK^)H ^AZXWQ;\3-!\(W::?-]HOM4D *6-E'YDG/3/8?S]JWY-;MO
M^$8DUZ ^;:BS-VAZ;EV;A^E><? [2DO=%O?&-^BS:OJMU(6N&&65 <;1Z#.>
MGH/2@"Y#\:=/M;J.'Q%X=US08Y3A)[RU(0_7O^0->DVUS!>6T5S;3)-!*H>.
M2-@RLIZ$$=14&J:79:UIL^G:A;I/:SH4DC<9!!_D?>O,?@C=3V7_  DWA.:9
MY8]$OBD#.>=C%QC\T)_X%0!ZU7'>+/B5H/A*Z2PG-Q?:I(!LL+*/S)3GIGL,
M_G[5U5[=+8V%Q=N,I!$TK#V4$_TKRCX&:<FI:=JGC*_19M6U*\D!F;DH@QPO
MH,D_D/2@#0MOC3IT-[%!XA\/ZUH$<QQ%<7UL1&?J>OY UZ9')'-$DL3J\;@,
MKJ<A@>A![BLWQ%H-EXFT&\TB_C#07,93)4$H>S#W!Y%<]=7FG_"7X;I]HN;F
M^@L5\J#SBOF2L2=J @  ?R [XH [6BO*8=5^+VH:8NNVMAH$-NZ^;%I<F\S/
M&>0">F['N/H.E;NB_$)/$GPYU+Q%96_V>^L8)O.MI>1',B%L'ID=#VH [FBO
M'= \8_$CQUX?BU#P]9Z/9QPIMFFO P^TRCJ(U&<*.F3W[BCP_P#$3QQXXLY-
M/T+1]/L=5LF*:A=WC-Y$;9("HHR=QP>#G&/>@#V*BO/? 'C36]4\0:QX6\46
MEO#K6F!9#):Y\N6,XYP3_M*?<'H,5SGA_P >^/?&=]JFE:)::5;R6-VZ2ZA<
M(_EI'DA%"@G+G!.>GL* /9:*\\\*>-=<'BZ7P=XPM+6'5O*,]K<VA/E7*#.<
M \@X!/X'@57UKQYK^J^,;GPGX(LK.6ZLP#>W]\6\F$_W0%Y)Z#OSGCC- 'I=
M%>76GC?Q3X6\4:?H?CJUL9+?4G\NTU.PW!-_'RN#[D#H.O>K6O>,/$FH^.[C
MP=X0CTZ*ZL[=9[N[U L57< 0JJO4X9>>>M 'H]<[I_B^SU'QIJGAB.VN4NM.
MB2229P/+<,%("G.<_,.U8'AOQ%XSM?%X\->*],MYUEA,T&IZ=&_D\9X?/"G@
MCMSCKG--LO%>MZC\2O%GAJUCL$_L^S22SDDC8$R,B$>80>5RW8=* .OTSQ#I
M>LW^HV6GW2SS:=(([G:#A'.?ESW/!SBM2O"/A(GB[_A-?$Q631_LXU/_ (FP
M(DW,V7_U/&,9S][VKJ+[QKXI\3>*M0T#P+:V*0Z:WEWFIW^XH'Y^50.^01T/
M3L.: /3Z*\VT+QMXATOQA;^$_&]K91W5XA:QO[(MY4Y'\)!Z'KZ=ACD$^D,R
MHI9B H&22> * %HK@;GXO>&[>X>)(K^X53CS(HEVGZ;F!_2HO^%R>'?^?+5/
M^_4?_P 76'UFE_,<SQ=!?:1Z'17GG_"Y/#O_ #Y:I_WZC_\ BZR_$/Q;TZ]T
M*ZM=*MKZ.[F3RUDF1%50>">&)SC.*3Q5)*]Q2QM!*_,>KT5Y1X>^+>G66A6M
MKJMM?27<*>6TD*(RL!P#RP.<8S6I_P +D\._\^6J?]^H_P#XNA8JDU>X1QM!
MI/F/0Z*\\_X7)X=_Y\M4_P"_4?\ \73HOC#X<DE5&M]1B4G!=XDP/KAR?TI_
M6:7\P_KE#^9'7>(M<@\-^'[W6;J.22"TC\QTB W$9QQD@=ZI^#_%^F>-="35
M=++B,N4DBE #QL.S $CI@_C63\3;B*[^$FN7,#B2&6SWHXZ$$@@UY7X<,_PJ
MG\.^(T,C>&=?M($U!<DB"8J#O_F1]6'I6YTGL_B_QC9>#;*SNKZWN)DNKI;9
M! %)#-G!.2..*Z*O)_CG(DWACP_+$ZO&^K0LK*<A@5;!!KT?7]7AT#P_?ZM<
M8,=I TI&<;B!P/Q.!^- ',M\4M!7X@#P>4N/M9D\G[3A?)\S;NV9SG/;IUXK
MMZ^=/^$3U.;X+OXN)QKQU$ZZKA?F"YQ^6/GQ7NGA?78?$OAC3M9@V[;N%7*J
M<A6Z,OX,"/PH YWQ7\4]&\,:H-'BMKW5=7P";.PCWLF1D;CVX[#)]JS]*^,V
MDSZI#INN:1JF@7,Y B-_#MC8DX SP1]2,>]<E;:T?A3\2?$EUXCTJZEL-:G$
MMMJ<$>_:N6.W_P >&0#GY1P>*Z[4]6\ _%S1SH2ZW&97=9(@/W<ZL#GY XYX
MR#@'@F@#H_&_C6Q\"Z+'JFH6]Q/#),(0MN%+9()SR1QQ7&?\+YTE>7\,>(U4
M=3]E7@?]]51^/=H+#X7:79K+)*L%W#$))3EVVQL,L>YXKV:@#F_"?CO0/&D$
MCZ/=EI8<>;;RKLECSZKZ>XR*Z2O&/'=G'X0^,'A+Q#I:+!_:TQM+U(QA9.54
MD^Y#_FH-=G\5/$G_  C'P^U&YC8BZN%^RVP7KO?C(^@R?PH ;X5^*&A^+O$=
M[HEA'<I-;*SK+*%"3*K;24())'X5VU> ZYX=D^&>B^ _$\$;)-IA%OJ:J.66
M7+,#]"SC\1Z5[-KVM+IWA#4-;M6258;-[F)L_*V%RI^G2@# \4_%'0O#.HC2
ME2ZU/5C@?8M/C\QUS_>[ ^W7VK*M?C1ID5]':>(]#UGP\TIPDE_;%8S]3U'Y
M8IGP1T**'P</$=T!/JVL2R33W+C+[=Y &?0X)_'VKOM=T.P\1Z-<Z5J4"RVU
MPA4@@$J>S#T(Z@T 7HI8YXDEBD62-U#(Z'(8'H0>XI9'$43R$$A5+''M7E_P
M,U"[;PSJ6A7LQEDT6^>U1B>B=A],AL5Z9=_\>4__ %S;^5 &%X*\967CG0FU
M:PM[B"%9FAV3A0V0 <\$C'-7/$_B&V\*^'+S6[N*66WM55G2$#<<L%XR0.IK
MS[]GG_DFTO\ V$)?_04K>^,?_))M>_ZYQ_\ HU* .DM?$-A/X6A\13/]EL)+
M873--@%$(SSCO]*X%OC=:W,COHWA3Q!JEE&2&NX;8[#CN.O'UQ1J^@ZAXD_9
MZL=.TL%KMM/MI%B!QYNW:Q7\0./?%5?"7QD\+V&CV>C:S!=:'>64*02136[;
M,J,'&!D=.X% '<>#_'FA^-[6632Y9$G@P)[6X79+%GU&3Q[@FNFKB]!T#PUJ
M/C";QSH6IB>2Y@\B9+61#"YXY8 9#<#OVKM* .#\8_%33/!FNPZ1<Z9J5Y<S
M0"=?LB*W&2.[ Y^4UC1?'KP^LBB_T;7;&%CCSIK5=B_7#9_(&LGQKKNG>&_V
M@=#U35;CR+.+3&#R;2V-PE X SU(K5\4_&#P)?>%]2LXKUK^6XMWBCMEMW^=
MF! Y8 #D]: /3;"_M=4T^"^LITGM9T$D4B'AE/>K->=?#^WE^'_PABGU^3:+
M:.2ZD16#>6K$L$'8GG\S67IVO?%/Q98?V[HMIH>FZ;(-]I:WN]I9T[$D<<]O
MN_ES0!ZS17(^ O&C^+;&\BO;,6.L:;-]GOK4-D(W."/8X/Y'K7!^%/'OQ%\>
MZ7*NB6.CVTMO*RW%_=!UB_V411N.['))R.>U 'M5%>=^ _&^MZGXDU3PKXJL
M;>VUG3T$H>USY<J''/)/]Y3[YZ#%46\9^,/&'B#4=/\  ]MIMOIVG2F";4M0
MW,))!U"!?\#V.1F@#U*N<\%^,;+QOHLFIV%O<011SM 5G"ALJ 2>">.:Q/!_
MC#7;CQ->>%/%>GP0:M;1>?%<VF?)N(\XR,\@\_SX&*\S^$E]XWN?"]WI7A.U
MTZ"..\>2;4-09BNY@N$55!.>,DX(YH ^BJ*\[\">-M;U'Q-JGA/Q396T&LZ>
M@E$MKGRYD..<'_>4_CT&*QHOB!XRUCQGXB\+:%I^GO=6=R5ANK@,L4$()!,F
M"2S$[< #UH ]=HKQR'XB^.=(\23>#]6T:QU#7YD#6$UJQ2%P<Y9\\[0 QX /
M&/>KD'C'QQX7\9:1I'C*#2KBRUB0Q07.G[AY<G P=V. 2.H[Y!.,4 >KT5P/
MBOQ=XA7Q7;^%/">G6\NHR0^?/>7N[R($_#J?\1P:P[SQ=X^\$:QI8\6)H]_I
M.H7*VQN+$,KQ,QXX./<]#G'6@#UJL?Q3XBMO"?AN\UR\BFEM[4*72$#<=S!1
MC) ZL.]</X_^(>N^&/'&EZ%I-A!>_;[0F.)E.]IV9E3YMP 7(!/MGD5D^,G\
M9O\ !GQ0/&45@DP:W^SFS[KYJ9SR1UP!^- 'KFF7\>J:59ZA$K)'=0I,BOU
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M@Z,;HWD;4KX=A#$#M!_WCD?E6;\%=6M="^#5YJMZQ6VM;F>60CK@!>![GH*
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MS6=\./&=YXOTN^75+..TU33KDVMU'$24W#N.N.XQD]*YO]GG_DFTO_80E_\
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MPHK2VVEINOK]8RB$9/RY(&<@[??<>PKUS1O^0KXA_P"P@G_I+!0!L4444 >
M?M-?\RM_V]_^T:*/VFO^96_[>_\ VC10!W_P2_Y)#H7_ &\?^CY*] KS_P""
M7_)(="_[>/\ T?)7H% !1110 4444 %%%% !1110 4444 9]W_R&-._[:_\
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M^!=6O2!IQ#P!V^ZLAR 2>WWT/X5WWCJ]M;#P'KD]W(BP_8I4^8XW%E( ^I)
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MNL RE3T(Q0!X!\/O#X\3_L\ZUIHCWS&ZFE@ '/F(J,N/J1C\:MZ%KQ^).J>
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MQ?V9&0% QCD\UUESX'TF\\7Z?XEN'N9+S3X?)MXV<>4HP1G;C.?F/.?2NEH
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M: .+L=:\9>!?'^B>&]>U>+7M/U8F.&4IMFB(.-Q[]^Y.1GTJWX5_Y.(\;?\
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MQW>H6]M-.+>.60(TK#(3)QDCTKTO_A2MS_T&X?\ P'/_ ,57I/\ PBWAW_H
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M#MQ(B:E8ZA(98"?FQA5R!W&5(K5^.>KVMA\-+ZQDE7[5?O'%!%GYFQ(K$X]
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M\.0Z%IRR"TB5@"[ NVXDDDXY.35?PKX.TOPAH#Z+8>=-9O(SL+E@Y.X $'
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MAT+_ +>/_1\E>@5Y_P#!+_DD.A?]O'_H^2O0* "BBB@ HHHH **** "BBB@
MHHHH S=3AOS<6EQ80VTSPLVY+B=HA@C&00C<^V*A^T^(_P#H%:5_X,Y/_C%;
M%% &/]I\1_\ 0*TK_P &<G_QBC[3XC_Z!6E?^#.3_P",5L44 8_VGQ'_ - K
M2O\ P9R?_&*/M/B/_H%:5_X,Y/\ XQ6Q10!C_:?$?_0*TK_P9R?_ !BC[3XC
M_P"@5I7_ (,Y/_C%;%% &/\ :?$?_0*TK_P9R?\ QBC[3XC_ .@5I7_@SD_^
M,5L44 8_VGQ'_P! K2O_  9R?_&*/M/B/_H%:5_X,Y/_ (Q6Q10!C_:?$?\
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M)_\ &*/M/B/_ *!6E?\ @SD_^,5L44 8_P!I\1_] K2O_!G)_P#&*/M/B/\
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MY/\ XQ6Q10!C_:?$?_0*TK_P9R?_ !BC[3XC_P"@5I7_ (,Y/_C%;%% &/\
M:?$?_0*TK_P9R?\ QBC[3XC_ .@5I7_@SD_^,5L44 8_VGQ'_P! K2O_  9R
M?_&*/M/B/_H%:5_X,Y/_ (Q6Q10!C_:?$?\ T"M*_P#!G)_\8H^T^(_^@5I7
M_@SD_P#C%;%% &/]I\1_] K2O_!G)_\ &*/M/B/_ *!6E?\ @SD_^,5L44 8
M_P!I\1_] K2O_!G)_P#&*/M/B/\ Z!6E?^#.3_XQ6Q10!C_:?$?_ $"M*_\
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M;%% &/\ :?$?_0*TK_P9R?\ QBC[3XC_ .@5I7_@SD_^,5L44 8_VGQ'_P!
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M^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\
M@QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._
M&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJ
MC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_
M (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3
MOQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^
M*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY
M_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^
M$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O
M_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->
MN?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #
M_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&
M;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#
M7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@
M _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@
MQF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\
M0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HH
MH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_
MX,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_
M $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ
M** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N
M?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA
M_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_X
MJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7
MKG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\
M8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_
M^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0
MUZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A.
M_&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9
MO_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_
MT->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X
M3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#
M&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8
M?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/
M^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\
M@QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._
M&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJ
MC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_
M (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3
MOQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^
M*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY
M_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^
M$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O
M_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->
MN?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #
M_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&
M;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#
M7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@
M _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@
MQF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\
M0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HH
MH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_
MX,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_
M $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ
M** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N
M?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA
M_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_X
MJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_^*HHH /^$[\8?]#7
MKG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\
M8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A._&'_ $->N?\ @QF_
M^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9O_BJ** #_A._&'_0
MUZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@ _X3OQA_T->N?^#&;_XJC_A.
M_&'_ $->N?\ @QF_^*HHH /^$[\8?]#7KG_@QF_^*H_X3OQA_P!#7KG_ (,9
MO_BJ** #_A._&'_0UZY_X,9O_BJ/^$[\8?\ 0UZY_P"#&;_XJBB@#/U/7=8U
>ORO[6U6^O_)SY?VNX>79G&<;B<9P.GH**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>silk-20231231xex10_1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231xex10_1g001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M)?\ "P_%/_04_P#)>+_XFO:M5_Y ][_U[R?^@FOFZOJSXHZ?_A8?BG_H*?\
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M*X'Z5DY/J:M6&EW^J2F.QLYKAAC=Y:$A<^I[?C6Y_P *\\4X_P"07_Y,1?\
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MZ+X,\;)XF$EK<Q+!J$2[RJ9V2+P,C/3!(X/Z\X\1K1T+5&T;7;/4%R1#("P
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M /7S'_Z$*^?I_&O4^GJ_PY>C/;J***^V/ST*H:Y_R+^I?]>LO_H!J_5#7/\
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MUQT^H-8U,1].45SG@;5O[7\*6LCL3- /L\I.>JXP<GJ2NT_4UT=(9\_^,?\
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M[>^*X&\^+5]( ++3+>$]S-(9/RQMKA]3U:^UF[-UJ%R\\Q& 6P !Z #@#Z4
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MXL_Y%;4/^N8_F*\<KW:[M8+ZUDMKE-\,@PRY(S^58_\ PAGA_P#Z!X_[^O\
M_%5R8_ U,144H-:+J=N69E2PM-PFF[N^G_#G >"O^1NL?^VG_HMJ]:E_U3_[
MIK+LO#&CZ?=I=6MF(YH\[6\QSC(P>"<=#6L0""#T/!K? X:>'I.$WU_R.;,L
M7#%5E4@G9*VOJSP2BO7O^$,\/_\ 0/'_ ']?_P"*H_X0SP__ - \?]_7_P#B
MJ\K^QZ_=?C_D>W_;N'_EE^'^9Y#17KW_  AGA_\ Z!X_[^O_ /%4?\(9X?\
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MR?+ST1,@?0YW?ABM3_A7WA?_ *!8_P"_\G_Q5=#;V\5I:PVT";(84$:+G.%
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MQF.SM8+="<E88P@)^@H&><>$OALZ31W^O(N%.Y+/ALGL7[8_V>_?N*].HHI
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M;2SWJ0M($#?*P;L?PH ZFBN4_P"$>\3_ /0Y/_X )_\ %4?\(]XG_P"AR?\
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M0$:)J(/!&HR_^@I7:4 96L:!::U-8SSM+'-93":&2)@"#P<'((QD#\JU:**
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M?%)F3P]9NC%66]5E8'!!"/0!W-%?/W_"3:]_T&K_ /[_ +4?\)-KW_0:O_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>silk-20231231xex10_9g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231xex10_9g001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M7ADDDDTKRRNSR.Q9G8Y+$]23W- '0ZGXZ\0ZF^6OWMH\Y$=J?+ _$?,?Q)K
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M-:QOF"Q7RAAL@N>7/L<X7_@-<=3$>B>&_B9?+?16VMLDUO(VTW 0(T>>A.,
MJ._&>_/2O6*^8Z]Z\#ZN=9\*VLKMNG@'D2GG[R]"2>I*[2?<TAG14444 %>%
M?\+#\4_]!3_R7B_^)KW6OF.@#I_^%A^*?^@I_P"2\7_Q-'_"P_%/_04_\EXO
M_B:YVWMY[N=8+:&2:9_NQQJ68]^ *O?\(WKO_0%U'_P%?_"F(U1\1/%(.3J8
M/L;>/_XFM.S^*NLPN@NK:TN(P?FPI1C^(.!^5<O_ ,(WKO\ T!=1_P# 5_\
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MP?\ <*<3R@_ZP_W1[>I[_3K]3B<3##PYI?(^,PF$GBJG)'YOL4/%OB@ZS/\
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MWW$IB.+^(VH->^,+B/<#':HL*8^F3^.XD?A7,6MO+>7<-K"NZ6:18T&<98G
MJ]XCY\4:L?\ I]F_]#-7O MNESXUTR-P"!(TG/JJEA^H% 'M6B:-:Z%I4-C:
MHH5!EW P9'[L?<_IP.@K1HHI#"O./BAX>B>S37+>-5FC8)<E1C>IX5C[@X'X
MCTKT>L7Q=;I=>$=5C<9 MGD_%1N'Z@4 ?/M>U?#._>\\)+#(<M:3-""3DE>&
M'_H1'X5XK7I_PA)QK R<#R3C_ONF(]-JCK.I1Z/HUWJ$F,01E@"<!F_A'XG
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M(]UHHHI#"LSQ&,^&-6'K93?^@&M.LWQ%_P BSJO_ %YS?^@&@#YUKT[X0_\
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MZ^IA.,XJ47=,^-J4Y4Y.$U9H\>^*_P#R--K_ ->2?^AO7"5W?Q7_ .1IM?\
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M(N);B1@J(TJH"3[]JU='T?5K[7QX@U\1Q2Q(T=I9QMN$ .022#@DC/KU[8
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M,M,75?"E_ 0-\<9FC..C)S^N"/QJ?PSJ;:SX;L+]\F22/$A( RZDJQX[$@T
M:U<5XX_Y#OA3_L(K_P"A)7:UP7Q'NUT^\\.WKJ66WN_-*CJ0I4X_2@#O:*\\
M_P"%M:=_T#;K_OI:LV'Q/L-0U&ULDT^Y5KB9(@Q9< L0,_K0!W5%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>silk-20231231xex3_1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231xex3_1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>silk-20231231xex3_1g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231xex3_1g002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MI;RDA3S)L'[KL3D#=ZD=2.<U:DNK>RU1UBU6XN9+4!KRWD?<JQOP&/& 01G
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9"*"",82.)0JJ/0 <5-0 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>silk-20231231xex97_1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20231231xex97_1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M7)KWE<**Y#QOK5_I!L_L4_E>8'W?*#G&,=1[UK^%[VXU#P_;75U)YDSEMS8
MSAB!THCB82K.BMU_7ZA/"3CAXXAM6;MY]?\ (V**R]>UN#0[!IY,-*W$4>?O
M'_"N?\&:UK&K7]RUVWF6H7.[: %;/ 'X9I3Q4(U51W;_  ]1T\'4G0E7VBN_
M7T.THKQ#_A./%4MXT%O>R2.6(5$A4D_0;:L'Q3XZB4N_VQ57DEK,8'_CM=)R
M'L]%>;>%?B1+>7L=AK"1AI6"I<(-HR>@8?U%=CXD\16WAO3#=SC?(QVQ1 X+
MM_0>IH V**\7_P"$H\8^([ESIYN @_@M8\*OU/7\S2Q>+_%OAR\5-3$SJ>3%
M=)]X>S=: /9Z*SM#UJUU_2X[ZU)VMPR'JC#J#1KNJIHFBW6H. WE)\JDXW,>
M /SH T:*\8L?B7KD>II+=RI+;%QOA$8 "^Q'.?QKV6.1)8DDC8,CJ&4CN#0
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>silk-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 23.3.2.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2024 1:15:14 PM-->
<!--Modified on: 2/28/2024 1:15:14 PM-->
<schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://silkroadmed.com/20231231" xmlns:silk="http://silkroadmed.com/20231231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns="http://www.w3.org/2001/XMLSchema">
  <xs:annotation>
    <xs:appinfo><link:roleType roleURI="http://silkroadmed.com/role/StatementBalanceSheets" id="StatementBalanceSheets"><link:definition>00100 - Statement - Balance Sheets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss"><link:definition>00200 - Statement - Statements of Operations and Comprehensive Loss</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows"><link:definition>00400 - Statement - Statements of Cash Flows</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails"><link:definition>40202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" id="DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"><link:definition>40502 - Disclosure - Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails" id="DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails"><link:definition>40503 - Disclosure - Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" id="DisclosureBalanceSheetComponentsScheduleOfInventoryDetails"><link:definition>40505 - Disclosure - Balance Sheet Components (Schedule of Inventory) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" id="DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"><link:definition>40506 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails" id="DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"><link:definition>40507 - Disclosure - Balance Sheet Components (Accrued Liabilities) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails" id="DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"><link:definition>40602 - Disclosure - Long-term Debt (Future Payment Under the Term Loan) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails" id="DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"><link:definition>40703 - Disclosure - Commitments and Contingencies (Balance Sheet Information) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"><link:definition>40704 - Disclosure - Commitments and Contingencies (Operating Lease Maturities) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt" id="DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt"><link:definition>40704 - Disclosure - Commitments and Contingencies (Operating Lease Maturities) (Details) ALT</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails"><link:definition>41002 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails" id="DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"><link:definition>41003 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"><link:definition>41004 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity"><link:definition>00300 - Statement - Statements of Stockholders&apos; Equity</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables" id="DisclosureStockBasedCompensationPlansTables"><link:definition>30903 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails" id="DisclosureFormationAndBusinessOfCompanyDetails"><link:definition>40101 - Disclosure - Formation and Business of the Company (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"><link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"><link:definition>40204 - Disclosure - Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"><link:definition>40401 - Disclosure - Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails" id="DisclosureBalanceSheetComponentsNarrativeDetails"><link:definition>40501 - Disclosure - Balance Sheet Components (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails" id="DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails"><link:definition>40504 - Disclosure - Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails" id="DisclosureLongTermDebtNarrativeDetails"><link:definition>40601 - Disclosure - Long-term Debt (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails"><link:definition>40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" id="DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"><link:definition>40802 - Disclosure - Stockholders&apos; Equity (Shares Reserved for Future Issuance) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails" id="DisclosureStockBasedCompensationPlansNarrativeDetails"><link:definition>40901 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails" id="DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"><link:definition>40902 - Disclosure - Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"><link:definition>40903 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Option Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails" id="DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails"><link:definition>40904 - Disclosure - Stock-Based Compensation Plans (Information by Exercise Price) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails" id="DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"><link:definition>40905 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails" id="DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails"><link:definition>40906 - Disclosure - Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails" id="DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"><link:definition>40907 - Disclosure - Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails"><link:definition>41001 - Disclosure - Income Taxes - Narrative (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/Disclosure401KPlanDetails" id="Disclosure401KPlanDetails"><link:definition>41101 - Disclosure - 401(k) Plan (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails" id="ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"><link:definition>41401 - Schedule - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DocumentCoverPage" id="DocumentCoverPage"><link:definition>00090 - Document - Cover Page</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical"><link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquityParenthetical" id="StatementStatementsOfStockholdersEquityParenthetical"><link:definition>00305 - Statement - Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompany" id="DisclosureFormationAndBusinessOfCompany"><link:definition>10101 - Disclosure - Formation and Business of the Company</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies"><link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureRecentAccountingPronouncements" id="DisclosureRecentAccountingPronouncements"><link:definition>10301 - Disclosure - Recent Accounting Pronouncements</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements"><link:definition>10401 - Disclosure - Fair Value Measurements</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents"><link:definition>10501 - Disclosure - Balance Sheet Components</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt"><link:definition>10601 - Disclosure - Long-term Debt</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies"><link:definition>10701 - Disclosure - Commitments and Contingencies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity"><link:definition>10801 - Disclosure - Stockholders&#8217; Equity</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlans" id="DisclosureStockBasedCompensationPlans"><link:definition>10901 - Disclosure - Stock-Based Compensation Plans</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes"><link:definition>11001 - Disclosure - Income Taxes</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/Disclosure401KPlan" id="Disclosure401KPlan"><link:definition>11101 - Disclosure - 401(k) Plan</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccounts" id="ScheduleScheduleIiValuationAndQualifyingAccounts"><link:definition>11401 - Schedule - Schedule II - Valuation and Qualifying Accounts</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies"><link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables"><link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables"><link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables"><link:definition>30503 - Disclosure - Balance Sheet Components (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtTables" id="DisclosureLongTermDebtTables"><link:definition>30603 - Disclosure - Long-term Debt (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables"><link:definition>30703 - Disclosure - Commitments and Contingencies (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables"><link:definition>30803 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables"><link:definition>31003 - Disclosure - Income Taxes (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails"><link:definition>40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Net Loss Per Share Determination) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails"><link:definition>40801 - Disclosure - Stockholders&apos; Equity (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"><link:definition>41005 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"></link:linkbaseRef><link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"></link:linkbaseRef><link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"></link:linkbaseRef><link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"></link:linkbaseRef></xs:appinfo></xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"></xs:import>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"></xs:import>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"></xs:import>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"></xs:import>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"></xs:import>
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" xmlns="http://www.w3.org/2001/XMLSchema"></xs:import>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" xmlns="http://www.w3.org/2001/XMLSchema"></xs:import>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" xmlns="http://www.w3.org/2001/XMLSchema"></xs:import>
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" xmlns="http://www.w3.org/2001/XMLSchema"></xs:import>
  <xs:element id="silk_DebtInstrumentCovenantMaximumBorrowingThreshold" name="DebtInstrumentCovenantMaximumBorrowingThreshold" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_CommonStockCapitalSharesAvailableForFutureIssuance" abstract="false" name="CommonStockCapitalSharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"></xs:element>
  <xs:element id="silk_TermLoanTrancheAMember" abstract="true" name="TermLoanTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_IncentiveStockOptionMember" abstract="true" name="IncentiveStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_IncentiveandNonqualifiedStockOptionExercisedMember" abstract="true" name="IncentiveandNonqualifiedStockOptionExercisedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"></xs:element>
  <xs:element id="silk_AccruedClinicalExpensesCurrent" abstract="false" name="AccruedClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" abstract="false" name="CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" abstract="false" name="PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"></xs:element>
  <xs:element id="silk_IncentiveandNonqualifiedStockOptionMember" abstract="true" name="IncentiveandNonqualifiedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" abstract="false" name="DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"></xs:element>
  <xs:element id="silk_TwoThousandNineteenStockOptionPlanMember" abstract="true" name="TwoThousandNineteenStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"></xs:element>
  <xs:element id="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" abstract="false" name="DebtInstrumentCovenantLiquidityEventPaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"></xs:element>
  <xs:element id="silk_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"></xs:element>
  <xs:element id="silk_TermLoanTrancheBMember" abstract="true" name="TermLoanTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"></xs:element>
  <xs:element id="silk_IncentiveandNonqualifiedStockOptionIssuedMember" abstract="true" name="IncentiveandNonqualifiedStockOptionIssuedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_ProvisionsForSalesReturns" abstract="false" name="ProvisionsForSalesReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_LongTermDebtUnpaidInterest" abstract="false" name="LongTermDebtUnpaidInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_LongTermDebtGrossBeforeAccretionOfClosingFees" abstract="false" name="LongTermDebtGrossBeforeAccretionOfClosingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"></xs:element>
  <xs:element id="silk_AccruedTravelExpensesCurrent" abstract="false" name="AccruedTravelExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_LoanAndSecurityAgreementMember" abstract="true" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_NonqualifiedStockOptionsMember" abstract="true" name="NonqualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"></xs:element>
  <xs:element id="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" abstract="false" name="CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"></xs:element>
  <xs:element id="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"></xs:element>
  <xs:element id="silk_SecuredRevolvingCreditFacilitySubfacilityMember" name="SecuredRevolvingCreditFacilitySubfacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_StifelBankMember" name="StifelBankMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_HeadquartersMember" name="HeadquartersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" name="AdditionalOfficeLaboratoryAndManufacturingSpaceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_DisgorgementOfStockholderSShortSwingProfits" name="DisgorgementOfStockholderSShortSwingProfits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_DebtCovenantRevenueCovenant" name="DebtCovenantRevenueCovenant" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentOfOutstandingShares" name="PercentOfOutstandingShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance" name="AdditionalCommonStockCapitalSharesReservedForFutureIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_FairMarketValueOfCommonStock" name="FairMarketValueOfCommonStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_Espp2019Member" name="Espp2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_AccretionOfClosingCosts" name="AccretionOfClosingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_LongTermDebtGrossAfterAccretionOfClosingFees" name="LongTermDebtGrossAfterAccretionOfClosingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_OxfordFinanceMember" name="OxfordFinanceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_TermLoanTrancheCMember" name="TermLoanTrancheCMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentOfBorrowingBaseOfEligibleReceivables" name="PercentOfBorrowingBaseOfEligibleReceivables" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentOfEligibleInventory" name="PercentOfEligibleInventory" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentOfBorrowingBaseInCaseEligibleInventory" name="PercentOfBorrowingBaseInCaseEligibleInventory" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_BorrowingBaseAmountInCaseEligibleInventory" name="BorrowingBaseAmountInCaseEligibleInventory" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_IndexRateMember" name="IndexRateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_DebtInstrumentMarginRate" name="DebtInstrumentMarginRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_TermLoanPrepaidInIncrements" name="TermLoanPrepaidInIncrements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentageOfPrepaymentFees" name="PercentageOfPrepaymentFees" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentageOfPrepaymentFeesInSecondYear" name="PercentageOfPrepaymentFeesInSecondYear" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentageOfPrepaymentFeesInThirdYear" name="PercentageOfPrepaymentFeesInThirdYear" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PercentAggregateOriginalPrincipalAmount" name="PercentAggregateOriginalPrincipalAmount" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_UnderwritersOptionMember" name="UnderwritersOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_AgencyNotesMember" name="AgencyNotesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_LoanFacilityMember" name="LoanFacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_SecuredTermLoanFacilityMember" name="SecuredTermLoanFacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_SecuredRevolvingCreditFacilityAmendedMember" name="SecuredRevolvingCreditFacilityAmendedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_PerformanceStockUnitsOverperformanceMember" name="PerformanceStockUnitsOverperformanceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_BenchmarkMember" name="BenchmarkMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_DeferredTaxAssetsSection174" name="DeferredTaxAssetsSection174" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_CashCashEquivalentsAndAvailableForSaleInvestments" name="CashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" name="RestrictedStockUnitsAndPerformanceStockUnitsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_IndemnificationObligationsLiabilityRecognized" name="IndemnificationObligationsLiabilityRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_AccruedAdministrationFeesAndSalesRebates" name="AccruedAdministrationFeesAndSalesRebates" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_ScheduleOfCommonStockReserveForFutureIssuances" name="ScheduleOfCommonStockReserveForFutureIssuances" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_LimitationOfCompensationDeduction" name="LimitationOfCompensationDeduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_AwardDateOneMember" name="AwardDateOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element>
  <xs:element id="silk_AwardDateTwoMember" name="AwardDateTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"></xs:element></schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>silk-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 23.3.2.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2024 1:15:14 PM-->
<!--Modified on: 2/28/2024 1:15:14 PM-->
<linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase">
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementBalanceSheets" roleURI="http://silkroadmed.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementStatementsOfCashFlows" roleURI="http://silkroadmed.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails" roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638447229067672629"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="us-gaap_OtherAssetsNoncurrent_638447229067672629" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="us-gaap_LongTermInvestments_638447229067673347" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="us-gaap_RestrictedCashNoncurrent_638447229067673347" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="us-gaap_AssetsCurrent_638447229067673347" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638447229067673347" xlink:to="us-gaap_AccountsReceivableNetCurrent_638447229067673347" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638447229067673347" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638447229067673347" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638447229067673347" xlink:to="us-gaap_InventoryNet_638447229067673347" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638447229067673347" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229067673347" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638447229067673347"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638447229067673347" xlink:to="us-gaap_ShortTermInvestments_638447229067673347" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638447229067677476"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638447229067677476" order="5" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638447229067677476"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482" xlink:to="us-gaap_Liabilities_638447229067677476" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638447229067677476"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638447229067677476" xlink:to="us-gaap_LiabilitiesCurrent_638447229067677476" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638447229067682607"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638447229067677476" xlink:to="us-gaap_AccountsPayableCurrent_638447229067682607" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638447229067682607"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638447229067677476" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638447229067682607" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638447229067682607"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638447229067677476" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638447229067682607" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638447229067682607"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638447229067677476" xlink:to="us-gaap_LongTermDebtNoncurrent_638447229067682607" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638447229067682607"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482" xlink:to="us-gaap_CommitmentsAndContingencies_638447229067682607" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638447229067682607"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482" xlink:to="us-gaap_StockholdersEquity_638447229067682607" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638447229067682607"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638447229067682607" xlink:to="us-gaap_PreferredStockValue_638447229067682607" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638447229067692594"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638447229067682607" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638447229067692594" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638447229067692594"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638447229067682607" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638447229067692594" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638447229067702560"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638447229067682607" xlink:to="us-gaap_CommonStockValue_638447229067702560" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638447229067702560"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638447229067682607" xlink:to="us-gaap_AdditionalPaidInCapital_638447229067702560" order="5" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_476c40f0-aeb9-4b82-a586-f05d1e28686a"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638447229067710594"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_476c40f0-aeb9-4b82-a586-f05d1e28686a" xlink:to="us-gaap_NetIncomeLoss_638447229067710594" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229067710594"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638447229067710594" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229067710594" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638447229067710594" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638447229067712522" order="2" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638447229067710594" xlink:to="us-gaap_OperatingIncomeLoss_638447229067712522" order="3" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638447229067712522" xlink:to="us-gaap_GrossProfit_638447229067712522" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638447229067712522" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638447229067712522" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638447229067712522" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638447229067712522" order="2" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638447229067712522" xlink:to="us-gaap_OperatingExpenses_638447229067712522" order="2" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638447229067712522" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638447229067712522" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638447229067712522" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638447229067712522" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638447229067710594" xlink:to="us-gaap_InterestExpense_638447229067712522" order="4" use="optional" weight="-1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638447229067710594" xlink:to="us-gaap_InvestmentIncomeInterest_638447229067712522" order="5" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_476c40f0-aeb9-4b82-a586-f05d1e28686a" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638447229067712522" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638447229067712522" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_638447229067712522" order="1" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638447229067722501"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638447229067722501" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization_638447229067722501"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_OtherDepreciationAndAmortization_638447229067722501" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638447229067722501"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_ShareBasedCompensation_638447229067722501" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638447229067722501"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638447229067722501" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638447229067722501"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638447229067722501" order="5" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638447229067722501"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_InventoryWriteDown_638447229067722501" order="6" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638447229067722501"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638447229067722501" order="7" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638447229067726712"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638447229067726712" order="8" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638447229067726712"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638447229067726712" order="9" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638447229067726712"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_PaidInKindInterest_638447229067726712" order="10" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_638447229067726712"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_638447229067726712" order="11" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638447229067726712"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638447229067726712" order="12" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638447229067732500" order="13" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_IncreaseDecreaseInInventories_638447229067732500" order="14" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_ProfitLoss_638447229067732500" order="15" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638447229067732500" order="16" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229067732500" order="17" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229067712522" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638447229067732500" order="18" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229067732500" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229067732500" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_638447229067732500" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229067732500" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638447229067732500" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229067732500" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638447229067732500" order="3" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_638447229067732500"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229067732500" xlink:to="us-gaap_PaymentsToAcquireInvestments_638447229067732500" order="4" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229067742448"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229067742448" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders_638447229067747235"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229067742448" xlink:to="us-gaap_ProceedsFromMinorityShareholders_638447229067747235" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638447229067747235"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229067742448" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638447229067747235" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638447229067747235"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229067742448" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638447229067747235" order="3" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638447229067752416"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229067742448" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638447229067752416" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638447229067752416"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229067742448" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638447229067752416" order="5" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229067752416"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229067752416" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638447229067752416"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_638447229067752416" order="2" use="optional" weight="1" priority="2"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638447229067752416"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638447229067752416" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_638447229067762402" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_LongTermInvestments_638447229067762402" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638447229067762402" order="1" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638447229067762402" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638447229067762402" order="3" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc31a761-72f1-451a-935c-be65438ac5b7"></loc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc31a761-72f1-451a-935c-be65438ac5b7" xlink:to="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_638447229067762402" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc31a761-72f1-451a-935c-be65438ac5b7" xlink:to="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_638447229067762402" order="2" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Balance Sheet Components (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross_637533885803523754"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross_637533885803523754" xlink:to="us-gaap_InventoryFinishedGoods_638447229067762402" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638447229067762402"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross_637533885803523754" xlink:to="us-gaap_InventoryRawMaterials_638447229067762402" order="2" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6952ac8c-5a8e-45b5-82c5-cd125dfdc61c"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638447229067772758"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6952ac8c-5a8e-45b5-82c5-cd125dfdc61c" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638447229067772758" order="1" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638447229067772758"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6952ac8c-5a8e-45b5-82c5-cd125dfdc61c" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638447229067772758" order="2" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Balance Sheet Components (Accrued Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638447229067772758"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638447229067772758" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638447229067772758"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638447229067772758" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ProvisionsForSalesReturns" xlink:label="silk_ProvisionsForSalesReturns_638447229067772758"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="silk_ProvisionsForSalesReturns_638447229067772758" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638447229067782345" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedAdministrationFeesAndSalesRebates" xlink:label="silk_AccruedAdministrationFeesAndSalesRebates_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="silk_AccruedAdministrationFeesAndSalesRebates_638447229067782345" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedClinicalExpensesCurrent" xlink:label="silk_AccruedClinicalExpensesCurrent_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="silk_AccruedClinicalExpensesCurrent_638447229067782345" order="6" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedTravelExpensesCurrent" xlink:label="silk_AccruedTravelExpensesCurrent_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="silk_AccruedTravelExpensesCurrent_638447229067782345" order="7" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638447229067782345" order="8" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="us-gaap_AccruedSalariesCurrent_638447229067782345" order="9" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638447229067782345" order="10" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="us-gaap_InterestPayableCurrent_638447229067782345" order="11" use="optional" weight="1" priority="2"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Long-term Debt (Future Payment Under the Term Loan) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385"></loc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtUnpaidInterest" xlink:label="silk_LongTermDebtUnpaidInterest_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385" xlink:to="silk_LongTermDebtUnpaidInterest_638447229067782345" order="1" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638447229067782345" order="2" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtGrossAfterAccretionOfClosingFees" xlink:label="silk_LongTermDebtGrossAfterAccretionOfClosingFees_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385" xlink:to="silk_LongTermDebtGrossAfterAccretionOfClosingFees_638447229067782345" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:label="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="silk_LongTermDebtGrossAfterAccretionOfClosingFees_638447229067782345" xlink:to="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229067782345" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638447229067782345"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229067782345" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638447229067782345" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638447229067792341"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229067782345" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638447229067792341" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638447229067792710"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229067782345" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638447229067792710" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638447229067792710"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229067782345" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638447229067792710" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccretionOfClosingCosts" xlink:label="silk_AccretionOfClosingCosts_638447229067792710"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="silk_LongTermDebtGrossAfterAccretionOfClosingFees_638447229067782345" xlink:to="silk_AccretionOfClosingCosts_638447229067792710" order="2" use="optional" weight="1" priority="2"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies (Balance Sheet Information) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_f7ccffef-5fe3-4faf-80ec-109df3e0ea97"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638447229067792710"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f7ccffef-5fe3-4faf-80ec-109df3e0ea97" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638447229067792710" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638447229067792710"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f7ccffef-5fe3-4faf-80ec-109df3e0ea97" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638447229067792710" order="2" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies (Operating Lease Maturities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e96607e-dcc0-41d9-b227-e48a2d03b6c3"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638447229067798560"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e96607e-dcc0-41d9-b227-e48a2d03b6c3" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638447229067798560" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638447229067798560"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e96607e-dcc0-41d9-b227-e48a2d03b6c3" xlink:to="us-gaap_OperatingLeaseLiability_638447229067798560" order="2" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies (Operating Lease Maturities) (Details) ALT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638447229067802673" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638447229067802673" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638447229067802673" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638447229067802673" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638447229067802673" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638447229067802673" order="6" use="optional" weight="1" priority="2"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638447229067802673" order="1" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638447229067802673" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638447229067802673" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638447229067802673" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638447229067802673" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LimitationOfCompensationDeduction" xlink:label="silk_LimitationOfCompensationDeduction_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="silk_LimitationOfCompensationDeduction_638447229067802673" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_638447229067802673" order="6" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638447229067802673"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638447229067802673" order="7" use="optional" weight="1"></calculationArc></link:calculationLink>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016" xlink:to="us-gaap_DeferredTaxAssetsGross_638447229067812660" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638447229067812660" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="silk_DeferredTaxAssetsOperatingLeaseLiability_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="silk_DeferredTaxAssetsOperatingLeaseLiability_638447229067812660" order="2" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_638447229067812660" order="3" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638447229067812660" order="4" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638447229067812660" order="5" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638447229067812660" order="6" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638447229067812660" order="7" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DeferredTaxAssetsSection174" xlink:label="silk_DeferredTaxAssetsSection174_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638447229067812660" xlink:to="silk_DeferredTaxAssetsSection174_638447229067812660" order="8" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638447229067812660" order="2" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638447229067812660" order="3" use="optional" weight="-1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638447229067812660" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638447229067812660" order="1" use="optional" weight="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638447229067812660"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638447229067812660" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638447229067812660" order="2" use="optional" weight="1"></calculationArc></link:calculationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>silk-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 23.3.2.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2024 1:15:14 PM-->
<!--Modified on: 2/28/2024 1:15:14 PM-->
<linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase">
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansTables" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureFormationAndBusinessOfCompanyDetails" roleURI="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureLongTermDebtNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails" roleURI="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"></link:arcroleRef>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"></link:arcroleRef>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"></link:arcroleRef>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"></link:arcroleRef>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"></link:arcroleRef>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders&apos; Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638447229067812660"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_638447229067812660" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DisgorgementOfStockholderSShortSwingProfits" xlink:label="silk_DisgorgementOfStockholderSShortSwingProfits"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="silk_DisgorgementOfStockholderSShortSwingProfits" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-Based Compensation Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229067832623"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229067832623" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_EmployeeStockPurchasePlanMember" xlink:label="silk_EmployeeStockPurchasePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silk_EmployeeStockPurchasePlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Formation and Business of the Company (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638447229067842562"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_638447229067842562" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_UnderwritersOptionMember" xlink:label="silk_UnderwritersOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="silk_UnderwritersOptionMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="silk_CashCashEquivalentsAndAvailableForSaleInvestments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_CashCashEquivalentsAndAvailableForSaleInvestments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:label="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638447229067852552"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638447229067852552" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_PledgingPurposeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain_638447229067852552"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain_638447229067852552" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnbilledReceivablesCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638447229067872506"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638447229067872506" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638447229067872506"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638447229067872506" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638447229067872506"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638447229067872506" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229067882471"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229067882471" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AgencyNotesMember" xlink:label="silk_AgencyNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="silk_AgencyNotesMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AgencyNotesMember" xlink:label="silk_AgencyNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="silk_AgencyNotesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_LongTermInvestments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AgencyNotesMember" xlink:label="silk_AgencyNotesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="silk_AgencyNotesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229067944115"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229067944115" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Long-term Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638447229067954079"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_638447229067954079" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LoanAndSecurityAgreementMember" xlink:label="silk_LoanAndSecurityAgreementMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silk_LoanAndSecurityAgreementMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheAMember" xlink:label="silk_TermLoanTrancheAMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silk_TermLoanTrancheAMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheBMember" xlink:label="silk_TermLoanTrancheBMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silk_TermLoanTrancheBMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheCMember" xlink:label="silk_TermLoanTrancheCMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silk_TermLoanTrancheCMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638447229067965636"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_638447229067965636" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LoanFacilityMember" xlink:label="silk_LoanFacilityMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="silk_LoanFacilityMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredRevolvingCreditFacilityAmendedMember" xlink:label="silk_SecuredRevolvingCreditFacilityAmendedMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="silk_SecuredRevolvingCreditFacilityAmendedMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredTermLoanFacilityMember" xlink:label="silk_SecuredTermLoanFacilityMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="silk_SecuredTermLoanFacilityMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredRevolvingCreditFacilitySubfacilityMember" xlink:label="silk_SecuredRevolvingCreditFacilitySubfacilityMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="silk_SecuredRevolvingCreditFacilitySubfacilityMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638447229067974034"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_638447229067974034" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanMember" xlink:label="silk_TermLoanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="silk_TermLoanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VariableRateAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638447229067977203"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_638447229067977203" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IndexRateMember" xlink:label="silk_IndexRateMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VariableRateDomain" xlink:to="silk_IndexRateMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_638447229067982924"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_638447229067982924" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_StifelBankMember" xlink:label="silk_StifelBankMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="silk_StifelBankMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_OxfordFinanceMember" xlink:label="silk_OxfordFinanceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="silk_OxfordFinanceMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:label="silk_DebtInstrumentCovenantMaximumBorrowingThreshold"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_DebtInstrumentCovenantMaximumBorrowingThreshold" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFees" xlink:label="silk_PercentageOfPrepaymentFees"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PercentageOfPrepaymentFees" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFeesInSecondYear" xlink:label="silk_PercentageOfPrepaymentFeesInSecondYear"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PercentageOfPrepaymentFeesInSecondYear" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFeesInThirdYear" xlink:label="silk_PercentageOfPrepaymentFeesInThirdYear"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PercentageOfPrepaymentFeesInThirdYear" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentAggregateOriginalPrincipalAmount" xlink:label="silk_PercentAggregateOriginalPrincipalAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PercentAggregateOriginalPrincipalAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtCovenantRevenueCovenant" xlink:label="silk_DebtCovenantRevenueCovenant"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_DebtCovenantRevenueCovenant" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfBorrowingBaseOfEligibleReceivables" xlink:label="silk_PercentOfBorrowingBaseOfEligibleReceivables"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PercentOfBorrowingBaseOfEligibleReceivables" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfEligibleInventory" xlink:label="silk_PercentOfEligibleInventory"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PercentOfEligibleInventory" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfBorrowingBaseInCaseEligibleInventory" xlink:label="silk_PercentOfBorrowingBaseInCaseEligibleInventory"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_PercentOfBorrowingBaseInCaseEligibleInventory" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_BorrowingBaseAmountInCaseEligibleInventory" xlink:label="silk_BorrowingBaseAmountInCaseEligibleInventory"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_BorrowingBaseAmountInCaseEligibleInventory" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentMarginRate" xlink:label="silk_DebtInstrumentMarginRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_DebtInstrumentMarginRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanPrepaidInIncrements" xlink:label="silk_TermLoanPrepaidInIncrements"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="silk_TermLoanPrepaidInIncrements" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_HeadquartersMember" xlink:label="silk_HeadquartersMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="silk_HeadquartersMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" xlink:label="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IndemnificationObligationsLiabilityRecognized" xlink:label="silk_IndemnificationObligationsLiabilityRecognized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="silk_IndemnificationObligationsLiabilityRecognized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders&apos; Equity (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionExercisedMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silk_IncentiveandNonqualifiedStockOptionExercisedMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionIssuedMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silk_IncentiveandNonqualifiedStockOptionIssuedMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PerformanceStockUnitsOverperformanceMember" xlink:label="silk_PerformanceStockUnitsOverperformanceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silk_PerformanceStockUnitsOverperformanceMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_EmployeeStockPurchasePlanMember" xlink:label="silk_EmployeeStockPurchasePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silk_EmployeeStockPurchasePlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638447229068137344"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638447229068137344" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TwoThousandNineteenStockOptionPlanMember" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="silk_TwoThousandNineteenStockOptionPlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_Espp2019Member" xlink:label="silk_Espp2019Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="silk_Espp2019Member" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_638447229068140139"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_638447229068140139" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AwardDateOneMember" xlink:label="silk_AwardDateOneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="silk_AwardDateOneMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AwardDateTwoMember" xlink:label="silk_AwardDateTwoMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="silk_AwardDateTwoMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silk_IncentiveandNonqualifiedStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveStockOptionMember" xlink:label="silk_IncentiveStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="silk_IncentiveandNonqualifiedStockOptionMember" xlink:to="silk_IncentiveStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_NonqualifiedStockOptionsMember" xlink:label="silk_NonqualifiedStockOptionsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="silk_IncentiveandNonqualifiedStockOptionMember" xlink:to="silk_NonqualifiedStockOptionsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_BenchmarkMember" xlink:label="silk_BenchmarkMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="silk_BenchmarkMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638447229068163114"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_638447229068163114" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:label="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="silk_CommonStockCapitalSharesAvailableForFutureIssuance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_CommonStockCapitalSharesAvailableForFutureIssuance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfOutstandingShares" xlink:label="silk_PercentOfOutstandingShares"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_PercentOfOutstandingShares" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_FairMarketValueOfCommonStock" xlink:label="silk_FairMarketValueOfCommonStock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_FairMarketValueOfCommonStock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TwoThousandNineteenStockOptionPlanMember" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="silk_TwoThousandNineteenStockOptionPlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_EmployeeStockPurchasePlanMember" xlink:label="silk_EmployeeStockPurchasePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silk_EmployeeStockPurchasePlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638447229068423409"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_638447229068423409" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638447229068433345"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638447229068433345" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638447229068433345"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638447229068433345" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails" xlink:type="extended" xlink:title="41401 - Schedule - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_638447229068443315"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_638447229068443315" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="us-gaap_AllowanceForCreditLossMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForCreditLossMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_MovementInValuationAllowancesAndReservesRollForward" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" priority="1" use="optional"></definitionArc></link:definitionLink>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional"></definitionArc></link:definitionLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>silk-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 23.3.2.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2024 1:15:14 PM-->
<!--Modified on: 2/28/2024 1:15:14 PM-->
<linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net of allowances of $26 and $3 at December 31, 2023 and December 31, 2022, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders&#8217; equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 7)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&apos; Equity Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&apos; equity:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value Shares authorized: 5,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: none at December 31, 2023 and 2022</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value Shares authorized: 100,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: 39,165,481 and 38,355,972 at December 31, 2023 and 2022, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&apos; Equity Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders&#8217; equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowances for accounts receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockAbstract" xlink:label="us-gaap_DividendsCommonStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockAbstract" xlink:to="us-gaap_DividendsCommonStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in USD per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations and Comprehensive Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss):</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on investments, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares used to compute net loss per share, basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common stock outstanding used to compute net loss per share, basic (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares used to compute net loss per share, diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common stock outstanding used to compute net loss per share, diluted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Stockholders&apos; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders&apos; Equity [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders&apos; Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under employee stock purchase plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DisgorgementOfStockholderSShortSwingProfits" xlink:label="silk_DisgorgementOfStockholderSShortSwingProfits" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DisgorgementOfStockholderSShortSwingProfits" xlink:to="silk_DisgorgementOfStockholderSShortSwingProfits_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DisgorgementOfStockholderSShortSwingProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disgorgement Of Stockholder&apos;s Short-Swing Profits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DisgorgementOfStockholderSShortSwingProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disgorgement Of Stockholder&apos;s Short-Swing Profits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_DisgorgementOfStockholderSShortSwingProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disgorgement of short-swing profits, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in unrealized loss on investments, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of deferred offering costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Depreciation and Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of premiums (accretion of discounts) on investments, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount and debt issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for (recovery of) doubtful accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for excess and obsolete inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Maturities, Prepayments and Calls of Other Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from maturity of investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-term Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from long-term debt, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal repayment of long-term debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMinorityShareholders" xlink:to="us-gaap_ProceedsFromMinorityShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Noncontrolling Interests</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from disgorgement of short-swing profits, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash investing and financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities for purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset obtained in exchange for lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Formation and Business of the Company [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Formation and Business of the Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&#8217; Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&#8217; Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation Plans [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosures [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ValuationAndQualifyingAccountsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Preparation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk, and Other Risks and Uncertainties</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development and Clinical Trials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising Cost [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment and Geographical Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Net Loss Per Share Determination</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets Measured on a Recurring Basis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of the Available-For-Sale Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-For-Sale Investments in Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Payment Under the Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="silk_AssetsAndLiabilitiesLesseeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="silk_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Maturities</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ScheduleOfCommonStockReserveForFutureIssuances" xlink:label="silk_ScheduleOfCommonStockReserveForFutureIssuances" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ScheduleOfCommonStockReserveForFutureIssuances" xlink:to="silk_ScheduleOfCommonStockReserveForFutureIssuances_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ScheduleOfCommonStockReserveForFutureIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Common Stock Reserve For Future Issuances</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ScheduleOfCommonStockReserveForFutureIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Common Stock Reserved for Future Issuances</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Shares Available for Issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Stock Option Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Stock Unit Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="silk_CashCashEquivalentsAndAvailableForSaleInvestments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="silk_CashCashEquivalentsAndAvailableForSaleInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_CashCashEquivalentsAndAvailableForSaleInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_CashCashEquivalentsAndAvailableForSaleInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents And Available For Sale Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued and sold common stock (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued, price per share (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:label="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:to="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Stock Issuance Underwriting Discounts And Commissions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Stock Issuance Underwriting Discounts And Commissions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of stock issuance underwriting discounts and commissions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unbilled Receivables, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unbilled receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for uncertain tax positions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale securities, credit losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:to="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units and performance stock units [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units And Performance Stock Units [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units and Performance Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper Not Included With Cash And Cash Equivalents [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Papers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Bonds/Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Government Agencies Debt Securities [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Government Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Backed Securities [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AgencyNotesMember" xlink:label="silk_AgencyNotesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AgencyNotesMember" xlink:to="silk_AgencyNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AgencyNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agency Notes [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AgencyNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agency Notes [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AgencyNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agency bonds/notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Current [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average days to maturity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:to="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts maturing within one year</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:to="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts maturing after one year through two years</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Less than 12 months</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Loss, Less than 12 months</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished products</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture And Fixtures [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software And Software Development Costs [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction In Progress [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction-in-progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities in accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedTravelExpensesCurrent" xlink:label="silk_AccruedTravelExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AccruedTravelExpensesCurrent" xlink:to="silk_AccruedTravelExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AccruedTravelExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Travel Expenses, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AccruedTravelExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Travel Expenses, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AccruedTravelExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued travel expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest payable</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ProvisionsForSalesReturns" xlink:label="silk_ProvisionsForSalesReturns" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ProvisionsForSalesReturns" xlink:to="silk_ProvisionsForSalesReturns_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ProvisionsForSalesReturns_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions For Sales Returns</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ProvisionsForSalesReturns_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions For Sales Returns</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_ProvisionsForSalesReturns_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for sales returns</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued royalty expense</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedAdministrationFeesAndSalesRebates" xlink:label="silk_AccruedAdministrationFeesAndSalesRebates" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AccruedAdministrationFeesAndSalesRebates" xlink:to="silk_AccruedAdministrationFeesAndSalesRebates_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AccruedAdministrationFeesAndSalesRebates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Administration Fees And Sales Rebates</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AccruedAdministrationFeesAndSalesRebates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Administration Fees And Sales Rebates</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AccruedAdministrationFeesAndSalesRebates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued administration fees and sales rebates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional services</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedClinicalExpensesCurrent" xlink:label="silk_AccruedClinicalExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AccruedClinicalExpensesCurrent" xlink:to="silk_AccruedClinicalExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AccruedClinicalExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Clinical Expenses, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AccruedClinicalExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Clinical Expenses, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AccruedClinicalExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LoanAndSecurityAgreementMember" xlink:label="silk_LoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_LoanAndSecurityAgreementMember" xlink:to="silk_LoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan And Security Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan And Security Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LoanFacilityMember" xlink:label="silk_LoanFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_LoanFacilityMember" xlink:to="silk_LoanFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_LoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Facility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_LoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Facility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_LoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revolving Credit Facility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredRevolvingCreditFacilityAmendedMember" xlink:label="silk_SecuredRevolvingCreditFacilityAmendedMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_SecuredRevolvingCreditFacilityAmendedMember" xlink:to="silk_SecuredRevolvingCreditFacilityAmendedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_SecuredRevolvingCreditFacilityAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Revolving Credit Facility, Amended [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_SecuredRevolvingCreditFacilityAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Revolving Credit Facility Amended [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_SecuredRevolvingCreditFacilityAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Revolving Credit Facility, Amended [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredTermLoanFacilityMember" xlink:label="silk_SecuredTermLoanFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_SecuredTermLoanFacilityMember" xlink:to="silk_SecuredTermLoanFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_SecuredTermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Term Loan Facility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_SecuredTermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Term Loan Facility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_SecuredTermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredRevolvingCreditFacilitySubfacilityMember" xlink:label="silk_SecuredRevolvingCreditFacilitySubfacilityMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_SecuredRevolvingCreditFacilitySubfacilityMember" xlink:to="silk_SecuredRevolvingCreditFacilitySubfacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_SecuredRevolvingCreditFacilitySubfacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Revolving Credit Facility, Subfacility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_SecuredRevolvingCreditFacilitySubfacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Revolving Credit Facility Subfacility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_SecuredRevolvingCreditFacilitySubfacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Revolving Credit Facility, Subfacility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prime Rate [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IndexRateMember" xlink:label="silk_IndexRateMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_IndexRateMember" xlink:to="silk_IndexRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_IndexRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Index Rate [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_IndexRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Index Rate [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_IndexRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Index Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Line of Credit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate outstanding principal balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:label="silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:to="silk_DebtInstrumentCovenantMaximumBorrowingThreshold_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DebtInstrumentCovenantMaximumBorrowingThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Covenant, Maximum Borrowing Threshold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DebtInstrumentCovenantMaximumBorrowingThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Covenant, Maximum Borrowing Threshold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_DebtInstrumentCovenantMaximumBorrowingThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of outstanding loan amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extinguishment of Debt, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt pay off</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFees" xlink:label="silk_PercentageOfPrepaymentFees" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentageOfPrepaymentFees" xlink:to="silk_PercentageOfPrepaymentFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentageOfPrepaymentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentageOfPrepaymentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_PercentageOfPrepaymentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFeesInSecondYear" xlink:label="silk_PercentageOfPrepaymentFeesInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentageOfPrepaymentFeesInSecondYear" xlink:to="silk_PercentageOfPrepaymentFeesInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentageOfPrepaymentFeesInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees in second year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentageOfPrepaymentFeesInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees in second year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_PercentageOfPrepaymentFeesInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees in second year</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFeesInThirdYear" xlink:label="silk_PercentageOfPrepaymentFeesInThirdYear" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentageOfPrepaymentFeesInThirdYear" xlink:to="silk_PercentageOfPrepaymentFeesInThirdYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentageOfPrepaymentFeesInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees in third year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentageOfPrepaymentFeesInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees in third year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_PercentageOfPrepaymentFeesInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment fees in third year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fee Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility fee</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:to="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of original principal threshold</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:to="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Covenant, Liquidity Event, Payment Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Covenant, Liquidity Event, Payment Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentAggregateOriginalPrincipalAmount" xlink:label="silk_PercentAggregateOriginalPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentAggregateOriginalPrincipalAmount" xlink:to="silk_PercentAggregateOriginalPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentAggregateOriginalPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent aggregate original principal amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentAggregateOriginalPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent aggregate original principal amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_PercentAggregateOriginalPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent aggregate original principal amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Maturity Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity date</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtCovenantRevenueCovenant" xlink:label="silk_DebtCovenantRevenueCovenant" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DebtCovenantRevenueCovenant" xlink:to="silk_DebtCovenantRevenueCovenant_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DebtCovenantRevenueCovenant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Covenant, Revenue Covenant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DebtCovenantRevenueCovenant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Covenant, Revenue Covenant</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfBorrowingBaseOfEligibleReceivables" xlink:label="silk_PercentOfBorrowingBaseOfEligibleReceivables" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentOfBorrowingBaseOfEligibleReceivables" xlink:to="silk_PercentOfBorrowingBaseOfEligibleReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentOfBorrowingBaseOfEligibleReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of borrowing base of eligible receivables.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentOfBorrowingBaseOfEligibleReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of borrowing base of eligible receivables</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_PercentOfBorrowingBaseOfEligibleReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of borrowing base of eligible receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfEligibleInventory" xlink:label="silk_PercentOfEligibleInventory" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentOfEligibleInventory" xlink:to="silk_PercentOfEligibleInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentOfEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of eligible inventory.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentOfEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of eligible inventory</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_PercentOfEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of eligible inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfBorrowingBaseInCaseEligibleInventory" xlink:label="silk_PercentOfBorrowingBaseInCaseEligibleInventory" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentOfBorrowingBaseInCaseEligibleInventory" xlink:to="silk_PercentOfBorrowingBaseInCaseEligibleInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentOfBorrowingBaseInCaseEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of borrowing base in case eligible inventory</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentOfBorrowingBaseInCaseEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of borrowing base in case eligible inventory</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_PercentOfBorrowingBaseInCaseEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of borrowing base in case eligible inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_BorrowingBaseAmountInCaseEligibleInventory" xlink:label="silk_BorrowingBaseAmountInCaseEligibleInventory" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_BorrowingBaseAmountInCaseEligibleInventory" xlink:to="silk_BorrowingBaseAmountInCaseEligibleInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_BorrowingBaseAmountInCaseEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing base amount in case eligible inventory.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_BorrowingBaseAmountInCaseEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing base amount in case eligible inventory</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_BorrowingBaseAmountInCaseEligibleInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing base amount in case eligible inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentMarginRate" xlink:label="silk_DebtInstrumentMarginRate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DebtInstrumentMarginRate" xlink:to="silk_DebtInstrumentMarginRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DebtInstrumentMarginRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument margin rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DebtInstrumentMarginRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument margin rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_DebtInstrumentMarginRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument margin rate</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanPrepaidInIncrements" xlink:label="silk_TermLoanPrepaidInIncrements" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_TermLoanPrepaidInIncrements" xlink:to="silk_TermLoanPrepaidInIncrements_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_TermLoanPrepaidInIncrements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan prepaid in increments.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_TermLoanPrepaidInIncrements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan prepaid in increments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_TermLoanPrepaidInIncrements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan prepaid in increments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:label="silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:to="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross, Before Accretion Of Closing Fees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross, Before Accretion Of Closing Fees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, gross before accretion of closing fees</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccretionOfClosingCosts" xlink:label="silk_AccretionOfClosingCosts" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AccretionOfClosingCosts" xlink:to="silk_AccretionOfClosingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AccretionOfClosingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion Of Closing Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AccretionOfClosingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion Of Closing Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AccretionOfClosingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Add: Accretion of closing fees</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtGrossAfterAccretionOfClosingFees" xlink:label="silk_LongTermDebtGrossAfterAccretionOfClosingFees" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_LongTermDebtGrossAfterAccretionOfClosingFees" xlink:to="silk_LongTermDebtGrossAfterAccretionOfClosingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_LongTermDebtGrossAfterAccretionOfClosingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross, After Accretion Of Closing Fees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_LongTermDebtGrossAfterAccretionOfClosingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross, After Accretion Of Closing Fees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="silk_LongTermDebtGrossAfterAccretionOfClosingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross, After Accretion Of Closing Fees</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtUnpaidInterest" xlink:label="silk_LongTermDebtUnpaidInterest" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_LongTermDebtUnpaidInterest" xlink:to="silk_LongTermDebtUnpaidInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_LongTermDebtUnpaidInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Unpaid Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_LongTermDebtUnpaidInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Unpaid Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="silk_LongTermDebtUnpaidInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Amount representing interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Amount representing debt discount and debt issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of minimum payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IndemnificationObligationsLiabilityRecognized" xlink:label="silk_IndemnificationObligationsLiabilityRecognized" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_IndemnificationObligationsLiabilityRecognized" xlink:to="silk_IndemnificationObligationsLiabilityRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_IndemnificationObligationsLiabilityRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification obligations for which a liability has been recognized.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_IndemnificationObligationsLiabilityRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Obligations, Liability Recognized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_IndemnificationObligationsLiabilityRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification obligations, liability recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Accrual</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities requiring accrual</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Renewal Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional extended lease period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets in other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities in other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, right-of-use asset, statement of financial position extensible list</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, liability, current, statement of financial position extensible list</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, liability, noncurrent, statement of financial position extensible list</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends declared</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionExercisedMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:to="silk_IncentiveandNonqualifiedStockOptionExercisedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_IncentiveandNonqualifiedStockOptionExercisedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive and Nonqualified Stock Option, Exercised [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_IncentiveandNonqualifiedStockOptionExercisedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentiveand Nonqualified Stock Option Exercised [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_IncentiveandNonqualifiedStockOptionExercisedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options under stock plan</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionIssuedMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:to="silk_IncentiveandNonqualifiedStockOptionIssuedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_IncentiveandNonqualifiedStockOptionIssuedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive and Nonqualified Stock Option, Issued [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_IncentiveandNonqualifiedStockOptionIssuedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentiveand Nonqualified Stock Option Issued [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_IncentiveandNonqualifiedStockOptionIssuedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of options and restricted stock units under stock plan</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PerformanceStockUnitsOverperformanceMember" xlink:label="silk_PerformanceStockUnitsOverperformanceMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PerformanceStockUnitsOverperformanceMember" xlink:to="silk_PerformanceStockUnitsOverperformanceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PerformanceStockUnitsOverperformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Units, Overperformance [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PerformanceStockUnitsOverperformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Units Overperformance [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_PerformanceStockUnitsOverperformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Units, Overperformance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_EmployeeStockPurchasePlanMember" xlink:label="silk_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_EmployeeStockPurchasePlanMember" xlink:to="silk_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for future issuance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TwoThousandNineteenStockOptionPlanMember" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_TwoThousandNineteenStockOptionPlanMember" xlink:to="silk_TwoThousandNineteenStockOptionPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Nineteen Stock Option Plan [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Nineteen Stock Option Plan [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_Espp2019Member" xlink:label="silk_Espp2019Member" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_Espp2019Member" xlink:to="silk_Espp2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_Espp2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP, 2019 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_Espp2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Espp2019 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_Espp2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_IncentiveandNonqualifiedStockOptionMember" xlink:to="silk_IncentiveandNonqualifiedStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_IncentiveandNonqualifiedStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive and Nonqualified Stock Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_IncentiveandNonqualifiedStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentiveand Nonqualified Stock Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_IncentiveandNonqualifiedStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ISO and NSO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveStockOptionMember" xlink:label="silk_IncentiveStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_IncentiveStockOptionMember" xlink:to="silk_IncentiveStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_IncentiveStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive Stock Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_IncentiveStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive Stock Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_IncentiveStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ISO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_NonqualifiedStockOptionsMember" xlink:label="silk_NonqualifiedStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_NonqualifiedStockOptionsMember" xlink:to="silk_NonqualifiedStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_NonqualifiedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonqualified Stock Options [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_NonqualifiedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonqualified Stock Options [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_NonqualifiedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NSO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 ESPP</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units R S U [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:label="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares allowable under the plan (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of outstanding shares of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:to="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise threshold as a percentage of fair value of shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of purchase of price of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="silk_CommonStockCapitalSharesAvailableForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:to="silk_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Available For Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Available For Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future issuance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfOutstandingShares" xlink:label="silk_PercentOfOutstandingShares" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_PercentOfOutstandingShares" xlink:to="silk_PercentOfOutstandingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_PercentOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent Of Outstanding Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_PercentOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent Of Outstanding Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_FairMarketValueOfCommonStock" xlink:label="silk_FairMarketValueOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_FairMarketValueOfCommonStock" xlink:to="silk_FairMarketValueOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_FairMarketValueOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Market Value Of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_FairMarketValueOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Market Value Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expensed not yet recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expensed not yet recognized, period for recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs of unvested RSUs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs related to the ESPP</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Allowance For Overperformance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Allowance For Overperformance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Performance Stock Units for overperformance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted/Awarded (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canceled (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Exercisable (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expect to vest (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in USD per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in USD per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable (in USD per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (in Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (in Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards vested (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards cancelled (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected to vest (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in USD per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards vested (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards cancelled (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected to vest (in USD per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost Of Sales [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expenses [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Name [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Country [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State And Local Jurisdiction [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in deferred tax asset valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, income tax penalties and interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at federal statutory rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LimitationOfCompensationDeduction" xlink:label="silk_LimitationOfCompensationDeduction" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_LimitationOfCompensationDeduction" xlink:to="silk_LimitationOfCompensationDeduction_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_LimitationOfCompensationDeduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Limitation Of Compensation Deduction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_LimitationOfCompensationDeduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Limitation Of Compensation Deduction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_LimitationOfCompensationDeduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Limitation of compensation deduction under IRS Sec.162(m)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General business credits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized start-up costs/Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DeferredTaxAssetsSection174" xlink:label="silk_DeferredTaxAssetsSection174" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DeferredTaxAssetsSection174" xlink:to="silk_DeferredTaxAssetsSection174_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DeferredTaxAssetsSection174_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Section 174</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DeferredTaxAssetsSection174_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Section 174</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and reserves</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="silk_DeferredTaxAssetsOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="silk_DeferredTaxAssetsOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest limitation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases related to current years&#8217; tax positions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases related to prior years&#8217; tax positions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage employee contribution</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer discretionary contribution</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contribution match percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of matching contribution of the employee&apos;s pay</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances And Reserves [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="us-gaap_AllowanceForCreditLossMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossMember" xlink:to="us-gaap_AllowanceForCreditLossMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForCreditLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance For Credit Loss [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForCreditLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts receivable:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="us-gaap_MovementInValuationAllowancesAndReservesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at End of Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of Year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charged to expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write offs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_UnderwritersOptionMember" xlink:label="silk_UnderwritersOptionMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_UnderwritersOptionMember" xlink:to="silk_UnderwritersOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_UnderwritersOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters&apos; Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_UnderwritersOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_UnderwritersOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters&apos; Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pledging Purpose [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_PledgingPurposeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pledging Purpose [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PledgingPurposeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pledging Purpose [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letter Of Credit [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Treasury Securities [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Treasury Bills [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheAMember" xlink:label="silk_TermLoanTrancheAMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_TermLoanTrancheAMember" xlink:to="silk_TermLoanTrancheAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_TermLoanTrancheAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, Tranche A [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_TermLoanTrancheAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche A [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_TermLoanTrancheAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, First Tranche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheBMember" xlink:label="silk_TermLoanTrancheBMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_TermLoanTrancheBMember" xlink:to="silk_TermLoanTrancheBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_TermLoanTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, Tranche B [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_TermLoanTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche B [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_TermLoanTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, Second Tranche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheCMember" xlink:label="silk_TermLoanTrancheCMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_TermLoanTrancheCMember" xlink:to="silk_TermLoanTrancheCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_TermLoanTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche C Member.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_TermLoanTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche C [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_TermLoanTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, Third Tranche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanMember" xlink:label="silk_TermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_TermLoanMember" xlink:to="silk_TermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Facility Lender [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_StifelBankMember" xlink:label="silk_StifelBankMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_StifelBankMember" xlink:to="silk_StifelBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_StifelBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stifel Bank [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_StifelBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stifel Bank [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_StifelBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stifel Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_OxfordFinanceMember" xlink:label="silk_OxfordFinanceMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_OxfordFinanceMember" xlink:to="silk_OxfordFinanceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_OxfordFinanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Oxford Finance [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_OxfordFinanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Oxford Finance [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_OxfordFinanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Oxford Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_HeadquartersMember" xlink:label="silk_HeadquartersMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_HeadquartersMember" xlink:to="silk_HeadquartersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_HeadquartersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Headquarters [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_HeadquartersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Headquarters [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_HeadquartersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Headquarters [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" xlink:label="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" xlink:to="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Office, Laboratory And Manufacturing Space [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Office Laboratory And Manufacturing Space [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Office, Laboratory And Manufacturing Space [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AwardDateOneMember" xlink:label="silk_AwardDateOneMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AwardDateOneMember" xlink:to="silk_AwardDateOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AwardDateOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date One [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AwardDateOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date One [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AwardDateOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AwardDateTwoMember" xlink:label="silk_AwardDateTwoMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_AwardDateTwoMember" xlink:to="silk_AwardDateTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_AwardDateTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date Two [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_AwardDateTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date Two [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_AwardDateTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_BenchmarkMember" xlink:label="silk_BenchmarkMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silk_BenchmarkMember" xlink:to="silk_BenchmarkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silk_BenchmarkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benchmark [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silk_BenchmarkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benchmark [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silk_BenchmarkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscLineItems" xlink:label="ecd_AwardsCloseToMnpiDiscLineItems" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscLineItems" xlink:to="ecd_AwardsCloseToMnpiDiscLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards Close in Time to MNPI Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" xmlns="http://www.xbrl.org/2003/linkbase"></link:loc>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase"></link:labelArc>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards Close in Time to MNPI Disclosures [Table]</link:label></link:labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>silk-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 23.3.2.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2024 1:15:14 PM-->
<!--Modified on: 2/28/2024 1:15:14 PM-->
<linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase">
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DocumentCoverPage" roleURI="http://silkroadmed.com/role/DocumentCoverPage" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementBalanceSheets" roleURI="http://silkroadmed.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://silkroadmed.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementStatementsOfStockholdersEquityParenthetical" roleURI="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#StatementStatementsOfCashFlows" roleURI="http://silkroadmed.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureFormationAndBusinessOfCompany" roleURI="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompany" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureRecentAccountingPronouncements" roleURI="http://silkroadmed.com/role/DisclosureRecentAccountingPronouncements" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureFairValueMeasurements" roleURI="http://silkroadmed.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponents" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureLongTermDebt" roleURI="http://silkroadmed.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockholdersEquity" roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlans" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlans" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#Disclosure401KPlan" roleURI="http://silkroadmed.com/role/Disclosure401KPlan" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#ScheduleScheduleIiValuationAndQualifyingAccounts" roleURI="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccounts" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://silkroadmed.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureLongTermDebtTables" roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockholdersEquityTables" roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansTables" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureFormationAndBusinessOfCompanyDetails" roleURI="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails" roleURI="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureLongTermDebtNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails" roleURI="http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails" roleURI="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" roleURI="http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails" roleURI="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" roleURI="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#Disclosure401KPlanDetails" roleURI="http://silkroadmed.com/role/Disclosure401KPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="silk-20231231.xsd#ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails" roleURI="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase"></link:roleRef>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DocumentCoverPage" xlink:type="extended" xlink:title="00090 - Document - Cover Page" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638447229068484742" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638447229068484742" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638447229068484742" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638447229068484742" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638447229068484742" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638447229068484742" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638447229068484742" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638447229068484742" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638447229068484742" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638447229068484742" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638447229068484742" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638447229068484742" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638447229068484742"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638447229068484742" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638447229068494648" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638447229068494648" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638447229068494648" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638447229068494648" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638447229068494648" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638447229068494648" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638447229068494648" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638447229068494648"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638447229068494648" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638447229068504626"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638447229068504626" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638447229068504626"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638447229068504626" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638447229068504626"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638447229068504626" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638447229068504626"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638447229068504626" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638447229068504626"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638447229068504626" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638447229068504626"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638447229068504626" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638447229068504626"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638447229068504626" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638447229068514600" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638447229068514600" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638447229068514600" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638447229068514600" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638447229068514600" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638447229068514600" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638447229068514600" order="35" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638447229068514600" order="36" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638447229068514600"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638447229068514600" order="37" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638447229068524574" order="38" use="optional" priority="2"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_104ef638-4555-4655-a1d9-7d9a752f6081"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_104ef638-4555-4655-a1d9-7d9a752f6081" xlink:to="us-gaap_AssetsAbstract_638447229068524574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638447229068524574" xlink:to="us-gaap_AssetsCurrentAbstract_638447229068524574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638447229068524574" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229068524574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638447229068524574" xlink:to="us-gaap_ShortTermInvestments_638447229068524574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638447229068524574" xlink:to="us-gaap_AccountsReceivableNetCurrent_638447229068524574" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638447229068524574" xlink:to="us-gaap_InventoryNet_638447229068524574" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638447229068524574" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638447229068524574" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638447229068524574" xlink:to="us-gaap_AssetsCurrent_638447229068524574" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638447229068524574" xlink:to="us-gaap_LongTermInvestments_638447229068524574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638447229068524574" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638447229068524574" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638447229068524574" xlink:to="us-gaap_RestrictedCashNoncurrent_638447229068524574" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638447229068524574" xlink:to="us-gaap_OtherAssetsNoncurrent_638447229068524574" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638447229068524574" xlink:to="us-gaap_Assets_638447229068524574" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_104ef638-4555-4655-a1d9-7d9a752f6081" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638447229068534961"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638447229068534961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638447229068534961"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638447229068534961" xlink:to="us-gaap_AccountsPayableCurrent_638447229068534961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638447229068534961"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638447229068534961" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638447229068534961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638447229068534961"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638447229068534961" xlink:to="us-gaap_LiabilitiesCurrent_638447229068534961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638447229068534961"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" xlink:to="us-gaap_LongTermDebtNoncurrent_638447229068534961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638447229068534961"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638447229068534961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" xlink:to="us-gaap_Liabilities_638447229068544523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" xlink:to="us-gaap_CommitmentsAndContingencies_638447229068544523" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" xlink:to="us-gaap_StockholdersEquityAbstract_638447229068544523" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068544523" xlink:to="us-gaap_PreferredStockValue_638447229068544523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068544523" xlink:to="us-gaap_CommonStockValue_638447229068544523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068544523" xlink:to="us-gaap_AdditionalPaidInCapital_638447229068544523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068544523" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638447229068544523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068544523" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638447229068544523" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068544523" xlink:to="us-gaap_StockholdersEquity_638447229068544523" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638447229068544523"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638447229068524574" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638447229068544523" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b0bcd9f8-b2b8-430e-9739-71709f845559"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638447229068554487"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0bcd9f8-b2b8-430e-9739-71709f845559" xlink:to="us-gaap_AssetsAbstract_638447229068554487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638447229068554487"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638447229068554487" xlink:to="us-gaap_AssetsCurrentAbstract_638447229068554487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_638447229068554487"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638447229068554487" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_638447229068554487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638447229068554487"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0bcd9f8-b2b8-430e-9739-71709f845559" xlink:to="us-gaap_StockholdersEquityAbstract_638447229068554487" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638447229068554487"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068554487" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638447229068554487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638447229068554487"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638447229068554487" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638447229068554487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638447229068554487"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638447229068554487" xlink:to="us-gaap_PreferredStockSharesAuthorized_638447229068554487" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638447229068559289"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638447229068554487" xlink:to="us-gaap_PreferredStockSharesIssued_638447229068559289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638447229068559289"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638447229068554487" xlink:to="us-gaap_PreferredStockSharesOutstanding_638447229068559289" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockAbstract" xlink:label="us-gaap_DividendsCommonStockAbstract_638447229068559289"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638447229068554487" xlink:to="us-gaap_DividendsCommonStockAbstract_638447229068559289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638447229068559289"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsCommonStockAbstract_638447229068559289" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638447229068559289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsCommonStockAbstract_638447229068559289" xlink:to="us-gaap_CommonStockSharesAuthorized_638447229068564464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsCommonStockAbstract_638447229068559289" xlink:to="us-gaap_CommonStockSharesIssued_638447229068564464" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsCommonStockAbstract_638447229068559289" xlink:to="us-gaap_CommonStockSharesOutstanding_638447229068564464" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638447229068564464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638447229068564464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_GrossProfit_638447229068564464" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_OperatingExpensesAbstract_638447229068564464" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638447229068564464" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638447229068564464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638447229068564464" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638447229068564464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638447229068564464" xlink:to="us-gaap_OperatingExpenses_638447229068564464" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_OperatingIncomeLoss_638447229068564464" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_InvestmentIncomeInterest_638447229068564464" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_InterestExpense_638447229068564464" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229068564464" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638447229068564464" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_NetIncomeLoss_638447229068564464" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638447229068564464" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638447229068564464" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_638447229068564464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638447229068564464"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638447229068564464" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638447229068564464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638447229068574451" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_EarningsPerShareBasic_638447229068574451" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_EarningsPerShareDiluted_638447229068574451" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638447229068574451" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638447229068574451" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders&apos; Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a42c6dbb-11a2-4bf7-a5b6-fb72b4a6475f"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a42c6dbb-11a2-4bf7-a5b6-fb72b4a6475f" xlink:to="us-gaap_StatementTable_638447229068574451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638447229068574451" xlink:to="us-gaap_StatementEquityComponentsAxis_638447229068574451" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638447229068574451" xlink:to="us-gaap_CommonStockMember_638447229068574451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638447229068574451" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638447229068574451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638447229068574451" xlink:to="us-gaap_RetainedEarningsMember_638447229068574451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638447229068574451" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638447229068574451" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638447229068574451"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638447229068574451" xlink:to="us-gaap_EquityComponentDomain_638447229068574451" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638447229068574451" xlink:to="us-gaap_StatementLineItems_638447229068584412" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638447229068584412" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_SharesOutstanding_638447229068584412" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638447229068584412" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638447229068584412" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638447229068584412" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638447229068584412" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638447229068584412" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638447229068584412" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638447229068584412" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638447229068584412" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638447229068584412" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_638447229068584412" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DisgorgementOfStockholderSShortSwingProfits" xlink:label="silk_DisgorgementOfStockholderSShortSwingProfits_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="silk_DisgorgementOfStockholderSShortSwingProfits_638447229068584412" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_ProfitLoss_638447229068584412" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_638447229068584412"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_638447229068584412" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6384472290685844121"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_SharesOutstanding_6384472290685844121" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638447229068584412" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638447229068594382" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Stockholders&#8217; Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d37fdaf9-c288-4fa8-a629-cba69fd9da47"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d37fdaf9-c288-4fa8-a629-cba69fd9da47" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638447229068594382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_ProfitLoss_638447229068594382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_OtherDepreciationAndAmortization_638447229068594382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_ShareBasedCompensation_638447229068594382" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638447229068594382" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638447229068594382" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638447229068594382" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_PaidInKindInterest_638447229068594382" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229068594382" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638447229068594382" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_638447229068594382" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638447229068594382"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_InventoryWriteDown_638447229068594382" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638447229068604358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" xlink:to="us-gaap_IncreaseDecreaseInInventories_638447229068604358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638447229068604358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638447229068604358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638447229068604358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638447229068604358" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638447229068604358" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638447229068604358" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638447229068594382" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638447229068604358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638447229068604358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638447229068604358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638447229068604358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_PaymentsToAcquireInvestments_638447229068604358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_638447229068604358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638447229068604358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638447229068614328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638447229068614328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638447229068614328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638447229068614328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_ProceedsFromMinorityShareholders_638447229068614328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638447229068604358" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638447229068614328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638447229068614328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638447229068614328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384472290686143281"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384472290686143281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638447229068614328" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638447229068614328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638447229068614328" xlink:to="us-gaap_InterestPaidNet_638447229068614328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638447229068624302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638447229068624302" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638447229068624302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638447229068624302" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638447229068624302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638447229068624302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638447229068624302" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638447229068624302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompany" xlink:type="extended" xlink:title="10101 - Disclosure - Formation and Business of the Company" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1920f754-b040-4818-90ed-4bba1246863d"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638447229068624302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1920f754-b040-4818-90ed-4bba1246863d" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638447229068624302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ce438868-61b6-4cb2-9e19-6902d33bc722"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638447229068624302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce438868-61b6-4cb2-9e19-6902d33bc722" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638447229068624302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureRecentAccountingPronouncements" xlink:type="extended" xlink:title="10301 - Disclosure - Recent Accounting Pronouncements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_659038f6-aea6-443a-bf2a-ec269e445648"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638447229068624302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_659038f6-aea6-443a-bf2a-ec269e445648" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638447229068624302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c2d60a53-4c66-454b-9dc6-208bf41c5031"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638447229068634275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c2d60a53-4c66-454b-9dc6-208bf41c5031" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638447229068634275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="10501 - Disclosure - Balance Sheet Components" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638447229068634275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638447229068634275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="10601 - Disclosure - Long-term Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f52c1e87-4de7-4e9f-b517-afd161939973"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638447229068634275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f52c1e87-4de7-4e9f-b517-afd161939973" xlink:to="us-gaap_DebtDisclosureTextBlock_638447229068634275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24833b92-29ba-48b8-baec-31f741afdce0"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638447229068634275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24833b92-29ba-48b8-baec-31f741afdce0" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638447229068634275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10801 - Disclosure - Stockholders&#8217; Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638447229068634275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638447229068634275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlans" xlink:type="extended" xlink:title="10901 - Disclosure - Stock-Based Compensation Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d43e9c4e-2b41-4c8e-b199-76a49b9c8a16"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638447229068634275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d43e9c4e-2b41-4c8e-b199-76a49b9c8a16" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638447229068634275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1eccc285-f3f6-42b1-bafd-22ae245c20b9"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638447229068634275"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1eccc285-f3f6-42b1-bafd-22ae245c20b9" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638447229068634275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/Disclosure401KPlan" xlink:type="extended" xlink:title="11101 - Disclosure - 401(k) Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_99382fdf-e3f0-4fe4-aff4-005e21690a64"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_99382fdf-e3f0-4fe4-aff4-005e21690a64" xlink:to="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_638447229068644249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccounts" xlink:type="extended" xlink:title="11401 - Schedule - Schedule II - Valuation and Qualifying Accounts" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_78c1eb30-5ed8-42ef-91d1-78efb2489bda"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_78c1eb30-5ed8-42ef-91d1-78efb2489bda" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_638447229068644249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638447229068644249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_UseOfEstimates_638447229068644249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638447229068644249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638447229068644249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_InvestmentPolicyTextBlock_638447229068644249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638447229068644249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638447229068644249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_InventoryPolicyTextBlock_638447229068644249" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638447229068644249" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638447229068644249" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638447229068644249" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638447229068644249" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_638447229068644249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_638447229068644249" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638447229068654223" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_638447229068654223" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638447229068654223" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638447229068654223" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638447229068654223" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638447229068654223" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638447229068654223" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638447229068654223" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638447229068654223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638447229068654223" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638447229068654223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638447229068654223" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_46f90a9d-7dd1-4e69-ad90-1979e21a7246"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46f90a9d-7dd1-4e69-ad90-1979e21a7246" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638447229068664200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Balance Sheet Components (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638447229068664200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638447229068664200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_638447229068664200" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638447229068664200" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638447229068664200" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638447229068664200" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureLongTermDebtTables" xlink:type="extended" xlink:title="30603 - Disclosure - Long-term Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8ab108ff-78de-40ef-a68c-775cdddfd32b"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ab108ff-78de-40ef-a68c-775cdddfd32b" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638447229068664200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fa213b5-adaa-4cc9-a117-eda299b086b0"></loc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="silk_AssetsAndLiabilitiesLesseeTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fa213b5-adaa-4cc9-a117-eda299b086b0" xlink:to="silk_AssetsAndLiabilitiesLesseeTableTextBlock_638447229068664200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638447229068664200"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fa213b5-adaa-4cc9-a117-eda299b086b0" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638447229068664200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30803 - Disclosure - Stockholders&apos; Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"></loc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ScheduleOfCommonStockReserveForFutureIssuances" xlink:label="silk_ScheduleOfCommonStockReserveForFutureIssuances_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="silk_ScheduleOfCommonStockReserveForFutureIssuances_638447229068674171" order="1" use="optional" priority="2"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-Based Compensation Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068674171" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068674171" xlink:to="us-gaap_AwardTypeAxis_638447229068674171" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638447229068674171" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068674171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068674171" xlink:to="us-gaap_EmployeeStockOptionMember_638447229068674171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_EmployeeStockPurchasePlanMember" xlink:label="silk_EmployeeStockPurchasePlanMember_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068674171" xlink:to="silk_EmployeeStockPurchasePlanMember_638447229068674171" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068674171" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638447229068674171" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068674171" xlink:to="us-gaap_PerformanceSharesMember_638447229068674171" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068674171" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068674171" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068674171" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638447229068674171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068674171" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_638447229068674171" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068674171" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638447229068674171" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068674171" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638447229068674171" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068674171" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638447229068674171" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638447229068674171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638447229068674171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638447229068684153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638447229068684153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_638447229068684153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Formation and Business of the Company (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60407876-497e-4caf-a745-a28dd215de42"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60407876-497e-4caf-a745-a28dd215de42" xlink:to="us-gaap_SubsequentEventTable_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068684153" xlink:to="srt_StatementScenarioAxis_638447229068684153" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638447229068684153" xlink:to="srt_ScenarioUnspecifiedDomain_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_UnderwritersOptionMember" xlink:label="silk_UnderwritersOptionMember_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638447229068684153" xlink:to="silk_UnderwritersOptionMember_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068684153" xlink:to="us-gaap_SubsequentEventLineItems_638447229068684153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068684153" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="silk_CashCashEquivalentsAndAvailableForSaleInvestments_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068684153" xlink:to="silk_CashCashEquivalentsAndAvailableForSaleInvestments_638447229068684153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068684153" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638447229068684153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068684153" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638447229068684153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068684153" xlink:to="us-gaap_SaleOfStockPricePerShare_638447229068684153" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068684153" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638447229068684153" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:label="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068684153" xlink:to="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_638447229068684153" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_62d772b1-441a-409b-a2ee-14d2aab58df8"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62d772b1-441a-409b-a2ee-14d2aab58df8" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638447229068684153" xlink:to="srt_RangeAxis_638447229068684153" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638447229068684153" xlink:to="srt_RangeMember_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638447229068684153" xlink:to="srt_MinimumMember_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638447229068684153" xlink:to="srt_MaximumMember_638447229068684153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638447229068684153" xlink:to="us-gaap_PledgingPurposeAxis_638447229068684153" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain_638447229068684153"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeAxis_638447229068684153" xlink:to="us-gaap_PledgingPurposeDomain_638447229068684153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_638447229068695251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeDomain_638447229068684153" xlink:to="us-gaap_LetterOfCreditMember_638447229068695251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638447229068684153" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent_638447229068695251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_UnbilledReceivablesCurrent_638447229068695251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638447229068695251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_DeferredTaxAssetsNet_638447229068695251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_638447229068695251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_638447229068695251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638447229068720191"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_NumberOfReportableSegments_638447229068720191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638447229068724043"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_NumberOfOperatingSegments_638447229068724043" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense_638447229068734403"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_AdvertisingExpense_638447229068734403" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638447229068734403"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638447229068734403" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_638447229068734403"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_AssetImpairmentCharges_638447229068734403" order="8" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_638447229068743988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_638447229068743988" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638447229068743988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638447229068695251" xlink:to="us-gaap_RestrictedCashNoncurrent_638447229068743988" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229068753990"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638447229068753990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638447229068753990"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent_638447229068753990" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638447229068753990"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638447229068753990" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Net Loss Per Share Determination) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638447229068763941"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="us-gaap_NetIncomeLoss_638447229068763941" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638447229068763941"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638447229068763941" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638447229068774043"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638447229068774043" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638447229068774043"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="us-gaap_EarningsPerShareBasic_638447229068774043" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638447229068774043"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="us-gaap_EarningsPerShareDiluted_638447229068774043" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17b387d6-ed05-49ab-9d97-0f68edfed618"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638447229068780405"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17b387d6-ed05-49ab-9d97-0f68edfed618" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638447229068780405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638447229068780405"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638447229068780405" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638447229068780405" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638447229068780405"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638447229068780405" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638447229068780405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638447229068780405"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638447229068780405" xlink:to="us-gaap_EmployeeStockOptionMember_638447229068780405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember_638447229068780405"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638447229068780405" xlink:to="silk_RestrictedStockUnitsAndPerformanceStockUnitsMember_638447229068780405" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638447229068780405"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638447229068780405" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638447229068780405" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638447229068780405" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9e170c5b-107b-4ca5-94b5-e8bfa69f431c"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9e170c5b-107b-4ca5-94b5-e8bfa69f431c" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638447229068785575" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638447229068785575" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638447229068785575" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638447229068785575" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638447229068785575" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638447229068785575" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638447229068785575" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638447229068785575" xlink:to="us-gaap_FairValueInputsLevel1Member_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638447229068785575" xlink:to="us-gaap_FairValueInputsLevel2Member_638447229068785575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638447229068785575" xlink:to="us-gaap_FinancialInstrumentAxis_638447229068785575" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638447229068785575" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" xlink:to="us-gaap_MoneyMarketFundsMember_638447229068785575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" xlink:to="us-gaap_USTreasurySecuritiesMember_638447229068785575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_638447229068785575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638447229068785575"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638447229068785575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638447229068795465"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638447229068795465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember_638447229068795465"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" xlink:to="us-gaap_AssetBackedSecuritiesMember_638447229068795465" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AgencyNotesMember" xlink:label="silk_AgencyNotesMember_638447229068795465"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068785575" xlink:to="silk_AgencyNotesMember_638447229068795465" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638447229068799675"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638447229068785575" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638447229068799675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638447229068799675"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638447229068799675" xlink:to="us-gaap_AssetsFairValueDisclosure_638447229068799675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Components (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_638447229068805439"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm_638447229068805439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638447229068805439"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638447229068805439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638447229068805439"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_Depreciation_638447229068805439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638447229068805439"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638447229068805439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_638191734392309630"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734392309630" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068815419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068815419" xlink:to="us-gaap_FinancialInstrumentAxis_638447229068815419" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638447229068815419" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" xlink:to="us-gaap_MoneyMarketFundsMember_638447229068815419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" xlink:to="us-gaap_USTreasurySecuritiesMember_638447229068815419" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" xlink:to="us-gaap_CommercialPaperMember_638447229068815419" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638447229068815419" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638447229068815419"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638447229068815419" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember_638447229068825390"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" xlink:to="us-gaap_AssetBackedSecuritiesMember_638447229068825390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AgencyNotesMember" xlink:label="silk_AgencyNotesMember_638447229068827088"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068815419" xlink:to="silk_AgencyNotesMember_638447229068827088" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068815419" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638447229068827088"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638447229068827088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638447229068827088"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638447229068827088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638447229068827088"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638447229068827088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638447229068835365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638447229068835365" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_ShortTermInvestments_638447229068835365" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_LongTermInvestments_638447229068835365" order="7" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068827088" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638447229068835365" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_638191734520520259"></loc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734520520259" xlink:to="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_638447229068835365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:label="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734520520259" xlink:to="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_638447229068835365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734520520259" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638447229068835365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_638191734634014997"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734634014997" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068835365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068835365" xlink:to="us-gaap_FinancialInstrumentAxis_638447229068835365" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638447229068835365" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068835365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068835365" xlink:to="us-gaap_CommercialPaperMember_638447229068835365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068835365" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638447229068835365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068835365" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638447229068835365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember_638447229068835365"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068835365" xlink:to="us-gaap_AssetBackedSecuritiesMember_638447229068835365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AgencyNotesMember" xlink:label="silk_AgencyNotesMember_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638447229068835365" xlink:to="silk_AgencyNotesMember_638447229068845328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638447229068835365" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068845328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068845328" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638447229068845328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638447229068845328" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638447229068845328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Balance Sheet Components (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_638191734740327813"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734740327813" xlink:to="us-gaap_InventoryRawMaterials_638447229068845328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734740327813" xlink:to="us-gaap_InventoryFinishedGoods_638447229068845328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_638191734740327813" xlink:to="us-gaap_InventoryGross_638447229068845328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85e4f411-3fd2-4d7d-8af3-64cdece48093"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85e4f411-3fd2-4d7d-8af3-64cdece48093" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638447229068845328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638447229068845328" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638447229068845328" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638447229068845328" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068845328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068845328" xlink:to="us-gaap_FurnitureAndFixturesMember_638447229068845328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068845328" xlink:to="us-gaap_EquipmentMember_638447229068845328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068845328" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_638447229068845328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068845328" xlink:to="us-gaap_LeaseholdImprovementsMember_638447229068845328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068845328" xlink:to="us-gaap_ConstructionInProgressMember_638447229068845328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638447229068845328" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638447229068845328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638447229068845328" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638447229068845328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638447229068845328" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638447229068845328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638447229068845328"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638447229068845328" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638447229068845328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Balance Sheet Components (Accrued Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccruedSalariesCurrent_638447229068856214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638447229068856214" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedTravelExpensesCurrent" xlink:label="silk_AccruedTravelExpensesCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="silk_AccruedTravelExpensesCurrent_638447229068856214" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_InterestPayableCurrent_638447229068856214" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ProvisionsForSalesReturns" xlink:label="silk_ProvisionsForSalesReturns_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="silk_ProvisionsForSalesReturns_638447229068856214" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638447229068856214" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedAdministrationFeesAndSalesRebates" xlink:label="silk_AccruedAdministrationFeesAndSalesRebates_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="silk_AccruedAdministrationFeesAndSalesRebates_638447229068856214" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638447229068856214" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccruedClinicalExpensesCurrent" xlink:label="silk_AccruedClinicalExpensesCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="silk_AccruedClinicalExpensesCurrent_638447229068856214" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638447229068856214" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638447229068856214" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638447229068856214" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Long-term Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_971e9a74-3daa-428f-93dd-81260786fd79"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_971e9a74-3daa-428f-93dd-81260786fd79" xlink:to="us-gaap_SubsequentEventTable_638447229068856214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068856214" xlink:to="srt_RangeAxis_638447229068856214" order="1" use="optional" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638447229068856214"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638447229068856214" xlink:to="srt_RangeMember_638447229068856214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638447229068856214" xlink:to="srt_MaximumMember_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068856214" xlink:to="us-gaap_DebtInstrumentAxis_638447229068865286" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638447229068865286" xlink:to="us-gaap_DebtInstrumentNameDomain_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LoanAndSecurityAgreementMember" xlink:label="silk_LoanAndSecurityAgreementMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638447229068865286" xlink:to="silk_LoanAndSecurityAgreementMember_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheAMember" xlink:label="silk_TermLoanTrancheAMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638447229068865286" xlink:to="silk_TermLoanTrancheAMember_638447229068865286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheBMember" xlink:label="silk_TermLoanTrancheBMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638447229068865286" xlink:to="silk_TermLoanTrancheBMember_638447229068865286" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanTrancheCMember" xlink:label="silk_TermLoanTrancheCMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638447229068865286" xlink:to="silk_TermLoanTrancheCMember_638447229068865286" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068856214" xlink:to="us-gaap_CreditFacilityAxis_638447229068865286" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638447229068865286" xlink:to="us-gaap_CreditFacilityDomain_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LoanFacilityMember" xlink:label="silk_LoanFacilityMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638447229068865286" xlink:to="silk_LoanFacilityMember_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638447229068865286" xlink:to="us-gaap_RevolvingCreditFacilityMember_638447229068865286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredRevolvingCreditFacilityAmendedMember" xlink:label="silk_SecuredRevolvingCreditFacilityAmendedMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638447229068865286" xlink:to="silk_SecuredRevolvingCreditFacilityAmendedMember_638447229068865286" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredTermLoanFacilityMember" xlink:label="silk_SecuredTermLoanFacilityMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638447229068865286" xlink:to="silk_SecuredTermLoanFacilityMember_638447229068865286" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SecuredRevolvingCreditFacilitySubfacilityMember" xlink:label="silk_SecuredRevolvingCreditFacilitySubfacilityMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638447229068865286" xlink:to="silk_SecuredRevolvingCreditFacilitySubfacilityMember_638447229068865286" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068856214" xlink:to="us-gaap_LongtermDebtTypeAxis_638447229068865286" order="4" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638447229068865286" xlink:to="us-gaap_LongtermDebtTypeDomain_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638447229068865286" xlink:to="us-gaap_SecuredDebtMember_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanMember" xlink:label="silk_TermLoanMember_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638447229068865286" xlink:to="silk_TermLoanMember_638447229068865286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068856214" xlink:to="us-gaap_VariableRateAxis_638447229068865286" order="5" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638447229068865286"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638447229068865286" xlink:to="us-gaap_VariableRateDomain_638447229068865286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638447229068865286" xlink:to="us-gaap_PrimeRateMember_638447229068875251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IndexRateMember" xlink:label="silk_IndexRateMember_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638447229068865286" xlink:to="silk_IndexRateMember_638447229068875251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068856214" xlink:to="us-gaap_LineOfCreditFacilityAxis_638447229068875251" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_638447229068875251" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_638447229068875251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_StifelBankMember" xlink:label="silk_StifelBankMember_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_638447229068875251" xlink:to="silk_StifelBankMember_638447229068875251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_OxfordFinanceMember" xlink:label="silk_OxfordFinanceMember_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_638447229068875251" xlink:to="silk_OxfordFinanceMember_638447229068875251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638447229068856214" xlink:to="us-gaap_SubsequentEventLineItems_638447229068875251" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638447229068875251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_LineOfCredit_638447229068875251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_638447229068875251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:label="silk_DebtInstrumentCovenantMaximumBorrowingThreshold_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_DebtInstrumentCovenantMaximumBorrowingThreshold_638447229068875251" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638447229068875251" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638447229068875251"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638447229068875251" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_638447229068885223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit_638447229068885223" order="7" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_638447229068885223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_638447229068885223" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFees" xlink:label="silk_PercentageOfPrepaymentFees_638447229068885223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_PercentageOfPrepaymentFees_638447229068885223" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFeesInSecondYear" xlink:label="silk_PercentageOfPrepaymentFeesInSecondYear_638447229068885223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_PercentageOfPrepaymentFeesInSecondYear_638447229068885223" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentageOfPrepaymentFeesInThirdYear" xlink:label="silk_PercentageOfPrepaymentFeesInThirdYear_638447229068885223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_PercentageOfPrepaymentFeesInThirdYear_638447229068885223" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638447229068885223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_DebtInstrumentFeeAmount_638447229068885223" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229068885223"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638447229068885223" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_638447229068892510"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_638447229068892510" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:label="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_638447229068895194"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_638447229068895194" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638447229068895194"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638447229068895194" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentAggregateOriginalPrincipalAmount" xlink:label="silk_PercentAggregateOriginalPrincipalAmount_638447229068895194"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_PercentAggregateOriginalPrincipalAmount_638447229068895194" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638447229068895194"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_DebtInstrumentMaturityDate_638447229068895194" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtCovenantRevenueCovenant" xlink:label="silk_DebtCovenantRevenueCovenant_638447229068902353"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_DebtCovenantRevenueCovenant_638447229068902353" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638447229068905302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="us-gaap_DebtInstrumentFeeAmount_638447229068905302" order="20" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfBorrowingBaseOfEligibleReceivables" xlink:label="silk_PercentOfBorrowingBaseOfEligibleReceivables_638447229068905302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_PercentOfBorrowingBaseOfEligibleReceivables_638447229068905302" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfEligibleInventory" xlink:label="silk_PercentOfEligibleInventory_638447229068905302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_PercentOfEligibleInventory_638447229068905302" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfBorrowingBaseInCaseEligibleInventory" xlink:label="silk_PercentOfBorrowingBaseInCaseEligibleInventory_638447229068905302"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_PercentOfBorrowingBaseInCaseEligibleInventory_638447229068905302" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_BorrowingBaseAmountInCaseEligibleInventory" xlink:label="silk_BorrowingBaseAmountInCaseEligibleInventory_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_BorrowingBaseAmountInCaseEligibleInventory_638447229068915137" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DebtInstrumentMarginRate" xlink:label="silk_DebtInstrumentMarginRate_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_DebtInstrumentMarginRate_638447229068915137" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TermLoanPrepaidInIncrements" xlink:label="silk_TermLoanPrepaidInIncrements_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638447229068875251" xlink:to="silk_TermLoanPrepaidInIncrements_638447229068915137" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Long-term Debt (Future Payment Under the Term Loan) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638447229068915137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638447229068915137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638447229068915137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638447229068915137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:label="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="silk_LongTermDebtGrossBeforeAccretionOfClosingFees_638447229068915137" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AccretionOfClosingCosts" xlink:label="silk_AccretionOfClosingCosts_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="silk_AccretionOfClosingCosts_638447229068915137" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtGrossAfterAccretionOfClosingFees" xlink:label="silk_LongTermDebtGrossAfterAccretionOfClosingFees_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="silk_LongTermDebtGrossAfterAccretionOfClosingFees_638447229068915137" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LongTermDebtUnpaidInterest" xlink:label="silk_LongTermDebtUnpaidInterest_638447229068915137"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="silk_LongTermDebtUnpaidInterest_638447229068915137" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638447229068925120" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="us-gaap_LongTermDebt_638447229068925120" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638447229068925120" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638447229068925120" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638447229068925120" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638447229068925120" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068925120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_HeadquartersMember" xlink:label="silk_HeadquartersMember_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068925120" xlink:to="silk_HeadquartersMember_638447229068925120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember" xlink:label="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638447229068925120" xlink:to="silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember_638447229068925120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638447229068925120" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638447229068925120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_638447229068925120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IndemnificationObligationsLiabilityRecognized" xlink:label="silk_IndemnificationObligationsLiabilityRecognized_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120" xlink:to="silk_IndemnificationObligationsLiabilityRecognized_638447229068925120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_638447229068925120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_638447229068925120" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638447229068925120" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638447229068925120" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies (Balance Sheet Information) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638447229068925120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638447229068925120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638447229068925120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseLiability_638447229068925120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638447229068925120" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638447229068925120"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638447229068925120" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638447229068935090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_638447229068935090" order="8" use="optional" priority="2"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies (Operating Lease Maturities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638447229068935090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638447229068935090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638447229068935090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638447229068935090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638447229068935090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638447229068935090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638447229068935090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638447229068935090" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="us-gaap_OperatingLeaseLiability_638447229068935090" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders&apos; Equity (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638447229068935090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638447229068935090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638447229068935090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638447229068935090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638447229068935090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638447229068935090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_638447229068935090"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_DividendsCommonStock_638447229068935090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders&apos; Equity (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_37f2a550-85b9-48d0-aa61-958eac17b583"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_37f2a550-85b9-48d0-aa61-958eac17b583" xlink:to="us-gaap_ScheduleOfStockByClassTable_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638447229068945063" xlink:to="us-gaap_AwardTypeAxis_638447229068945063" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638447229068945063" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionExercisedMember_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068945063" xlink:to="silk_IncentiveandNonqualifiedStockOptionExercisedMember_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionIssuedMember_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068945063" xlink:to="silk_IncentiveandNonqualifiedStockOptionIssuedMember_638447229068945063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PerformanceStockUnitsOverperformanceMember" xlink:label="silk_PerformanceStockUnitsOverperformanceMember_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068945063" xlink:to="silk_PerformanceStockUnitsOverperformanceMember_638447229068945063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_EmployeeStockPurchasePlanMember" xlink:label="silk_EmployeeStockPurchasePlanMember_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068945063" xlink:to="silk_EmployeeStockPurchasePlanMember_638447229068945063" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638447229068945063" xlink:to="us-gaap_ClassOfStockLineItems_638447229068945063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638447229068945063" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cccbfbd8-df4c-4949-899f-a629ab1c7c10"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cccbfbd8-df4c-4949-899f-a629ab1c7c10" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" xlink:to="us-gaap_PlanNameAxis_638447229068945063" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638447229068945063" xlink:to="us-gaap_PlanNameDomain_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TwoThousandNineteenStockOptionPlanMember" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638447229068945063" xlink:to="silk_TwoThousandNineteenStockOptionPlanMember_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_Espp2019Member" xlink:label="silk_Espp2019Member_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638447229068945063" xlink:to="silk_Espp2019Member_638447229068945063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" xlink:to="us-gaap_AwardDateAxis_638447229068945063" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_638447229068945063" xlink:to="us-gaap_AwardDateDomain_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AwardDateOneMember" xlink:label="silk_AwardDateOneMember_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638447229068945063" xlink:to="silk_AwardDateOneMember_638447229068945063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AwardDateTwoMember" xlink:label="silk_AwardDateTwoMember_638447229068945063"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638447229068945063" xlink:to="silk_AwardDateTwoMember_638447229068945063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" xlink:to="srt_RangeAxis_638447229068955039" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638447229068955039" xlink:to="srt_RangeMember_638447229068955039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638447229068955039" xlink:to="srt_MinimumMember_638447229068955039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638447229068955039" xlink:to="srt_MaximumMember_638447229068955039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" xlink:to="us-gaap_AwardTypeAxis_638447229068955039" order="4" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638447229068955039" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068955039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveandNonqualifiedStockOptionMember" xlink:label="silk_IncentiveandNonqualifiedStockOptionMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068955039" xlink:to="silk_IncentiveandNonqualifiedStockOptionMember_638447229068955039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_IncentiveStockOptionMember" xlink:label="silk_IncentiveStockOptionMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_IncentiveandNonqualifiedStockOptionMember_638447229068955039" xlink:to="silk_IncentiveStockOptionMember_638447229068955039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_NonqualifiedStockOptionsMember" xlink:label="silk_NonqualifiedStockOptionsMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_IncentiveandNonqualifiedStockOptionMember_638447229068955039" xlink:to="silk_NonqualifiedStockOptionsMember_638447229068955039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068955039" xlink:to="us-gaap_EmployeeStockMember_638447229068955039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068955039" xlink:to="us-gaap_EmployeeStockOptionMember_638447229068955039" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068955039" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638447229068955039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229068955039" xlink:to="us-gaap_PerformanceSharesMember_638447229068955039" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" xlink:to="srt_StatementScenarioAxis_638447229068955039" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638447229068955039" xlink:to="srt_ScenarioUnspecifiedDomain_638447229068955039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_BenchmarkMember" xlink:label="silk_BenchmarkMember_638447229068955039"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638447229068955039" xlink:to="silk_BenchmarkMember_638447229068955039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" xlink:to="us-gaap_VestingAxis_638447229068965012" order="6" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638447229068965012" xlink:to="us-gaap_VestingDomain_638447229068965012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638447229068965012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229068945063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638447229068965012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:label="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_638447229068965012" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638447229068965012" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_638447229068965012" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638447229068965012" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638447229068965012" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638447229068965012"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638447229068965012" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638447229068974978" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638447229068974978" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638447229068974978" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638447229068974978" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued_638447229068974978" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="silk_CommonStockCapitalSharesAvailableForFutureIssuance_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_CommonStockCapitalSharesAvailableForFutureIssuance_638447229068974978" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance_638447229068974978" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_PercentOfOutstandingShares" xlink:label="silk_PercentOfOutstandingShares_638447229068974978"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_PercentOfOutstandingShares_638447229068974978" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_FairMarketValueOfCommonStock" xlink:label="silk_FairMarketValueOfCommonStock_638447229068984892"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_FairMarketValueOfCommonStock_638447229068984892" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638447229068984892"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638447229068984892" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638447229068994807"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638447229068994807" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638447229068997838"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638447229068997838" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638447229069004800"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638447229069004800" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue_638447229069020100"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue_638447229069020100" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638447229069024715"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638447229069024715" order="22" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance_638447229069024715"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance_638447229069024715" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638447229069034771"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638447229069034771" order="24" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638447229069044684"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638447229069044684" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638447229069044684"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638447229069044684" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638447229069044684"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229068965012" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638447229069044684" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bae0a3c2-ecc6-40dd-b7c7-cef31d1706cd"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bae0a3c2-ecc6-40dd-b7c7-cef31d1706cd" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069131119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069131119" xlink:to="us-gaap_PlanNameAxis_638447229069131119" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638447229069131119" xlink:to="us-gaap_PlanNameDomain_638447229069131119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_TwoThousandNineteenStockOptionPlanMember" xlink:label="silk_TwoThousandNineteenStockOptionPlanMember_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638447229069131119" xlink:to="silk_TwoThousandNineteenStockOptionPlanMember_638447229069131119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069131119" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069131119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:label="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069131119" xlink:to="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_638447229069131119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_638447229069131119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance_638447229069131119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_638447229069131119" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_638447229069131119"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_638447229069131119" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_6384472290691311191"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_638447229069131119" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_6384472290691311191" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638447229069141040"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638447229069141040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638447229069141040"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638447229069141040" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638447229069141040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638447229069141040"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638447229069141040" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638447229069141040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638447229069141040"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638447229069141040" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638447229069141040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638447229069141040"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638447229069141040" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638447229069141040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638447229069146082"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638447229069141040" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638447229069146082" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638447229069146477"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638447229069146477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638447229069146477"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638447229069146477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638447229069146477"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638447229069146477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638447229069146477"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638447229069146477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638447229069146477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638447229069146477"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638447229069146477" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638447229069146477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638447229069146477"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638447229069146477" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638447229069146477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638447229069146477"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638447229069146477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638447229069146477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384472290691464771"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638447229069146477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384472290691464771" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638447229069151021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638447229069151021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638447229069151021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638447229069151021" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638447229069151021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638447229069151021" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638447229069151021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_638447229069151021" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638447229069151021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637557229537511460" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638447229069151021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638447229069151021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638447229069151021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638447229069151021" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638447229069151021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638447229069151021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638447229069151021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stock-Based Compensation Plans (Information by Exercise Price) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638447229069151021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638447229069151021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638447229069151021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638447229069151021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638447229069160988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638447229069160988" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_727096e7-3a24-4aa8-8016-d55317716a2c"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_727096e7-3a24-4aa8-8016-d55317716a2c" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069160988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069160988" xlink:to="us-gaap_AwardTypeAxis_638447229069160988" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069160988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069160988" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638447229069160988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069160988" xlink:to="us-gaap_PerformanceSharesMember_638447229069160988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069160988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638447229069160988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638447229069160988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638447229069160988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638447229069160988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384472290691609881"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384472290691609881" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_638447229069160988" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_638447229069160988" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638447229069160988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638447229069160988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638447229069160988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638447229069160988"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638447229069160988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384472290691609881"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384472290691609881" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638447229069171463"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638447229069160988" xlink:to="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638447229069171463" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26037b07-dbd4-4329-a099-efb0a4ead311"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069171463"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26037b07-dbd4-4329-a099-efb0a4ead311" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069171463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638447229069171463"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069171463" xlink:to="us-gaap_AwardTypeAxis_638447229069171463" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069171463"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638447229069171463" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069171463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638447229069171463"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069171463" xlink:to="us-gaap_EmployeeStockOptionMember_638447229069171463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_EmployeeStockPurchasePlanMember" xlink:label="silk_EmployeeStockPurchasePlanMember_638447229069171463"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638447229069171463" xlink:to="silk_EmployeeStockPurchasePlanMember_638447229069171463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069171463" xlink:to="srt_RangeAxis_638447229069180955" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638447229069180955" xlink:to="srt_RangeMember_638447229069180955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638447229069180955" xlink:to="srt_MinimumMember_638447229069180955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638447229069180955" xlink:to="srt_MaximumMember_638447229069180955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638447229069171463" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069180955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069180955" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638447229069180955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069180955" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638447229069180955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069180955" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638447229069180955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638447229069180955" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638447229069180955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89629370-35dc-4b80-8fe4-b745d68d10db"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89629370-35dc-4b80-8fe4-b745d68d10db" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638447229069180955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638447229069180955" xlink:to="us-gaap_IncomeStatementLocationAxis_638447229069180955" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638447229069180955" xlink:to="us-gaap_IncomeStatementLocationDomain_638447229069180955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638447229069180955" xlink:to="us-gaap_CostOfSalesMember_638447229069180955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638447229069180955" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638447229069180955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638447229069180955" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638447229069180955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638447229069180955" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638447229069180955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638447229069180955"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638447229069180955" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638447229069180955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bef67955-c557-4703-8054-97eb9fce3d70"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bef67955-c557-4703-8054-97eb9fce3d70" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638447229069190933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638447229069190933" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638447229069190933" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638447229069190933" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638447229069190933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638447229069190933" xlink:to="us-gaap_ResearchMember_638447229069190933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638447229069190933" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638447229069190933" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638447229069190933" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638447229069190933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638447229069190933" xlink:to="us-gaap_DomesticCountryMember_638447229069190933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638447229069190933" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638447229069190933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638447229069190933" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638447229069190933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638447229069190933" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638447229069190933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638447229069190933" xlink:to="us-gaap_OperatingLossCarryforwards_638447229069190933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638447229069190933" xlink:to="us-gaap_UnrecognizedTaxBenefits_638447229069190933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638447229069190933" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638447229069190933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638447229069190933"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638447229069190933" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638447229069190933" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_22592af1-667e-458f-a3e9-c8d6a3979931"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22592af1-667e-458f-a3e9-c8d6a3979931" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638447229069198470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22592af1-667e-458f-a3e9-c8d6a3979931" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638447229069198470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638447229069198470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638447229069198470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638447229069198470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638447229069198470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_LimitationOfCompensationDeduction" xlink:label="silk_LimitationOfCompensationDeduction_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="silk_LimitationOfCompensationDeduction_638447229069198470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_638447229069198470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638447229069198470" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638447229069198470"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638447229069198470" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638447229069205938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638447229069205938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638447229069205938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DeferredTaxAssetsSection174" xlink:label="silk_DeferredTaxAssetsSection174_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="silk_DeferredTaxAssetsSection174_638447229069205938" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638447229069205938" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638447229069205938" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="silk-20231231.xsd#silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="silk_DeferredTaxAssetsOperatingLeaseLiability_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="silk_DeferredTaxAssetsOperatingLeaseLiability_638447229069205938" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_638447229069205938" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetsGross_638447229069205938" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638447229069205938" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638447229069205938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638447229069205938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638447229069205938" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638447229069205938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638447229069205938" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638447229069205938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59" xlink:to="us-gaap_DeferredTaxAssetsNet_638447229069205938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1dcd7a49-b5ca-4536-9fb2-4a754a13e3e8"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dcd7a49-b5ca-4536-9fb2-4a754a13e3e8" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638447229069205938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638447229069205938"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638447229069205938" xlink:to="us-gaap_UnrecognizedTaxBenefits_638447229069205938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638447229069205938" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638447229069215897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638447229069205938" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638447229069215897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638447229069205938" xlink:to="us-gaap_UnrecognizedTaxBenefits_638447229069215897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/Disclosure401KPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - 401(k) Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638447229069215897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638447229069215897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638447229069215897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638447229069215897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails" xlink:type="extended" xlink:title="41401 - Schedule - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_a3e5c2db-d446-4f0c-96da-351496f74d5b"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_a3e5c2db-d446-4f0c-96da-351496f74d5b" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_638447229069215897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638447229069215897" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_638447229069215897" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis_638447229069215897" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_638447229069215897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="us-gaap_AllowanceForCreditLossMember_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_638447229069215897" xlink:to="us-gaap_AllowanceForCreditLossMember_638447229069215897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638447229069215897" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638447229069215897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638447229069215897" xlink:to="us-gaap_MovementInValuationAllowancesAndReservesRollForward_638447229069215897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_638447229069215897" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_638447229069215897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_638447229069215897" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_638447229069215897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_638447229069215897"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_638447229069215897" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_638447229069215897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_638447229069226359"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_638447229069215897" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_638447229069226359" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc></link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag_638447229069226359"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag_638447229069226359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_638447229069226359"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_638447229069226359" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag_638447229069226359"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag_638447229069226359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_638447229069226359"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_638447229069226359" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc></link:presentationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762217888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SILK ROAD MEDICAL, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8777622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1213 Innsbruck Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">720-9002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SILK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,174,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001397702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Portions of the definitive proxy statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, are incorporated by reference into Part III of this report where indicated. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762356208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,210,000<span></span>
</td>
<td class="nump">$ 55,358,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">161,264,000<span></span>
</td>
<td class="nump">158,316,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $26 and $3 at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">23,573,000<span></span>
</td>
<td class="nump">18,007,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">29,876,000<span></span>
</td>
<td class="nump">19,293,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,912,000<span></span>
</td>
<td class="nump">3,924,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">240,835,000<span></span>
</td>
<td class="nump">254,898,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">9,456,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,114,000<span></span>
</td>
<td class="nump">9,372,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">6,904,000<span></span>
</td>
<td class="nump">5,260,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">265,309,000<span></span>
</td>
<td class="nump">269,685,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,676,000<span></span>
</td>
<td class="nump">2,523,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">24,607,000<span></span>
</td>
<td class="nump">21,965,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,283,000<span></span>
</td>
<td class="nump">24,488,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">75,626,000<span></span>
</td>
<td class="nump">74,596,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">8,249,000<span></span>
</td>
<td class="nump">6,726,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">114,158,000<span></span>
</td>
<td class="nump">105,810,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value Shares authorized: 5,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: none at December 31, 2023 and 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value Shares authorized: 100,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: 39,165,481 and 38,355,972 at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">550,495,000<span></span>
</td>
<td class="nump">507,715,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="num">(166,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(399,455,000)<span></span>
</td>
<td class="num">(343,712,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">151,151,000<span></span>
</td>
<td class="nump">163,875,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 265,309,000<span></span>
</td>
<td class="nump">$ 269,685,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451758794448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances for accounts receivables</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockAbstract', window );"><strong>Common stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">39,165,481<span></span>
</td>
<td class="nump">38,355,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">39,165,481<span></span>
</td>
<td class="nump">38,355,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762218800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations and Comprehensive Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 177,134<span></span>
</td>
<td class="nump">$ 138,638<span></span>
</td>
<td class="nump">$ 101,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">50,048<span></span>
</td>
<td class="nump">37,876<span></span>
</td>
<td class="nump">25,446<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">127,086<span></span>
</td>
<td class="nump">100,762<span></span>
</td>
<td class="nump">76,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">41,324<span></span>
</td>
<td class="nump">36,449<span></span>
</td>
<td class="nump">27,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">145,033<span></span>
</td>
<td class="nump">116,317<span></span>
</td>
<td class="nump">96,387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">186,357<span></span>
</td>
<td class="nump">152,766<span></span>
</td>
<td class="nump">123,497<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(59,271)<span></span>
</td>
<td class="num">(52,004)<span></span>
</td>
<td class="num">(47,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">9,957<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,871)<span></span>
</td>
<td class="num">(5,098)<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">442<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,743)<span></span>
</td>
<td class="num">(55,010)<span></span>
</td>
<td class="num">(49,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="nump">238<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">238<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (55,505)<span></span>
</td>
<td class="num">$ (55,176)<span></span>
</td>
<td class="num">$ (49,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used to compute net loss per share, basic</a></td>
<td class="nump">38,804,343<span></span>
</td>
<td class="nump">35,775,672<span></span>
</td>
<td class="nump">34,635,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares used to compute net loss per share, diluted</a></td>
<td class="nump">38,804,343<span></span>
</td>
<td class="nump">35,775,672<span></span>
</td>
<td class="nump">34,635,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757278880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">34,249,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 346,318<span></span>
</td>
<td class="num">$ (238,891)<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 107,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">643,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">34,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">52,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DisgorgementOfStockholderSShortSwingProfits', window );">Disgorgement of short-swing profits, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Change in unrealized loss on investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">34,980,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">367,907<span></span>
</td>
<td class="num">(288,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">108,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">2,674,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">453,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">148,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">99,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Change in unrealized loss on investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">38,355,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">507,715<span></span>
</td>
<td class="num">(343,712)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="nump">163,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">199,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">410,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">199,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Change in unrealized loss on investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">39,165,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 550,495<span></span>
</td>
<td class="num">$ (399,455)<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 151,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DisgorgementOfStockholderSShortSwingProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disgorgement Of Stockholder's Short-Swing Profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DisgorgementOfStockholderSShortSwingProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451761090800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statements of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 6,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757884640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (55,743)<span></span>
</td>
<td class="num">$ (55,010)<span></span>
</td>
<td class="num">$ (49,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">38,893<span></span>
</td>
<td class="nump">25,023<span></span>
</td>
<td class="nump">14,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums (accretion of discounts) on investments, net</a></td>
<td class="num">(6,497)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) doubtful accounts receivable</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventories</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,610)<span></span>
</td>
<td class="num">(6,172)<span></span>
</td>
<td class="num">(2,769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(10,781)<span></span>
</td>
<td class="num">(1,447)<span></span>
</td>
<td class="num">(5,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,988)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,063<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="num">(1,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">2,854<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(1,215)<span></span>
</td>
<td class="num">(690)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,014)<span></span>
</td>
<td class="num">(32,581)<span></span>
</td>
<td class="num">(38,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,507)<span></span>
</td>
<td class="num">(5,005)<span></span>
</td>
<td class="num">(4,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(174,969)<span></span>
</td>
<td class="num">(168,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments', window );">Proceeds from maturity of investments</a></td>
<td class="nump">169,300<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">77,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(7,176)<span></span>
</td>
<td class="num">(162,068)<span></span>
</td>
<td class="nump">72,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">3,887<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">6,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from disgorgement of short-swing profits, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,887<span></span>
</td>
<td class="nump">139,699<span></span>
</td>
<td class="nump">6,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(35,303)<span></span>
</td>
<td class="num">(54,950)<span></span>
</td>
<td class="nump">40,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">55,513<span></span>
</td>
<td class="nump">110,463<span></span>
</td>
<td class="nump">69,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">20,210<span></span>
</td>
<td class="nump">55,513<span></span>
</td>
<td class="nump">110,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5,821<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable and accrued liabilities for purchases of property and equipment</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="nump">$ 2,504<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">$ 3,307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759383248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Formation and Business of the Company [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Formation and Business of the Company</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">1.&#160;&#160;&#160;&#160;Formation and Business of the Company </span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">The Company</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Silk Road Medical, Inc., or the Company, was incorporated in the state of Delaware on March&#160;21,&#160;2007.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company, has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke. The Company's portfolio of products enable a procedure referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles. The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company commercialized its products in the United States beginning in</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> late 2015. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Liquidity</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of December&#160;31, 2023, the Company had an accumulated deficit of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">399,455,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company expects to incur losses for the foreseeable future. The Company</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> believes tha</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t its cash and cash equivalents and available-for-sale securities of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,930,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> as of December&#160;31, 2023, as well as its expected revenues will provide sufficient funds to allow the Company to fund its planned current operations for the next 12 months from the issuance of these financial statements. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Public Offering</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2022, the Company completed an underwritten public offering of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,674,419</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of its common stock at a public offering price of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43.00</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. The shares include the full exercise of the underwriters&#8217; option to purchase an additional </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">348,837</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares pursuant to the underwriting agreement. The Company received cash proceeds of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108,992,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> after deducting underwriting discounts and commissions of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,750,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and expenses of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">258,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762145744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis of Preparation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2023 and 2022. The carrying amounts of certain of the Company&#8217;s financial instruments, which include accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments. Management believes that its debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash, Cash Equivalents and Restricted Cash</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are recorded at fair value, based on quoted market prices. As of </span></p><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December&#160;31, 2023 and 2022, the Company&#8217;s cash equivalents were entirely comprised of investments in money market funds.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,210</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,358</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted cash </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">155</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash, cash equivalents and restricted cash </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,210</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,513</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company had </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted cash as of December 31, 2023. Restricted cash as of December&#160;31, 2022 consisted of a letter of credit of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">155,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> representing collateral for the Company&#8217;s facility lease in California. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Investments</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term and long-term investments consist of debt securities classified as available-for-sale. Short-term investments have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss). Realized gains and losses are included in earnings and are der</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ived based on the specific-identification method for determining the costs of investments sold and were insignificant for the years ended December 31, 2023, 2022 and 2021. Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. The Company evaluates the securities in an unrealized loss position for expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, current economic conditions and credit ratings. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company did </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t recognize any credit losses on its available-for-sale securities during the years ended December 31, 2023, 2022 or 2021 and there were no impairment charges for unrealized losses in the periods presented.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, U.S. government securities, U.S. treasury bills, agency bonds/notes, and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2023, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023 and December&#160;31, 2022, a portion of the Company&#8217;s cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of the Company&#8217;s cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. On March 10, 2023, SVB was shut down and placed under receivership with the Federal Deposit Insurance Corporation, or FDIC, by the California Department of Financial Protection and Innovation. On March 26, 2023, the FDIC announced it had entered into a purchase and assumption agreement with First Citizens Bank &amp; Trust Company under which all of SVB&#8217;s deposits were assumed. As of the issuance date of these financial statements, the Company has not experienced any losses on its deposits and all of the Company&#8217;s cash deposited with SVB has been accessible to the Company.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s accounts receivable are due from a variety of hospitals and medical centers in the United States. As of December&#160;31, 2023 and 2022, no customer represented 10% or more of the Company&#8217;s accounts receivable. For the years ended December&#160;31, 2023, 2022 and 2021, there were no customers that represented 10% or more of revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its commercial products in-house. Certain of the Company&#8217;s finished goods,  components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in finished goods, component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, competition, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies. In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accounts Receivable</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company estimates allowances for expected credit losses. Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#8217; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. These specific allowances are reevaluated and adjusted as additional information is received that impacts the amount reserved. During the years ended December 31, 2023, 2022 and 2021, the Company did not experience any material credit-related losses.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inventories</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate. The Company&#8217;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements. The estimate of excess quantities is judgmental and primarily dependent on the Company&#8217;s estimates of future demand for a particular product. If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Property and Equipment</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are recorded at cost less accumulated depreciation or amortization. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three years</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five years</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Impairment of Long-Lived Assets</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value. The Company did </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t record any impairment of long-lived assets during the years ended December&#160;31, 2023, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Leases</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for its leasing arrangements in accordance with Accounting Standards Codification, or ASC 842, &#8220;Leases.&#8221; The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset. The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain. Variable lease costs represent payments that are dependent on usage, a rate or index. Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred. The Company elected to account for contracts that contain lease and non-lease components as a single component, consistent with its historical practice. The Company does not have any finance leases.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Revenue Recognition</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives and is primarily comprised of product revenue net of returns, administration fees and sales rebates. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer.&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it. Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title. The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Administration fees and sales rebates are accounted for as a reduction in revenue, calculated based on the terms agreed to with the customer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023 and 2022, the Company recorded $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">227,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">148,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Costs associated with product sales, which include commissions and royalties, are expensed when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160;Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the statements of operations and comprehensive loss.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accepts product returns at its discretion or if the product is defective as manufactured. The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the balance sheet.&#160;The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods </span></p></div><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sold. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cost of Goods Sold</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its portfolio of TCAR products at its California and Minnesota facilities and purchases other products from third party manufacturers. Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, manufacturing overhead costs, direct labor, scrap, product rework, reserves for excess, obsolete and non-sellable inventories as well as logistics-related expenses. A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs. These overhead costs include the cost of quality control, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company entered into the lease for its additional facility in Minnesota in May 2021 and did not begin commercial production of the ENROUTE Neuroprotection System until the third quarter of 2022. During this time, the Company experienced additional overhead expenses related to its investment in the start-up phase of its manufacturing capacity expansion, which were recorded as a period expense. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Research and Development</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#8217;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development. Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses. Additionally, clinical studies include costs associated with clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Clinical Trials</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accrues and expenses costs for its clinical trial activities performed by third parties, including any clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Advertising Costs</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company expenses advertising costs as incurred. Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items. Advertising costs of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">461,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">347,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">221,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> were expensed during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Foreign Currency</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net. The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2023, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock&#8211;Based Compensation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board, or FASB, ASC 718,&#160;&#8220;Compensation-Stock Compensation.&#8221; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units, performance stock units, and shares issued under its employee stock purchase plan. ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model. The fair value of stock options is recognized over the period during which an optionee is required to provide services in </span></p></div><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis. The Company accounts for option forfeitures as they occur.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant. These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for performance stock units with market-based conditions at their fair value on the date of the award using the Monte Carlo simulation model. These costs are recognized over the requisite service period, which is usually the vesting period, regardless of the likelihood of achievement of the market-based performance criteria.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for its employee stock purchase plan based on the </span><span id="_Hlk157943524" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">estimated fair value on the first day of the offering period </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">using an option pricing model for each purchase period. These costs are recognized on a straight-line basis over the offering period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company also follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes.&#8221; ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> liability related to uncertain tax positions is recorded on the financial statements. It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Comprehensive Loss</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale. For the years ended </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December&#160;31, 2023, 2022 and 2021</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive loss. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets as a component of stockholders' equity. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and performance stock units are considered to be potentially dilutive securities. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share was determined as follows (in thousands, except share and per share data):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,743</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,010</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,811</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average common stock outstanding used to compute net loss per share, basic and diluted </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">38,804,343</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35,775,672</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,635,358</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.44</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.54</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.44</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock options </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,632,684</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,839,858</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,780,939</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted stock units and performance stock units</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,536,197</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,329,824</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">530,274</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,168,881</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,169,682</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,311,213</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Segment and Geographical Information</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company operates and manages its business as </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reportable and operating segment. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Primarily all of the Company&#8217;s long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment. All of the Company&#8217;s revenue was in the United State</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s for the years ended December&#160;31, 2023, 2022 and 2021, based on the shipping location of the external customer.</span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762016800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">3.&#160;&#160;&#160;&#160;Recent Accounting Pronouncements</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Recently Issued Accounting Standards</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segments expenses. ASU 2023-07 became effective for the Company on January 1, 2024. The Company does not believe that the adoption of this new guidance will have a material impact on its segment reporting disclosures. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09, which enhances income tax disclosure requirements by requiring specified categories and greater disaggregation within the rate reconciliation table, disclosure of income taxes paid by jurisdiction, and providing clarification on uncertain tax positions and related financial statement impacts. ASU 2023-09 is effective for the Company on January 1, 2025 with early adoption permitted. The Company is currently evaluating the impact of adoption of this new guidance on its income tax disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451761574704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">4.&#160;&#160;&#160;&#160;Fair Value Measurements</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 &#8211; quoted prices in active markets are identical assets and liabilities;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 &#8211; observable inputs other than quoted prices in active markets for identical assets and liabilities;</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#8226;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 &#8211; unobservable inputs.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company&#8217;s</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> investments</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> are classified within Level 1 of the fair value hierarchy include money market funds valued using quoted market prices and U.S. treasury bills valued using broker or dealer quotations with reasonable levels of price transparency. Investments classified within Level 2 include commercial paper, which are valued using model-based valuation techniques, and corporate bonds/notes, U.S. government securities and agency bonds/notes, which are valued based upon quoted market prices for similar instruments in active markets or quoted prices for identical or similar </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">instruments in markets that are not active for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following tables set forth by level within the fair value hierarchy the Company&#8217;s assets that are reported at fair value as of December&#160;31, 2023 and 2022 using the inputs defined above (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,899</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,899</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,150</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,150</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,438</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,438</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,556</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,556</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,677</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,677</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">31,382</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">158,821</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,776</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,776</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,515</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,515</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,270</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,270</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,996</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,996</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency notes</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,884</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,884</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74,934</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">138,540</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were no transfers between fair value hierarchy levels during the years ended December&#160;31, 2023, 2022, and 2021.</span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759581872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">5.&#160;&#160;&#160;&#160;Balance Sheet Components</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Investments</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The fair value of the Company's available-for-sale investments as of December&#160;31, 2023 and 2022 are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross Unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized Cost</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gains</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Losses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,896</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,899</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,160</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,150</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,398</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,438</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,501</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,556</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,693</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,677</span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,131</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">145</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td></tr><tr style="height: 0.19in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Classified as:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash equivalents </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term investments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">161,264</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Long-term investments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,456</span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross Unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized Cost</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gains</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Losses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,772</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,776</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,528</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,515</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,432</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">164</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,270</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,000</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,996</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency notes</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,876</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,884</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,641</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">181</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Classified as:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term investments </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">158,316</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the fair value of the Company&#8217;s cash equivalents, and available-for-sale investments classified by maturity as of December&#160;31, 2023 and 2022 (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.36in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts maturing within one year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">180,747</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts maturing after one year through two years </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,456</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Available-for-sale investments held as of December 31, 2023 had a weighted average days to maturity of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">163</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> days.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2023 and 2022 (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Less than 12 months</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Less than 12 months</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Unrealized Loss</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Unrealized Loss</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21,842</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,490</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,684</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73,329</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">164</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,994</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,964</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90,490</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76,813</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">181</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> available-for-sale investments in an unrealized loss position greater than twelve months as of December 31, 2023 and 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inventories</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Components of inventories were as follows (in thousands): </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Raw materials</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,512</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,913</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Finished products</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23,364</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14,380</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total inventories</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29,876</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,293</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023 and 2022, there were </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> work-in-process inventories. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Property and Equipment, Net</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and fixtures</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,052</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,822</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,776</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,046</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Software</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">296</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">296</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasehold improvements</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,561</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,246</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,685</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14,410</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Accumulated depreciation </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,907</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,355</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add:  Construction-in-progress</span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">336</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">317</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total property and equipment, net</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,114</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,372</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation and amortization expense was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,696,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,127,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,032,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accrued Liabilities</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued liabilities consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued payroll and related expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,113</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,216</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,703</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,844</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued travel expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">944</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">775</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued interest payable</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">517</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">519</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for sales returns</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">500</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">540</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued royalty expense</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">405</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">973</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued administration fees and sales rebates</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">405</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">338</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued professional services</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">326</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">781</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued clinical expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">256</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">249</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred revenue</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">143</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">253</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued other expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,295</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">477</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total accrued liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,607</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21,965</span></p></td></tr></table></div><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759413680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">6.&#160;&#160;&#160;&#160;Long-term Debt</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stifel Bank</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2020, the Company entered into a Loan and Security Agreement with Stifel Bank which provided for a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> loan facility, comprised of a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured revolving credit facility, with a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> subfacility for the issuance of letters of credit and other ancillary banking services, and a $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured term loan facility, provided that amounts outstanding under both facilities may not exceed an aggregate principal amount of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at any time. Interest under the revolving credit facility was the greater of a) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% above the "Prime Rate" as published by </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">The Wall Street Journal</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or b) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.75</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. Interest under the term loan facility was the greater of a) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.75</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% above the "Prime Rate" as published by </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">The Wall Street Journal</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or b) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.75</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The Company drew down $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> under the term loan facility in October 2020. Concurrent with the Loan and Security Agreement, the Company entered in a Success Fee Agreement in October 2020 with Stifel Bank, which requires that the Company pay Stifel Bank the lesser of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.75</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the original principal amount of all credit extensions made under the Loan and Security Agreement or $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">375,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in the event the Company completes a Liquidity Event (liquidation, merger, sale of the Company or change in control). </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On May 27, 2022, in connection with the consummation of the Loan and Security Agreement with Oxford Finance, as noted below, the Company repaid all amounts outstanding under the term loan with Stifel Bank. The Success Fee Agreement obligation of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">367,500</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> survives the Stifel Bank debt repayment and terminates on October 29, 2025. The Company has determined the probability of a Liquidity Event to be remote and accordingly, has not recognized a liability as of December 31, 2023 and 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Oxford Finance</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2022, the Company entered into a Loan and Security Agreement, or Loan Agreement, with Oxford Finance LLC and its agents, or Oxford Finance, which provides for </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">225,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> loan facility, comprised of a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured revolving credit facility and a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> secured term loan facility. The term loans are available in three tranches. The first $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> tranche of term loans was available at closing in May 2022. A second tranche of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of term loans is available through December 31, 2024. A third tranche of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> would be available through December 31, 2024 so long as, at the time of draw, the Company has consolidated trailing 12-month revenues equal to at least </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the sum of the outstanding term loans plus the amount of any requested third tranche term loans. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Upon request of the Company, the revolving credit facility will be increased from $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The revolving loans are available subject to a borrowing base equal to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">85</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of eligible receivables plus </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of eligible inventory, up to the lesser of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">40</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the borrowing base or $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, in the case of eligible inventory. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The revolving loans and the term loans mature on </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">May 1, 2027</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The principal amount of outstanding revolving loans, together with accrued and unpaid interest, is due on the maturity date. The term loans begin to amortize in equal monthly installments beginning on July 1, 2026. As the Company achieved a specified </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consolidated trailing twelve-month revenue target, it has </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the option to extend the first amortization date for the term loans to July 1, 2027. Such election may be made </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no earlier than June 30, 2023 and no later than thirty (30) days prior to July 1, 2026. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the Company exercises this option, then the maturity date for both the revolving loans and the term loans will be May 1, 2028.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The revolving loans accrue interest at the greater of 1-month Secured Overnight Financing Rate (SOFR), or the Index Rate, and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.85</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, plus a margin of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.00</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The term loans accrue interest at the greater of the Index Rate and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.85</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, plus a margin of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.00</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The Index Rate is capped at </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for purposes of the Loan Agreement. Interest on both revolving loans and term loans is payable monthly in arrears. The Company may borrow, prepay and reborrow revolving loans, without premium or penalty. The term loans once repaid or prepaid may not be reborrowed. Term loans may be prepaid in full, or in part in increments of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,000,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company is required to pay a prepayment fee of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for prepayments of term loans made in the first year after closing, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for prepayments of term loans made in the second year after closing, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% for prepayments of term loans made in the third year after closing and no prepayment fees thereafter. Upon the earlier of prepayment or maturity of the term loans, the Company is required to pay a fee of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the aggregate original principal amount of the funded term loans, which fee increases to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.75</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% if the Company exercises its option to extend the amortization date and maturity date. The Company is also obligated to pay other customary fees for a loan facility of this size and type.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Also in May 2022, the Company borrowed the first $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> tranche of the term loan and used a portion of the proceeds to pay off and terminate the prior term loan agreement with Stifel Bank totaling $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,181,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, which included a final interest payment of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">181,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company recognized a loss on debt extinguishment of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">245,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in connection with the early termination of its prior term loan agreement with Stifel Bank. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Obligations under the Loan Agreement are secured by substantially all of the Company's assets. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Loan Agreement requires the Company to maintain consolidated trailing twelve-month revenues of at least </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding principal amount of the term loans, measured as of the last day of each fiscal quarter; or if the revenue target is not achieved, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Company must have maintained unrestricted cash and cash equivalents (net of outstanding revolving loans) subject to control agreements in favor of Oxford Finance equal to at least </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding principal amount of the term loans</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting the Company's ability and the ability of the Company's subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of the Company&#8217;s obligations under the Loan Agreement, the termination of the lender&#8217;s commitments, a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.</span></p></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, the aggregate outstanding principal balance under the term loan facility was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> with the variable interest rate capped at the maximum rate of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.50</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and no amounts were outstanding under the revolving credit facility of the Loan Agreement</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. As of December 31, 2023, the Company was in compliance with all applicable financial covenants.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Future payments under the Oxford Finance term loan agreement as of December 31, 2023 are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ending December 31:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,719</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,703</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">45,699</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2027</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,517</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">91,638</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add: Accretion of closing fees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,329</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">92,967</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Amount representing interest</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">16,638</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Amount representing debt discount and debt issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">703</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Present value of minimum payments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75,626</span></p></td></tr></table></div><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451764036000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">7.&#160;&#160;&#160;&#160;Commitments and Contingencies</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Operating Lease and Rights-of-Use</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s operating lease obligation at its corporate headquarters in California consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2027. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2023, the Company extended the lease term for an additional </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three years</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and recorded an additional $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,504,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> right-of-use asset and lease liability from the remeasurement. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five year</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s non-cancelable operating lease obligation at its facility in Minnesota consists of additional office, laboratory and manufacturing space and expires in November 2029. The lease agreement includes a renewal provision allowing the Company to extend this lease for two additional </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five year</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> terms.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance sheet information as of December&#160;31, 2023 and 2022 consists of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Operating Lease:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use asset in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-dd16a680-3f25-4cca-8f06-df833283191e;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-80d6598d-c247-4749-a960-856924837d92;">other non-current assets</span></span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,489</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,081</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-4a367e19-bd2b-4833-a2ee-41da1810dd33;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ea9efef9-505d-4191-897c-64e4a2fceb36;">accrued liabilities </span></span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,703</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,844</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-24d00192-026d-4075-a91f-bdd0fa580324;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-18ad6fb4-b92c-4419-9e27-7f511e1beb87;">other liabilities </span></span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,304</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,998</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating lease </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-7adaddd6-e390-4787-853b-b3d3af6f96a6;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-3f9f30e3-cce1-4745-9a9e-9d186b53fb29;">liabilities</span></span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,007</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,842</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the Company's operating lease payments as of December&#160;31, 2023 (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.19in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ending December 31:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,991</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,130</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,255</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2027</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,068</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,233</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Thereafter</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,158</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total lease payments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,835</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,828</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Present value of lease liabilities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,007</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Purchase Obligations</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. As of December&#160;31, 2023, the Company had non-cancellable purchase obligations to suppliers of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,660,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, the Company has minimum purchase commitments under its amended supply agreement with Cordis from July 2024 through February 2029 which require a specified minimum volume commitment based on the actual units purchased during the prior year period from July 1 through June 30, with the unit purchase price dependent upon annual volume during the same prior year period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Indemnification</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the normal course of business, the Company enters into contracts and agreements with suppliers and other parties that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director or officer is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director or officer may be subject to any proceeding arising out of acts or omissions of such director or officer in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t recognized any liabilities relating to these obligations as of December&#160;31, 2023.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Contingencies </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows. From time to time, the Company may pursue litigation to assert its legal rights and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> contingent liabilities requiring accrual as of December&#160;31, 2023 and 2022.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759499712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">8.&#160;&#160;&#160;&#160;Stockholders&#8217; Equity</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Preferred Stock</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, the Company&#8217;s restated certificate of incorporation authorizes the Company to issue up to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of preferred stock with $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.001</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value per share, of which no shares were issued and outstanding.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Common Stock</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023, the Company&#8217;s restated certificate of incorporation authorizes the Company to issue up to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock with $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.001</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value per share, of which </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,165,481</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares were issued and outstanding. The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. As of December 31, 2023, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> dividends have been declared to date. Each share of common stock is entitled to one vote.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023 and 2022, the Company had reserved common stock for future issuances as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="3" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding stock options and equity awards</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,168,881</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,169,682</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for grants of future stock options and equity awards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">532,627</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,209,072</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for Performance Stock Units for overperformance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">809,225</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for employee stock purchase plan</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,356,463</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,172,686</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total common stock reserved for future issuance</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,867,196</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,758,908</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759454208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">9.&#160;&#160;&#160;&#160;Stock-Based Compensation Plans</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2019, the Company's Board of Directors [and stockholders] approved the 2019 Equity Incentive Plan, or 2019 Plan, effective immediately prior to the Company&#8217;s IPO. The 2019 Plan replaced the prior 2007 Stock Option Plan, or 2007 Plan, and the NeuroCo 2015 Equity Incentive Plan, which the Company assumed in connection with its acquisition of NeuroCo in December 2018, with respect to future grants. The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants. A total of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,317,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock were initially reserved for issuance pursuant to the 2019 Plan. In addition, the shares reserved for issuance under the 2019 Plan also include shares reserved but not issued under the prior 2007 Plan, plus any share awards granted under the 2007 Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. In addition, the number of shares available for issuance under the 2019 Plan also include an annual increase on the first day of each fiscal year, equal to the lesser of (i) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares; (ii) </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.0</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors. As of December&#160;31, 2023, the Company has reserved </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,952,134</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock for issuance under the 2019 Plan.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A summary of the shares available for issuance under the 2019 Plan is as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Shares</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,790,687</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,369,985</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">847,080</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">163,620</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,477,212</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,399,235</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for Performance Stock Units for overperformance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,600,996</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">141,089</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,209,072</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,534,238</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for Performance Stock Units for overperformance</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">601,757</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,893,796</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">284,870</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">532,627</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The exercise price of Incentive Stock Options and Non-Statutory Stock Options shall not be less than </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">85</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, respectively, of the estimated fair value of the shares on the date of grant as determined by the Board of Directors. The exercise price of options granted to a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% stockholder shall not be less than </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">110</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors. To date, options have a term of ten years and generally vest over </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> from the date of grant.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock option activity under the Company&#8217;s 2007 Stock Option Plan, 2015 Equity Incentive Plan and 2019 Plan is set forth below</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="9" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options Outstanding</span></p></td></tr><tr style="height: 1.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Exercise Price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Remaining Contractual Term (in Years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Aggregate Intrinsic Value (in thousands)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,237,828</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">16.56</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.38</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">197,407</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">323,057</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53.94</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">643,507</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.49</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">136,439</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">40.30</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,780,939</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.45</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.71</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">91,900</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">587,015</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">37.69</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">453,199</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.42</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74,897</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41.16</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,839,858</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24.22</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.41</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">112,755</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,898</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33.57</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">199,642</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.44</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27,430</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">47.09</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,632,684</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25.02</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.52</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,942</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and exercisable at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,184,646</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22.62</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.19</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,942</span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and expected to vest at December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,632,684</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25.02</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.52</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,942</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,857,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,575,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29,355,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17.67</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">37.69</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23.83</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, respectively. The total fair value of options vested during the years ended December&#160;31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,207,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,816,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,076,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively, based on the grant date fair value.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Restricted Stock Units </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, the Company began awarding restricted stock units, or RSUs, under the 2019 Plan. RSUs generally vest and are settled in shares of common stock over </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in annual equal increments. The total award date fair value of awards provided during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">46,939,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30,486,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">28,110,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively. The total fair value of awards vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13,203,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,135,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,893,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively. The fair value of RSUs is based on the closing price of the Company&#8217;s common stock on the date of award. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A summary of RSU activity for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Restricted Stock Units</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Grant Date Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,396</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">46.16</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">524,023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53.64</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,964</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49.95</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27,181</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.99</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">530,274</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53.01</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">806,513</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">37.80</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">148,239</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">52.14</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">66,192</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">44.38</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,122,356</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">42.70</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,162,465</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.71</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">410,085</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43.44</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">147,764</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41.23</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,726,972</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26.02</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected to vest at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,726,972</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26.02</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Performance Stock Units</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2022, the Company began awarding performance stock units, or PSUs, under the 2019 Plan to certain executive officers and key employees. PSUs generally vest at the end of a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> service period, subject to continued service to the Company. The total number of shares of common stock to be issued upon vesting and settlement of the PSUs will be determined based on the total stockholder return, or TSR, of the Company&#8217;s common stock price relative to a group of Benchmark Companies over a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> performance period and range from </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target value of shares awarded, depending on the Company&#8217;s performance against the targeted Benchmark Companies. The total award date fair value of awards provided during the years ended December 31, 2023 and 2022 was $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14,950,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">16,000,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There was no PSU activity for the year ended December 31, 2021. A summary of PSU activity for the years ended December 31, 2023 and 2022 is as follows:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Performance Stock Units</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Grant Date Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77.12</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77.12</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">711,433</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.01</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109,676</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76.66</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">809,225</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27.86</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected to vest at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">809,225</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27.86</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The shares expected to vest as of December 31, 2023 reflects PSUs awards performance and vesting at </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target value of shares granted.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2019 Employee Stock Purchase Plan</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2019, the Company's Board of Directors [and stockholders] adopted the 2019 Employee Stock Purchase Plan, or the ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions. A total of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">434,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock were initially reserved for issuance and is increased on the first day of each fiscal year by an amount equal to the lesser of (i)&#160;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,200,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares (ii)&#160;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.0</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors. The price of the common stock purchased will be the lower of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">85</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. The ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">465,952</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock have been issued to employees participating in the ESPP and </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,356,463</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares were available for future issuance under the ESPP.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock-Based Compensation</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company estimated the fair value of stock options using the Black&#8211;Scholes option pricing model. The fair value of stock options is being amortized on a straight&#8211;line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following assumptions for the years ended December&#160;31, 2023, 2022 and 2021:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term (in years)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.25</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.25</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55.1</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48.2</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">45.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.60</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.84</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.41</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.08</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The fair value of the underlying common stock is based on the closing price of the Company's common stock on The Nasdaq Global Select Market on the date of grant. The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the &#8220;simplified method,&#8221; whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected stock price volatility assumption was determined by supplementing its historical stock trading volatility with the historical volatilities for industry peers, as the Company does not have sufficient trading history for the Company&#8217;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the&#160;Company&#8217;s common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the&#160;Company&#8217;s stock options. The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has elected to recognize forfeitures of share-based payment awards as they occur.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2022, the Company awarded an aggregate of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> PSUs to certain executive officers that vest at the end of a </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> service period based on the TSR of the Company&#8217;s common stock price relative to a group of Benchmark Companies measured over three performance periods. The Company estimated the fair value of the PSUs using the Monte Carlo simulation model, which is being amortized over the requisite service period of the awards. The fair value of the PSUs was estimated using the following assumptions for the year ended December 31, 2022: peer companies volatility of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">59.4</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, Company volatility of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">60.6</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, risk-free interest rate of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.09</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%-</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.20</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, correlation with index of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.41</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and dividend yield of </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2023, the Company awarded an aggregate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">99,350</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> PSUs, assuming target performance. Up to one-third of the target award can be earned and vested at the end of the first and second annual measurement periods based on the total stockholder return, or TSR, of the Company&#8217;s common stock price relative to a group of peer companies, and up to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target award at the end of the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> performance measurement period. The fair value of the PSUs was estimated using the Monte Carlo simulation model and the following assumptions for the year ended December 31, 2023: peer companies volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">62.3</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, Company volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">61.2</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, risk-free interest rate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.58</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, correlation with index of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.38</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and dividend yield of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2023, the Company awarded an aggregate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">612,083</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> PSUs, assuming target performance. Up to one-third of the target award can be earned and vested at the end of the first and second annual measurement periods based on the total stockholder return, or TSR, of the Company&#8217;s common stock price relative to a group of peer companies, and up to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the target award at the end of the </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three year</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> performance measurement period. The fair value of the PSUs was estimated using the Monte Carlo simulation model and the following assumptions for the year ended December 31, 2023: peer companies volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">56.9</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, Company volatility of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">71.1</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, risk-free interest rate of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.72</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, correlation with index of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.35</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, and dividend yield of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The fair value of the shares to be issued under the Company&#8217;s ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2023, 2022 and 2021:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term (in years)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">47.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">119.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.6</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">46.9</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.6</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.64</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.43</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.07</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.64</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.03</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.10</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of goods sold</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,671</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,138</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">635</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,589</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,240</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,909</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Selling, general and administrative expenses</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29,633</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">18,645</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,068</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">38,893</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25,023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14,612</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, there was total unrecognized compensation costs of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,645,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> related to stock options expected to be recognized over a period of approximately </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.63</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, a total of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73,195,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of unrecognized compensation costs related to unvested RSUs and PSUs expected to be recognized over a period of approximately </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.76</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">years and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">679,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of unrecognized compensation costs related to the ESPP, which the Company will recognize over </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.38</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759517600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10.&#160;&#160;&#160;&#160;Income Taxes</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of income before taxes are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">United States </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,743</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,010</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,811</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">International </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss before income taxes</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,743</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,010</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,811</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tax at federal statutory rate </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,706</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,552</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,460</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">State taxes, net of federal benefit </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,311</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,206</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,852</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Permanent differences </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">392</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,893</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,224</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in valuation allowance </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,549</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">18,237</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,918</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Limitation of compensation deduction under IRS Sec.162(m)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,320</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General business credits </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,536</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,166</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">852</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">119</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">401</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">490</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for income taxes </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company's provision for income taxes amounts are not significant and are included within other income (expense) on the statements of operations and comprehensive loss.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2023 and 2022 consist of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Net operating loss carryforwards </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">85,945</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">82,768</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Research and development credits </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,753</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,898</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Capitalized start-up costs/Intangibles </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Section 174 R&amp;D capitalization</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12,892</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,816</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Accruals and reserves </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,775</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,820</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Stock-based compensation </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,353</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,209</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Operating lease liability </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,272</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,973</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Interest limitation </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,114</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,013</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax assets </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">126,104</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">114,498</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Valuation allowance </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">122,993</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">111,444</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax liabilities: </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Operating lease asset </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,636</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,278</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,475</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,776</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax liabilities </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,111</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,054</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax assets </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-75d41ec1-bd07-4439-8d82-3e992d798b22;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-3bf04cf1-1a9a-405d-aa3f-bedeb093e2ab;">&#8212;</span></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management believes it is more likely than not that the deferred tax assets will not be realized; accordingly, a valuation allowance has been established on U.S. net deferred tax assets. The valuation allowance increased $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,549,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">18,237,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,918,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, the Company had net operating loss carryforwards of approximately $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">331,957,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">288,608,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards begin to expire in 2027 and 2024, respectively. Federal NOL carryforwards generated in tax years beginning in 2018 are not subject to expiration. Federal NOLs that arose on or after January 1, 2018 can be carried forward indefinitely against future income, but can only be used to offset a maximum of 80% of the Company's federal taxable income in any year.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law. Federal tax legislation enacted in December 2017, commonly known as the Tax Cuts and Jobs Act, contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company&#8217;s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The Company may have previously experienced, and may in the future experience, one or more Section 382 &#8220;ownership changes,&#8221; including in connection with the Company&#8217;s initial public offering. If so, the Company may lose some or all of the tax benefits of its NOLs and tax credits. The extent of such limitations for prior years, if any, has not yet been formally determined.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Tax Cuts and Jobs Act, research and development expenditures are no longer fully deductible and are required to be capitalized and amortized under Section 174 of the Internal Revenue Code in tax years beginning on or after January 1, 2022. The capitalized research expenses must be amortized over five years for research performed in the U.S. and 15 years for research performed outside the U.S. The mandatory capitalization requirement increased the Company&#8217;s deferred tax assets, which were fully offset by a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">At December&#160;31, 2023, the Company had $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,122,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,869,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of federal and state research and development credit carryforwards, respectively, on a tax return basis. If not utilized, the federal credits will expire beginning in 2027. The California research and development credits can be carried forward indefinitely.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023, the Company had $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,364,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of unrecognized tax benefits. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits would increase or decrease within twelve months of the year ended December&#160;31, 2023. If recognized, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> would affect the effective tax rate.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. There was </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> such expense recorded during the years ended December&#160;31, 2023, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A reconciliation of the unrecognized tax benefits from January 1, 2021 to December&#160;31, 2023 is as follows (in thousands)</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance at the beginning of year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,788</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,314</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,019</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increases related to current years&#8217; tax positions </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">571</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">474</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">704</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increases related to prior years&#8217; tax positions </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">591</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance at end of year </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,364</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,788</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,314</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception. As a result of the Company&#8217;s net operating loss carryforwards, all of its tax years are subject to federal and state tax examination.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451853337600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">401(k) Plan</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">11.&#160;&#160;&#160;&#160;401(k) Plan</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code, or the IRC, under which participants may contribute up to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of their eligible compensation, subject to maximum deferral limits specified by the IRC. The Company may make a discretionary matching contribution to the 401(k)&#160;plan and may make a discretionary employer contribution to each eligible employee each year. Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the first </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of compensation deferred to the 401(k) plan and at 50% of the first 6% of compensation deferred effective January 1, 2022. The Company's matching contributions were $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,256,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,872,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,313,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759448032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. The table below presents Schedule II, Valuation and Qualifying Accounts, detailing the activity of the allowance for credit losses for the years ended December 31, 2023, 2022 and 2021 (in thousands):</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Description</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at Beginning of Year</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Charged to Expenses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Write Offs</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance at </span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">End of Year</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for credit losses:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">45</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31, 2021</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762096928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis of Preparation</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America, or U.S. GAAP. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2023 and 2022. The carrying amounts of certain of the Company&#8217;s financial instruments, which include accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments. Management believes that its debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash, Cash Equivalents and Restricted Cash</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are recorded at fair value, based on quoted market prices. As of </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December&#160;31, 2023 and 2022, the Company&#8217;s cash equivalents were entirely comprised of investments in money market funds.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,210</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,358</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted cash </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">155</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash, cash equivalents and restricted cash </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,210</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,513</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company had </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted cash as of December 31, 2023. Restricted cash as of December&#160;31, 2022 consisted of a letter of credit of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">155,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> representing collateral for the Company&#8217;s facility lease in California. </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Investments</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term and long-term investments consist of debt securities classified as available-for-sale. Short-term investments have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss). Realized gains and losses are included in earnings and are der</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ived based on the specific-identification method for determining the costs of investments sold and were insignificant for the years ended December 31, 2023, 2022 and 2021. Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. The Company evaluates the securities in an unrealized loss position for expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, current economic conditions and credit ratings. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company did </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t recognize any credit losses on its available-for-sale securities during the years ended December 31, 2023, 2022 or 2021 and there were no impairment charges for unrealized losses in the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk, and Other Risks and Uncertainties</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk, and Other Risks and Uncertainties</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, U.S. government securities, U.S. treasury bills, agency bonds/notes, and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2023, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2023 and December&#160;31, 2022, a portion of the Company&#8217;s cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of the Company&#8217;s cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. On March 10, 2023, SVB was shut down and placed under receivership with the Federal Deposit Insurance Corporation, or FDIC, by the California Department of Financial Protection and Innovation. On March 26, 2023, the FDIC announced it had entered into a purchase and assumption agreement with First Citizens Bank &amp; Trust Company under which all of SVB&#8217;s deposits were assumed. As of the issuance date of these financial statements, the Company has not experienced any losses on its deposits and all of the Company&#8217;s cash deposited with SVB has been accessible to the Company.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s accounts receivable are due from a variety of hospitals and medical centers in the United States. As of December&#160;31, 2023 and 2022, no customer represented 10% or more of the Company&#8217;s accounts receivable. For the years ended December&#160;31, 2023, 2022 and 2021, there were no customers that represented 10% or more of revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its commercial products in-house. Certain of the Company&#8217;s finished goods,  components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in finished goods, component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, competition, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies. In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accounts Receivable</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company estimates allowances for expected credit losses. Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#8217; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. These specific allowances are reevaluated and adjusted as additional information is received that impacts the amount reserved. During the years ended December 31, 2023, 2022 and 2021, the Company did not experience any material credit-related losses.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inventories</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate. The Company&#8217;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements. The estimate of excess quantities is judgmental and primarily dependent on the Company&#8217;s estimates of future demand for a particular product. If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Property and Equipment</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are recorded at cost less accumulated depreciation or amortization. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three years</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five years</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Impairment of Long-Lived Assets</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value. The Company did </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t record any impairment of long-lived assets during the years ended December&#160;31, 2023, 2022 and 2021.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Leases</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for its leasing arrangements in accordance with Accounting Standards Codification, or ASC 842, &#8220;Leases.&#8221; The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset. The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain. Variable lease costs represent payments that are dependent on usage, a rate or index. Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred. The Company elected to account for contracts that contain lease and non-lease components as a single component, consistent with its historical practice. The Company does not have any finance leases.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Revenue Recognition</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives and is primarily comprised of product revenue net of returns, administration fees and sales rebates. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer.&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it. Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title. The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Administration fees and sales rebates are accounted for as a reduction in revenue, calculated based on the terms agreed to with the customer.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2023 and 2022, the Company recorded $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">227,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">148,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Costs associated with product sales, which include commissions and royalties, are expensed when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160;Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the statements of operations and comprehensive loss.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accepts product returns at its discretion or if the product is defective as manufactured. The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the balance sheet.&#160;The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sold. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cost of Goods Sold</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its portfolio of TCAR products at its California and Minnesota facilities and purchases other products from third party manufacturers. Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, manufacturing overhead costs, direct labor, scrap, product rework, reserves for excess, obsolete and non-sellable inventories as well as logistics-related expenses. A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs. These overhead costs include the cost of quality control, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company entered into the lease for its additional facility in Minnesota in May 2021 and did not begin commercial production of the ENROUTE Neuroprotection System until the third quarter of 2022. During this time, the Company experienced additional overhead expenses related to its investment in the start-up phase of its manufacturing capacity expansion, which were recorded as a period expense. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development and Clinical Trials</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Research and Development</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#8217;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development. Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses. Additionally, clinical studies include costs associated with clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Clinical Trials</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accrues and expenses costs for its clinical trial activities performed by third parties, including any clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Advertising Costs</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company expenses advertising costs as incurred. Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items. Advertising costs of $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">461,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">347,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">221,000</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> were expensed during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Foreign Currency</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net. The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2023, 2022 and 2021.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock&#8211;Based Compensation</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board, or FASB, ASC 718,&#160;&#8220;Compensation-Stock Compensation.&#8221; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units, performance stock units, and shares issued under its employee stock purchase plan. ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model. The fair value of stock options is recognized over the period during which an optionee is required to provide services in </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis. The Company accounts for option forfeitures as they occur.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant. These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for performance stock units with market-based conditions at their fair value on the date of the award using the Monte Carlo simulation model. These costs are recognized over the requisite service period, which is usually the vesting period, regardless of the likelihood of achievement of the market-based performance criteria.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for stock-based compensation for its employee stock purchase plan based on the </span><span id="_Hlk157943524" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">estimated fair value on the first day of the offering period </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">using an option pricing model for each purchase period. These costs are recognized on a straight-line basis over the offering period.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company also follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes.&#8221; ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> liability related to uncertain tax positions is recorded on the financial statements. It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Comprehensive Loss</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale. For the years ended </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December&#160;31, 2023, 2022 and 2021</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive loss. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets as a component of stockholders' equity. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share </span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and performance stock units are considered to be potentially dilutive securities. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share was determined as follows (in thousands, except share and per share data):</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,743</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,010</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,811</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average common stock outstanding used to compute net loss per share, basic and diluted </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">38,804,343</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35,775,672</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,635,358</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.44</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.54</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.44</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss:</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock options </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,632,684</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,839,858</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,780,939</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted stock units and performance stock units</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,536,197</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,329,824</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">530,274</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,168,881</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,169,682</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,311,213</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Segment and Geographical Information</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company operates and manages its business as </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reportable and operating segment. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Primarily all of the Company&#8217;s long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment. All of the Company&#8217;s revenue was in the United State</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s for the years ended December&#160;31, 2023, 2022 and 2021, based on the shipping location of the external customer.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451763876128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,210</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,358</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted cash </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">155</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total cash, cash equivalents and restricted cash </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,210</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,513</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Determination</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,743</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,010</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,811</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average common stock outstanding used to compute net loss per share, basic and diluted </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">38,804,343</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35,775,672</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,635,358</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.44</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.54</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.44</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock options </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,632,684</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,839,858</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,780,939</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Restricted stock units and performance stock units</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,536,197</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,329,824</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">530,274</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,168,881</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,169,682</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,311,213</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759413392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,899</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,899</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,150</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,150</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,438</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,438</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,556</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,556</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,677</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,677</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">31,382</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">158,821</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Level 3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,776</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,776</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,515</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,515</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,270</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,270</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,996</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,996</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency notes</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,884</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,884</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74,934</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">138,540</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451756031280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Fair Value of the Available-For-Sale Investments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross Unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized Cost</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gains</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Losses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,896</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,899</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,160</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33,150</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,398</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,438</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,501</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,556</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,693</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,677</span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,131</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">145</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td></tr><tr style="height: 0.19in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Classified as:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash equivalents </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,483</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term investments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">161,264</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Long-term investments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,456</span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gross Unrealized</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Estimated</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amortized Cost</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Gains</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Losses</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Money market funds</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. treasury bills</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,772</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,776</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,875</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,528</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,515</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,432</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">164</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83,270</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,000</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,996</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency notes</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,876</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,884</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,641</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">181</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Classified as:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash equivalents </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,158</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Short-term investments </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">158,316</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.36in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts maturing within one year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">180,747</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amounts maturing after one year through two years </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,456</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190,203</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">213,474</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Available-For-Sale Investments in Unrealized Loss Position</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, 2022</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Less than 12 months</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Less than 12 months</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Assets:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Unrealized Loss</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Fair Value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Unrealized Loss</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21,842</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,490</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercial paper</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,684</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. government securities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73,329</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">164</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Asset-backed securities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,994</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Agency bonds/notes</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,964</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90,490</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76,813</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">181</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Raw materials</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,512</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,913</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Finished products</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23,364</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14,380</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total inventories</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29,876</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,293</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and fixtures</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,052</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,822</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,776</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,046</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Software</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">296</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">296</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasehold improvements</span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,561</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,246</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,685</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14,410</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Accumulated depreciation </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,907</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,355</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add:  Construction-in-progress</span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">336</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">317</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total property and equipment, net</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,114</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,372</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued payroll and related expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,113</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,216</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,703</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,844</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued travel expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">944</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">775</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued interest payable</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">517</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">519</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for sales returns</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">500</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">540</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued royalty expense</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">405</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">973</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued administration fees and sales rebates</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">405</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">338</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued professional services</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">326</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">781</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued clinical expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">256</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">249</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred revenue</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">143</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">253</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued other expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,295</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">477</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total accrued liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,607</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21,965</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759529520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Payment Under the Term Loan</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ending December 31:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,719</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,703</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">45,699</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2027</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,517</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">91,638</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Add: Accretion of closing fees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,329</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">92,967</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Amount representing interest</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">16,638</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Amount representing debt discount and debt issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">703</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Present value of minimum payments</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75,626</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762798960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Balance Sheet Information</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Operating Lease:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use asset in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-dd16a680-3f25-4cca-8f06-df833283191e;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-80d6598d-c247-4749-a960-856924837d92;">other non-current assets</span></span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,489</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,081</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-4a367e19-bd2b-4833-a2ee-41da1810dd33;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ea9efef9-505d-4191-897c-64e4a2fceb36;">accrued liabilities </span></span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,703</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,844</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liability in </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-24d00192-026d-4075-a91f-bdd0fa580324;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-18ad6fb4-b92c-4419-9e27-7f511e1beb87;">other liabilities </span></span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,304</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,998</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating lease </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-7adaddd6-e390-4787-853b-b3d3af6f96a6;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-3f9f30e3-cce1-4745-9a9e-9d186b53fb29;">liabilities</span></span></span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,007</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,842</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturities</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.19in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ending December 31:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,991</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,130</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2026</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,255</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2027</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,068</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,233</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Thereafter</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,158</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total lease payments </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,835</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,828</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Present value of lease liabilities </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,007</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759574560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ScheduleOfCommonStockReserveForFutureIssuances', window );">Schedule of Common Stock Reserved for Future Issuances</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="3" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding stock options and equity awards</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,168,881</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,169,682</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for grants of future stock options and equity awards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">532,627</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,209,072</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for Performance Stock Units for overperformance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">809,225</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Reserved for employee stock purchase plan</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,356,463</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,172,686</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total common stock reserved for future issuance</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,867,196</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,758,908</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ScheduleOfCommonStockReserveForFutureIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserve For Future Issuances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ScheduleOfCommonStockReserveForFutureIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451753688768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Shares Available for Issuance</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Shares</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,790,687</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,369,985</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">847,080</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">163,620</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,477,212</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,399,235</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for Performance Stock Units for overperformance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,600,996</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">141,089</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,209,072</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Authorized </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,534,238</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allowance for Performance Stock Units for overperformance</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">601,757</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted/Awarded </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,893,796</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">284,870</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">532,627</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="9" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options Outstanding</span></p></td></tr><tr style="height: 1.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Exercise Price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Remaining Contractual Term (in Years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Aggregate Intrinsic Value (in thousands)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,237,828</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">16.56</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.38</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">197,407</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">323,057</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53.94</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">643,507</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.49</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">136,439</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">40.30</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,780,939</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.45</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.71</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">91,900</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">587,015</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">37.69</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">453,199</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.42</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74,897</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41.16</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,839,858</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24.22</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.41</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">112,755</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,898</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33.57</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">199,642</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.44</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options cancelled </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27,430</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">47.09</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,632,684</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25.02</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.52</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,942</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and exercisable at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,184,646</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22.62</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.19</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,942</span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and expected to vest at December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,632,684</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25.02</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.52</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,942</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cost of goods sold</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,671</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,138</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">635</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,589</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,240</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,909</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Selling, general and administrative expenses</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29,633</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">18,645</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,068</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">38,893</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25,023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14,612</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term (in years)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.25</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.25</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.25</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55.1</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48.2</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">45.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.60</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.84</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.41</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.08</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected term (in years)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.50</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected volatility</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">47.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">119.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.6</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">46.9</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.6</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.64</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.43</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.07</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.64</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.03</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% - </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.10</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;%</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Stock Unit Activity</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Restricted Stock Units</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Grant Date Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2020 </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">68,396</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">46.16</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">524,023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53.64</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,964</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49.95</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27,181</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">51.99</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">530,274</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53.01</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">806,513</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">37.80</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">148,239</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">52.14</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">66,192</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">44.38</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,122,356</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">42.70</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,162,465</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.71</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">410,085</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43.44</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">147,764</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41.23</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,726,972</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26.02</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected to vest at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,726,972</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26.02</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Stock Unit Activity</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Performance Stock Units</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Grant Date Fair Value</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77.12</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">207,468</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77.12</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards granted </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">711,433</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.01</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards vested </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Awards cancelled</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109,676</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76.66</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balances, December 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">809,225</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27.86</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected to vest at December 31, 2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">809,225</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">27.86</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757930432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">United States </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,743</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,010</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,811</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">International </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8212;&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss before income taxes</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,743</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">55,010</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49,811</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year Ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tax at federal statutory rate </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,706</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,552</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,460</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">State taxes, net of federal benefit </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,311</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,206</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,852</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Permanent differences </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">392</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,893</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,224</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in valuation allowance </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,549</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">18,237</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,918</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Limitation of compensation deduction under IRS Sec.162(m)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,320</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General business credits </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,536</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,166</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">852</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">119</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">401</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">490</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Provision for income taxes </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">29</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Net operating loss carryforwards </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">85,945</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">82,768</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Research and development credits </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,753</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,898</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Capitalized start-up costs/Intangibles </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Section 174 R&amp;D capitalization</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12,892</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,816</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Accruals and reserves </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,775</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,820</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Stock-based compensation </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,353</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8,209</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Operating lease liability </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,272</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,973</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Interest limitation </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,114</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,013</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax assets </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">126,104</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">114,498</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less:  Valuation allowance </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">122,993</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">111,444</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax liabilities: </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Operating lease asset </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,636</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,278</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,475</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,776</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax liabilities </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,111</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,054</span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax assets </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-75d41ec1-bd07-4439-8d82-3e992d798b22;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-3bf04cf1-1a9a-405d-aa3f-bedeb093e2ab;">&#8212;</span></span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance at the beginning of year </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,788</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,314</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,019</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increases related to current years&#8217; tax positions </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">571</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">474</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">704</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Increases related to prior years&#8217; tax positions </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">591</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Balance at end of year </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,364</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,788</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,314</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451758089152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (343,712)<span></span>
</td>
<td class="num">$ (399,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_CashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash, Cash Equivalents And Available For Sale Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares)</a></td>
<td class="nump">2,674,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 108,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share)</a></td>
<td class="nump">$ 43.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 6,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions', window );">Payment of stock issuance underwriting discounts and commissions</a></td>
<td class="nump">$ 5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=silk_UnderwritersOptionMember', window );">Underwriters' Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares)</a></td>
<td class="nump">348,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Cash Equivalents And Available For Sale Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Stock Issuance Underwriting Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=silk_UnderwritersOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=silk_UnderwritersOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762363104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liability for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 461,000<span></span>
</td>
<td class="nump">347,000<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff', window );">Available-for-sale securities, credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762795440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,210,000<span></span>
</td>
<td class="nump">$ 55,358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 20,210,000<span></span>
</td>
<td class="nump">$ 55,513,000<span></span>
</td>
<td class="nump">$ 110,463,000<span></span>
</td>
<td class="nump">$ 69,776,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451758086976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Net Loss Per Share Determination) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,743)<span></span>
</td>
<td class="num">$ (55,010)<span></span>
</td>
<td class="num">$ (49,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">38,804,343<span></span>
</td>
<td class="nump">35,775,672<span></span>
</td>
<td class="nump">34,635,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">38,804,343<span></span>
</td>
<td class="nump">35,775,672<span></span>
</td>
<td class="nump">34,635,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757084640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,168,881<span></span>
</td>
<td class="nump">5,169,682<span></span>
</td>
<td class="nump">4,311,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">3,632,684<span></span>
</td>
<td class="nump">3,839,858<span></span>
</td>
<td class="nump">3,780,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_RestrictedStockUnitsAndPerformanceStockUnitsMember', window );">Restricted Stock Units and Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">3,536,197<span></span>
</td>
<td class="nump">1,329,824<span></span>
</td>
<td class="nump">530,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_RestrictedStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_RestrictedStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762720768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details) - Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 190,203<span></span>
</td>
<td class="nump">$ 213,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">55,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">11,899<span></span>
</td>
<td class="nump">19,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">33,150<span></span>
</td>
<td class="nump">48,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds/Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">39,438<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">83,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Agency bonds/notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">68,677<span></span>
</td>
<td class="nump">2,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">31,382<span></span>
</td>
<td class="nump">74,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">55,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member] | US Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">11,899<span></span>
</td>
<td class="nump">19,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">158,821<span></span>
</td>
<td class="nump">138,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Commercial Papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">33,150<span></span>
</td>
<td class="nump">48,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Corporate Bonds/Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">39,438<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">83,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Agency bonds/notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 68,677<span></span>
</td>
<td class="nump">$ 2,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757984224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Weighted average days to maturity</a></td>
<td class="text">163 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process inventories</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">2,696,000<span></span>
</td>
<td class="nump">2,127,000<span></span>
</td>
<td class="nump">$ 1,032,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762772592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 190,131<span></span>
</td>
<td class="nump">$ 213,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">190,203<span></span>
</td>
<td class="nump">213,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">55,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">161,264<span></span>
</td>
<td class="nump">158,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="nump">9,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">190,203<span></span>
</td>
<td class="nump">213,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">55,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">55,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,896<span></span>
</td>
<td class="nump">19,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,899<span></span>
</td>
<td class="nump">19,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,160<span></span>
</td>
<td class="nump">48,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">33,150<span></span>
</td>
<td class="nump">48,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds/Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,398<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">39,438<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">17,501<span></span>
</td>
<td class="nump">83,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">83,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember', window );">Agency bonds/notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,693<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 68,677<span></span>
</td>
<td class="nump">$ 2,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451763640064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear', window );">Amounts maturing within one year</a></td>
<td class="nump">$ 180,747<span></span>
</td>
<td class="nump">$ 213,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears', window );">Amounts maturing after one year through two years</a></td>
<td class="nump">9,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 190,203<span></span>
</td>
<td class="nump">$ 213,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757830256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 90,490<span></span>
</td>
<td class="nump">$ 76,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">19,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds/Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">21,842<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember', window );">Agency bonds/notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">48,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="num">$ (43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=silk_AgencyNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451758120992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 6,512<span></span>
</td>
<td class="nump">$ 4,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">23,364<span></span>
</td>
<td class="nump">14,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">$ 29,876<span></span>
</td>
<td class="nump">$ 19,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451762740640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 15,685<span></span>
</td>
<td class="nump">$ 14,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(7,907)<span></span>
</td>
<td class="num">(5,355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">8,114<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,776<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,561<span></span>
</td>
<td class="nump">7,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451758029120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Accrued Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 17,113<span></span>
</td>
<td class="nump">$ 15,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">1,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_AccruedTravelExpensesCurrent', window );">Accrued travel expenses</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ProvisionsForSalesReturns', window );">Provision for sales returns</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty expense</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_AccruedAdministrationFeesAndSalesRebates', window );">Accrued administration fees and sales rebates</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_AccruedClinicalExpensesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 24,607<span></span>
</td>
<td class="nump">$ 21,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccruedAdministrationFeesAndSalesRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Administration Fees And Sales Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccruedAdministrationFeesAndSalesRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccruedTravelExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Travel Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccruedTravelExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ProvisionsForSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provisions For Sales Returns</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ProvisionsForSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451753145456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (245,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=silk_StifelBankMember', window );">Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold', window );">Percent of original principal threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember', window );">Term Loan [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_LoanFacilityMember', window );">Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_LoanFacilityMember', window );">Loan Facility [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of outstanding loan amount</a></td>
<td class="nump">$ 49,181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt pay off</a></td>
<td class="nump">181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_LoanFacilityMember', window );">Loan Facility [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Aggregate outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DebtInstrumentCovenantMaximumBorrowingThreshold', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentageOfPrepaymentFees', window );">Percentage of prepayment fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DebtCovenantRevenueCovenant', window );">Debt, Covenant, Revenue Covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_LoanFacilityMember', window );">Loan Facility [Member] | Term Loan [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_LoanFacilityMember', window );">Loan Facility [Member] | Term Loan [Member] | Prime Rate [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Secured Revolving Credit Facility [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Secured Revolving Credit Facility [Member] | Index Rate [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DebtInstrumentMarginRate', window );">Debt instrument margin rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Secured Revolving Credit Facility [Member] | Secured Debt [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_SecuredRevolvingCreditFacilityAmendedMember', window );">Secured Revolving Credit Facility, Amended [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentOfBorrowingBaseOfEligibleReceivables', window );">Percent of borrowing base of eligible receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentOfEligibleInventory', window );">Percent of eligible inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentOfBorrowingBaseInCaseEligibleInventory', window );">Percent of borrowing base in case eligible inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_BorrowingBaseAmountInCaseEligibleInventory', window );">Borrowing base amount in case eligible inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentageOfPrepaymentFees', window );">Percentage of prepayment fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentageOfPrepaymentFeesInSecondYear', window );">Percentage of prepayment fees in second year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentageOfPrepaymentFeesInThirdYear', window );">Percentage of prepayment fees in third year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentAggregateOriginalPrincipalAmount', window );">Percent aggregate original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_TermLoanPrepaidInIncrements', window );">Term loan prepaid in increments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility [Member] | Index Rate [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DebtInstrumentMarginRate', window );">Debt instrument margin rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=silk_SecuredRevolvingCreditFacilitySubfacilityMember', window );">Secured Revolving Credit Facility, Subfacility [Member] | Term Loan [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement [Member] | Prime Rate [Member] | Stifel Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheAMember', window );">Term Loan, First Tranche [Member] | Secured Term Loan Facility [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheBMember', window );">Term Loan, Second Tranche [Member] | Secured Term Loan Facility [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheCMember', window );">Term Loan, Third Tranche [Member] | Secured Term Loan Facility [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DebtCovenantRevenueCovenant', window );">Debt, Covenant, Revenue Covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Loan Facility [Member] | Index Rate [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Secured Term Loan Facility [Member] | Oxford Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentAggregateOriginalPrincipalAmount', window );">Percent aggregate original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_BorrowingBaseAmountInCaseEligibleInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing base amount in case eligible inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_BorrowingBaseAmountInCaseEligibleInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtCovenantRevenueCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt, Covenant, Revenue Covenant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtCovenantRevenueCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Event, Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantLiquidityEventPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantMaximumBorrowingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Maximum Borrowing Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantMaximumBorrowingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentMarginRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument margin rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentMarginRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentAggregateOriginalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent aggregate original principal amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentAggregateOriginalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentOfBorrowingBaseInCaseEligibleInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of borrowing base in case eligible inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentOfBorrowingBaseInCaseEligibleInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentOfBorrowingBaseOfEligibleReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of borrowing base of eligible receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentOfBorrowingBaseOfEligibleReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentOfEligibleInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of eligible inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentOfEligibleInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentageOfPrepaymentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentageOfPrepaymentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentageOfPrepaymentFeesInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment fees in second year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentageOfPrepaymentFeesInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentageOfPrepaymentFeesInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment fees in third year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentageOfPrepaymentFeesInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_TermLoanPrepaidInIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term loan prepaid in increments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_TermLoanPrepaidInIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=silk_StifelBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=silk_StifelBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=silk_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=silk_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=silk_OxfordFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=silk_OxfordFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=silk_IndexRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=silk_IndexRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=silk_SecuredRevolvingCreditFacilityAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=silk_SecuredRevolvingCreditFacilityAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=silk_SecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=silk_SecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=silk_SecuredRevolvingCreditFacilitySubfacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=silk_SecuredRevolvingCreditFacilitySubfacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silk_TermLoanTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757485136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt (Future Payment Under the Term Loan) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">$ 5,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">5,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">45,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">34,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_LongTermDebtGrossBeforeAccretionOfClosingFees', window );">Long-term debt, gross before accretion of closing fees</a></td>
<td class="nump">91,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_AccretionOfClosingCosts', window );">Add: Accretion of closing fees</a></td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_LongTermDebtGrossAfterAccretionOfClosingFees', window );">Long-Term Debt, Gross, After Accretion Of Closing Fees</a></td>
<td class="nump">92,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_LongTermDebtUnpaidInterest', window );">Less: Amount representing interest</a></td>
<td class="num">(16,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Amount representing debt discount and debt issuance costs</a></td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Present value of minimum payments</a></td>
<td class="nump">$ 75,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccretionOfClosingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion Of Closing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccretionOfClosingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtGrossAfterAccretionOfClosingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Gross, After Accretion Of Closing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtGrossAfterAccretionOfClosingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtGrossBeforeAccretionOfClosingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Gross, Before Accretion Of Closing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtGrossBeforeAccretionOfClosingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451751589632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_IndemnificationObligationsLiabilityRecognized', window );">Indemnification obligations, liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities requiring accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Additional extended lease period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="nump">$ 2,504,000<span></span>
</td>
<td class="nump">$ 2,504,000<span></span>
</td>
<td class="nump">$ 903,000<span></span>
</td>
<td class="nump">$ 3,307,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=silk_HeadquartersMember', window );">Headquarters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember', window );">Additional Office, Laboratory And Manufacturing Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_IndemnificationObligationsLiabilityRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification obligations for which a liability has been recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_IndemnificationObligationsLiabilityRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=silk_HeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=silk_HeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451751922624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Balance Sheet Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets in other non-current assets</a></td>
<td class="nump">$ 6,489<span></span>
</td>
<td class="nump">$ 5,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities in accrued liabilities</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">1,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities in other liabilities</a></td>
<td class="nump">7,304<span></span>
</td>
<td class="nump">5,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 9,007<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating lease, right-of-use asset, statement of financial position extensible list</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position extensible list</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, noncurrent, statement of financial position extensible list</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities<span></span>
</td>
<td class="text">Liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451751610464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Operating Lease Maturities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">2,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">10,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 9,007<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451758036624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">39,165,481<span></span>
</td>
<td class="nump">38,355,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">39,165,481<span></span>
</td>
<td class="nump">38,355,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451751620848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Shares Reserved for Future Issuance) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">9,867,196<span></span>
</td>
<td class="nump">8,758,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionExercisedMember', window );">Exercise of options under stock plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">7,168,881<span></span>
</td>
<td class="nump">5,169,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionIssuedMember', window );">Issuance of options and restricted stock units under stock plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">532,627<span></span>
</td>
<td class="nump">2,209,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_PerformanceStockUnitsOverperformanceMember', window );">Performance Stock Units, Overperformance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">809,225<span></span>
</td>
<td class="nump">207,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,356,463<span></span>
</td>
<td class="nump">1,172,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_PerformanceStockUnitsOverperformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_PerformanceStockUnitsOverperformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451749852720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,857<span></span>
</td>
<td class="nump">$ 17,575<span></span>
</td>
<td class="nump">$ 29,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.67<span></span>
</td>
<td class="nump">$ 37.69<span></span>
</td>
<td class="nump">$ 23.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,207<span></span>
</td>
<td class="nump">$ 9,816<span></span>
</td>
<td class="nump">$ 9,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,867,196<span></span>
</td>
<td class="nump">8,758,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember', window );">ISO and NSO [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember', window );">ISO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of purchase of price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember', window );">NSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of purchase of price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation expensed not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs of unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,162,465<span></span>
</td>
<td class="nump">806,513<span></span>
</td>
<td class="nump">524,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,433<span></span>
</td>
<td class="nump">207,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units [Member] | Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.20%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.40%<span></span>
</td>
<td class="nump">50.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.84%<span></span>
</td>
<td class="nump">1.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=silk_AwardDateOneMember', window );">Award Date One [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=silk_AwardDateOneMember', window );">Award Date One [Member] | Performance Stock Units [Member] | Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=silk_AwardDateTwoMember', window );">Award Date Two [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">612,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=silk_AwardDateTwoMember', window );">Award Date Two [Member] | Performance Stock Units [Member] | Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,317,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,952,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance', window );">Additional Common Stock Capital Shares Reserved For Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_PercentOfOutstandingShares', window );">Percent Of Outstanding Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,939<span></span>
</td>
<td class="nump">$ 30,486<span></span>
</td>
<td class="nump">$ 28,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,203<span></span>
</td>
<td class="nump">6,135<span></span>
</td>
<td class="nump">$ 1,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,950<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Minimum [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Maximum [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Award Date One [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Award Date One [Member] | Maximum [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Award Date Two [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan [Member] | Award Date Two [Member] | Maximum [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_Espp2019Member', window );">ESPP, 2019 [Member] | Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued', window );">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_CommonStockCapitalSharesAvailableForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,356,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_FairMarketValueOfCommonStock', window );">Fair Market Value Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Common Stock Capital Shares Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CommonStockCapitalSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CommonStockCapitalSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_FairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Market Value Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_FairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PercentOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent Of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PercentOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=silk_BenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=silk_BenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=silk_AwardDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=silk_AwardDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=silk_AwardDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=silk_AwardDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=silk_Espp2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=silk_Espp2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451760680448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details) - 2019 Equity Incentive Plan [Member] - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,209,072<span></span>
</td>
<td class="nump">2,477,212<span></span>
</td>
<td class="nump">1,790,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="nump">1,534,238<span></span>
</td>
<td class="nump">1,399,235<span></span>
</td>
<td class="nump">1,369,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance', window );">Allowance for Performance Stock Units for overperformance (in shares)</a></td>
<td class="num">(601,757)<span></span>
</td>
<td class="nump">207,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross', window );">Granted/Awarded (in shares)</a></td>
<td class="num">(2,893,796)<span></span>
</td>
<td class="num">(1,600,996)<span></span>
</td>
<td class="num">(847,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod', window );">Canceled (in shares)</a></td>
<td class="nump">284,870<span></span>
</td>
<td class="nump">141,089<span></span>
</td>
<td class="nump">163,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">532,627<span></span>
</td>
<td class="nump">2,209,072<span></span>
</td>
<td class="nump">2,477,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Allowance For Overperformance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757710544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Summary of Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,839,858<span></span>
</td>
<td class="nump">3,780,939<span></span>
</td>
<td class="nump">4,237,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">19,898<span></span>
</td>
<td class="nump">587,015<span></span>
</td>
<td class="nump">323,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(199,642)<span></span>
</td>
<td class="num">(453,199)<span></span>
</td>
<td class="num">(643,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="num">(27,430)<span></span>
</td>
<td class="num">(74,897)<span></span>
</td>
<td class="num">(136,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,632,684<span></span>
</td>
<td class="nump">3,839,858<span></span>
</td>
<td class="nump">3,780,939<span></span>
</td>
<td class="nump">4,237,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">3,184,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expect to vest (in shares)</a></td>
<td class="nump">3,632,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share)</a></td>
<td class="nump">$ 24.22<span></span>
</td>
<td class="nump">$ 20.45<span></span>
</td>
<td class="nump">$ 16.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share)</a></td>
<td class="nump">33.57<span></span>
</td>
<td class="nump">37.69<span></span>
</td>
<td class="nump">53.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share)</a></td>
<td class="nump">7.44<span></span>
</td>
<td class="nump">7.42<span></span>
</td>
<td class="nump">7.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in USD per share)</a></td>
<td class="nump">47.09<span></span>
</td>
<td class="nump">41.16<span></span>
</td>
<td class="nump">40.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share)</a></td>
<td class="nump">25.02<span></span>
</td>
<td class="nump">$ 24.22<span></span>
</td>
<td class="nump">$ 20.45<span></span>
</td>
<td class="nump">$ 16.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in USD per share)</a></td>
<td class="nump">22.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share)</a></td>
<td class="nump">$ 25.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding</a></td>
<td class="text">5 years 6 months 7 days<span></span>
</td>
<td class="text">6 years 4 months 28 days<span></span>
</td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">5 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">5 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Awards outstanding</a></td>
<td class="nump">$ 7,942<span></span>
</td>
<td class="nump">$ 112,755<span></span>
</td>
<td class="nump">$ 91,900<span></span>
</td>
<td class="nump">$ 197,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451763683712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Information by Exercise Price) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">3,632,684<span></span>
</td>
<td class="nump">3,839,858<span></span>
</td>
<td class="nump">3,780,939<span></span>
</td>
<td class="nump">4,237,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">5 years 6 months 7 days<span></span>
</td>
<td class="text">6 years 4 months 28 days<span></span>
</td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 25.02<span></span>
</td>
<td class="nump">$ 24.22<span></span>
</td>
<td class="nump">$ 20.45<span></span>
</td>
<td class="nump">$ 16.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">3,184,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 22.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451753043936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,122,356<span></span>
</td>
<td class="nump">530,274<span></span>
</td>
<td class="nump">68,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,162,465<span></span>
</td>
<td class="nump">806,513<span></span>
</td>
<td class="nump">524,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,085<span></span>
</td>
<td class="nump">148,239<span></span>
</td>
<td class="nump">34,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,764)<span></span>
</td>
<td class="num">(66,192)<span></span>
</td>
<td class="num">(27,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,726,972<span></span>
</td>
<td class="nump">1,122,356<span></span>
</td>
<td class="nump">530,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,726,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.70<span></span>
</td>
<td class="nump">$ 53.01<span></span>
</td>
<td class="nump">$ 46.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.71<span></span>
</td>
<td class="nump">37.80<span></span>
</td>
<td class="nump">53.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards vested (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.44<span></span>
</td>
<td class="nump">52.14<span></span>
</td>
<td class="nump">49.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards cancelled (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.23<span></span>
</td>
<td class="nump">44.38<span></span>
</td>
<td class="nump">51.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.02<span></span>
</td>
<td class="nump">$ 42.70<span></span>
</td>
<td class="nump">$ 53.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Expected to vest (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">207,468<span></span>
</td>
<td class="nump">711,433<span></span>
</td>
<td class="nump">207,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809,225<span></span>
</td>
<td class="nump">207,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.01<span></span>
</td>
<td class="nump">$ 77.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards cancelled (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.86<span></span>
</td>
<td class="nump">$ 77.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Expected to vest (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451756094960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">55.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.20%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.40%<span></span>
</td>
<td class="nump">50.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.84%<span></span>
</td>
<td class="nump">1.08%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember', window );">ESPP [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">47.40%<span></span>
</td>
<td class="nump">51.60%<span></span>
</td>
<td class="nump">46.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.64%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember', window );">ESPP [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">119.50%<span></span>
</td>
<td class="nump">74.50%<span></span>
</td>
<td class="nump">51.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">5.43%<span></span>
</td>
<td class="nump">4.64%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451756127904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 38,893<span></span>
</td>
<td class="nump">$ 25,023<span></span>
</td>
<td class="nump">$ 14,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,671<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7,589<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 29,633<span></span>
</td>
<td class="nump">$ 18,645<span></span>
</td>
<td class="nump">$ 11,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757007488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax asset valuation allowance</a></td>
<td class="nump">$ 11,549,000<span></span>
</td>
<td class="nump">$ 18,237,000<span></span>
</td>
<td class="nump">$ 17,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">4,364,000<span></span>
</td>
<td class="nump">3,788,000<span></span>
</td>
<td class="nump">3,314,000<span></span>
</td>
<td class="nump">$ 2,019,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">331,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">288,608,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">10,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 5,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451760797328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Before Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (55,743)<span></span>
</td>
<td class="num">$ (55,010)<span></span>
</td>
<td class="num">$ (49,811)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">$ (55,743)<span></span>
</td>
<td class="num">$ (55,010)<span></span>
</td>
<td class="num">$ (49,811)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451753042224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of U.S Statutory Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="num">$ (11,706)<span></span>
</td>
<td class="num">$ (11,552)<span></span>
</td>
<td class="num">$ (10,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(2,311)<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
<td class="num">(1,852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(392)<span></span>
</td>
<td class="num">(2,893)<span></span>
</td>
<td class="num">(5,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">18,237<span></span>
</td>
<td class="nump">17,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_LimitationOfCompensationDeduction', window );">Limitation of compensation deduction under IRS Sec.162(m)</a></td>
<td class="nump">4,320<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">General business credits</a></td>
<td class="num">(1,536)<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">119<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LimitationOfCompensationDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Limitation Of Compensation Deduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LimitationOfCompensationDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757058608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 85,945<span></span>
</td>
<td class="nump">$ 82,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">10,753<span></span>
</td>
<td class="nump">8,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized start-up costs/Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DeferredTaxAssetsSection174', window );">Deferred Tax Assets, Section 174</a></td>
<td class="nump">12,892<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">2,775<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">10,353<span></span>
</td>
<td class="nump">8,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silk_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest limitation</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">126,104<span></span>
</td>
<td class="nump">114,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(122,993)<span></span>
</td>
<td class="num">(111,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease asset</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(1,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(1,475)<span></span>
</td>
<td class="num">(1,776)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,111)<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DeferredTaxAssetsSection174">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Section 174</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DeferredTaxAssetsSection174</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451760522240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of year</a></td>
<td class="nump">$ 3,788<span></span>
</td>
<td class="nump">$ 3,314<span></span>
</td>
<td class="nump">$ 2,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current years&#8217; tax positions</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior years&#8217; tax positions</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 4,364<span></span>
</td>
<td class="nump">$ 3,788<span></span>
</td>
<td class="nump">$ 3,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757073392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage employee contribution</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer discretionary contribution</a></td>
<td class="nump">$ 2,256<span></span>
</td>
<td class="nump">$ 1,872<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer contribution match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percent of matching contribution of the employee's pay</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451757873376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts - Schedule II (Details) - Allowance for doubtful accounts receivable: - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to expenses</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Write offs</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140451759595296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#+?XO=UQM:PO3R_G/M0AB#@+7-6T#2F)@W&X V-B/V5V.\\#,;0W4DS#('.
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M5"N _'W+N3A^42_H;]K?_1]02P,$%     @ 1X-<6./0LN">!0  F P  !@
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6RE5UUOVS84_2N$6W0OBBW+=F*W
MB8$DW; "*QHD[?8P[(&6KBPB%*F2E)WTU^]<RG+L+@V&[246/^[AN>=^D#G?
M6G?O*Z(@'FIM_,6@"J%Y.QKYO*):^J%MR&"EM*Z6 4.W'OG&D2RB4:U'69J>
MCFJIS&!Y'N=NW/+<MD$K0S=.^+:NI7N\(FVW%X/QH)^X5>LJ\,1H>=[(-=U1
M^-+<.(Q&>Y1"U62\LD8X*B\&E^.W5U/>'S?\KFCK#[X%>[*R]IX''XJ+0<J$
M2%,>&$'B9T/7I#4#@<;7'>9@?R0;'G[WZ+]$W^'+2GJZMOH/583J8C ?B()*
MV>IP:[>_TLZ?&>/E5OOX5VR[O=/%0.2M#[;>&8-!K4SW*Q]V.AP8S-,?&&0[
M@RSR[@Z*+-_+()?GSFZ%X]U XX_H:K0&.64X*'?!857!+BP[UZ(^IA!7K<>Z
M]\*6(E0DKFW=2/-X/@HXB@U&^0[VJH/-?@ [SL1':T+EQ<^FH.(88 2.>Z)9
M3_0J>Q'Q/>5#,1DG(DNSR0MXD[WCDX@W^3^.BS\O5SXXI,Y?SVG0G3!]_@0N
MI[>^D3E=#% OGMR&!LLWK\:GZ;L7^$_W_*<OH?_WP+T(^SSI\5#\.[D^'WS?
M*7TO;JTLQ$<J5"YU(CZ8?)@(ZPYM$K&57BB36]=8)P,5&,0-/F#$)[PG+;?2
MX=N(C]+EE<AB'J1GP\,3$U$!J: -.DT#&"D"Y96QVJ[Y>/TH9+&1)J<BX4I2
M-<^=*+.1'HU!>*O;Z" ZG6C@*YG@48VA$KET-B@@ND#N413*$QJ!V%96,"T9
MA%/^/AHB6^P]'?'ZR0MX%DJKE65W&F>+-@<V&;G2,.<9L&H!A99$SH%\ +07
M2#WCOSO=$0CGK99.?8L1B8I^OKZ\32 ;N.2V7G%THH@K,E2J$"-%IK"];:>-
M^MIB'T?4MRZJ!"Z(A6HT^2,GT'-,6Z(0P')G@4[J^UA],8HC=\<APV3XSF5F
M]^3WME*((2M7D%=KT[F+Y8TJ,*<<.C;:=<X)A@7&/]8@$526%/LYY&!0CANH
M=.IWT0B5L^VZPD44$?8:)Y&]MF9] JP: %SAR@0FVI_3: EICA6 KC6Y7$FM
MOG&6LI.]2\_*L**U,D:9-2]K3N8L'<^&XC?(K@H5'E$0G7>V=3ZF.H/&BTHA
M_WQR5%Q55R=MS ]MO=\%PM!:1BERZ2M1XIKUHG2V%J@"%S/$"Y1K3A&=/QJ>
M'(I+WU573O6*W+ZY?G\J5.?;,V_K5L?ZQ*6G<A7U>BTFBT4RG<V2-$W%L5[T
MT!!K@Q!&VCWG<M< \(L&0[$&RI83Z]A^15JAF#F/4<J1?/20?8X?!!DW4L<Z
MY4FYD4HSW F@3SQ6D*0X.&K9L1TOTF0Q22-;^2/WL;!%<O,O']KY ;]1>62X
M8+9*ZWV^^K9D.< "7I@B^HO.@FY^*",F>;7+&BT-)WT,)>?=4YQZ;0P]!(%+
MM.XNT1A.GE?>M]S"=HT725,J@PDD9=<O:U9C*&[:E5:Y^(0R<9R 2+1/>;#L
M)WS,CD.,Q$:]LX<(-$B2VT*S0$8T'8SM87!JEIR>39/I>"%\)5VG:PP-JL-R
M!=K\GCNB_(<Q.DM'_+683H8( -SN0+JX[_"0*[J%KC%%6@A-#UQUOO?YB2$Y
M_^;5/!N?O8.$L05P&VEQ07!WYJ0M4&68ASB3Z3R93\[Z0["+A0Q]?]EC,E&Y
M=A2%/,Y'M"5"F>V2+_83*J+_LL'H 1=*(-PRR+)TGBP669=E)7BB9&*7 OC1
M2;A)4/M]_K*$"'!,A&=09\G9;)>YV,Q9:3P]NS.;S7?U^-Q#8W3P6D1#6\<W
M,0<01+J'XWYV_^R^[%Z;3]N[-SMN8[0X+S25,$V'9[,!FF]\!W>#8)OX]ES9
M@)=L_*SPKP,YWH#UTMK0#_B _3\CR[\!4$L#!!0    ( $>#7%C+Q(<"'B,
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MP*;J$I\;8#\\C^C9AJD XFL#.F"9] F)N<XLBI?*V.)W9!+2]#*HPJL6K/G
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M.;8D*9L!K-<T%1E8H"V)\+PN',A+:XSKI_HIRB?F_!PV<@?,,W\%4PI,V1E
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M;;H[;5N2U*@(\EV/&8D!C!B$> VR>@,J?<@' ?:7:!GVF+.#>(?YDVQL@IC
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M1#]B855;? "^7W=@S^07G"#\X;D?_Q=02P,$%     @ 1X-<6%'+M +H P
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M,.)^GB]JH@"KN^0N!721MWNM<^XX%U(1KB5#7+1: F.0 +3HHBE+NLR$*<M
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MD?4;;?>H]C+KSM0YA>USJ EG<#H8EU0V!"RCE$Q$,ROWXI[<FL#%Y 1CBEF
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M,34N>&ULQ99+<]LV$,>_R@Z3R8DC/O2B'$DSMN-.>\A48R?-H=,#1*Y$C$&
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M2[/?('9: ZJ^:AHY[8U<U$2*X[-5DN1M0>^!+IQ=4F[<4I%^E"2W27V#;&_
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M]$_4S\[ZA[;:\D]@KZNVK3;\YUHF@',:@.^KJFK[!UI@^$WTZ_\!4$L#!!0
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M0FL:@/=+8WQ[0PMT'VFO_P=02P,$%     @ 1X-<6 ^T.$M5 P  S0<  !D
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MHMF&A\02UT&Y.&TG[_16W<01_10>'[KWS-!Y6Q#84FH^>WV1@(F/1S2<[L/
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M:N@Y4\)H#23?[;).YA)L'TP%$QUJP/=6-]JHNC[B[_K0\?,X_GU3X:=;7(N
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MOS\1R;TS7D7]VY!7B4^2"254UY#+1RPMV0J18*24N-":5+ZC-BK(P>6)?Y+
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M1HJ1PO?6Q!:V4^BI_8LQ$:SFB<).@Y+KE/KCZ!B'M%  8.R"@NNO-VY"K/U
M/13 H^ 2:IGX2SIY=@37.I1HE!(W#I3=N/J=H-FC&LG8T&;R"D08U5]'G0I<
MMDV80D."*;[RI!QJU7C@ "FP4[\'."DJ L+Z%6!<Q2E%E5C>ZZ/$<V<0/"(!
MR5A: 2$NE#Y9X&*8Q:J$!,<S?VD:>([C0MO9<K[OC"3C-&,]Y,%D\]X?)5Z
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MX #X?=."J)4/N(!_D_.+_P502P,$%     @ 1X-<6-4H<2JL P  )0D  !D
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MRP!WO[8;8>;3#(XP%W-6?H:'3NA#S_?]DUMB=TE1#"CJE FA:$I'=?"<QT/
MPB#RTKA#CP-/D <./?8@SN)O0$_OY9?0D^1>%*1?76CECM2Y9*ASR7?4.:?9
MFZ-F7J_11ZL1:ZL.O^[IA.I<[1N]]9MKW_,4 ,XWUB5 /6+8+M&^S4JT!%S3
MGC-E@Y#[7A9G)WYZQL06\/&1QZR4W"Q79';2;1PR\A#NIYDY2!X)0#H$(!T-
MP'A; 0Q.\]TF-#U(+>R$=<[MHW?]"[>_Y[C8K%A+F#::;MHXM^?R#! _@=53
M]4>.SE<"ZVTOC\,NM9*N+GMQX7<;MBX\JSBH1"DRM*=_6GA&"LA3TBSRHK 8
MRLE+=>0IFZTA<5]/SO0C5+XBC0_-Z"GS 6Y V\'*OAUEJ9<'T;'&C. O&_"7
MC>+O$:\=U:9VZ6^!UQJI8-$Y<(T*^F9P.3Q]8#N;C5PA9#;"*0J[#7#L%;#O
MK6@%1NR*UDI6FQ)I$"(,<%@0>U'N]PX21VTM1@I7HUTC#HNQJ34?/)./>N9!
MX55,F;U'#QA?C:M_MNJM+6;.^6=4W/?YY^U&M0+%BKM;%^*+73LS/3\)70+D
M(!O4H<1UWL3SXY0>Y<+L&'A#]#'[]QYMFZ]D79%HX-(M[VH+QJ4TP&\(GB!!
MPB36P7'@N]2^HEE9;II-[>:+BD-I))A[M0,>O<+/ ,E7N#)*;([-J@J=3;:8
MYS?N!?!"M!>X;*ELF8@BC(S!8>!:]YYUQO&##1ZU&$I^I-P+7!_%2)B%(W$L
MAC@6WXQPF*0VMMP(AAG&Y>ZY2(X*_+Y('FY<L[V2=>U,5KQS*O^"=WWMXHK9
M-7"9C4"$:/5_P$%P-GI5;8-'=:_P'I'/T()L18P'X7B'VO+Z**_ 68;1ZG N
M6J0:>HK5PO8:2A"+)"@(&-\*]\*_D(HTNH^&=@ ;IL<$DU$2^X,0)?>LA@+]
M+13["14H3(=S5C4V;XWJ0++@D&6M/4B=,U?ZP!5ALA_\HN0"" $'@&%]*4K[
M/A"FE*'"':A*Q$"4[,3$$/TYC NX?<&5LNIQE ,TE0 U-4R.:DF\O*D3/E2'
MA.)A^&<]67U$A$VSV$O];H1 I4[.H7!Z\A$ S6?I/G5H*NVHT7T/&':'KRFS
M[B/"D;S[%/,[4TL[K]=\ 5;_,L/TI+K/&]V#D6OW26$NC9&-6ZXXJ[BR!#A?
M2+25_L%>,'QCNOT?4$L#!!0    ( $>#7%@U';>XM (  -H%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;(U4VV[;, S]%<(;AA7(ZEOB-%EB(%E7
M;$ +!+UL&(8]*#83"[6D3)*;]N]'R8F7 6FP%YNDR,-#2N1DJ_2CJ1 M/(M:
MFFE06;L9AZ$I*A3,G*L-2CI9*2V8)56O0[/1R$H?).HPB:(L%(S+()]XVT+G
M$]78FDM<:#"-$$R_S+%6VVD0!WO#+5]7UAG"?+)A:[Q#^[!9:-+"#J7D J7A
M2H+&U328Q>-YW_E[AV\<M^9 !E?)4JE'IWPMIT'D"&&-A74(C'Y/^ GKV@$1
MC=\[S*!+Z0(/Y3WZE:^=:EDR@Y]4_9V7MIH&%P&4N&)-;6_5]@ONZADXO$+5
MQG]AV_JF@P"*QE@E=L'$0'#9_MGSK@\' 1?1*P')+B#QO-M$GN4ELRR?:+4%
M[;P)S0F^5!]-Y+ATEW)G-9URBK/YM9+K#Q:U@$M<6GA_SY8UFK-): G<N83%
M#FC> B6O ,4)W"AI*P.?98GEOP AL>JH)7MJ\^0DXB46YY#&/4BB)#V!EW:E
MIAXO_;]2?\Z6QFIZ%;^.%=M"]8]#N4D9FPTK<!K0*!C43QCD[][$6?3Q!-%^
M1[1_"CV_:FRC$1;LA5Z_A0?JIP9;(=P[\M>*R6.,3V(>9PP_D&EW7URNJ2D%
MBB5E2N,QS(1J*#5UO@]O8= ;QB.G#)P8I4[,H#_H92-O'D+:[PWB(8SB7I9>
MP*PL":(H-/K)4RLH:F5<DA6B@;B7)B,8);U1-H1K-*;+I]&3D];Y<DF7A88>
M)<29QST[X5VZ.RVY*?P1DV5KX<8T3!8(A3+6$)2C?P:+-A">6-V@(TBCQ44C
M8-,VW5#50ZHOR8[=9W@P;P+UVF\5 SYU.WJ=M5M<LW9>_[JW6^^&Z367!FI<
M46AT/J0]H=M-TBI6;?ST+I6E7>#%BI8O:N= YRNE[%YQ";IUGO\!4$L#!!0
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MJDNQ>4=B>QB#&F/0ICZ]#L,B+1*J(-)%AH5,-<%K%3D57BDV,&*ZFF^F'_W
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MR'_1NF@[&#@H6@K)TC)8C2 EM/C'+Z406P$=[YV H P(W@0$P3L!G3*@<VA
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MD!"\(L$/X*/@NE+P/2]I>4C@HA^3*<&S*7?!2<:<%M<0^E<0>$%H2>C^_/#
M$IZ?'^Z?4!-.6QSV?.%_W^+?;Q^5EG@7_[!MP_":R/X:4Y]N5$L*NG"P "DJ
MM]3)OOW&3[SO;!9^3;+\*Y$=V!M-]D:GV#-S$VJ\"3;'ALA9'VD*\#9['\>S
M",_4=M\+*\SSO4-8;H%%'U+?GV '^<=3_O')_#_WI9&60+948J6'0C0-5F0L
M/<43X)=":;R7YIAT"E%:&$#;:0I\5 XMUH#^6E^9&LP*N, ;/=SS2YLM0T+)
MGI P3;TH?&&,!1C/9G$R"XZLL0"C)(S#.+6;DTSF)/^C.26K.T/VACW)N?98
M@'9[+,"3]LPF>V9GG?T7)\ F:Z#ZL']\_>LH.M)D1<5'J/PMK@,UZ:0F_==J
MQBVSZ4G/TF-%O=#S%M>@Q]W[SC=4;OI^24%?QX>OV[0ZM62W?2=RM'Z'K=K0
M6?U#,_1Y'XG<,*Z@IFND]*YG>+/DT#L-$RW:OIMX%!I[DWY88;M)I0'@\[40
M^GEB7C UL-G?4$L#!!0    ( $>#7%AY?02(IP,  #0/   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;,U736_C-A#]*X0*% G01I^6I=0VD%@I-D#3
M&C&V/2QZ8*2Q380B59**L_^^)*4HEJ,864"'7&R1G/<X\X9#:69[+A[E#D"A
MYY(R.7=V2E67KBOS'9187O *F%[9<%%BI8=BZ\I* "XLJ*1NX'FQ6V+"G,7,
MSJW$8L9K10F#E4"R+DLLOE\#Y?NYXSLO$_=DNU-FPEW,*KR%-:BOU4KHD=NQ
M%*0$)@EG2,!F[ESYEYGO&8"U^)O 7AX\(Q/* ^>/9G!;S!W/> 04<F4HL/Y[
M@B50:IBT'_^UI$ZWIP$>/K^P_VZ#U\$\8 E+3O\AA=K-G<1!!6QP3=4]WW^!
M-J")X<LYE?87[5M;ST%Y+14O6[#VH"2L^<?/K1 ' #]^!Q"T@. 8$+T#"%M
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MFJ:?O,-B2_3KGL)&4WH74_T&%4V+U@P4KVS3\L"5;H'LXTZWM2",@5[?<-V
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M>8+*XJ-K/IY+&6</Z(3E<?X!O3_C!8L3]>K3RL6?ESR]X_*7.GE[<X;>O_N
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MV*F"<X5F%D\K. R*'(#6L&/K-'V+^!YNT=YX9:[UBH9ZX-GX&=U5.B5[5:?
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ME1=($X#?%T+HNXZ9H*GEXK]02P,$%     @ 1X-<6'_:?]"&!@  WB@  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULM5I=;]LV%/TKA%<,'5#'XH>^
M.L= DZQ=@&8(ZJ9[*/8@VTPL1!)=BG::_?I1LFI:(L5(G?R26/;EU;G7Y#F'
MM*9/C#_F:TH%^)XF67X^6@NQ>3N9Y,LU3:/\C&UH)C^Y9SR-A+SD#Y-\PVFT
M*@>ER00YCC=)HS@;S:;E>[=\-F5;D<09O>4@WZ9IQ)\O:,*>SD=P]..-3_'#
M6A1O3&;33?1 YU3<;6ZYO)H<LJSBE&9YS#+ Z?WYZ!U\>TF"8D 9\26F3_G1
M:U"4LF#LL;BX7IV/G (13>A2%"DB^6]'+VF2%)DDCF]5TM'AGL7 X]<_LK\O
MBY?%+**<7K+D[W@EUN>C8 16]#[:)N(3>_J35@6Y1;XE2_+R+WBJ8IT16&YS
MP=)JL$20QMG^?_2]:L31 $A:!J!J .HZ %<#<%GH'EE9UE4DHMF4LR? BVB9
MK7A1]J8<+:N)L^)KG LN/XWE.#&[B)(H6U(P+^?,)4LW+*.9R,'K]U',P9<H
MV5+ [L&[710GT2*A8]F]\3Q**+C.=C07:1']&WA]186,D*_&X&Y^!5Z_^@V\
M G$&/J_9-H^R53Z="(FWN.MD66&[V&-#+=BNZ/(,8/@&( =AP_#+[L-1??A$
M=NG0*G1H%2KSX=9\"P'F=+GEL8AI_N:H)W(YC?.B)U\_RD'@6M T_\=4\/X.
MQ'R'8LF^S3?1DIZ/Y)K,*=_1T>S77Z#G_&XJ?Z!DM6;@0S.P+?OL7<JXB/^E
M*SEG<F$J=3_>+\<79+*;P="!&$XGN^,B]# $L4=46 T>.< C5G@?.,MS<)=)
M9DM*E!\DHQFGX#Z/=PR3N V,IA@S/O> S^V'[Z.\ID: KG;SL8\;  TQ,&AI
MH7> Z%DA_I&+6-*DQ*:8P(3/TYL3.LAI0M3#Y/=,_)8^^@>0OA7D992O ?VV
MC7=R]4DB,@'T#0!)T,2G1[DN= ,SO.  +[#"FZ_E*AD+RE-)A0>V-($,=) >
M1!YIH#2$N0&&GAEF>( 96F%^9-G#'N6U'66HW3XDKM? :+W73](2=)2>.=9:
M/C,1)4:M<;I-5$.<;:;"(Z6%5F0W4EF?P4W$'Z72OM]*201?;VBZH-PH%?9L
M?;5BJ&SUVI5TPM-K)QQ4/(?*5F^(DD_X?_6S2O 2;QG"+,0%E8!"NX)VI7]H
M$$<33#W,!E/I*+0+Z=T<?)8BFF_Y,[B(D^2%-65-UGL*#92M7KK29^B=?DU9
M/4#OA@R4K=X0Y06@W0QT6%,&+P"#L*E@IK#0]U'+9%5N -KM0'=7"G6AUU:4
M'M(F4<H'0+L1Z+SH=2-0]#%L0C2$R3ZVN!6D-![9-5YN4U/*EW&4@-MH0[EU
MS=MS]=YS#92M7KGR$ B>?@\ZJ+$8*EN](4=[<JM.=UCS58+:4I*.V6G,54,8
M"0+?;9FK2NB17>B[KWED4/(F2.N]?K;9RA.@GKOJ]ETKTO5^#+5RK+?[V7*4
M=T!V[]"5[9"^O98SR-5FD!YFFT%*YY%](W[)^(9QB1-<,+EIF/S%!+7;''O"
MWBO\%*J.E*HC__249S4.O1LR4+9Z0Y2+0'87T8'R#.XAQ&'0G+"FTP348LF1
M,A'(;B)Z,)[N#UR-(TYQG("5U<!VJ]&#\K!^<*!3GC$(FUN.E2W ]J.%KDQ6
MI:E/#(*;$\,0!EW80F18:36V:_7=V?P,?& [RK/BA.EH45O9S)ZU[^(=*EN]
M!T?'YOCD;(8'<@%50T[A*;#R%-CN*3K\D& X8?!=1_LA00\+,,$MFS:L7 +N
M>53?2F=8-P :G1EBVA J@X#M!J$/1PWJ#+!^J#^&7LLN%"O%Q_9]?&<V,VS3
M?5<[CS:$!1CY3@M,I</X!1V631;CBVCY*)%VY3)KRM[]'RA;O0%*Z'%X>BX;
M2-ZKAIS"+!!E%HC=++S,9?8$?<LEAI\J'*=E8A/E)HC=3?3@$WNFWO7HOF/<
MPB9$N0YB=QU=V<2>IG<I^G$"#,.6DR^B[ -YX6>#!YHMG\&BW AF+VX$[=EZ
MUW0*IT".?M(G)Z<;,M")0]604YQ?$.5,B-V9=* ;W6UX@1<VCY(-82AH.Z8E
MRI>0GKZD_2$,P],!?A.D'M.R527*:1"[T^C#=+J+&!.MD:<X&2#*D1"[(^E,
M=?LT?GU:^%K']3 4!$U"GAP]?%8\^7<3\0?Y-8.$WLMASIDO)Q??/TRWOQ!L
M4SZ/MF!"L+1\N:;1BO(B0'Y^SR2O51?%(VZ'1QIG_P%02P,$%     @ 1X-<
M6##*G_B< @  W 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULK55=
M3]LP%/TK5H8F)@%)D[0%ED:"=FA(FX0HL(=I#VYZDUCX(]A. _]^MA.B @'!
MM)?$U[[GY)QK^R9IA+Q5)8!&]XQR-?-*K:MCWU=9"0RK U$!-RNYD QK$\K"
M5Y4$O'8@1OTP""8^PX1[:>+F+F2:B%I3PN%"(E4SAN7#*5#1S+R1]SAQ28I2
MVPD_32I<P!+T=74A3>3W+&O"@"LB.)*0S[R3T?%\;/-=P@V!1FV-D76R$N+6
M!N?KF1=804 ATY8!F]<&YD"I)3(R[CI.K_^D!6Z/']G/G'?C9845S 7]1=:Z
MG'F''EI#CFNJ+T7S'3H_3F FJ')/U'2Y@8>R6FG!.K!1P AOW_B^J\,68!2_
M @@[0/A>0-0!(F>T5>9L+;#&:2)%@Z3--FQVX&KCT,8-X787EUJ:56)P.CW%
M%/,,T-(=F;E@E># M4*[9YA(=(-I#4CD:(Y5B;[=U62#J5W?,P@A]?X52(8P
M7Z,?@A=M=,XWH#2S65_0[@(T)M2,]M'U<H%V=[Z@'40XNBI%K0Q0);XV/JP:
M/^LTG[::PU<T+R [0-%H#X5!& W Y^^'AT_AOJE>7\*P+V'H^**/EO#WR4II
M:0[JGR&/+6D\3&HO[[&J< 8SS]Q.!7(#7OKYTV@2?!UR_)_(GOB/>O_16^SI
M"1.UM6ON5"T)+\P)UJ7985,%] !8#IEO&:>.T3::33HZ#*;Q-/$WV[9>IH6C
M*)[&?=H3P7$O./Z88)QKD+U>I$LIZJ)$NA%N8O"(MI^8;$D[BL>39_K?U/&/
MVS+N78[?='DE-*9#RL<O:W\4A$'T3/O+M,':^UN]Q_;]GU@6A"M$(3? X&!J
M>&3;2]M B\JUHY70IKFY86E^/R!M@EG/A="/@>UP_0\M_0M02P,$%     @
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MABB;C6QVX6KCT.B&"?L5ET;A*4.<22\HIR(#LG179B[+2@H01I/#)5Z8O.9
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M*Z:V3 3@<9844]MUG)8=8\*LH)>-#430XZFBA,% ()G&,1;/%T#YHF\UK.7
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M:5L_NB(O.O..XDE6MXVXTE5@UISI0AV$"=#S$\[5LF-*P;+T#_X#4$L#!!0
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MA6R<].5&]K; U 3Y?$6I>!FH[JGNEJ._4$L#!!0    ( $>#7%A>SUW<!P,
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M&J?NJG$;R]<'QO?U=\2W>E8O-WZ\I\&S?2E&NTM4BU%-H)JLM6;N_&$P:-^
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M7_.$T??\(C_^LBHV%.<+>FLR/OQJ$&;<#O6A&2HZ,E2(P*<B9RL*HGQ!%GT
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MH&'@>(XGD*#\[7,7/YU@D2:P'N?0ZMI1:SSK:ZXF "O *[]XBO@6]_3CIQ[
MN=1K18MTH?7)/] "4-D"?J]E%:?__I647":"J%U P&.9Q$1*.]39$FI%FVM%
MBW2A]7.#NMR@"_K"2G"M>==>3PSYO&A@PX-Y@1P#B2N[S,PR'+'YD9A!SW"%
MZA:I8[F4JT[)0&6'+FT/1S#5@$)T6$)L0^SL9E([W_#$)DAFY]I&Z(AD_0JY
M 3N] =6"0]XLCJ#+&8;G&\Z@W,K-D$B6W$Q<Z]6Q7,I5)SO@.-W1[QE'<.4.
MHW-\PPI%LF1VT(">R);,SC)LD:U?(4)@IT*@6H9(VL<15'G#T)!K6(."Y8VI
M:W.9V;"N11*S?EWK4]!I#*@6&8HF<@05OH0*9'@#*C1IA)8QG6B1+K0^_YV
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MF]T[S0DKUO7VE.>"L2*K#U<$+TA9&?#[+T7!=B?5#^SW4$W_!U!+ P04
M" !'@UQ8D>U4KHL#  !(#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6R]5UUOVS84_2N$.A0)L%H2]6$EM07$EH;EH:N1K"N&80^T=&T+D425I.WD
MWX^D9-5V9-4IC+W8)'7/X;WG7GZ-MI0]\16 0,]%7O*QL1*BNC5-GJR@('Q
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M0;4/DJQA!G#2:H5J-8B$U8SAPRXI29SM&],N*4D8(WKJ>0U;;P*5RVW)<F8
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MQ8MHPO._8%^T]2<6B+9<T+0TEB-(25;\1X<R$$<&T'_%P"T-W)<&@U<,O-+
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MQDPUD.^7E(KG&]5!=?0\_P902P,$%     @ 1X-<6!=QZQ69 @  ;P<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULK55=3]LP%/TK5H8FD ;Y+##6
M1J+-IO' A"AL#],>W.2VL7#LS+YMV;^?[:19RT+5!UX2?YQS<L^-?>]P+=63
M+@&0/%=<Z)%7(M97OJ_S$BJJSV0-PNS,I:HHFJE:^+I60 M'JK@?!<&Y7U$F
MO'3HUNY4.I1+Y$S G2)Z6554_1D#E^N1%WJ;A7NV*-$N^.FPI@N8 C[6=\K,
M_$ZE8!4(S:0@"N8C[SJ\R@86[P#?&:SUUIA8)S,IG^SDIAAY@0T(..1H%:AY
MK6 "G%LA$\;O5M/K/FF)V^.-^A?GW7B940T3R7^P LN1=^F1 N9TR?%>KK]"
MZ\<%F$NNW9.L6VS@D7RI458MV410,=&\Z7.;ARU">/X*(6H)T4M"\@HA;@GQ
MH82D)20N,XT5EX>,(DV'2JZ)LFBC9@<NF8YM[#-A?_L4E=EEAH?IC<AE!>2!
M/H,FIV0BJUH*$*B)G)-V<PSF>&TPQQD@95R?&/3C-"/'1R?DB#!!'DJYU%04
M>NBC"<S*^WD;Q+@)(GHEB# BMU)@J<EG44"Q*^ ;1YVM:&-K'.U5S" _(W'X
M@41!%/<$-#F<'O70L\/IX1XW<?>38J<7'_*3?E[/-"IS7W[U);H12OJ%; VY
MTC7-8>29(J%!K<!+W[\+SX-/?4EZ2['LC<1V$IAT"4SVJ:>/@B$49(H4H?=\
M-O0+1[>5<I6>#@87B3DZJ^V$],*",-B%93VPY.-E&':P'1.#SL1@KXEOI@EP
MJ369-?>1-:<"[:GH\S0XS%,O[']//; ^3_Y6*:I +5Q)UR272X'-]>U6NZYQ
M[8KEB_6QZ29-\?\GT[2B6ZH63&C"86XD@[,+$YIJRGLS05F[@C>3:,JG&Y:F
M(X*R +,_EQ(W$_N!KL>F?P%02P,$%     @ 1X-<6!(^+/C. P  A P  !D
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MKQ>O#EM!V*0,>V(*JD+QS2AZUTWDGJ1T9L&VDE0<J97\_AL.G#],(?XBL*N
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MZDY6#13?E]>:%5=P22H?=W"/I4(;P/<-Y^IUH&]*S<TX^1]02P,$%     @
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M1$^X$T;D0@I3:?)1E% ^)O!1VR P>A XC_8RYE <D3@\)%$0Q2,.G3\?'HW
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M'%N4KJ/X1]/U-Q=4X0>K"8<E4@9'*9::ZGJ&;F)DXU[1&VGP37;#"MLL4-8
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ 1X-<6,<1L2B%"   HS0  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $>#7%AR<,:+YP4  &<9   8
M              " @<D0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !'@UQ8AW?;X4(#  #"#   &               @('F%@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 1X-<6+J<PQ^:!0
MG1@  !@              ("!7AH  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( $>#7%A5F,7+@P@  .Q%   8              " @2X@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !'@UQ8J;W'
MT6@"  #O!0  &               @('G*   >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ 1X-<6.4P470_"0  =2\  !@
M ("!A2L  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( $>#
M7%CCT++@G@4  )@,   8              " @?HT  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !'@UQ8R\2' AXC  "$;@  &
M        @('..@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ 1X-<6%'+M +H P  4PD  !D              ("!(EX  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !'@UQ8/#'LI(0&  "K$0
M&0              @(%!8@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( $>#7%B$RR=+?P<  +(3   9              " @?QH  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 1X-<6'NQT%=A
M#   C2,  !D              ("!LG   'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !'@UQ8''WE.YH(  "N%0  &0
M@(%*?0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( $>#
M7%@G;?LZY0,  +$)   9              " @1N&  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ 1X-<6 GSCC/^$0  'ST  !D
M         ("!-XH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !'@UQ8JEB:U2 +  "P'0  &0              @(%LG   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( $>#7%@/M#A+50,  ,T'
M   9              " @<.G  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ 1X-<6!?P8I\U P  <@<  !D              ("!3ZL
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !'@UQ89,=(
M7Y8D  #5>0  &0              @(&[K@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( $>#7%C5*'$JK ,  "4)   9
M  " @8C3  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M1X-<6!+9+KH[ P  . @  !D              ("!:]<  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !'@UQ8,1ZB!-D&  !O$@  &0
M            @('=V@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( $>#7%@U';>XM (  -H%   9              " @>WA  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 1X-<6'R^DCX= P
M9@<  !D              ("!V.0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !'@UQ8?17]:MP"  !.!@  &0              @($L
MZ   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( $>#7%B#
M$PR!J0<  +H;   9              " @3_K  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ 1X-<6 J(,_UD!0  /0T  !D
M     ("!'_,  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $>#7%AY?02(IP,  #0/   9              "
M@<,( 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 1X-<
M6%OD$$TX!@  6S,  !D              ("!H0P! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !'@UQ8-L_[30T#  #7"0  &0
M        @($0$P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( $>#7%A_VG_0A@8  -XH   9              " @506 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 1X-<6##*G_B< @  W 8
M !D              ("!$1T! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !'@UQ8G=(6L4($  "#&   &0              @('D'P$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( $>#7%B.173,
M=P(  %H&   9              " @5TD 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ 1X-<6)K>3MOK P  ZQ,  !D
M ("!"R<! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !'
M@UQ8)!%$/Z0#  !B#   &0              @($M*P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $>#7%@?BDG.W@T  -&N   9
M          " @0@O 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ 1X-<6"U0]<@C P  ]P@  !D              ("!'3T! 'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !'@UQ8Y3N71DL$  #3
M%@  &0              @(%W0 $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( $>#7%B5HY%Q4P,   8,   9              " @?E$
M 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 1X-<6"-#
M)9 1 P  .0L  !D              ("!@T@! 'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " !'@UQ87L]=W <#  #E"0  &0
M    @('+2P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M $>#7%B/U"L)A@,  &40   9              " @0E/ 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ 1X-<6$K;3>)M%@  EE\! !D
M             ("!QE(! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !'@UQ8U:'8T(,#  !-"P  &0              @(%J:0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( $>#7%A&A0/]-P8
M $\E   9              " @21M 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ 1X-<6)'M5*Z+ P  2 T  !D              ("!
MDG,! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !'@UQ8
MA"+[Y3$&   A*P  &0              @(%4=P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( $>#7%BTI<']_P0  % C   9
M      " @;Q] 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ 1X-<6&1=0U3$ P  +Q(  !D              ("!\H(! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !'@UQ8\7"^J<D$  "&'@
M&0              @('MA@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( $>#7%@7<>L5F0(  &\'   9              " @>V+ 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ 1X-<6!(^+/C.
M P  A P  !D              ("!O8X! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !'@UQ8T+G@6!D$   E#P  &0
M@('"D@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( $>#
M7%BHT(J9-@,  ,0)   9              " @1*7 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ 1X-<6.%7D7KK @  " H  !D
M         ("!?YH! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
M    " !'@UQ86=:SB24#  !O"0  &0              @(&AG0$ >&PO=V]R
M:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( $>#7%CZ5J690@(  )$&
M   9              " @?V@ 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL
M4$L! A0#%     @ 1X-<6*UGKAPV P  [!,   T              ( !=J,!
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !'@UQ8EXJ[',     3 @  "P
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52P4&     $< 1P!H$P  .K$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>231</ContextCount>
  <ElementCount>397</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DocumentCoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompany</Role>
      <ShortName>Formation and Business of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureRecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureLongTermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/Disclosure401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Schedule - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureLongTermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlans</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Formation and Business of the Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails</Role>
      <ShortName>Formation and Business of the Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompany</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Net Loss Per Share Determination) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Net Loss Per Share Determination) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Balance Sheet Components (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails</Role>
      <ShortName>Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40505 - Disclosure - Balance Sheet Components (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails</Role>
      <ShortName>Balance Sheet Components (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40506 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Components (Property, Plant and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40507 - Disclosure - Balance Sheet Components (Accrued Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components (Accrued Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Long-term Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails</Role>
      <ShortName>Long-term Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Long-term Debt (Future Payment Under the Term Loan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails</Role>
      <ShortName>Long-term Debt (Future Payment Under the Term Loan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Commitments and Contingencies (Balance Sheet Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Balance Sheet Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Commitments and Contingencies (Operating Lease Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails</Role>
      <ShortName>Commitments and Contingencies (Operating Lease Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Stockholders' Equity (Shares Reserved for Future Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity (Shares Reserved for Future Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stock-Based Compensation Plans (Information by Exercise Price) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Information by Exercise Price) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40907 - Disclosure - Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of U.S Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41101 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/Disclosure401KPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/Disclosure401KPlan</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41401 - Schedule - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="silk-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>silk-20231231.xsd</File>
    <File>silk-20231231_cal.xml</File>
    <File>silk-20231231_def.xml</File>
    <File>silk-20231231_lab.xml</File>
    <File>silk-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="silk-20231231x10k.htm">silk-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>silk-20231231x10kg001.jpg</File>
    <File>silk-20231231x10kg002.jpg</File>
    <File>silk-20231231x10kg003.jpg</File>
    <File>silk-20231231x10kg004.jpg</File>
    <File>silk-20231231x10kg005.jpg</File>
    <File>silk-20231231x10kg006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="888">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "silk-20231231x10k.htm": {
   "nsprefix": "silk",
   "nsuri": "http://silkroadmed.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "silk-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "silk-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "silk-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "silk-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "silk-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "silk-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 348,
   "keyCustom": 49,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 29,
   "hidden": {
    "total": 21,
    "http://xbrl.sec.gov/dei/2023": 7,
    "http://fasb.org/us-gaap/2023": 14
   },
   "contextCount": 231,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 579,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 888,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://silkroadmed.com/role/DocumentCoverPage",
     "longName": "00090 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://silkroadmed.com/role/StatementBalanceSheets",
     "longName": "00100 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical",
     "longName": "00105 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity",
     "longName": "00300 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquityParenthetical",
     "longName": "00305 - Statement - Statements of Stockholders\u2019 Equity (Parenthetical)",
     "shortName": "Statements of Stockholders\u2019 Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_10_31_2022",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://silkroadmed.com/role/StatementStatementsOfCashFlows",
     "longName": "00400 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompany",
     "longName": "10101 - Disclosure - Formation and Business of the Company",
     "shortName": "Formation and Business of the Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://silkroadmed.com/role/DisclosureRecentAccountingPronouncements",
     "longName": "10301 - Disclosure - Recent Accounting Pronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://silkroadmed.com/role/DisclosureFairValueMeasurements",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponents",
     "longName": "10501 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://silkroadmed.com/role/DisclosureLongTermDebt",
     "longName": "10601 - Disclosure - Long-term Debt",
     "shortName": "Long-term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://silkroadmed.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "10701 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://silkroadmed.com/role/DisclosureStockholdersEquity",
     "longName": "10801 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlans",
     "longName": "10901 - Disclosure - Stock-Based Compensation Plans",
     "shortName": "Stock-Based Compensation Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://silkroadmed.com/role/DisclosureIncomeTaxes",
     "longName": "11001 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://silkroadmed.com/role/Disclosure401KPlan",
     "longName": "11101 - Disclosure - 401(k) Plan",
     "shortName": "401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccounts",
     "longName": "11401 - Schedule - Schedule II - Valuation and Qualifying Accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://silkroadmed.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables",
     "longName": "30503 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://silkroadmed.com/role/DisclosureLongTermDebtTables",
     "longName": "30603 - Disclosure - Long-term Debt (Tables)",
     "shortName": "Long-term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "30703 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://silkroadmed.com/role/DisclosureStockholdersEquityTables",
     "longName": "30803 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "silk:ScheduleOfCommonStockReserveForFutureIssuances",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "silk:ScheduleOfCommonStockReserveForFutureIssuances",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables",
     "longName": "30903 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://silkroadmed.com/role/DisclosureIncomeTaxesTables",
     "longName": "31003 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails",
     "longName": "40101 - Disclosure - Formation and Business of the Company (Details)",
     "shortName": "Formation and Business of the Company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "silk:CashCashEquivalentsAndAvailableForSaleInvestments",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:UnbilledReceivablesCurrent",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:UnbilledReceivablesCurrent",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Net Loss Per Share Determination) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Schedule of Net Loss Per Share Determination) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails",
     "longName": "40204 - Disclosure - Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails",
     "longName": "40401 - Disclosure - Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details)",
     "shortName": "Fair Value Measurements (Financial Assets Measured on a Recurring Basis) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails",
     "longName": "40501 - Disclosure - Balance Sheet Components (Narrative) (Details)",
     "shortName": "Balance Sheet Components (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
     "longName": "40502 - Disclosure - Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)",
     "shortName": "Balance Sheet Components (Fair Value of Available-For-Sale Investments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails",
     "longName": "40503 - Disclosure - Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details)",
     "shortName": "Balance Sheet Components (Fair Value of Cash Equivalents, Short-Term and Long-Term Investments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
     "longName": "40504 - Disclosure - Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details)",
     "shortName": "Balance Sheet Components (Available-for-Sale Investments in Unrealized Loss Position) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails",
     "longName": "40505 - Disclosure - Balance Sheet Components (Schedule of Inventory) (Details)",
     "shortName": "Balance Sheet Components (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails",
     "longName": "40506 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details)",
     "shortName": "Balance Sheet Components (Property, Plant and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails",
     "longName": "40507 - Disclosure - Balance Sheet Components (Accrued Liabilities) (Details)",
     "shortName": "Balance Sheet Components (Accrued Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails",
     "longName": "40601 - Disclosure - Long-term Debt (Narrative) (Details)",
     "shortName": "Long-term Debt (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2020_To_10_31_2020_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails",
     "longName": "40602 - Disclosure - Long-term Debt (Future Payment Under the Term Loan) (Details)",
     "shortName": "Long-term Debt (Future Payment Under the Term Loan) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails",
     "longName": "40703 - Disclosure - Commitments and Contingencies (Balance Sheet Information) (Details)",
     "shortName": "Commitments and Contingencies (Balance Sheet Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails",
     "longName": "40704 - Disclosure - Commitments and Contingencies (Operating Lease Maturities) (Details)",
     "shortName": "Commitments and Contingencies (Operating Lease Maturities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "longName": "40801 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DividendsCommonStock",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails",
     "longName": "40802 - Disclosure - Stockholders' Equity (Shares Reserved for Future Issuance) (Details)",
     "shortName": "Stockholders' Equity (Shares Reserved for Future Issuance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "silk:ScheduleOfCommonStockReserveForFutureIssuances",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "silk:ScheduleOfCommonStockReserveForFutureIssuances",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
     "longName": "40901 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)",
     "shortName": "Stock-Based Compensation Plans (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails",
     "longName": "40902 - Disclosure - Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details)",
     "shortName": "Stock-Based Compensation Plans (Summary of Shares Available for Issuance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember",
      "name": "silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember",
      "name": "silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails",
     "longName": "40903 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Option Activity) (Details)",
     "shortName": "Stock-Based Compensation Plans (Summary of Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails",
     "longName": "40904 - Disclosure - Stock-Based Compensation Plans (Information by Exercise Price) (Details)",
     "shortName": "Stock-Based Compensation Plans (Information by Exercise Price) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails",
     "longName": "40905 - Disclosure - Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details)",
     "shortName": "Stock-Based Compensation Plans (Summary of Stock Unit Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit1",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
     "longName": "40906 - Disclosure - Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)",
     "shortName": "Stock-Based Compensation Plans (Fair Value of Stock Options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails",
     "longName": "40907 - Disclosure - Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details)",
     "shortName": "Stock-Based Compensation Plans (Summary of Stock-Based Compensation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "41001 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails",
     "longName": "41002 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)",
     "shortName": "Income Taxes - Components of Income Before Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails",
     "longName": "41003 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of U.S Statutory Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails",
     "longName": "41004 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "41005 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://silkroadmed.com/role/Disclosure401KPlanDetails",
     "longName": "41101 - Disclosure - 401(k) Plan (Details)",
     "shortName": "401(k) Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit13",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit13",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails",
     "longName": "41401 - Schedule - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)",
     "shortName": "Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "Unit12",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "silk-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r804"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net of allowances of $26 and $3 at December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums (accretion of discounts) on investments, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "silk_AccretionOfClosingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AccretionOfClosingCosts",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "silk_LongTermDebtGrossAfterAccretionOfClosingFees",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion Of Closing Costs",
        "label": "Accretion Of Closing Costs",
        "terseLabel": "Add: Accretion of closing fees"
       }
      }
     },
     "auth_ref": []
    },
    "silk_AccruedAdministrationFeesAndSalesRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AccruedAdministrationFeesAndSalesRebates",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Administration Fees And Sales Rebates",
        "label": "Accrued Administration Fees And Sales Rebates",
        "terseLabel": "Accrued administration fees and sales rebates"
       }
      }
     },
     "auth_ref": []
    },
    "silk_AccruedClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AccruedClinicalExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Expenses, Current",
        "label": "Accrued Clinical Expenses, Current",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty expense",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r778"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll and related expenses",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r778"
     ]
    },
    "silk_AccruedTravelExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AccruedTravelExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Travel Expenses, Current",
        "label": "Accrued Travel Expenses, Current",
        "terseLabel": "Accrued travel expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r179",
      "r667"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r96",
      "r186",
      "r663",
      "r685",
      "r689"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15",
      "r35",
      "r538",
      "r541",
      "r610",
      "r680",
      "r681",
      "r852",
      "r853",
      "r854",
      "r867",
      "r868",
      "r869"
     ]
    },
    "silk_AdditionalCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AdditionalCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Common Stock Capital Shares Reserved For Future Issuance",
        "label": "Additional Common Stock Capital Shares Reserved For Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AdditionalOfficeLaboratoryAndManufacturingSpaceMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Office, Laboratory And Manufacturing Space [Member]",
        "label": "Additional Office Laboratory And Manufacturing Space [Member]",
        "terseLabel": "Additional Office, Laboratory And Manufacturing Space [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r804",
      "r949"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r706",
      "r867",
      "r868",
      "r869",
      "r928",
      "r951"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "silk_AgencyNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AgencyNotesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency Notes [Member]",
        "label": "Agency Notes [Member]",
        "terseLabel": "Agency bonds/notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r485"
     ]
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForCreditLossMember",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance For Credit Loss [Member]",
        "terseLabel": "Allowance for doubtful accounts receivable:",
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowances for accounts receivables",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r284",
      "r331",
      "r334",
      "r336",
      "r946"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r591",
      "r791",
      "r792",
      "r857"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Backed Securities [Member]",
        "terseLabel": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r880",
      "r885",
      "r886"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r181",
      "r214",
      "r257",
      "r271",
      "r275",
      "r318",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r527",
      "r531",
      "r572",
      "r659",
      "r730",
      "r804",
      "r817",
      "r894",
      "r895",
      "r934"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "silk_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Balance Sheet Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r190",
      "r214",
      "r318",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r527",
      "r531",
      "r572",
      "r804",
      "r894",
      "r895",
      "r934"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r340",
      "r658"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r340",
      "r653",
      "r873"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "silk_AwardDateOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AwardDateOneMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award Date One [Member]",
        "label": "Award Date One [Member]",
        "terseLabel": "Award Date One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_AwardDateTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "AwardDateTwoMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award Date Two [Member]",
        "label": "Award Date Two [Member]",
        "terseLabel": "Award Date Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables",
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Preparation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "silk_BenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "BenchmarkMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benchmark [Member]",
        "label": "Benchmark [Member]",
        "terseLabel": "Benchmark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_BorrowingBaseAmountInCaseEligibleInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "BorrowingBaseAmountInCaseEligibleInventory",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing base amount in case eligible inventory.",
        "label": "Borrowing base amount in case eligible inventory",
        "verboseLabel": "Borrowing base amount in case eligible inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accounts payable and accrued liabilities for purchases of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails",
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r176",
      "r776"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "totalLabel": "Total",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years",
        "label": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years",
        "terseLabel": "Amounts maturing after one year through two years"
       }
      }
     },
     "auth_ref": []
    },
    "silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfCashEquivalentsShortTermAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year",
        "label": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year",
        "terseLabel": "Amounts maturing within one year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r131"
     ]
    },
    "silk_CashCashEquivalentsAndAvailableForSaleInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "CashCashEquivalentsAndAvailableForSaleInvestments",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Cash Equivalents And Available For Sale Investments",
        "label": "Cash, Cash Equivalents And Available For Sale Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails",
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r108",
      "r211"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r108"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r945"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r256",
      "r401",
      "r402",
      "r403",
      "r405",
      "r408",
      "r413",
      "r415",
      "r698",
      "r699",
      "r700",
      "r701",
      "r793",
      "r831",
      "r859"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper Not Included With Cash And Cash Equivalents [Member]",
        "terseLabel": "Commercial Papers [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r929"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r78",
      "r660",
      "r717"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r354",
      "r356",
      "r772",
      "r893"
     ]
    },
    "silk_CommonStockCapitalSharesAvailableForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "CommonStockCapitalSharesAvailableForFutureIssuance",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Available For Future Issuance",
        "label": "Common Stock, Capital Shares Available For Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r867",
      "r868",
      "r928",
      "r948",
      "r951"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)",
        "verboseLabel": "Par value (in USD per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r718"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r87",
      "r718",
      "r736",
      "r951",
      "r952"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value Shares authorized: 100,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: 39,165,481 and 38,355,972 at December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r662",
      "r804"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r195",
      "r197",
      "r203",
      "r654",
      "r673"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk, and Other Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r154"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction-in-progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r429"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds/Notes [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r796",
      "r947"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r646"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of Goods Sold [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods Sold",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "silk_DebtCovenantRevenueCovenant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DebtCovenantRevenueCovenant",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt, Covenant, Revenue Covenant",
        "label": "Debt, Covenant, Revenue Covenant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r212",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r387",
      "r394",
      "r395",
      "r397"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r82",
      "r83",
      "r133",
      "r135",
      "r217",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r592",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r860"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "silk_DebtInstrumentCovenantLiquidityEventPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DebtInstrumentCovenantLiquidityEventPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Liquidity Event, Payment Amount",
        "label": "Debt Instrument, Covenant, Liquidity Event, Payment Amount",
        "terseLabel": "Redemption amount"
       }
      }
     },
     "auth_ref": []
    },
    "silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold",
        "label": "Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold",
        "terseLabel": "Percent of original principal threshold"
       }
      }
     },
     "auth_ref": []
    },
    "silk_DebtInstrumentCovenantMaximumBorrowingThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DebtInstrumentCovenantMaximumBorrowingThreshold",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Maximum Borrowing Threshold",
        "label": "Debt Instrument, Covenant, Maximum Borrowing Threshold",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Facility fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r373"
     ]
    },
    "silk_DebtInstrumentMarginRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DebtInstrumentMarginRate",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument margin rate",
        "label": "Debt instrument margin rate",
        "verboseLabel": "Debt instrument margin rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r788",
      "r930"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r217",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r592",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r860"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Amount representing debt discount and debt issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r383",
      "r398",
      "r789",
      "r790"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Available-for-sale securities, credit losses",
        "documentation": "Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value, Less than 12 months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r343",
      "r787"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized Loss, Less than 12 months",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r343"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Fair Value of the Available-For-Sale Investments",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r887"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Weighted average days to maturity",
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "verboseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r342",
      "r787"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r134",
      "r504"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest limitation",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Capitalized start-up costs/Intangibles",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails",
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "silk_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r927"
     ]
    },
    "silk_DeferredTaxAssetsSection174": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DeferredTaxAssetsSection174",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Section 174",
        "label": "Deferred Tax Assets, Section 174"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r927"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r927"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r927"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r927"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r927"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/Disclosure401KPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer discretionary contribution",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/Disclosure401KPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosures [Table Text Block]",
        "terseLabel": "401(k) Plan",
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://silkroadmed.com/role/Disclosure401KPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percent of matching contribution of the employee's pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://silkroadmed.com/role/Disclosure401KPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer contribution match percentage",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://silkroadmed.com/role/Disclosure401KPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage employee contribution",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r443",
      "r474",
      "r475",
      "r477",
      "r798"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Summary of Shares Available for Issuance",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r66"
     ]
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Components [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_DisgorgementOfStockholderSShortSwingProfits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "DisgorgementOfStockholderSShortSwingProfits",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disgorgement Of Stockholder's Short-Swing Profits",
        "label": "Disgorgement Of Stockholder's Short-Swing Profits",
        "terseLabel": "Disgorgement of short-swing profits, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r122"
     ]
    },
    "us-gaap_DividendsCommonStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock [Abstract]",
        "terseLabel": "Common stock, $0.001 par value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "verboseLabel": "Document Financial Statement Error Correction Flag",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r826"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Country [Member]",
        "terseLabel": "Domestic Tax Authority",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails",
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r246",
      "r248",
      "r250",
      "r251",
      "r252",
      "r254",
      "r557",
      "r558",
      "r655",
      "r674",
      "r782"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails",
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r248",
      "r250",
      "r251",
      "r252",
      "r254",
      "r557",
      "r558",
      "r655",
      "r674",
      "r782"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to the ESPP",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expensed not yet recognized, period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs of unvested RSUs",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expensed not yet recognized",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "2019 ESPP",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables",
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Common Stock Options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "silk_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables",
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r168",
      "r199",
      "r200",
      "r201",
      "r225",
      "r226",
      "r227",
      "r232",
      "r241",
      "r243",
      "r255",
      "r322",
      "r330",
      "r416",
      "r478",
      "r479",
      "r480",
      "r512",
      "r513",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r544",
      "r556",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r610",
      "r680",
      "r681",
      "r682",
      "r706",
      "r757"
     ]
    },
    "silk_Espp2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "Espp2019Member",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP, 2019 [Member]",
        "label": "Espp2019 [Member]",
        "terseLabel": "ESPP, 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt pay off",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "silk_FairMarketValueOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "FairMarketValueOfCommonStock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Market Value Of Common Stock",
        "label": "Fair Market Value Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r568"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r568"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r565",
      "r616",
      "r617",
      "r618",
      "r789",
      "r790",
      "r794",
      "r795",
      "r796"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r566",
      "r567",
      "r569"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r431",
      "r436",
      "r565",
      "r616",
      "r794",
      "r795",
      "r796"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r431",
      "r436",
      "r565",
      "r617",
      "r789",
      "r790",
      "r794",
      "r795",
      "r796"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r616",
      "r617",
      "r618",
      "r789",
      "r790",
      "r794",
      "r795",
      "r796"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r569"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r18"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r332",
      "r333",
      "r337",
      "r338",
      "r339",
      "r341",
      "r344",
      "r345",
      "r396",
      "r413",
      "r545",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r672",
      "r787",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows",
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r57"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r214",
      "r257",
      "r270",
      "r274",
      "r276",
      "r318",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r572",
      "r784",
      "r894"
     ]
    },
    "silk_HeadquartersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "HeadquartersMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters [Member]",
        "label": "Headquarters [Member]",
        "terseLabel": "Headquarters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r115"
     ]
    },
    "silk_IncentiveStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "IncentiveStockOptionMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Option [Member]",
        "label": "Incentive Stock Option [Member]",
        "terseLabel": "ISO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_IncentiveandNonqualifiedStockOptionExercisedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "IncentiveandNonqualifiedStockOptionExercisedMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and Nonqualified Stock Option, Exercised [Member]",
        "label": "Incentiveand Nonqualified Stock Option Exercised [Member]",
        "terseLabel": "Exercise of options under stock plan"
       }
      }
     },
     "auth_ref": []
    },
    "silk_IncentiveandNonqualifiedStockOptionIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "IncentiveandNonqualifiedStockOptionIssuedMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and Nonqualified Stock Option, Issued [Member]",
        "label": "Incentiveand Nonqualified Stock Option Issued [Member]",
        "terseLabel": "Issuance of options and restricted stock units under stock plan"
       }
      }
     },
     "auth_ref": []
    },
    "silk_IncentiveandNonqualifiedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "IncentiveandNonqualifiedStockOptionMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and Nonqualified Stock Option [Member]",
        "label": "Incentiveand Nonqualified Stock Option [Member]",
        "terseLabel": "ISO and NSO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r519"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r97",
      "r139",
      "r257",
      "r270",
      "r274",
      "r276",
      "r656",
      "r669",
      "r784"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations and Comprehensive Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r353",
      "r741"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r741"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r489",
      "r495",
      "r501",
      "r508",
      "r517",
      "r520",
      "r521",
      "r522",
      "r703"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r161",
      "r242",
      "r243",
      "r262",
      "r493",
      "r518",
      "r676"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r491",
      "r492",
      "r501",
      "r502",
      "r507",
      "r509",
      "r697"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Permanent differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedTerseLabel": "General business credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "silk_IndemnificationObligationsLiabilityRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "IndemnificationObligationsLiabilityRecognized",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification obligations for which a liability has been recognized.",
        "label": "Indemnification Obligations, Liability Recognized",
        "terseLabel": "Indemnification obligations, liability recognized"
       }
      }
     },
     "auth_ref": []
    },
    "silk_IndexRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "IndexRateMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Index Rate [Member].",
        "label": "Index Rate [Member]",
        "terseLabel": "Index Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r141",
      "r202",
      "r261",
      "r590",
      "r742",
      "r815",
      "r950"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r209",
      "r210"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Accrued interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished products",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r777",
      "r804"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r175",
      "r188",
      "r347",
      "r348",
      "r350",
      "r645",
      "r780"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process inventories",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r779"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Provision for excess and obsolete inventories",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r260"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r693",
      "r694",
      "r695",
      "r696",
      "r763",
      "r764"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Renewal Term",
        "verboseLabel": "Additional extended lease period",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetailsAlt": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r214",
      "r318",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r528",
      "r531",
      "r532",
      "r572",
      "r716",
      "r783",
      "r817",
      "r894",
      "r934",
      "r935"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r136",
      "r665",
      "r804",
      "r861",
      "r891",
      "r931"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r174",
      "r214",
      "r318",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r528",
      "r531",
      "r532",
      "r572",
      "r804",
      "r894",
      "r934",
      "r935"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Liability for uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "silk_LimitationOfCompensationDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "LimitationOfCompensationDeduction",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUsStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limitation Of Compensation Deduction",
        "label": "Limitation Of Compensation Deduction",
        "terseLabel": "Limitation of compensation deduction under IRS Sec.162(m)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Line of Credit",
        "verboseLabel": "Aggregate outstanding principal balance",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r135",
      "r944"
     ]
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r860"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate During Period",
        "verboseLabel": "Annual interest rate",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line Of Credit Facility Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r860"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Facility amount",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "silk_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan And Security Agreement",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_LoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "LoanFacilityMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Facility [Member]",
        "label": "Loan Facility [Member]",
        "terseLabel": "Loan Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt",
        "totalLabel": "Present value of minimum payments",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r135",
      "r384",
      "r399",
      "r789",
      "r790",
      "r944"
     ]
    },
    "silk_LongTermDebtGrossAfterAccretionOfClosingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "LongTermDebtGrossAfterAccretionOfClosingFees",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Gross, After Accretion Of Closing Fees",
        "label": "Long-Term Debt, Gross, After Accretion Of Closing Fees",
        "totalLabel": "Long-Term Debt, Gross, After Accretion Of Closing Fees"
       }
      }
     },
     "auth_ref": []
    },
    "silk_LongTermDebtGrossBeforeAccretionOfClosingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "LongTermDebtGrossBeforeAccretionOfClosingFees",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "silk_LongTermDebtGrossAfterAccretionOfClosingFees",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Gross, Before Accretion Of Closing Fees",
        "label": "Long-Term Debt, Gross, Before Accretion Of Closing Fees",
        "totalLabel": "Long-term debt, gross before accretion of closing fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Five",
        "verboseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r217",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r217",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r217",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r217",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "silk_LongTermDebtUnpaidInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "LongTermDebtUnpaidInterest",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtFuturePaymentUnderTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Unpaid Interest",
        "label": "Long-Term Debt, Unpaid Interest",
        "negatedTerseLabel": "Less: Amount representing interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r55"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities requiring accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r832"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r438",
      "r644",
      "r677",
      "r708",
      "r709",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r774",
      "r786",
      "r793",
      "r797",
      "r806",
      "r896",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r438",
      "r644",
      "r677",
      "r708",
      "r709",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r774",
      "r786",
      "r793",
      "r797",
      "r806",
      "r896",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails",
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r110",
      "r140",
      "r172",
      "r193",
      "r196",
      "r201",
      "r214",
      "r231",
      "r236",
      "r237",
      "r238",
      "r239",
      "r242",
      "r243",
      "r249",
      "r257",
      "r270",
      "r274",
      "r276",
      "r318",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r558",
      "r572",
      "r671",
      "r738",
      "r755",
      "r756",
      "r784",
      "r815",
      "r894"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureRecentAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r163",
      "r171",
      "r229",
      "r230",
      "r233",
      "r234",
      "r244",
      "r245",
      "r323",
      "r324",
      "r514",
      "r515",
      "r516",
      "r542",
      "r554",
      "r560",
      "r561",
      "r562",
      "r577",
      "r578",
      "r579",
      "r597",
      "r598",
      "r611",
      "r650",
      "r651",
      "r652",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r228",
      "r231",
      "r232",
      "r233",
      "r235",
      "r238",
      "r244",
      "r254",
      "r286",
      "r287",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r352",
      "r478",
      "r479",
      "r480",
      "r510",
      "r511",
      "r512",
      "r513",
      "r523",
      "r524",
      "r525",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r570",
      "r571",
      "r573",
      "r574",
      "r575",
      "r576",
      "r588",
      "r589",
      "r593",
      "r594",
      "r595",
      "r596",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r647",
      "r648",
      "r649",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r228",
      "r231",
      "r232",
      "r233",
      "r235",
      "r238",
      "r244",
      "r254",
      "r286",
      "r287",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r352",
      "r478",
      "r479",
      "r480",
      "r510",
      "r511",
      "r512",
      "r513",
      "r523",
      "r524",
      "r525",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r570",
      "r571",
      "r573",
      "r574",
      "r575",
      "r576",
      "r588",
      "r589",
      "r593",
      "r594",
      "r595",
      "r596",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r647",
      "r648",
      "r649",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "silk_NonqualifiedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "NonqualifiedStockOptionsMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified Stock Options [Member]",
        "label": "Nonqualified Stock Options [Member]",
        "terseLabel": "NSO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r270",
      "r274",
      "r276",
      "r784"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails",
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Operating lease liabilities in accrued liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, liability, current, statement of financial position extensible list",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities in other liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, liability, noncurrent, statement of financial position extensible list",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets in other non-current assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, right-of-use asset, statement of financial position extensible list",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Formation and Business of the Company [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Formation and Business of the Company",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r129",
      "r690",
      "r691"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Unrealized gain (loss) on investments, net",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "verboseLabel": "Change in unrealized loss on investments, net",
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss)",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r14",
      "r130",
      "r194",
      "r197"
     ]
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r101"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "silk_OxfordFinanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "OxfordFinanceMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Finance [Member].",
        "label": "Oxford Finance [Member]",
        "terseLabel": "Oxford Finance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Stock Issuance Underwriting Discounts And Commissions",
        "label": "Payment Of Stock Issuance Underwriting Discounts And Commissions",
        "terseLabel": "Payment of stock issuance underwriting discounts and commissions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails",
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs",
        "verboseLabel": "Payments of deferred offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "silk_PercentAggregateOriginalPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentAggregateOriginalPrincipalAmount",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent aggregate original principal amount",
        "label": "Percent aggregate original principal amount",
        "verboseLabel": "Percent aggregate original principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "silk_PercentOfBorrowingBaseInCaseEligibleInventory": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentOfBorrowingBaseInCaseEligibleInventory",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of borrowing base in case eligible inventory",
        "label": "Percent of borrowing base in case eligible inventory",
        "verboseLabel": "Percent of borrowing base in case eligible inventory"
       }
      }
     },
     "auth_ref": []
    },
    "silk_PercentOfBorrowingBaseOfEligibleReceivables": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentOfBorrowingBaseOfEligibleReceivables",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of borrowing base of eligible receivables.",
        "label": "Percent of borrowing base of eligible receivables",
        "verboseLabel": "Percent of borrowing base of eligible receivables"
       }
      }
     },
     "auth_ref": []
    },
    "silk_PercentOfEligibleInventory": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentOfEligibleInventory",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of eligible inventory.",
        "label": "Percent of eligible inventory",
        "verboseLabel": "Percent of eligible inventory"
       }
      }
     },
     "auth_ref": []
    },
    "silk_PercentOfOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentOfOutstandingShares",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent Of Outstanding Shares",
        "label": "Percent Of Outstanding Shares"
       }
      }
     },
     "auth_ref": []
    },
    "silk_PercentageOfPrepaymentFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentageOfPrepaymentFees",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment fees",
        "label": "Percentage of prepayment fees",
        "verboseLabel": "Percentage of prepayment fees"
       }
      }
     },
     "auth_ref": []
    },
    "silk_PercentageOfPrepaymentFeesInSecondYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentageOfPrepaymentFeesInSecondYear",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment fees in second year.",
        "label": "Percentage of prepayment fees in second year",
        "verboseLabel": "Percentage of prepayment fees in second year"
       }
      }
     },
     "auth_ref": []
    },
    "silk_PercentageOfPrepaymentFeesInThirdYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PercentageOfPrepaymentFeesInThirdYear",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment fees in third year.",
        "label": "Percentage of prepayment fees in third year",
        "verboseLabel": "Percentage of prepayment fees in third year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Stock Units [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "silk_PerformanceStockUnitsOverperformanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "PerformanceStockUnitsOverperformanceMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units, Overperformance [Member]",
        "label": "Performance Stock Units Overperformance [Member]",
        "terseLabel": "Performance Stock Units, Overperformance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_PledgingPurposeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PledgingPurposeAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Axis]",
        "documentation": "Information by pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r800",
      "r805",
      "r835"
     ]
    },
    "us-gaap_PledgingPurposeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PledgingPurposeDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Domain]",
        "terseLabel": "Pledging Purpose [Domain]",
        "documentation": "Pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r800",
      "r805",
      "r835"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock, $0.001 par value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred shares (in USD per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r401"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r718"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r401"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r718",
      "r736",
      "r951",
      "r952"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value Shares authorized: 5,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: none at December 31, 2023 and 2022",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r661",
      "r804"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debt, net",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r698"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments",
        "terseLabel": "Proceeds from maturity of investments",
        "documentation": "The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Proceeds from disgorgement of short-swing profits, net",
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows",
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r193",
      "r196",
      "r207",
      "r214",
      "r231",
      "r242",
      "r243",
      "r257",
      "r270",
      "r274",
      "r276",
      "r318",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r526",
      "r529",
      "r530",
      "r558",
      "r572",
      "r656",
      "r670",
      "r705",
      "r738",
      "r755",
      "r756",
      "r784",
      "r801",
      "r802",
      "r816",
      "r854",
      "r894"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails",
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r178",
      "r668"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails",
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r657",
      "r668",
      "r804"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r155",
      "r158",
      "r666"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails",
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Provision for (recovery of) doubtful accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r335"
     ]
    },
    "silk_ProvisionsForSalesReturns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ProvisionsForSalesReturns",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provisions For Sales Returns",
        "label": "Provisions For Sales Returns",
        "terseLabel": "Provision for sales returns"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r430",
      "r438",
      "r469",
      "r470",
      "r471",
      "r619",
      "r644",
      "r677",
      "r708",
      "r709",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r774",
      "r786",
      "r793",
      "r797",
      "r806",
      "r809",
      "r892",
      "r896",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r430",
      "r438",
      "r469",
      "r470",
      "r471",
      "r619",
      "r644",
      "r677",
      "r708",
      "r709",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r774",
      "r786",
      "r793",
      "r797",
      "r806",
      "r809",
      "r892",
      "r896",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Principal repayment of long-term debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r701"
     ]
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of outstanding loan amount",
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r488",
      "r942"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development and Clinical Trials",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research [Member]",
        "terseLabel": "Research Tax Credit Carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails",
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r846",
      "r858"
     ]
    },
    "silk_RestrictedStockUnitsAndPerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitsMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units and performance stock units [Member].",
        "label": "Restricted Stock Units And Performance Stock Units [Member]",
        "terseLabel": "Restricted Stock Units and Performance Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails",
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r122",
      "r664",
      "r684",
      "r689",
      "r702",
      "r719",
      "r804"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r225",
      "r226",
      "r227",
      "r232",
      "r241",
      "r243",
      "r322",
      "r330",
      "r478",
      "r479",
      "r480",
      "r512",
      "r513",
      "r536",
      "r539",
      "r540",
      "r544",
      "r556",
      "r680",
      "r682",
      "r706",
      "r951"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r269",
      "r272",
      "r273",
      "r277",
      "r278",
      "r279",
      "r427",
      "r428",
      "r646"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r775"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Secured Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease obligation",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r803"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Issued and sold common stock (in shares)",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock issued, price per share (in USD per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r439",
      "r832",
      "r870"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "silk_ScheduleOfCommonStockReserveForFutureIssuances": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ScheduleOfCommonStockReserveForFutureIssuances",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserve For Future Issuances",
        "label": "Schedule of Common Stock Reserved for Future Issuances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share Determination",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets Measured on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r93",
      "r94",
      "r95"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Future Payment Under the Term Loan",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Unit Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r120",
      "r121",
      "r122",
      "r183",
      "r184",
      "r185",
      "r256",
      "r401",
      "r402",
      "r403",
      "r405",
      "r408",
      "r413",
      "r415",
      "r698",
      "r699",
      "r700",
      "r701",
      "r793",
      "r831",
      "r859"
     ]
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Available-For-Sale Investments in Unrealized Loss Position",
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value)."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r224"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "silk_SecuredRevolvingCreditFacilityAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "SecuredRevolvingCreditFacilityAmendedMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Revolving Credit Facility, Amended [Member]",
        "label": "Secured Revolving Credit Facility Amended [Member]",
        "terseLabel": "Secured Revolving Credit Facility, Amended [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_SecuredRevolvingCreditFacilitySubfacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "SecuredRevolvingCreditFacilitySubfacilityMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Revolving Credit Facility, Subfacility [Member]",
        "label": "Secured Revolving Credit Facility Subfacility [Member]",
        "terseLabel": "Secured Revolving Credit Facility, Subfacility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_SecuredTermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "SecuredTermLoanFacilityMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Term Loan Facility [Member]",
        "label": "Secured Term Loan Facility [Member]",
        "terseLabel": "Secured Term Loan Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r278",
      "r785"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting term",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Awards cancelled (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Awards cancelled (in USD per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Awards granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Awards granted (in USD per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "verboseLabel": "Awards vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Awards vested (in USD per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of Stock Units",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock reserved for issuance (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Allowance For Overperformance",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Allowance For Overperformance",
        "negatedLabel": "Allowance for Performance Stock Units for overperformance (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period",
        "verboseLabel": "Canceled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross",
        "negatedLabel": "Granted/Awarded (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized",
        "terseLabel": "Authorized (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)",
        "verboseLabel": "Number Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in USD per share)",
        "verboseLabel": "Weighted Average Exercise Price (in USD per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options cancelled (in shares)",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in USD per share)",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in USD per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Awards outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Options Outstanding (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)",
        "terseLabel": "Weighted Average Exercise Price (in USD per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expect to vest (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in USD per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Expected to vest (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Expected to vest (in USD per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percent of outstanding shares of common stock",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan",
        "terseLabel": "Number of additional shares allowable under the plan (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockUnitActivityDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansTables",
      "http://silkroadmed.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r447",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Vested and exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansInformationByExercisePriceDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Awards outstanding",
        "verboseLabel": "Weighted Average Remaining Contractual Term (in Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of purchase of price of common stock",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "auth_ref": []
    },
    "silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price",
        "terseLabel": "Exercise threshold as a percentage of fair value of shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      },
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r850"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software And Software Development Costs [Member]",
        "terseLabel": "Software",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r33",
      "r168",
      "r199",
      "r200",
      "r201",
      "r225",
      "r226",
      "r227",
      "r232",
      "r241",
      "r243",
      "r255",
      "r322",
      "r330",
      "r416",
      "r478",
      "r479",
      "r480",
      "r512",
      "r513",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r544",
      "r556",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r610",
      "r680",
      "r681",
      "r682",
      "r706",
      "r757"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r255",
      "r646",
      "r693",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r737",
      "r739",
      "r740",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r757",
      "r810"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r439",
      "r832",
      "r833",
      "r870"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r255",
      "r646",
      "r693",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r737",
      "r739",
      "r740",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r757",
      "r810"
     ]
    },
    "silk_StifelBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "StifelBankMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stifel Bank [Member]",
        "label": "Stifel Bank [Member]",
        "terseLabel": "Stifel Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r32",
      "r61",
      "r122",
      "r388"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r86",
      "r87",
      "r122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r86",
      "r87",
      "r122",
      "r698",
      "r757",
      "r769"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails",
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r86",
      "r87",
      "r122",
      "r453"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r33",
      "r122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r86",
      "r87",
      "r122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r86",
      "r87",
      "r122",
      "r706",
      "r757",
      "r769",
      "r816"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r33",
      "r122"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://silkroadmed.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r90",
      "r91",
      "r112",
      "r720",
      "r736",
      "r758",
      "r759",
      "r804",
      "r817",
      "r861",
      "r891",
      "r931",
      "r951"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementBalanceSheets",
      "http://silkroadmed.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r168",
      "r169",
      "r200",
      "r225",
      "r226",
      "r227",
      "r232",
      "r241",
      "r322",
      "r330",
      "r416",
      "r478",
      "r479",
      "r480",
      "r512",
      "r513",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r544",
      "r556",
      "r581",
      "r582",
      "r586",
      "r610",
      "r681",
      "r682",
      "r704",
      "r720",
      "r736",
      "r758",
      "r759",
      "r770",
      "r816",
      "r861",
      "r891",
      "r931",
      "r951"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Text Block]",
        "verboseLabel": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r213",
      "r400",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r416",
      "r546",
      "r760",
      "r761",
      "r771"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails",
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r612"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails",
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r612"
     ]
    },
    "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://silkroadmed.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "silk_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_TermLoanPrepaidInIncrements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "TermLoanPrepaidInIncrements",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan prepaid in increments.",
        "label": "Term loan prepaid in increments",
        "verboseLabel": "Term loan prepaid in increments"
       }
      }
     },
     "auth_ref": []
    },
    "silk_TermLoanTrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "TermLoanTrancheAMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan, Tranche A [Member]",
        "label": "Term Loan Tranche A [Member]",
        "terseLabel": "Term Loan, First Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_TermLoanTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "TermLoanTrancheBMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan, Tranche B [Member]",
        "label": "Term Loan Tranche B [Member]",
        "terseLabel": "Term Loan, Second Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "silk_TermLoanTrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "TermLoanTrancheCMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Tranche C Member.",
        "label": "Term Loan Tranche C [Member]",
        "terseLabel": "Term Loan, Third Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r282",
      "r283",
      "r285"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://silkroadmed.com/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r396",
      "r413",
      "r545",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r672",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "silk_TwoThousandNineteenStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "TwoThousandNineteenStockOptionPlanMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfSharesAvailableForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Stock Option Plan [Member]",
        "label": "Two Thousand Nineteen Stock Option Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsAvailableForSaleInvestmentsInUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r794",
      "r943"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureBalanceSheetComponentsFairValueOfAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "US Treasury Bills [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r794",
      "r796",
      "r943"
     ]
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnbilledReceivablesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled receivables",
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "silk_UnderwritersOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silkroadmed.com/20231231",
     "localname": "UnderwritersOptionMember",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureFormationAndBusinessOfCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters' Option [Member]",
        "label": "Underwriters Option [Member]",
        "terseLabel": "Underwriters' Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at the beginning of year",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r497"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current years\u2019 tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior years\u2019 tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecorded Unconditional Purchase Obligation",
        "terseLabel": "Purchase obligation",
        "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts)."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r152",
      "r153",
      "r156",
      "r157"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in deferred tax asset valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at End of Year",
        "periodStartLabel": "Balance at Beginning of Year",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r223"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged to expenses",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "terseLabel": "Write offs",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowances And Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleScheduleIiValuationAndQualifyingAccountsScheduleIiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureStockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails",
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares used to compute net loss per share, diluted",
        "verboseLabel": "Weighted average common stock outstanding used to compute net loss per share, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r252"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://silkroadmed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNetLossPerShareDeterminationDetails",
      "http://silkroadmed.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares used to compute net loss per share, basic",
        "verboseLabel": "Weighted average common stock outstanding used to compute net loss per share, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r252"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001397702-24-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001397702-24-000015-xbrl.zip
M4$L#!!0    ( $B#7%A<_H79V!(  ,_1   1    <VEL:RTR,#(S,3(S,2YX
M<V3M7>UOVSR2_W[ _0\\'W#H ZSC.$F?I\TUS\))FEWCDMH;I[M[GQ:T1=M$
M9<I+24F\?_W.4.\2]68[J14%*%)9XLR0OR&'Y'!(?OGC\\HDCTS:W!(7G?[1
M<8<P,;,,+A87'=>9=S]U_OC[?_['E__J=O]^>7]+#&OFKIAPR$PRZC"#3#?D
MBDD'7UUS>V9:MBL9N:."+IA*>')Z='IT<G1"NEV?T26U@= 21'$\.>J'7ZY\
MII8X)R>]DT^]D^.3,](_[W\\[Y^1\5V8\ YR..>E*>W9DJTH@3(*^_S9ON@L
M'6=]WNL]/3T=/9T>67(!=,?]WM_O;B<J:<=/:W+Q(Y'Z>2K-(/UI#S]/H11!
M<OS*"])S83M4S!+I#2<DB"?^V/,^=@AU',FGKL-N++FZ9G/JFD#BBG^ZU%2%
M!U69"N-$@MAGA\H%<[[1%;/7=,9">38W?TB+&BMF',VL%6)WVH=_0?;P>^7$
MAB.[SF;-;'WYX7,//R/=2??XM!M25M &Z)"0+\_V.17"<J@#E52]\E^NUUS,
MK=^_H#K.I66R!Q!$\.'[_3"W /B]-P%N"KM+:J)F)DO&'+M#N''1R?GFRS'8
MG NNL@*9/3XF71(2P+-/0SRB+[TTC<?$A18P$K^KY[5D-M"JTMW""Y_&3Y)-
M/Z/FS#4K)X]D:U+W$M#MAF3X8(_FHS63*H?V0!A7U@K*N&3"YH_LUK+3,-<@
MU.G@)*.#B"&QYB1B2:@P2((I0:YM5=(5M9<WIO54I(\HC0[ZLQ+HD9HH\A9@
M''5_$W>UHG(SFD_X0H MGE'A#&8SRQ4.]*MCR^0SSFRT<89K,@]DK.[PW]=_
MNOR1F@C@-7,H-WWEO!3SK%;/H$%!9QWOS4&MGE#4:4PLB>220##Y$(@.*X!J
M=?@0D_\+^>!GX9=658UXEX*6R!*(Q@WE\J_4=$%=@T< A4Y-[/4G@-50/#+;
M6154B'VPU%6#C]EJD.C<2"2,?$!Q1,E#M8<2NR"RBS))3.B[[G,4E6JCDZ4E
MG0<F5]!\;RVQP,<]5(?MI.AKR.FV-21M#_Y 5#ZZ*%T9#,R*]^N]YN3H-++Q
M")%P++FI52<*Z/7:_EA=V_%.(.3^KKXX_&-IP<C4V8Q-[,&%@:UAC=6\EA)+
MN>A5^6MU5082_D"4#-4Z0RGO*HTK \9#TF7&+:=3;D(^6#TCG4^N5^)OU97H
MLR8QWFU57=#)7;.I<^,Z\&9,-UB7OPN#2?QR:U&1H[AZQ#JU_9H=5JF^SL&^
M#ME"5ZD8$Y\S4:R)LV1$]8<HH*VZ@RJ]XMY80/D'U-R#"9QXQ)O44,PMN5+Y
MS]'C]HQT.OTM.Q"*"?#=#C$1Y$.RI<;$O&LVHQ#?@2,6MXS:[(Y"XRBRK3MP
MTNOVK*9N0RE$B2&1G'?EUE7)P'3VIU]D]HHJ)H/;AU:I>2C@)7N@S\R.QAXX
MN\#7EPQLG/<QI^'6)=>HLG^<[5T]>J)(/<T&HR(U-U$?/>Y^FG:VT1CZ]VQF
M044WN<KF:/[=1K>NBU.X>^JP<O559*!78*8K32DPR1R5^/UH0D(!!"6\Z_ ;
M@QG@G$G)#/@]L&V6ZS&J2*775L9RIK0%'$G $E\2CVFK%*1=69DXUNS'TC)A
M;&_C=-K9%"S#:!+KUF-.2]9CXFS^AZXM^W^)QZT%2HBMH" **@@!^P(F;)5'
M=&[8#^BTSBZYE!)DE7%Z_#EKR10C/_XASDIY5J!->-S:T"0B6&Z"F0\,YBY=
MFPMFX[HCH$-%GC^S$HUNI-<_[J=U$O)2X[R &[86G''[/%MEKNJN-7ZC$@?#
MCWD#@RVYZ)<F,_JKLS09RFCK1*SNXO'8PL@N3DUS<\U-%Z&;L)D_U?EF.=#9
MFZ[!C*&XBHH\FG^E4@ _>\SD9$GE;A7CQ7*CKV"9 <VV:]^QW)(@NR3*+X$,
MDR#'A L2RS.2![DF,-4D*M]MK;3AVN4=S+7AMQK.W'!!819 36\\Z7\"X?>(
ML 3DH)OE>4/>?;#459\S3?\2K7O&A9$/H;A@2!P(Q-!(2D*A1$EMJ_+U*R5E
M74Y%*OVR2D:%^<LJK>]0<A:R\B-.AN*[D(R:_%_,P."[L67S C_]WOGK59XQ
M^@4K:6%LRUP3VX*&/,J "B\D01;:6D?B:V9E#;<PK7XY+=-<T\MIK6^D!1[S
M,GW4(=6[UC/J*7&MMUY;65^/&OW9]U ^^<@,L'G> O'0METT4GFCZVWYZ/3X
M21,3FN=,@F&P$D0"200L)?$7M0-AK=:NWI=4.H^N0:K3X6?-Y+G$(?7>&/,Q
MCV:OJK;'QR156N;.3/4JUC?3 A7'I[=>LPV%JG;[WF K* O3C-;*(SF#Y@)&
M<!?5YW/3Z[RVGSFN<TQ*/&DD$/>NZXQV8B$ZEYNOSTS.N,W&DF_3R,MYZ?6<
M=4V5Z#DF"#=J!J*(DO6NY)(F^!WRLZ_FK..E5W(FR+IV8T99[TTY7S.QO1 Q
M4YN[WVIK1GK]9B*OR_2;W#@1M]>M=0I6;G:9-+NVXUR&>F5G(K3K-F9-TK8J
M/1ZF4C)3*DJJ#V/)S(S282P!FY:"?W;<_S^LHCF IS_K0-:LO0/9AQ^_J+K?
M*ER#9<+@_R%'^QY$-/Q%G>"PX6+AKS':4;H$_KNST>G)6\,*5S)CC\,A_ I%
M*.==)"18$+53%&W2Z[5_.LJ5]<CDF"Z8WTXRKW7!6]!=8/L(#EA!1RDD)YB^
M!=#I#]T84PFOELSAD-VBTSF2"77P]M7(.O^H#O(AP:,-U;5BJ&&1$NI0ZB,6
MTUHIB%C\[T\G_=\B+W/K]%4Q *Y6M)Q&*_VMP^1:I8-JT4O;Q3QIM;)3\%NK
M5'//9BP!J[0$/,X\NY)624EJG2I.LZKPN"2@3_!IE0*T\565@K"T<%</JVH5
MROK@F&HA-%J<:\0^M0KH>%1*4<2*%M32")5605D04%(C]D0+=-U8DU;AGK?=
MJ#"%#N5/.5$$VD%Z^R#6.Y%K^)NUH-<.W6@5\#%W;X$G6 =LF>>W53 &3MP\
MYZX6P&*O;@OPJ^N$W<YUJ\5^5T]M"[13=^*]V[2]8/I^LNNQFL%3NQQ=U7#/
MV;9;AS:KL5/06#:RJH;&6KF;5S>GUZNG**E.&V=9;>3NK6HC]/IYOA[[PK0Z
M\&L=]=E&].-N #WFFA0ZI'_-(IW>T-)&? N< 7JXRPETZ-<_R:V-RLBZ"@H.
MSM"ETT'_*2>.6;_%I(VPQR:S>KRS"31 EQZQU$ILZYY%\(TY:GMI=*8 V&<N
M"H,,7T"$)H!GUV%K_ P#/+W)V\,:'$) $MEH:RQBUK!5VKQ53*'399FW-6D4
M6[]=J^@,.B'A#=3]?ZFSS2Z9@%Q5.1.M)B.-%L'B9J+ZRP^UBXE1!Z<%@AJN
M6OR#=V?=LWEP&Q:^TMT&U?_\^7-/?>T0]=\YE3-D5YRXM_9.+ =KU@ND!0R6
MDLTO.EB+NL%%5O\PZ?0(<A(DR0A(WN6E:AR0,/,V*DE BS==(?O5VL0@OUZZ
MQ >+ :B]+@:IFO)6D( :71>)9"-X*T" Y:@+1-K8U(:B%[_6K9>]^ VO?0-R
M2SI$9*ZU*[IWS[L)\-::*5X%)/BK&]!U\56W?](][1\]VT;'RY.7@6WR$\%>
M+S\!W1[SH[V73Y<KNP*E^FUOD27]S8<5P0D($)6/VPJWV>QH83U"&^;J:L-\
M$+3)\4$UF3W4C\]>(Q)L@9=@5H/!E#)!A5A\QAK2_U7EJ/I5B[6R/J?V5'%Q
M[>Z"TG45Z+0T/68Z=O F O*%LIU0(9L9=30>),>'%\]HB)4MG5K8!ND]7.'7
MOK+J7S6JALG83_P#79%#L),RW-H@8$IY1Y_YREU=6E):3S"O?(">Q<;)2D>5
M$H;8M<FXJ0XCN.@ #5A.KQ,);QT]ARX- R^'#EOA*!. <J>VPQT78?J3M-SU
M14?=SWK.(0F@H)Z!BEO&@^+E67NG+D ^(OD(H>/0$FJZ=D77W*%F]E"'Y DL
M'4(A[Y+.G(O.G)K847BH;<,J#5Q!P4L@\R#WWMA*;HAV12B"BU$>).1MR09W
M;#5E,EY<+X]>:?-2EY?(<+VK/BL6*:I%AK6B7-0M%DSB\(C'1Q;;_EM<M"**
MPRT>%<8W*[IX.);WX$@!HV*Q:W Z.#A4D\L$;0TDU%+OKNO+393$O[QG\$2E
MX>_6'JBR^Z55'IO($-HCU\'&B!=O0UN>,XZ-&4F^/J^Y?W_M4(Q5Z7/-Q 'E
M<._:V\7\^+=?7<$X&O<*088!&V9?N1)W$.7"6496P\)ZGZ;>DNE%9R:9P>L9
M7K#_S*%R4[?L^OM?P\7WR"GEW6$B%G_CSI*+D6#_SZC,[Y%V9+L]=@:;OA)T
MU^FK$)+WRP1WJ6UR0:K.H EP^ ;#W^@7##34[61/>*:Q6*#65629=WGWBMLV
M6H5<?';@6,>^_+S&]UH&^9N;[GU_2K\09..0AIX5AAX[CUT.=LBBGVW=<M A
M-('-5[R8=>Q-H$;SD>0++J@Y!G,]XVMJQF9AN09N3_Q?$+GT!+'JE.7)>EA:
MKHU:Y]#Z&1,QC6-P<\DDIC+]P=6:US(7?P*&3CAFA.+8^5W%3\W300UF*[4Y
M'X 5]IV[M=XDI_=N-]O?C>8#PU#+/Z%;QG66EL25VY]>GZMD\:"J=^#\J>8B
M.E@;ZHWW04NQ&Y=O&;QD*KKJ@3T[ER9T!_F3S\H,7K#L3B!E1X??92V'W^7!
M:G775AMKF']C?+%TF#%XA"GA@MTSS ^\Q_!21 B&F0C+P <L#[J?F:.7LAL.
M^@M>2C73-!"Y%M(TK2<LGG>U]Y)Y>^-VM.>[BF_8U KG]'MP#B?9')Q9&$OK
MD2O'A'\AB7W/'%<6>3[R*1KA5?RZ6IO6AGG+&&-7SI90K\LG1:5D!Z?:^*Z-
M[V)-N3$4#H/&DC^L+B)I@I\OGG\U ?)N1T9O./-"(*],R\9E ,;R:WA-+HVH
M]9$%SS'RTQPCK_Y$J[4 A)IGWENF">T?/Q;V[R\ELI$=>(61S&"QD"H>!AH>
M9,7F,[4H\8ICJ=(<'!3T_D(7#+\?6=W5L1RB1K1GG'/ #,N_E'$S )VI%,6=
M6!G5P?5A.8,JN[B8950'5\S:2Y*#.73+_HKDPQ*RM5@^/%GX*[];VZ^0)@P'
MMNZ!_/H2!':$WGYJ4W]- &:9EG?3C;J1HGAR]4I9V/<$:^>%"&5GF''/'BWS
M$:?CRC[>T)E:.IZXT[G_&#9,#[/:9"6!=JE&63_.+N89WF^@W<3A<V9>4O$C
M!4'V?7/+N/78Q%FB^X#ZOF+[KS /8887ML-F\/A@X2O=*NZ.@Z+M!6NUI/54
M'$ZTYROBE'+4)6X0^@EJ*\E.>?RNRL@!JO3/C!HP!)+0@=M)RZ+]TEC;$KD>
M1_,Y*.V63BT09<D-J/V."G>.WE\<S$PP2CT)Q;;$C44+AG@+H&:QR"5O-^YD
MLK2D,WGRCA#&K9KA0FLMD@+KEQG#[82+?MZU;[C8-%Q:AL$($RX+?L;7H?.3
M-#;^?VL3G%W/3=EDY<FYIDYTAM+.9G\[F3^IJOJ3GSWK*PI4BOHV;RTF]-H7
MI7CQ>OH*]C]OGTGNG<'97F ;%B\YWGLQU+ =W%'Y@SG^'7"QD@>PE*1I;I7Y
M:J_7)\?]S\FQ0.9M8SOYK>VH5]F]]<J=C7**61.G1=GUGBO+CD9&^9]?MFLI
M<S[O&87,8ICR"N:NA>D7T(IIWA1>H^>Y)8T;+E!*TL;H/S76T*1"GZZ2A<W]
MVMCRAD.H<*\O6KW1_*O)%QQ*A->H\$?_=+/4J*L227/[U+"<0<&& B-P82:=
M04*7X@T4/*'@H;B"O^585"1J+CR) GJ!V"78U*)X4W.XH3#8\SW,4I-V-/NZ
ML08T&;0/DXL%%U@R?5!_XGMSFT#0#XXE\^*IAF(6WBJ5["KU2=Y4)8^6+D=S
M55PU8XB/'0M3-+<:Y!=K*"9X@I[A;RXN 2&5^FT"\K#DLC(>\<2-AR,,OLKL
M. RW,<4!J9"\N9"$FZF9M%.;514&!=\;VT4.\'#NS3?+8:EE.]V'QI82.[L;
M;>B']DMCR^D'L@3]N[[(98F:7OJ<,)X!)#9B&R,J1/ZD21J+#%CO.5Y*C/=8
MH#_]N^"./7ID<AU]2 )3BZ*QN+S6SE)O@Q) =F/)%(BOO<FU."N-7%UZN87<
M\1[U5%-8<X=1ES!P6*ZH3$489E\WUFQDSBJ";@0%]7\[RSW.*)'DYRQ O,P,
M&\.[4R'>8(OBIRWBGCWTHME.P@NQ#>%; NZ>X0X4#!.,>E@ 0-OS)IO25I2-
M;6WHD%QY]W"HQ;RIR1?>$7KAH6#WX?'_<2]F':*W5+'\W48#8\4%QTT"F$_T
M7>!.'&__[!2F\(F%Y8KIW]3*:71]3"S4Q(^]R83>A&C5IBII>-ES(PZH[=WR
M%7?\RSSBXYUK@&#F2?3GT142OBG'LAK388S?2*2C?'5?&FM]P](\/%DYY8Q_
M.?1R?NEYAX/__F]02P,$%     @ 2(-<6,MY_C(]%P  PT\! !4   !S:6QK
M+3(P,C,Q,C,Q7V-A;"YX;6SM75MOXSJ2?E]@_X,V^W(&&'5TM>7&Z1FXD\[9
M8-.=($YV9I\"6J)BX<A2AI)SV5^_I"S)DJT+*<N6: 5HH&.;M_KJ8Y$LDL7?
M__Z^=(57B +'][Z=R5^D,P%ZIF\YWO.WLU5HB\;9W__V[__V^W^(XC^_W]\(
MEF^NEM +!1-!$$)+F'\(%Q"%Y*M+)S!=/U@A*/P$'GB&44)%_:)^4;XH@BC&
M!7T' <[H>T)4HO)%3G^YB OUO:^"<JX8YXJD:(+\5=:_RIIP]S--^!.WT'9J
M4[J.]^<<UR9@*;W@*_GX[6P1AB]?S\_?WMZ^O,^1^\5'SSBWI)XGJ<_BY.\[
MZ=_4*+4\F4S.HU_3I(%3E! 7*Y__\^?-S%S )1 =+PB!9Y(* N=K$'UYXYL@
MC,"O;9=0FH)\$I-D(OE*E!51E;^\!U;<1!JY,62"$('V%?DNO(>V$$GY-?QX
M@=_. F?YXI+&1]\M$+3)=^Z?N$)%E95U=?\Y"[$*B>:_ Y<(.UM & 9G BGQ
M\?XZ;0?)B7Q@+:'UQ?27Y^3W\[+,]"+\?IYM?[L2I7\$M_;M"T21XH*I9UWX
MRQ<$%] +G%=XXP?,XK*4W#\L+D"PN'+]M[W$SA32J80;*S9;+9< ?=S:,^?9
MP^;&!%XX-4U_Y878/-[YKF,Z,"!]VUJY<"T!41G^[\>_5LXK<(EDES $CDL+
MS<%J[PFFV7Y-N.U[I)57P$'_ ]P5%F/ZBML+YBZ\\M$,RW#MO<(@7.Z#9"MU
M\H+?EOYG"Q^%#Q M,35N?.^9_'D,2!LVH]<H;_H::;H7^NBC7?RJ*N@U,G?(
MQX-6^''G$B/E643S+T2S[>)37TVO4<+6&ZV@=>. N>,Z(;;>[<)347Y/<$FZ
M_B6<AU>K$']S!SZ( A\]"R+RRXT/O*:H,);>$TRP_I;.V@Q&\[UH>,=K,*R^
MK)JO/=M'RVA>V!2?/6KJ/U;QK-E[OH&X'3\!5O]>76R?JKA':^J&1P0LJJTG
MF%U[6#3X -YAL#&L9#PF7W^'N&>L?VQ**^;R^X?+/31]K%;7B4S$K?T8D&7<
MBLQ6[O%RK@5D:&OH'S:_()Z+V! A:.'/TR" S>?8M,6V@(()7'/E1FC?X,^Q
MY"1=0W=-!DWX'D(\_EKIMTY(BI4D69($44B+P'_'I0CL7A\B"A'&-W-UN\2Y
MYJ.\*DEQ 2XO*LL&P3PJ<!6(SP"\$#^B>@[=,$B^B;0>:3S^XFF-?U(H7CA"
M-ZKJ*9_@25=- .7Q6)2!/!$US91$8Z[JHC4!BF2 D6XHDT@IOGE< 6[#!43K
M1O["'6V%>>6%6_)4IGT:J8:FC15E(HW&H[$RVA$DPZ@IRLL$D)G4A?_,D6Q7
MQ7&*\X!X0TAIHH/IDN2WD;]L#GW2*K^!M(*/\)SRVYE\)JP"+(#_0AH'W#/A
M#3K/BY#\@A')PW!<+1>LLTMT7)!R2V95U<:GH6%*61/]*OW5[SUN/W+,$$8^
MO]J.7);\9#7-(G"B;K6_ZEZC<5&IXUR:DU5LK92)-K4>:W/MR2=37>B\$M\S
MGN/5*+<B2[]T3:^H N4R2LG!0'R'X MPK!_O+] +(%X<9V89U2JGR'DZFF\H
M+ <C=>K-QU0NT70VR>FHM$XJ#H;=XFW5:7@!$/IPO.=HOZM$J51Y3T?;C<7E
M8+Q.-S#K5U-%24]'R;32)3K5*W0JO"#'1T[X0:QWYX-TR=YBN<VNRK(%R5@;
MCTYC\LTJ- T/NG:4;#9,L4"ST#?_7/@N;G5 A L_*CQ]=5F?X%RS;6,BB:JE
MSD4-SN?BQ(1S<63-;<O6]9%F*)WX #,M+_,*;5+TE\WM**#(3U0M/0?+CHP$
MU:N,W83]TC>M2BJ56"$9![I,5L5WX(,LB>D<!?G$><D-923U80I"J:%R/T&]
MD'RH=^OD3JV&B].?GI+IY>3 $1!Y-#+2T.V^%6;HO:8I5<PF(0<ZSIY"J]5O
M<>)3T2V]=#PX@LK/-Y6Y?\IS]$O#1YE0,Z+!04^O72F6)QR@_NE X, 0W*'X
M*%8D497_MR!EOQ3/J)O"/1L:"?F8@J^6I'*XWG?*7;Q;'\4CU^]^P?#6?@#O
MY1-SEE+R6$T4?:+QS(86I.? [-^3@Y<>M'X Y.$A+,A(?0EMQW3*3^#493PQ
M/C03F(,A@,QE?*_6_F\GRTD[EA1])/&L7AKQ.-C:FUJ6LV[4'7"L:^\"O#@A
M:6&QA2].?6*J99"RV09/?!1]Z^!YFT?2F:[49Y11>EY=V3FOOJE"\&UA4XD
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MM20R5Q.;:'E+H9YP-]Q+?VS*5FR%TJ#T2ORR;,HF.:_OK2,DGB7?59:^&IV
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M>,Z3 X(7372WRX.)KK<*KH!/8+$=NOSF?T)'RXZ_!D06@!(4!!-S;P5-$6?
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MT<XMWKN5[=[Z934 *QE!^K-KL;OMK-4P+#Z./OAT5GQ."*+J,4WX\)"(P;3
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M*[MDM=$NP%S)"FR5%,*Q>U*W,?7(*$B(?0PCVQ\%$?8"XCFJFYP[Z1K,K;'
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MGSPW$T_'5%0E KTL'43US/G/_#PZ5DMP8(:0OP:O3/-Z6 P48\C,W)\ U,O
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M<P7,H[E\BXY7Y/TJZTV)H-Z@!6HT25!#O5&<'LIFH:I=J&H8^L*;AD3;K"]
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MFHUH;!ZSS7YGS*F#E("GU.$0=S&JN0;XA#J"[6/O:.W%O_7XBD?!1<-0K65
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M^01KENAS&)&_#HQ&8.91@;K%/M[N>.=VXY1($X'Z-9T[YH/8KY80M&8X'0)
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M^&95QKII2)*9>/@&TW5$M^*Q-Z[I,U=]_83IKOJ#G()[U8;#OOU!*8E7ORI
MSC4PSM17:JIR A'*%FA/G76>M8^)+4C4Y&H?%Y.^,H!)S[>[('K!F;7%8Y=\
MG41.G]U5X'"FIODE47:4!\B.NA89S]5R^7D?+]]3O5'&!M.RGTV;W>"YR1&X
MN[D9B;@&[T:)3=M\B_B*A/@RP5O9AJFL+ A&TS*XOJ'36M ]#E/MR*A-,.V^
MV3Y_N?/_A4M&0K3UG1"'#)['>ZLS6Z?>CB1>(/9YXEL<8_J$_8N(7J1)2G$Q
M3Y7A9B 'EM>; M5@A+Y"@+&%L7G&CE4[![E N=)L)S9&A5KQ=':F&!6:K?.,
M+:BRI2-:AV:=04.*E:AO""LF6O.M978J=I059[#VBH#BE#;SZG11_SLL)FAM
MN?%4OCHOX<+Q*ZV#4["//'4?5H)\S&CD<RKN'>>Q:." M;+[K]']8Y3&?..%
MQ<<)QF%MTT6]:-:C+@A'- *D7$;3K>B>VW:NI_4VS;33,T6HT(0*5<UMRSG7
MFZ2+;:\5$/4"W&RHO/_AW4\H/ZE8G0;0!&+(QD*\VW'=BGV$_1)PB*_=N&J7
MH/%G@"0F,6#(:O "B9YHFXW&MBP7YP:IV/QLTYZJ&W2>#B#!](:DSQDZL+34
MW[:)S\U9IS,+B#@!R. C<F.A<G>=]1#VWWDXLA\I'@D+]J"]H^*Y*8G-31X[
M-HLUB6H:9IJ4D23$&LM9J;,&'&;2,[YD)W5Q@ RE:9!IYY7&%[%UICIZR]6,
M-;7YH['6X%VTQA&Y5E)3EP1!9AK&UC?56HJY1UZJG365 2.=]K3MIE.:FBTF
MW]W<6/;-V_+N475*__;NL])+N^J \E<M .J>JZP RX?U3#'MXI7TQFV56W2'
M/COCVU8@<&1<[DP%(LL$\BGES;]>9^?8EFGR&%'R=^Q+,)Y"#RB.F0SH7CF%
M^BJ!Q673F6_J_$+@R8,RFQ!/A5<OUT@FM$!9V\1I\NR<:]4\V\3I*-[BZ/U*
M>OYU_(.ODC4=77@>9/ L?5^\.5Z<%EX&0?259TO\S*^%WS^*.T9M\\K9-(.@
M8 L?HURKFD>M>S3=N>8U,S##"%R=#J[,!J<D\.LUJII<<GG1:"1:C5BSK=[E
M?/LJ%K^*>JT0R*>IPA6OPC4;99%7XIKE-4D8KCRKB4-74(Q#FAM,^>Z3M\'7
MZ^LTB1,O]$FXR=:+O&>R3;=C1U%Z*D$,T7/"/\J$24.?>X/R)'.G/DA8G$95
MS>3<5&MHOBJ3-Q7LE&J.SY#K$+FK:@#&K9.NZ:94#PIX'B2#8+ZQ5N0ZY$^2
MQX]1X'NQ5R$791/2&TH.+C[/KQT$;UOZ*,WIU2RJW6-SO2G6O.!8)/B\T576
M6U2V&WDL]MP; ;+TW:+U5B=;;]_']O?1F';!^$@EL$D3V%T#V+5'*'KR@E3\
M*QN[H4ZZQ/_[%<?\83D&*HG\=V/'5>TJ0 S.4\([RB2J1;Y[P^PDDR:5Y18Y
M.GM\(6\7RAH&=D8T!<8%-*S5BJFBVZ2Y-S#%EV&&CGC3]S),* ECLOJ5CQ!C
M?Y)^JE\'R1I\CE'(MX?>5T+*)HBX%%#'B(0Y:2]0V5XD&@R6Q>?\*,O-AHI7
MC?F#P3EZ9:1<9&O'Q?,;P/G_%U8P*>'\#9/-8X+]Y1.F;*(@_GC&D+A@LX4I
MAX+^K7A5HX+A1QIS@.C9A-<U5IB"X\*PD;6]/F84[4>Y 5D1Q$U W(;C&$KF
M_F8EJEZ.ZD:@ZG-4:XLQ? _\\]T97ZW)5F6<V I7K7S)#ASD./.Y$O8+G$L\
ME2LTTZB#-V1,"/O!V#"!+H"#P)0HN,#V62/K;.\8H[OX 2X::^7%#.!)J(/*
MSN7[!'S/X7I=RTR<;TN,_9%T%+X.AM:&?A2.[M3V2EA:'P>;QY/*5TUX*SG;
M-'.=YTT%R]33?X3:X:1= 2;_N<!SGK-))O.2[#AN]LS@D)._78)!D.SX4/:^
MBZ&4ZAYICG;50L]NBR29M2=_/]3U*Q+'@N8 1I2]>K%\\DC [P%T/3=C+@4.
MUYF#5!);?Q$ 66R D:9.IGQNIM2++F9_;T9*3F\@Z9[KLX!4CHE78C+I:SP2
M3JYN@0U]"VP$<7!8>@382KH>( L@;X]AK?&&?G4%L4Y3TI?#'&+RHX5MV$/U
M?(K?O. DVM*&H+(T'.;I-KK^\+RD*$#>T#!FZ%+1]=Y%P(ZS\-,ZO'OV#O!4
MOG'RT:._XT3LQ#06_-J,[R@/QUMU#"_]5548H,=JF3-H*RZ3GFU:\MY<'YUL
M^:VK5L^;UI4% F2%V]?&/D5AMF4J%IYB<7*S_O?3*$X^1<E?<7*+5]$FY)F@
MZMEP)7L1<^D&03Y6/DAK,MLI%;M'BJH=RWDA&6,EN5PAKA:1%ZAL8?-,R0+Q
MIK&_)NB%L5/5N@5:;J/4_EXE#/@;B_?XF?_,D YS5&FI]%B)/C^S$]'\5[R<
M[(C@[(UXH_[.3S3+&-#:@K?!0 .;^48%Z6B0-5 L=M>:>+2CPS3?0W>86/#S
MXP7<5 =NV,-')2FK=)T\\EQV7FAK[M#=GK=!I<^'FV>.T=&8MZ&F'TSSC3KG
MSZL@%:N9KWY6,O7'^1Q6PPP_35F-1RO6')'_+2V^SNW=9]M)928#>NX/^S9D
M[ $_RY#P1OGAZ"\@#)Q('#F!3T[0% <>QSF)1.;EX2]/C7T0_OR/E"0OEV&<
M4+'3=#"&=:8EL*$?!#E;^S##3]\;*'>/O*<[I#\$'HNGS[-FHUJ[D6@XHR8O
MW$M2,',&@O&/_K]](S#9<3H_5?.RL1C9)TN2,[0Q((8FZR@=3"KLM,2]04LU
MX[",T3!6_*#)BA\&L*)9P@4GPVYFP#JB6]D=@+D4@V"S^3_%#!%V3:M[+&4Q
MM&[#Q?UXK=;JXXNDC_B3  ^<FWG79@\K#M2#&$YL?99YPN&F;O>&%CL!L 05
M]UEL/Z/DQ*/+$Z8/T42Y(N?^2-D^098:DN%_! \BEG.V91RGVR*+\PZOF'V_
M1@$3$S"$;[UD]%637II?QRC0_V.,,@#HJWTEW&\ B$7:KQ8L4*V]_-!-UF)4
M-1GQ-@/F^QD_3(G>4RGWF#C^EL2_7U",+]E QKYR,A?#2_2^7GY7?8C)V+U-
MZ2OF=B4<#C([;R_B#49%BX^1V"?Y*ESHR9I#1PKHJ!(Z>-1>C%QGY(GX./3G
M#M[W]+Y>:E=]B,D#][K25TSM2C@<I/8R["P:/ >S3_>8QVR?I(3KA>!@FCR9
MPL('!0BR-V:S5:,R9=TZHF)9ZC8*@HN(\C]*-U\F4P>"E>>"??A#Y=VZW./@
MZ5XF[X&&10K.%W.7C42/V2FY+[RI*&_K?X-[>?P-_U%&/Q@?H15!MXXNY9LQ
MR]#_%.4[,X<[-U7*LT_I]@%3Z<>8LP7 ALG9/\[P4TU&ZJ$.IO,#-.D)S _*
M$YAYPQ%K.;\^=I+]NV67>E'/=[A F07@SCR]?:<IOE.6)^,\]-4#-)P/=IYE
M]7SP OU$XB,B>9=X-#D6+#_@#0G#WG"""8&NUU6.YRS66Z;)8T1;[K>[U[JW
MT,G\HUH*JU1->PNYQ@ /[##/,]K6$LX7,\_2PM<1KKU]8[OK,,?QH2M11Q.O
M+(,@^LHCL(N(7C]ANIOH+MJHS7J+4 P^X^RAB:)-;S')(-0 #E2E6>(UFSW#
MCCT&>?NFXWW3G[)O&N(-3[9D/>J8\M-6^/+MH=H=QOR]J,\A26+QMZBI^6BB
MD^8MH%]H%+<^166W.6_12(_/-GL4TM*6M^C#""V (U1^8_*R2A(B3#KV>./M
M*QY1A#'%Q_PENP?[O6C/$:UFL"!LC0E_*9-7.7_>$2HTR=(B.->XMUC"^)/.
M'EETMNPMSA@!.X#C5<TX4;=F7C6('7L,\O:%[=WJ.[(/?<K7-(+C2-N1@UO#
M3WZ;9')E(**->2 ?Y5J?4I-[T< D=_GT,+!X>Z%,IU1_J]N->PN.@Y\?-HC6
MHSQM[A('MUY<F%+/:V7>PTL(DREYM7P[Z@'UT:G6A>/G[H+NZB%S=Q$S/$H.
M;B ?":YBQEL/?HYG6M6]7SRMIE<UK'?L\DZHYG4-[=/MYHTSN.^GI9UGDW7*
MI%83 E_P[Q%EHLU-ZKOW-J?>5\7+O7;,9E/ZNCA[KMV/<1B\OIWA[6UG3)YM
MO'G<XG[JD'KZ+U-0_$IL6QS7OL7Y,Z8K$O.<)9.NF;7I>54D+@5Z3-(^4/*Z
M2%INO@ND7&O=3&MFDR]GC ]X_@H<'[1P)7S&): 9IB'CHY9OY)SW10S$$)5U
MB6QL%^DJ[R/^J[EV>WJH?U4#6M_/,N8XIZO[=0U_O5%Q852L$7Z9<3>)Q*]M
M;#--/F3.]I$:(RE7Q6%]XFG6CV=HJ*'V&R:;1XXL&\"]#<Z'0GQ#R0KS,Q/K
MN4YDZ3?D50T7YI]JHD,%FJUX74/( 'Q<&$P:XT5A ,HM*,)CC(0-Z,OR(4ZH
MMTJ.Z7C87%^M ]S7,:[8_9QO(XCRHU@8-M[&"A4HT :((SO0-NDW:CGF]OGN
M##$;LYG&\9UVFQ3.]C-PLR+J2M R=:32"UDW@I>XUS&7*0*845MP7$',^!^G
M5R SGOHC"V8F &;*@"8V/ZQG-ZP9/FXX]*7:#O<=UUA1X&5UN.C;B-<U8AA]
MHE$'C5XM>&7CAADV3@P=9=-?T^@Q[_<J!I#\+ O((63H^4L+*ZA#VW1< \P<
M'W#6H^>O:/B9!2H75F:UCJS#'YZ<_I[M!]V/:K2J'9&T,"[I:W]5(U#/CS+1
MB?FW4<44%!?&C\;I^B,?)>;Z/HK#^+/N1<U[)O]M-VK>T_L6QN'!C7I5P_,X
MGW#>\_]O@_G(6+DPQNO?%3CR ,#R-SVX6I!]A_)RP9@#V$0)Z.50W>*M1_C9
MF],H%,>#4R^XQW1;G!;>^Z3V6P-B++(/4SD(66Z*>Z//Y$GD1P#+A>%'/<*4
MIJ":+8@; S4S_"O_; Y<$('^&?N@S0.'OV*/NG$I\:$;[X?1\'ZO"A-G;PF(
M>,*!CW4PH9VW&>[%$9VS6$L 01Z$G)BI OMN0G^,HDJU(^O3P'!\E:.W?"-
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M3@C#,)3)7ECDENP3E;[O+3TP#O[Z4GU1G>AGS=.)!NN =?,+,[0Q0Y2+M&S
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M_=WN*-74&PS0-&#_E*$#Y:+WG/VB][^MII-E?--[]'.FO[_\-.R;W\9L:1K
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MOE5I<D@TK!LG"=\<VK^RQ+:R(I8?$J^X0) P)_2%Z^"KD5YTUF?Y?UP@(:P
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M1.]NKM#L[Y[E![HR74#F:Z27YH=%?WGFIS(R$EZMV8-R../C&T@Z=B%;]C:
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M!R <@^)I&=_I9#Y9R:DD%&]:/%MAA$)N#V4*!+S60TN^U.N7##,6O;Y0U*I
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MHQ]>Z-!1=C7LE5_ #,[UJ;%6#%5=**HYUA5M80!E-I^HVL)<JL9\7=]FII+
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M?/##G%K2@"%IX.AI0,J!5R6;KE 6@V=ZK43,]QSEP0L<]L#'R^EM'('Q-N?
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M.5Z$*TE"V@)%"W8Z_VDECZRPHS%""%(,WLS"55PCH) O11D3N)NW7*./Q=@
M21L?@>D=H;\P(3/LX>10<!? /<@9LZW<\473F(83+R!YX""[@H<&DBAKT!F
MDQ!%) 0: $,""!9>&N$.RD] R#!N?V3PV6U;D(TDM=E8,7W"J>""6F%"P+\R
M3,X/G1:G%N!^"P /%[ DYN<;G"MR4BQ3U-_*O-":SR/*!Q3!P_C=+2ZSJRLO
M-A'29#B@M.^J0ZO3 2'=)ZK5&0Y5H]-U:&\XM#7-6!;28FX3'U!QR\%X-0?L
M*JEM_ %F%B)D46H7A?;EEXNGI/8OYK"E]SNMGCZLD<A^ RX_KB$49U>G7S^?
M?[F[52Z_G%[=7%_=G-R=GRF__ENY.;\XOSG_<GI>H_Y+NT3!FPQ,J)Q+\5R
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MC:X7E,(==TC$S,7]X)SS700]:A<*X3#@'3E2*"Q&1.J(X9?BZ>"&U#+K+PD
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M/&G(DQ%$QWG,[T6;)6]S[Q4')\!Z9RP]#TNIH:V<1'Q>'V*]Q4O[T7WP_?S
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ME;>FK+R5E;>R\E96WE9 RE;3*EMK#Y72:4N=RT#=8UYIYK(4O4-QL%Y0]&+
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M("0O[45VYAG>6!$51$B+8!O:8]XX(N56 ('9,@8]4=F]OHB?1WEMAA-@,^D
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M/D( =CQF7HJ3O(TG/V('&(99P:SC\:GW?-)]7A"6G93B(!Y@@!G?DSBJC_G
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ML0P?2W$@%8*D !D^/EJD2[8_=@J0X>.=-=<QE-N8!C'OK=-@BI'&XK'+#!E
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M'Y(HI/Z05"'UAR0*J3\D452%**3^D%0A]8<D"JD_)%%(_2&I0NJ/MR.*9]H
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M\4 D0HU$ S]X 4; 0"00 0)A" ($PA $#(0A"! (0Q @$(8@8" ,08! &((
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MW59>7*#>UMI5=/M9SS1CU/$DS37'3>-W-(85B&#<29$C=PP#<!?#'A=#(3E
MTAJZ,64.Z XU9, J4F/;D^]%XQQ+JQ_99A4G[!8,ZS4?J8,\L'$LHD4]3(DP
MG)>&121<W^*QM5LE(CF:IG5M6&-N9@G%+2[(63.?6:F28)TIB'P+R]SYHQ'6
M8?1*OW\_U2!\$T%W9RLVNMV%BQ8@,&*50,A'H_L*5:X[SJF[C*/6;$GSP66]
M>7UZ%/EK"\#*M6U<?>S=U> @71@-!R-XC!P D-7B5N"J11PJ7W9N4"R>3=(
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M=M!"\Q(:OUJ+%MO?2-96;XY?*!!Z]WOJ+$7K<]B<?+ 7-.-L4Z]H8BS#WQD
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MP4L_Z[Q!J](@PKWLDL?/3_&]>E_"Z;G,O&[!.JHB<>%V2K[M)]73" ,++CC
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MS .\%II\?N8Y@CNHU]W ;ATW<!4D '@\YBQ27'1FT2>L!S-J:@K[SM(I50K
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MX*NKI*7*-*AG5!+19^"1](CR'?=[(53B>3@?H$K1-3^>+ZA@A%)$!&PB(95
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M_56U16"NXKLW8)?!]5$\0Y%EQ271 .I'&7+053S+!ESSU[FI,08<SH68_4(
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MC@R4"<9\H/GR<P6I;X^/7[Y\]>IN).W50"KD:JV ZWK)_->S&](H 20!I.L
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M@&;Y-;QV8P1:+\0'3*I+G1AX]X,JS7E:U:5%H7%1JC]_>S <]I^?I=D']:Z
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MK%](4CG>=\:U#8TQ/,_)ILHWP>A0B.U1-!*($0MVU%@9O*U$6)6_N:MUJ.2
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M"647S9,\344/;C(,565I2KE!1V;;NS9\MQSRX$N><@#=.^D\,+073FIV4'G
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M@GO\=(\A"5X_*:,-33N> Z/:]0C-.Y-NO!32SHQKAA0S!7EV,G;R1<--:_I
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M#Y/GGSS_Y/E_QJ2CE BV\4>"("A*J%AYH4SRJ3HCDXYD[;#CY;N3F &!)"3
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M-:FCU[D:+EFX6*ZRNOB;>H]MU6?IS(GD+Q)'?@-U_5"4YNK8QHVL8[ ?/S?
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M8Q":'NJ"(IQV?=D/'B/*_@ S"3=5M-$$!&[^^(9115Q):/-=*;9&X#.Y6C*
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MH4O(;?"1 F@G3*\<(3RM8D?W,$C[CFP\+_G0YC 'B4"X$6AZ: C:X#']GI9
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MI[U#>;W+[G- P;CI>_<GFQ.G#0315,*[6AC(S[F"AE_5TDQ(EJ@4)R98?W3
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MV9 M$87YFDXW=R,08'0@XI.^7T6[T41R=W1W>CXF5,UO ?E'[S/=0#EYA0C
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MNV]]&B7S-048\7-8^QA7"JUMI31WWOJCEIV[[-QEYW[DG<N-6>>2"H9#/7=
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M,3^>$EEMD_;NM!R#R*)IN=!R6*S#8AT6Z_# UN%Y<SBZ7A3N6(I5VGU %-B
M51#Z>*=U6Q:COTA@$9='5;VS=3,H+-%-Y4ZW@G5?D<JT'LHH8J@KD58PGA8K
MV"RF8C$5BZEX8%/Q/3IAZ9GRPHB/;LIV"*U6;"SHAY/TI6^E+5W="ZE>F+$H
M_RD$IVV4!_5BL=ISG?<2B.#[:,9F8]&?K+_,ET_/X[CQ3:-0' FN+P9E,2B+
M07DDW1P=9,0WKJI,705*B"T7-ESE-DIIW.[H&9RO6D@]HE-D1TLQ1SV(/H%$
M*_:7(.6K3>_G5*R/%/\P\()^Q>P833W2"NY$U+QS[EJJ*5U^0]]8C,E"W_:+
MHF_[9*%O^U>;M!?ZMH6^[7'L](6^;?%]%]_W$?N^>W8B3>A;R ABHO -!<7X
M0,',PYY_1:MM"(4-/92"@>&_:C^#I_ 9^[X,Z<&70A =\GF"<N:@NHR:HJ6)
MVK.YY,S>(NQU09B(%A(\]U5^H'$.#.B#P@R&R&-G7CGVPA<_>C%,BV%Z!%D^
MIWMZ&Q?S+1[.ZYX"Y2/G\Y0R,'#:T6,QXTJ[BJ4!%9#,0*&N.3 K5-VWCTEJ
M;-GMRV[_%>[VX(9X!("P&C"\C_-Q&\ *.8%.(>J%5>3&K0L_$Q0@W WA^QYM
MM-DW#;L]Z/)BQEJ0M'KG)'5DYFD,]<E!K1DU><HSE:UT?3T:XL#%Y?C%$"M^
M*/<G3MQM7E:<<]Z.T+>T>IGZ6-:LX7 '] :%$S:+R1'75;E37*[LCEE?W>*(
MA]@ '\A5_OGQ<7&[?O@N^H$;T$_PH#QG=K:B^*=@+#9Y6(R X.H#S7O-?P9X
M@H(B(;',JZID'F_[^UFX-K-'=RYO-_O,K&Y"/&V<Y@?7LA7^IQN5.9B3NP:M
ML"$T<&T/^/0K9_6W3E@UN0TV>8BCL&U%8243VWHJGC^O?E/^5JHI1O]MS.:C
M!C>&D0M_>LS\_05=8'(%X8HV[F=G!1_^[+G;3<G"\?&;T:</*#UC)&A2MB56
M8>DE=G7PCN3.]H*^QX5Y!]*EZ$IP7P;4N7&UO 6?"$?Y("S$=L0;WV).]^51
MAHJ6E! 5NLV^)E]HY\]/\KD]F;HM!58.HSN5?*N(0CYF?2ZL3X!/7&'PEAI\
ML\V$R'N\:H2+L4W6BGTE73)-&]71T(>TT\_1(=RNR[Y5MNUOF]8!_I])%##J
M,V@=]RE(7($FHVO7@P]^_:..$O"(/3<[XH6[1JIZM+ RUC@=CL)\?5,VE:.]
M A=E"VZG=I"%[^F<\'5Z^Z&E[V/(NIYW'-:",G1+#@-!RNG"\Y+3%-_D&T$D
M%'F?KSJW&< -*<V7._) :(4,;8N!F^7\=_5-V3;<_4#[YZN/8O2QRJS'Z_'8
M_%_;H?[J+,NZ9T2.)FF?<V:MW++Z "V)H68+!CC]AE:42'R377$;<)49X?PY
M=$MLP_'[LJ:5B35S^02D27X1QSUC!+"-[>#H!I#*E&(9R+SRJO#SPOWA;8'#
MG-4D>]VRY+7=.!5XUJ9,+RX@^=SUT*^NG3M*P.9BV4F<MNN+O.O<@<P#D!.^
M]9,7R+:LRVY/7PEVO*:56!>7J^^]1(@IS$?/J@\R6F/1"O<G5-JDFK@ND1]T
MZ\+*CI-+X6D3S8\[4%VC8032M(\>O':N\!$@>35069#/1\\<1$V\W(9X.'H]
MO*$(=D3I[KE->NX9;VW_1U&K&&FA1&<2DZTTVXVC;%KC98$&G-M^;^(8O:J%
ML.J@YTVW@")]N&B^0K(.$-W>[4[A@K3&O$HY<R]O%"7,CY37 :O7L&Z)_!ON
MT3L,4\8_S3_;U+I%\C4*. S7,95D2"1,"2&-T24+<$!IIZ:MU6R:RKZ>P=!&
M2R[27MXY6JO<K0T_).:'3I.;M$I[7<;YM:M5JMW1YQL48=+OL4^/5S,_<N-\
MOS8-8N)@":$EZT'D(*7N-FVY=LJO7W9P/MBK6BSZ??30F U1XXV.UY\XO00.
MT=&J3SF(\Q4Z7B*W.1BDM5,5IV;=D<_:\WZBC5FVO'83;1[[SFV+42HH8N 5
M)3\VVRT9I>=-K9%^IJX$HS"@Y@-;^FZW07^F:Z<F=RM1P)ES14\"SRKPOI;?
M1U=0AU!O1^6)WOMNWE4>2T-=KK[A$2@:O@6W'OBS+.CYO/]]N!BJ;'*C,[CP
M$M&*8]1S$"JS\CZXWCGU(.:%,06AD6Z/G!4J\C-6^/'3R>AJW'$/Z2<\=XC1
MOPDQ#;TA+5[8M/=^:\B,M4> >J38TZ3KQ937*-S:]?N3GKT5$.((J96,(E(]
MTKGGL0IWB=>!M*#28KC%$:TWD%.88M:HR40/!UTW@U^\\RN/HUY\LZHR7X+^
MN8N4+L)Q:NS4V=F3N"!^9=IY68RDU69$FF2EUI:U\[6X>EQBYXN_5R1P5O%I
M.3ON)0Y4B3GUF?.Z'@(:F=?7%N248IG*7<WR9'7O76Q9?]L!@6+KMHRK@,,@
M$+M31!9GKM+/#_:_Q[9=?4>NUIN&+L<C\RN-^'^>/M*=<YULOHEO+X 8*+WU
MHN_([@!^JAH5X_+ H(S7!9IM1DLF45_*C$.H; H:X@OY%YM_Y"'UC(JB-S3W
M1>M2[=[!Y?!K:05>KJXV&TCWU3LX&9HVM'=C:U:[(*G8ZKU!K,AU.KD>$K1D
M"H<CNH,ZB2<*E>3#=50Z*EK4$G#-CNT$WS_:41&^B)^1VY6<I&Y]E'5(#''.
M8J)]1PZZG,Y(P#6<S,OBZV7_OLWYGG6]!\&-/I'=]Y5.N3'2O-/J^L"5&\[R
M:O#3@XPW!\;-YOIR]:4+PHGAHK.K+;M[LT5["O=4-=1XZ8^63FPXQL)\NJ>X
M9W:ZJ; /97EC+$RS$]?< U887RR ^^C/ETNOQF-#<-_9J_'ITJNQ]&HLO1I+
MK\8C,+._$GS2KS""E>KS3)3PH#[BA[Z)\(^4VZUKG=>IA6YM-B-<RQXB?S8;
MA5A<C8,'M1O*(M<4/BA2\SJO3N32"35!VG$!N5QV(Y,;*Q:'45H[QI>PIYD^
M"?ZI50CT*,]ZJ9([!;VT6Y(Z]Q%L8 T@Q\DPG1)2];?L@W- X1=&ZW9YZR/\
M:5P;M,G&R'H?KVA2@/.>K4-S.J?D-7])CAI2B0 ??_*'+[J5Y?JY9J3Q!,B&
M10.5G^YR]3W*1_:, 4E;=TS3A;BX:6_IN2^JIKEF701:S):R1+1 SY&W4JU,
MGT/V48<PJ:(-PQ_)-*%J,!Y)&Y#_.!R.@8 ,OY.25X2?XLC;TP>US H@'.BZ
M0_PKO8JW8ZG:$/:87-NEP+]TM_1=O!E'98JHX[\>AW4EQ7!<Q6'!^_&[.M *
MHKV_^J:FT>T'&<WGKNWE%5_CNQO.C RUX?6 ,'(EOQ!R"UCH1\>K'8NB!.((
ME7?Y:BY?92;GLCU@[4DR10<D?!>FI>TEURT)"J&#QON4%3+N[B?:!K73,B7>
M683O8F.5\1U]&J=N9!D*^AKW  4"%P/H&8X4-BJ6RS\20^>030%30AA%CVA#
ML:1O%DMT3TG'>.4+:D'2 !'^<KS?@J& 96$C4#'& >;%]DP]R-*O5H:!X^IZ
MB?P*IIB/PPB@%YV3/KV0A5JX D^%;^S&1:P^,<\PO9FK-XI7&:?EUN[4:$4C
MRLK)G\*+>\1>_-9CS*5:X]!02=_IY,AF=&(HPI65 08N5S\X0P;@U6$7 7;M
M2HZ:AAY96[:]4(_F1T,79RNH@O :*"#2@BL4[G.#C0PX(9E@&AEA/8(O4?*U
MF&!I72E&4IZD8.0/?H:IBZ_G#PFME8GK9@[;QB=BM_0*(<VY592+/"K."*R&
MLL9YA&_G'0-AH(T7SCG&(3 2LNS25Z')*#M?C8H."/@I9;<9NBY-0M&#X+11
M6RV.5*=NV0TMUJ:EA[J*?\^6B/Y9=8V9[R@93(_RH]MXX(6!2Q1+%9_</*=:
M)I:B(ALZE1,OM>"V5?LWNBX-=@-L=#@_UB?^7&10ES+;O4@LQ*>_4J&7V*.T
MWX'5@<$!2WH>"B,ERK8UDJ>>3(Q7>*>E%]X@VXF[HK_R1G<[M+6?^Z$3>R&H
M<:EP,\2^E=_/E&QX1:;;=%1G:48VGG.^D) R9 ?;*I:N]1MMC7PPP(,L'L/0
M(MBH.]S"J]12A,>5+3/R(31K3N\78,<1J!7( ]VWEJGFG4K;L*&7_Z>3H58G
MKHQ8IQG^IMO5%=&69D/#3U64!\8N2I1$#I"X26G0I%?G;\%.VC49$U%A2=E(
MX"^[AB$WWM@("K?=J8T>^G0 I!4 .T9</6E2$T0A[8-!WXI+/C4MM,4$W(,)
MN&+@I,<6D@F&&9#:7$G^OFR,M-QIX,>5B,2MFHT ^"7,5O^#^09O).XBQZ-L
M-\.A8V B8'@]%E"_]\"\*PG=WO#1@.G_"M[R)\\N_F?".<:FY5QN173@-%\A
MQWF=F *+K.BDL4]MG-^)!B")$3URKB?XRSVLA%S$K^X](\Y"E@(]$L=C4]:]
MTC^D>\T+R.B'XEW$I;?HU)8$QX>F-%8_L'L:\%SF:<3U..&3B.):])/<<IPE
MT74<48^W<JULE>Q_1*%EZ'5Q0%C7L(?2K&%5[D^???H[?U6;.[KHJTW?K/7O
M49#=MR5Y;F)6\L1CCH&TT@*%4>#QB;-(]K%"#X[59Y_2_G#7XG+2X_Z?S_YX
M^>SW6'A_R>F5Z8$_H0?@Q^1[VN>97X0^_OGELS_BT_Z!/Y=/+S;KHV<D?W"*
M]_+P_;X!DID^@Q"<3VS=)QZ-+GA!;3+*<<R+S?"$[@^&^/G R7OJ<!^8TK/3
MA7C!J'-L;A$:1"&YHD_$)G?YUBG9K2#^T$QF^&)KPS10G[\X[($ "AQ[@[E%
M(8S8]=V;TK)_B8.(\T-T%$H6[JL75Q<;LG.PD7XMJ5[JZN5W;U[][?N7J^]>
MOY5(5]&77D55_3I9P>AKP5FQA:.-(CNM*P#C%64+L[[)VZ8O$:W3'^!6.C:O
MB0TL.S:!6\8ME&BSC/KX^;B4+S.PJ>D86*J8^\DS[UW>[T<0V*-K_9L++\E=
MK]ZA!)I-)A+-@3JX_9YF?M_@_'/HO.3WQ=<:!,"2N./GHQ5]H@A".=53V4:,
M[C &ZT:D!3C1F1"!SVQK77W^\FH53:]21^EST:';(^F2<^H"[8.T!2"*F^#.
M:(1N$"31QS:2S$SFB),PX6^5ZRSN920Q^?_($U;T4&T_8#).M,;HC*P0M$QL
MU$RW#I[#==KA&) PW>SZQ9*E\(K"+6F- 'N5I=;/[<,G<(8]+C/XH2?82[01
M%=H'_BY#&/+8G*9K77E8H\GMH*EM;4B2C0\+2'/^I"J,V_RF:?GM.>P4!PU9
MHZDN*]Q3; A=R])[#7N)CB':'@I37V,+&"^R=1/BYPT:J=$6(!![[6Q(A]22
M5E'K5"!C6KJ [Z=S:/4M66_RIS_EB(2BD 9Y[P(GD)\,0::RI8SVP>QIQ+_5
M(O$Y%6!_X-/=_S+4+MS^B6$ZPVBQY_'\V[>9R:$SQ6"^5A!3B-O>-AN&]V*8
M_IYWR/VUJ[?,'G[R9=+7,D*KM^)UO6IW>6V]=X$AZ.__^TW&+A9/2<'-M;KI
MO%7C6B0?8^^:#1-,P4/2E?VS\&7H 6]<22^$B/2UY)@O5U? &OL.0BR29-'@
M(3AP'RV<S+K(U928^= 3N3JI,K5TO>C3<:?:(X8CTSMSZ89.A6QUH""[O! H
M)^ 9]:YR%SGY1$]L?<^<"UFD OXAI]^]/SMR":@22WKYXK9IR0GNZ=^]I-FV
M[[4AQD&!!0 #<\M@;SRQ*;U\:FOP&XF<(NUY\4^\<X(?2^<=$PED4T!#\%[P
MK<B:2N,=HRW@NW2QRR.5,X^F\CV0W#?B?7YDUN#:<WH+W].RA>^/\WE9N2X=
M=U;,T9@:02_Z]$#=0N] 804>"Y94&W4Y<R(5FGY?M/DM#\CX-+9MBC+DR5*?
MK29Y6X5RF*Q-V8G1#50L=SU-A!/2C#,G+"T\C?MS_2^'3E.]DE&EHS&,P3$_
M(?F*)L&F*+<G)>B1]S12F<A]3+U&+_LWVTQH4CY!9X=;;4.F/,P)<J_<X8J<
M.B^$<KMH03PZU/&=_06_6_H+EOZ"I;]@Z2]X!&;VZ43]MU)DE1+F050P>Z?P
MMB&X)IKN%V_ CMOIN1]"TBA'F@&_ @= *TC>T9AG#@AXO("H"*&E:@ O% $/
MD#1\'DB'% ],YU[%@ )#UR;>V@X_,(?@R'$3-47+&HW5$"6B2OPY[3R0=2+Y
MV^8XR_!H-!+>[>5R]Q.+=):U?$]5T:TKF&<F6JEE)QT&] <L0WA[7$;CM2^Y
M;FZ1$7!KI@@1\+%B7RCZ@;?%!IDM>O2;<J.(V&->%EHQY._]K>8JW5NN62()
M2@=;60R<8<D]$2O0:*X&67@%0+Y0Z$B>T10$OV6MXA+$G"=A0HKHQF13A"K=
MJ'R'@"Q49.U:_+1\+6.2PG.?N^2*+;,A5QA3ZY$DYUC8[/*]@OI1B06^&H\7
MB36@0G?@1ZI&5J0[=3U(4L\A%946-6)(S223DRH[! 9YNXU$1ITF/@',M,*1
M)'2WY4\,:RYV3@)_Q,25UL #::*F!D*J*29"#;<7HAT.J4'EHY$YC;:2$H7,
M>Q:OTT;YE"^DKR(9FLO52S"\"K46H\NDFVN-VTR,*[,_<@FLY/O2[JG#\V4C
M]'O( *B)C18[!^0TRO$ZC8AE>;E%7&%,4]M' "M:R]@K66KO1W1"G6,X>$JF
M&*A_ 3@-C$O_&')=5DRJ%/[ :*7%:;@'IP&98VV/DO+I=MM$+-T1H]AQ:,FL
M\NF/AU:*L+#FL0GBE%U"1/4NMU)T&Y1;<4MO(2MJ60'W4UL$")PG7CH_F/\<
MTK36/!-.EKFS4>:860C!\@-@$B^@K[%,5J_#NGDU2>E^_?J5MKGA6-D)0]P+
M8;L[K;YS_6W37LM'OWGQ'9T^^()\GGX$]VF#&K_SLKMYRZTGAU 9L'.C<#CJ
MA4BEMDZAHNP$26DH4Z9T;8""U22DOT6A5HG1CQ1L566B11Y3Z>L8C)^V/QWQ
M)+"!VCTHC-QR0*_ !;=KVM/%^G1A_]8.&#O;\J3Q:5WR+(IW#I:^+\M"7)FH
MMXBSL+W!/+GB=60+R\A7HZQE_3?.I*C;7I#U%[FXVZ!IW$1PF53N344(+E<O
M@IX<,NW5*7EB:9LPE!6-C@V.'XOH?9R0^LXPYPF< 7B$3"@ E1W9_01L$@#X
M=CD/[K+%D/^HJ\Y/R^7J*X$"'9I6\6SJ$>%9*J<A$PRB+%_V+DZ1'30-Z1B*
M/)_V_J_&TTN2(>3N V:UOX&SZQB:Y%JW/J6HI$B5^K_X=;&-E]/Q7CBX&3"N
MVHIY6%;:"XP5+*9)0#)*WF\@&;^+X69O\PW.-*;GX]..R1>]L>2((5Q/6[IG
MUC&N)0:J;J+.6>G2JY5:ENNF?!?N=,'>$8B^4(_I<8NZBK=)AQQMP.2DPBD3
M0((/>/3L-YIK]6"96S/WIH2[]X!!;2KG']P%$DQ!ITR&; 1+]8.6I:/CXF^F
M-HX1H-Q>HT\IQ4"I.AH#YVB;S]F>Q$)C;$3>@FE$:;Z;H=<JV?HT?B &HGW^
M#$_QIV>K@L)2BT_(=)4;-\-X%[V=M$V(,1F!-.V5R(N7J.O&!8L2B7=J_T,K
M/?/< B7\%.N3CVGTX#NG7)];GX1U#JC=60S-?0#XYPABM:LF/N(Z6@*=0+Y/
MP>EA4!^?"I-C9YF]>S@FO@VZ2+*C4Z>SLRAH7W8\<<@_M.:-LG/$P3=-(SD\
M,/ []I8F]OW6!7L^6B23A3'G@L0K23^C_8V:&+G53A)Y4+.%>G0(9"$R$ISK
M96E>@_2?\/X^VS$"9'BTFUB>0W[M4'Q TUFY@1%BN+;_.&>&I-(A66?1'&HD
MO9Q-,\LJ5(2$CHOIHFV;,!_%(#V<JPE07EU@KUA@O-[FNS)L4GL7O/B*,?&,
ML^0A%AAGR:7/O \/T]3>@&L'0K)]E8!<6T\WTC; #6F1W;_E?OY6$853J03:
M(%WG380TOVJF+XOI"=ZEQRP=>7Q8U"(@,=+R^F9&>L:O.'DNR2$)BD.:]3H!
M\4OB43=!>@D0TY-GS>>D_Z3V^(=?C&\Q>%]9!]_1H$BCOI QV.JB.ZS=.0:*
M\>K)1CS;[6%*JCE? UM=T>3+<PW2$IB$GXAHFOKB;Y=O+Z,$)">9_;1$NI3)
MG#Y8L]9G'V;J/WMDIOY##^JPOCVG/"V7FYQYW'/S\4\^<%W'J]B4Y63?FHZ+
M2U3U !^3KS)'3\DMQ%YUS;[FF722Q:\9FWAYSF[H,ZMS<13N1=,IP*>]89QH
M>R22 C2CM. H_("Q-I"DZA<%A3WA#Z@OMJ6KB@MI\^0P+_,:--+BD60=(KDE
M?H[U4%:<4XHD]-X.=7VZR='L]QQ\7$U;E[DM,RC(E$Q:+%VE8!K/VY4#FP*%
M(M= ,.!H9RHL-KWL7R"_41<PKZEZ@AU?<0->+JOV=74B5P."1=^6-5VLZ<-^
MNUR]E29"Y<K28=0_PXRNQZ3XHH912-&+QJ,Y2;!D@G[L*M47'!5'XGY&M!9>
MD*$0+2=O:&3(-XE0I()@C%OER'<2$16N4%X8#%(;X6[1:BB4Y[&@H#D</<:3
MUC\(?F@0C7Z&+B)"$IQ=XBG,*#:4"BG/$G^2Y9H.QXK>5,\5EA=3-\7G%R*I
MA_F5)FHB&RL9KM4^P3_T_?61EXDEIAB5P!4=*9\$?$)F![SYO"CE<OU/GNHV
M,%4SDH$-*8R>\(_XM:OX4HR)_5CA4YX%#YQ'B+5L8\A:R)@@WWF"15H,R2SK
M7]4\0[0#@AGB/B2^J# NM(YY/(J1\)7E!6*?G(GY:;"$/7R!MCXVP-N=T-;?
M+]#6!=JZ0%L7:.O#^\9/QP_68Y-L&.27X0%9/J*;X:T1;@NDXGTFPM@+[O14
M4$^\8?\/%<'#FBE@O42GT3 $43PD[A)MTZ!PICE6'Z@5488EM,]$F"ME*$P2
M6)-DG,\>Q()LF@&9A(^@A5 @V$BK37!33!48'B A5V)5OXY"5HX\,JDV0].Z
M.9*#*'ZJ.=J1U_PA$(X%&?QXMUN2Z!3FS9/-VQGY.@;^L;ZA%>A&F<D@@!<D
M[]I1%HW>,#?UT3%QJB#1PV+CY.'Y!S*_.5J=N-UL&!> [C$R3=XF!M8-743'
M$L59$TG=R1[U^VQ&-9%SP0:!SHS^<2K.][$VU.JMZC-.T-<M9[';LF(0 ^K%
MHA4OW>TQ8#%*9&':S%1:%=*-YPT (K8AW*37&<^X9S%3[4E$2O"-FTYA(- 7
M0J3=R(]LP\*EY]-H_A74Y/G7ZS6SYF[*AJ;6L)ZFV!A),$E!F:/B.(^G+1,2
M,=*Y4W?,IZOW4^BG'YE<&=QDQ&;5)QG7@]M4'LG36&"8:#UZ:L#1W<)G.HYA
M%VMY3RE>[KLI8W B4PO!(B6\,D+<X/'3Y4%64(II%& 0IW]H/M=FOZ2:I0[+
M:MTV>4'_RUDZ9/QD[VNJ_[;?^](?W<05:N:2T@-_0!(3RT*Y[VQN?*;2<,.0
MRPK@LMU9;'2/LAULZ\XU.WHUN&.@]F^""X>*D,+-4VK2N(!%I@CH-2S2S*??
MZ%]-+S#NI& W\WQGREFBB3!E%>6SEZ^"7&I*R,0@H)G%/\(6^URD/_EG'@MO
M*Y!+Y2:2(YQ>"_P= KAC)K3QV&8)="YD["26B, W9VZ,%U0$(P^J[K=C(V05
MY.: EX*9Y7JWV==<[N>8@?8)_R B"V548G5&I\Q]+"U9 7P.QZ.B+>/&*;@1
MLP_+!<+QH^:T9K'[HT'%5SFSZ!OJA4B\9JJU."?I$]:W]+2^.B_.276:6Q1S
M==[6^2KOS'B&>PO?.1^!=,^#>!@!;,;/BT,9)0<@"]XQNOQK50K91-#B<N81
M4RY?Z'"PP42&_%UW*6M[:F$WL-=)UMD=U=^ &1B-+/+FYIA(0MM#0K@<$D10
M9#C#0):B#Y I:(29YP53<&J&.:S(GG&G_(0*)DHOR.Z-48\)X4;HVQ#R?KD4
M-+19'-X\JZ^"4>*;\!SS/<X_OJ3SCZWX/8-R>#C/!#>IJDNZ7LV00--F%Z)<
MXKW.X',(8T^>*0!F'05F8$]LS%V2VU:KK\=[9XPZV6N#$:(6<S)H[8!N;3QF
MJ !UXKA&FD_S15X/&IX1MQ7H9>3\B\PH@T,51A/:22,?R+4M+(;!Y^6W%'8-
M&\DRC --'A//>W5N1LIZV^;^*G&Y+"#,QR,1;A\]%/MC>U<=L9Q@5-W*9-C1
MW.!)F\6?TD2+J%ZDYRD(N#UG"YO2SODAT1*A5V]E#C7T/LCS%&6GI2U;'^$W
MD[ER13);7 1J.7R1&?'8?Z!/F7SYB77+FOAX[*O<N6"MUX&35V7;];2(JBV6
M +W^[Q>_]G[210STQERIT?4L[;)W>'/3:5B/W5"UO1Q!^]8)V_99V//BSQI,
MDI9!7C($*C8$:7 %>E9UQ$+VA1M^M0/'0P>9Y'H2'9%QPG24VU.H$6_:09I+
M1Z=4]*"SSYF:(6^TV9UI! V8K83L"3VC.%2LF9GM$7<!5/FM^0O6@&E)-;&Y
MI73:5H%*21OD#&6HN8LNP:N)C!P<EUI'(>^UL>?)D8I]CW88P9B$%QP[2(FS
M&;D7G!3OVP;R#').79,_U*4.WG7=W%:N4$Z$$E "&BP]9SM-I!WHB?>=3U2M
M'?IPD1GBRWJE)%6'Z53'/0D;%+=UHR)SWJ_1[)8X@@:)M$ IW4]\O>@,%;]:
ME0S\-D632BNJ0X6<K0$@Y@$0MC>4#$U:I@6(R9%2I7%BE#Z-NP)];2%7?0LZ
M80O:7#$VN' '=CW&</2I^V,QRK4[3291?)$(]9AN?;_CIUE8-5?CUN2(<UOE
M\CH!DPA0(]);HMLK1UOJVV8^8Q-YTCW'*E,G-XLAVH7KRJAR) I=FJ5D]%7D
M8JOL.T*W4F2$-(VH\Q!-678_6>7EX+WG.@W70D8'3P$M2F'&M*A%S$)4^..\
M/ML"9#QP<$@_5Q06A5VT5M.0&TV&"G@RT,LJI=Y:X<07 Y: PJ,C>GH&V^KG
M_*9K?=)&NOWKH-H2(+&"3S^J5Y[*FS#\S:_FZ#&BUYNDG!AX:.Y*P6/:)X!
M+'KZIK;WIM>@Y]JU^:%['\L]378Q-]-/3%+1\Z'],PSV-*ZR/!+76=0>S=%[
M2U+9IY-MJ"7+'">AO)F*OG5^AOA(HROV&HXC5#5S>KGZLM4C#\E'&!5?AO>+
MUK^]T7 TB6D/S]N&\4A.+Z<4&G2 G&A(LY7(HTZ&SM]16P@,,AA-C(+ZZ,OL
M<P4,K!\I2S,8&5>21HJRD0;GE;?O+;+A:_A,@UV$O#+N[ RI$JY>A4$(PV]"
M='H02R(BC[<W76%H:V_C6T%;ZGOH4O3M,[HA?=L/IG=4=U "FVB!X"#7=7&&
MW>ER 2X^-CC3G<#%SQ;@X@)<7("+"W#Q$9C9]QKICSA@2T#S,: 4W^\3_9ZT
M]-W-$,3X2G!<G.3RIM9E+/1N?!QQAOC?T[H)#[P'?3%+1BM":6TF^1Q?[,%'
M=_#$=MQ#W,8^F/IG<E>N V8BI:ERSKZ;3Q\Q\TJ44CNB6!HUB*$61]A*<Q+.
M,WY-E2%[5SQ$DON)-W+^/,5[>GB*5]O3_&K,8C"C%'\D?9LTDODZSCI52(I[
MR>.&\"@:HK/2/X'4XDH:.X10SZ,<9VG98/VDR*J:>B<'Z;@O5[#).]B527T-
MS(UMSCI[SETKD:%(-TF_O>Z?R<:)28)C) H+QNU9FS[B"&#I0 5ERUC<F&H.
M9#L<CT%G+>L')H4T.8^NJ0:?S9W?SPJ$8/:FPYAL(91CK3N/HLK-WFJ4^X%[
M\*Q5?ZS2*OIWHKWS5_=M7M((>,F?C"+OS66V^IJ#>K>Z^C);?9G_!-N0\&#J
MQ[YW[7!HE*2SHEELC^HJ9:L?+O]Z^76C!?@K [YW<@?^Y<L"M&#=ZJ_EUG6;
M4F1XHVM<KMX*-V:PC9YR*I)T5%6GYU=OHP&A'73<2P%"=!"O2QZP7AH4T8BN
MQ0FZUD\T08"2K%%WL% 6 Z9T%AG+WKI;:7M<TP)H;(V+6B) J$)?9&1K-L)7
M:QB<U5]%<DF+ME]20$Y7?\NQ+'96.G+/F^;:CZD,]'-PZ73IQ^@3R/;CB:O-
MN^=B=78R,O%@=TUR4V6IZX[TUM^^T&E['>GY^MHZ8 QS5PBZ42_??/7JS;=7
MWSU_N?KFF[D+^X\^O_AZ *,G$GO?O'CI5518%$/K#H+E94&H;_Y^A06N(LY8
M!M\U-PP?$BW>^?%_[]>5%#,H+(*D%M)J77PV3_1%K7X>6ZAL3(_A3V:8NYIU
MU$.5IN>6C(SM7-$..T'U!H:/L>:C$<'IAU59.J)07[L>>UCXT[-4*S4+]]4I
MS91P0Q)'<!+4/TBK$9;+"E[#^VIQ,B@Y8FDZ&=N(='7W24^T)&=G+-F(A"3&
M4:"VL!&<HN>%E^N0I9Y=$VQHQ\_H9PO/Q,HV*A(KTHQ,)-ELMRIZL\V[O145
M8B:58!5P!\V?*6"?K%:Z@.AR%W(YM6N\HA;?_7[0K3QK+JP&^3GM+<I6.9QF
MM&&G1&->;?P&13XZ/F,@J7H/7&MG)SR2'4[RS+;7?(;>4#6R>%+T6,AAQ\E]
M.R4M8RU$!8K5+J;H5@_X\6_BZA^;DZ\'QXLY+V[H%ODNV6]_?BRBF)>?/:,U
M]P&9CXL/6:9Q,NK9LR_H1*;#@-ZHK/EIUU6SN7Z0%)7?<U_<ED6_E\WWC%\+
M)^NGGW_QB!7QOM8%'^JSC'(9R.\%=I&A+GXS?/&45MJO),NS[,1?R$Y\FP3Z
M=A#5.;>-;9I=S7[=L@67+;ALP8^T!5]&;N%,T_M,DLDGVCB3Q:[@T>$8%;Q_
MZ[; BP/7X:.Q+&*=E-[AT DKG);+'E_V^++'/](>OPJ)'*:)2W.ZVLP?0[V$
M_KQU:U:? #"%(N4J2D_XS]B9S50<@U:#*$Q#GO%&P%X[8>";C>F^P-V?TM)>
MMOZR]9_2UH^/]]G."]:#IQ=S@2L7Z9M:E6$>(A&X;,Y_:Z+T7X#>/(HTZ8A4
MI.,FT6T$%H@J_R<OJQG*K* 9GZUY)D#?8\,]/%'R$>6_*5>[@9NE961"<_UN
M['.^VX'H6EI?T]Q\S%QEQ9ZHXMU=,J5T]&9'J<@H4EJ_ JJ5P*%N&>44B$&W
M]N#S>;4+Q]WA DT^ P$QQR$0IGJBL!B<':I2&^:*;_C]Y1FYCL2/DL _D!\N
M&<(2.FBYX4<Z."LL&UL#8*/I7/'$&J]6WSU_\=2:Q3Y]=OF'%1=./_EB]=JU
MFZ'/:X=6VN];NFDUH$Y;K:[J7=G0V=TQNQ%7$GR#<BIAZ>5R,96XQ-;1,L46
M3!<<%]($NL^<=J?#D0PAQ9X;Z_:K"^A]>< #"+&L6AA+%U0N+^*."M_%-&YY
MP[ZP:M]34?EX7';^0Z%LHYX7,UO2I=+-M*.4==W<2!-.U"P@#(4L;\? L=A\
M2AN.MGE)-\X3F-:G7^=\!THQ 805IYJ>;),%@!5CG>AERD*I!D:\,/YD&9.U
M!YP8+Q3&]^#\]'BM&,<0'_I*^M#WCNQ,#+S@GAY%G;D1LL(O6./LL?,5FGWS
MK9IQ&Z7QE(_43'"JETPHOU?"[,#;TK#X%MH81Y=,@&J13%7TCO.\'K-;:J0#
M8\_%6I3-&EID?>@%MZ:@6P6$2+=JWHV$:H+<60I%'7-W+]OS'K;GB]#=%F]+
M:=TRA@]83>C8=CCD=]&16L#4LLI +JJ@'EGEN^+1]:2BU#+?K1L=KJO_;FY1
M^L\24J&P"J7?.6G"BTECK$,NI:8ZUT$9-ZX)V5N.KN%$-5J(-L_=/E8^LCMR
M:"+?X([M].R1;:@2GZ[> [ODE<J]$9IMT*3Q,UB$J$\EN*/T11\"%O'0^^67
MF2AZ%)9!M"7 Y*7$'LJ1)SCJWIV!Y]7.%6E!9VE6? S)P#N;%3]?FA679L6E
M67%I5GP$9G;)XR^>T]/VG.8S!DDR*D3M:4 0)ZF@H\7BV4V%1@#)63T$5&99
MJK_8I9K?-&7!Q(#T*X24GF(:]'BT[C;]()&NZ,SQA"OGL:&XRH?!22^K\A>[
M*J->,DX*F8J$)EJXK4P8AD#1DV].1N@;Y5#Z_:K((6*)S!.]G^\ZLQZ_A*A0
M6N"69;PLXW_C,F[6GG@J<$PI'2D$L3:5RUF*4QHND\;Q]_$6EN6Z+-=_XW)=
M.Z56_>K%U07J,E69&T]A@(VII=5>=6%M+83<U];KLBZ7=?GO343? *)H&B41
M(W03(;>&+E+Q6);BLA0_WHGN5Z+', FS;PQOLGI_5/<6_A:M]1G+^%2Z\J%@
M\<NZ_<6NVY"1BNBX!"UE@-8YY9#>Y0<1,QF!J19HQOTP1 ")$#30MLV&:9;
M6L7L"DP_.\$/&&-(%L,6DG@B?"+2])W]E/3Z&>:7E16ZU=J=&@3/9[BDOF)H
M54[^(T7OVZ:JFEMA?]BX\LC(W<\^>?:;Z]^&^$>"=,1)Y'HB!_K6'7O/J_-I
M)@3"K L(Z+47S%1<6>LJP7=L$R:7E_46L"K!I]K#OOE_JR^%46GUHJ0_"U_%
M\YQNCDXFH]Z@ZY#72T8>[Z;J*)]* 9R=Y/&M"Y%3Y?2$ ^'[Z+N_NWQ_BS'J
MA;G_\M%4SY9F#E0>K[^]\F&J8.WS(^/+0(I4[@83XQI-A*?4^<M0.Y'9D=2X
MG]$G9D[/+4!;/:RKDRZ WS^A^7]BL\$!ZORV!'M6+<1T9P2/9J&0:4_'M!4C
M,^D97>[M:NMRY9\?[ H=ARDQ;UY91YSBFYR%QCWK#@@2O;[@"GSCC6#B8EUV
M5G\;B[!$,@1>9D_%6%B'K*))XBW)MORLG'O, #2KVN89V&/<9LG=,YV YYG1
M1]5^1VQ%="S I+H6K2AH0ZM/9B9B]"T]4*.L_7570M-G'7%#Y =TF>)[VP&X
M<*]S??:E3%U R$3!']I8SRL3;S'!OT@&*"(PWZAB\?I$(]?N$LHE_KS 6W&(
M<*_/A$%):.3?\4 B=V#B)]PV&\VS#8/%&>^>-!449!3RI-%'.F7>-40STW%.
MMG1Q_^ZA;QL\=5$?6>$H./**@98/KO*A9C).5A9*&%5$R'@BY%'SH116"Y><
M=V#GBQ5?<3D5PPF"L[+\7<(9'!3,U(>+B.Q8& 178J%/IMR,7H.I???JN.7^
MC:*U&6-=U<,ZMXRS*9UAE&E'FYB[S2)RTR#GH<$.@/KV9/,DL_>A [1LK'N6
M 6*9#MY#DQIBN14%H/+ 'FZKK1WLNLJ?(G2&1\O*QC'AREG!4ME,4-V$8S!R
M+$ ^2HX,_;__V+0?+771\??DR>WPIJ 'JB:\?P_<AD/CT86.# XLTTNGHJNS
M4I(T@2S0PQ=;5NQ';XY[X3#TXF:*OX I5%+=8J:5-VUWC!H6: 63VP*/5$OH
ME6OEPM#KW2E];[P$$V% T_6IW4[$^([#&M*)_6E9!?=$J>[UL<HNID]/^LW+
M[GJZ0*2]VE-[9RGA V95N^Q-$\T*?)XYF%GY$4K!+Q=E929-7#?%*3ZHV=E$
M"RY_T_?AJGO-W2R.]<%_'-3-1KX([D=11IF@0]GQ$X$:M2)W?S,GBK1B<@"^
M".3_=O5JR[J?"8\Y>P^RAT:&$RY04W.V7C=69M?1+V0I0ZX2W'B_',0W5<.B
MX(%5Y\+:^<H:^?Y<0R,)&KHF/1V&&GLQ\@V4P8"'YR1< 'F_5Q=)!M,(5.E^
MY(0=)AM>]WDDXX E4+3Y+802MJ+?WG6#B8_EB3U0(C NKV73ED6Y5R3-/#81
MV8Q]D,R9'H1)Z @V -:V3K*&=R12/N'P-!!DXW,W345QH: KY,VW7H>R:OI)
M0BK)"+[E[-3;4]>[0^PARK(2*G0AR-^4[68X=+U -LAE9H>T% )GM:V:2:#W
MHFT$]A555(.S:Q^AI_%96QAU:0*-&I6U7TVX&)JU>>\L: "Z-5XHZU,VXNGN
M-BUMYUJZ[3*?3PVSMOBN3_T,^(%7A)3#?1;REMP\VGXGL;CICFUA4IU8=IMV
MM6VZ,-A(\2$"(K^M9;54QI9YOGAYHU$2016? Z*KARR,K%)KZ3VVI=@4N8=L
M<7-:KSJV35@[RKZ2M^&X@ 'UQ7S_2ILJ+P^> 2!Q@)E]A/FI?5P:NK;!( H:
M %:.QS81JR",)2I+.#XC\]%M/?.V\5^S.O" U!]##=H5W;W@GLPT8Y8VC_*U
MM *"9SI)JPR;!']#/E<*=V :&YWB0HCAO7+NW*UCXR(7YR?ES\M'M%6<OYFD
M]?006_;M?;$@))Y5JC@S57N)O+M L1/<]!6O;I\%*NV,D/URN7KE6=?U+"5+
MD-L.J-WF.KB%:Y:X5?D8;CIN=S2HY&$6$.5IP?$BE JLA]&IAPG'P<Z/&_Z]
MY;GIT'.%J-"W9G+(WY!SB[PN6O'X7>W:&W-TZ. ]-1N6XL">V>:M?A@2X]=6
MJR9'R.)3&YY!:)5"%A:F9.D^?6P]:7=VG_YAZ3Y=ND^7[M.E^_3AO8RGXU%
M5=K)^4[A[XT4N2/_@ N>D5@,3GL?%IA:6X54DA>AAHO0F8^ M(ZOW[!/Z_V1
M<UZ'R;2GV1F1MY&D3WX\LL_?2"@JV1M$&N-\1^8ER+6@'L@F7-LV[2B1,[U
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M%%JX9SX\B)0[^)*(,3;0V*W(-%>K9ETIBM[3H8Q8703 U$4),']8A,&@G[*
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MJV]4:?XKF;_5RZ#G^Z)I#UIIX$WSS5<O7V0LXRERH%N>S#/FWZ1SEF^\;AL
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MB%@2I=A\3CK9,J;!GLY'U(P[C-6#<&3ZG<0%37PYI'!R.9XUZ56H4"S,&>9
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MQU&BF\#+!A\H[R7A7G2:MQ>'OC'P)%=^4D^>"U#!S:U*C<6SF'6O LK%<MO
M4E06RPF,P$+X77*]@,!"]LM?$,EV\?>X I(./88G0TWCWPH]9?2U,#_R<YX"
MGE]0$QUB5"=)Z-XXAE"E<[^W=A[^N6MFQ\U\U5>J2ZH-LZJL65"#,J>F=F?\
M4*!%K)7YT[C#8R)X<:4OAO7/A9J!7J,@^S+YAZ\.84;[JE"&(G8(2WU@#7I:
M#XQE,@*+Z?++'" <9<C\D,"N9?PD'L?BHC3?&%$MKO=W)O?XC?2$(YC(WC=T
MC]0AIV)CWHA@"%FS.[YU8>R?G_R3N;_I=*/H5':VM81W0; .4A%".W<RP.3=
M1J=9QK@MN@,9.$,>\& E')C,[XD8\P"PF%SM?/4W%V;XL(="'JUP/9)4Z<,B
M]O_05.4;R<L'T@M:]/Q.D7+/^]S98M],&NOS;;-'6;T#O:$D_R$OM1>;Y-A$
MDB9X1;)'6!57W?I24#1<\)5<Q&"5UP!TVZ"(L.$U%N^C9<PFU#J=R9_?P@Z8
MEDINL'4\#+(R'\'J>_S)5\5P-BW]"30V&V:Q-(L6JS6!5I)MB[SN+9/^,)Z%
M1<PRI =: 1TX;IBVD7Z(L$BQM'W>@;]!AQD%@=S].EY<57&)(_Z,OM=+$5@U
M8-P7,Y<2V7IR60\/==^._:S)G^/OO&\AM3[Q6Z127JJA#S_E/)$@5S '4K"?
M//F\WIN[*?VI+>G0;1T$8WR7ENNA]>KEVU5W[/H"A!EUT8/DT_C>I-O'S[%(
MHM-YA48"(-9@7LA5BN@"&2S^J:1%QMS3-PW \X>K8\=[OS.CI7=WX[^BR;_)
ML02Z9M?COV)%E'^K;"RQ6'H@&X7' X$K.X\[M1DYPZ%1+*77B8'B_T/[@@)B
M^2QFTA:/\&DL41@@I#VW0I2"B5*R8/,TXQI7)^XH[Y%FH5C5 UE((#;"0PM4
M7\'OR$"?.5>6Z7%@#J\;A?0AYQJJFTFRK6J&K2YXF/(AO D\!7A@>,EBO92L
M4I9I&WLW J3L-(4MO=-UP!22>Q<I=$1J,'RH*-_ KE/O9%V/+#LOY4"?I.>&
MZZ6Q]]%V_U]<BA@;[PZF]Q',",7^E]R_C67Y07;]UY6@?D2NQ"]#(/;@/]MS
M]TO!SF-Y68LKH$;TA,_ Y_U0YP-=JF4N.NWS$=B9<CY(&9[LC[3I[-H\H,9M
M%^5]\(IC<=]P-_J=9,^ZV 4&+K-2[/50P>-59 9G";>H. 18SS;?8W'I$F_5
M2Y(G,>2Y_P26AM<JW:':#;7!IY@Y078./0X#F_ CFH9N3^=?WJHIJW $[H=:
MS9CL=]CTEBV<MG)T"5U;-_;S=.8VO.W4S:+-"@^I5]"2W["6C =+V/Y0-<="
M+O$O81:2V>03F*^Y.5(<<P8UTLT[_OD>#BICT-+Y_T.T3(S!/R)P@;%,+J"F
MA@)C&H.%JH"" /6U1]:VY3"S)ELN_TW/1PO_K-F=V;O0:\'>LXTK:EK,1=&:
M^9/GH;5;LS.IOF+L(8B9 5E%;!2U1\@9LE):_8#=L>]JT!H:#MS"_\P337G/
M6E9*NL:E>R4//'UPV3-O5+D)KS J$G6G+3-C?7-9NJ':L<G>R1_#ZI[;E>Q_
MH3$/I[E[A7V;;Q$6T(G1N]Z54X8^FW=,LCO]$=GMYAXE$RJ#[W.Q!65G#H;T
M\;AN46,G+JYH.T;?4<G'1CPKD1DU=H?-8.'G$$" E G.JZ@C57)O<#3+F?#'
MS%JJD,2=$?-9QZ=2K!AZ<\,%X;W*$ CI&#AGL''&7H.[!9T;Y;8ZLJMPK2F)
MKCF@FN@M"SO<K,?6L+IW(1V2(>NG_=SB?AK?ZJV6U0RKE'F'CJFN#/@V:Z<4
M/FF?1;.E'$5[;;=AM)8W3^Y?=AA@:&?B/-B6#DX$\]1+-F??,"\@?!MV"UTK
M<E\BMW)!+EJV>CV05Y>'(C.,-*-+?WC78G$IZDOP#(,[=DZ.@)Y&G(H"2Q.L
M/SST]&7&"0CLRF9B(%:3;WP\'S>E&5&G:^&HG'QG![0#\G9SI67B*?^^WR58
M@6%^'6VW%*YU03("V9H"8+MH0&?%EBQ+^FB=^JTT<&FQ/0/C+KFCRL>)$K'\
M*_PD "&UD9-==A<D&/7 N/TJV"W\C'P)1E  *XD^ZIA@%NR(O(F$V \+KZG!
MB225:0U&>-_0_TK/%_G7I1*RTAK5O@S.<00$N'?H$SK0T#R-^$/!)N+8#*V.
M4S$PEC )W@F_H+"'-$J.RT9:0/2,Z=24,>I[O$?"RM0USC.&H"%X,9TSF32+
M?!]_6"U9E/MJY!57P;\,]04S'-?\ZCD:2FVL7QEJ&M VT*4^:XC!;C28N]N:
MVHKQ_&ZB2\+,;X ,8_>)\[)I[%;*INA]I;E^]'" QL2DV:!?QWI-0<3'Y%ZW
M3Z1[RCN\L\G3_@S/"^;%)S9N^8WW^28Q>D@"A<;B47#>I"DB'[D%V9KV/0Y:
MO462A)MQXESKV2:IR3&/JLQQ]I[O7&PWBZQSU!FJE<:$/,H.6Y&.2TGQQ6>1
M[>7V%>! \M,^'*^<RZTXJ1I'VG-)7VX#H<N'CV34)Z]M*S_S8IF172<<I3B3
MZH(]7*LG2YM5J.F%?"VP-.6>-P0=U5O->B';=^DR .S& /YH\22^%(DS>)6$
M]B1SNMWJ+;9!8=@/PT%+O<# #G$%K^V"WHAT SXV)H>X(03_6!<WJS=?OV",
M(?/3)VZ6MP+*XN]%KO3C@H7)\P4C]^"0,[=BY#Y?,'(+1F[!R"T8N4\?53V>
M",I"<PG8?0<#3M*7B*R>GC_Y@LFFZ5AEDK4_@V.-X_K9]$QPB0/07M0GG$X:
M.ZO=IBW7)MYKG\3 !'^7E!^%W!L*4;3$4>[50]=V2?7/7-8_N:+E*^$KY_"T
MUZSF]DXR<J,OI1<5=)IWUE-NH?<1<4,V2'Q?[WF)\SO.O&"^-DIJKIF-.PH8
MF;;^OR_AW*1=G!.KR.RVVR5A<1^05,:4VKLZ-"@*:2^,]4*;2*02E!1UAW\-
ML> <4VC*$FC@ND#7\$LBIAC\*YC0!NO'Z 52AI$<#W:-Z9%RAC7LNR S@EB*
M948";C!3HJOQS3;<?@1B1HF?Z(-M$>".@X6W@6\=R5/:1XPS6%?*%U:KQD^F
MAF=G'7G,Z)#I^J^4@QT<!WMZ]WT6 RCL5Z7]5PX*3SEA5!3+#KIO77$MAUL.
MVH">+A$=*7\8/IP*B:N2')=2I"Z669W>=,J$9Z?XJ13$CH?>F" Q#DK]NV)/
M"U[MG:8^WA7%886IE%2\)M)Y<+'3T*>47"+*8UA"Q8IQ67KF7 Y5SIJQ)AN@
M3 ,.' .V.(] 4,RA;!T%(XX@77%<7-=B&-&/ S^1 AN%(60^VQ;+"PFHQ=+F
M5BZC%X>A01V(2]*!:)7S_/:P40'V9)U@6AV()5E0%/1L2HRT ME 4+.0[=WF
MDOW7F>'_'@Z7;2Z_U$IC7H>SW[]^S[:4^;<*9V<HJZVOW&G%6@ A4S%>MYSD
MC845]6LNH#LFQ2#.(!2:AT)%U-AG<_Z$M4^X+)\]A;(W!M9;'%E%>FXLUO/>
M]&[KQE.W=(5T[*8ZY+'#%*_HAYJ7R9N>@7#&'+MFZLS$H13%=#Y=MTU2G@B7
M%L,E#>)&1'/;W92'=Z\T+K50+9D#D9P'CXHO(]=:D]0A@,B!K>G<E$7H./>*
MTPY6D=8$]BVLI)D[##+V+!DQ[EAR\(\0O&3N% GJ\5KM'9GCK51TPUAN>5>_
M]3W\2>*%BGR9,];R52:M(Y.E-[QQYW?M_)9-N/;2I7= (8GEB%_6IN^8*PF1
MZ*?JK3/7Y/2.>="E$#$[G!)066T[6_U[?L@E4GYQ1:O0A]5SIY$<G@Q*T02]
M<W98F_DZ!SS:L"M](TPRXIG(#\O]&JAZ]OY,2" ]=%.ZM <L%S#//:CHCO!A
MTYY\$]/YAZ*6E(F,7A&9D7RH-U>3'TMW']/[MT%FV1@Q<PVT)G<8"><:& X7
M.3IP1\Z*I^CYX^Z7@V++YKB3-3:^_=7.#C@1!/WPZ\FST0?\:&/I6WVB5),S
M/1AG3]G9@?H#[>;#3^SYO<],%TR.$SI*/OW9G30-;A]9Z9%/Q4<V9H<E==:?
M[3/B+:P5M%ZL1827W0%GI__U$YSNLZ6/\R^>T(G] ?6/LP\YY'U)ZLF3YQ!2
MKW)ZHK+FT:ZK9O/NDQ2J@L?R_*;<]E?BNCSAQP+HZ-F7SQ_P ?95"9'EH3)]
MBJZ'SKMBSSF;9A8M]4Q&"&/S82SF]?!PRZJ;6\$>;H:&W,RT:>R&"8(GA,C/
M'],"?W^']>/4Y![Z_"P&X&$9@.^P]P]010>TCB+EL!DYB\4;-K_I?%Z3=[UH
MG7:!&2P+8&_Y%V+A5K*9X.)H>Q'3**V_2+#P[-C)#UP<D2AC1"Q5@KARL<8!
MY4S]IE(>=XO-6&S&8C,^DLUXK<I:C5"X%]N0J@=BLFE%G83^8\/.0^N*>^9)
M3-N^^=V+#X(6EQ!Z/7]42W79RLM6?DQ;^7N7EPOG+XNA<9[QAHM[(=<WEX*)
M(@ZV81_3>ESVZ[)?']-^?>U=8X>0B,5]QB(E/3-<_97.G)J[7]#S0M,?:DDX
M<P<A)EJV\+*%ERW\4;?P"Z;/_DD9A495W0<\[EC"D]R@&!ZI2[Q?P2;)*>XU
M\0#F/Y8F]3\E9Z3< \#CY(GY>YZ>#067W1F( Q7/LIBMQ6PM9NN>*@6[4B+Z
M5._.3$%U!.N*-Q>Z[=,R@B^1+[MWV;V_E]T[5W8>/?@GW^"'HBYZ)=<5,)O3
MF3;5%?2O-Y%=P8NJ,JU +<C5P&FI?"\*^!@4]10]A%:9> J6_BZ[JV*[V(7%
M+OQ>[,*];_JW=D@+HC ERIHX[R&W(%LY6(,@KHI&A&6_+OMUV:\?:;\R4WW8
MG Z+::=U,?*PP\F]FZ/6(+=\V.5*X^AW.]*#5;5 ;SZX'7XA(WG(9"1_7,A(
M%C*2A8QD(2-Y &;V4Q]7#_TX7US/A^5Z?A,85K0#P2"@Z(1S<EV;XZ9B30W+
M)QU-$863P8+X!BO IBBO83\S5(H*=& ;F#30(X8Z&9E8^])U7@W%&8T,+BS]
M('2P,ZN@:NGLQ(,UV*KXPI$C!HUU(@9 GK1P_PG!BS[#;.F*VSOA*9/C;(,1
MHI[-D3Y4:2OVP7<5P.\"E5U\Z,4H+4;I(QFE'VHAG2^V"3U&3K?:P20P\_\Z
M;]O2A#9.X,P?S"Y=-NBR07]#&_3M5(PU\I"P4",K5.AQFK1XJ'YZ)RQQH?7D
M.1.Q,,2<:8"VNLM]?XE1O\4_F.0K2M43EX(">*9M:POIN.^Y:F4,,+Y&S2B=
M;9O?P)T L1>/[;ID?@@F5/;)-QF8ZPNW)+J?D7;4/;</C3/:0R,]+:D@##M'
M)6-TO17+E#H(8A11L<RLX?32/PY-GR<BMY.IS*RG9M6L*V,X]M)P%-Z?R2VB
MH06Q#JZT6-7%JBY6]=>WJE\;-\Q-D;^K1]SU9;VK(IU_X)P!CU]O%0/4]U'H
MH_@L;X,=5,J9P"7$I8,'LX>7^&79R+^UC?QZQD>!)JF7B-N)M.<LZP?G/-08
M=%'C&&T[DJ50H5)R%;H@&*J1D !JE^V];.]E>W^LG*G+ P;1HH-)UM-_,-\%
MO'B1OM6Z_F4!F9C#%1WP^_(GID@%F].R59>MNFS5CX>$JSM6:^:P?$M'Z='(
M;9STV+('ESVX[,&/M ?_/A6=CN%KPHGJ8ED?^M[D(Z'J^/.A1E8+Y.0]8W5P
MJM)]D'?+5NOFN*'%Q/DSL@!E9=3DFL&+0LP<$R<)LN?X^#&M^L4J+%;A,5F%
MUXYAUG !FOIF9F3N*)'0U[?$*]I@4%!L9)8SW=RVJ58B9!&+ DZ3+Y8<!/(U
MPZ/YC>;-7HA>Z.I5BTM!O.!"0 A/__*G/W$6[IL7KRZRU0_G_W&^^BOT=>A9
M]"O/GCQ]$IXK;QE0-LNXA?#!$9N6GX;7>;$ZORKO]2\ X3T(ZM(+T3H766H@
MR<%U+ (M3M6C.JZN\G8O0DU"3WR*8YV/VH1<4G0ABA^' A?*A'G72>ZJ5&J
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M^,(N,^]P4/9X$03%.0),2D@2=,!#X>5P1*Q/DPO R;\6C%CNU;0\^3JF4^_
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M9O0KL:XGI"KZ:.(DZ@$F?[-*<SA3X\,'!U%F+^4&UPH"9[[%2&X82#VI;/.
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M!<QX"RO$-N'4"@M2I1\"Z?O ]LPH/#DFIPQLE&-!B5C.4%.#@YTS#MH?=4O
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MNVW#'9ESH<^1O,]D[9,[FS.QHOGPE@Q[_X3!@UA SYY\3N]PJ)D&PX&'TZ!
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M8ED?[#)]=&&1\Q04J:1JH[INY^RFZ$5R_;O8413$17VEJ/#]^E=-(W1?SON
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M+R*"1'3:T1V$"ES!\CV'+VA'64L;1-TQ8\><#>&*6X#*9_/@_<18?(BM4-$
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MJLIWA21MRGI7#85)VLTQN@3I Z2)7)VH8,[*F4J'>+D<SZF#YSPK+7^(TS,
MHVXR57R5 ;B:HEULUV*[%MOU,5MM7[RZL+:@_SA?_;4MUV@IB@IO3S*/F=7V
MBKX\VS1M.PB-7O2 0@I81(I4SBRH(0H ==G3RYY>]O0]^".O D?7*RWGO!D
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M7*^N\J.HU&%YE;1V403 K1Q6P+D!-^9GPA%<%"#NY?A/!#A'C@ ]F(C@.4?
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M/VQ-YJIO5@8."KRXIH#3\7QF)6B<_?& 2W 'NK,&5ER.A'UNQ]K/Z>13],R
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M@PEA",QHB$D,NB?Y0BU0"-\X9>,!96DZH1Y],2,X*5(G'9HIMHTCA)J#]6&
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M/ A0K),3;)VLZC)/HM<&+2,.SHVBCQVL/XU^-DG13LCR/GG]\>>8J9:C@5+
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M$.=<0I0X(=H'9NEK*C0F&%F2LM$NF]F;DP[;D'-DMBN!LK,\Q:BQI@-N9?P
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MK/5T%:?5O 1]/LEGK.3]/)!)U;1Y8;AOL#8*-Z_LKNQ^<TH^U.(V0FU#=G\
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MI(A.@OS@O[#*BO,,'J\"'DDEJMA&Z^X.LXK4/D<%YU(P2T>(@FM(<!(UG6,
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MI>RW%MG?^J[V Z&!4A@<[*Y6^'C\Z7/T[MU#H)4'IQ#6V"^#P>Z2*ADP3\&
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MHK-/,&%?=:6-S@P._D+ &@B2M?1N\9NUJ7S;6DTW-I4/M*E<F\JUJ5R;RK=
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M>#X77%*N'.D%T@LCD[U@L*0@F:1'X4N[0^\:AJZ+"RYVEHCCRENL9?%6ZVJ
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M=AB;3L.4][GL8>ZIFX9$HM95=E''SG8"G*)WA>RX=[U!JLB/VP:O*FV<]U^
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MHK(1?43Q6(\63O(D)!7/:,33+(L#+W /&G,K5;B[K"$)."DE,A,5?$IU\OJ
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M9GS8:M5<.-^F^*AM_+3EU:TUQ^>$*.)4QTZ8M1S5TBW*EQT#DB;GP#DW9,Q
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M1/2#M)-A[XF\4,3T6<PP 7*T2@G],:W[!H6T=$ )9=)%.S!W?I-G7,0-AEQ
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M9YZCIX4!'2TRWH;#9<H.W%K%H-1@/*TG[C L!!+4UD,AO'%*)7TU?'<TAV^
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M.90[-0LA/Q.I3EJ? $%JGM3\TP_U+@G27N0QVTTT9MF19NLFTP++\+7$B\S
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MUTI81ZQB@4BF!7&>4A)%%)IGRC6UV[3XW99-F*63*9N 0^ \4W(>J %J (>
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MT36_MO3'-Y':#CX>>Z! :B UD-HX?7;2\@"I@=1 :GLF->E#HCX*$G2D1,K
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M-D5X77GMXWS^]6KN%^EE"N6IJWGJ1M.A(.3,ZL^OZCZ\RXWU/F!P,#C( K(
M]PRHS#01&<%T$%U@.I %3 >F ]-!=!E.=($L( O,Q(;IP'0076 ZD 5F<<-T
M1B<CF ZB"TP'LD!Z;;"F@R6^!Z*F06KG\]-UFW)=JW1ZMFC?I73QX-EZ&4Y<
MEZJSA6LFW9Z":;GWL$,)-'OO)0!$P73;:]-M>7:*.:](HK4F,O6;V03O20Y1
M^U1>K [\3M-M'U_8ZN9)SR],]7GQU/',LU5\5M=Z4O-L1QBNX%AP+.1:( %
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M(6C8?^84V4ZL,C\U6]JCD#8W'_'ESHO]%/FSU'2;N^W>]7UA3CS: 3$"@BR
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MM=1VINX#R_8+:X!.117L@8$H( J( J+XFBC@'U %0@5$ 5% %/ /J *A J*
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MI=E-1VJ[*W<.3VG[SO[L5"6#@R+(!7+98]W\'F:3X3J0Q3V)&] '] %?F8)
MX"N0Q7#B!O0!?7RCKPQ$#]^S6O/N%')3:G;T;H(T[+>F8;\LGV=I52W:[HO)
MUM&+9ZI6<[!,&10Q(D7L,9K<>D>)<8IFVD2R1YWL;KO1[S^V6VP@H4U.3@E'
M&+6:R"0X<77,Q'@:7-2".NT^W4#B^;+-\]4_BM5>W03BU_7YRGB_L=\N=LAZ
MU6Y[3X@/FW\J-:NEV-LF5]]_-::V]^?]L"&0""0 ] !Z#% G(T</JHN]ZQP)
M]8P2R8(HZ&$]4=%E&KU*P5S;N^JVZ,&OH ??/GI01H$>0XDH4_8=H,>]EP#0
M ^@Q,)V,'#UDX-S55!#OO2(RNIHX9R,1S.;,>%39^F]%#W8%/=B6T4/:F6&?
MWQ%S>%?C.GJ@WV+LKG3@U/Q1_.]UMSK?Q&/55LM4;L<P7Z2JN:@ ]H_V7X>^
M-6/=I5C-FQO[,AX.84X"0&G,]4.H!"JYKRJ9JK]!%X@>D 5D 5G 1: +A O(
M K* +(8M"[@(.BP&G7A]0,V\F4#V]==4#B7,-S6/RC6Q<J=MN1C_<_Y ^N,L
M-5V:=AEQHA:$'@PH HK 5(-A%9"KX=:V;S/)46C+<]1$>,V)I#H28U0F/HGL
M%.-9>/[I3(/CU4E:?FRS1TT\^LAD]]]U\3.?::M'-.O@3S\R37^:=H29J.?
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M]X5:O2$F)4YT8)$FJ:.P\>O4^I&7'F)=,SJK#1LUKTXJMDS4;6 OD  D ,(
M8=R-,)*FQF=*J**RWVQ $F]K1;BGO#QNHM;U%@EC)T4[-I-R3,N" ##@+I
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M[_Y5#/AI\_32?8_>F^_^BYA55P13GEXH><9J/2)(QC3S,7K1-,P': (Y@$7
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MT7):?8W5WI3U=4_F(9G)#Y.IL=*FU^^[:XFL1^*'>+$NFF&R>["79/<?1%W
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MQ<UZW5F'W(8H$BB"4_86?:_5ZW 2O]2%1Q>JS['%.272(&D;CB6U/"JU[!Z
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M6SM*]MI\X*'1TRX"?LQU89M.V#5<V;$]U(V;S/"1F.&V2>TV2Q.[GP#+%M7
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M9[$7Z%2K-%-9<*BT@UV>/8&T TMNYP-.2WI<DL%#"+)? E.2P81EP@A5X*W
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MP;PH]AC/ .6EKO!8F/-4QUD6Y+&W!Y3WE;C=@5">3(3K14D";Y-)QKT@9%D
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M.*&BI.-05D\Z4:!LQ'PO@Q@[1;>'*8PCJ[,] I8:1\+,@89V/@N[D/^& -(
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MS]&N4H/O@"V1E:O&J8NS10'VH8 [MG<&8/UEJ1<UFB"#-3F9EH C')WG"$?
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M-%P]@CF#A^"#I@*"Y@"X1/\Z5QBP@6M-9BC:=WA)&[C-='.I-0;PJD]PHZ7
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ML8$!7 +( "X!8 "7 #" 2SH0?^D\3"#6LC,DO3;U:1'^/1M>F%$83^N^Y8
M\70AX@\D RB S0F  /@ 0 !\ "@ /@ 0 !\ "( /  7 !P "X(.N^QGO+776
M?9Q  ;,]F946WML6!<R\P=B2P)'U7"%NB4!&NA(YS8EW3AH2R/4"9MD3_].5
M(_[E]+693"[3I_ZW&<W"8<J6#;AZ5-4R..L#O/"PQ?3^M)I,T31,SHKA^"+4
MT[,O1J%Z":E^*PU(B8#=*" #=J@ #. 2  9P"2#CZ,@ +@%@ )< ,(!+ !G
M)0 ,X!( 1ANY!,)G3R]\1HR/I7$&*6L=XL)CI"(MD?214LP85?9&^*P))'P(
MD[.W5V&$@P3-!!E0P7<;->O\BH8(V<[6R\]5'O1K ;)^9U. 3H#4*]A?/DT4
MP%X20 !\ "  /@ 4 !\ "( /  3 !X "X(-#@.!Y45>CH2^^P<U_:7SSA[<7
M#4 ,@ :(*D%4:9NHDA:4:RLL\L1:Q 6W2!-'$7>:8NP]DT1<CRIEY_L1@DIZ
MP$OQF)"2AH-8/;#XAUQ 'ZJI&3V]S -0#)"2 MM+0 9L.0$8P"4 #. 20 9P
M"0#CV"8#@ '  "X!9 "7M D8SPM?S>PH%)^'8U]]SN-:T)/R<4&1VZ,LP#!=
M\9S>6]KP*2$*XFT0;UN+MPFII(ZF1)(KA[CG&EF<?AA="NT%<0*;VXH@7B^$
M./9'.]NE\8#B;2LB?C\U:2&G?_WPHEV+H&6L^_BA:<W([%B.))QE5 _',[,
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M'N+JMAKYN_#T8W#AS(9)P<B@H)A2,$!@@%JN6XYU(.).5=L6.#S*Y@!">GG
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MG #" $  P@"$P;WMBC&-@FN"F"<8<4<Q4DXHQ SUPI2,2O]08>#<[&PVRM4
MFK(D5U5)\L&Y5R&1=/A@_NR(6N @%( CGAI'  B>(@@@?'[T\'GW40.FXRF:
M#N /  %$LV&C><]&$UN&+<<**>X]XDIS9$+0R)<F.Z"=EB0>.9I]$,^S^+J(
M=D\2ZR#*O:<5^+HZ.PN3#.[BW)R'21O2J$!T=$QT]!,8;=S(@A Y7BC<4LL(
M<2A(1A''FB%+74!,V/0O+K71N"6A\"NC_ENVZ3OU:ZN!DB6<E0;: -H /0'
M ,=XJQWC_402F!@P,< ]  S@'N >X!XP,< ] (SV @,"NN!'W0SHFA@T0\KD
MX\D41V2DL8C;2(E2F%+UQ<SA/0=T6^ _A=/)W2.)P\9M)^?5Q$Q#&N*QK[\?
M5]/[VSQT'CP@," [K)T;61 31Q,3,CAN V$H.%4B;ER)C% :,<X9ML%8Y;]8
MZ^1@0=F%Q=[\O)TFB@U*^K ZUATT"."/ %8 :0 @ !]W"WS<W4<-F(ZG:#J
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MVSTX[#::::N1OPLOKT>FKH=Q&'QAZN<]2_X!HMEG\D\W00"[E2>) MB9  B
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M,GQ,?]Y#HJ)+/O\MT_E.I; >",4?Y,CKH)W86C&TA1L>8R& +4 R  @Z+1G
MJW8LS2 )X]99B1BE!O$R&J0-MXA)QX.),3#'VN-5:X>$Z$]"5??M&9 :D!J
M $#05F7386?(7[]1E- 7/4,-.-/!= !_  B /X[%'U NIA^&Y9!@^M?)^Y/B
M4Y7&>YRW^D6]<C^T(4,.)$O'V*HGP  9 \  :=,B:=-[)(&) 1,#P !@ /<
M]X") 1,#P !@M!<8P#V0'[V6ZT3+$(TU C%O+>*."Z0$C\C9H PGKE1.=:+>
MP;_>_V/E"GWY*:27AGI_IP<E&S"JH?8!I%$#T8 " 6!T7X% NO6Q)$A4)EA&
M U+84L0%(4@[Q9!5)9>&DE+S/9?=WD\1@\,J$B+N/L'50EQ 08,^T. A$=/T
MW4:9$X/?,M>A@_"!O ;(P@,E#2#HB&KNL-^NGZG\8#K =  (  3 '\ ?8#K
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M9-9@)4K/ [E^<FJ5%IS8_I<EV1^B]I<8E(0^Q:ZH3Y@U0&8 8%IK8$%F@,P
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ME LA[4Z52+M3Y9$O2ZU9J:QGY=?#@V[ XS&$DN!!J.P:/!K+TG&$.")*RV5
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M6_H79.Y_;T9F,@SUZ]ED<J 62T0."&%0^O9)\08(#0!,:TWLTQ8:=R;G@-
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M.<1I^F&\%(A&0ZR60C$:KI><>+LH\_C;O,KC <_Q,;I%B^=>+68P\&#@ 1.
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MSJ];'5\;QQ[/S6637'GE2R_,).%M4F\6?&N\IDV$/?<0SG7CFHM-POS!F^&
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M0TZ4HJ1&IO^_48W]X2KQ=!+"@70B9KO5B;UT28%VW*5V%&UP.H"4Z)B4 &
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M;\W2;Z:X!R=\A#H1^\I,Z^EJN^?L1G=1<3;T?A2NTA4E@ ) <3V'%4 !H'A
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M89'[LIF(5$A_"N)S^281*3%/(IS'=0C[H9RT+,$G"?1R9_12CLP3 502W%%
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M1'@1Q\X@);5*=IIQ5!LGM/+06GIXN;?;R92*W][0#SJ#OIQ^L7O+R 90 "@
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MS?MYU\GC[W75-'?[3,B6SX0\);S.*)O@\AX-.X>]Z,%A :+_9?DD  3#]2F
M_C^8_@\TQI";R>FH*.(X*J09EXC22%W@7-M;FLG=I?^;!Q& ^\>['\@+'A#^
M+MF1YD *#BT(@!2 /@ 8@#  %("% !8":(2!R0+8(PJAJ><.3865.71W<&HD
M:(* U5#3K""(E0X:KA/K+P/W8@4ON<,*<>DPXHP&9$.DR!DFHM64*HNO>;%R
MS^3W3;,,_F_+>KIN+-_5\MMHXMZL'5)^;T$JP=FD'%9BSGTK^0Q9"(')#.H)
MS&@ QKA,:PB^'8RVE-PR;2A%WBF..#$.&>TY"BYJSB,5$9MG#[ZMZ4ROXF_R
MB&O8?0J4 C3'@#0'0 .$!B"C3\@ .P2  =JD+R&^P>,$PGG/'LYSN?3K; 9[
MS88,G/UGD@R[2R+$ZR!>M^7X4H$%R@A&F)5YJWW42$7OD,O>,"LY)?+9=YV]
MJ^H8IHME'9JW<__C'Z?3SIEUX0?;6WB/,#'A['9_5P_G],[PWIBU55^44T_I
M\#C5%9 70$._C64(VAVN3!#QW%A1(FU*@7B4%AG,1"X&&%Q)96"/"-H]E;OT
M(8;'\1'#L(?NT*(!B .HBM'@ :0"H&#P4@',"4 #Z C87@?QN'T:>H]KP4A>
M0#( A.J&FB4"'1C! W9X#U@4.@G*:!&W+B NL$!6XQ(I25DDH90ZL,-V8'Q:
MB<B)5'BB[PC0@6X K@K*X270!^AT\7([70##.-Q^?D(=5J5 2FF'>,D4LJ5B
M2.KT'_:&6K/+5AR/[L#XE/ 9Q4>\!,H!E ,H!V@+Z,!X6P=&RT*D/# 42LX0
MUUXB4Q*+J D,,TTH+>D#,QX&U8%1',E+'R5T8.R/   ET2\E 78IV*7 -'J&
MI8';I<0)QFVPB)3,(^Z=1=H3CI3G$4O*C*&Q'RTBKUFBCVL1J<E$XWLD=<*V
M6- MCUEST(!Q-+"!Y% (I@.E>+BKVY>DQ,(B97 N7:LE4DH9Y!T-I13.E2$<
MO $CW7*9T*=$UTLE)Y@\S-$]P$4/_@H0_2_+)0$@ )<"Z/\'ZW_IL!=,$L1U
M#G7;*) Q94",!QI((,;TN 'C5WC! Z+?3!Z)AR7<#5 2 "D ?3 (?0 P &$
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M><\HD0*Y4@C$F2>)")01$6NDU$(211Y>"6-?G:>_0@L>TGF:'96W5\08B20
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M-@>5 2H#3%4P58%N#(1N]/#9[M-6R!D;K;2H5%%G Y4CI7!$)$9B"//)7CV
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M427BG'FDK6$($R^P\[C$>(\DYR'E97KB-"%<32B[/;^VA[" ^C*@#T$? C
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MD&?4>>]8Z>S^J<\R\9*!![BE.!*W4R((<(],#?6AP@+K@UL9*BP,E>.,#2'
M>X#WW-%N) J*B?(H$.81YXPA6TJ"#"L#T3S(*%0_*RP<P,.CL)Y06D*%!= S
MH&=>LK<%*BP 60&RLG>R(IUV4NE$5KADB"?BDGB*ETAZ67+MK/%ZCUL:GZG"
MP@$V'<@C]4B?S "9"_A?=K1@?_SC-+B\MV!1M;L,"K-XF"]F@& "&KS+D-)
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MO[L76:;[YS.R14GQFV9Z<CJ;QFGZ\B0LCBL_:;\@63R'.MCS&RX?_K4TLVY
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M\T]/P8V8-N6BG5\8^FY^U[JN6P'DPLF%?M7V<WG=Q\:%U_JP\[O[63ZWA_9
M5_3UYI4#1,46&ZL#*'H+"G9$ !6 BK7[(0,H#A44("H %2 J !3KB IRQ $5
MCT>%[X4.]NESX-&]W31;ZO-Z %+DJ0;KB?U%5OG*\'=';FQ)G5CHN2__]H*_
M6!,4KX*Z'.=ZCE8[W@ZC?4$'NT?'=$5F/+5-_!8"/;(<Z[OP]-\N/?C=C?1@
M4$^@GD ]/44][4\;/4OB;%=![4DIW7[!?3I+NB(R>J*=7(1R_Z)E/S"ZQ[LR
M"!1U0?F Q.D'5G8J<0A(G&&B""3.3KR\?<?*]G-Z'Q! ^+'6]T\G)^_>O7\_
M ,/JL.SO7>;SSA/Z [L.SH*?\Z+-G?UE35$V'(AM,1>J>PC;N<K;*DZ 73].
MUSU8?$4^O%M(/F:WT%<K6V[OHB&9B4@2(LQ"@EB:<B0YB9'041HJ*:-8);O+
M6[ZE/(H3AKV0X^&1ZSYU>Y&4@Y'A [940(J#%.^J%&=9J"C!&4IDX@H*BQ )
M*5/$<91@S$.CHG 3;51!BH,4[_**!"D.?J?^2G&5)8P;SJW85B%B(LJ0U#1R
M99U8C%,:&_S 5G^\(L4Q2/'[I/AMOKO>BV[PTVW=3W=52>X^<=][)($[;N,4
MH/^8Z*VMUGWYLDZI5"XTRWB$F'35D@G+D""8(\J9$2DW,@YQYPL]WE)R/"_N
M*CG^2,ZRB?J.+#YB?2X\%*!A5=S26!BA0XR4H1EB%$LD6$)1(D,B&39"QKNI
MN+5AT-]=9W\/H,<X/>IS[;D_#UKM@C\&R!B0L8[I)26PIEPP1"+&K%Y2$J6*
M$Y2*,)%<*L+X=JL+/T4O77?S=YV,<7P4]5DM#8V,B3B5.HUB2\9(@EB4&)3$
MU@(A,I.)$)ASTDO0=XJ,Q0RX6&>U+G QX&)#"G]U7YZLTV"<)&FD#49ADEBU
MQ!*!9!0F2%#%62H)CDCW? 37@W5=YV*LY[V AL;%,B*(,3Q!860,8HK'CIYI
ME$F36L,D833K7N.L-4#?*2[6=P,$=JP<1@!SEZ#Z?'O_J"XD/T&$O-\1\F'B
M!!RU^^1)+*0T2E*,A)#,\21B/^D("981G$C!)#,=;V&U)]/@$>W<(HB9=PCR
MSMXEF<HLVF.,F%81DK&6*+1@3ZA0DJ>R?Y#?A6&P-N3Y$:-]AOS!:6%PW )?
M [ZV;[FS3MM>H3 AL48)S0ABQF1(1I2@+$E%9$+),Z$[IKPZ$E9_1*?1,.ZS
M\AH:7XLBPW$49RA2B=OY$PN4AJET00P<2R.)$G'_(-\IOM9W$^7@M##P->!K
M$'S?M]Q90WF%/,M4%(7(:%="QH4@990ER/"(<BI#K@CMF/+J2.C],7RMU\Z&
MH?&U)&-)$KD]6#S#B+G225+S&$76.-$4IY(D/81\I_A:>(1[W?]]K<![[U4O
M!-FW!:"W^7FN3:&#R]R,];"3)R&.#@FU3_7!WM;)HU<L_JX7>!XZ_O)30C!Y
M#;GX [+[0'2 Z #1 :(#1,?>/8D@.AXG.KSQ^[(1<FSLWSH_OUF7K<,K<=^=
M3)X_-)T9F:X-3 <PLTNOPM=38V\Z'I<7]JO K\>@GI[9H^T=ZJ"Q/S=E(\;V
ML4OU'?FZEE:.7/DK _/#?7:I_VH\==U)\\*?5C>B\6[,.BBSH)R8UOU8!Z)H
MKU"94WMB?FZ"<5G7S@L8B/$XL ?FI:X#^WOM9)OV+3":TW)J1T'7O[P:W'R#
MC-BIC+BWOJLZ-7HZ-A^SA4_;5.>Y,G<XZ^W"4?[3Q^RS4>6WPCZP_N01?%+6
M3?W5:NHW]ICOMY5W36*J>8(-,F$6(D8E0TDF$T0(-JFD*C%A^J@<V1>!J968
M.#=9-35VF*U>O<-Q9G]L%_L-D+1,:Y5V6>(P%I/:COW\TU-P(*9-N2!68>AY
MU0$T*D[OII#/]68.=(4>1%_B"$ !H+@&BO H!50 *D!4 "@ %  *T!^ "A 5
M  H !8!B1_IC:\E[0T;% R64A@*/;7JR#BTOS][1??FW%\F+-2%S>QNWOF G
M/ J'FEZQA9B=+,?Z+CC]MQ%5\*YPD;:W1OD$^X#B$0@E$$H;$TID;T)I/\TJ
M03IM2CJY,.3^6?.>6I[>;5,- D4@?$#X=%WX$! ^@T,1$"&017THG/" :,('
M7'K[H(RT7>;ONBQ#EU_[K70YLU9DW+LS>%?@ZIP*!) ]!V1_.F!,W1-2WQN&
MCD*>%_>H17]</Z UK#(P691D/(DT,I&BB&4\0U+)"!E*,>59C!6_T79HED-N
M].TIYN_:[16/JY4\K]7RH5#EF?DRWXGQVRQ9W5=NF1_C-,C'[(L8F_KV<BUD
MN5P+6JM1"GWQ*QY%,;ZS7LOAE"([))TTK))U0&* Q P$4T!B@,2L36*DU*&6
MG"%.$X%8DB8HT2%#E)@L9#JD*MT*B;E>0+@3) ;3!$C,0>DD(#$ F,Z*[\,F
M,=VKT ,DIJ,D)HHB3;@,42Q2C)C!!DE&&!**$4,R3KBYT4!A$R3F>E7=#I"8
MB/*'*<PPB]%"V&E;'5]-;42E3GTQ%VW.S;B<.%S/J\'4PZX*=DCT!BK%@8^E
M Q)G6/2$QDPDD4Q1*"TS84IE2&9$(6XBC#$S0LJL:X&BN<P_+O3;*XD_N^TF
M"4L\XDGZ**]+_Z4':!30*( )P 2P#& 9F^M*I)*4)%JA5"8,L3!.D!2"(QSR
MD,LTB02]T95HWY&<G;$,/B+L[H9"PY0>H%% HP F !,0:@&6L;FDUY11$2F&
MI&'&LHPD08ED!&4XE@)G&-,X[%JH96<L@XS2< U?!NP$&J2^V>5*_6+&]N6_
MC8)OIC"5&/O0C-!G>9'7C5LYYV:MZ,Q#L.MW'1J@.SM/9>HY8,#C EQH;2X4
MAT)S:3*DA$H0TVF$$H8UR@R)E(Z$RICN6EQGICC^K54;EA$=KRB-V?TWFI)"
MTE%$[VY@#HFUH(U &P%@ #! 7SK."89%7Y3.I"!AA%([MX@IF:%$FQ2I.-;:
M2)UEBG<M8+0'^H*34<362*H%^@+:"+01  8  Y&H;G*"8=&7*&'4<!TA+,,0
M,<$XDEJ'R$2:<AUK(K.MT)?G1*+V05_P*(S6V-8,>X)ZKX-VVDIZK3[1ZR9.
MO IT.74-:N>*BQSQ/E;4/"C*TYFMT(-$$KAR@ NMSX5P1$.=2A3*.$*,LPBE
M(B8H)=B$H5!8XUWL,-H,8Z')*$D?%R_J/5$Y*,6Q^\3,P6B%0X()\ O@%\ O
M.L$O6(*))")"49C%B"D>(IEI2S+"+$LD3N),[Z)*W(;R4?C(]RT"?C%0Q0'\
M F#2,1E[B/P"8CG +];E%R0E&9$A2@5-$&.8HH1IA4BBHY@2E6715O8N7XOE
M;"CBPD81)FM&7%XVPJYV^[?.SW^=G_/[],Q.A.K6XGF*V-VB.A[$T.QR&1[7
MKG70O(OP7W["4?B:XE'@''>CH#DUE0DN1!TT/K(S+2JCRF^%O?NUT(XJZ\9?
MZD_KBZ NRIR$49Z(!".N:808S0P2(DQ10J/81()'6-Z('[\[FXS+2V.^F.H\
M5^9VR?-[69R;V@JFXPM1Z=I'RI9_=Y4??R^;_S96TLR'^(L+I'V<N)_K59%U
M7/_Q,;LMV]]?_>OEQ*Q$F!=/>'7!9T>3?^4N VYDE<>=0JV#$ @J,W;JP0*Z
MC5,&93N^/CBI9K]($RP!O;2D)A#!Q#Y/J1W&Q612E3_L*#1F?+F0/RM2>E<0
M^>0?ZGU9S;YRQUF-=87LV?.@C,6I3$R&>,93:[J;",DXL=^'D<BL?@TY?N(&
MDT=#;@E3=I+5*SVM+HVHNBD@K?%SU<WXFB+NX.,&;B3KD85K*[$'()$Y5M3B
M#6D=2\0PR9 TB40TR30FBL3,F-U)Y,65VI,^.@WY]504FY#2G^W36%PU,\'O
M!'+]^<L_GR^I8SK":?]$M<7N0X1C29I/9[,9V"&K_<[G3^[#P,5ZA'%,E6#(
M4,X1BS.-4BE"I PV(A0AEFFZ2;'^ $9[)=K)41SU2;2OV(H+R]#-;5Y,_9S^
M^B^!_>^O_C?[1Z#&HJZ="50VICJQ!PIKV50=\[_<XWIY3'/?;LS2?,A5\^]&
M:%.]]T/_27PS+NF2]L16[?<<W+923JOYS$SL7+RIC/B^&/7957 R:0)W\\"*
M6'<4DNZP5T%33<WKX.H;)#([(J\",;X0E_7K%R]7%MNIG_=M+S;BVW1O:JKS
M0MM9=KY0XGRA]IE%<%HY;?'35^>)*C/W/O:0>M7S;QE&V6J3F8/Y&2A9=DB^
M?[]KA^2-UYG:(:G<F+NT5C<&CB',1V&!+[&]I;SM&>[S:O9_+NFZ:VKP%IY$
M548TQADR2BG$0LE1FK(08<JR3(6,X3!&R]= K*5-]M^6N37/OQ[OMMKM)D7S
MUJPG\WVW8G$F%8LQ$IS[7$R*+#FG2$K#1!QJZA,E=V1=;,Z7^'S;-(K3@1NF
MS:D)WGWY]&GD!*HZ]?]V,R2*R^ B'X^O;-+6).V'X4FS-#.1H2C*F+2&)R4H
MQ8(@G46I2#"5*=-;\R?VTMP,CUPCR?Z8FU[V'JTHW^OF9L<5VC9H >\FN-K(
MW3*\5B>JXP;G?%#=#'TQ7@-0\K"ML8:D;#=@?A4_WN:U&I?UM#)?[>7>C*T8
MN35.HB0/$Y:@,%$8,1$1E,0907$6RS".F,GXXQQJ+P)3*S%QKV'MR'M)Y3KW
M7D5CN"\TRG*L[PR9A$<M'&_^V<Y&8*=CJ0+E-5GHH/KPRGW*6&UV[/%0"#VD
M8G1"A'^UO- Q22O;BC:7(F]7BS26YYB@<8LFL$0O$+5]NO&XO*B#G_/"$LIR
M:A]+U[^\&MP$=!6;G1F9S0[,?9KTBSHU>CHV'[.3!4H_9@O].DNM>V,*D^6-
M=YG=JVBCR' CI*5>..'6(HXCE&HK8T62,F7-B81%[#F*MG7*WIZG;'_T&78W
M8=!FR*ZFRRJ[UL2DMJ,[__24F1;3IKS*@PU]&NS=Y;[]Q ^@/A2G1_&VDL<'
MN@;O*>\S%%1@  6 X@8HR/;VF0 J^H.*LUSKL0%1 :  _0&@ /T!J #] :
M_0&@V+K^V%I9R"&CXH'&=4.!QS8]68-UM,_%ABK'[LN_O4A>K(F1?A>M]KF;
MW8X//C7'>\?!Y/\VH@K>%=KHQ2[E@.(12"&00D^70N2Q4N@B+W1YX0;X^8)H
M/Z570")M2B(17R=LW]1X7Z6@[I0^@T 1R!^0/SV0/P3DSS!1!/('Y$\/Y ]^
MK/DUG(9W S? =IGPZO:*6;/>-T>JG]7A;--*[8:XZW% XL! =6]-U5WC:,?D
MZ)X ^-Y L\'JJCO'4O!SAW>AKK'I.,0&1TIHE$B<N0*J,4J45DA%DO!41%&6
MQ-<W';?YW+^5=?V^*L]<P8.\F-J;?IR8-ONZ?N.W(RSRODW]UGZH+2YWWQ4F
MJ"V&[.$O?N5\%+.[R[=W</Y^Z8*@ZDHJ1E=TVG,D4S>:O0(5 BH$5*BC5"@$
M*K0G*J2XB9*(AXAB*1 3FJ$T30E2DFH<L91)<Z/^RM:HT#8:V*Q0H1#WJJ *
M4*%A*3E@0L"$.B5@#IL)W9G5"DSH )E0DH4$JQ C5W0.,1JF2(9*H%!H05/*
M0Y+)G3&A;;3:N6)"+!TE&/>;"=T66.LA_8$@VI80\\'%B0N_J,3X$:T)^YQ=
M/6QBM(]&E?U"PS5;JHN^GIZ2F[_\E!!,7E^K)CB,WK<0C  A BH%T  J!50*
M.'5!AH!& 33L4J-TSPT[2(T"F>C#D#"[1-3OI@G&95W/2RW/"B\W*V7*GQ Z
M>A7H<NKJS"[%#JT@Z./^F6&KL]X$(X>$J"X:69"NOK_()*%896F(D:)4(I:F
M$9*"QRB*(X$3*051>@.1R7<_FDI8[.>%J"X_-.:L_KTL7)"R*L<61-]\1,74
M#:2S0PX7>)#WG,0U)'T'# H8U"$P*,CMVA>#2M-8A))0I+3K,DIPC*2.!8I"
MPBE/J4E2T1D&!5GPP*"&K!&!0 &!ZJB> P+5X:@,$*A]MFE7),FD1CQ)$E<Q
M(432.:-4HFA"N$K#1'6&0$'R_%K)\R]]JS_[M\[/;W:;[=+*[QC5&,30[!*
MQT%E[()5^3AOVQ:76="<&ON4HIDV9749_//HRU&0&:OTQ#BPJ]D$3>D/<2TU
M17'I0]OQZSHP6>;:8)_[(&1[9%Y#X]?G0GJ]_J;OYH._$-F?[01\7IG;AQN<
M&BX,S;! 62H-8J'(D#0F13JF42AD:%(MH,%IWVU83H\(= W9E D[%%3@HP1
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MC7B69)R:*(XRLT[RVOR[68_@SS.)>ESHN:3=A6. C.(8]LF#5#\XJ0X@ !"
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M^NJZ];7+--HW8NS[4,UV!BY5SLG:_7MK:KFM@JMS>@Y MKGFIP,'T3UQC*Z
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M&$E.M41<N@0'RA1*,R$0R3*B)-<1Q8]H&W0+8_GDY'8W@A:00PEA#- -0":
M3&Q4I@"9V!R,O&E#7H-B&HK4 3$#>@GT$ABY/==+_39R<6AX2#.!$LT2Q R)
M41(S@R+LK%RNXS1^1'_831FY6W'*\W2-S#S(_^^* .CF<E^J6V0*O5:UHE6]
MH<NIZSFXM/V/'/$^%E4;+.O8.:;NW4\X5/0 !0$*,O.S1Y9L<(R1$I(A)H1!
M*=,I2C,3<8E32MBZ?O9[-Q)NR%?.1C2"_+XAK=7=)W,-29 ##0 : #2@ _CI
M.0W0-.)&:HH(91%BB:!(9#Q#/%:42THICN)>ERD<,@T8@*@'%@ LH .2$E@
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MOAN[L+0E!&Y)E86HW)>-.G4,6"U-I+N7N\SRLO)+S]'<.R]EVJFO;ES*"+O
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MDUD:ITB"9)IJ1#,14QHQ+63V.!KWUNBIOW8]$.9&"#"W?:]"8&X=0L$ E#:
M )@;,#=P#G:5N?7<.:AD2ID1#*4T=O'EV'YB]I^&8TU#$48Z23<?7^XRAXP>
MYI!0&@O4R@;3'TD7TJV!LO:,L@X$&$!C]T!CAXD=H+9 ;9>HK0XSSN,T1D+%
M"C%IJ:T4H4&$:\XC372<B,U36]Q=:KL&LQV>C "/*3 /H*0 #*"D>]?90$D[
MH6_L0?VEI#_WFY,*.VL\3!3*(APCEC",TBS5*):,N:T^AFB\@UQ,LA+1[^YN
MGZ"VB+2'W[?MIX- ^.4 !!WP:J!/P*L!&,"K]ZYN@%=W0M_TVM7K.E5A\OH
MD 3$!?03$!< !A"7O6L=("Z=T#>])BX==@.MLZDG2[*$QPE*!,6()2)#:99A
M),)0B2C%$3<4ROM H4G0*AO)M,0#R^T'QKIIQMI#$  [A8U P$3W#I>^,U%#
M"#,A1U3+##$B4\M)68QXC..0DXRG6;QY)AIVEXEBJ#2Y=WG0.T_HD%$P /H
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M,."E 2]-9[TT'+PT0_;2W%*NA0_8P])FLOSO-&\NEWPLX%:!4BNP;;VS3A+
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MFL;Y\<?/G5_B]XP.3E_AIAO(Q2]PU)=!R)Q#?86&?AEU]EF<R;2[Y%7RBQR
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ML@[WTDS2)?*I.@MD(?J=/L7E@ R8IZQ>:+W:WWB8CID05JT!" $(&:,V "$
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M(0$A 2%55F0*(4%?($C%$:2& X($@@2"!()4I79+$:29$W>!:(!H5*.VVYQ
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M,0RLB7@5[(W:"VN6;TW$JZPR)ZQIDS41KRK#4T(<:WT*6.O0EZG(U=<N#V3
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MPCYBPK2R1_(]C;RS)FI>/#'^NXW% 4="%Y<:T,*/GIH:C\K6V_"6!P9+OH7
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M\EL+_=K'S!UW'OB.J*:[2$_?8.DR"TNK3R@K5SE]NGJ-VT9W#]HFNJ?_EH#
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M)Y!SQ?Y]&<'39:-):ZSMD/G>9/C^!-QCBY :7B61\!>F>DN;>U[2S&^H/^U
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M8M8D]C 8L\8%"8$0M:+:6/(2!=Q2L=#(VN^![@ B4V1L<'!H!#PY"K^KQA;
M6%2)B"IZ.M>(]M"V?+D,QII>Z?;FDLDB;_WV9?;X8Y8_<91B>@^S!8E0U*&2
M[>2GO;_%P$EK979;L&[V*3I+L"PCSJ0782_3:XA+72]])K4(G@O=24&$>=9;
MC"?>SO6"@M#AK,D1%"0ODF."(*LK)E^.[4.?^UP[# EFO#D1VS4OO,S.'UN
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M(J.'2'/AK1/>(QQTTC)Z"]>]M?9;Z@@MFE1((CT?NI9I>R:1?*JAQ/[=Y*V
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M'8_APE4U#.$LS_7>(H) BCY;+ -+MN<68>?N[\/.=__VY?NIC0,@X))JC;-
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MNR'%SVW +7PWS>T'J.*?&PXR?@=02P,$%     @ 2(-<6+O!JB > P  &P0
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M5@$&4 HGE0>[T/(8@/%LH9?-Y5^]"5*QSYF5S),T.<C&17 BB1@+2/P)DJR
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MHX\[4Q<L^_PZYI%;L(K978N]Z/M([J(KIYMYV4$[X8CRG[_<5]<<L#6#LW?
M4^@K[+DAYFOYVD#A7VV\BN3D"B)87<"W15L:CZRE3E66FZQ29$]2 /;J*@P0
MYI%QCV[EY26IT:77P,KCA]^33N/R4/H!>Y'Z=2MXHNI4N#)MB]X_6)7C?/2M
MH-4+"44Y=W>AA?BI^[E6^Z^(=U),UQ]/W(X-JQYI90"X>.6.KD"!Z#J9U(DZ
M-9NZR=D6I3 8@6;^0T*V9N>\13*@"R3)]YH\PQD)QSLZS8'MX\(%;TGANG/[
MREOL8"MI<D6+352QW'T,EPB T 8G  AVB[K,5+!F GIH^/O2TE >Q4; -4;/
M5RP*?RLX@_1;((TZ6^N_]9S;IH*MUQO_:,PUIN".J\MO(1LI4Z93=;4^'3Y(
M*7#1S%.(X%]I[?Y%4B4VQ8-_M2!"SP7\8N35U.&RS>U060Q;4YO^0]C\KPF4
M5M685GW@*W7J\*A;>KSJ^_97?)B>U3  F;ENX-C5V!HK%Y\;CTP:KQIS6N[?
MW)PI=F\Y.G+3^>8IJIZ]>]NA+Q%Q3EXX##T&U1SR+88NZEHP+N.KDY!U7U%&
M![_OVT,XI-.!@ST4M3J%L#94"G',IW^_[?LJ,.F&AT)<,1#])8F5_L-2$WE1
M8%I;DLIUYTH9K^VROO=ZD+SC@+"9V;6'N-NY4)L'1I%R]Z0F$4XL);Q7X-9_
M0_\ SKS:"C[/7'3#02O GU]]LQ0Z/\=$1>WH&+V;FVE,9*7+1XY<VUZN?MO_
M1MN4BLS[OM4;.(:Z4[-W!!$[AN #CI[POAF$:C7=_6X'%R&TQQE#0VWXRI*@
M6(NB_^7P\/^#.N/C/P!02P,$%     @ 2(-<6%^;XV^\Q $ E'@" !D   !S
M:6QK+3(P,C,Q,C,Q>#$P:V<P,#8N:G!G['P'5%-;M^Z.D=X$Z2TH*"A->B<@
MTD2:!9"JTHWT%GJ3WN$ BG2D21/IO80J(KU()_2>4".$Y''^^\J]_[NOC_??
M.]X[FS'#'LD>>WW?7'/.]<UD)?AI_!)PX[&*N@H  H& N:L_ +\,&"K#;:T
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M86] J5#H\<SP'+#/6*I(W6=)9]Z1Y_UJ%M+*P:< L>J5W^4=:KY2MW<G<O'
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M99UAN%),97?\[^/?P2N7(WL*["&^:*HGHS[4ED@3+9*]R1.ZLMUV*KZ0AA>
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M-1NW2BA9W![/9T7RJ+-\*)^UQRO&8OGV8:(B/>UPK&H!1O_1)[T)Z\.RW)7
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M+_E3JG\QO9?R<,&DF=31,OZ8'=$@']1HN(XU6C*AZAFP:9P3>5R;_^.AU$>
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M&\0B$OO 7/O,<P05L[ZSO!RYS<_>QCL3*N<8H!7@%U>%<A7-0,3V-,^A!VC
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M+[?T.&Q-N.4&Y@M/I[M8W!4(OW[9*!X9,BJ9OV^SM12@RCEO@ZNE 2MTVTJ
M4\*<G6S8);PIZC_'?7TK0IA^6;.&"A2INB1B=U3J:C6E$_GOMGSW0VZKLD9^
M^[.FP/Y%@411LO^OD+J_.P2N\O[_AI#7\*CV<_7#*;>'; \$SQA@[=\K=GH;
M,"ZXS#**-45Y8!C%&N-'FKIVHR#U 6.!JV:S::KM/AW?PF]\XPL8'MG6"E-Q
M#OC5>RO0Q?%S(I4T624==&,-,E$QPSFSLBLU/>:D&>!WS&AT'=P::GCN7EHA
M/YSPV,YY,,8I4))4KI0F]CZEG1OGV#>0"^/WF6D#9SA.DF^'#\K[(5P!ZVQO
MD=3F"PEZ\YSUPJG6:&7__(*5*EZ-ZG$YIAH$=HF)+@M8T1UL0)H06SUEU:R3
MGB3W^/>*^47@>!BV>_VF=O.]"R<_1$T42EQRP\:]I0&$DS],WXBGKMH^YW#<
M?"RFR42^1P,R(SX10[$8Y:Q^U[(^M2$%>A@P(4-%MP/6;^F-2@C5-69"4AE[
M^N;>9:4' =\Y)=Y[^>:?<8%='8#MVS%P"AU4L2WOHST9V]R8S981^:V81/GH
M8\2WQFRA<?6""XIG%[YX/Z)>$>SW&S5,4;.4^TBJIS;/9R]4O'PE+8; @Z)V
M5'7O!NA(MAI7R2@S]PGJ? OZW,";C8&Q.Y/XV-L+?(.''K+>NI H\H0P5XC]
M[/TKOSM(.7UKUISI5$[NAH7)*$5-RQ-G1[6#[K;2 !>3(G1$)][P -Q#[<"-
M?K!=L L^YF.GT-=?NP)5>F43U70Y88-)A 9,O88OZ#PM2\Q!!&0>L\O E"FD
M&L>LK1.%8#XY33YPK$F4Q#'6(OT@P3!NPD3:]P_MO)1OEZU<*.43ZRRP;CG)
M:Q&W4?)F>6IQCD,CFHL6@R5]$I7*"KH?$XK@P^C>*P)E1?"I/ (&/,5V&9IA
M&?6MZ=*'#:>4&9P(?<&5X,B[Y&O"!_<\B%?^J)#>9/>=;3T51'G6/WL J]]W
MJ)GA#]0<+ T$RX5'^3IFSL[%)<OKO9V)9[1.-SFN)N!;W.U\[J[O@*99YD-+
MMO;B5-O*-UT*"K]&C=R]:Y_.0MZ;=)K,SR>Z0@V'J1R^7Z;[%"M<;RXHV GW
M5/M9BGQ?J05G^!//O[S1I7H<F2!F<@\O49FC5 4O0)U$DLNG:L&;"9W+]\*O
M_VS7O(<)[U%-?'BY-&Z'PCFK9--A=9/S9^%R_Y2_BOA\-5:1<:<TMA/;F'%P
M)+;=SI,L8U4"+0;$^L,O)^XZ%NJ>U?PT>("ZE?.9VWPTXY9D!']B]"N)H6,I
M?[+%R>7_F%V\_&\8*M4RP'\DJ3/J#>96"3VYFC(0#KXQC%8$=P0H?#_M?.:>
M%A1,SZ%N4)/25PTCVGJ*3/)T9Y-@^D@5(A)[Z]/2]SR+[U4+VYNS11U*5,=(
MK#<X2DVP<;KJ$Q,/BN&'3@_C2/G^2[&HAJ;Z80GFO13IR?O^#:6F5(<:L5D[
MD9JOVU)FT9<83P;YPV_YLK4)MEF??>48.'7KH' ;_7R3B-:U42&#\2K3_&CY
MJ]:!UQ_=?CQ3O8#ZX0&5[&C\LP-;:1G9321,\=>(4D?CW;QK_^.(GS3HG6GQ
M-V6QR+ O=R4[P;S?92^?/6LO?M9U0C>]X8DWTON_XKBM!M3LIZ0""(AMMFKH
MZC-)B:,[SQY71]>[GMQ7X*_E7$[4.\KO\B-(^W;3E\KZ^$&LKX!"J>!C!/OI
MUL.*OT@F*41H9[ 0+C.V3C(R4 S+<DN_RH[/)_EYZN"<X_RE;?0VTCKGI0H*
M@XJH_ #C@ 0KXCES3:=7?".GO\-Z.02!9WLM!>O]F828/,N5F1.5ZPXM;FPN
M2O"(S=*8J8R.#+:T :Z5:#  9MV?_>F4Q2:!B\TH(>9BY3ICY6)$745'IR?6
M_+WS?F ?LYG83A0'!_]4=<U_0Q"#\<\LG?'U7^!7&^>,5S5ZO^\I]5!9?2+Z
M55O0[)Z.5Z(>8_RJ\7CU2[7+UD2D[D IP8K;Y*7XFK%VTYTGEH$3 :'15/&A
M2!AO9]LF_U+*X%):>!QFBK.W_SK>S\-2NZ.?>RB$Z)BIX4_@.+0 />7EZJB#
M#XZ:11SNT+D)X8! )D1J_2XHSFMY7 =U"A BL%:&IL1REI3PG1E6%Y)#ZJ46
M[0+KE5/[-_3]QG/3TZE9[M8#&H TCUWU*X7'>F4=V:>U'AT#\NF?<2XJP<G)
M0:!5&E"%YEP:^7.7X]#2\-^\Z?J79I(4J$7,H,2C/CH97FEB9+>4.!Y%B:.B
MMQ#-$3.G'N&M"BKJGT09O?58[K\';F@>-MYDTS?<C7'R4A$WTAVOS)[2U^ ,
MZ?MWH?^3C1.&I7-!HLV-FN&--\K'+L(4I!67<LD[O9!R44'E:T;Z\7>_'FZ"
M$!-F+^.-&^RJ/"FI3O?4#V%0/N2  !--WM!B92^ES^]]K/,RNSU/:!;.2G+8
MI1*8]FM70Z@G&>>.!EW'P-G&B78WJX?$U2]*I0IU2BNN=))WOB(5B6Z?G*@L
M@_2U\E[M#@BZMZ72R5YEK: K.,\W7T>1VC0GP=O7I0\OYYOIOFA]N0429VOV
M))UL>'99?$LX1Y5WQYVG5M3K_*3)U-Z:OYQ1T_#3BJ[ U=4:U]RUP1I+BLQH
MPW5#8@I6YZZY;*VVPD31A,00#0CB@W>-\I?2E?35BX" @/IEF?! [LX1V+WM
M*>M.'0G^-,NQMP7(U=(W$\28XK%5:Q%NI:"OF9PA=A(<(37LF;G3M;S]H[(6
MZR?7Q;V/OS:L>*P3$OJ(;U9A5L4XR$ZX-'_$UO9!QO&.#PT& V'^,V%4KK&[
M]F[0X@=H-2^(Z+>S(EFGT]F'J3Q((>2G'= ^MQ>*M!-% ]0YO0;=#+M0>*,"
M@\@\,>N]J^-FYF,6)5PO\#?.[-P9%J&(^D=B%YCNF$-2<\,O': $C^H3T^:]
M==\&\PP]7&^\[L&V[^A2WXS?X"8@[!5N85^H<>4Y=9K''_0U1>+7#6=5NV/2
MC%/Y;'8&Y_?@!W-VH-32ZP_QJ+=RGE$Q!D]@5+^O@94TH-,=WBG7K>(MLE[8
M;BB="XHP7!+7MAF4C95CT1R?*LN G9_4.FB$Q(P$2RXEY\T._:II?*YF,E%V
M@NQ'$?LA2P-.$D/-VJK2K(:[A2\:6Q5-'WQ@(!21IJ/<LVPHX1MWS#$/94IT
MZFU5WQ)()JKW[1U*D^*^FX"L.M.DOHA9S^A""W0"9!)DOYP]6SZ)-@.UZW)H
M''&_NDO4.,G3<D*!4"I:!SJ:<8E\U\VM9/SC;@JH?O]]3+2_P/%-R\1%-8C&
M^.+1L\.+%?:0-$=L?N3WKH;7 4S>]$E%D_7P[GPN+JKM%5"R3L!A7X:6@AI>
M\6:L*0V0,42&JLB^/IT]AE\]#NZKIR+>K(+;,_-'I*Q<@J_BKQ,3L,M2&;;A
MX/HC=OOBZM-@O&'5+,+2<4R$>K-Q/E ,,W]0)Y"FEEQ(Y3R/6PC/9=#ZS##^
M$]P"*S(.0&VS%6 %"&"91;'-,Q#SC&+S&1>?ZZ>DOL>:3+(\\=.G 2@Y<O%*
M2/:RJ(=L_7DMRC4;7"'WO:&4C3'S:-+-9HR.K2ARWV\_\;/<:.8(%;P0V.E:
MO&+\_+BX-U/!1>NW?#U%8, EM_[.VD9[:JRVU/?+U8'/(C/E1P[G%1U-<8FR
M'Z\1R#V8;B*$6'+.=E\7> 81L+ZLDL2G6(L87E81_C71S-4K/6$UH?YY%OJ^
MK8KM>2["/Q.&^Z#^^?@>G9;8S^U'/':D#%#N(MF'*B$4+KQ;Q<^>ZZ=WSC\Y
MO:3E;F4/[Z !IUI:UXV-N4_,G.SJQ/>![Q&DU_C$ACPBZRTRZ=RTE?-NWQ5%
M\4VBP#K$T=7^>/C@M(@@Z-N9HZ!WA:O?Q8.53:^!( ,2CPE;GTRHCXPI$>TT
MX/@TV_24I5EU7AOC?BG&.J%E!/93U>_1ZK= ,+IK4Z1$S(;7UV$GY%C]HYXI
MSGPC89P"HLT[CB'WF('TR?10TYJ:C>A+_XN]]XYJ\MO6A:.H**(HO4>E=Y0.
M@8@(" A([R "T@24WJ,BO2E5:N@]1'HO4J5)[SWTG@"!$$)R<=]Q[OZ=/<[>
MWSW?'>,;=WQC__'^P1AO%FNN-><SG[G>M9Y%IXC0I0[CHHN_U_"U*)LU_:,F
MJ^'?A-\<-UN0"1"KE0OB?;\&C[Z6K8M%[_W]*@8>!B$O#P]2ZE;K@6]M<&D)
MD9Q"->IUH^3?D2^,DAP-LAK[.H#TPGZ@1LGG9 7]-Z[EKX8 "U?Q9I%>NBTH
MX@Y_EEX3LTK1#;R^D?\>F-$90F[O[2D9.[X9E2SA9Y?<1).TW_P $[W<0D:L
MY"0_,,+HESYY=_J8(P.GZF4=(B-DG_S-L[)@5+6&Y4KPX"5__<1,O"2.+@&3
MX411'"$D('>%B?$@_V&W.$WI8"T,J5XA!K(T$9P7LC;.A.8)E.!>9'U* -1+
M@$,W1NHEWH_)\!F,]WQI]U5/NJ3"+)WO*IM\.O5*'!P.1!@^^WO=XHL^_8X$
M4YC&+A, GRDDE*K.4?0K[ N3"5@:$%DK$.;#5P5K2KU]O>3^'_#YRAW=JET5
M^=)U+4=8@<J%.V:$GB6E&DD3Y" <ZCKE^OW:D]))=X8<)[_NU$FB/%_J>Y@\
MQ>8TJV'$0\0K?R_(M,SW@QW33GES1OD7"X,NR;1%/YIRZQ!X,8S,*Z4"C)4*
MYUEZ1SIDZ1H!P(+QUDO'>'0:3@:X<=@KT0G.6E=]9XJ,RH!;'$PT%Y5*=4'N
M'L.I.T8#J>N_FL6L$2^<?,#)+<)<ASNW>O2TW991,SZ2V*SN+R"O'$SS(O7!
MJAEG?T*,6+_TY'G[XIF>EAGGCN'=FJ5Y$XMZ)8<\!;[K'2^?^D+(!2^+N(@C
MT^REZ(C[<U[>D-"D-XE9II^^.)UV6^R+8S5A7\HW<HNH6:Y8[7%N1YMD?6.R
ME'=]_:N=N]?Y)CJWE&+@7\JRKOFJ+MUAZ,C,]<3W><MV=K!<@YX$*^#]T>,:
M6N(*=B-ZCUQ7-)Q[3(#BGK&MV,$@QAZ0J5L&R.39+;/N>BC,SM,,X0[+/'.?
M[%B<BA)M\$<15WA@@2--6\.6"HJO>MNOO_CUJ/&TXQ+G7/=>-?W^VF?NVLT.
M\M]J(5O&B9^4WEJV5CW2@+#T%WXN5##&>!R*Y*+N!B,6;]DI3.BO\]BR5#5F
M.$4$BK.I9^[SM-JM%V;;X>F;#N&ODR?DOI:2]:YDMM^]20#0_R9/QXWY.>Z/
M4R4=-TIU: O.C7U(W_'SAK2RP2Z#UC/25P#&) N+;'TL[$.TMRW[^[T?3TID
MW8/3TI2?Z4S!'=A9VR-U5I('MD09UU;O[Z!AA>IIIAR3YA6\_!8?$QZ9W2@L
MG3@^'WP>O'(W9G&G<F<,/5W54@"S-PM=H*XC\ENMWO51O0T1N:;' _Y9^!-L
M/9'M),M69[;:5>$H<]\>]=F\KBQE2HKK0@\(<S7-VO12OQ,SAK$3.8(42<L
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M&+*YU.U:M='G-S8G-+-C :F7W/]]"]V4P&#&9S_Y!?")\H@(517(V%]>1X<
ML IN<-R!I$B;AAT.8DSN$1W91$E_<"7#]^D<R C'$MWFH^7MSE85U?8'D.+?
MY.DG:\Q#I<*K[\]4*)W4.^VKIM<8).>'5/K11"IJU-2\L[:0,8X^503G>O+#
M4$0=R:W3_%E(>0( M-?B#B:_1*52FX-OX8]Y.U9CO"=YRTY'4AV]PIDD1U;;
MM9PAD*5H;12T\S:?BF+]J+"Y.UR@[R3S"^W!1^?WBD.3,=TD"LY/E/;M1N29
M)X5>] 3V[IE,RP1_BX:+W'&9Z$!(>+'N0N48?2M()4_$H1XI1EY>!,#/JU>V
MN13V&A3<L7?CXE#<"DGN )*V".F<NEL]/[0_3,4'P[2^23?YW)E9""JUQ:IE
M%@VNZAL,N#R@XZ'?(%H<J<%=L5^&>>B)U@_,E2F_N/?L?>CCX_G4C=EHF,]%
M%-0ZSXBO*;)2%T6V'/GA#)M\S*R/V)/*GNFVU&<46OVRQG&H<CAVAI9A]*Q6
M2Y:*/LV+@(@6?_/E1AE#_4=NMBS6FFTEGV*Y$ZXFNGL5\V3/_\'H=@N,%(*=
MSB=-0CJB5!T?H*F$A&A_)DY>T2Z+$A^K$.M_3[QL.J_OSSOBA!ZX82+9MBWU
M]OLGEEJ.U?T;TI[YO%1LU".U:XG#$49*-=N^(]O%+-S5:]<^3NT<J,)5+[U*
MH/#2JW1'\1@[\++*-N28JI( :*9O) "*)O!:O=@$EC-5")FO"+*Z+-MP^_&@
MWZ/^CU^MS.).&04LC) X 62J.%\^* <RJ!*,_Z*=?@/9E;ML)!4NU3#%[S ?
MT,5RC5(:>P+2,S+-Y;ZWIJ:A)UTO;N<;VGM+B'SQ)YZQZM6C85[/_:$@<%(/
M[*9KWVT(6E1T>.7\&R<^WC%L_AF/I6N!_+N 7$H-;8U@Q#Q8>]P7+!T4RWI?
M%?SK0"C^BM0*X,A4ZQ+@7#H@1^@\R.(D 8#@F2LHX5[.U%E0%'G')CFRGK3<
M@LP'_3F28VC]MR,Y#>!;&!(C/NX55113:8K/%8>A<O+?2=M/M.]CZ \V"X/(
M4YF&*9'"MGU)S [%.*:14LKJ1 ^1U+08]06.T;)+@DRCA[%"F/"%JLCZT)SN
MJ:T0 +ZIP)'F@*P\3TG-:?WD)#^Z7=BF[T\+V$XZ<]VTO9>;-:O#T7,E /!9
M<'2_GE..K\78ZX<B]IREL>=(*%_W\B]PKO="9O96?>5;J7,&GW@68&,$N4QP
M 8XG:+R9;//TQ4">\:"5@)7%.L>JUX4]6;%>+D[">!V;QQZ-S'6[\(V,Y$"H
M!U7I !8NHK0FI#(K" #F\Q:86^@C%?H>AN)LTF*NRU1 K(<Q0Z@*[@?-"V3A
MT166T46IP#Z1P9GMY,5@QUZCN?FI ;JS+-92LOIT,@17B=4+6UT6?6SE?/%3
MK);VV.L1X8;P\]B0C&<;B[/;-B-H6A$__@7\U#K7D/C)"3;L[-P(M5^#N//0
M=?;LX>/@N[]#JZ!,4>(77*Y@H+T_\PB#6IFG;_G:>(YJ?]*N1!>8!&(6#/YF
M-O/^!#I?@_"C5;NAZE(/C6H4R[U!L?VC,;P[\<H1@PQ40+VK\2X!T$&_WB Z
MVW!>G/!UZ3GM'L?0@Y5#JL)<G"1*M& G4@*6+6U9+Z,/#%ZXX *]6]]39FWL
MRIDO:-NP*O*U5HU(5DOHC%;B3P% 6O5P]F'C_@\PB7H,;&.F-ULVTGX<=J__
M@:(59<SCJTS8ZKQ#R*B4U0SX(!NZRE,UTDBQ/$\+R=KZ6IGFVQ/\?3'%&AC$
MY<.K:A8Y#3$)W'T<WRQA #&))AK%2<#M8>O36Y-Z#P>Q([6:D 60?]7T%O0&
M6JE-)A=RO2A=68$T0KJ!;&RR$@!HI27*H*S*$:2<["RL I7'N:74K<@\1E(E
M!.:VWXC,VY8,/!XX>GD_YW[!3EO$5;^=H#_WH9C]N0\EGP#X& ,)] /+4PD*
MQM:[D]0Y2/1N39U]\;3OX/Z9^'SL)_&#<"7Q"YY-,N)MFOK@H#VH1E5M36.$
MEV8)*HY7$?4:&[:059D9I&TR*M+^>OR6:*Y/(*6&B:+Y/VH2P\DP]@0 VU$W
M^&26 %#D\PG\V\* )_&>" 'PI.:BB0#8H^?\ZQH6P.,?EZG@8 P; < :_.SR
MC>@+()OW]7^]Z/#?7S;YLS1&U:A4;$-/SI_BN%W#FI,8D&/:7LLQ4=5HMC+/
MT7:/*@T_[-O^>$9A\?&I!8YE\1@.Q<DC8/9=AC$B<Q%+U5-\YL1O-C)NSYVC
M2^?XF35C4A.",S^W]3KKL#:-S[6^Y>W\'G.9HKQ$1'+G.P/G]'3+*[4Z?GX;
M6PHP2I[\A-XC4JX9<[LMQ"CD!ECM\B$^9B\R\30RJ!C*F,@O^\;++FZ@[O1,
M\169A6E1*OW<*96RLZ%(:? PGGBBBLFGG?JT/BW%Z/><)9*-*?5NZZ2B*05R
M!>%C:ZH66=IKV!WX>:U.\%RLB  0R%=W551B,6#Y#X))A7C#I9PZ/Q'\^TU!
M;[RBF^4)DSRE+K'@_]M3*7JQ..T)-VDQD_*H;HV&ZDA8S9-VH0<<+BX?[2=X
M.IL%5"F;V:I>K"K8['VNU8K)_R NDTH?!KVU:_E*JXN-S>VM,Q09[QF,#TA.
MQ%\'8X8)@%MZ(9!-B4+(TB5$1UIJ&$]:SUV81A\*U#$U5Z'N;F@@OT@R7G5-
MRM+?+UV-Y7M M$ZT,Q<[NF-,Z?ZU>_B*3'YR6:ZAZ4[]*KT:E/IM_$D"*)!I
MZOS*@!]5%D9(;FAO19_7/,:-R/6P=,-B9U ]H[2;!!FF.BW4#H]H71OH2A7@
M@*-=VET/;MO/3$SS'L^&:IR1U\[D+[J\IM\3'@R85/N%S<MF5!K/KM$<.)Y[
M3[QJ/VE3,LY: PK#R845Y@IG-9]B"(!O?5N7"5 L5]"MC.9)]$J=C/76Z'%I
MLOA*T&/&%P7AK3JT5Y,^N%S/(9/N'VXG(:V,$=0!:MH'3>!Y-[WM:4NH515>
M2W8?*I"==\.7[E 4JB6?ID7?IHIT.-)+NS 8MEL@&W*;_>E1J']V].56RV^W
M)6LBDE8/$03S$WQ'.4JC>N3=YQG#'TIZ ^Y'^L"4&"7F5.WDQ0[(?7OE809X
MN5$LOG1R=7"\'CI(U1.CU"/!40@7H@B+&,^(YJ!)G4P348Y;S6I<5*V42AGP
M:=7HD.E<-@K-G1U,\7C$"0X@ARC#W%!B'9HSL-R<'U-&63>''4:_9KR^,Q [
MVJ2-5 SF;52'I3#T3?.UJFZ7%;"_= .D0[_!WXS@&3 6*N8/?IR_#,"4IO03
M -W^!ULZJF]XBO,MQ4+Z/Z#4<G4G4T!L%(:H.[_':&8BVF-/<UG.$/4. LMZ
MH2)DR0C.=Q;HM,-N_-6ZBP^F*-)[L\\??68->SRL\>P3AB2F.NJJU,#<^[Z'
M34JB7GF)2">53W)V'J/SX-,W5X7Q.?@W#7Q";=YWH\)X*QLLS7'O4A;QV'?)
MTUGUF<]292C=M=HU\Y$=/-\;,#[+/N<]CON5[:Q'CSU<7 18"8#6XORLTE<1
MS6PN2J-?CF/J>B!MY4C(WSZP.^'YXWR%D!\?1')<<P7;7I+O\-+RL&@+E3.]
M.<7Q30+@T?G7,5E&N_"T(@ =*[1_M""K2O0_RKDG(A!26_KQB),:=T&$>7_(
M)V/@P8V=9*2T^G)IBQ7B^[$GB]=*:NR=7\1O?XZ5[45$3(ZXZH[92^J5US61
M[$?NQM9UV@))01(668H6/A9,N]WK"<L]=P<6K]U[>E*4:'8#Q_%>*8RGX1T!
M,,C5<\G9*DP_R2L7BS?DO;0?"W?DGP1YGR^]).VLO'!^;MKS 6!! /A=!<>_
M7O E1S&2&,YLMVTP44JQ /LMT'!(5G64:/FVJZ)@AR)L,+&TF=&SN1\J)%?[
MSB.D!(J])?*-EWXA@)TMC !0=X:$FCZ"Q/M]>-%;FFL@Q[5]\Y=(>3_;29:K
MHC!T)LRZ3Y<9C#)-A@RC^\K!#4)>V8>^XTUF".M0-(SM>*>XMN,)I,0F^^9O
MZ5M,Q9OV<%(;L=;P-/HV8S2?8QT.9>JP,OBE.J\337;'R$OKN9B2#>VW!P2
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MZ@%72*>G3)1VJD47OMX:BJ[L ">BZWHW_9DG<%;%3PQ9$\DKB*3[2Y3S?"J
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M]E]H8O=@+BEK,.X),]>^_ZAG/M"JYF$J\"1:'N=U4A3!)F93G'A3V7%8S]K
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M *C%;]:-M)7JV[,4Z7 N)?**)*(O]%=!%,BL[F>'!^AH_E,-QB*+Q_+'Q =
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MBWUU QPPM05A!CGE/7>?4;^F%TBLNO8J-OK<9HP ^.APTG)S.[DR@Z%X3].
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M6S+AZ*17'9@_F@L.@_ ]5P-T#7G]DJD:#(IWWU/3+5M9*I-(8 _(56OA?>C
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M,L%')S.4CF?&)5%%7EW7F_5DV39;?J$N% W&JCAU>1H*WT:(+N5G2$OJOIW
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MRV\A!31%UE'YH.5&'"W?>US;IAJ:G<-[,HFCXZ*GY>";LW$FHKVM)P!SMW?
MS>,K4\I9YE_ZA42(YA2=/H_]@!ZO?UN3H_&CHQLSAKY3I.L$IV;;P<^=,A$E
M2;P)BEZU'^+C; 4S#_A=?:^8N:1%_T+(,*GG5$@,X<_L'_]T_>>_ZN;3 B0-
M ?X 5Q0EEI^O,6^LW 18I<(5M2:3@2$D<[^(+S*B<K^A,-^^)AX1;^M]-34^
M*JA!;ZKJQ^CK9^K^$'4^;<ZH"\W>MD>U:']SI0%G5H>+>UJ'H;+D+K? 0<<F
MP[KSW2,MG&R3RXK<:<TUJRTJAI('W&N=,I[+_JB/9G(,.^;TAY<'+\&-:M-,
M<9&])<YL3WWO:!#!N>%.H152^LAQTXEE1LVI\?MQQNK/L3%4"KQL-+JI(KVT
M-@Y!K;[9TZV1+ZNYE=BCO/>:.]ZI)[:#+]+6#1N)O;<LBXEVB32>[ZV8/#+H
M.[O'2;T#H29LSK1Q4"2SVAN/W5FNH$VYJR,I\&&DCRIHG\XL_B^U()UK\?RS
ML;94M*(";51-3X8AX77Z602(HK_&PY@7UD^T+G5]/8H_W<)A&I&TAM/C* R,
M=-GG6IK/L8E7(EMZ[UXS,<<)\"502(22V)B S%'!I"JW2R$2'64^":19Y726
M/%)\7.V\P09'LON2BYD)X'E:_9_-*.*_G@#C+/Q=I&NBY28,X%B8R=;,M3R;
MY)0T4)VA>.C.,QB:;O"[;=G*>CXQ1QYJ(!WR?%%=UMCTF\@,@XWP4B(^<S>1
MMY6"O2$Z9]"#)%!D*.&NOA)%I!"IY%G]5$CKQ!$Y:O?X$BYX4,S3*]92MR01
M;"RH_1D$DQ]->Q!N_E*\$HF6[KZV"RMCYS@V)LT^WK]V^\>3YVOAVW9_*2$5
MRQAC*06;:XRFE_FYZ@KG)R9::C-33X":]X%B@DZQ'2V8=;G[\G3WFWU>I\?!
MO]1YM0;0UA,^?("U&"*A<0\K?$?<K.P?01+9\_@^/8]\]JQAQF1[9B#@YL3D
M2L(^3]BA^$<;P0 QX_)-O]BXCH'7MU.P \/51W3:[V9GPI_@UDMJCVG4E)XF
MJC=(\CFA\FYO+Z7U5J>3BX%Y\9RM_$XS=_'EG8-E?+&TO4;C;LS;K]-&)+F*
M[BVM9"JX.<F3W11"7D+'#QX'L72/N*N)MR,XJ@:<=7E*:^"A)FQ>^CK+4B]-
M8,VF=]8WFC8-3;L73H"GIP$)_<Q,U.W*S1[PVW221<29H3I6;&,9U&GY*JY^
M=Z&N.!6^SD9% =/9=_'5S_Q+SHM!V6@P4:EO8T<L\G-%PH:DG&NM71R\_Y.?
M.=91N+GB=?UL,F9SOL)H=$)@*<=)0FOI\\(^WJ0G"0]&&0^=^F$7\8*A&]O2
M47>$8I3]J@Q;72LEF'A>2Z <O@?>VJ8F,B>< *UX:(XI7J^0,2M7,-4A0=@A
M9 @6=&YCXP6X^GO!XO%M/"BP3@$4XN=[JZ:D6MI!M.Z1\;C"CS,:EW8^2^8U
M, PO$'0P/#C]5]Q\[TWN]=NR1*3%/$QY8SD1UYL!#F+91EZ$.FO@O4($MFMQ
MB(>Y1I+PPT\N0D74E<M"TGTD[>UU%Q/ZC2?OQLG?B/_U7,@RZ3I?KPSOK*-U
M,X=(,C_+&C<N>+P,:2\=N[OI2;;#@TQ?>$U6BK,VJ!L.8!E5\5'M<MAP^)3V
MPR;7)6>SZ9"O\:]5^'@\'"XR RJLHVV7W<WQ]!Q?VHVH,?2U9@]MG$\&!O'@
M3WZR:$<-?9I7+#UC\P]EF9XW@<>0M_O!+#.$VM;A8ZXAOT<%V96P"]7!:T_'
M**L>Q6NFNLB&G0#LA>(8QE3,RDH:"!IQM[%OPSG]R3U!$IEY"_GQ>VQ8"6RY
M)92GK=*<VB.-("=C+-#E87D4E]M(=O,)+FAW(=O'?3N=',&&;ZA$F].BT-2<
M0F5Q;+;[-9%7FQ:)?7=[D>9&<5C%0;TT7&BW.T;ZWDY59K+28H:\)"0$=F,9
M?(5PRD[(BW)RWR'-OCM[%QY ;TM]O%RZ-'J@+XY.O3*"@3<?G9.Y5RK-1R+$
MAQYM6PU<.,IB.U(#GFP,-HC8&T3EE.!DWTQ6?6G(N(*8:CD!!)$:EM&BX=Q1
MPN7TUSNY9WT1:HI6UHXYA@K6UF?D'<^?C19A.O^A^.-O)TN*?%'@2[#S!#[=
MX?>1*OQEDE'WL+X7\M,<BO/,;A&>YQ"T?7W/EE</[D0460P4C+A'2OZ I\\>
M''@4\'&R+,$N*&7-IKK=K_\FRO?.T_S35!'S8.3Z';DY__743\+=@)6!']^@
M:/?Y&9-:?'89XG+M*R<]#"^>PBK0(@,DP8PZZR^MNT%&V#+HE[DGPXIMCY95
M@>\SOD\G71^1X!B3A7,$$0\C V4,O="R6@&<T.8@<;T3X-H[GT-E-T:7_#1S
MC:[<A2Q"(;J+']:4'%3)%+V@\:IHS8FH56E1N'E; G4"Y 5*]D9>W-WW"C\D
M]O"_'M+!?D<E^_6+.\&;/;#4AY]"=0E=18H?IR*B(,V>PD[E@;=5!$TUIKG=
M@>CZ&JIGRHJ/T@T.-0FNZ'PXK3+?YU?LK0R.V4K Q\[M1YWM7CAYRL(ZSUT\
MMV9'AK:()H/<(L!^#KA'0B+[FTZLVF \5"C%]620Q-GG3-OM#Z[4W[P9YQ9T
MO,71^G+EA^;91EH_+?&7A^2P?*-T^RQR>F;F\ZMR% %)O>CPN8MHJBRQ5(Y,
M&<<"Y"L3,J-%]0>LO=)W/"8FD.CQ(GE,% ^F**D *JQ=7/NMW))1K7#<KRN2
MP6,IA3V'S75-\U *G]63")4YASDT6A&34[253KDZ:;D^B\AAEPTXU8P<Y/CC
MCQP-TU3X.E[[HIQ#W\E<<G;,+E>%A@0*Q$[$5##S:C\+$8/7:=K;SVQA)=>M
MCI^[E'+APY8D^8_AC0Y!ZO'E %#-D.I1FE;_Q37/1-76R]ID)@<G@ Q+L=_M
M;#\57&-PN<:%IGXU"JTI!O,WDD]8XT/W5 #L>*!D%&.7 :$40^Y,NXS!:N#J
M(QN>)CUF^C!Y:XF+9H(+.2L=MRHRBKUG:8!1O-=W3E<K$%@$<GY+AYE8MU/3
M3T-UFM?<LH,O[NED9=5%"Y4(+WR'R%%CPZW#&[C&%_^??+FB'ZJT1*V#>\>M
M1VH_P)#AQ?YT#![>FEP9G%-1U>^12W("G(HL!X_.9A4V!D'-W+R73II)D/TX
M,:[LGTV8,-2@R>D9$>[Y[513\'[<MFC6K$:8>&5-60,=WO'3*"%AU+5CL%:K
MY]?S3,I<51<.)?!S6P_\V#'ICC*J%C(9WU/(RXE#=*9*7JY+LN/26+9M6%LL
MVW!2$W;[-TNZ'5TD'I/GCOI[7X*[KML0<Z&2U]/0O=%2)(7Y]Q^7E?4_=9'K
MO'GW ^"3@BD@F-\;;KA"B)[H0'!M%;B_TY_YL)0WK[(=@U_9/Y+:T3>C^>;G
M31TJNN;TN;R[CERJ->6R0%Z[B1>P!<>+C@8RW,D%B )!=H#1KTY=T2\Y<\=?
M<^9<O^3,#7[)F6??)3[Z\/+E9RP]$4\[]85E(\[0U;4R;UIV!=WZZ!;6T"6J
MP_F&NH#RGDF_RT/N$T\&962Q:H\\%CL68M?]<9/B+OIL9_R] D0JDQ%)^)P6
MJ1"X7>F2SV[:I23'H@"5R_'/B$X ]\V<JE[U^(\X+(;<_OFA-.;< 6?X39B7
M#"W.>N+0?@*<[J],#YS&(2? A>P1IW49:0R?^>H&W1B%&C'%3>S!$L$B9B,F
M9N =WOJ5^\QY/]?CD:%,OK,L1)OQ2D;*0FPW#A!V&QU38'YIU6)\5HR!:.J-
M98B 5G,\64?KRLIV;Z''>,[S;4&ZE1K]L')I,=]:B89[;P]#(;>FZW=3L"L]
M-L2QN("7A83>-DWH1KN2L<'CSG[WMF?ON6792T:X1I !M_B&%O_B&L\&7+<?
M1Z39?EBLD>T=W2CO&BHUKGO2%,KZ%E;^&87=R5XY >C3BX>_?ROCI];"4^[D
M=O>/9O""2BRHN]?@3G5Z A]]K?&)S6YB(0,&T)?WJ@RQE6GDW,("+M2E%H'^
MRK*WY<XMM/A;WWWN(4@&K=4['@US<F](\]/G87MQN\-_CWK!^ 2@#KA,S4 >
MQ:-;<=R+9X=W>=E,.J'.C4S(U@:4I5$=7U;$Y%L/B(H<7 Q;+66?RDSC?5QW
M46L)\:%R@*08?,M0.<..!115-OMXJ' #6P&[.3NI-/;CWD8?/&-?D^1I+68-
MTGP"L.ZLZ>OR5_!S2*R]U]IZT/;Q?&.T]ZYH'Y2KU>A[)1(9?6BRV>KS65]C
M0"N\L$ 9 O7BY@A=]FYB5_\PJT:NBP].>[7A&#DR'./MFL^&>OVL0+^:66+_
MX/R2S5].-FX56F/:Q,;+AU/1IQ0M!_POVMXSJ.D%^A8-11 1(DIO00%1:8)T
M" &5)D($I#>53JC2(73I)10!!2$HO1<ITGL3D$[H$'H+)-0( 9Z><_YW[KMS
M/[Z7F7S*3":3V;^]]]IKK[7O)O0N'QC2WI> 0@2<WGM"-D0 ^Q&IDX6"! @:
MS(R=,H9]EU+QSEH/Y2)Q7SR)W1/:FA5%^&-;3+ #S[2QT$A1I?&[FJ,&MG<H
MS.I/-@$\BQ"-R;12(WF<8UO-V48(EZ?HQ>V5H5 FN=M*'*O=/O I4O8/T>SX
M;3\07/X[+C=C>.#;F&$UBZ"=Z9K%VS8+\O0Z0CW(B>3/C^N\+F-A(UH] 'J+
MXHOMGV58*F"E?^4UB^QD![Z#[^UW)[/?Q'>MI+^X8(?E!LVP2+\F=QW0>$R>
MN73;'_EB$1^?UX/>9\4;=LT8>DF%=)WI&2M^\<T57XF?"XS_[7T#<Q][/\1Y
MQ0UG?K+@D!W/9PVZ1AL=@+\\>?QDEI9H$$_>;C ^TYDAAH,?^-O/*VI2BKXK
ML*&YO-W</%__)2,C\3^(HIM&>#HAJO8'5X "7=-.QPQ?J]RO;T+L%RM3S(15
M2$.W]E^.7PJVIJ"<\/X=];DMCN;.;EZ683^?S9$$?_$#A1>WT-035+"_/J^8
M7E/N,!JQ$(BK1 \!&E]*9WS:E>=L DAKXEV6H>0%$P3*97[%=>L4UQGW+,$O
MM9RS 4_P5L.1NS+75OH%6;:@]Q3MW7BUUA;T(0L13<XHFS9">%:KG^Q8HW/V
M[_)XLJSKLQ[F&QL1]:Y[>16$WZ5*W>X/T8Y1)O0XZH_/M788R+K/KC'>>3@C
M;H:*1SI5$?VRN92HQGK$^MTS4B5-,:B>)SS6T[^7/O98F C_OHX AC7A_9<P
M.K_.5KK\'C8D^-_:IJC^IGM/VAI_[[&4N=^SVO<>=['W@X$Q#G#]$^.S[,VB
M.JSV=<:YK.^W #RS<QLY_S6;3^68> !NHNNZ2(:<U/5=O&.[=T9#WHR02EGF
M;S.NOS0#XK + .GVJ!\*)WC8+!GSODY4J16S/#G; QT/I-5\>#:[LX\)CL_'
M6W6W4-/NL#.C!-TNI&1$%]+R(9_6R'6>70) ):]1QTHX6F;3+L@U"N[&T;;@
M5Q5^3%^W?RJ5\^1Z<L0F;5W>QCFDK("I^:$O/PE_H7C+LQ&"^UE^V;1)) -:
MOA#OKK_IG9NZ2NP^2.F+-ZU'XO9-1',]T7\^\V?OLK<]K;_,*@JWLZ=369"'
MW]FE=-U'=KK=UNM9&D(PVVX]LT!&<*1@=/+]M..)[)?<5_U*C.?S@EQ9!!E,
M/#-XA2X*W+^:*$I2=E-H3,610?%? M["P5CP>I3H4'CC,_=3/Z[Q%'%JP[40
M=6!R5AXHA9'5;3__;V+,5>5S>GKX8H?5N<#*7>(&N28T!R#;V-)5N6TBB(]B
M",2XZ1\UB2T,F"STV[D/RAH2D;BS(@:.<XT)MA]\OQVJ8FN^%UC7#.@8JS_
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M70&46FKL*TNEK,Y;_<PJZ+H\BSIG'$-D)67+BI1UKHL YQ\PV;#V.A7M>94
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MAS<T -6QP%8#6Z2W]3@45JH-)Z(\[QYB(SI92FS=F(83+7U?NKC_ULU7]*3
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MB,@[!]FW[/D(AEFY;C'7!I:H;V+]^Y6':H3](0:CXR+SP&5$(.9#M]+8OK8
MI_44N2([82GV]:6H+GHQ_+C)Y65#!>Y^DFAN46XO_QZ7>:?+%RO>68DVB94X
M)2/JHI>CNZZPZ[NN.WJ8$K-?O5F,)%R)9XER9)]S]:UG[)C=D0[))^4<RBOR
MK:#Q\XGZ?]9=/N%ZHL(^N'KFAHZ4N5'V)<_\G%"7F3;,A;YY0))7=AO_.6O;
MCQM?ESV]R?!N['7%Z R&9RN(%:/I8X[#3Y3H=OG?;J0Z47/LNK4EGLHW^LCX
MV;ML<.G>%R3NC;<'6=-;.SOD*V,-^V5Q2] #HVN_H\U#9Y$OHX?)V;#GRT "
M5X9[5(G\"?".'B%%IU1HW:RHK+;6,4<>QP.M&\TKQRTDWA$]B77V8&9WX <N
M:NU$KWJ_][E1\><_/B5P-:M_SU([ =Z>0F,<XE;\I#C/O=D77]0M06YMLS_$
M'G<:7,9SIU\4AX[N29I=S V0<_O*#W'F *"EGO[R^"1TU%W7(=$/)6QSPL]G
M54 73LH04X--NUU,U<X#N]TE9?ZO<O'=P42O78D_YVY->BNF.^9-R<49&&8J
M?U./?#3Q[W M3$*""1SR/D,:%YU!][TRJ+T?,_,K1WQZEU_US9-32\@\$]/9
MR8Z1_6+DY5U/SM=C#G"C5.V]*%^IV=Z31Z]GI5U7 Z NBQ(RD8!@M%)8%91A
M\ZRT:5F:TE?5L*XI6;JE1JFQ+?HMK?A\*U@)W/#:&Q7J9OHA!;-L>IVI5$96
M62HV84_OWJG;4%Z9QB*G1,5R"4@7[[A<A&#!VY+5CSK\PIBJF\P/1$*>9'1F
M=*XTC\!MT&5WK#5MQ>ICOAOP>?U0F7[=+M0;#X6NR;%"(]P>W-I$TC5*&<"T
MY<GRF&]^YM=;6O7W8B$LZ5HL0V]80VY5-8DLTF?\DM399@C!K3]D>W(Q"I0H
M?;:T%E*-"FU4M8O[G0&J']]0%7%R;^2REQAR6$SW]DU/;T9:4*5GJU(U7N>,
M%65]%!AP#2![_6YU;>S" E<DX_@CQ4CB?#8 26;!OX()Z1Y9H7KL^=:9>I1Y
M[27'!%O"Z/PO&CDF&]!%_#';Q0.2_''N5"JQ;9@UH6\E9$;D\A"@#$KW@K0C
M*#UA7284OC#]BMJ):ONG7GZ+HJ/DKKX;-^K.D0)CW4#(2SWV1[C3X$:U' -\
MF\CLA:!VNGW">MN+W[<K6ED#D9WOI7&1.:53MBT4<"V795_Z&=4ARFU@BU8%
MHJ3!WU?I;2(**[$T3&J0&U-$8!I7KT.O9YRV"_\X=T_=-2[Y3K"%'A*HO2?+
MPLLP56HN2OCTK%[ND?TL56/==]BW9A\^GA>T2FX$\'ZOQEF%-#Y#I\4HB/)*
M5GVG89"%!= HKQFQ*['%.+>0B_PX!H;6GC#$R=3S3ZRUS_2(^?FX!!YWN^#7
M Z2N '?PO$]Q=:.EHLH#N&EERR@S>"4O49)LH5,>MC1!8O3!I,2(I@B1]NLW
M &DBM:#K)24K0=<G'[Q[%1[^F$ZN%>#]^N._CC]&NC'PM_DVWC%A83*25FP;
MX6YT@K<'E",7A":5>AR [(MR7CN"])ZS[0M/QD0<F;E#UF)++[6K,9%)-/W3
MZG+';$KPU:5(P&JUH>!M4X(ISB-"AN6!N)1DK0I'V[V=T[<F,AZ0NRNSL<XF
MM4O^K%L+$B.7$[!/@G>E!7;G"%A(2[Z$! 1UKQ9S="ZM&O494_(MTC /*/TM
MP/R-4.*V$^\ON/.2O6*/WA7@PVP;8[#1!\OM$:4^[_3ND8D6Y&0 V[(I/K.9
M8P9?^?B.XN2-:=M6IXJ^/ZA]'=P4<7:&TE@6)+:6Y9VH:E+5KGFBFI=@9D1(
M( D. W42,?4<W4=FS\W@]]O<#VWK9>+:?-DM*QN@S\ZBHX.W(C>UM6\]RO\K
MA6HE#@ 0YVL# (\!&-5_!G1."T(X]S+[TID_[5:-T]Q.K0;3@F'"<['R#999
MU@R"O^Q'HCG4+Z0E3I@@CT-$$^[!)\8<.Y],!W;-$)VWQ:[:DZ.^Q'J?&@A&
MR9AEXO?Z.]A%8W^N@S7TIDVG'VK/97&KRPV]';ZEO$WEK9"+M'IS"K2Q9^5W
M>9CJR._<U NH.&VE)8I9&F+:\A,;'M,80U(__CY;\1OMOX?<]$'QY@/Q<K+<
M'84<#S/Q\9T,;T#)E"U+<'>J7D@$N! 936 J]#0S\F?%,XG-(](TQE[#4U0(
MSX$FJ\#\C3(W2SNX/5J:-T;UQ5M']_A?]@)C21RA3*!7P!]GP]?L'5L-@.%P
M:!YL)JDB=;OKQK<[Y[4;O#\\VG[)-J[7>_]GX%QG&F$0<I*$W3!J&HOB'W=?
MY!1\31HP &Y/\+_1C].-JN[!R?C18'VKJ^I;$@0$2DO[#NS-P,+DW+%*91IM
MF*1,?&)GT0J%#,7*K"%O&8;2R@=6I-WIPJ%5I[P233)%$_N;+(#/TQ1=%B0*
M#3NS;8ZW=SMI,$]5;8? ?_VDI.%98-T(<,;HB7G4M[2E>U,]T:Y+_8,K/!+L
M:AKBUG:GCG1.V'J>C7O0]K-@GBUE_'!M>JGFL=0PK5+= /BN7W%)?YGUMZ=W
MA]P21=[<]J>L5HV*.N>-XHVR/)>.('%,89)KP3B0Q#:^(C/GD[F&$[>MD9%>
M3EEDH=:D7-QD]<L;UM7*]P0^G9 QLUGVZ3<3/2XV,;+M$5IE+:*9#U6'G+7G
MXY\HJD'19:$8@KSE]W[2QP,%P@?1C5_/ A&3#5+_R;L;#SO]^''47Y?[X-Q+
M^7R#Q\4P_HN+]9<Z;:':3E(5*Z@R]6S G_158,NLV\%FL*%NJ1*NG/I\._P7
M73B!^LFLJ$D'VC%0%$2N/Z.0/:M&6LX7 0^^TZSH\3O=9X,-7 3IF-EK*-@Y
M0W;LLT_-#(I,VO-YB#4JR?"LR?C)L /9>!D4)JM!P:FMV,7P@5IV^HQG%^D%
M&/Y5JW0$8MQ]6T(&H):U/3/4[D\SZ^G8J:MIZOGN^,1FYN.73XQ'2N"P6H>L
MZ,"*+-"?4.0RLA9PMS;AL*P?ZV/4<_!?RY8[VL@'R>O(\MKZL8S+TIOVN?C8
MR'C0.%18K]XT>?O3KD<KXP?FR^1IV-'K9FQ8:&B3]?WFBB"F@$_PD8&"Z M%
MJ,D1H!(/?/H#]P-G]U>X4\%G"[I&%T:$N]A]8U4#AN7^Y]_V,*&?]5:?2/%M
MB?'O%9N U=3#)JNNC/NH1@TO= N)@GE,WAO3;=TZH>Z-;%N I /0;/AH1QTK
M'M4H[[&LIMK.+OB]UEAG5! LP-^S5WJ/Z^8*;J?'2>Y>@,SW5E3S?:QBN(R]
M%<F"Y[NS==,:O4SIKW)=SXNF7.*1=NR=OC19.\P>X57A;FQB: &[/89''?\8
MKI+EU8P5EX@<E]=6ATJ+:@9=DR]_N"TTQIIZ8/SL^:3L'<_ ZK*;,T/^Z*AI
MN:;1;]<RR'B(LD!:%T!&#A+3=CLXU4K#T+4!YYQM[K(J2QXBZ;[K9VXD8SO&
M,NPDPV]P)4-1UTHQFJ[:_4N%MQ[K*UER *#X+SM&-C7,V9,,M>XJ7),Q&X9,
M6NL1D4M(L^!+9]W_68(\!#_K9N?'W:_+M\D@K2RGG[$+94E7?<5?L<9F)B>-
M, )U1 =X\V/&Q<3$&3RH:A@Y;;AD([-XCN@.K0)!72 @0<AJQ5!OX;2C=N\*
MX%C^RN-IX=KSX(,=//MCI3("&)?[==EJPM7TUM:65:F->H$;,W"^M^3+8U(D
M5%.2U*WT%PN+J@]=1>@,(X9.[#H=0*XYS=ML)N#!E"VS4K2,A "_>>RA6E-X
M%O"5(I.>.UB>KH<@78_LF*G)6J)ZH60U=@48%>DSVOA59=8Z5)@8? 68+.9=
M!,+\*65>BOI3S$#S/=]?6A@.WN?[_K1S2<2LO&_IDCR:9ON]#;/O0HE5\:!E
MRPS]B(S3SX[U&%.6L*TSI)8<4XW?]6$[N+'/LJ?=%6#9QAW@Q;C*P\BM],Y)
MV+\3I? _VJ]/<(LOU2VA1T6?,]A &A.WV9XJ^-8AHA^" __>7;$1D-%:@3)N
MS\34!B:J5XVY;ADLJ#V] O!O_&S2!I #O%=P;(^:$<[B7:8W=Q9H</8)!C #
M\\B$OEMHH[WI>]''O]45G90J,JF:/-#D'T1]']J7N/:Z]G_2HC]UAU6,A#V=
M.K\"8 5\=RC;_>Z.VXL:(D(O92G!G2/"^@N2OQW?<L1DG]I9D9>]\MH!?9#Q
M\D*SR<.95C;H4;>H:@P^AIWJTL0R\%\!OH.^MFU? :(/]><[T/FNTU]3.B$S
MSN#([M:^J@T>!+K7Q-M9CKF%VE% A JJ@27+XVR<<=ROFC9%2HT@^H<*,X!K
M,[5'$")K61"..J]4?S;1/U_9W(M+\N"P_]&_^IJ:[%$[[HFEB>SJF+*EB*^1
M[V4M%#GBS_PA6O]K='2 Q+]H=%N)*'. 4Z=:9,38<"K036#Y3F.;W&_>8LC3
M6"Q[ ]B/LA.$/UN:)WD5OS)\S()B2-/+CRN=#U?>I#"[5+#%(]#D(<=IUXRE
MNOE97@7ZCY3NZO8_Z/CZ1JAAV^NTV/#V(F,C58'US$7AUME>ROMW'HALK?S?
M1L!GO9P\S< 7'L&R]^:L3UNPX9['(;%E]A^"3K3"2\>^I?=$(TTN>R(!T!NP
MT_J/J#^0&NY/[_:$A$MK(VK*>9P=$Z LVR,3;/#7Y5FZ"%3KR:.7XI[S[;&>
M<2A55\$50&<%10(X<UZHE'T(CEF,)#"PIW.]QP>*2LR(?ECK:GZ_5D&0L4+Z
M>Q^U[*8!,4B,?V7/12;'.02)2.O_Y7[I2A2#1A)MFM"VC#M6S=K]H\'A7?I(
MNO'N3,#'S_>:Z_A?_D;K'Y^ZG#?QW3F?$7+D7,,D.Q'X.C>JO/9!KSP."@Z:
M!^#I3T1G5X!'&W<Z%V\18->ZRY:F7/O9Z'DLJL5;/SNZ)U"POE54E.P!GZU\
MPZHW(VED.)W9&W*>IX@=5N<<%T=]/+Q#SL&.5.]TRZ2F;#?A0,G2B:5EX:L:
M%]A:(IA'STDOXJ>(S>R. !GI];'"Y.6P5 5$)%S2+=<H*7GTA.TKB@J59"';
M0PJR330<$;D"T-C<V?+.J1R"2:&3PCB'@Z=BNQMGVWF73<.:>8/;3LN-;1?8
M&_A<=U8U!^W(N4V'J:\ GXXRJ19#4R?&S]PV0HYSR?6'D;MC#CLBI@>_Y("O
M=$%#33!/I59OAJ"L>F:%"GT!<T&N2M;F)W$!)QI3.J,V.C3;A[9],,:65.Y0
M%=PAK::R:2[TX(CNOT'8(\K^'WQ\>8WU<4J.I/9<L?XA<GV0)"]-3\2R8Y3(
M;[@\.LI8N$>9-$W:L-S IYKM@LSG)J+,&X#"HYUI36\</V!U2-[6NQOBG#"T
M7N2\'R(ZA#?M].[I8--$M9N(I@R,Y@)LZBM^=1['].U2]$ \+N9HIO%/3*OP
MB*5-QS^U0C3YX0G4\=Z:IF>OI-&!-,V<:\DBC:?+2YQ.E%A2X6R$_1J;M["X
MI=94)""JRX3M#X8(=13Q^6+_ SK?%_W;05(7]"RR'>]3JKHL2#5O/3-#-E%5
M(\8<K>ZR_N86:.[Q_MQZA0R58 2!;5D!JUA]K3LG5U@DU2$_4ED95=CK0Q0'
MCB")4P0S4SUJG]6J'_]:%2'H,$'OE>1G0QPM *T&F..?M4D)!KG^YA<)9X*C
M!/E&_S=IC3'=/YO%6J_'2ZI\'^UH-KY/GJP0J2QGNOO:?/A:_8'_+0-]?,I*
M>FS8,N#^F'W58M7TC/)B0ZK]7 (D*L#S"F U)DJ$ W89NRCYW]FL,=#._5P[
M6#.6IWEZIU.R#Y,@!=#];:GVHAT:Q4XV0GC[%;C[)X"FDA.F-O 3X=9]1]SO
M*8XW"C(I%_CPJA:\ M^7AE/9F^P/V^V54FA_7-[."D2^$MJFTA@[5L!7+,VK
M=G@WFDY?/AI3-P;^-$N7W2W:?-+6\_(\<AHKV'D.]K_D9EXR%NQ,WOB9,>KR
M?>#M>*ZO?\.X3RSLWA:FU-^Z1,#XMO)J EA6>V* BX[DYBU)4%<Z,BZ3.JTM
M==1SI4UK>H>&QO>6+T2[5H:&@\4P[V6LY_%)"93"$Z*"-8FM=TBDT.9QK:P;
M2*@M FT-ZZ3G)KU]Z^7C 8/1ZC*4<M7%,Y IDECS8$%#XQ,__VT*BX=N[23[
M,0\+BJ:=W)N9!&-BBUT"LN82 &>H3POXEN6/4DH$;INO6RK?"G_W0"W-WG-T
M>U3\>A+KN74Q T!J5%?BR'OV=X=N=:;0N]>_25&O3OLTWW<MS0:-6+@"-/L6
M_LG_LK3Z\W23< [.$1EYV&'[2:82:[8_Y8,E*Q3(:$Q&(Q,4?DD_TFB*[A'S
M/FY\M]W]+,"P+@*AGA7DN3.5^GVI)3+5KSPF!Q^1-4)X9@=OB(+E'G24;_="
M6<_<SF*M2;XPERQVEET?<AA. ['A;=]**010)$D'7DRVD;I+8*+/&,*.?2'+
M#(')7IQD+%/,E#^$Y6-PU<.GC)!A%)VCLU6AWS!V'N]GG1?*QI_X.G4N].GT
M77G.H.GIWSZZN3;> NE9E%_S9KF(M]&EEK.$]^):<G1P(;0];SLSGX%)(GG*
MC?>_YAICYC^=0E;_6X-'+"/_/(#0#H_4B9.78GUQ41-37QXAWBO3$E68J.":
M!W8<T6#B!<?[9^>:%^,!YM]"VAPD5YP@(?+Y^*CEP5#$%8#"O,;@Z5:^S)9(
MTDW+6)".G5L/#SE"_5L3CTJ:.DXQ)<LS;#?<J%. /U6.LMWXL1SDJ7PF-6=K
ML]0X7[4__BG<3B;F/2AY<@OQ!]6&\Q2!3*X !HM_REA#C$?'ED=.0NI"$D?C
MV+RBBMMJWD@8XW$7=*6,>.M28E1VR D>M>GGH]H)DA$\WFO..IN$=L1X=%:J
M^J#+Z&P.KP#6-F_EQHD3Z7ZRT^[M];#Y+&V0,@-&*NI&+Q_")3L[Z,\^R!IW
M6OM9<[,I@6^4DUI-3:X'HB_$.YA%F'62',IGGTJ .GL:A/:@)= \&S'FYUI*
M>3,]#HDO#WMO^6XQKGWZG\#\O[RQP/_MKH?&_WYL#+#_?]P3,_D_CW[\'U^6
MV5A'[R[.\!+!$2H6]PWXN?Q)X'X7 &IB[>C8: J*AE\K9<R<H#,NGM>U5758
MW)[RQDB0[QR7M  ("J-PW[P^_DRQTW+DHGYO:_U-;,<$M,0*KCHF4.S7L>)[
M3W@F.7PV3T%"G#[OXAW(Z&;\UI WH R+[%H^566GG4C<S> 82=D]F&TA>ZY.
M C1Y#-P8'FM^Y/G8UL &IYAP!3#'4<>%+K-\6.J-Z'NVT^V,S'NFNFQZ;0HN
M]WVL41<]>Y@'NR>2.GHI=(IBNK'DIX\9B^\R4[\",(K"*."27CDV8CM2C/<G
M)C40?-'T-U@D.2^0K>Z 73]6L:1\3\W%3F9WY+7LF?)SA<6//^8?2YMBY_)(
M"+#28N3-3;%+!NQ$:)1MU[>J*,OEQWH;?(L17)>B)?]RPFP_BDUI/?/4L+'1
M9QEYG*3SE1)9+!FZ8!JE]S D%H5P\X491ZFW8-7+<GI$[+D\G@#CB"YV V,[
M2'CBNP NM;AM4SHX4Q'>$H<IEE'-L;UQ7_VY.1DWJYOTBSL(YWUC1(Q(D[\N
MEJ]>,8V_R);!AJUIX->-?,76^'%?8>>,S_N1;;A=83RTL]X?L1L?3;,\I!>C
M*XV9"JCT?;UR5#K[NJGQ"O#!??GT:2C+3DWP0)5B(L5#3MZA/']_#3EVE5*X
M) X4!)<2G2?I-LA&&;R^NUKSPV6UT5I2^^42@'Q><FNF0=H1Z&FV[!\JDNYA
M,,*_^J.N5I^RP-S)N7<N^_:3+\1J+JB9E$Y35AM^- I;:<WKVJR]ER73-F'6
M,U@AM7JT[7V\!Y96'"TY M/WOZ@BWSV)*_Y_V'OOJ";?Y5\T"!*0$E%Z"P**
M4D4ZA*;2I*,4J2H@)?0:.H* = $5J0'ITDL(O84B(KU*)P'ID% #!#CNO?W^
MSCZ_>]=9]X]S[[IKK^]:^?S[OI-GGIEYYIUYYG.OL0A@R3,[1&+,$%$33[G>
M@5*NC!J99?VHV <VX/DDMSR1\4^?$8:&,ZQ=@$9'=O4S/GR?N15R>X&_?ZUX
M]B)]B!2S,S5#1A7_(2$A=4]J<:SE'EYZ'S5Y?-WN@F?8D_M,\9I_U;.,,J!9
MGEI/P\1 !B[Z49I^O-:$Z+FA0J8#HU:1\PIW\,'J[QS<;TQ..I; A0Z0[SFR
MURRDL"GAI-QY\XZ"AVT,<T!+U(K)N&F* X:R*(V6E>;4-0JC?&2RB;]#5/7=
M)V=D'TA/9N"3ELKR%AV!%S?D*?$%!M!MP5O<PV::#5*6NM^N 0&@)2E&QG+C
M"2<$/7:N?S+"$MG88BLQS1__;C:A?7 T850NI]2G>=-?#?<K[1) =G@1ZKRT
MJ=;==[8O^;[!VVC(3>10WACP,[KM@@8?^\4ND'M<U"AQ[VA:*A?&]H5?M7=@
M=%!V4.[PYUHJ=?)2_P-9&=7JN(EQ*;+0HD.>(KE?!:.B9P$\ZHC14MK2YA)U
MRA?I&5_O__FB3D?W+7WZAX#&*\S+O9BLCU1Q(G&NJ6VXH-B:5M+IA\<A)M%]
MGWY"K1T:?V4TT_JZ25TT&0 C+OB--\PYHQ4G:C0?*8P)DCHFGI#=. 6H,O(@
M&65%4@'?]CS!48$TE6%E+T>;U+(V"IWI'\\6\UN%>,5UNLE8T>R:&79:4-M?
M"&#'?-DS/*EJ#)]FM:2T?^^0LZSQE@G!I:)PMG*DN'%X["TBC]+'I7%562\$
M87&6!VO:!1.-VC=-H2XPKU]!5#,F9ALO%4.D%LAF]P\QM2H3P9"TKDS2\196
MNR#L)YAE9T/NOE&8A-?QWDGD RLA!4#;X*-,Z>M*?NRQA67EV5/V3\*%O9V2
MWO+(>-^5/(?^<%[$'7?ZJ1X(6#R*1J4^>E";+3]-$B^I1_VM[:R>"[):8-XS
M7BKPLJHZ?&3NBB()E-56/DRA#?P1\*\!L70_8,B>5(G03V2[,<<,2#!NU]H.
MG"+:7,?^.\5E287/!%65_4[__,N1/@)'0:+^F:_E3,]LZ'Y5SLSYZPTUB7U%
MN;.%([+M.1941*VV$B0]IV42:>-42!OD@?Y/AILLO5T+VNGFX@J<R!._'\DF
M J03>@<MRA&O-N5Q"OZJR,GW#D,$A3YH(<"E8O82T">E>@ )Q:?^/BXG+&D^
M[4XUBXNV\Z8K@]_^YG?":'UT]WL8&ZA_<]L4%-TD7$S@BY)GP =U&N=MT3R)
M#H(6:OXBUX\322?JY?#X-J!8;H#SG'Q70I#GGV>HK&T:^SA68@A"/%G]U</%
MPU8EG[TH5+/+XJ\IWF#>^D5E:9OT'KU)^]$;?J22-EG=60YA^2 +I%]=KS[#
MXE?73@Z!<H:.D3*!!PIR'QL-Z]+R%G84LA*I_\N9OL:_03S&'F5-WXW9@!*S
MO.1<4<>\B>K$_?9MD'NRB!!C,_M_\H\<V34HFP=:KDG*KXI)A$+,)**VRZ8Q
MBF,>D=M6-&IT:$ON&"R,)\8F#ATL!7,$HVVQSM$'F]]*=FI2%K;?-]S0CQOF
MAFVYU3%M_2QU?I=)/0YQF%;.N'KZW$YGEB6ZWE#.:P5\9V!N)G.6^4>2/.B"
MAS_TWM(EX&8OXA+0>'77<@M\<L[W%?=Q-;)$U K>,>V).-_XT6(ETC+;L^#,
MQ8,CK!'W09Y^L0\B$W0@J.="IS]>?!3H: ^R"1)*-157DVIC7=R/"9W]U=BO
ML@1Z@S![O##XA?/[JGO) XAMS]RS-R>O*NZ,0"QP?+H5T9W3$&GZ-Y8/9M7L
M7]]4]^88(%51N@2PGS>_"KY54U-;41,U,D"VB(Q\V$-K3_?,%\!K_\]*8P).
MI5.3!\6 6X?;-(\=VAFZ&=EA3ZJV#[DJS@,*B0V[DIF["L(0%!E$G$E/PX4>
MT'ZD(.WA?N');<..+Y.;U&:7G81PX8#*K5%SCB\]ZL/&ZCE"F(5'26Y@>*8F
MRL-:>&SE[K8Z\@M,I!7?XIBRISEQ2Z=,=P\]V-PVFO;^9Q-8DIW&$UMV;G?9
M;*Z5\%T\9O#%G,HBT!<PA#L.05BPV)^*58RUH+Y,BYCV<[.:^J"(O#)#0US\
M6 _1=<T6RF,7-_#1:JVCA\5S*JC3C]/3YL\7>G^]-VE] 1N4!,:PAIHG8S0?
M=1D[AI5<T(V4(NX]7EB_WW]GQ+('NR<UZ(];@R9&*.-L.D'7[9#S]T8YAP[,
M!*WKH]HT;G]"OQRJIHZ2!VT Q)U:J/$W=O4D1FQU2V)F4B67/6+@QT1MI]1\
MM2%DCB_B*&")=RUUBEA_KRQU,-'0LP]_AK4=QQY2V:AA\^9SLKLH)[T:7]OF
MD>Q&:IF" NI+RNG\56NP%U\;!.'Y%E#?80OAK2V=RDC?E6] < )!LLB?#G=3
M$Y>>[,4Y@=$>=Q0YBJ9 H H'1'9$VM=4\@ Z52,F7>PB0W*W;$]CU%Z<NC^"
M4*>EM'.',2Y>5QO,-C_)Q;4&'\JSP J>B-@[OOQBI#P2CI"L$TF*(U^"$0/3
MW3>?$1X$+1'C0[V7[JF:@8T$_'*%%U5X"#5OO8Z)US?-P+%B\O3KNE.#2P'T
M"\^T[Y^7W;L]=>;:9@Z'RTKK #-;X"7^MW'=D6R9E3Z%>'?C>OHJDWFU9K1[
M,)FLR( ;8(!,-M;/VB<<G@V#=\_SCB)VZ:>4<M>GGZ8XU'1^4-T5 LM4;$FV
M':U/RL'_XG2D0#M'-?!$>*J)UCDZ'T+QRIOO//#^@QR^]=^(":NT1 68.0NC
M(<B#Z99X$O?S.*M/.W>87B.!JS-KK@NC8FD%ML"G^% [S)R([MOUY%3C#ASM
M[>5!7L6U5M3F4(QW*9P"5JV$&W@WV6"9\D(J"G9'0]0J3C^YX-$.E5LFN3?6
M)GJW">C6LZ6WTS)LEE;R> 6]VI ._S%$,B^(]RN$C78?)2<WE-1*B\,=E%JG
MX [;7,MJ^^"&^PR9;I*'96[="X9X0QR+\G!XJ7<1WMW<*XJ[P7%$D:-M\]!Z
M/5@18F7HCI&UZ#96ZH]I81X2.(3*IVV[ULS<'G2L7PP(=,XJT;R)FN?":<<X
M0@S19Y(>:S7CUJ,>->]5=3]3?MN2Y"$ B5F#??7_(@]T"Y2?1%A0VAXU]+^E
MD,U C+ IB3L%56<REM=Q@R]JH7R=8-KM@[G7&+5A45GU3H9/Z7/19'W<[)W!
M/D<]FV;*\86*Z%T*)6^Y#%=GYP!R$-0K6'STO2)[!!(!>&E[P1B$-SJ>%Z\:
M>YFD.5[":7'W'O_R513Q$-77EF;M)S]P/"B374;8GJ;ATPF>JI'M[;#F+W8C
M#BEO>@-^*!(G^A(G1%E$($7P-J9C@>"-&S(!\1+2S\K<?TU7GM4?ZKF>'-$5
M8ZB@W0W*I:\OP-CMEO)\QL%IAL&?@@1<S 'CD53ON@*K<I)ET"+\76T+<%S(
M:A(B4?:(2R'Y.[?P@Q 7]XL=:LEEUFM;#H$@/(OV^%/=T,>/>,4/U&Y[QVJ7
MC;B>C M1XIT[F0=CDKHS!4,H^*)AQE3RFI'(\PPMQ==.8>]X]K='FIG_8N64
M'[\06*=GCNV*2\G;.%W^%,&@G3_CD] >EYTF&Z3M"QC!+42*@<B[\C:&55A3
MI<W(#C6R!1/DOY>1K1&SPU:CHE$M-]*>X'XUH]4=E9D\YNPETQ6*/\T#Y^=&
M66N%SW?M*[_ X"CY&QXLC7Y2;[%]-%$;([I51J@K]_M.]AY(;AI= J@0%*6\
MO].S*QLCR2W# X[<KOU=V6<QLJY#IRXRS("B$L+]5IQ-G">5I?%$F4/)8W6H
M#7T*3S*74KO,5"CA,2[.A8\%52LQSX8CM%(C-LNWYX Z-= T[=JR(PV;4/BQ
M20%3.V-O66N7[VZ<1T @UQ?8:RI+%=M 1^05J<<IA[) K9X-7N1;B$B9&2P_
MB!E6^3)4+Q%4;6STT%N@Y/F@P%P\LNBP#8#,)7!C#:*_YN?9Y A-<SD.GU0U
M146,\=T0(137_L73$X\KB!)JXBFR3:Y2H1FZDSYC?^.Z=X<)N\EJEHY[*FH\
M4-@8%>!)'[:T_=0<4<5M9OZ\6T,X89(J--T7RY<]>JA)C(X/<2*YFEO9%)N5
M*<&8R-#S4.;^8NB!*!$H#,+FN=1*!TO68\"I%VP<7T%+7F%;(R2J>VRH]D!>
MU??MAAG.W\4%5I;"0DT;$'%Z EM+(\M[@^_K^)K>NP]R6Q8.YD$)(A."$R/[
M'<9]JT9#I@IJBX- 0O5[/YHW)[XC^.1.=MD1B&IO+EYOP7 X]39-C?<M;M!L
MI2RP%E3FIT,*1IUE>'=<R+=BZ<L+>XNF;Q?,\#M9<S?D*[3SI+O!MI%Q5+Y=
M+N;DV+**U//C&(@>CLK^]!:E5P5K7B['ZFN_3-*@T\/Y?[6J*]VZ]:SZ.H")
M^ZC\P5B+N!U]XJ! >'2)O:]9]19<#Q%Z_]Z193O!-16P,-FD[_,/;@+;6N_W
MW0WT^;%.2 ZV7L_T0LLIFK9CGI&T13"Y!4S)LT[0*3MU>E\G<>.G#MNWTG.T
M'U8ZT!\G7FF92]# 4I1F=/0Z^H%3[-P>4.K=.S$9NXXB"5!2PJYV(MDYL)LF
M&T\L)VIZJ3*S6=C]NS#>PQ'RID- #C@YHA]J."E6:M*)]-7_E>/RY%%^"RVG
MM:4@;&X/$R<OEWS!")W>8N>8(-"@93XU-X]<:9)P[%.CZ99@+PC7(U_-]-7?
MMNQJD1DA//*#.BY:%JZ?7!E 4V35,RZWN,<%A,N>CL,!,&V]4<%#[1NPR*6
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M-3QFS0T)%X/V[>%\8+;-Z"7G=UYN=IF"U7H"GA3*-"RY&^+IU[5=NZ4QK%&
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M@!1)D&_M;?SJDL]!C[2]A9G]@(:+7>MK9^'E 5I6JQ?G[G$_T;5R=#"]U8Y
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M5#'F5[XL@CJR1[<$/)JEYSN^WPZ?GA=FU2U7TKG/V_]?OO@U+/H1$L<3X7P
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M48<90@;C'"*]+Y.85Y<_L"NX$A3874U\,Y,*-L7AUF,E2XW(^?*5'V_"%]U
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M"XK4&7,6W%Y&AG^?9OKU&7E3ZY4.H'>9C_6"SF*;G?,2D&60? D(O2>/[P)
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MO<I&G2Z=VIRR$E>@;/% W"5%7W)(A[5Y6D<NAS@%>3;Q\(MC:VU]YIUKP-J
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M/@_J&NC688$O#VG!%$>/+UGU^Z/MZ;UB%QX[)MWX&IO9!P[-L,0S473TT2(
M'S>9E%$H@9OTT*6B=HQ?&I&G-AZNQ:YDT.#&LM[YD!M(XJF##7/6ZS63G_+5
MV$[_T'"^2;/0E./<CDU-F?3F0 8- O$C2#8U^FB8%#YMRO8PK7/A44UMI/YA
M[&F]6-BY 8]P!NBG!"$.'*QW4L[F<%$>Z^3'O13#*^E4TB%>?];3\DGG3-Y<
M?5/Z""$Q"/B8T:Y-(<31.N$MSPHV Z1J*Y,6=0,?CC^OF*,)A/*&[LMO2IT5
M&Y_%XH$%L[_2N7 K03MZ>VC>IKEY@HS6K./6]^()9!K"9P2<.RU=@&D;?H;.
M+T*^WRO3W=&.XDRR 0V\ZU0C=<O =M6^A#MWFPO7HN&HZ>CC >\IPR<C]C[N
MSJMH!%3F_E+\W$J9FU85VKR^$*N!MHDHM:S0V;T421I2YWCY)/:]ZB>%-=?Y
M2 U@YWCXUI;/("[7NF">[\ANC&3?,S3,+2M-=A@L4:J!2@B+6C[ :/D]T=>"
M[JX\OP:B*NYJ_?X;>")CR3B\<%KV];*W[3Y:/+J6 M115W>?,GW!;+T@L"$[
M($ /U*; "M'N2@>.+W@':P28X9&:Z/#V,*RS@S7KY#)=97L5_YJV*NJ##UM;
M9H0DX862T-?4US>"D]272 %CWN!&3"NRV3<RZFY[@Y[$T=THSZS\=?!Q83O2
M%>Z%\ZO5^<_:9>C_)NV(99A>P3_/AY5V(PO5*(-WP7+&!5<7>!L84])^"VLR
M7N[.6VSV8.9"NC%YP(CKL=Y3.'<$M\30?1D]SG(7368%WB.V<F5OU<@V_JTI
M8]K2LF)'_WMS]]=J/GP5JF !#8 R+$6+K@&RY*[VH[7O@8MX$X9IHGN0;-"@
MRJR0=YZ@]+7E"$?/'1FX,? "C^//\/[2?;/M$<9578]I\5F4>J=7U".Y!M=
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M+"*A)[N!F.\ZF&?T%L?0R&N  .^+:<W_*KM?N=:[55\J46$70V1T<+>5IZ_
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MQ>ET@8LD^7PS#%1EHN4>..)$)/UB:/Y&'^>^S.3LCP\=E/(K<IENIO/MG6:
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MOQ=11+VKN7.SI<CE#TT(Q.+)> L_ZD %57H\$RNTL+CM]O"O0/G&D37'N 1
M*2LLSZ(=_!TSO!P^5.1? (^2@>7.FGZQS8GX:_6Y0JI2EI+D -O8/^[>,QIH
MFTG=J^5S:=1$I_MYO27-E^/3JK0\CBJ6Q?=RVLT;%:.2;- XX3YH8CIJU>PZ
M+;B5AM#54.__V7ERX:N7"4,:1-24.CR9W*7;7[CHS S[ZC@H^2KB2/.&28@J
MP[8M"/S?#[G5-)G51DO>F_D4ODK$Z-]K#ZO9<6:<QQ2QX<=N>]YQ57=E8$9L
M!<0X_$MZ6CH;\ZI43@ 3:18RL\UK5*I[_UX#P%=-7>+7_H+T^\V30<"'R%LH
ML'^P_QIX:;'-.^4 P)6TV,2=Z9P;<*-BB]:\+=Z^<I^& IF 9?<U\.G'*89X
ME?A/UT#?_0"AP+YK(!BO2I+^B':V"_\((8QS_Y&Q/&<BE<9F/AH?^H^*T678
M3;L%GC3-I*M]VIK9;TVA_>\:7<8]%7YB"T&A*EK2IRF9Y2SL$R(?ZL(;R%6$
M<A=7+<V&HUO,\N$:9/=%"1'Z+8TFMG?K]6QL9%%J*UAE\1[$S5$_&T=RGSQ=
MOJE=XX5U\%\^SFO HYU@FB/ZYT@;[6:Z7"5EJ8?O=P?QTVM@^][D0[\#[JO1
MX(N-V=L$<].I%GYL0@N#]\I**N7WC:B0G(6RU0B'B<TB%]VY[1\K#D@3=VL'
MA/HU0&J_@0M]%K@DB0?$[ZUG/Z1C^.76=[?1$B%<'PJ#8O<(5\IK?5G%U,8,
M9R2IS,6)C RM\&O[?5^)S-%AEWH#!"(&FY!26/ZM'<F N@:N@)IA+&$"E@=O
M@RV[\.AY8QR&HH:A2JZ29;-.TM.PEX'!:^DZ/XI.S.Z./S4SENCIUF17NBGM
M*AR[7H9GS/1&/)U-6& H\:!U\OY5],+M")(DG@^.CY5)O\L"K/=/ H:X$V3.
MF%;GK*TWVW\>*J#L5V1VGEGB6H?Q"<8,%B7RJ48@3*KW,XA>3>1OQ/IV=Q$G
MCC-][T%J>;["?U5K&W4AFN,GCQ".(.T"@Z>*E/GCG^A;1O4HJ]24I25)#$<:
MF^77HDS4QP66J6?F_M:XWMDG$]<)6&Y1ZJ,WS@KW$_9"[>@?<6F:3#2-.^FH
M!AVL',&"YV1YMQ8AFYYMS"..(KYT*:6ESZW>Z!-5)GFS0RPT^M %77MD?>]F
MN<J2^5)_/W$SJ3  3DP_P+?.]5BX[Z$3]#(P.FJHVM#@P'(MU@9SG.%L5M<]
MU7%1T;2N ]:MF;=,'N4)*_%C)-W/>JX^,Q+(]TK*3!NY+?ES'?5<!$8YL:UK
M#LI!N1;$7-9X.AEG8S?693;&FHP!M$58ECW*(*YV.'(F]JMV6FI2<(UZQWSP
M?AZ+YXQ#)6HX80D-CCH9IK!/_?!GT5!;E\?*?]$VEN:(/'C795/9WKX-/%;K
M3&_7QIVD6>C!2S3+K,"NY]&/# 9S)$F_LR^/"6""._>ZE4[E.O,9_&S6WY_2
M>2@O[<F.8Q\!RZ)A'0'D<C23HG:[_"([/]GM[C36WZ"V JT1DA-S+KD*#[J:
M\S5/"%P#;V0?;+QX..V$MLXZ$(IBN /3(PUDVMEM(\*\9NYIF! 0]3>\\ZO'
MUY51MHI6 8:0+:Y JX:Y#]/!?2\I+P<C!EP?T77?,6L%EH)@I$#S5[50^?&J
MG6N K1*/\E8&'['J$^SHK 0_@:4K+N5F!X=.KP!4A76X 0NU!"'%WXO@A5I+
MS$VDR$NM_;IM6'!9+V3U:S.4#,/1A:.,>#SZE@Z<QO;V=\^JGT_E!ML\#VBH
MC8]_,1;KG(TAT_[\ND-\6K?JP!!%.9?P$L)Z1CH^T<:&V3$8?RBR<P#-FTHC
ML4P2&[]%#-YTJ!CWH\VW0^ MOG:2F5:117X_DPW1,SB>/$"DX("4T1%PHM^=
MEN07J#>U2_[Z6O5-)II6*T54<DN".Z$-_H*JG;)&(L5D!Z#M^+J+ML\>7'\L
M0CFM-GAWAG1&0LUZTH*/,V&]]8@'M;Z?RLLY#C?B3+UUQC,;A@*>^IP4^AFA
M=KK:A!*Y)TKSXD\%:P7X+0925*=SL K9)!Y940A6U&FS2]Z.@(<EY[/S*)&I
MW;L9CO/O9S'OMTZ6&Q-"] W$GV$2>M(>R7"8M0G)QTL>3E0.KZ\&=MC/P4 R
MC\:B1#7W'/1G2+^:+U@_]74$<+6C</$?!@O4EUJ?I\L$CC\ 574-"DUS5JO.
MVUT,H.S3;,K4_;\"?!NUR5>FHS6."8J/'/H#2+8%-ROL%T@F\FYM-_GO5#W&
M>K]W^75Q*'S\RKS3-"U&CAGCU2O\;2J'<&11)4?W<$SGX5.PMC<831PD*J.W
MK/G/-N"1?FL*[:O83Z-?B UPM&QY&08)6.7)$^?;?G2C6*4B.P?':X"&9#V5
MI)_CUWF*X4;V:]5UWHI*S#WD>X'<Y@FG6C/KKY*/)YP>OY>5 &PVX:?E\BWC
M>Z(4<F9R^PN2CERQO:@J[#=_0?F;#H5_Y[<2[1^9JDRY/N8RJ@[_H^*VUP//
M"C8TATLO!Q0[9U68:[E.;3"0WY#D#""OG82&2 'SSFR5Y3W?JIT<104J"4Y[
MA1/ZY$YF>I"9#V:[J.&>8W/&6\.@SBHV$GU"FF2$-S>WS A8$*6GB.48J1!,
M%(2=76C\Q@A]9^Y]"\QYG'?*=4%7S#8B6F V2 O(S&:3[Y.INIRP-V_(%X7I
M)-DI=WU?L#&CRK*0@7L"%3)[5SF>9\G>0\R4\RY!CWA 8?A<C<U(B('M,D-P
MP13"2_Y[Q0+1N_K*]"[;A[^V$!KBP)50GH&7'9)5:J#7)S+ZM6]HH85BA4;)
MR@!ICGQ'K\(YV.<0&FD.&O?3 [\OYVR>$+E2H7@#7VD=WR?7)5S:X_Z@8@O*
M0=_'C5_E8'F)$B$/L^PXZY\47!E_P("/H&<C^5B^=&E(E+G<&#[Q>Q5J^CRD
M,BE)W'=+/*8LP!&9M8=AP5_A(CI<B.1!;Q=<V^&^CI"=7&EPWPAI:$\@I;L.
MG7E/H:GH?&H!Z5[\1:_S@Z?2-]XI8*OE61+Z&'.;+,@V*R0<-3;TXI;C='[?
M?F?RQSKRG!86U2* 3&"!+^^SBINTCOF9%'3GVSF&WN$-KD%\J2!94UN*WFP1
M1PTHH=:+K\K>M$V*FKYR]KB/W:*186T!I(^F$;7<T7+,FXC[$[F3]U(ONE[$
M>?+O9\%2'H+EM4E@J;:@F,JI%NLE"^@F@GFZ%EZ[!]/GDK"^7V?[7F+.]VQ?
M6\7_P6)XX.JR#'XJFK\+W*0RT$*V1S2)1WHX[T4T3HAJF=@]\RTR]1YCYP [
M@Z##B-J"5T@*<6UT1,$RW'QI<5NPQ(U70C H1WY&,/%,U0= XJC0RXOO-7RN
M 0=W/*RHFT9VM5-L2^57+V=*01CLF42OZG(YM!S?@@\(.+TS#KT) \QKM_90
MU0IL(O@U.G_!7W'J^#=W$@_W#493EK6/13*(OS?RT.)=_)#N],))[.R>L!X
MJ=L:/]<5DV!<"CW9.9!G,<]!\C+#V#!.B^;H_:)"^]$A[LJZ5(J-",+5A";*
MA8*1"X/*85)3DW["7,&?X0P^(8\</J+:N_PA/V9BT_-TS1>WD^[KMTUP'UEW
M;A-T@ Z'6SV."5:?^]%^^+U.84=H=*[4H0Y:)/Z,IQ-]/)VX_(=.BO_PE%D4
MC>ZZ!-H@KX$TM$T"'AA2_@&&.=A_ <.1YB5\3Y0LQM:&GJKGCG**"FAIA=W'
M8/+)]VV]CT(5G8165$8P5 S<"Q<D98$CZ,/1IIB26W3FQ+VMH];\NW66)?K'
MI,^KT&162Z(^WNB&2(D0#3<CQUBK .YVZ? 5\3^[*6[_;.GDX?OE1RY> %N!
M&# 4HU_U_6NX'NGW1P #\$P31(O>ONWZ1QEF5[[@#<;>-\FZH.BY!H(VKH'H
M;Q8AU?O,)PVG&QDF&7CWI+=SK-_^//?/["4,@FV/D=!YGRIHET5\XDNBR;"W
M2VAO4@0$Z\(#%:O0XIU[W&H3'(O.;OF*>2LITBH,OJ$A<BGC#C/\Y>]K> ?O
MGN29.#1@&\F?@ @R4&IR*5R)^0I?-T]]K(O<B/)XR=\HI3[(!7%/->E654E3
MJQM!!3&A>I,BF6+#R-,F3M]6;H,(3<T0B=2Y54B'E>6?E5J?R-[B_MIG.1BF
M'[KUQH-CG]\)U]V353L>AJ% 9EXQ<JR;<D)ME6T32>Y-59+Q)EZDOX4S2S^X
M"F,'C9V)[9+@2!D3WCGUPCYP(G5SPL-[O92CL1O)0X'OQQG[!+H66;D^BO2@
ML:]_*JV2!%9SS*ZM."VT"O:\P3(T-J#6:Y<AD1<QJ5DZG^9,!!DH(QG9/<$\
M75<KYOVFD\,A(LU9S+/P&DT/R@)"<X/]#))54ZI(0K?./O.NL2"A%L:5@4#Z
M!?L+N2([9YNB/Z8U_%;#[3Z4XN3!"+?Q K;:(:P12CS448:CT$%Q;%9C(EOK
M=-QXF8.S$>D9SY"\A[@J+D0;_#B@@#==7BH>,L>8*0',S??]&BFE;$)NGG&(
M)N;[05"MF8=FBW/V/LV]G8D"^Z!LC@* '"=YFZ#7[UES6QL>*&)*U:K--3DI
M>,7UY4P._7]V8AT6R=\3:Q9"C3>P%DN# KU-,L;F^=-4LST\*0%#2&UY=@]P
MO$."11#B-CF9A8.K@(=#9>@Y/V"%:;L08,&^1K5%YFFD/;(=JYW?'15;4V14
MUU5E9 8NZJ1U_90B\&XE\/9Q.<F65Y%]^@NNBV5+Z">.Y)!&\["$M(3301^;
M"#]H#EQQ=.]8D[">^I:57ZHWR5:J#([U 2NDT]@\>)G"Q+3.]W/YB>J\3'*#
M8R[GGBE!\,^331Y0]+0<"WS#;-2I9O8:8.WS<A;"CK1E1+.$)OZ49 D>5$:-
MG3HS^'%-8/GA"^:YEBQ-;X,O"MG#.'U=VU%,)S/K[H$@.V/ZZ%K8K3_J[FE2
MJ0&C-S\P1'%+DL5N2![,C8#OH70L$G!4J:C,2S)_&]54-:NZ#\A?!YRWI)>2
M)([9:NN+L?JH]? B>V//0J?=_9*1IIM+//7RY+BMYE7TT(.^Z#9&C%O/M(.O
M+_GI3$@0T5H&PK2!50B_$BB4\. ATFP^;U) -,Y8,5ROW%FX6K9W!&8Z0A@(
MJFG^*2-0Z."%9BB8*C??>Q'+FIDPDM3M^[I5[C'UXY\^C]AQHH,8\2[CR/!2
M[HK&:9M)OH_?__)WOY0A$3Y,A?K6K_7RYF=#V#$@#]JLR!-GRCFUJ"+#;6K&
ME]SKO;2N8)>4N[4!DMNG=5 *@1*KE(#) '0//K%]H>:E29"_C4O)60X,:V-$
MJ^3/9(0<Z$RPK.V_O4=5G:5+PI[E9[-0; LE]A/(V7:QUVT]+?*F <>=W P+
M9O " -GS04!8#TU[#70EA/O0(L=P$U.HV4X/1M?\6T]O^'A*0.,\WDQW!0B/
MO6Y,FNK2J\H$<?13_WP4D,N.^UHKP+=W0B99LH]4WUM73%)9>?#+)]3<P0T%
M[:(0;HW(+;6KE#S/KFUBAJ'7N$]$"((+[/39J##70,%6 ,WK.@-/IYFXKVIF
M=\\-8U<S7&_%7EQ.-Q@((*&1."A*5\/]BXTX#;FFA_1!2E^.;&3%C:9H 'T-
M4)F8F >,XJ 1^R0%X36-XIR%C#H##R5D#+Q*X":=XUOB9$5;4AK&A%SJY/?9
M.N-S@HC43HBK6\Q0]8KH_$JZHB)3>RK3'I+P@$&A[)F;LA-'_26&;3<P"J:,
M&Y/[SV7Z1!=_!1ZD@$^R(3*C 8N%N&%S@9JZ)._=4F?5/P-).DGES!5L08#.
MLD,%RCG4P\RA\T+O- O-;!@]HVEU@T$QY7UP2&@6DCWA1^MSK5'W>0ZU!/7*
MJ@AFDI'LH(<O0J<E=Q#G.Z8BBT0U5"["=DUUS7DS0^KI0S_.K'2R7E, !IA7
M>79TYCSH>[U9RPZM]L=5/0'C"C4W"=ZRSC.@YA^T[V*RX<3HH-5MW0W<N<8!
M5A3IR/%#ZNEXC:\S%^OL7')CGO.!H*R6$A)*LK5 -L8Y[E[? &=[D_%_[L@!
M+L;.V(SXVGC8LG;6Y3T%%'EI0:1HYMTWH*?5$ZOT5%DM0@!APO?Z-;-C.>KQ
M;'3F<'3B/JSF(7]/=9'+VA[#IF &-K?U-284Z1E5MB-0HN!19,>4$4H]MY7&
MIJF).R,,X+A-4-'V<!S:.X@TG+(3I:V[?!(?G2]BH2+Y4U:BS\54_)\O<6,W
MN'_BV_#58<I?C$['C'AH$K)F#6%2G/PE9J!(IO_;13TTFU8\S(^C "Z@EJPU
MMH!<\DYWM7DWV! $8:>4N$W08]=^Z&H\?!6\<@W,>-!WB8*7R[LC^N[NLT,F
M\4LJZ<$=5&HF.';?[T6"RU6.BQ-_IF:"@&V?0NS&&NM6$W>8R#S(;*HV1KS!
M(=-<.6E5;:F0PU,LB%@.O9,.+#O+PVKJTM6V<@6A7T;1#CB5@\CV4SI<Y;0S
M=UC-EI\=)/HO?DSNUHE]S^E+J]BH$T;XVZ+!834'U/9,RGM'<WQ->GTS_-W:
M '_?PD])*,]Q-B6W*1H:A55%B^UT!K!,O!I='M^;<OA2'Z;.D70;J; "E<(5
MR/+&8C*1.UD0/!' N,I7*#0-V[_HQI:V[%+?DP^PH8I=6@W.\CEQIL&*C6*U
MBOM*_(N?C8O:CK]L'2\XS&-W!X=F;1P8)6,94#UKR:K^+M\7S)N+,U66#WXW
MGOL W2\I?4F!7O1KOJP:FY#)#G8CM3]RV4]4MWFS,:/7 &>"^37@";UB974R
MPXAKM:$#TI:]UYH<E;3"NBA9%1_=">83[#\?5GRP$>4'LUDNA\S;-H4^J:M7
M>!Q!1[K(2\S R;8M_10<;K@YO4BZC-I(X&C\\JRRK2Z>W\C,=30OB)9W$Y@!
MR[Z +'=<4(_MDUU*..U9&SEN*'"ZWD=^C U]8=)UX=?&R 9%"(LA^)6+C"@U
MV<URN:?CVVHAX2W"#DA6:MF[O>O[OH:?/O5,!/\"#8W(L]APLQT3]&*]KX$D
M _S'/Z>$FZ^K6ORAI[3UP2W.=&N.@CDA6Q\]0AX#&UM'$ RMCW@T5N#5"BNQ
M%E37>VI&U8"+F/3O\\1^\/F+]/J(XRN''X<8'[25 ^,=0VV2A1LKA"P>A*"Q
M( D+(BA&7<9@!<)0#8YT&><CD;S!T_=;M9H%.M0 A<S,F>$&TG<].ZI+_WX(
MGM=7^]PNKX,T/T >4-CA&%&K4G09561J*4$/.YJ=.).T)25%+7ZT48YA[V3+
MQ;S:T'IS*%S1^')U'[CU#NAC^TBP@:! .167PF$:;>,X#@<J$_6W04HDNI6W
M'CUUPW)2873AS[MF F3<T\6CG$5;]7T-ZIJ%.BN\_[QK%U?AW&?17_U?I!</
M'!.J+A')RF,W(UN?3+FWKSXW)G[V"9$?)(%G?:^Z,RA9B>-K=AT;OE%3;@]+
MCD?#2S^J_6"^=OZ7JO"H/5:SU^/Z]QEUB"9Z(6OCJ-)Y$R1;>*$#S7:JP45=
MG(NK>B.3]?3':ILR%8B%\Z]RC .R/A++75)7E/>MVTVT_N]G8_E?7>RI,E:5
M'&6VH#B,AR/_?@+Z[A3Y^;B]ETM?P@$M>T!^K1QHKI.[2]KW\;F3X\,W\4@(
M>8EIQ<\+JG,#2^0PJ1V.WE]KE\U3*F[6;'!#XJVTQVS0(U[$)(YZTR>^4J[8
M.K#8MMZ+\TO$V'Y+SD.?U9>'_H4W!&C]],9%)+"JSI;.HE.YN1T)=V9D,O=_
M?2<#982L<(!R:%-R,6Z]"SPC>Z*.%GWC?SJ]2!K$+MZ205-CA<"?.UF@72=E
MS>H8;V0KM*L^G45,Q<1D*6!JO-&;6ZYDH>U3+T2CLPXC_'6VX*^)*?IVTU-)
M)LMM0I,KL2!*&!/0C:%T[((W\COE-05[",P/\QYX&ZQWT>UK"Z?77LI< _UB
M:;@?U/B)>]\L*\*/(A>C> WH-HYVC^1G_QHSH6/3I1T2([?RD!W4^E\?LP!O
MY_'0]O$:.!EL3X$?=,ARJ[=A D7JF_Q3NK_BY-EL]6:9G\<FCK6F/Z96&:U[
MUQ&:X'-8<Y6%O4>]%W]IHC!-YIY[#5AE0Y1B%$>R4^Y%:HSG)E*NN=?+O[@(
M =-N&!RIY@>,B=&85ZB5UX025;># M0[Y%J@OU^TH[*QO->  JO7-7!C^AIX
M7S;0C2,;;3'[IOSJ^X]==NELA/@LGU:LM0DV&E@)@,W/*J'&-+T_^VWM?[UU
M7V:5)0D&!$J5HEV5ZT?\:-PXB*)9S2?G/RWQD&JKESDL#W>UBG?)W4C3E8HH
M^FYQ]94G:>59XY$Q)R>VN -XQ_NG5H!B"\&+RI#2+P5G.G ^JZ>H30EB>.E+
MA:<BS@63&3^QZ37$B\>^]SET=1;>,#R5[;_;DMS3?OC6G.T:*/MP#8B7G8XO
M%42^CLMMG1#-U*"-RPWA'<C><B+AX,F1_SG,^/.TM%0)V1M5!+\[_.-Y/UQD
M1T4_+DF9FK6Q5WO.2[80E(KYZT:$B$.:%)=CSB*-0M0#YTG5KWA'_)2*C(SA
MFL\FN%.%W]3%KYU9&VEDO#P;/BD#KWBT/-]"T-5])OS07]K)G.MNS1X"01H$
M(C4P+@7*Z=> \9<G<6=]W_I]M*J@\@U#^$ET6'S)^P7V-Z)[CE<@Z[OW*&_@
MNU3042<LSK<\_@5W%[_+BY<//_. <("],PU&0!UM$6DY4JYOR/?:W<I$E\9I
M1!X4 G1N14],NA?[6RHWC94]"5G8I@M1C*2HB66!&@,;<K<!.3H,G"#AV/0:
M6.EMB52O;6B^0K18LU;P[135A%%NE].(;][$\B[6L-)-=S71(A*MQD1K\P),
MW^@3O1_R9H<8YR 3P'8!M\?V:W:@4B8.10@[_;70U0H@/L@R_O\^J>EG=5%P
MJ%6A5:,>BEP#-&8[!M]2>4_3*;+5R%[N;_9%;.ES8?BS8Z*^:$W6SG--N3Z9
M\J1OONMW><NA'#4=7I- LJ6D/;K7\LG+V55[/;&]I1M/G!T!P]'@(&<&2NUO
M#P,//A:)+)Y+\CO@.O <N2>UY\>!9)7N]'F<[I1Z!@']'D^6CG#L!KP!EXX"
MI?_UX<P(F Q5B/?M/S!)TM> G6H?EM3^Q&?9*8!N4Q@SZO?\]D7XM[/T:G76
M%N3KE,XA(XWD(4D@>J\0^)]OT92;E_EV+E",RU#EJ>=OZ;BBU 4_?8DDGWT/
M*OSG%_TNJT8'F]SL?$FB>@UDRWI<U'=!B>UG_.H2D/-2LSX?N&KJU*R4MAGE
MK^#%;8]0GE]6_%E%!O7VJ0D_/:%H#G?LH)H([>-J(@70BQ$S)V=AV.<NJ(UN
M99F?;8Y".[8ZLE+!!XD_#SXH^^C_]_=KAM$&036!].9V9].E;LZ^+R^S&VL^
M<(9F!*F#V:FRK@&CX@MVWB),$!V?\@4YHN"*CA3X^\_U"ATPN_+SE/:]@VO
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M*U<QZ'Q<HY-A8P%>;*#$(*_KY=_&,NW([1#*MOGE3& ?@I@S6Z;H$?2\H,)
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MG!N)'!F GDB:"+V"4$<X^*"Y.Q,.N=Y?)(-;,0L5!+TZ>*60,4C9 SOQC[S
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MDCH3F$@8"S3C!\Q<!*9?55>J<T@*<NG&' ,>C;H[1ITLDH,+7_@ @7F]&*C
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MO8YWX4:-\9[&AOF1TTU!N9"OBU7SF9QWJ\P-*Z4LJ4TVB7-T-[51HPL4FO9
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MW=X""LD,7OYMCMMXH<!0V*!%:EO=NB.JN%3S1ZGT-9>Z:'J'&/8\_HF[ F;
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M+0#3__UD0)Z_(LC3<L>UP2K_[Y[!3G!77:8ZRI/%#WCO:35+?_C_4$L#!!0
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MCU]ZHPN4DFS$*0\\:WK*MY2,F6.?_A]02P,$%     @ 2(-<6%2.%0,W:0
M1H@% !@   !S:6QK+3(P,C,Q,C,Q>&5X,3!?-2YH=&WMO>ERXTB2+OI[QNR\
M0]SJZ6.2&:42M>5676;J7.;DO;7DR<SJL?G5%@2"8G2"  J+E)RGO^X>$4
M!$60 J$@A6ZKJDP2#'ALOOOG/_T_)R?_Y^NOOS _\O*Y"#/F)8)GPF?W,INQ
MMR+)\,-W,O6"*,T3P7[E(;\5].CYQ>G%Z?GI^<G)S__KWW^"D=[JWT;A:W;^
MX_G+'\_/SB_9^/7XU>N+E^S3K^K!638/X+__]M-,<!__\&\_93(+!/WQW]Y_
MG\F)S-CX[/2*P>\OZ($?BR=^^M'\[*=)Y"]^_LF7=RS-%H'XVP]SGMS*\"00
MT^SUU66<O=$?)/)VIC_Y0;TPKO[D]46<L3/]S_CJY2D^FHGOV0D/Y&WXF@9X
M,XW"[&3*YS)8O/XJYR)EOXE[]CF:\U!]E\K_$:_9^#S.U&O^[2?\V+S*EVD<
M\,5K)L- AD+]Y%X0;9,H\*TQ< @@E?WO<)+&;X9_=_5O]M./N,@_;[TO9[0O
MYHQV,]KXK)MQ3KL9YJJ;81K.KEDO=:/CU3<1;^#YE;J.]C7T@.N(I/][^+__
M\OW#^P\?WNPK_5\^_O+_/797]4K01G8SUN??;]ZY1]6O[]]]?'OSR\@]RC[^
M]O:TS0D\JYU ^LO%E1M'\?QL_,J]I7W_?__X^/6_W:,+MOS];U\__N.]>Z1]
M^N7FMY:GL?4INWC\*;M8R[ M??%>^MD,!-;97W_X^:>,3P*Q_,T;1E^<  %1
MGKUF4_E=^&]^8)X(@IC[O@QO__;#F?I[&G-/_QW&2^ ?OSK@Y9C(*Q?)^KB<
MA!*@2##HO3Z-<D>W]F\_9%'\ ]-_1C7WA^I [/S\].RL4'.MW;"N_K_R-)/3
MA>(&^B^O);*#$^F+Z#;A\6P3QJ"U[->O3L^N2C7:D%#=RN9'U[Y,;W88)7,>
MZ/?C@-5/BM.YZ61171G;O+4\+68#JN?BHG$;Z6/KCP_N:&43[>UU9N?6W\':
MBOO"BQ*>23#_\M 7"3WH14&4O/[+&?T/^4:>Q%$JTM9<:)N7;,CHMGE%--WW
M&60SL>]3^!3P<(L7U(=I;SFM'F/KV=8'^KK5MNR,G'C[^[HSFK:Z>SNC)IM)
MIU:GHTO1&3T\$:_-,(4$_!'5HQ])M8+_@DZV0GL\W4A/T*+M; ,]LO19+"V
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M[.*('ZM*[U'19U!O5A!$]Y9,+L'6SFVDM0+PH1%GO!D=?%2O*&\^[*LRA!O
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MJ99+^,5#MTF4QQJ'0K6N-#WD4O*E<TUH4W3D4(3(\V(@XR=E(*U=P V/.\9
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M>\S:7T[G4EJO&HV/J[TV/K8P+BXIVWF#&O3&'[AL8*RK6OK>I?TPCWRLJ40
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M-3KX@_"6S6&95#,SX"98)( C,;C*?RWJ]+(HXP'V(YN03787T0]C;'=$Z?_
MC+R I]H)H?T,5?\-.KI6N&]&!0:2^=&*V90I1/#-T97-:E2J,GJYNC[)+L,B
MO5@!Y+L6O[=UG/5J19SUP>+B'G3JBY;:],7N]>C&4N)M K;U[,&'([9GS1';
MLS)B>[;N%+2.V#JXV[N,B.Y[7/>]!HS=]WE\0I#<?9_$=A$(IZ;P%K&3?=%=
M!]6GRA9X+OA>+P=\K^WPO=H?L.43MHD/UUVO;>_%9./+)OVRCJ.V"Y_LRXVP
M(:I/=ZU+;C3?&M+EJ]-7=:2:/LI0GKF2X73NS%>WO%UQ.]BROLBAP)]+!(GM
M[]+N]JRC>]$902W1!?LBQS&'LBKB<(DBMQK:3IS:+9FF>0W2O6@-4T%0*Q,?
MBXR8)D"5I4[JTPC1'U!%&#*S.VRX=_FJV>M&GW>B(*_TN Z5+:6C=.RJH]3=
MTI;EK "7^*%CPA0#A2[1XUK,TB5JBEBA2T2IL&4' U4#$H,,W[^TQ/'+)Q3G
M3N4==@R5>-,92I*=:A$6)>%/D6AA9U:XQ,^Z2O* 22NX@5HGS,+."2,6B#15
MRU2IYJDLF;UF'[#JXU=5]?$/JOHHWQ*%E<20#E:"=OD1 :RS+3CR]:8,^1KY
M_L"1G>/(AP&AOZ;L]>^[X<N+DC$K4"AB$3:_]FW8Z9@GG,A%0<'D?"Z #64B
M6# ^B>[$8]F1Q;VW8T6/Y2.#8O?D;.1R7>1RJ)O?JF+DO#,&4BU]>*C2NG=^
MX)1VUREK&O2:9\>0C)K2EB4U/>\X4[KHC"G]5D-R4.&:1-Q&\+?1*L R F?@
M*SF44^QDVJ'2Y-+$'/-2NU=#Y!(U='%<(L@$>UVBR:T8?:N&H[TM#9R?E'NN
M@2H41JY+1,EPY!(YCH'^2*<.D%.73#4-<XDB#VL=TJQE_]:^J$+M;U0 .UV>
M7Q[QX]+Y[HO!D;37*?#CIW(DJ7#$)ICHC;]PS'8;U]/A^\B'_R\N*7;W235,
M1;PZDR+/WH&FW@D^([NQPI%EEJ =?5S*#53.*[@1QL6%Y"%#L9'=S$C:ZC3&
MI9H'#5!D("KPO@B,5V6H$M+@'':&8%&H8Z3$-$4Q5?'.E6,/3&N?F=83]X \
MH"X.]<2&QS2 :L^O/D0*;Z'SXL[EEC%U!D*PI)XGXLP@AQ(EGDT)X8EJ5J$0
M0PM/?=GYFKI/BVRF&E3K!G:GK.[V?Q!FZ/&DNJ0H<J?45L<<9B@U7:+'08>9
M4U5L7W+/*0!)9V\]:%8ND:-M:)=(0NZ?B,"I98JFKUTBIZRJ<((<[$';Q3C=
MK<^Y6^LS$]ZW?A=H:44N6JU(=R^,DV@NTS1*6MWC[MX;1IEHY>'N[I7M(C,=
MOJ^=JM;="U6?@I[/#VKU6<M.;=V]=M+S<;V)XT!Z:+#T^]Y?^'W:\S4YNNR9
M!5'N:;^O5*7=/2^L@4?LFPNU,V"[>R-!1.H.B#/>KHJLN[?SANR7=J9%IYR_
M2/U+\R01U(A%_)GSP%23ESUD:GF1.@1E.DBF9=L86M=:$7O5JUP <)(#63E9
MBLXV7\K>%-CZ!MO2Y %U)J%F,/Z=2%)A&I;@K]#F )I%Z(G4D*W+4D9$V)*G
MIW#RI#BLS%HYZ#L\>%'?[!F^]Q*!.[+5SQ_!I*]Z9M(;&^K=O3H1GI!WAZYA
M]*XMZJO<[TO)>=ZS0.CYW"31-Y&<\)1R'GH^M$? A$F=.D97_8QR1BWY@L&2
M.3NZGPE=[I-$^2WFP"JBF?GU/3R.%3YQ0,#-)4**J4H$[@X,(=3)$Y1(2VW)
M AZ^84?7Q_A\".+7O!L^?'&LVW+1JZN!"91=2T&'HOT9(KM0^V3X3@NQ:F.V
MP@;!UY::.D/E^0U.ZNCEL0ZQ(MRV>J>6LT6:L"8@M<,>VT=3A^8U#B%K#S@O
M)<Z+/^"\# ".ZUZQ513-J1ETU[9HR*C9XXR:M4BX0SUIJWR:LR= P_V41)[P
M\T3UP7U?:)*?<>+D&>$J]606!2V-BG5WG=V DEAK%@/:JFAMM:QY0:?-JERB
MQRTH2*N'LDMDH6LMP3OE$E%NE2NYEMT$AJ53 +!NI3<YMEOH?7")'L=JIMS*
M8TP=2T3#1$:GKKICI\<Y%6@G!^@!(T__VS*?E/)^@I;(ZZO+0O<_251'E]+T
M6+(-+TC?-W@(:/^LZZF\@0GRS!KSO&KW6&&O#(UY=G((EY=AS898Y4Y@RJT!
M8Z<(02HH)I#-V",ZI6["@7[X^2;<H 'V9D-CZ1:&X2M!?+1T.9LFJDA> 2Q1
MR..T.+_VK7[0Y?1@A\&N^,UV_JJ'/50-5]*"4;TZ?75E.% %I6=3%T<OZW/>
M;GVLDV;U)X!3[5N'XWXFPDH43@?&T]>60Z;#$\KQ?+8$PMELY'9FS&9C;M+P
M9;.1C]JA#6PV:%OU9;-1L9AJ!P>AE6*\V9@M;<<-V;4M,W;"LG=P$&+A 7O:
MP5EHV2Y^PWTCU.963J/-!]X!$]O1*NSB],8B28'_8UU-%BB,UB)WHZSY'I$N
MA 7X;)J#I*AG2Q1I?J GP1]BW<%FJ2Q=II9H.<JB6Y43HD#1RAP*_#LZV*DV
ME'\7Z?$I^V"_%_4879VD*D,7K9([> Z?)" D'U#X*GD=#0H?/63R3G:@_>FE
MU)V%\A@WY\&60OI)K9Z&?%ZD<]K=YK&WD)S"YOR9B]2:G?7,:-T8./,9;"&L
M%.Y:&D=Y*D[9'W!V6@4&'#CN[=MK;2BMVB&!;C:HVMD=Z!:[D*T"DX!#;Q?T
MMLN*=.!T 0M+HCB1+0']-ES@,&M7+[6A6KP#/7,GBSN)HF\[.+>[, MV,O\-
M4F<W7($=:*WD1/!SA&DO92Y!\4U!<O!;ZBM1:3IQ/$)49G)CHNIP%V$E0V+,
M3>9+XB]^:II3J)3.Q(K+IV5<7@E'\1WU@[I28NDK5K,]"Y<B; !VM45PJ<_L
M0/Q_M4QMF@0) 88YMA[/42F+2J%_7"FRP*K*.,,E1X_<*K5K!S3_!LOGH\>#
M]".CE\RY+[1OR6Q>D>NK]QF_+77$!!,T?%7#(G$Z$K7+J,2TMDM4$K,&(Y@:
MEIS@&2A*44"1,2!KX\M"E;$4MN?KTGIA^5Z7@8#VVY_UO@%GANE:(P51:'!A
MO$1P;>&$^7R":>AEGC=FWZ@[Q.^X#- D&3&8Q8P.;)PG<:2[YYAC1:HQ?IER
M,%\H;%6QGK2RO?0JN])JS7WMZL0^Y8E\5BCN QJ@=3;V%0WP*P6(BN*-SR*@
M/Z<S&>MD0)'<807E)R5ZNLD(_(C:DVUY>\BM4BW[EU\ZLEOID,N@9KK#I3P_
M&[]Z T-8$]+EE+HF<]G@+W[E4@C>%SQS*HD#N/X[S/N3@<P63N$GNY8J59XL
ME\A"7V*AWI?N+9=(+#Q^!/9).K_&_\1+2QBBZ#%DRJTO2V]@W7=9+6&C@NVJ
MVG&GG(.U3C(VTSB:Y%2_#<::N,-1@",:UJ/&CF52J7;#7ZNB]+*4'.A=%UD_
M+@  ^205NA2/6W.DB3?_=F1/BU2^1,RY+%RI!@00JQ&%P*X@; Y;,$O+ANNM
M6"@Z/ZG>L:A@+&V0YO[N<OK0XM8]KK C&*[7NZ*T1<L#J]"P*BB(6K'THCM0
M8IU*YM+KD8=Z-C'LO75*JIL%U#O%)(:,Y34YL$X!#J+^I'P@#]PM/Q+J=C4P
M?U;EN 54<\E\FF]W_2";]XM1$3:J7E <9PEB0QU_PZR[WJ M:LIZZ76Z1R5E
MO=N2W8 T=^B/6>J$NFDC5(?LS(>795V;U'Y0GDL+ ^5EMYKTYO:F,GW7VXVV
M8;3$?U?HW6QGRNZSUG/O17 'BN[X_$ U7;:Q>FG.Q[/17ER:8W&Z72(*_?Z.
MM<!R3-/O#.'@8(N22XW?):H<J^MR[%2W3PKKBR(GW3<N4>-:)>? &-<-Y*)/
M;UG_VU4MIB'T\$HAQV?MGBMLY&=;"_FL0) Z]5@]+I/%<E==;.2L6GYZ[2O[
M<54UK<?:;F1W?;BI,#B_ P^52V(#S7.7Z*EX!216X<PD\!.G:%Q*6'&)N(?:
M9K9PDE%"RM/%YM7KE[R5.!-\+%(_KTQJ9Y[,44-5D;U0*3 Z3L5'(A13>( G
MBU'I1Z3765^Q&;QT(D1H_[1("WY@,S#E4_7XLWK^Z?6M>"G)]0UKUNK-3153
M&99'V\NT=(+TKU2='4?G8PS&)JP6ISZ&#WG/8;^YRH*O#'*4'JNLT6A>.R$F
MP1[]H7&>(()QZ>9L>@.Y0V%\7# ""B/(XP):.>#WJ3ICJ6=*WWQ<.PG'C9S"
M3^RY7GT&MO)7<ZLK;W&UGLI++>=SX6,I4;!H\ECCR:WN/E*61G;M_LKHM?9T
M[B1>_=A@\P!@6D=$'C>#6*O/.]'?VZ!8X^\.#<)Z_9Q(=[[; +]ZM:75TN;:
M!KQZUWM3V1K;SCLKO1[D!CFY&"NH%*:/N7&&G+ZR_Z</]$YLD*\@';;#NW0*
M3/I]H95U:4 U#/70=IXM[^3E\@W:;"?KM-VX9 NXGOU.6I13!!F%SB6B'.NC
MRX,TJEW C?6B4BO:$73?@Q.LSTBKTFW69OM57;;3>?:Z23ESMAIN7S3,WO,9
M+Y\,(O\@:^/&+VO.WO'6OM[ZD94#^//J@3:!?^N+I@&M>Z_"](4ORR6B'-LU
M*P^R@]&86S>DT86)CM\\;:XP9D>MBWV5 [-2H'K,[J,\\*U&K($TF>4*MZ
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MXM(&J5B[2=N@J15N*5KR-<O!,R6+@R@5K3;E6!=>\H>J+@?#:C"LGFV3VJ?
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M:2RM1*!+U=,M;5V:B/+IZDQ9EPB+><))&2?4"@/0K?MO6&5)(^5]%"6"/%8
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M855"Q95$&(O]#AK9$(PZK&#4^=D0C-IE>:]IDK7OT8,_XOV/X7Q,$8MQJQ(
MI^:QXU@4:P^HTM:I,XC+P8&QY\UD]S"@\XNXY0$K(28.S4UK&J1:5<(26+RH
MPNX6V?XF"Y+<LAJMV^CXND.VMKFE%A3:6ULV_Z%G[=<^X+VM0#1,\X3R_NN(
M%983V8OR,!4!97M64?,;@,<[6#VO.!?;L^GVS/EZ4]Y\C2)@8,ZN,>?+TZO-
M"@8:?^ X<^XCCO8QQ.;!Y!O\+&*XW_"GSOIXG+(;+ PM>O26X:B2[QF^6.W1
M@4%YT\J!G& B2:/0_+!:U*2Z.VC:%;OC"159&=PQ#.MKQR_]S.J2H!_1S!1A
MAB8"AP?6[<VHBW04 F>=$IQ"L52*IZK"4.H$K5^N4&3T3(&+!H0C@1Y0.<E-
MS:E^EYP67<NC6(;:G[J"_8X,,E)2V20LV3)8:D/5_^%590UQND?RT/-Q#Z55
M'T,=T<!;_[N*T=_DP!V2;J(<*FM)%F^IE<!CL9)Z*3<O5>4X5. O;O. $Q+D
M)/(7!E#R7WDB4U^J>AOE<"9%3*##N0*@U@BJHT<NZY@*E)(_<]B[:8G'9G-7
MY>K&W]IM=:@D%1OKL(#?C^AKTU#')2V?B#-(!'D@E&*MEY?ZSYO)"B_'T)I^
MXOUWD"/A+6W7'#1Z"JP2A!-F<2#>F/JZ*/ U73W5:"D'V>4%/%7""3X*60#K
M+E0M+ZZ66OC;"*R#$'=(+6EMXXM0H#DBH\H&CNH;E] D6:F=J^I@. )%F%"?
MOS*N9V27 O4LDTV03O].IL2VC6"K&#<I#PH);9!/35AII*R7!.P?H1MEZ3>[
M=#PT\;!6^I+"=336DM[**9=!GE"V#=F'=/!11["U DYHJVJO-$(%7+U48E'=
MUEM7F*;4:FR"\6/%,1ZE-0Q*PU.;7T^F-+A7K=TMS,3Y>0]JPUL0*1/N?=MA
M7K/IZ$2 .TL H(7ULQI[)RW0\5(4S?Z/,/!$A&**%=%UEU =T,)V,R74KH_8
ME8<\*0@T\P)Y,!4R \98O""!U<MCA5%JZK*I'#L1H<*>\$2B,B%I?A(KB>\4
MC3A3O[0V"5B[=(BA 0=[/D)[<HKGB,8K$=9,F$S+=K3;O$*XF^D1" ;.';26
MT+5V3HZ)18("25UK"^I60HAC.))8^9^ VN823<1$72(HFTFG3C2!7+A$4"<U
M>-WF7+E$D(/9? [>,:?X8D=UI=W!EL_XDI;5;)9K/9/%$>A!"W8DR58]1EL3
ME408 C0=T(]D.E/@[:B$44HX_'6I&:C2-17ZC>VF7^H+JC4[Y8P !4\K9%K%
M,W"\U18HY+K@0&E2@;8W85'\J7&?JQ!KF3ZIHP@T#O4\20E$NND)7SGMM6)+
M^-K8#U7X^B?J X5A1AHH;DV4R@:?UG,#>'FYAP ORVZ-YPGYLLH%TMK;\?,2
MI37+_GH+2WRCS7X,PUS%,>PL#0H7BF2>%FD6AC=IYHGL*:WY-C%[(DXD508/
ME72#LVVH%][,V7;1@[/MN=0+VQB'MF98I'CIX(U50XR\SJ5IU+/.,$GB7@1W
M@AV-SX_9''X]2^MPL78;HR;TP5/V!;EY8^FT62X3$S%I&;K)"*7CZ8(<@<[3
MLGV=DB46E^]@^H\2%"K-:7SU\O1\&XDQ;B<QUHB(GS@+P7SXVP]?9/#MGY\C
M[O_S5^'#"@7__.<_/P!'^6<T_2==R'_^3I":R*+Y\]&A7^VA#MV!Q@RC&H4<
M(](_X]BS;![\_/\#4$L#!!0    ( $B#7%BV!$R2^5$  -C+ P 8    <VEL
M:RTR,#(S,3(S,7AE>#$P7S8N:'1M[7U]<]LXDO??>U7W'?AD;Z_L*L7C]\3)
M;*H\MI+HV<3VV<[,;5T]E8)(R.*$(K5\L:+[]$]W R!!BI(HF9(AF3NU,[)$
M HT&T.AN=/_ZU__S^O7G^Z]?+">PDP'W8\L..8NY8XW<N&]=\##&+R_=R/:"
M* FY]97Y[('3HX='>T=[AWN'KU]_^/=_^Q5:NI#O!OX[Z_"7P[>_'.X?'EL'
M[P[.WIV\L6Z^B@?[\<"#__[EUSYG#G[XRZ^Q&WN</OZE_;/O=MW8.MC?.[7@
M_2-ZX)?TB5]_4:_]V@V<\8=?'??1BN*QQ__^:L#"!]=_[?%>_.[D>!B_EU^$
M[D-??O-*=#C,O_+N:!A;^_+_!R=O]_#1F/^,7S//??#?40/O>X$?O^ZQ@>N-
MW]V[ QY95WQDW08#YHO?(O=_^3OKX' 8BV[^\BM^K;IRW&CHL?$[R_4]U^?B
ME1$GVKJ!YVAM8!- JO6??C<:OF_^7=>_K5]_029_6'I>]FE>U!JMI[6#_7K:
MV:NGF=-ZFBE9NXI?8D</I^]$W(&')V([ZMO0!JG#P_7OP__\Z\^/[8\?WU>A
M_WCOI# "\4==(V&6SP;0W9WK_?A^&S#G^U?NN#;SOG___C$(!]^#WO>[.+!_
M?+\>QF[@O_KPZR]L^<D4#+CK?/G'4Y>%9"6MA'K:NKT^OS2/JJ_MR\[%^9>6
M>91UKB[VJBQA;<VFZ_?HQ(RM>+A_<&8>9]O_]:US_T_SZ((9;U_==WYOFT?:
MS9?S*^ON_OKB'];US7WG^LHZ_W3;;G\%>BNMT;V33&5[WPU"AX>ONT$<!X-W
M!_"M'_C<^NOE&?YC55ZF^T]?IOL+GQ@XB).]MW(XIVJ?N;X#>^S=T6E^X_V9
M1+';&XNOY!_O7-R,KUV'!P\A&_85/^)@6,*,NIA5<4^_^O#-]W@455DVBRRQ
M5Q^"N,_#D1OQ^IMV> \^./4W#!1SUZ]T."S6,/!B!8WR<+""B5L9=UU_0QB+
MVEO]K:(Z6'^K4K]<P9KM^/:>5?5$7ZSI]K\2-QY;T ,(4?>16S<>\ZT=F$P+
M9#/T>?$>OQ&?+]_O6B/7\ZP^@R?QF0AT;$LN4VO F>_Z#Q&T#C^ZD47ZM27T
M:^O\(>3D#VE9H[YK]^$IVTL<$)O8T%40NS:W@E[^I4\A ^ISY&1/TH\I92UJ
MYQYWHL5\Q[H(?,?%1J(IK;(X9G8?Z$99$P<6BRH9JG2@.-P.0H:-O4O@_ D5
M-Z7!>UZ-^8+D]D\>VB"=%0]62-=O5>E"!C*8:#HZ+"Y>%WQEPR$'SMHP<45*
M=_"5.'C@^)88G)HUR?EJ_:=+)9W<:OIXF:Y3?K:O0M%YBEZSKVDU:[859JV;
MJ^O[SD4M2O&L7NI3EV?U<OUQ.\9!ML!V#$48-*ONQ?IT>[Z,L62\,:3^?WRH
MJ)UHOD[SY(:%<#ZY0S@[W[T(;J[37W/N."$8?TLP=@ML^K/MM>GO00<B813!
M $!3TC81:-&1U>7<MQY0'X4?0?.6>A(H4\,DM.$)#HKL8 !?"0T655FPB2PT
M82QE<5AD(.2T9'@)^AAKVG&4=/_D=HQ-XX-QJBC;.449?R,; '\B+7Y2?P>Z
M>X'G!:,GK%?S]#+M@G3D.G$?WMG_VZL/O\:LZW'+YIXW9(X#!L[?7^V_HK^C
M(;/5W_)-.3H;V,.&$7^G/KS/W;GN[V5WK'_Y-0[%!_CD6(^TU/_^"OA3;%1<
MSRZ^J.7OU/747\OG0S#B</_-WCXR4#* MNTISJH<PMQ)Q]EXW1=2X^!D_V]+
M;+3Y>XW,NOI-Y*MDT.6A6NEJN=!ENU-MXF9S?MZ\S9GV61-W<':T=V+ Q"EV
M3[(./H7KW08S#X8I,[51V^"2Q9E[Y/F6[4P^3YO#9MF^V&7[.P=]SG\@=8?[
MM@B=PK7<+.%F"6_&$A:: NGH?0;FG!#!W&E6<+."-V,%IW<1-R%>10QA-=-2
MMG9<W_JV=[=G7:)!$T:[S9I>;!;V*\_"A-'Z'S-8W>R!VO? ?1 S;P4WK7)K
MU=\R[=6=5=SIXXZOO]5&A#0BY*DB1/'O[=[;DP4GHS@%1WMO3I9R^5<0)>/A
M"O8[Z)?5'A2>V\W>9ILPT1/;[3O^;X%4"@KQD0$X>J3*MN[:T[W312?SB9>)
M"T]AX:9@LS?/$OPV=:-<!7X4LSB)@W#\?'MEF;TP;]XW2TGFX>"7]L^A*P(N
M5NRH6VHO5./W!KDYX ->10)_'??1U-" 92,!1#[8V<G>F1H!!6+DF/L6Y-B;
MOQEUPS\K\$AYM.\P1C+Q*FJ"U:[4LUDNCYHPB4>O/MR)V(,5!)T'];?);)M[
M/,0,[?H;?Q1K8@54KR#_(.(KF+)>$,;]^IOM<B\8K<#6"E]P]@7& :TD!<==
MP6+-:X'UM8L)#ZM8KA87#D$\TEN8,C'J!QZW@A _#UD8TY<@C$!8,[ .!=($
MAF>)V"L\62)YLE0,PSJN'(>U29K#T\["VL^Z_ZFR .S "\)W?]VG_Z$Z/0)J
MQZ][Z  8PK+ N^^=PY._[:J0/'FA6 CBDZ%Y41\3+_!HL3!V$'[ (>X<[%IC
MSD*+^3ZT&T8L'"]#6_5E77PSZ*VWOXI"L+X.?Z]^FM?7J1X@L=Z>T<BK=![4
MUR7S*REA-:Y9'P5L")N1C(X^;*-?CM_&_2D[L:* JBQF#E(Q(X:@&A8V7TT@
M/AA]6I9*O7B4=8TF1)Z%:M+@J;^_.GCU(?4.(2^F1.K^^[]-9;]N1L+ CQ8V
MTG-3DI'Z[_\F)Z8?2EJ/4L^&7%EG]+]7%E$*8T%2+>D($>@0"#W2#S]DA _9
M W_=#3G[\9KUX(%WS!NQ<90MZVF8,,\\L9.,6TQ\3SO4.+/[U@!:(OT'^(),
M44>=2$%E8[4_Q7-,I)5.#2JS=C"^W>V)!BTW@F%:H&K!UAYB/#R\ VVV5"<>
M S**G>2#ZO7(?AM^=OT$6X%?0-=CUAT/'S&DXB8,'H';(303!LE#7PPN2N!?
M#M"U]_]JCJC?5$V.O#\F>3%F>7K0&^KZK*H!4D_FW:Q6;GCH!A7=%W7G<&S:
MBMMJ3)%[+8.'4O?SAB>J.I4N7HJR^G] ?'&0HD>[0A9&_V^95BPAR7.BD[,(
M,0&FB,V6E1!*BI"8<;;O4(0["2](8I'_=/8>?N,,C@48[26.W/7<>"RM;L0B
ML#'1*B[P:KV*9V%BEFD")_-_XA'W'M'Z.USSU.PA@ $Z*:*8B1-4."M"_A"0
MLP*5'3B#B>UPVO)'/(P'<*CJC,_8@ EQ1(/"=2C>-^$A/Q2=PZ/= $9=3%K#
MUJ%%[9@&@]ASL5%MZ>CM &UW\"A^?7"L)\35#4&PN6)2W-%LFZ3\;5PN.#!Q
MD\4(Z2H6%]>^D<LCY$/0&X$/C"(XQ+?U^PQE3J=%KNY6;FLJTM0C#),UX1L6
MY[8#?%*YIJ0MT'L/L'%"S$WMCI^<&2HP7=3>KP[&TC("C8403WKR2,"HYP%S
M4-*A-U9P  \9B0"\@L#(W(S:/_Q@Y''G 99VR&WN#HD&!K,R')<)IA41@EG*
M(7]T^8@[%=: 1> _W TMC&>"J81C%IOH,\IO#H;#((P3'T&'8):#;LS$"Q9S
M'B6NCQTD?L0]D,DN'&@HLW]R.XG%JBI/2 9J>HGGC66N-1Y $4TGR?6H^A)>
M-3-A<7?E]J23%"\;86(Q$]RE0[.%NPXV40221 X,CBF/!@/K7(T%;PE@HX+<
MB5ENAYX[<*RY40S[ 1Y*AGB\@4#X5X*6,#X7<H_%TC(M\(.OFQV])"2 H8P?
M?H!'14Z6I6.P^\Q_X'*!P3@B.$KP8H0)[ 0+&6@3L#9)R*H8GNLYAXX6/J:/
MECFF7]!@GI/8-6(%"&5K<[ "#M\*BA>(ISK83R% ]I?0(Q=7!>=K@S?GM_>=
MB\Y-AART3%3;G%E818"HFH6%@]J>8Q*F![T9"ZEP>/)F[W@#6#LO(JLB4OF"
MP)H5D<87!-9< "E\06#-#.G;W+CA@ER=7.)1X+F.)5TWE@KZ/GRS=[;YZ[2&
M,/QG%\)&3@@:_3W0DM]9?=<!/5J;H?U,WUBAC'Y"?D,J@S=S+]3 ^O5G_RPD
MG-3<EL_&DNDHJQ)'3T@2NE.>P"T03P;,RK/+I&7UQG*QU.R"35>ES#@O7K+N
M9/@,;+1RM+&\W4SM9_,%_4WH5@LYGKQL7@Q/7'_UB@TV6KTR9-J-]KLMI#\9
MPM MVT<;A2=A[AW#\R).;)*P,TNE:-2U35+75@B_L81H:>3)XI,T=QI>GO+T
M-!R3%Z,\W6.%^RJ*3!6XE T#2=G?V]?BBZWU)S<O5J;FL$AL57H69N52T46+
M<R??9).CN$2.XCS&+YA#2$\O61BL.BR17J;^^:M[SXQY_N_/G=\Z]Y4M1*/K
MPYU7$S,;56;LY$#+GGC>&O'W[=NO=W7,8;T5S\^O*L40K9>HB^NKRPY6*S20
M8?54MJR7IMJJ5-;,JMHJ3FY)7<G9@<P3O[RWZ(?70$"0Q.^LGON3.^]?S8MX
M_H"&/QI'N0:/!1\S=FE?9X,08Q 8&*#C3YA8\C/:5J_R#5E@1>YK@0-91RNT
M$]]K>HXR<7+SMX@"*J?5#\(!\V1/V$K^F_Q9NL"P<!$?Z&D2V;I0K,ZO@./2
M":.OM8\SYRXW7?I$/N\<534T9JLLQ23:RA7IENYAJ0N!Q;JH"#>^=/O5@=L*
M710;TD-YQ7I#5\#"J*FKD,^9.)Z80$.%\VGI5C^M2S03O7H&\9O#YQ/46FYS
M!;%=>/K9A7C.IW=XE!N(M<-V<_+]"=OK7LO)DWF,E$P<J4Q"S+][=)V$>=:.
MJD,[D5)]^7[7\ME 9-KC6U=!+/,^)]."TZ3;B2S37+';K EZ*^N($D[IS=SS
MHK7L,;W:+C[G%^MX13PF4+#^)-%I^C)]KZ +,'<U5S]I7@MY O-EF,J+^,ID
MY5S&=@U"=.D#I=B0ECQ.0RZ;195V2D"C,N_:Q>?AV!@&!,%+2PT:Z$J8B)#W
MX O?YGO67<:,%++A;,?>U3-]6XK? FU")E#[/<^%%[L\'F']Y1E9[R9QM"*H
MP+K(0?::1(]AZ]^PV:+U;1)!ADU7MNM-HLHT 50-N'E=]-1F.=1&489)81)5
MC2AJ1-'6B2*CEC2!J!"^WC#DC\SUGN"+V%_"&7&ZJ"^"8C\VQAEQ4NJ,2(NY
M;8\S0EPWG^2B]V:Y(\J>G]OM>AT2QP6'1+<VA\3'(!0UB6/V<\C&/(Q:.HB1
M@KMTN !L0Y# R.*N0!SRK?*2>YGKHG-WG;D(H"MF3:T]EKUTI;U4"3QI71*J
MT],9,<4)P2)BS-UUJP@;AY/L(SXB&-O_2F U],;9TQ),3AGAQX>'R@3OX-I
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M2JSIZ<:T>#I*NB+((BY8UF 22*?!!.A2VI["2E0YP])%#RL#^.H[4>:[<3
M1+D7I='^VZ[E!#0$.Q@,7&J?P(U"+D/I_$!S,U/W<9B .1CR26#W!P5?-8UY
M^#X,)[&I>@E'MF&L<[EUFO>*%RQ=ZL7NNUS6;!4.G<1C(7D]1&!+)9-OD7,K
M7Y*X<!V00=[7WVUQ]+!@!P%- ?,MW"-_)J$;.:Y8P%T>C[#JR61!$[5:G(J8
M-(M1*==>R#W^2(N5_23G62 FA9P'@4<W)E3D5U3M3IUL+6OF351E<YC\+!@
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M%K3 "QEDE",Q3,(4_\UF'I:?ICL;% X1QV!9&=X8 ?]D>*.6Y= B[%O?@:?
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MX[VAT[)L%O71@$[$I4G2A?'&"5[<]/"&$,05:!D^ET8X:AGBW@@4_Q W.='
M;'EQT,,')<"?R!9\;VD^X:TIS]:H(VLLS545>K/L><,4DL.)6I([/^K$WS1)
ME^@%GA>,#(L/)C6-:@^91!4;#LUR/06^6?28%0K5N'F;]( :]UH2HR>(=*9O
MOHNJUUT,JE6T?%7;1E=Z)EWI8/_M,RM+6U7'M(A57E^R<8FC0\*4@PGTIZQ&
MJ#^T8.D$M*68AWDT/15))^Y*&L]LL[V7V-Y;AB)0K)GBUK>S#57.]%KV1M%E
M5L0>!6<8Q:"XSXQ:2&:%3QB8\WC+8?>[AJ5@43R1201UN>6Y=$0K!07^"V>
MGSJ'+?+O]KP$TP-(J>GR>,3S84Y9A)6X?+:3$#-7QJE6E;-H3&+ 9>"!?F82
M1:9)FHK0>VL[&NAVP22*#'.X-EB<FS1;Y@$"FQ6G9M;B,2STG@V"Q(^-.D\=
MLV2/6: KAAJEPR2,$L-HDGZW-#$QAP1(@?[P%\8I\'\E&%44,4\$1I85.QX&
M?MK2$R,1&N];XWW;$N_;X83WK3[WFQ]8ML?< ;G&\\%_10>YPP;L 3WNE&O#
M0MSMO3 8H"7:XRX5$LWO?MC<B4<!1O0<_E)+AO*.LH$EPM4(++$HP.K&K><
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M$656#EP4U)(.N:7<&898FY@@^TPBBW#;3"*(+Y_PO#*:#,ONK':9ORYR#-0
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M56Y7L=%\D%8],W,:[2[Z*M:A"KL\PPE\Q:K<FU3M2LY1C9/A]!CE9D66L')
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M+?@[(UJ>+><BS^YD'75%R]'+1R):(CPHX18+E_,5A,OA4JHXM*+EL),L*[.
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M1PD7<R<HJ*X?8ED(%Z?,*1U-8+W:*6#8*[G\'T?E>SP8[ <Y=A+$5DQ/*5)
MA(R;P*4-+;<E+_6RU8U/L6DQ*)0A!=QHQ#=Y2YEI(8>RG(FZHF;,1.9:O(]%
M^HV]13IAJQ2MR1 ^QL\P?&?!C/15"478\+#'\VU%"]@B#6F"'+3.<MRMR3OO
MN [\MSR*%T['\[=:.?/W..P^"(FIMX>,GULA8?7C*C'0^0<V4\!*P4KLQ4W
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M'#5VFZ5Y7_>&L<10V?Z[-EW_OG0);)V4,"V"!#]T##( -X_HJD1YW'CKLXB
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M$PO:A/:#G$'_4Q&*9-8C[!<9I:;+;PE@.BE%"QF"VJV]UDXM3P7W34-)B<&
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MW?RI0;YEDV"V9D.^R1%+OLIEU1&K8JW/5L/ SG?Z;%/,_R!\!5!+ P04
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MY?OV_D'KH!E@G$V?&2^>0>M+N/OR/-R=EY-L87?4.ANFL?K=L5OVKY\'ANT
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MD]G8S\;^^D*?C?WL-$1V&F)#3T.DX*#-DUPY=PISWM4]D5149H,U >=8_^1
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M) ,6L[8",R23NERH'?3&4?WYL/[Z#(ILE<JR5>JJ%F\E(*P+C5XPBZ30V&7
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MG$L+AMO G;1@M =C#]("E^/.NI!4*.GB;(<=2,9W>I$=(^MX(%_+T#(J-C9
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M@401K.FVKX$-M(X _B&T_J;NT#I<:-G<LAK4^#A9#?044K]:45,B_ZP[I:8
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M=@X)%3^UT'1%YI\&>1A:9(NOM?Z21D=35 J#8>#B:HD+_F=<2SG)5"Q((ZX
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MX\]($-!=I30H,"FTL1<_L7\,(Y[/H;&J+I)W([70I;K066/4?S\X?/#@H5I
MA]4,I[87/[E_>!><\',^'6]A'R9%EA67-I^JU%1):1>T3[ +L-6MA586-D15
MS1S6:4F'(2U@C'E1JT6#)ZA6=:'&>)[FB\S4YE ]J_&EJAG_"=N/O^);?S6P
M0A,+VVIS9>M*P?+9TM1+-5["P9G J<D3@T_C,5F4Q86M8$B5&]-K4]6DOZ+:
M"PTE\ %_@W,='63LZ52.#_[MW_II"<<>3O/ES"8SA8=D8C-\" ;"VEN%?6-/
M\Z*J840HY=1IGL.XH1F:*'3P<U'.82\._DW-8SO6#P"::\UE!O_:_)"E"/__
M'P;FG4 OH*:K9=%@GZ"7I[N;(GV'2Z@7BPR:&&?=U<0?/1<0_JK.HAZ>ZTNU
M]_27L^?[<$Q*I=/4XO?PE,WABSD]=7@SV;4%F7P"TN>TJ6=%"5_ GNB%K6$)
MWB!1W$INWXAG?'@N\1).I [S3V3^S!02.$O ZND\/7SP[0@8&?Z/^2]]VWI^
M$[<>X=-$EL=]R[K&(GQ<T\E>^>5$T0\',-FBJ8^!RM^;].2>2DR6+? DY],?
M[SW@S]5")_(9VBOA?VF[0=HI^&W1\W58+UXN'#"8PBFU<D$[^^,]$"#WE/R-
MEN^]=D/JX?>P%O0Z;YGO:-OC<95&L\7Q.>D[OS+ ]J'J>S#NZ,UR#F2U]5'?
M/)?N086AJ7_^X_U/_SJ)3D\X/FY'6NO^H'=;\=OPU\;];6UIO-F?R3[>CC>T
M]9=[3QXR\<<, $4+*!8P;Q)-(&5CG>($A90SJ_RZWD<2O$_D^R1R:0P,8(N#
MTZ^Q?H;4WS>1+X+T[W0'=TOW*V)_E>H7I VC05A%>M.5-'\=X^SO:KUW5QFM
MM;R9CT%? D4ITL@B72NVUT!C[ZRZFNLE6FA@J8"M46$,H(1]<A_VQDU-]MS8
M@$E(YD'H3SJIT99AVP&LQ*8&DR-'5KJ/%@]9&Y.))<O@PJB+@NT6_'X&>K4I
M:90:QO$GC!U,/C !X2&T/A?%)7>$#TMG:!G6:)R!<41M3=E(R>A%?-!DXEB
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M%/L)2@K2R!BA<W/? QO9/1MQZ"JTVA[<R&G%@]K[L7A&P.LDL*[U")P3<IJ
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MTD[\VF?&(\_QX _5:88&T'2&IW\,9JGA*TK:GA97W=-44C8/2A^72G#]3LJ
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ME4@5H3R]^_"12"^]&/E(#J*A4(5ED9  I4+.QWFJA7/&!5S/?BRRE*0@Y)K
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M[,E8A8O7./<LFT>O_Q]02P$"% ,4    " !(@UQ87/Z%V=@2  #/T0  $0
M            @ $     <VEL:RTR,#(S,3(S,2YX<V102P$"% ,4    " !(
M@UQ8RWG^,CT7  ##3P$ %0              @ $'$P  <VEL:RTR,#(S,3(S
M,5]C86PN>&UL4$L! A0#%     @ 2(-<6 29M8ZU*@  R?$" !4
M     ( !=RH  '-I;&LM,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( $B#
M7%A3'SC'DXD  $5,"@ 5              "  5]5  !S:6QK+3(P,C,Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " !(@UQ8[]$U1OM@  !5&0< %0
M    @ $EWP  <VEL:RTR,#(S,3(S,5]P<F4N>&UL4$L! A0#%     @ 2(-<
M6/HV:RC)[00 [<E2 !4              ( !4T ! '-I;&LM,C R,S$R,S%X
M,3!K+FAT;5!+ 0(4 Q0    ( $B#7%B8/4P,50L  "8,   9
M  "  4\N!@!S:6QK+3(P,C,Q,C,Q>#$P:V<P,#$N:G!G4$L! A0#%     @
M2(-<6+7GI3&<"0  ?@L  !D              ( !VSD& '-I;&LM,C R,S$R
M,S%X,3!K9S P,BYJ<&=02P$"% ,4    " !(@UQ8(O\+/Q8+   Z#   &0
M            @ &N0P8 <VEL:RTR,#(S,3(S,7@Q,&MG,# S+FIP9U!+ 0(4
M Q0    ( $B#7%B[P:H@'@,  !L$   9              "  ?M.!@!S:6QK
M+3(P,C,Q,C,Q>#$P:V<P,#0N:G!G4$L! A0#%     @ 2(-<6+K(RL@A#0
MB \  !D              ( !4%(& '-I;&LM,C R,S$R,S%X,3!K9S P-2YJ
M<&=02P$"% ,4    " !(@UQ87YOC;[S$ 0"4> ( &0              @ &H
M7P8 <VEL:RTR,#(S,3(S,7@Q,&MG,# V+FIP9U!+ 0(4 Q0    ( $B#7%BL
M<^XDE$D  &-M @ 8              "  9LD" !S:6QK+3(P,C,Q,C,Q>&5X
M,3!?,2YH=&U02P$"% ,4    " !(@UQ8X4,FX(X,  #0K0  &0
M    @ %E;@@ <VEL:RTR,#(S,3(S,7AE>#$P7S,V+FAT;5!+ 0(4 Q0    (
M $B#7%A4CA4#-VD  $:(!0 8              "  2I[" !S:6QK+3(P,C,Q
M,C,Q>&5X,3!?-2YH=&U02P$"% ,4    " !(@UQ8M@1,DOE1  #8RP, &
M            @ &7Y @ <VEL:RTR,#(S,3(S,7AE>#$P7S8N:'1M4$L! A0#
M%     @ 2(-<6"3(\L\W00  P(\" !@              ( !QC8) '-I;&LM
M,C R,S$R,S%X97@Q,%\Y+FAT;5!+ 0(4 Q0    ( $B#7%C;NKNZ<P,  )H,
M   8              "  3-X"0!S:6QK+3(P,C,Q,C,Q>&5X,C-?,2YH=&U0
M2P$"% ,4    " !(@UQ8'EYL/7P)   V5   &               @ '<>PD
M<VEL:RTR,#(S,3(S,7AE>#,Q7S$N:'1M4$L! A0#%     @ 2(-<6 5V^X*0
M"0  'U@  !@              ( !CH4) '-I;&LM,C R,S$R,S%X97@S,5\R
M+FAT;5!+ 0(4 Q0    ( $B#7%@.MC51?@8  (=2   8              "
M 52/"0!S:6QK+3(P,C,Q,C,Q>&5X,S)?,2YH=&U02P$"% ,4    " !(@UQ8
M084624Y,  "6N@0 %P              @ $(E@D <VEL:RTR,#(S,3(S,7AE
M>#-?,2YH=&U02P$"% ,4    " !(@UQ89]QQ@U<E  !>_@  %P
M    @ &+X@D <VEL:RTR,#(S,3(S,7AE>#1?,RYH=&U02P$"% ,4    " !(
M@UQ8X'9$+-@A   #2P$ &               @ $7" H <VEL:RTR,#(S,3(S
B,7AE>#DW7S$N:'1M4$L%!@     8 !@ ?P8  "4J"@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>silk-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:silk="http://silkroadmed.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="silk-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2007_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:BenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:BenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:BenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2023_To_11_30_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_srt_StatementScenarioAxis_silk_UnderwritersOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">silk:UnderwritersOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_31_2023_To_5_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PledgingPurposeAxis_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilitySubfacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredRevolvingCreditFacilitySubfacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredRevolvingCreditFacilityAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_HeadquartersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">silk:HeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">silk:AdditionalOfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_27_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">silk:IndexRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:PerformanceStockUnitsOverperformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:PerformanceStockUnitsOverperformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:AgencyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2023_To_11_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">silk:AwardDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:Espp2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">silk:IndexRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">silk:IndexRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:StifelBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:TermLoanTrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:Espp2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">silk:SecuredRevolvingCreditFacilityAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">silk:OxfordFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="Unit15">
        <measure>silk:segment</measure>
    </unit>
    <unit id="Unit14">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit13">
        <measure>pure</measure>
    </unit>
    <unit id="Unit12">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit1">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-3f4135f7-dc2b-4427-a8fa-fcd69218e321">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-91e9fcc1-cec5-4ec2-a101-60eff0e7862f">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-afb1181f-bd0f-4a14-b3db-532ff894ea69">0001397702</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-aef27b65-cf7b-4cc7-b3da-deb310ab56d2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-345f206a-af04-4574-9199-1a58b605bd88">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-ed693c40-c884-4f7c-b718-eef6f8cd52b9">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-c940220e-b236-4523-a334-4ad39b637ffa">Yes</dei:EntityWellKnownSeasonedIssuer>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-5d95aa1c-7eb9-4f49-8dc4-aea9daebaaab"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023"
      id="ct-nonFraction-a637edb1-7f74-4201-a99b-726573bfe3e9"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-3bf04cf1-1a9a-405d-aa3f-bedeb093e2ab"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023"
      id="ct-nonFraction-75d41ec1-bd07-4439-8d82-3e992d798b22"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022"
      id="ct-nonNumeric-4a367e19-bd2b-4833-a2ee-41da1810dd33">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023"
      id="ct-nonNumeric-ea9efef9-505d-4191-897c-64e4a2fceb36">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022"
      id="ct-nonNumeric-24d00192-026d-4075-a91f-bdd0fa580324">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023"
      id="ct-nonNumeric-18ad6fb4-b92c-4419-9e27-7f511e1beb87">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022"
      id="ct-nonNumeric-7adaddd6-e390-4787-853b-b3d3af6f96a6">http://fasb.org/us-gaap/2023#Liabilities</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023"
      id="ct-nonNumeric-3f9f30e3-cce1-4745-9a9e-9d186b53fb29">http://fasb.org/us-gaap/2023#Liabilities</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022"
      id="ct-nonNumeric-dd16a680-3f25-4cca-8f06-df833283191e">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023"
      id="ct-nonNumeric-80d6598d-c247-4749-a960-856924837d92">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-2cfee51e-ab0e-4f50-aac2-b407cda5d91f"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023"
      id="ct-nonFraction-d65a29aa-c14e-4d87-b47f-02ec4e8f510e"
      unitRef="Unit12"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-0d3604eb-27ee-4b68-bc35-bdd0b9a10683">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-6fad6067-ec3a-4be7-8abc-95d56e1f8897">true</dei:DocumentAnnualReport>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-0828b7c1-d154-49c2-a03a-896f7bd906d6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-ad223540-056e-4621-a1d8-4930e0c56c43">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-5046205c-3ce3-4237-8e8d-d4d6b7d5e928">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-f57c9ce7-deb8-4b8d-8eb9-648c110cda52">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e1e56ee8-457d-441e-aeab-ad9041716110">001-38847</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-891e1de5-ea4d-4b4c-a124-ee1693d775b5">SILK ROAD MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-311e5e23-dcc3-4ac8-afc0-89e9c489fb78">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-a241acbe-bb48-4aa4-8f4b-a17a42800785">20-8777622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e2d167db-83bd-4f38-9bbe-879d1bb3381b">1213 Innsbruck Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-5c21be81-58fb-48a5-924f-cdcb8b37ec52">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e440fca8-5560-4908-9b85-58b3193e79c5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-cd84ac79-0fd1-4bf0-b38e-70dfcd470820">94089</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-60c51588-dc2a-4579-806c-15dd0d4b4f64">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-1bdcb93f-832c-4237-8557-db398c549294">720-9002</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-f63af8ee-af3f-4335-9917-4fd4205a0f4f">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-1efb1325-7770-4a38-9dd1-2f1b87a7bdfb">SILK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-d451d1ed-0681-4c73-8369-39b3a56262fc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-632b9be8-2c16-443a-a313-991f94521c9b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-2c5f7dd0-a69d-40d3-89d2-f35a9fdaf886">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-112d6883-c055-4127-83a8-b6d8d1dc77c3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-4c248e9d-9ca9-4e0c-b8e7-d803c0af237c">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-f39a3e83-fdbd-4b4b-b423-03735204a10a">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-5736e00c-6957-4184-8916-907e18b3bea9">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023"
      decimals="-8"
      id="ct-nonFraction-d1b6a537-88bb-4629-9f71-de292aa28cdd"
      unitRef="Unit12">1200000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_23_2024"
      decimals="INF"
      id="ct-nonFraction-da98ee7f-9b44-467a-b499-245de699c002"
      unitRef="Unit1">39174619</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-264efae9-54d9-40d9-b6f2-c6b3833f2f0e">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Portions of the definitive proxy statement for our 2024 Annual Meeting of Stockholders, or the 2024 Proxy Statement, are incorporated by reference into Part III of this report where indicated. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-dbdb8bdb-4728-4617-a5cc-3ef229539c4e">238</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-63e5b38c-a5a5-471b-ac4c-56a069ae7855">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-cb1e355c-3f95-4414-a9f4-0eab408ab67c">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-8a01f8fe-8d64-4aec-a765-7fba6b951669"
      unitRef="Unit12">20210000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b154d7a1-f492-422f-8906-d669b9cfeb3f"
      unitRef="Unit12">55358000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-979d7000-c090-44fc-b015-72a5904d1cd4"
      unitRef="Unit12">161264000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a5864c82-0797-4098-8f57-eabce967855e"
      unitRef="Unit12">158316000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-001c33bd-de74-419b-b29e-2fb0f1240d70"
      unitRef="Unit12">26000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b8556836-f4b4-41cc-bbd9-eecd97da3a6e"
      unitRef="Unit12">3000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-8ec3ee82-a5f5-4196-94f8-e2d20220eccb"
      unitRef="Unit12">23573000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-fc69540a-9be5-420e-86cd-81b565afa416"
      unitRef="Unit12">18007000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-b2a4c56f-1a70-4862-91a8-8bc43853a77b"
      unitRef="Unit12">29876000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-64a6a187-a40a-4ada-a6dd-d4a6bc52a485"
      unitRef="Unit12">19293000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-95aca519-2028-4d02-9e71-7fad40ebcbe0"
      unitRef="Unit12">5912000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6df1c26b-d983-42ca-84b5-66c8eac618c6"
      unitRef="Unit12">3924000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-57dc7265-65ad-44d9-8fd2-be18a04d7653"
      unitRef="Unit12">240835000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b7c7a46f-a34c-402a-9318-f7c297f62996"
      unitRef="Unit12">254898000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-da4f6640-5c09-4164-9bba-875f49b60967"
      unitRef="Unit12">9456000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-17f41c34-b677-4478-ab37-783f06eeb4bc"
      unitRef="Unit12">8114000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-80f9e379-ad1f-449d-a796-33b462a1eae4"
      unitRef="Unit12">9372000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-7e100489-4c54-4ab8-b01a-e7936671a101"
      unitRef="Unit12">155000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-f02e1a9e-9eae-4f4a-9051-0a69c8b9a6e3"
      unitRef="Unit12">6904000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-11945113-48c2-4b8b-924c-596b0c7166cd"
      unitRef="Unit12">5260000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-79ed036a-6cf0-4d8d-9e7e-3b9fb7191522"
      unitRef="Unit12">265309000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-fa80caf6-2b5e-43e4-ad65-7a836aa8d10f"
      unitRef="Unit12">269685000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-a5c45f17-390b-4252-925b-7be66a1c053a"
      unitRef="Unit12">5676000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e1f38124-fb63-4cdd-b9a4-f90a0ee2c2e8"
      unitRef="Unit12">2523000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-af51e4d7-74f1-43e2-908f-c14eaff0c80a"
      unitRef="Unit12">24607000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-46d69562-caa9-4018-a8b6-e8d78c63ce3e"
      unitRef="Unit12">21965000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-cd2271c3-71e6-49ec-a4fc-5799d9ec3e50"
      unitRef="Unit12">30283000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d60f01f2-5a89-40fd-9574-c488ff99ca80"
      unitRef="Unit12">24488000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-5cdf34d3-f08d-41a1-bc88-ff47f5f571e7"
      unitRef="Unit12">75626000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-77dc75f0-7ca4-4425-96d5-3e469859fe5c"
      unitRef="Unit12">74596000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-cb2e071d-7e27-49fb-acac-9ff7d6deab87"
      unitRef="Unit12">8249000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4736b69c-34b4-4272-804a-006ed507d677"
      unitRef="Unit12">6726000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-ef9dc0ab-3e37-4f96-b88e-42dec3540838"
      unitRef="Unit12">114158000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b622fff6-6c4a-42bd-948b-77c783ad1bdb"
      unitRef="Unit12">105810000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-b6f97c6f-bf0b-4440-9e22-e5f231de404c"
      unitRef="Unit14">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-0013cd6c-93bf-4f47-af6c-cc8fb690d51b"
      unitRef="Unit14">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-45dd4530-4ee0-43f2-91c9-d3116e1a67dc"
      unitRef="Unit1">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-7f209ef9-340c-4704-ab3d-aca432eed82b"
      unitRef="Unit1">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-332e647f-8317-4302-aab5-26e0ab07d432"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-a1aa765b-80c3-4703-826a-d57d1453f4da"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-dd7949bc-e93f-43ef-8406-960073a98719"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-55bd66d7-e026-4c2e-a6c8-8a666deebd4f"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-6b201076-689d-40fc-b951-d4fd790dafae"
      unitRef="Unit14">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-a22d7ec7-33ab-41c8-9dd1-19c579b25d32"
      unitRef="Unit14">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-ef0f8c2f-346d-4152-afb6-ba6b0720b1c9"
      unitRef="Unit1">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-38d775ce-6e33-496d-96b4-225bf0bab13d"
      unitRef="Unit1">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-5681b80e-6694-422f-be34-5bd6a2b91523"
      unitRef="Unit1">39165481</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-6ee1dcf9-dc94-4f1f-98fd-de93f85bb342"
      unitRef="Unit1">39165481</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-c7f422e2-2979-4c0b-9833-e5b0ece38573"
      unitRef="Unit1">38355972</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-13a0ef29-5ed4-45e1-9174-81b9464fe788"
      unitRef="Unit1">38355972</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-b354d0a3-e08d-4354-840c-03f0d0a3537f"
      unitRef="Unit12">39000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-de74bf65-8584-43ab-9a61-86c69d97bcc5"
      unitRef="Unit12">38000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1ddb7b14-8fe0-4548-a1ee-c580da77c2a5"
      unitRef="Unit12">550495000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f35d4a97-4d54-49ce-9a71-07c453d89365"
      unitRef="Unit12">507715000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d1ba76d9-709d-499e-a762-0ddc700a600c"
      unitRef="Unit12">72000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-62b0fb90-9ebc-4d12-8fc5-2ff02e35f117"
      unitRef="Unit12">-166000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-0a3f2343-d00e-4f40-b5b0-ee29a91256f6"
      unitRef="Unit12">-399455000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b1cf982b-e28d-4451-854d-0a942a06ecbe"
      unitRef="Unit12">-343712000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-9dbba149-dd94-4dc6-984b-cc350667ca82"
      unitRef="Unit12">151151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e34129e6-03d7-46a1-a99a-93b1fbee2833"
      unitRef="Unit12">163875000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1e6faf5e-f8de-4c3f-b014-307c29684f27"
      unitRef="Unit12">265309000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-82c25e71-4ec7-4bc0-b19d-2176ee68a59b"
      unitRef="Unit12">269685000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-a163ea4a-9203-4a2d-8146-ce824b8c0fb8"
      unitRef="Unit12">177134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d69a3144-90c4-4848-b6d7-4ce9031a75ce"
      unitRef="Unit12">138638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-9044c1be-b212-460f-8ba7-d35a81ef7e36"
      unitRef="Unit12">101475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-fd715232-ff84-482e-9526-4211d78a005b"
      unitRef="Unit12">50048000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-bf0dcba0-eefc-44c4-adb1-3add833e4700"
      unitRef="Unit12">37876000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0786c3db-5cf1-4841-8680-2994309320a0"
      unitRef="Unit12">25446000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-3134c32d-ccb5-4606-99ed-ef3c79b540e1"
      unitRef="Unit12">127086000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2463a5b6-4d20-4f74-9490-9161212d006c"
      unitRef="Unit12">100762000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-484e89d5-fc73-47ef-a60e-22850f04564d"
      unitRef="Unit12">76029000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-ebb2f3b2-db7e-4c80-ad85-7cd16d874eaf"
      unitRef="Unit12">41324000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-95100842-225e-4569-97e3-ff7c042fdef8"
      unitRef="Unit12">36449000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4f53c027-56c2-46a4-a390-7242cf56379e"
      unitRef="Unit12">27110000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-5c2d0976-17a1-42e2-a221-c4775064c579"
      unitRef="Unit12">145033000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5aa4d36c-9fce-4402-83d6-cfbc132577c3"
      unitRef="Unit12">116317000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-548cb99e-9e3c-4b3f-911a-fb9f66c822f7"
      unitRef="Unit12">96387000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-03bb73a5-8bc5-4564-9171-c8331888bf88"
      unitRef="Unit12">186357000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4669b1f8-d563-4b17-b57d-4eb8da8ed7ab"
      unitRef="Unit12">152766000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4922bb95-1a03-4777-810d-f82bc8102d5d"
      unitRef="Unit12">123497000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-534c6f09-89c7-468d-94ac-95ee58aba03e"
      unitRef="Unit12">-59271000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-517160e1-d51f-4d9d-b086-c6957b773531"
      unitRef="Unit12">-52004000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4c9bc691-8d2f-427c-ae06-24c15211ebba"
      unitRef="Unit12">-47468000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-756709f1-b29d-4c7d-b507-250b1cbf2d8f"
      unitRef="Unit12">9957000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-1a611d87-b533-4b01-a5a4-082909bdf72d"
      unitRef="Unit12">2527000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1ad3bfb2-236c-4768-b366-32a4e929cd7c"
      unitRef="Unit12">198000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-f3d645ff-a683-4d5f-b11d-ae44685c247d"
      unitRef="Unit12">6871000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2e90c210-5a64-4985-b52b-1ff3a61c5e8c"
      unitRef="Unit12">5098000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-94401612-209d-4804-a5a8-72206fff9b01"
      unitRef="Unit12">2518000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-528f4df0-f828-4633-aadb-c691af82ec4f"
      unitRef="Unit12">-245000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-2a6e67c4-3390-49f8-9cf0-2a7cc9c78fea"
      unitRef="Unit12">442000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f826539a-951c-4163-ab00-d3d362f02609"
      unitRef="Unit12">-190000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-034c559d-0a05-45b5-aadb-b9d30fc5dacc"
      unitRef="Unit12">-23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-7228b14f-497a-4178-8816-259d396e3f31"
      unitRef="Unit12">-55743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b613f71a-0d8a-4fc3-8aee-79cc47931f2f"
      unitRef="Unit12">-55010000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1df67c56-b8d0-4c53-ad58-ce30e06e3bdf"
      unitRef="Unit12">-49811000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-b7a3964b-6a05-42a1-8e39-f4dff89dad2b"
      unitRef="Unit12">238000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-7de5e483-1f17-453f-8ce5-068e7e39ffa3"
      unitRef="Unit12">-166000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e3b6f479-7286-42b3-9042-70baec7ed2ab"
      unitRef="Unit12">-39000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-53f44826-ee84-4468-b475-199eb8680ba5"
      unitRef="Unit12">238000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-83c4b1bb-50ee-4957-9c9d-0d6beed4ea0d"
      unitRef="Unit12">-166000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-86c4b723-5a71-4058-a84e-5ac56d3d463c"
      unitRef="Unit12">-39000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-fb75652f-dab5-45cc-8b80-432a33cf34d8"
      unitRef="Unit12">-55505000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-56f06b08-f9ca-4f99-a96f-5e68dd728a0a"
      unitRef="Unit12">-55176000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6554b639-02c1-4acf-b46f-8849cff14ad6"
      unitRef="Unit12">-49850000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-befdb4c7-105e-40ad-a579-d14e7d80cb99"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-f1962dd7-4c98-433f-a9f2-c35da2435486"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-b3299564-65db-4c02-b75b-f61b52899c61"
      unitRef="Unit14">-1.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-b19676c0-5518-4935-b0ad-15a8d6786725"
      unitRef="Unit14">-1.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-4bce0bd3-c6d0-44c2-9768-e89694b1e246"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-f61a8ad2-a992-4c36-aa40-c39b6bc3807f"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="0"
      id="ct-nonFraction-7ba6b661-7daf-4a35-a52c-f2123c87a234"
      unitRef="Unit1">38804343</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="0"
      id="ct-nonFraction-18dfbd5f-edfe-4322-89b2-e20a90b86441"
      unitRef="Unit1">38804343</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-e5dfd4bb-d4c0-40e6-9721-06a417963d5a"
      unitRef="Unit1">35775672</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-10d1b442-8306-459c-9255-fa10567f2652"
      unitRef="Unit1">35775672</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-e3fabcda-d32f-450c-abd4-f7a271af85d2"
      unitRef="Unit1">34635358</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-4104a2b0-ac5a-4b68-b100-faac10bd19dc"
      unitRef="Unit1">34635358</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-50999f6f-50cd-4c0f-80cd-ad3c32476ad7"
      unitRef="Unit1">34249649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-c2db16c4-0490-4f33-bcc0-775f0922e47d"
      unitRef="Unit12">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-ca753ac4-b573-40c7-9749-9eca3909f304"
      unitRef="Unit12">346318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-68cb9f74-480f-4e95-b9d4-bc91e67d28e1"
      unitRef="Unit12">-238891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-07d63988-30c9-4c57-a5c7-ade3be23f568"
      unitRef="Unit12">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4e0b9dae-21c9-4dff-b3f6-c941cb84e623"
      unitRef="Unit12">107500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-bffe753f-618a-4275-bebd-9f22f8b673f6"
      unitRef="Unit1">643507</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-b6f5526a-e8ad-4d0a-b8cf-fdd832478c91"
      unitRef="Unit12">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-f25c359e-136e-4acf-83e9-4548b2439893"
      unitRef="Unit12">4841000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c729ba19-e3ae-4bb2-be41-fb77d1c0be78"
      unitRef="Unit12">4842000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-17046b1e-eafe-4833-9342-1c558cdc957a"
      unitRef="Unit1">34964</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-2fa51ab5-e076-4eff-bcbb-fcd6beadd7c2"
      unitRef="Unit1">52776</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-3415a0cd-b917-43b4-954c-2e306c42d776"
      unitRef="Unit12">2104000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-9ad665a0-9f09-40f6-a15e-7f91a1d3eb4e"
      unitRef="Unit12">2104000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-e49995e8-62a5-4195-ac0c-6ee1c36f0ebb"
      unitRef="Unit12">14612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2eb955b8-a2dc-49bd-bcf3-d6c0dd094e46"
      unitRef="Unit12">14612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <silk:DisgorgementOfStockholderSShortSwingProfits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-dc40ce2b-f6b3-4383-84d1-def6d246bfbb"
      unitRef="Unit12">32000</silk:DisgorgementOfStockholderSShortSwingProfits>
    <silk:DisgorgementOfStockholderSShortSwingProfits
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7c6d0bff-f592-427c-abf5-034846b982ec"
      unitRef="Unit12">32000</silk:DisgorgementOfStockholderSShortSwingProfits>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-5ca14ff4-66ba-4cd2-bdfa-8c08da96768b"
      unitRef="Unit12">-49811000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e0c71ae2-4020-4efe-b49d-09650f85f790"
      unitRef="Unit12">-49811000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-ad5dc879-3eae-412e-892b-071bb0f660ed"
      unitRef="Unit12">-39000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e60e32d8-3ff4-4318-97e1-113ecacb5095"
      unitRef="Unit12">-39000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-d6f1a71b-0131-4582-97ae-b5c71ba60375"
      unitRef="Unit1">34980896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-e8085cca-9119-46cd-bf43-055ecc275356"
      unitRef="Unit12">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-73755160-2863-4cab-9a3d-e4a7d7535ba5"
      unitRef="Unit12">367907000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-08be4825-a9d5-4e8d-aa78-3294f3701611"
      unitRef="Unit12">-288702000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4c47b218-6f49-49f9-b1e8-859fe36a34b2"
      unitRef="Unit12">79240000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-454dc3ac-25d1-4553-a5f1-b7b3c6e37f63"
      unitRef="Unit12">6008000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-c8aa534f-8dda-4338-98cb-a6b486a9e111"
      unitRef="Unit1">2674419</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-5ca4a94e-a23d-49b8-8458-206c60a7ed5d"
      unitRef="Unit12">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-e65f2949-f936-4777-a68d-e410f1e279b0"
      unitRef="Unit12">108989000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-646381c9-9a48-4e7a-b69b-8fe416d060e9"
      unitRef="Unit12">108992000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-48c0a9f6-f009-4725-9256-7bc577906d00"
      unitRef="Unit1">453199</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-e230b2bf-d2bb-4cf4-a202-127a589538bb"
      unitRef="Unit12">3364000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c153e756-c2e6-411d-b94a-d391d98bd15e"
      unitRef="Unit12">3364000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-724252b9-a1b3-4cc0-af3e-573a9e980b7b"
      unitRef="Unit1">148239</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-1a89d073-2903-4859-9bbb-ddcf1f6c4427"
      unitRef="Unit1">99219</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-e940fc17-1a86-420e-90dd-bee3bb8b6827"
      unitRef="Unit12">2432000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-1b0696d0-abcf-4bff-aca9-26370bd74b78"
      unitRef="Unit12">2432000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-761410fd-7433-4198-aa63-ee8d4af577cf"
      unitRef="Unit12">25023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-7e0e24ae-f5f3-4545-b746-01d660a0886f"
      unitRef="Unit12">25023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-4252c9b8-efc0-4351-84e0-411b4c788d20"
      unitRef="Unit12">-55010000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-7dbe2ffa-9e78-40cf-bf77-a078924dfa38"
      unitRef="Unit12">-55010000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-c146c3b8-7801-496c-a6ff-3e1919d70e4c"
      unitRef="Unit12">-166000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2bdfe8dc-20e9-4ed6-9924-b60ec8284f7c"
      unitRef="Unit12">-166000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-f7a85f4e-067d-4a5e-b756-d70e1a3319ee"
      unitRef="Unit1">38355972</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-02532738-9c61-44bc-a240-66a1d35693ca"
      unitRef="Unit12">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-426abf27-7deb-4ed0-9e14-cb934e4bc182"
      unitRef="Unit12">507715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-9265a4f0-f455-4df7-aa0a-0cb8f8877dc6"
      unitRef="Unit12">-343712000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-32ba48ab-5561-4ffa-9827-583540dd00e5"
      unitRef="Unit12">-166000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a2131420-a742-41c6-a69b-860d9a605e66"
      unitRef="Unit12">163875000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-ddb1e7c1-8b1d-4e2a-a819-94c5a81e47e3"
      unitRef="Unit1">199642</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-ca4b9e88-c3d7-477d-b26a-691a6a19eb70"
      unitRef="Unit12">1486000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d703615a-b052-48e3-a5f3-bbe4b97a5c09"
      unitRef="Unit12">1486000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-98066ad7-ebcd-40fc-a439-9b6f6925d70a"
      unitRef="Unit1">410085</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-aec91df0-212b-4b9c-a613-f32307d1ef79"
      unitRef="Unit12">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-953e29d7-7a46-4e9e-84e8-73c91a36b4e8"
      unitRef="Unit12">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-9ad39b51-b2ac-455e-bf24-ec3a03088d19"
      unitRef="Unit1">199782</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-b886b86b-f4da-4370-9b3a-b85397b2ce19"
      unitRef="Unit12">2401000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1b128eb2-e451-4ffd-a23b-933ef27d330c"
      unitRef="Unit12">2401000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-6d1dffea-ab66-4add-859b-7d909fa24bf8"
      unitRef="Unit12">38893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-2abdd448-7c6d-43c6-9b2e-0697a15111d6"
      unitRef="Unit12">38893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-a6311a34-bfdb-491c-8276-a43cea7de454"
      unitRef="Unit12">-55743000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-9b157b13-1f27-46ff-befa-ae601c8e4dee"
      unitRef="Unit12">-55743000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-b8b93078-91f9-4e36-8b98-94fb53b5f591"
      unitRef="Unit12">238000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-fc74620f-c4ac-4da2-a117-00fcf00866a1"
      unitRef="Unit12">238000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-348a66e5-3724-4f27-9edf-f8cd298329f5"
      unitRef="Unit1">39165481</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-84406667-eb28-4ffe-885a-d15e8f505172"
      unitRef="Unit12">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-23b45301-2ecb-4b11-b34e-4eeaa3060c18"
      unitRef="Unit12">550495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-c1edc28a-082a-43c6-b750-06b385b8162c"
      unitRef="Unit12">-399455000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="ct-nonFraction-f136b8f8-5466-44c0-a598-92ed26a82227"
      unitRef="Unit12">72000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-e707152a-da36-4053-8bf8-001b095a81a6"
      unitRef="Unit12">151151000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-68fea53a-1096-4e32-a7df-8b0cad630a6a"
      unitRef="Unit12">-55743000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-06dec6fd-0b10-41c3-a79b-5daf0db5ec86"
      unitRef="Unit12">-55010000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4c22a703-bbb5-4da7-aa9d-319ff12d5f9b"
      unitRef="Unit12">-49811000</us-gaap:ProfitLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-03692fd6-3b62-406d-885f-be3fa512f3b2"
      unitRef="Unit12">2696000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-fce627e6-9061-47e8-b2ef-580819ae4ca1"
      unitRef="Unit12">2127000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-64b3efb2-f35f-4a5d-a8ff-f50e03e7c529"
      unitRef="Unit12">1032000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-00bee32c-c3f3-42e5-b2d0-e24cd0104389"
      unitRef="Unit12">38893000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ec586112-b257-4af3-8914-c8256d102e9e"
      unitRef="Unit12">25023000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b0b40b16-47f1-4515-8b59-6c56b6487b68"
      unitRef="Unit12">14612000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-dcba9e98-2d5a-40df-84e0-7130afcd0985"
      unitRef="Unit12">6497000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-754a1f64-a761-4294-8614-3672e37d7f68"
      unitRef="Unit12">1419000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2eb83f85-a93f-4aa4-abc3-be32281cccb8"
      unitRef="Unit12">-577000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-2346ddd8-fe4d-4ba7-9f0a-48e774105548"
      unitRef="Unit12">232000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e2c5cb49-6dec-4535-a931-e817bc9644d3"
      unitRef="Unit12">218000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4c364071-f203-4621-83d4-bfc3ca1ab516"
      unitRef="Unit12">158000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-5d68639b-830f-4bbd-8e1b-82fd980734fe"
      unitRef="Unit12">1096000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9b4cd153-2952-4329-a537-8f49db3228f0"
      unitRef="Unit12">1041000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-27f74847-1394-4b91-8d2a-e5d2c609874b"
      unitRef="Unit12">887000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-0defb280-94fa-42b0-865b-c95c5a135c49"
      unitRef="Unit12">819000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2de2d356-da50-48f8-8fb3-cd419422a74e"
      unitRef="Unit12">1037000</us-gaap:PaidInKindInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-44003d09-e59a-491f-aa3b-7f476c924e1e"
      unitRef="Unit12">-245000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d51eb86d-daa1-4c4e-9f15-42bd4c4be680"
      unitRef="Unit12">-160000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a1d5e56e-aec1-4e18-a67e-b2784290b78c"
      unitRef="Unit12">-180000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-36f65fac-1559-4bcc-bc05-3d19f9c09e3f"
      unitRef="Unit12">-9000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-97f80814-3843-44d6-bdc5-fd5b80d0d70c"
      unitRef="Unit12">45000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-37ab3a93-bc34-4d44-bdbf-2c00c8633c49"
      unitRef="Unit12">-3000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-486cf2a9-1e10-42c9-8a01-dade8f61e83a"
      unitRef="Unit12">6000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-77704097-1822-4d58-9300-fa80dcb761c2"
      unitRef="Unit12">198000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b7775505-28b3-4195-a298-3f309cdddaa4"
      unitRef="Unit12">6000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ec90e726-bd91-48fb-90bb-45c600fec09c"
      unitRef="Unit12">77000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-ccc9de45-c915-46e2-9640-8f41dfbe26e6"
      unitRef="Unit12">5610000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5d8bdfc0-2a52-497e-a437-eb1b45f694ef"
      unitRef="Unit12">6172000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d594fb6c-348c-411c-a46e-087083d04661"
      unitRef="Unit12">2769000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-508f5e89-fa2b-41b8-8ee2-6c1d0e46d39d"
      unitRef="Unit12">10781000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5e608bf0-0504-42c4-b975-2b028bf8d667"
      unitRef="Unit12">1447000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a6a8e74b-0432-4588-b373-1ff5ad662a15"
      unitRef="Unit12">5563000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-2f8fc79c-1f6b-4894-a895-8092dc881d94"
      unitRef="Unit12">1988000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-84371899-b61b-4aeb-a892-734ff4f71c74"
      unitRef="Unit12">525000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2be55b8a-9f8b-430f-a5d2-68dffb310902"
      unitRef="Unit12">772000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-fdab76bd-a0db-44f2-bddd-b92d9e94e1dc"
      unitRef="Unit12">236000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e18c5344-caf6-4ea0-96cf-b3e8481e5e61"
      unitRef="Unit12">27000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-42f337fb-ccc9-47f6-90b5-04014b4d4288"
      unitRef="Unit12">117000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d013e2c8-c0ac-4f96-a81a-7f944c00e95e"
      unitRef="Unit12">3063000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-86e307cd-4b78-4b5a-bb38-0ced5089eabd"
      unitRef="Unit12">967000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-07644f44-eec6-45ff-9e7a-eaf25aa3554d"
      unitRef="Unit12">-1159000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-59110115-295e-430b-ba4a-3007d42a1761"
      unitRef="Unit12">2854000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f8e2be49-e40a-45ea-82aa-c02922e00f75"
      unitRef="Unit12">1868000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-56ea61d0-be4f-4021-8c15-24ff0ebe1fe7"
      unitRef="Unit12">4418000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d8397726-1397-40e4-9e85-f7f934f836b4"
      unitRef="Unit12">-1215000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-3595c1c1-be47-448d-8073-bd6f3fbbd760"
      unitRef="Unit12">-690000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7182305a-0fd4-4faf-af2f-a20d82ce7710"
      unitRef="Unit12">-520000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-724b4490-dadf-40f7-a141-9af77fc0b563"
      unitRef="Unit12">-32014000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-437230f3-aef7-4a33-9136-c19a119d7aa7"
      unitRef="Unit12">-32581000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d42029aa-9b62-4cf8-a5f1-10e85ed4f4a4"
      unitRef="Unit12">-38935000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-a9ded64f-53b9-4fe4-a8b9-eca7b2cb1ab2"
      unitRef="Unit12">1507000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e3c8edc6-fc7a-45b4-93f1-603dbf03db03"
      unitRef="Unit12">5005000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d2890a68-27cd-40a1-84a4-c370fbe3c82e"
      unitRef="Unit12">4758000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f185dc8f-8e46-4b41-8628-b6d0d3b25f85"
      unitRef="Unit12">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-50b066b4-25c9-4ac5-a671-156ab6691196"
      unitRef="Unit12">174969000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e991da6b-403f-4448-a2b9-0f465d198e6f"
      unitRef="Unit12">168163000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-85aa03b8-6361-4b6a-94d2-04e2c8e86a64"
      unitRef="Unit12">169300000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-587d4ec4-fa8e-4bd9-b5bb-d5739028b023"
      unitRef="Unit12">11100000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c45e2108-0cc0-4dfd-b243-e2937c250080"
      unitRef="Unit12">77400000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-6cedcdd3-2324-4c8b-875c-80c357d335f9"
      unitRef="Unit12">-7176000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-055509ab-eeba-4568-a268-754c73b8229a"
      unitRef="Unit12">-162068000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-22166f62-5921-40b5-8c4f-572afbfdbc3a"
      unitRef="Unit12">72644000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5eafa089-da6e-4dc1-b4a7-78ac0a199770"
      unitRef="Unit12">108992000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-067c8c47-4e28-4dac-88ac-3a3a32ccaa72"
      unitRef="Unit12">73911000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d937812c-3e33-4551-8203-df62aedd7a2f"
      unitRef="Unit12">3887000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e7054d4f-9c7c-4c47-a750-a7f319e38bd6"
      unitRef="Unit12">5796000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3560e473-c05e-43ae-afa8-3f08a9ad2264"
      unitRef="Unit12">6946000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b255c1af-d45a-4be4-8f21-f5adf4146800"
      unitRef="Unit12">49000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b15459fb-db6b-4cd2-9958-000e61d0761c"
      unitRef="Unit12">32000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-422f6a87-1614-48f4-8ab1-e86a077c3f14"
      unitRef="Unit12">3887000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6874fbc3-48b5-407c-a519-414664c92c69"
      unitRef="Unit12">139699000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-996d906c-a13e-4794-afa8-5099049a8b9a"
      unitRef="Unit12">6978000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-06203175-dd77-49f3-92fc-443cb422bcad"
      unitRef="Unit12">-35303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6fd26d30-4187-42bc-bdab-92dee073bf18"
      unitRef="Unit12">-54950000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-563fa0c2-0385-4e34-9ed0-6945478952f0"
      unitRef="Unit12">40687000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-cbb7684e-49f7-47c2-a341-dad6c9fa5c42"
      unitRef="Unit12">55513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7f9c0f38-9523-4ecb-87ec-aa9a83971ce0"
      unitRef="Unit12">110463000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3a542af6-5746-483e-b9eb-c94d5669da2c"
      unitRef="Unit12">69776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-4cb9e7d4-e9bc-4c47-ade8-0bcc87fedd0f"
      unitRef="Unit12">20210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ea2d8cfa-49d1-41ac-bbc4-211004a83392"
      unitRef="Unit12">55513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-9f062ffb-e481-4e34-903b-b052f1e81122"
      unitRef="Unit12">110463000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-0cd8ffba-fe8d-4378-8213-dadcf7af7913"
      unitRef="Unit12">5821000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ce413c12-80a2-4d2d-8d96-262c3b9d8fa9"
      unitRef="Unit12">3843000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b928082c-a47b-4fa5-a57d-0fa9b834db5b"
      unitRef="Unit12">2360000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-302274b0-0727-4689-9375-da82380e7d02"
      unitRef="Unit12">67000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-301fea03-b7b6-4864-b172-8879093365a4"
      unitRef="Unit12">117000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3b2a9706-0ac6-451f-a861-3296da26dd4c"
      unitRef="Unit12">1138000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-2eac5241-0e4c-4969-bfc6-fecdb5f033f8"
      unitRef="Unit12">2504000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9e3e3b65-bda1-48bc-af06-1baa409fc867"
      unitRef="Unit12">903000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a6b6e21a-a19d-4217-bc93-1e788b324dca"
      unitRef="Unit12">3307000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-c01dc991-1962-4f19-80d2-587478d66e86">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;1.&#160;&#160;&#160;&#160;Formation and Business of the Company &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;The Company&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Silk Road Medical, Inc., or the Company, was incorporated in the state of Delaware on March&#160;21,&#160;2007.&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; The Company, has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke. The Company's portfolio of products enable a procedure referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles. The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; The Company commercialized its products in the United States beginning in&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; late 2015. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of December&#160;31, 2023, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;399,455,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company expects to incur losses for the foreseeable future. The Company&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; believes tha&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t its cash and cash equivalents and available-for-sale securities of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,930,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; as of December&#160;31, 2023, as well as its expected revenues will provide sufficient funds to allow the Company to fund its planned current operations for the next 12 months from the issuance of these financial statements. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In October 2022, the Company completed an underwritten public offering of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,674,419&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43.00&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; per share. The shares include the full exercise of the underwriters&#x2019; option to purchase an additional &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;348,837&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares pursuant to the underwriting agreement. The Company received cash proceeds of approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;108,992,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; after deducting underwriting discounts and commissions of approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,750,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and expenses of approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;258,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-4c5c480d-af0e-4bcb-941f-76c150e0b5bf"
      unitRef="Unit12">-399455000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <silk:CashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-62962a53-b4d2-4376-9819-8bfbdb8b842b"
      unitRef="Unit12">190930000</silk:CashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022"
      decimals="INF"
      id="ct-nonFraction-2184c9a8-d856-4903-97eb-43e6c89b7d4a"
      unitRef="Unit1">2674419</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_10_31_2022"
      decimals="2"
      id="ct-nonFraction-b64b87a9-bdd2-4c1d-bef8-b8920e466844"
      unitRef="Unit14">43.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022_srt_StatementScenarioAxis_silk_UnderwritersOptionMember"
      decimals="INF"
      id="ct-nonFraction-536b21f6-4f7d-4a19-8cbb-4b26dae08206"
      unitRef="Unit1">348837</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022"
      decimals="-3"
      id="ct-nonFraction-8f1fa4a6-785e-4a2b-ac20-b757c60e1022"
      unitRef="Unit12">108992000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions
      contextRef="Duration_10_1_2022_To_10_31_2022"
      decimals="-3"
      id="ct-nonFraction-1f4557db-dc08-4797-b536-4962bec56207"
      unitRef="Unit12">5750000</silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_1_2022_To_10_31_2022"
      decimals="-3"
      id="ct-nonFraction-cf8abd6e-c0c0-43f1-89ca-505e98f8b63f"
      unitRef="Unit12">258000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-68ea5a49-395b-474c-b242-74e022abbe9d">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Basis of Preparation&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America, or U.S. GAAP. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2023 and 2022. The carrying amounts of certain of the Company&#x2019;s financial instruments, which include accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments. Management believes that its debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are recorded at fair value, based on quoted market prices. As of &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;December&#160;31, 2023 and 2022, the Company&#x2019;s cash equivalents were entirely comprised of investments in money market funds.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Restricted cash &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total cash, cash equivalents and restricted cash &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company had &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted cash as of December 31, 2023. Restricted cash as of December&#160;31, 2022 consisted of a letter of credit of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;155,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; representing collateral for the Company&#x2019;s facility lease in California. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Short-term and long-term investments consist of debt securities classified as available-for-sale. Short-term investments have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss). Realized gains and losses are included in earnings and are der&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;ived based on the specific-identification method for determining the costs of investments sold and were insignificant for the years ended December 31, 2023, 2022 and 2021. Amortization of premiums and accretion of discounts are reported as a component of interest income.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. The Company evaluates the securities in an unrealized loss position for expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, current economic conditions and credit ratings. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company did &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t recognize any credit losses on its available-for-sale securities during the years ended December 31, 2023, 2022 or 2021 and there were no impairment charges for unrealized losses in the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, U.S. government securities, U.S. treasury bills, agency bonds/notes, and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December 31, 2023 and December&#160;31, 2022, a portion of the Company&#x2019;s cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of the Company&#x2019;s cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. On March 10, 2023, SVB was shut down and placed under receivership with the Federal Deposit Insurance Corporation, or FDIC, by the California Department of Financial Protection and Innovation. On March 26, 2023, the FDIC announced it had entered into a purchase and assumption agreement with First Citizens Bank &amp;amp; Trust Company under which all of SVB&#x2019;s deposits were assumed. As of the issuance date of these financial statements, the Company has not experienced any losses on its deposits and all of the Company&#x2019;s cash deposited with SVB has been accessible to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s accounts receivable are due from a variety of hospitals and medical centers in the United States. As of December&#160;31, 2023 and 2022, no customer represented 10% or more of the Company&#x2019;s accounts receivable. For the years ended December&#160;31, 2023, 2022 and 2021, there were no customers that represented 10% or more of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company manufactures certain of its commercial products in-house. Certain of the Company&#x2019;s finished goods,  components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in finished goods, component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, competition, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies. In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#x2019;s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company estimates allowances for expected credit losses. Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#x2019; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. These specific allowances are reevaluated and adjusted as additional information is received that impacts the amount reserved. During the years ended December 31, 2023, 2022 and 2021, the Company did not experience any material credit-related losses.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate. The Company&#x2019;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements. The estimate of excess quantities is judgmental and primarily dependent on the Company&#x2019;s estimates of future demand for a particular product. If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment are recorded at cost less accumulated depreciation or amortization. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;five years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value. The Company did &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t record any impairment of long-lived assets during the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for its leasing arrangements in accordance with Accounting Standards Codification, or ASC 842, &#x201c;Leases.&#x201d; The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset. The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company&#x2019;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain. Variable lease costs represent payments that are dependent on usage, a rate or index. Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred. The Company elected to account for contracts that contain lease and non-lease components as a single component, consistent with its historical practice. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives and is primarily comprised of product revenue net of returns, administration fees and sales rebates. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#x2019;s products to its customers, either upon shipment of the product or delivery of the product to the customer.&#160;The Company&#x2019;s products are readily available for usage as soon as the customer possesses it. Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title. The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Administration fees and sales rebates are accounted for as a reduction in revenue, calculated based on the terms agreed to with the customer.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2023 and 2022, the Company recorded $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;227,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;148,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Costs associated with product sales, which include commissions and royalties, are expensed when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160;Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accepts product returns at its discretion or if the product is defective as manufactured. The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the balance sheet.&#160;The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;sold. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company manufactures certain of its portfolio of TCAR products at its California and Minnesota facilities and purchases other products from third party manufacturers. Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, manufacturing overhead costs, direct labor, scrap, product rework, reserves for excess, obsolete and non-sellable inventories as well as logistics-related expenses. A significant portion of the Company&#x2019;s cost of goods sold currently consists of manufacturing overhead costs. These overhead costs include the cost of quality control, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company entered into the lease for its additional facility in Minnesota in May 2021 and did not begin commercial production of the ENROUTE Neuroprotection System until the third quarter of 2022. During this time, the Company experienced additional overhead expenses related to its investment in the start-up phase of its manufacturing capacity expansion, which were recorded as a period expense. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company expenses research and development costs as incurred. Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#x2019;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development. Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses. Additionally, clinical studies include costs associated with clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Clinical Trials&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accrues and expenses costs for its clinical trial activities performed by third parties, including any clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Advertising Costs&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company expenses advertising costs as incurred. Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items. Advertising costs of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;461,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;347,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;221,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; were expensed during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Foreign Currency&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net. The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Stock&#x2013;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board, or FASB, ASC 718,&#160;&#x201c;Compensation-Stock Compensation.&#x201d; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units, performance stock units, and shares issued under its employee stock purchase plan. ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model. The fair value of stock options is recognized over the period during which an optionee is required to provide services in &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis. The Company accounts for option forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant. These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation for performance stock units with market-based conditions at their fair value on the date of the award using the Monte Carlo simulation model. These costs are recognized over the requisite service period, which is usually the vesting period, regardless of the likelihood of achievement of the market-based performance criteria.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation for its employee stock purchase plan based on the &lt;/span&gt;&lt;span id="_Hlk157943524" style="text-decoration: none;"&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;estimated fair value on the first day of the offering period &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;using an option pricing model for each purchase period. These costs are recognized on a straight-line basis over the offering period.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company also follows the provisions of ASC 740-10, &#x201c;Accounting for Uncertainty in Income Taxes.&#x201d; ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;No&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; liability related to uncertain tax positions is recorded on the financial statements. It is the Company&#x2019;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale. For the years ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;December&#160;31, 2023, 2022 and 2021&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, the Company&#x2019;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive loss. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets as a component of stockholders' equity. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Net Loss per Share &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and performance stock units are considered to be potentially dilutive securities. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share was determined as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,743&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,010&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,811&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Weighted average common stock outstanding used to compute net loss per share, basic and diluted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;38,804,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;35,775,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,635,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.54&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#x2019;s net loss:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Common stock options &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,632,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,839,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,780,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,536,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,329,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;530,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,168,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,169,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,311,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; reportable and operating segment. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Primarily all of the Company&#x2019;s long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment. All of the Company&#x2019;s revenue was in the United State&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;s for the years ended December&#160;31, 2023, 2022 and 2021, based on the shipping location of the external customer.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-5738e872-c7b2-416c-9985-e8ef50594ad2">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Basis of Preparation&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America, or U.S. GAAP. &lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-52409ac7-fc5a-4ab2-babf-18c5c455ff2d">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Use of Estimates&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-486052a5-4189-4d5c-a15d-54c8b33a4700">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2023 and 2022. The carrying amounts of certain of the Company&#x2019;s financial instruments, which include accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments. Management believes that its debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value. &lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-0b4feacb-dd58-4419-a4d3-8588abd9dcfe">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are recorded at fair value, based on quoted market prices. As of &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;December&#160;31, 2023 and 2022, the Company&#x2019;s cash equivalents were entirely comprised of investments in money market funds.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Restricted cash &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total cash, cash equivalents and restricted cash &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company had &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted cash as of December 31, 2023. Restricted cash as of December&#160;31, 2022 consisted of a letter of credit of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;155,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; representing collateral for the Company&#x2019;s facility lease in California. &lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-f15a373b-0151-49de-a4d0-3b075f11067e">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Restricted cash &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total cash, cash equivalents and restricted cash &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-63a99401-0cea-41a5-bef8-7cd756682166"
      unitRef="Unit12">20210000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-fe935585-6cb6-4b77-b353-6ee67e2ae2d4"
      unitRef="Unit12">55358000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8c03c604-609b-4bcc-9302-1327040b4413"
      unitRef="Unit12">155000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-5db1aca5-166f-4200-980a-c499d3bfbcc4"
      unitRef="Unit12">20210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6b4e8841-bf8d-4908-a018-9e13db4fe29c"
      unitRef="Unit12">55513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-e40c6885-3ad2-4da9-a7ff-a575e96de3ef"
      unitRef="Unit12">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_PledgingPurposeAxis_us-gaap_LetterOfCreditMember"
      decimals="-3"
      id="ct-nonFraction-684114aa-20f4-4aca-861b-bead9de46b66"
      unitRef="Unit12">155000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-f52d5d30-d4eb-42ce-bfa2-a92e3589e2ac">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Investments&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Short-term and long-term investments consist of debt securities classified as available-for-sale. Short-term investments have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss). Realized gains and losses are included in earnings and are der&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;ived based on the specific-identification method for determining the costs of investments sold and were insignificant for the years ended December 31, 2023, 2022 and 2021. Amortization of premiums and accretion of discounts are reported as a component of interest income.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. The Company evaluates the securities in an unrealized loss position for expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, current economic conditions and credit ratings. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company did &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t recognize any credit losses on its available-for-sale securities during the years ended December 31, 2023, 2022 or 2021 and there were no impairment charges for unrealized losses in the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-14c303de-dbf7-4431-bf9c-3099754ab2e9"
      unitRef="Unit12">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-6be0c5c0-d216-44b8-8039-5ef4662c67df"
      unitRef="Unit12">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-992c49ca-7892-4d72-a243-cc300eaac53f"
      unitRef="Unit12">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e36186fd-cb07-4494-ba57-f137543db95a">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, U.S. government securities, U.S. treasury bills, agency bonds/notes, and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December 31, 2023 and December&#160;31, 2022, a portion of the Company&#x2019;s cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of the Company&#x2019;s cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. On March 10, 2023, SVB was shut down and placed under receivership with the Federal Deposit Insurance Corporation, or FDIC, by the California Department of Financial Protection and Innovation. On March 26, 2023, the FDIC announced it had entered into a purchase and assumption agreement with First Citizens Bank &amp;amp; Trust Company under which all of SVB&#x2019;s deposits were assumed. As of the issuance date of these financial statements, the Company has not experienced any losses on its deposits and all of the Company&#x2019;s cash deposited with SVB has been accessible to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s accounts receivable are due from a variety of hospitals and medical centers in the United States. As of December&#160;31, 2023 and 2022, no customer represented 10% or more of the Company&#x2019;s accounts receivable. For the years ended December&#160;31, 2023, 2022 and 2021, there were no customers that represented 10% or more of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company manufactures certain of its commercial products in-house. Certain of the Company&#x2019;s finished goods,  components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in finished goods, component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, competition, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies. In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#x2019;s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-0f252899-5a7c-4637-83d5-ebbb658c91f3">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Accounts Receivable&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company estimates allowances for expected credit losses. Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#x2019; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. These specific allowances are reevaluated and adjusted as additional information is received that impacts the amount reserved. During the years ended December 31, 2023, 2022 and 2021, the Company did not experience any material credit-related losses.&lt;/span&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-c775eb07-1148-4b67-938f-3d4454dc57ba">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Inventories&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate. The Company&#x2019;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements. The estimate of excess quantities is judgmental and primarily dependent on the Company&#x2019;s estimates of future demand for a particular product. If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.&lt;/span&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e1ecb903-1556-46ec-8dd2-beb28ef9c6f8">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Property and Equipment&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment are recorded at cost less accumulated depreciation or amortization. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;five years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember"
      id="ct-nonNumeric-66e4bc74-f742-46aa-8b80-6c3c31595686">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember"
      id="ct-nonNumeric-f89343eb-e0f7-4e97-9295-e60b7bc3900c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-c17cd862-e768-4f28-9e64-1663597cc6b4">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value. The Company did &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t record any impairment of long-lived assets during the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-c115c9da-fbb3-4925-9216-4570bfa6c650"
      unitRef="Unit12">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-429c85a1-4929-4698-bd62-244972b52c82"
      unitRef="Unit12">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-1b7fee94-4673-4d67-a0b8-abd08ca28a32"
      unitRef="Unit12">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-90fcb880-3bc8-41e0-8913-625178e1ab0a">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Leases&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for its leasing arrangements in accordance with Accounting Standards Codification, or ASC 842, &#x201c;Leases.&#x201d; The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset. The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company&#x2019;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain. Variable lease costs represent payments that are dependent on usage, a rate or index. Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred. The Company elected to account for contracts that contain lease and non-lease components as a single component, consistent with its historical practice. The Company does not have any finance leases.&lt;/span&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-4ac7d6e7-06b1-4a57-b977-063d08746273">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Revenue Recognition&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives and is primarily comprised of product revenue net of returns, administration fees and sales rebates. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#x2019;s products to its customers, either upon shipment of the product or delivery of the product to the customer.&#160;The Company&#x2019;s products are readily available for usage as soon as the customer possesses it. Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title. The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Administration fees and sales rebates are accounted for as a reduction in revenue, calculated based on the terms agreed to with the customer.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2023 and 2022, the Company recorded $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;227,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;148,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Costs associated with product sales, which include commissions and royalties, are expensed when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160;Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accepts product returns at its discretion or if the product is defective as manufactured. The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the balance sheet.&#160;The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;sold. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1ec5035d-0f71-4476-9fc2-6d8b92363886"
      unitRef="Unit12">227000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4d4f7b5f-b3f6-4319-90a1-ede753b50c28"
      unitRef="Unit12">148000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-888c9d43-8aa5-464b-8472-1704f694717d">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company manufactures certain of its portfolio of TCAR products at its California and Minnesota facilities and purchases other products from third party manufacturers. Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, manufacturing overhead costs, direct labor, scrap, product rework, reserves for excess, obsolete and non-sellable inventories as well as logistics-related expenses. A significant portion of the Company&#x2019;s cost of goods sold currently consists of manufacturing overhead costs. These overhead costs include the cost of quality control, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company entered into the lease for its additional facility in Minnesota in May 2021 and did not begin commercial production of the ENROUTE Neuroprotection System until the third quarter of 2022. During this time, the Company experienced additional overhead expenses related to its investment in the start-up phase of its manufacturing capacity expansion, which were recorded as a period expense. &lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e0ea2ef0-f197-48db-a77c-3cd0f5a4465e">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Research and Development&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company expenses research and development costs as incurred. Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#x2019;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development. Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses. Additionally, clinical studies include costs associated with clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Clinical Trials&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accrues and expenses costs for its clinical trial activities performed by third parties, including any clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-45194000-3c56-4411-98d3-69849a46d345">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Advertising Costs&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company expenses advertising costs as incurred. Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items. Advertising costs of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;461,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;347,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;221,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; were expensed during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-0343db5b-823a-4fed-94c3-296ebdec7a88"
      unitRef="Unit12">461000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ab787038-c5d4-416d-a749-10b530ece226"
      unitRef="Unit12">347000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-613af11b-a1e5-4190-8608-3eebd4408e32"
      unitRef="Unit12">221000</us-gaap:AdvertisingExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-203a9d2d-5343-4eb9-a2c9-401633263014">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Foreign Currency&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net. The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-68243c0b-6b72-4967-96a4-a0dcfa248ff7">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Stock&#x2013;Based Compensation&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board, or FASB, ASC 718,&#160;&#x201c;Compensation-Stock Compensation.&#x201d; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units, performance stock units, and shares issued under its employee stock purchase plan. ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model. The fair value of stock options is recognized over the period during which an optionee is required to provide services in &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis. The Company accounts for option forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant. These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation for performance stock units with market-based conditions at their fair value on the date of the award using the Monte Carlo simulation model. These costs are recognized over the requisite service period, which is usually the vesting period, regardless of the likelihood of achievement of the market-based performance criteria.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for stock-based compensation for its employee stock purchase plan based on the &lt;/span&gt;&lt;span id="_Hlk157943524" style="text-decoration: none;"&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;estimated fair value on the first day of the offering period &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;using an option pricing model for each purchase period. These costs are recognized on a straight-line basis over the offering period.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-a409f090-b5c8-4c02-ae4f-713e9ed9bdb3">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Income Taxes&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company also follows the provisions of ASC 740-10, &#x201c;Accounting for Uncertainty in Income Taxes.&#x201d; ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;No&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; liability related to uncertain tax positions is recorded on the financial statements. It is the Company&#x2019;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-93c32e1b-062e-4830-a792-dccbcedc251e"
      unitRef="Unit12">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-1ddd3cd4-35c6-48cb-8061-d49b3da2584f">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Comprehensive Loss&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale. For the years ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;December&#160;31, 2023, 2022 and 2021&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, the Company&#x2019;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive loss. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets as a component of stockholders' equity. &lt;/span&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-f174a5b6-3858-45a6-b335-241b21fb5f52">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Net Loss per Share &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and performance stock units are considered to be potentially dilutive securities. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share was determined as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,743&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,010&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,811&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Weighted average common stock outstanding used to compute net loss per share, basic and diluted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;38,804,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;35,775,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,635,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.54&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#x2019;s net loss:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Common stock options &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,632,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,839,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,780,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,536,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,329,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;530,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,168,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,169,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,311,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-6e84a853-77ac-4786-b95b-9c694988fe9f">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,743&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,010&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,811&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Weighted average common stock outstanding used to compute net loss per share, basic and diluted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;38,804,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;35,775,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,635,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.54&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-88a3d94c-5b3f-4880-86ae-0a6654af4be6"
      unitRef="Unit12">-55743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-907d0c93-62ee-4d07-8117-29d31f211eb8"
      unitRef="Unit12">-55010000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c7154c3d-a32e-4106-886a-b63f7aee4f37"
      unitRef="Unit12">-49811000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="0"
      id="ct-nonFraction-07840930-6a30-4960-88f4-b43424ffd1e6"
      unitRef="Unit1">38804343</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="0"
      id="ct-nonFraction-8b091b81-d6b5-4e6d-86bd-6a2f1c3155da"
      unitRef="Unit1">38804343</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-e28c7507-cada-44ca-b1e2-3cf92e23488d"
      unitRef="Unit1">35775672</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-cbb6f996-a8ae-49dc-907e-cce49b900e8d"
      unitRef="Unit1">35775672</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-423d1bbf-f6d4-49e4-a268-cb042e7cd5a9"
      unitRef="Unit1">34635358</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-a352e428-58b3-48a5-91c4-332b9e582af9"
      unitRef="Unit1">34635358</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-5b67ebf6-772b-4fd5-8279-cc0821ff2662"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-749b7d16-2756-403b-8466-ec33a499224c"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-c8c1d24a-1671-4bd5-90a1-5f49e7bb3f71"
      unitRef="Unit14">-1.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-c8a01688-5fbc-4135-b388-c7a75aae7cb1"
      unitRef="Unit14">-1.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-be0d3451-048a-44a2-9e78-2361195ed2de"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-d6819db4-6389-4957-a08d-434aeda13b64"
      unitRef="Unit14">-1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-6c5e1f12-5d1d-4c4a-8087-9be55e3ebf0f">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Common stock options &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,632,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,839,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,780,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,536,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,329,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;530,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,168,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,169,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,311,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="ct-nonFraction-729741ef-a377-4183-bc64-92e3375089a1"
      unitRef="Unit1">3632684</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="ct-nonFraction-d4d49296-23a3-4987-acb0-f029d77d67a8"
      unitRef="Unit1">3839858</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="ct-nonFraction-951d60dd-ef00-49bc-9bff-4d92b29c54d3"
      unitRef="Unit1">3780939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember"
      decimals="0"
      id="ct-nonFraction-10bf222c-1cfd-4acc-a7ae-3e8f6d919275"
      unitRef="Unit1">3536197</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember"
      decimals="0"
      id="ct-nonFraction-03368f05-845b-4b3c-80bc-e5d138962509"
      unitRef="Unit1">1329824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_silk_RestrictedStockUnitsAndPerformanceStockUnitsMember"
      decimals="0"
      id="ct-nonFraction-cb806a83-0fdf-4323-84aa-04b6a10ec0d4"
      unitRef="Unit1">530274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="0"
      id="ct-nonFraction-5834183a-e518-4d7d-9dfc-f486fa400c9c"
      unitRef="Unit1">7168881</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-42946ef6-8f37-4367-ba0e-5cba598d2365"
      unitRef="Unit1">5169682</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-15927554-28b9-4949-824b-39158aba05e9"
      unitRef="Unit1">4311213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-dd1fc03e-b3a5-4ffc-8663-4aa3699cf434">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; reportable and operating segment. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Primarily all of the Company&#x2019;s long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment. All of the Company&#x2019;s revenue was in the United State&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;s for the years ended December&#160;31, 2023, 2022 and 2021, based on the shipping location of the external customer.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-cef8a22a-c014-45ca-8035-169f50b0f724"
      unitRef="Unit15">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-ff9f1092-9101-47ab-9e28-31bb9ae1d824"
      unitRef="Unit15">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-bcb0b1c7-df3a-4fb7-8498-01d484ad2303">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;3.&#160;&#160;&#160;&#160;Recent Accounting Pronouncements&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segments expenses. ASU 2023-07 became effective for the Company on January 1, 2024. The Company does not believe that the adoption of this new guidance will have a material impact on its segment reporting disclosures. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 105.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09, which enhances income tax disclosure requirements by requiring specified categories and greater disaggregation within the rate reconciliation table, disclosure of income taxes paid by jurisdiction, and providing clarification on uncertain tax positions and related financial statement impacts. ASU 2023-09 is effective for the Company on January 1, 2025 with early adoption permitted. The Company is currently evaluating the impact of adoption of this new guidance on its income tax disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-2b9071fe-590f-4d22-969a-7dca6e823d72">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;4.&#160;&#160;&#160;&#160;Fair Value Measurements&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#x2022;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 1 &#x2013; quoted prices in active markets are identical assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#x2022;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 2 &#x2013; observable inputs other than quoted prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#x2022;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 3 &#x2013; unobservable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company&#x2019;s&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; investments&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; are classified within Level 1 of the fair value hierarchy include money market funds valued using quoted market prices and U.S. treasury bills valued using broker or dealer quotations with reasonable levels of price transparency. Investments classified within Level 2 include commercial paper, which are valued using model-based valuation techniques, and corporate bonds/notes, U.S. government securities and agency bonds/notes, which are valued based upon quoted market prices for similar instruments in active markets or quoted prices for identical or similar &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;instruments in markets that are not active for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following tables set forth by level within the fair value hierarchy the Company&#x2019;s assets that are reported at fair value as of December&#160;31, 2023 and 2022 using the inputs defined above (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;31,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;158,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;138,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;There were no transfers between fair value hierarchy levels during the years ended December&#160;31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-626e2557-a3aa-4f2b-b7d2-79e94aa404f8">&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;31,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;158,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;138,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-d39cf893-6563-4ca2-8c94-e665cf96f36d"
      unitRef="Unit12">19483000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-9bcdcccf-be74-4bf8-923e-3d379c1e3b54"
      unitRef="Unit12">19483000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-70ba2d2a-2c0b-4f8e-9759-a62c317581b5"
      unitRef="Unit12">11899000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-524238ee-45c0-4879-a4b7-7cf36afd2514"
      unitRef="Unit12">11899000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-e09ec75b-e0d9-45b7-836a-15bf48248cbe"
      unitRef="Unit12">33150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-49ff0d6e-ca47-4268-9c9c-054f94f01069"
      unitRef="Unit12">33150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-8334f8ad-3fd1-493c-ac06-7eb56e0ac644"
      unitRef="Unit12">39438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-32b9b822-4cb0-4032-a17f-fd49fe7af20d"
      unitRef="Unit12">39438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-a3be0527-6d71-4e4c-b6e8-4d94fad4c4a9"
      unitRef="Unit12">17556000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-61bad5d4-24a4-4fe5-a06d-e40e9345224d"
      unitRef="Unit12">17556000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-023d808a-5087-4445-84cc-1e7989d0cfa4"
      unitRef="Unit12">68677000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-b5a56dbf-d118-4656-b7a0-dffc5157db72"
      unitRef="Unit12">68677000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="ct-nonFraction-528a6c40-9d75-4a2c-889c-e596a69d94c6"
      unitRef="Unit12">31382000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="ct-nonFraction-0d2ff667-132f-4bfa-ba46-e6294572274a"
      unitRef="Unit12">158821000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="ct-nonFraction-1f786a2e-5536-4724-8c75-08a843cde262"
      unitRef="Unit12">190203000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-245b8b3a-53eb-4dcb-a1d3-d85789766da7"
      unitRef="Unit12">55158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-c425871e-b4ea-4310-a214-ac5bb313566c"
      unitRef="Unit12">55158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-37911340-3688-4b6f-b9d0-007999a7b21e"
      unitRef="Unit12">19776000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-e84882ad-bd31-41db-bb38-c9ab4e86e53e"
      unitRef="Unit12">19776000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-98532d04-f231-42ce-8d71-b4dee657bc3c"
      unitRef="Unit12">48875000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="ct-nonFraction-6e9276e6-9e53-4ce3-a16d-c88c5e984836"
      unitRef="Unit12">48875000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-952d4edc-cef3-4474-b644-d0c528d6099c"
      unitRef="Unit12">1515000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-8bc19f8d-354c-49dc-bb63-f2d75d514645"
      unitRef="Unit12">1515000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-bb2bbf0d-d243-4504-971f-193c76acfac0"
      unitRef="Unit12">83270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-7240522e-6751-4bb6-83ba-66c60a7c4cb4"
      unitRef="Unit12">83270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-421d2e79-ea84-4b90-937d-8e01f09f12f2"
      unitRef="Unit12">1996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-e896a2e2-82ef-4945-a5d7-de591fa7eb4c"
      unitRef="Unit12">1996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-c133feca-3c78-4bf7-878d-3a3c03a9ce0c"
      unitRef="Unit12">2884000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-e5ea3236-ff5f-4140-9092-2b1ecf208cd7"
      unitRef="Unit12">2884000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="ct-nonFraction-83a9a050-8ac5-4e8b-8f73-2af1a0465ffb"
      unitRef="Unit12">74934000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="ct-nonFraction-e23eda9e-ed95-49a5-9fab-a0d0a15121aa"
      unitRef="Unit12">138540000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="ct-nonFraction-15fcc812-7a32-4b12-9c46-a58546c4bec8"
      unitRef="Unit12">213474000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-6288702d-37db-4db6-bae7-a79acdf66777">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;5.&#160;&#160;&#160;&#160;Balance Sheet Components&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The fair value of the Company's available-for-sale investments as of December&#160;31, 2023 and 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash equivalents &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Short-term investments &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;161,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;span style="white-space:pre-wrap; "&gt;&lt;/span&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;164&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;181&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash equivalents &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Short-term investments &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;158,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following table summarizes the fair value of the Company&#x2019;s cash equivalents, and available-for-sale investments classified by maturity as of December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.36in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amounts maturing within one year &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;180,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amounts maturing after one year through two years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Available-for-sale investments held as of December 31, 2023 had a weighted average days to maturity of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;163&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; days.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;164&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;90,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;76,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;181&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;There were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; available-for-sale investments in an unrealized loss position greater than twelve months as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Components of inventories were as follows (in thousands): &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Finished products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;23,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;29,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2023 and 2022, there were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; work-in-process inventories. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Accumulated depreciation &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,907&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,355&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Add:  Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,696,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,127,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,032,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; for the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued travel expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Provision for sales returns&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued royalty expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued administration fees and sales rebates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-563170c8-c58a-4b5f-9190-1befd35165a1">&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash equivalents &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Short-term investments &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;161,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;span style="white-space:pre-wrap; "&gt;&lt;/span&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;164&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;181&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash equivalents &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Short-term investments &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;158,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-85ddd0ff-7c0e-44c4-b3c1-1803202e2c20"
      unitRef="Unit12">19483000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-0981bc1f-8703-4f09-b94b-e92daa7f3851"
      unitRef="Unit12">19483000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-0620bcab-2e07-4ee3-b4fe-8ac75030dd79"
      unitRef="Unit12">11896000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-612fc508-1c2c-4be0-bf58-d5ce2bd2e7f4"
      unitRef="Unit12">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-f34912e9-909a-45cf-9c47-17bee481bc1b"
      unitRef="Unit12">11899000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-43aeb3b9-5e0f-44a7-9a55-8ff1f13be5be"
      unitRef="Unit12">33160000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-5a200c88-bc9b-44a4-a5cc-8388a874ac98"
      unitRef="Unit12">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-4838e68d-11fb-4030-9893-4921c9021965"
      unitRef="Unit12">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-f04033c5-6d99-4a7d-814f-069d0d76d291"
      unitRef="Unit12">33150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-763b3f44-70d6-4f83-9be9-87c98cfbb19d"
      unitRef="Unit12">39398000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-26a8b9d5-8282-49c4-98dc-96d31238c952"
      unitRef="Unit12">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-c2b969bb-a825-432b-a1e1-93958cda540a"
      unitRef="Unit12">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-28ebc4fc-6191-41a3-a7b5-479861048abe"
      unitRef="Unit12">39438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-58f10aae-9b52-4523-a1a7-7ed786a866c0"
      unitRef="Unit12">17501000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-d882715a-a319-421a-9287-fdce049f9380"
      unitRef="Unit12">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-a67c9333-3f79-49fb-9ab6-95e6cd97f0e4"
      unitRef="Unit12">17556000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-ec3ad026-2734-4e0f-bd1d-cc1606ad4a15"
      unitRef="Unit12">68693000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-07ad6ada-2bbc-431e-92b7-4d5160d319f7"
      unitRef="Unit12">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-b49ed640-e9fc-438c-ba3e-432a11bc649d"
      unitRef="Unit12">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-85117a3a-2def-469e-9984-430e8276bc9a"
      unitRef="Unit12">68677000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-8488bff8-80ab-4647-a3df-a008cc226f05"
      unitRef="Unit12">190131000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-92ebf6af-6c26-407f-b999-c536b3137c52"
      unitRef="Unit12">145000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-7b88a86d-4a0c-4876-a2bc-99a445a223aa"
      unitRef="Unit12">73000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-92dfc8b3-3d6a-4251-8db7-6e3ae50bd0b3"
      unitRef="Unit12">190203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-da00b1e4-bd48-4b16-a7c5-c941dcc7a1e1"
      unitRef="Unit12">19483000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1adf5aca-8bbc-46d0-8f25-7df2203328b1"
      unitRef="Unit12">161264000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-96249b6b-d1bb-464b-91c2-4c9200dd3716"
      unitRef="Unit12">9456000</us-gaap:LongTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-67879fa5-748c-4d49-b049-a9569d61c60a"
      unitRef="Unit12">190203000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-4c6e0a6a-41e8-4134-857b-3f47507859e8"
      unitRef="Unit12">55158000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="ct-nonFraction-d3875fb6-d4ce-44d8-b1b0-fdfe229bf83e"
      unitRef="Unit12">55158000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-3e0c2af6-0dee-45be-a639-1a5d7c3019c9"
      unitRef="Unit12">19772000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-602f6491-3d10-4c20-8c68-3a2d6a5327d9"
      unitRef="Unit12">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-0b30b408-84dd-4894-aee9-d5a7c30c971f"
      unitRef="Unit12">19776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-3b2b311c-e732-4093-b2ce-36bb2c059a90"
      unitRef="Unit12">48875000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-0b3afe93-8ace-420f-a7ab-4bf218802289"
      unitRef="Unit12">48875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-7ec4be13-ec85-4ac5-a689-34430beab8de"
      unitRef="Unit12">1528000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-59e99a65-beeb-4186-9499-ed9c99423119"
      unitRef="Unit12">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-22e61833-1eee-4f57-9b92-5db82139ec07"
      unitRef="Unit12">1515000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-631d9dbb-9d7e-4fec-a6fb-febe7cfc3afd"
      unitRef="Unit12">83432000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-c4f77a8c-6ff3-43c8-aa53-f0feb95412a0"
      unitRef="Unit12">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-4d0866f7-ebdc-46a2-96c5-f9729f0204ac"
      unitRef="Unit12">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-86640f8e-9412-43cc-a7be-feda415d386e"
      unitRef="Unit12">83270000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-a89e5317-fa88-4ee4-941c-b7a78538f108"
      unitRef="Unit12">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-ea59a8c5-982e-4b2e-ae1c-8308065c29a2"
      unitRef="Unit12">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-5d433fa1-1d02-4f03-b569-ec2cdda1064c"
      unitRef="Unit12">1996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-f321f927-252e-47d1-97bb-83de4c1e7ccb"
      unitRef="Unit12">2876000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-f341bd01-4c2c-46ff-8d3e-ec49b1c9a35a"
      unitRef="Unit12">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-04521197-342e-4b08-82b1-9e82f1d9a4e4"
      unitRef="Unit12">2884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-78eb640a-8cb2-4338-974b-4eb717e97499"
      unitRef="Unit12">213641000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-467dbc4e-6a08-43bc-8e59-638d3784f177"
      unitRef="Unit12">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d09ac577-a370-4f60-9509-903479924d78"
      unitRef="Unit12">181000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9e7d1a1e-d293-4dab-93d2-0faa67c349c6"
      unitRef="Unit12">213474000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-1fffc3a0-ad50-458b-90ce-44ddce5da069"
      unitRef="Unit12">55158000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9bce6e88-e06a-4bcb-b6d1-13d1c33cc703"
      unitRef="Unit12">158316000</us-gaap:ShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ff774692-a264-48d9-a94c-cc8bf4adfafb"
      unitRef="Unit12">213474000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-6e883a0d-600d-4519-b90d-70257487367c">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.36in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amounts maturing within one year &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;180,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amounts maturing after one year through two years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 17.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;213,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-047df09f-657d-4c97-b100-32e4e6bc9847"
      unitRef="Unit12">180747000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a2a5df89-f4f3-4bec-a49a-d1d76d9da807"
      unitRef="Unit12">213474000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-536477ae-779e-4d5b-8f10-c1bd198b1218"
      unitRef="Unit12">9456000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-6ff9ef2e-eb15-4ef5-a418-68f3b0cb05a2"
      unitRef="Unit12">190203000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ee12530b-5cb6-493a-9797-e498c15ab959"
      unitRef="Unit12">213474000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="As_Of_12_31_2023"
      id="ct-nonNumeric-99fc91e1-90ce-4ce3-bfde-e20c8a339e92">P163D</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-d0a985fe-967f-4f0b-987c-5dfc5bd2b8cb">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;164&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Agency bonds/notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 37.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;90,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;76,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;181&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-9681ed4c-39ff-44e1-b651-bfd675d857a1"
      unitRef="Unit12">21842000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-9105ae0f-1f73-4afc-b763-51371d4e98d4"
      unitRef="Unit12">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-59119c32-3f87-4045-9c0b-186634145a96"
      unitRef="Unit12">1490000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-642df3f5-b77b-4da3-a4f3-fb87b1fa7e9e"
      unitRef="Unit12">13000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-8e9ca0a2-d23d-4c7f-b02c-926277f42306"
      unitRef="Unit12">19684000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="ct-nonFraction-7134bcb7-322a-45fa-9a4b-37c4eaffe3c3"
      unitRef="Unit12">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-25efaba6-3dbb-4c46-864f-cbe8a41c58c8"
      unitRef="Unit12">73329000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-f8aeb32e-80b2-4611-9c83-b8547a215941"
      unitRef="Unit12">164000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-e6e5ddbe-18f8-448d-9640-bc7a1b82c03f"
      unitRef="Unit12">1994000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="ct-nonFraction-0073cbe9-09b3-4e81-9c3d-b93e0228ed9f"
      unitRef="Unit12">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-09c320c6-50d8-4574-a37f-43714c4255ec"
      unitRef="Unit12">48964000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_silk_AgencyNotesMember"
      decimals="-3"
      id="ct-nonFraction-b3a54bbf-4c3a-4ad8-9d54-ac5cfebc9c25"
      unitRef="Unit12">43000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-a9660ade-b8d1-4dc6-bc87-2a5e33364d6d"
      unitRef="Unit12">90490000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-a96146dc-6982-4ef9-8567-f4347d6b8b24"
      unitRef="Unit12">73000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-57ad6d51-cc19-4769-8c1c-63825da67f33"
      unitRef="Unit12">76813000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-08add11b-7be1-4c1f-95d5-81504d059a9a"
      unitRef="Unit12">181000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-be8d921a-da6e-41c0-a48a-3cd4fa2a2230"
      unitRef="Unit12">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-333ad2b6-04a2-49d4-bd79-46b55c73d4b9"
      unitRef="Unit12">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-851e68b9-d86d-489f-b2ca-c96601a66274">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Finished products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;23,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;29,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-5f56f1ea-a538-4931-8df5-f3ba0865d4e1"
      unitRef="Unit12">6512000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5a9bccb1-f76b-49e7-a358-73bd0fc51e94"
      unitRef="Unit12">4913000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-af31b588-a78a-48c2-8e48-7b6a6fae0a67"
      unitRef="Unit12">23364000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8f34b356-5da1-415a-88a7-ecb098b994ea"
      unitRef="Unit12">14380000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-46f1b4fe-e2b5-44f0-9c5a-4fa98dadd4b7"
      unitRef="Unit12">29876000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-abe90338-e777-4ff9-8785-9266bc61cacd"
      unitRef="Unit12">19293000</us-gaap:InventoryGross>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-2c1310ae-7a0f-4692-81ec-a6660b300e14"
      unitRef="Unit12">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-c06a9cee-0ca5-432e-b36e-dbb3ede8b8cb"
      unitRef="Unit12">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-3db1c9ce-6f02-4bd3-975d-00722e6a8ccf">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Accumulated depreciation &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,907&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,355&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Add:  Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-2d977c19-2caf-40c6-98d5-fa50fa5e73b9"
      unitRef="Unit12">2052000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-2c2f4699-9e46-4349-a241-dd2d7739bfd4"
      unitRef="Unit12">1822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="-3"
      id="ct-nonFraction-41ac25bc-c2e3-4c96-8c15-1b5d72298958"
      unitRef="Unit12">5776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="-3"
      id="ct-nonFraction-63fb6359-4e39-4a1d-9a37-f6daef549bfc"
      unitRef="Unit12">5046000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="ct-nonFraction-a64f898f-e6e7-44f2-ae79-b848872a1143"
      unitRef="Unit12">296000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="ct-nonFraction-102d402c-12e0-40ed-8008-b60d91b87fb3"
      unitRef="Unit12">296000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-adcfbd9c-8a5d-434c-ad8e-071348ba57d8"
      unitRef="Unit12">7561000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-424115fa-b00f-435d-a09f-09c49100e96f"
      unitRef="Unit12">7246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-a5241457-6301-4700-83da-78fbaad2fdd4"
      unitRef="Unit12">15685000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-41d34c0b-5415-4b74-96ad-900c793620d0"
      unitRef="Unit12">14410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-b3fa6711-0e3b-40fe-9352-8531369d9efb"
      unitRef="Unit12">7907000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6ca7a825-7120-4b8c-a2db-f491e0eb2fe1"
      unitRef="Unit12">5355000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-5ea13a96-de71-4fb7-808e-74d6751b18c6"
      unitRef="Unit12">336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-527576b1-2176-4f14-a310-43a116b878cf"
      unitRef="Unit12">317000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-cb82c492-a349-4c0f-9096-e06f3e79ed58"
      unitRef="Unit12">8114000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-0b454c52-5679-4b41-acc8-ccb8ae7d2d80"
      unitRef="Unit12">9372000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-e363c294-c342-4091-b5d5-ebc758615e64"
      unitRef="Unit12">2696000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-23d6c90a-8cee-4c86-908d-d5599358bd35"
      unitRef="Unit12">2127000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c165b47e-278a-4276-a43a-c97bdfec6d0b"
      unitRef="Unit12">1032000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-95b0dfb9-b184-4472-a575-ec5f34155cdb">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued travel expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Provision for sales returns&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued royalty expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued administration fees and sales rebates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accrued other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-8d5cc949-5205-4501-b704-7b664fa49b2a"
      unitRef="Unit12">17113000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9644f3d7-7417-4179-b953-118ee685cb73"
      unitRef="Unit12">15216000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-9df298ae-8d69-4c18-90e2-2f005456188a"
      unitRef="Unit12">1703000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ffce4c68-b6bc-46cb-a8b4-9ce656a006a9"
      unitRef="Unit12">1844000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1efaf639-6d86-43c6-93f7-d4f419c4f171"
      unitRef="Unit12">944000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-16aed67e-3c6d-4876-85cf-1708c63a2121"
      unitRef="Unit12">775000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-45350e0a-f448-4f99-ad9d-3942beef9645"
      unitRef="Unit12">517000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c01b6daa-4b73-47fd-ba02-1b39d88ada31"
      unitRef="Unit12">519000</us-gaap:AccruedProfessionalFeesCurrent>
    <silk:AccruedTravelExpensesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-01662ba6-dffe-44f1-94c0-f76b0f750fbe"
      unitRef="Unit12">500000</silk:AccruedTravelExpensesCurrent>
    <silk:AccruedTravelExpensesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-823bf571-5658-4d53-97a3-4256513c70d0"
      unitRef="Unit12">540000</silk:AccruedTravelExpensesCurrent>
    <silk:ProvisionsForSalesReturns
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-006ace88-126e-4710-9ae2-b9a9e64903b0"
      unitRef="Unit12">405000</silk:ProvisionsForSalesReturns>
    <silk:ProvisionsForSalesReturns
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a9862a51-2dd0-4e6e-958d-e3880400a394"
      unitRef="Unit12">973000</silk:ProvisionsForSalesReturns>
    <silk:AccruedAdministrationFeesAndSalesRebates
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-6734e8b5-cf9c-43cd-95f7-68f4351fb6da"
      unitRef="Unit12">405000</silk:AccruedAdministrationFeesAndSalesRebates>
    <silk:AccruedAdministrationFeesAndSalesRebates
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8fc990e2-1627-446e-bb19-2ba540859b98"
      unitRef="Unit12">338000</silk:AccruedAdministrationFeesAndSalesRebates>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-817f4174-ed8c-428c-ad76-2fa1b976832e"
      unitRef="Unit12">326000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ea251e1b-67ef-404a-9a48-20467479d5f9"
      unitRef="Unit12">781000</us-gaap:InterestPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-2b0cbf99-44d8-406c-aa8f-dbe35192b509"
      unitRef="Unit12">256000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a2d5afe8-5373-4526-9d23-83a83a3ee503"
      unitRef="Unit12">249000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <silk:AccruedClinicalExpensesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-801fdf60-c89b-4c90-aaaf-677b174d3dcf"
      unitRef="Unit12">143000</silk:AccruedClinicalExpensesCurrent>
    <silk:AccruedClinicalExpensesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-09709b30-c41f-4872-a282-47c0783161a5"
      unitRef="Unit12">253000</silk:AccruedClinicalExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d789c83a-d116-42de-a695-6fbe8333c92f"
      unitRef="Unit12">2295000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4d647963-4194-4fe8-9e6c-f939fc6f5a9d"
      unitRef="Unit12">477000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-5d2f50db-8afe-41bd-a862-25fa3b1a14ed"
      unitRef="Unit12">24607000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-fe7fe197-ef0d-4e5d-b775-be0f950afc2b"
      unitRef="Unit12">21965000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-7378d61c-87a3-46f0-a0f4-8b9728e0dc6c">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;6.&#160;&#160;&#160;&#160;Long-term Debt&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Stifel Bank&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In October 2020, the Company entered into a Loan and Security Agreement with Stifel Bank which provided for a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; loan facility, comprised of a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; secured revolving credit facility, with a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; subfacility for the issuance of letters of credit and other ancillary banking services, and a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; secured term loan facility, provided that amounts outstanding under both facilities may not exceed an aggregate principal amount of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; at any time. Interest under the revolving credit facility was the greater of a) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% above the "Prime Rate" as published by &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;The Wall Street Journal&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; or b) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.75&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%. Interest under the term loan facility was the greater of a) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.75&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% above the "Prime Rate" as published by &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;The Wall Street Journal&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; or b) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.75&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%. The Company drew down $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; under the term loan facility in October 2020. Concurrent with the Loan and Security Agreement, the Company entered in a Success Fee Agreement in October 2020 with Stifel Bank, which requires that the Company pay Stifel Bank the lesser of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.75&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the original principal amount of all credit extensions made under the Loan and Security Agreement or $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;375,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; in the event the Company completes a Liquidity Event (liquidation, merger, sale of the Company or change in control). &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On May 27, 2022, in connection with the consummation of the Loan and Security Agreement with Oxford Finance, as noted below, the Company repaid all amounts outstanding under the term loan with Stifel Bank. The Success Fee Agreement obligation of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;367,500&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; survives the Stifel Bank debt repayment and terminates on October 29, 2025. The Company has determined the probability of a Liquidity Event to be remote and accordingly, has not recognized a liability as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Oxford Finance&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In May 2022, the Company entered into a Loan and Security Agreement, or Loan Agreement, with Oxford Finance LLC and its agents, or Oxford Finance, which provides for &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;225,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; loan facility, comprised of a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; secured revolving credit facility and a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; secured term loan facility. The term loans are available in three tranches. The first $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;75,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; tranche of term loans was available at closing in May 2022. A second tranche of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;75,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; of term loans is available through December 31, 2024. A third tranche of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; would be available through December 31, 2024 so long as, at the time of draw, the Company has consolidated trailing 12-month revenues equal to at least &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;90&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the sum of the outstanding term loans plus the amount of any requested third tranche term loans. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Upon request of the Company, the revolving credit facility will be increased from $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; to $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The revolving loans are available subject to a borrowing base equal to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;85&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of eligible receivables plus &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of eligible inventory, up to the lesser of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;40&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the borrowing base or $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, in the case of eligible inventory. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The revolving loans and the term loans mature on &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;May 1, 2027&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The principal amount of outstanding revolving loans, together with accrued and unpaid interest, is due on the maturity date. The term loans begin to amortize in equal monthly installments beginning on July 1, 2026. As the Company achieved a specified &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;consolidated trailing twelve-month revenue target, it has &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;the option to extend the first amortization date for the term loans to July 1, 2027. Such election may be made &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no earlier than June 30, 2023 and no later than thirty (30) days prior to July 1, 2026. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If the Company exercises this option, then the maturity date for both the revolving loans and the term loans will be May 1, 2028.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The revolving loans accrue interest at the greater of 1-month Secured Overnight Financing Rate (SOFR), or the Index Rate, and &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.85&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, plus a margin of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.00&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%. The term loans accrue interest at the greater of the Index Rate and &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.85&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, plus a margin of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.00&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%. The Index Rate is capped at &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2.50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% for purposes of the Loan Agreement. Interest on both revolving loans and term loans is payable monthly in arrears. The Company may borrow, prepay and reborrow revolving loans, without premium or penalty. The term loans once repaid or prepaid may not be reborrowed. Term loans may be prepaid in full, or in part in increments of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company is required to pay a prepayment fee of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% for prepayments of term loans made in the first year after closing, &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% for prepayments of term loans made in the second year after closing, &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% for prepayments of term loans made in the third year after closing and no prepayment fees thereafter. Upon the earlier of prepayment or maturity of the term loans, the Company is required to pay a fee of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the aggregate original principal amount of the funded term loans, which fee increases to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.75&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% if the Company exercises its option to extend the amortization date and maturity date. The Company is also obligated to pay other customary fees for a loan facility of this size and type.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Also in May 2022, the Company borrowed the first $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;75,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; tranche of the term loan and used a portion of the proceeds to pay off and terminate the prior term loan agreement with Stifel Bank totaling $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,181,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, which included a final interest payment of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;181,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company recognized a loss on debt extinguishment of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;245,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; in connection with the early termination of its prior term loan agreement with Stifel Bank. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Obligations under the Loan Agreement are secured by substantially all of the Company's assets. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Loan Agreement requires the Company to maintain consolidated trailing twelve-month revenues of at least &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;75&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the outstanding principal amount of the term loans, measured as of the last day of each fiscal quarter; or if the revenue target is not achieved, &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;the Company must have maintained unrestricted cash and cash equivalents (net of outstanding revolving loans) subject to control agreements in favor of Oxford Finance equal to at least &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the outstanding principal amount of the term loans&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting the Company's ability and the ability of the Company's subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of the Company&#x2019;s obligations under the Loan Agreement, the termination of the lender&#x2019;s commitments, a &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December 31, 2023, the aggregate outstanding principal balance under the term loan facility was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;75,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; with the variable interest rate capped at the maximum rate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.50&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;and no amounts were outstanding under the revolving credit facility of the Loan Agreement&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. As of December 31, 2023, the Company was in compliance with all applicable financial covenants.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Future payments under the Oxford Finance term loan agreement as of December 31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;45,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;91,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Add: Accretion of closing fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;92,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;16,638&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Amount representing debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;703&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Present value of minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;75,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember"
      decimals="INF"
      id="ct-nonFraction-24157294-6fb4-4cfb-be5f-bfa80ff5f8e6"
      unitRef="Unit12">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember"
      decimals="INF"
      id="ct-nonFraction-0ca3637f-a0f2-4665-922e-f345b56e7f33"
      unitRef="Unit12">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilitySubfacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember"
      decimals="INF"
      id="ct-nonFraction-53f54dc7-fa65-4e17-9c34-4a0313cf88c9"
      unitRef="Unit12">2000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember"
      decimals="INF"
      id="ct-nonFraction-3ce1b0e2-90d3-4e78-8bf0-7be3bbb397ae"
      unitRef="Unit12">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="INF"
      id="ct-nonFraction-af2318d5-d6d8-4781-ace3-032ffeda0f6f"
      unitRef="Unit12">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember"
      decimals="INF"
      id="ct-nonFraction-e418b2fe-9a15-4beb-87e4-daa93e114b47"
      unitRef="Unit13">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_silk_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="INF"
      id="ct-nonFraction-46f2c81e-1681-4a8b-874a-78e1333e9da1"
      unitRef="Unit13">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember"
      decimals="INF"
      id="ct-nonFraction-9f628f3f-faf3-4a0d-8545-a207309c34d8"
      unitRef="Unit13">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember_us-gaap_LongtermDebtTypeAxis_silk_TermLoanMember"
      decimals="INF"
      id="ct-nonFraction-3d817d9a-3c72-4b54-a7c1-7b3a75d4ec1b"
      unitRef="Unit13">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="-3"
      id="ct-nonFraction-10c12e15-3ac9-4c84-bcb1-01f2ca298293"
      unitRef="Unit12">49000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <silk:DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="INF"
      id="ct-nonFraction-e34fed12-7b17-4d0d-bc9a-af1a0acc35b8"
      unitRef="Unit13">0.0075</silk:DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold>
    <silk:DebtInstrumentCovenantLiquidityEventPaymentAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="-3"
      id="ct-nonFraction-eb239e0a-de52-4b8d-8915-44f5786e44dc"
      unitRef="Unit12">375000</silk:DebtInstrumentCovenantLiquidityEventPaymentAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_5_27_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="0"
      id="ct-nonFraction-f7b8137b-3836-44e2-84b0-a9e635ecce81"
      unitRef="Unit12">367500</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-c287ff1c-7cce-4141-8a92-d02d3e96b96f"
      unitRef="Unit12">225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-99f9ddf2-8934-4e76-a634-f543369eefd0"
      unitRef="Unit12">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-9426a078-4411-4d76-a945-feaf5b8a5532"
      unitRef="Unit12">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-0b4bcdce-0b8d-4c9c-a12d-33a4c7810589"
      unitRef="Unit12">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-ff486294-5341-420e-b918-278e78399c9e"
      unitRef="Unit12">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-997a33fd-0741-400e-b94b-c6304a0bb851"
      unitRef="Unit12">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <silk:DebtCovenantRevenueCovenant
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-43c6b724-50b6-479b-a6a6-9d02977d34fa"
      unitRef="Unit13">0.90</silk:DebtCovenantRevenueCovenant>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-fca29310-193f-4d11-8919-70758d49b374"
      unitRef="Unit12">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-6e018455-545f-4635-a9a2-806ebc02e084"
      unitRef="Unit12">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <silk:PercentOfBorrowingBaseOfEligibleReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-c7670a0f-5eab-4bb6-9ade-16f82c76001f"
      unitRef="Unit13">0.85</silk:PercentOfBorrowingBaseOfEligibleReceivables>
    <silk:PercentOfEligibleInventory
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-1173eebd-c9e6-4548-a94f-6b556a3ad210"
      unitRef="Unit13">0.50</silk:PercentOfEligibleInventory>
    <silk:PercentOfBorrowingBaseInCaseEligibleInventory
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-25d9c544-c60f-46d3-ae09-75d10e2e3a0b"
      unitRef="Unit13">0.40</silk:PercentOfBorrowingBaseInCaseEligibleInventory>
    <silk:BorrowingBaseAmountInCaseEligibleInventory
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredRevolvingCreditFacilityAmendedMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-fbe9ed3f-3739-49d9-813d-976414d6b663"
      unitRef="Unit12">10000000</silk:BorrowingBaseAmountInCaseEligibleInventory>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      id="ct-nonNumeric-82610ffe-01e1-43b9-ae23-8240ae9f9122">2027-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"
      decimals="INF"
      id="ct-nonFraction-fa2832e4-d565-49c0-8837-bf27c9b63e75"
      unitRef="Unit13">0.0085</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <silk:DebtInstrumentMarginRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"
      decimals="INF"
      id="ct-nonFraction-eadbca54-294b-42e8-8dfe-dc3fb751e990"
      unitRef="Unit13">0.0300</silk:DebtInstrumentMarginRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"
      decimals="INF"
      id="ct-nonFraction-c2165ea9-219e-45f5-98c6-a981ef25c9c1"
      unitRef="Unit13">0.0085</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <silk:DebtInstrumentMarginRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"
      decimals="INF"
      id="ct-nonFraction-438b6f07-c918-4ef0-9e51-caea1f7e95f8"
      unitRef="Unit13">0.0500</silk:DebtInstrumentMarginRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember_us-gaap_VariableRateAxis_silk_IndexRateMember"
      decimals="INF"
      id="ct-nonFraction-77cc7da9-63ff-444a-9ea3-faf2015d2a87"
      unitRef="Unit13">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <silk:TermLoanPrepaidInIncrements
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-22c057cb-303a-4d3c-ae9e-1021493738b6"
      unitRef="Unit12">10000000</silk:TermLoanPrepaidInIncrements>
    <silk:PercentageOfPrepaymentFees
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-93518dce-c7dd-41fa-8d0c-742bd4026e28"
      unitRef="Unit13">0.030</silk:PercentageOfPrepaymentFees>
    <silk:PercentageOfPrepaymentFeesInSecondYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-cc1e5bd3-8eca-40c7-adab-59550b227af6"
      unitRef="Unit13">0.020</silk:PercentageOfPrepaymentFeesInSecondYear>
    <silk:PercentageOfPrepaymentFeesInThirdYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-c6477f4f-de06-41ec-9f63-be1ca8d3d1f7"
      unitRef="Unit13">0.010</silk:PercentageOfPrepaymentFeesInThirdYear>
    <silk:PercentAggregateOriginalPrincipalAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-2fc07b02-8ab3-4d22-a869-08a1dadc0e70"
      unitRef="Unit13">0.050</silk:PercentAggregateOriginalPrincipalAmount>
    <silk:PercentAggregateOriginalPrincipalAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-6ef2fc4a-8ec6-4fa0-8e46-de6347e7a804"
      unitRef="Unit13">0.0675</silk:PercentAggregateOriginalPrincipalAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_SecuredTermLoanFacilityMember_us-gaap_DebtInstrumentAxis_silk_TermLoanTrancheAMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="-3"
      id="ct-nonFraction-9b5ba34b-8712-48af-9396-c12924ca2840"
      unitRef="Unit12">75000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="-3"
      id="ct-nonFraction-5ed17ec3-c1fb-4274-9bc6-67615b343d67"
      unitRef="Unit12">49181000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="-3"
      id="ct-nonFraction-7576dcea-df21-4597-b13a-99b25638115b"
      unitRef="Unit12">181000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_StifelBankMember"
      decimals="-3"
      id="ct-nonFraction-19bbb080-61f3-4976-906e-8de1930c4c1c"
      unitRef="Unit12">245000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <silk:DebtCovenantRevenueCovenant
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-b1a163c5-6b3d-4cd1-bcac-6a11ad7e5cce"
      unitRef="Unit13">0.75</silk:DebtCovenantRevenueCovenant>
    <silk:DebtInstrumentCovenantMaximumBorrowingThreshold
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-cfe09f02-cd19-43d7-9f34-a6e08ebaa7ca"
      unitRef="Unit13">0.50</silk:DebtInstrumentCovenantMaximumBorrowingThreshold>
    <silk:PercentageOfPrepaymentFees
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="INF"
      id="ct-nonFraction-b3ffe620-7673-4c4d-ae7c-5e89917d0a58"
      unitRef="Unit13">0.05</silk:PercentageOfPrepaymentFees>
    <us-gaap:LineOfCredit
      contextRef="As_Of_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="-3"
      id="ct-nonFraction-b41f4573-aeee-433e-ac49-aca6b20cdb44"
      unitRef="Unit12">75000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CreditFacilityAxis_silk_LoanFacilityMember_us-gaap_LineOfCreditFacilityAxis_silk_OxfordFinanceMember"
      decimals="4"
      id="ct-nonFraction-5c993d44-1ad5-4726-ae8a-e3febff0d4e1"
      unitRef="Unit13">0.0750</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-ff0ade50-3507-4b5e-aee8-d685161eb1f3">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;45,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;91,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Add: Accretion of closing fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;92,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;16,638&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Amount representing debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;703&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Present value of minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;75,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-6cdcdc2f-970f-46bb-a16c-3795fa0d829a"
      unitRef="Unit12">5719000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1f878372-cda2-42b9-adfc-c65652a72a70"
      unitRef="Unit12">5703000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-ba9dca1e-a006-4de8-8d5a-b7cdfb4fb25f"
      unitRef="Unit12">45699000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-f0c08bb0-2286-4d45-96d4-90c43847cc5e"
      unitRef="Unit12">34517000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <silk:LongTermDebtGrossBeforeAccretionOfClosingFees
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-9b02b4a5-9636-48eb-8dad-ea9bd9597ba7"
      unitRef="Unit12">91638000</silk:LongTermDebtGrossBeforeAccretionOfClosingFees>
    <silk:AccretionOfClosingCosts
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-51d005b7-b054-4487-b965-283437562297"
      unitRef="Unit12">1329000</silk:AccretionOfClosingCosts>
    <silk:LongTermDebtGrossAfterAccretionOfClosingFees
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-f18127cb-f24f-4eec-b131-e870023ee88b"
      unitRef="Unit12">92967000</silk:LongTermDebtGrossAfterAccretionOfClosingFees>
    <silk:LongTermDebtUnpaidInterest
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-bc0f34d5-fd94-42cd-9345-77d74d09bfba"
      unitRef="Unit12">16638000</silk:LongTermDebtUnpaidInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-93a103c5-a88b-47e9-a890-a46d96c97bc5"
      unitRef="Unit12">703000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-a80479cf-a663-4582-b88b-9c210bc13c64"
      unitRef="Unit12">75626000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-4ad7673e-bdb1-46e4-94b7-5a43219b71d7">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;7.&#160;&#160;&#160;&#160;Commitments and Contingencies&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Operating Lease and Rights-of-Use&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s operating lease obligation at its corporate headquarters in California consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2027. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In May 2023, the Company extended the lease term for an additional &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three years&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and recorded an additional $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,504,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; right-of-use asset and lease liability from the remeasurement. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;five year&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;s.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s non-cancelable operating lease obligation at its facility in Minnesota consists of additional office, laboratory and manufacturing space and expires in November 2029. The lease agreement includes a renewal provision allowing the Company to extend this lease for two additional &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;five year&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; terms.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Balance sheet information as of December&#160;31, 2023 and 2022 consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Operating Lease:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease right-of-use asset in &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-dd16a680-3f25-4cca-8f06-df833283191e;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-80d6598d-c247-4749-a960-856924837d92;"&gt;other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease liability in &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-4a367e19-bd2b-4833-a2ee-41da1810dd33;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ea9efef9-505d-4191-897c-64e4a2fceb36;"&gt;accrued liabilities &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease liability in &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-24d00192-026d-4075-a91f-bdd0fa580324;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-18ad6fb4-b92c-4419-9e27-7f511e1beb87;"&gt;other liabilities &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total operating lease &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-7adaddd6-e390-4787-853b-b3d3af6f96a6;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-3f9f30e3-cce1-4745-9a9e-9d186b53fb29;"&gt;liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following table summarizes the Company's operating lease payments as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total lease payments &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less: imputed interest &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,828&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Present value of lease liabilities &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Purchase Obligations&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. As of December&#160;31, 2023, the Company had non-cancellable purchase obligations to suppliers of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,660,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In addition, the Company has minimum purchase commitments under its amended supply agreement with Cordis from July 2024 through February 2029 which require a specified minimum volume commitment based on the actual units purchased during the prior year period from July 1 through June 30, with the unit purchase price dependent upon annual volume during the same prior year period.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Indemnification&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In the normal course of business, the Company enters into contracts and agreements with suppliers and other parties that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director or officer is or was serving at the Company&#x2019;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director or officer may be subject to any proceeding arising out of acts or omissions of such director or officer in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t recognized any liabilities relating to these obligations as of December&#160;31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Contingencies &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows. From time to time, the Company may pursue litigation to assert its legal rights and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; contingent liabilities requiring accrual as of December&#160;31, 2023 and 2022.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="As_Of_5_31_2023"
      id="ct-nonNumeric-e18abce8-d3be-44b4-a7b0-7a1198c5ee27">P3Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_5_31_2023_To_5_31_2023"
      decimals="-3"
      id="ct-nonFraction-d4165da9-d5a8-4bf7-8e4e-d0743139219a"
      unitRef="Unit12">2504000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_HeadquartersMember"
      id="ct-nonNumeric-621d40fa-6606-41ad-9a90-1f89aec6605d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_silk_AdditionalOfficeLaboratoryAndManufacturingSpaceMember"
      id="ct-nonNumeric-27d5a463-d1d3-4d34-b073-a79e8aaec8bf">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <silk:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-527e3fe3-4af9-4f3e-bac1-7a602cc2df7b">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Operating Lease:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease right-of-use asset in &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-dd16a680-3f25-4cca-8f06-df833283191e;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-80d6598d-c247-4749-a960-856924837d92;"&gt;other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease liability in &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-4a367e19-bd2b-4833-a2ee-41da1810dd33;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ea9efef9-505d-4191-897c-64e4a2fceb36;"&gt;accrued liabilities &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double windowtext 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease liability in &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-24d00192-026d-4075-a91f-bdd0fa580324;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-18ad6fb4-b92c-4419-9e27-7f511e1beb87;"&gt;other liabilities &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total operating lease &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-7adaddd6-e390-4787-853b-b3d3af6f96a6;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-3f9f30e3-cce1-4745-9a9e-9d186b53fb29;"&gt;liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</silk:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-9de3bc70-05a1-44f0-967e-c32d3752d102"
      unitRef="Unit12">6489000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-553c88af-2c8a-4ed0-b66b-7d4d7d74b1ec"
      unitRef="Unit12">5081000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-b9685ef7-aeae-42eb-b715-632759c2a85e"
      unitRef="Unit12">1703000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-596a9254-a9a9-434c-926f-cac57f47c4c9"
      unitRef="Unit12">1844000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-91e8cc67-4883-469e-90c2-8fe0006aa4a5"
      unitRef="Unit12">7304000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5074026e-7cde-43c2-9b66-dbe1f56ac78b"
      unitRef="Unit12">5998000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1787d31e-015f-4165-9b35-5f5af3492429"
      unitRef="Unit12">9007000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-74d20c2a-aebc-47f1-b80c-d8d4f64c81b0"
      unitRef="Unit12">7842000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e8fa9705-1bb0-48aa-8cf7-051531e8ca32">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total lease payments &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less: imputed interest &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,828&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Present value of lease liabilities &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-b7767911-8f01-4b7b-b451-0f6ff0cff46f"
      unitRef="Unit12">1991000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-27aebe1c-d9e2-4e25-a63d-0690591df3a9"
      unitRef="Unit12">2130000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-9d0bf1fb-c06b-48af-8efb-61d50746f21a"
      unitRef="Unit12">2255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1a968053-4cc1-46db-bff5-6a8a2771f0d0"
      unitRef="Unit12">2068000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-07e67a8c-aa2e-4045-9a37-b07c0cd0ee2e"
      unitRef="Unit12">1233000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-9336715c-f096-4a70-81a7-3ba9d73cb31f"
      unitRef="Unit12">1158000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-b889535b-1b10-4a1b-8673-da47759e371a"
      unitRef="Unit12">10835000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-44661f2e-114e-45dc-b9cc-dc58e17ed944"
      unitRef="Unit12">1828000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-743f4044-e48a-4a9b-8297-6da867dc6ff7"
      unitRef="Unit12">9007000</us-gaap:OperatingLeaseLiability>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-db4d310f-cab6-4244-9d3a-313d811fc69b"
      unitRef="Unit12">15660000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <silk:IndemnificationObligationsLiabilityRecognized
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-9ca7486a-c5e5-4317-a222-b07c609097ac"
      unitRef="Unit12">0</silk:IndemnificationObligationsLiabilityRecognized>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-8126a362-9981-4657-8c9a-1bec79e0c130"
      unitRef="Unit12">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-4d72c503-b722-4981-bf10-b32ccd2b05ee"
      unitRef="Unit12">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-b7afcf8b-5ff9-4813-8691-1e08b3de4ce1">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;8.&#160;&#160;&#160;&#160;Stockholders&#x2019; Equity&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December 31, 2023, the Company&#x2019;s restated certificate of incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of preferred stock with $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.001&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; par value per share, of which no shares were issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December 31, 2023, the Company&#x2019;s restated certificate of incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;100,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock with $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.001&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; par value per share, of which &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,165,481&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares were issued and outstanding. The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. As of December 31, 2023, &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; dividends have been declared to date. Each share of common stock is entitled to one vote.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December 31, 2023 and 2022, the Company had reserved common stock for future issuances as follows:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding stock options and equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,168,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,169,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Reserved for grants of future stock options and equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;532,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,209,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Reserved for Performance Stock Units for overperformance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;809,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Reserved for employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,356,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,172,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,867,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,758,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-6b4d4287-1353-4a82-a06e-4db202bba16d"
      unitRef="Unit1">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-b3097fe1-af44-453d-96b8-9aa3ee40ffcc"
      unitRef="Unit14">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-861296b0-e9af-4e11-940b-728e6da4700d"
      unitRef="Unit1">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-d8931998-93da-4a12-ab63-89f6b5e4ded6"
      unitRef="Unit14">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-8cdaa8b8-707e-4204-b42a-9975361075c1"
      unitRef="Unit1">39165481</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-fb8b3e07-dd29-4479-a357-8e0c353b7a4e"
      unitRef="Unit1">39165481</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-9cf3dc01-b26e-4070-9be9-87efae631a9c"
      unitRef="Unit12">0</us-gaap:DividendsCommonStock>
    <silk:ScheduleOfCommonStockReserveForFutureIssuances
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-80c5a898-65aa-4ea8-add0-170d994fbdab">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding stock options and equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,168,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,169,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Reserved for grants of future stock options and equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;532,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,209,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Reserved for Performance Stock Units for overperformance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;809,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Reserved for employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,356,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,172,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 73.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,867,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,758,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</silk:ScheduleOfCommonStockReserveForFutureIssuances>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember"
      decimals="INF"
      id="ct-nonFraction-680b1b24-2682-45ac-a251-1928d55244fd"
      unitRef="Unit1">7168881</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionExercisedMember"
      decimals="INF"
      id="ct-nonFraction-f5ac8f7c-f39d-4b49-a4de-0b0b7a081c69"
      unitRef="Unit1">5169682</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember"
      decimals="INF"
      id="ct-nonFraction-ef199ea0-6070-4bcb-ac07-cbb6268e00c1"
      unitRef="Unit1">532627</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionIssuedMember"
      decimals="INF"
      id="ct-nonFraction-47aa19dd-732a-4518-819b-52aba0e0bf3e"
      unitRef="Unit1">2209072</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember"
      decimals="INF"
      id="ct-nonFraction-9f789abf-7559-4a66-b68b-572601877794"
      unitRef="Unit1">809225</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_PerformanceStockUnitsOverperformanceMember"
      decimals="INF"
      id="ct-nonFraction-0add89e2-9f9b-42f8-a9b0-e9d38493ba67"
      unitRef="Unit1">207468</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-37718fcf-39bf-4b69-9918-0326495952bf"
      unitRef="Unit1">1356463</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="ct-nonFraction-e89bd1c0-7138-4ea1-abcb-08d012f4b0ad"
      unitRef="Unit1">1172686</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-ce9eaf2f-8778-42f0-a3b1-17e07225343b"
      unitRef="Unit1">9867196</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-cfbb77b0-d829-4ea9-b972-a82920f67c48"
      unitRef="Unit1">8758908</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-3cf2d11f-eccc-40b5-9940-134ffc044107">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;9.&#160;&#160;&#160;&#160;Stock-Based Compensation Plans&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In March 2019, the Company's Board of Directors [and stockholders] approved the 2019 Equity Incentive Plan, or 2019 Plan, effective immediately prior to the Company&#x2019;s IPO. The 2019 Plan replaced the prior 2007 Stock Option Plan, or 2007 Plan, and the NeuroCo 2015 Equity Incentive Plan, which the Company assumed in connection with its acquisition of NeuroCo in December 2018, with respect to future grants. The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants. A total of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,317,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock were initially reserved for issuance pursuant to the 2019 Plan. In addition, the shares reserved for issuance under the 2019 Plan also include shares reserved but not issued under the prior 2007 Plan, plus any share awards granted under the 2007 Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. In addition, the number of shares available for issuance under the 2019 Plan also include an annual increase on the first day of each fiscal year, equal to the lesser of (i) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares; (ii) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors. As of December&#160;31, 2023, the Company has reserved &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,952,134&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;A summary of the shares available for issuance under the 2019 Plan is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2020 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,790,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Authorized &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,369,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted/Awarded &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;847,080&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;163,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,477,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Authorized &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,399,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Allowance for Performance Stock Units for overperformance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted/Awarded &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,600,996&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;141,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,209,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Authorized &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,534,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Allowance for Performance Stock Units for overperformance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;601,757&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted/Awarded &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,893,796&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;284,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;532,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The exercise price of Incentive Stock Options and Non-Statutory Stock Options shall not be less than &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;100&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% and &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;85&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, respectively, of the estimated fair value of the shares on the date of grant as determined by the Board of Directors. The exercise price of options granted to a &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% stockholder shall not be less than &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;110&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors. To date, options have a term of ten years and generally vest over &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; from the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Stock option activity under the Company&#x2019;s 2007 Stock Option Plan, 2015 Equity Incentive Plan and 2019 Plan is set forth below&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 1.06in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2020 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,237,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;16.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;197,407&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;323,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;643,507&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;136,439&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;40.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,780,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;91,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;587,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;37.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;span style="white-space:pre-wrap; "&gt;&lt;/span&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;453,199&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74,897&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,839,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;112,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;199,642&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27,430&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;47.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,632,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,184,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,632,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,857,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,575,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;29,355,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17.67&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;37.69&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;23.83&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; per share, respectively. The total fair value of options vested during the years ended December&#160;31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,207,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,816,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,076,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively, based on the grant date fair value.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Restricted Stock Units &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In March 2020, the Company began awarding restricted stock units, or RSUs, under the 2019 Plan. RSUs generally vest and are settled in shares of common stock over &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; in annual equal increments. The total award date fair value of awards provided during the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;46,939,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;30,486,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;28,110,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively. The total fair value of awards vested during the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13,203,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,135,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,893,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively. The fair value of RSUs is based on the closing price of the Company&#x2019;s common stock on the date of award. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;A summary of RSU activity for the years ended December 31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2020 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;46.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;524,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,964&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27,181&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;530,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;806,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;37.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;148,239&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;52.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;66,192&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;44.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,122,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;42.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,162,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;410,085&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;147,764&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,726,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,726,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In November 2022, the Company began awarding performance stock units, or PSUs, under the 2019 Plan to certain executive officers and key employees. PSUs generally vest at the end of a &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three year&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; service period, subject to continued service to the Company. The total number of shares of common stock to be issued upon vesting and settlement of the PSUs will be determined based on the total stockholder return, or TSR, of the Company&#x2019;s common stock price relative to a group of Benchmark Companies over a &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three year&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; performance period and range from &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the target value of shares awarded, depending on the Company&#x2019;s performance against the targeted Benchmark Companies. The total award date fair value of awards provided during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14,950,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;16,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;There was no PSU activity for the year ended December 31, 2021. A summary of PSU activity for the years ended December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;77.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;77.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;711,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;109,676&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;76.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;809,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;809,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The shares expected to vest as of December 31, 2023 reflects PSUs awards performance and vesting at &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;100&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the target value of shares granted.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In March 2019, the Company's Board of Directors [and stockholders] adopted the 2019 Employee Stock Purchase Plan, or the ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions. A total of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;434,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock were initially reserved for issuance and is increased on the first day of each fiscal year by an amount equal to the lesser of (i)&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,200,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares (ii)&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors. The price of the common stock purchased will be the lower of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;85&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. The ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2023, &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;465,952&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock have been issued to employees participating in the ESPP and &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,356,463&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares were available for future issuance under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company estimated the fair value of stock options using the Black&#x2013;Scholes option pricing model. The fair value of stock options is being amortized on a straight&#x2013;line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following assumptions for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.25&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.25&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;45.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.94&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.60&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.84&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.41&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.08&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The fair value of the underlying common stock is based on the closing price of the Company's common stock on The Nasdaq Global Select Market on the date of grant. The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the &#x201c;simplified method,&#x201d; whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected stock price volatility assumption was determined by supplementing its historical stock trading volatility with the historical volatilities for industry peers, as the Company does not have sufficient trading history for the Company&#x2019;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the&#160;Company&#x2019;s common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the&#160;Company&#x2019;s stock options. The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has elected to recognize forfeitures of share-based payment awards as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In November 2022, the Company awarded an aggregate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; PSUs to certain executive officers that vest at the end of a &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three year&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; service period based on the TSR of the Company&#x2019;s common stock price relative to a group of Benchmark Companies measured over three performance periods. The Company estimated the fair value of the PSUs using the Monte Carlo simulation model, which is being amortized over the requisite service period of the awards. The fair value of the PSUs was estimated using the following assumptions for the year ended December 31, 2022: peer companies volatility of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;59.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, Company volatility of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;60.6&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, risk-free interest rate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.09&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%-&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.20&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, correlation with index of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.41&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, and dividend yield of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In March 2023, the Company awarded an aggregate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;99,350&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; PSUs, assuming target performance. Up to one-third of the target award can be earned and vested at the end of the first and second annual measurement periods based on the total stockholder return, or TSR, of the Company&#x2019;s common stock price relative to a group of peer companies, and up to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the target award at the end of the &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three year&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; performance measurement period. The fair value of the PSUs was estimated using the Monte Carlo simulation model and the following assumptions for the year ended December 31, 2023: peer companies volatility of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;62.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, Company volatility of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;61.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, risk-free interest rate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.58&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, correlation with index of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.38&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, and dividend yield of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In November 2023, the Company awarded an aggregate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;612,083&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; PSUs, assuming target performance. Up to one-third of the target award can be earned and vested at the end of the first and second annual measurement periods based on the total stockholder return, or TSR, of the Company&#x2019;s common stock price relative to a group of peer companies, and up to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the target award at the end of the &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three year&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; performance measurement period. The fair value of the PSUs was estimated using the Monte Carlo simulation model and the following assumptions for the year ended December 31, 2023: peer companies volatility of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;56.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, Company volatility of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;71.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, risk-free interest rate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.72&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%, correlation with index of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.35&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, and dividend yield of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The fair value of the shares to be issued under the Company&#x2019;s ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;47.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;119.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.6&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;46.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.6&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.64&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.43&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.07&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.64&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.03&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.10&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cost of goods sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;38,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2023, there was total unrecognized compensation costs of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,645,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; related to stock options expected to be recognized over a period of approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.63&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years, a total of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73,195,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; of unrecognized compensation costs related to unvested RSUs and PSUs expected to be recognized over a period of approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2.76&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;years and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;679,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; of unrecognized compensation costs related to the ESPP, which the Company will recognize over &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.38&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2007_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-6753d297-e693-4a7d-be39-124d1c39ddef"
      unitRef="Unit1">2317000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-7f92b412-8b79-4897-ba86-9b9cef7b5356"
      unitRef="Unit1">3000000</silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-af27e224-f29c-4a47-afc8-d13d52794e57"
      unitRef="Unit13">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-fb37e98b-b060-49d6-a252-efb2df4a1e3a"
      unitRef="Unit1">7952134</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-721614d2-227e-40ca-8798-48ac29ac698d">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2020 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,790,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Authorized &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,369,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted/Awarded &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;847,080&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;163,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,477,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Authorized &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,399,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Allowance for Performance Stock Units for overperformance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted/Awarded &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,600,996&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;141,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,209,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Authorized &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,534,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Allowance for Performance Stock Units for overperformance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;601,757&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted/Awarded &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,893,796&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;284,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 84.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;532,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-2b56d8f2-6676-4e20-a1e0-7c2ee76a5474"
      unitRef="Unit1">1790687</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-2aa094a4-31e0-457d-bd39-aa37884948af"
      unitRef="Unit1">1369985</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-d0c107e8-36a3-4633-8a06-6a9fb4015bc1"
      unitRef="Unit1">847080</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-d646efe3-32fa-43fd-81a1-1328939f7349"
      unitRef="Unit1">163620</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-24cdb4b1-26c9-43d3-9f94-4d7b231a84d0"
      unitRef="Unit1">2477212</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-b30595ba-c914-4e49-a7d5-c08f635c4f22"
      unitRef="Unit1">1399235</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-57c0706a-47b5-4513-9fd1-2d901011197a"
      unitRef="Unit1">-207468</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-c4dcd589-eba3-4f4e-bfdd-226b4286498f"
      unitRef="Unit1">1600996</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-4e22c34a-bc27-473c-8fbf-0912da566e3d"
      unitRef="Unit1">141089</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-d85ed1f4-610c-42da-a4d3-8a45838bf147"
      unitRef="Unit1">2209072</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-9627bcbc-4dff-4d3e-bff2-d4ec497b97d9"
      unitRef="Unit1">1534238</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-955e5c2d-3560-4928-b710-a93f36ae3976"
      unitRef="Unit1">601757</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingAllowanceForOverperformance>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-e54b1d12-b0d5-4335-868a-2948e5885ce7"
      unitRef="Unit1">2893796</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-9946a424-61c9-4d24-87eb-3eb41f0d6957"
      unitRef="Unit1">284870</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-813d95a2-65b0-4500-9f18-1129c0cfb22f"
      unitRef="Unit1">532627</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember"
      decimals="2"
      id="ct-nonFraction-3ccf25fd-784b-4f31-8a8f-fe0e3bee73bb"
      unitRef="Unit13">1</silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice>
    <silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember"
      decimals="2"
      id="ct-nonFraction-50769c29-179e-42d8-a622-931631eb4c69"
      unitRef="Unit13">0.85</silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveStockOptionMember"
      decimals="2"
      id="ct-nonFraction-44871c22-f358-46b3-90f2-5d433329556f"
      unitRef="Unit13">0.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_NonqualifiedStockOptionsMember"
      decimals="2"
      id="ct-nonFraction-b982aada-64e0-473c-a89b-bc1454b77cf5"
      unitRef="Unit13">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_IncentiveandNonqualifiedStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      id="ct-nonNumeric-a2abe759-ec29-451b-9154-a3ba94204835">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-3f6b910e-5f25-4860-88d8-2228c18af539">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 1.06in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2020 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,237,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;16.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;197,407&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;323,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;643,507&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;136,439&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;40.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,780,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;91,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;587,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;37.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;span style="white-space:pre-wrap; "&gt;&lt;/span&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;453,199&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74,897&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,839,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;112,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;33.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;199,642&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options cancelled &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27,430&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;47.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,632,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,184,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,632,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-6eec236e-efe3-44d5-811e-18310cf770ff"
      unitRef="Unit1">4237828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020"
      decimals="2"
      id="ct-nonFraction-08aa6775-6e6f-4993-b26a-443ec5e51c9b"
      unitRef="Unit14">16.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020"
      id="ct-nonNumeric-66e38af3-0751-49f4-9fa5-689899259c74">P7Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-2ef60fdd-b333-40c4-9ba4-3b69359c74e6"
      unitRef="Unit12">197407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-be5d907a-450b-4d8b-8926-5de40eef80ab"
      unitRef="Unit1">323057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-e2ffeada-9f82-40f8-9347-22f2ce449bf5"
      unitRef="Unit14">53.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-eed74c08-47c0-432e-bef2-ca36fb9228b0"
      unitRef="Unit1">643507</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-54b39a22-dc84-41ac-a9d4-ecf944f26f0a"
      unitRef="Unit14">7.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-8e3e2310-0353-40f9-8fdc-c9a22b74217b"
      unitRef="Unit1">136439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-21d4ab65-9a56-4f7b-a036-49fec527e30a"
      unitRef="Unit14">40.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-f69021fb-4bce-4606-b905-8723f1e579e3"
      unitRef="Unit1">3780939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021"
      decimals="2"
      id="ct-nonFraction-e12c0856-889c-4538-b583-799990da2ba6"
      unitRef="Unit14">20.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-b3ef24e3-e543-49d7-a51b-2ae303912252">P6Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1c634beb-153d-4dcb-9d14-8d4f0723aa2f"
      unitRef="Unit12">91900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-ed51506b-8a00-4397-888a-dc2e576cc5ee"
      unitRef="Unit1">587015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-7c0d6371-499c-4bf6-aa5e-34e2e1e1aaf5"
      unitRef="Unit14">37.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-d5a6c307-8dd6-4dc7-a77e-7cfa1d849a94"
      unitRef="Unit1">453199</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-f909709c-4bc2-4cb0-9fac-461ee5583c88"
      unitRef="Unit14">7.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-587b0228-fd62-4f93-9d46-4dcbc6134c30"
      unitRef="Unit1">74897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-db6ad32e-f4eb-4ca4-8a0b-f50924f006fa"
      unitRef="Unit14">41.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-863c3f44-74e0-46fe-aceb-420533ca550d"
      unitRef="Unit1">3839858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022"
      decimals="2"
      id="ct-nonFraction-f0b18789-604d-4a0c-ba69-7ae3493e8527"
      unitRef="Unit14">24.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-8af71e66-79f4-4b62-b8e7-f473abfec244">P6Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-78714ea3-947c-4f1d-b096-84baf2c90f95"
      unitRef="Unit12">112755000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-85466df8-b54c-4248-a574-be4030ba9f81"
      unitRef="Unit1">19898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-cdd32176-c566-43d1-b55f-1ba779671810"
      unitRef="Unit14">33.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-331e38f3-fc12-45e9-a2f9-8a84791aed67"
      unitRef="Unit1">199642</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-a6f452a9-ee09-4977-9615-9ac4f32a3292"
      unitRef="Unit14">7.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-271be3b6-7418-467f-a0e7-5a395aed7ffd"
      unitRef="Unit1">27430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-d2df73d1-9c83-4194-800e-960c03a57c85"
      unitRef="Unit14">47.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-a4d152f6-6b50-4bf3-8b74-1a16ce4b0c72"
      unitRef="Unit1">3632684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023"
      decimals="2"
      id="ct-nonFraction-96555e25-a8fa-45d8-a40f-3693ca941d7f"
      unitRef="Unit14">25.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-5970578e-afe2-446a-98ed-e7b88c5089b4">P5Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-3e683539-a093-4aa9-9352-435099f6d493"
      unitRef="Unit12">7942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-7b0747fc-6363-4149-a685-db64b31baac5"
      unitRef="Unit1">3184646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023"
      decimals="2"
      id="ct-nonFraction-0b43d449-5f40-48b8-800f-bf2b00fe77da"
      unitRef="Unit14">22.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-024d2e46-0703-4b1c-9feb-7cc310cc1c3e">P5Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-f3249287-deb2-4815-9d47-4182bc63f606"
      unitRef="Unit12">7942000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-aed99fd3-4167-4cc5-84c6-c4127266ab39"
      unitRef="Unit1">3632684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023"
      decimals="2"
      id="ct-nonFraction-66393283-ee46-4483-ab40-414200f47457"
      unitRef="Unit14">25.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-8f56a5db-4b2d-40cc-ae08-c67176926e29">P5Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-dcabfb7b-58f9-4144-880f-1ff1a13d2009"
      unitRef="Unit12">7942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-cea4620f-ca7a-4417-b7c0-902ea3d5dc74"
      unitRef="Unit12">7857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-47da6877-76e6-4f10-a481-8c4776959be6"
      unitRef="Unit12">17575000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7966cf5a-0b85-490e-9bfc-171d8b1ae6a7"
      unitRef="Unit12">29355000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-a206334e-5f08-40ca-a828-63a6734ffaa3"
      unitRef="Unit14">17.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-ba093325-2810-413a-82b9-ab9a97b7e8bc"
      unitRef="Unit14">37.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-a0ea55dd-e21c-423d-8936-7019bd1da72c"
      unitRef="Unit14">23.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-72057ab2-c225-47c4-bb27-d18c9c1aae8b"
      unitRef="Unit12">9207000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d8f1dcf6-b9ec-4830-ad88-681c4e4b7ed5"
      unitRef="Unit12">9816000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-11579048-17bf-4b1e-adf9-48d1dc63cdaf"
      unitRef="Unit12">9076000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      id="ct-nonNumeric-ceaa849e-73d4-4b73-a227-92b2c6803f5e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-1afdac3d-5e3d-4e6d-af44-7d59413ae86b"
      unitRef="Unit12">46939000</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-74588f7c-a7f1-4796-84f6-e279a615c55d"
      unitRef="Unit12">30486000</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-f7257802-e534-4abe-b23d-bd2d59f83040"
      unitRef="Unit12">28110000</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-d9633f05-4bcb-4399-a2ba-28d20ea58a1a"
      unitRef="Unit12">13203000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-52f85901-3056-46a1-81c0-6dd5644fb90c"
      unitRef="Unit12">6135000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-7b8fc1bc-ae88-4ae1-9823-d08f09e235e0"
      unitRef="Unit12">1893000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="ct-nonNumeric-0e3feb2d-fc1a-444c-bac6-61e440a7e38d">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2020 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;68,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;46.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;524,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,964&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27,181&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;530,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;806,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;37.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;148,239&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;52.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;66,192&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;44.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,122,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;42.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,162,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;410,085&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;147,764&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,726,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,726,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-f529edd7-e8bd-4e29-8ade-91291ca7d93c"
      unitRef="Unit1">68396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-6075c6b9-e322-476e-bb74-9a8b40671efc"
      unitRef="Unit14">46.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-f357db83-e401-489b-a9ac-85dc798129ac"
      unitRef="Unit1">524023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-40dd7232-eea0-4685-b6e9-3d84bbda14a6"
      unitRef="Unit14">53.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-46d3de3a-e16a-4210-9494-73fee0dab375"
      unitRef="Unit1">34964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-6de458c3-d6e9-43cf-a477-f351bfa387e5"
      unitRef="Unit14">49.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-8d345e0e-637c-42f7-a0e2-c78dbb2c3a9f"
      unitRef="Unit1">27181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-e754da56-8a74-45b1-8c64-5ea87c6eef08"
      unitRef="Unit14">51.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-30b44e1d-cb2c-490d-89ad-74d75f04ba15"
      unitRef="Unit1">530274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-9333afda-ca22-41c8-bf30-cbd333ab6385"
      unitRef="Unit14">53.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-e063815c-4908-4066-abe8-32b748ac7ab9"
      unitRef="Unit1">806513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-62f87d1c-a7ef-4bdb-84d9-38699a8cc4ce"
      unitRef="Unit14">37.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-5dc56968-3885-443d-9ba3-01d60cd0500e"
      unitRef="Unit1">148239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-797c2a76-4de8-4402-b6c0-a501b15b3206"
      unitRef="Unit14">52.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-7035400c-823f-4cad-9858-a62c93333596"
      unitRef="Unit1">66192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-aa199148-9882-48da-99ff-135058834258"
      unitRef="Unit14">44.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-09213bf1-7258-44ae-8660-7c1ea015fdd4"
      unitRef="Unit1">1122356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-f4c49aac-715f-42d1-a144-4f55429fdadf"
      unitRef="Unit14">42.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-66c94a42-c03d-47b7-85ca-5ceae9294cc4"
      unitRef="Unit1">2162465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-d7ed368c-126c-4365-b08f-0e10bc89586b"
      unitRef="Unit14">21.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-5ddf7ad7-1b8a-4c85-922e-d42a3bcf8021"
      unitRef="Unit1">410085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-fbc4f8b1-3779-4bbc-8d3e-ec52bc8d745a"
      unitRef="Unit14">43.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-260c3a0f-bc5e-4459-916e-a387825f6c8e"
      unitRef="Unit1">147764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-4f2eddda-d97d-40e7-9b07-18736bee7585"
      unitRef="Unit14">41.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-f389f577-dc2e-4fbb-bb50-98f2d0882e6e"
      unitRef="Unit1">2726972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-aa097e09-f0b3-488a-ad7e-a15e1c48874e"
      unitRef="Unit14">26.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="ct-nonFraction-66c64840-4b42-4eca-aea4-74ff00f856b4"
      unitRef="Unit1">2726972</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="ct-nonFraction-f6202a64-ff7d-4e59-af80-004dca91da62"
      unitRef="Unit14">26.02</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      id="ct-nonNumeric-06125f65-d4d4-49cb-b0ae-51630f893f6b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      id="ct-nonNumeric-79702ec9-7a3d-4387-bf66-7e761223609a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="4"
      id="ct-nonFraction-13cb3f03-f3be-4aa7-a519-36105c465409"
      unitRef="Unit13">0</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="4"
      id="ct-nonFraction-ed677fdf-d4f8-462e-b47b-4f7b0627a502"
      unitRef="Unit13">2</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-7494d7a9-f234-4142-8960-35136515b87c"
      unitRef="Unit12">14950000</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="-3"
      id="ct-nonFraction-1bd591c2-a8af-460d-8160-16abdbe6100a"
      unitRef="Unit12">16000000</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonNumeric-7237b2fb-8ae6-4eaf-a2cc-d0eba03c40d6">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 18.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;77.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;207,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;77.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards granted &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;711,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards vested &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Awards cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;109,676&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;76.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balances, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;809,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 60.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;809,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;27.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-cb22cb2b-8ce3-4cbd-a6a5-9e0b486b73cf"
      unitRef="Unit1">207468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-9d978959-968a-4aa6-b7bb-35d6d599621a"
      unitRef="Unit14">77.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-2c185cd5-d4f0-46dc-b9d3-43def4fd0af2"
      unitRef="Unit1">207468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-cd3d715f-0540-40ed-992d-5eb5e7c518e5"
      unitRef="Unit14">77.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-622f4601-6690-4ce7-b55e-7221719076ba"
      unitRef="Unit1">711433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-a6a5e6ab-8b57-4f83-a687-c2b00c03cc7b"
      unitRef="Unit14">21.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-61ac2678-2fa3-4981-a520-f6025a10a790"
      unitRef="Unit1">109676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-b6c1b0b2-c669-4924-a44c-d32cddc35cb0"
      unitRef="Unit14">76.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-9f62018d-e13d-4433-b571-a35e194e7f68"
      unitRef="Unit1">809225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-7c9c789d-e473-4201-a3d7-7d7549cbad9a"
      unitRef="Unit14">27.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-c68bc8bf-9663-481d-bc7b-c4a367c59c1c"
      unitRef="Unit1">809225</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-81a8b1e1-aea8-4dfc-bf56-a0b71271687d"
      unitRef="Unit14">27.86</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="4"
      id="ct-nonFraction-5f3227d4-1855-453a-842a-8a51d5fcefc6"
      unitRef="Unit13">1</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-3e2afcd0-a054-4c09-b22d-b40a118c7063"
      unitRef="Unit1">434000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <silk:AdditionalCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-1de23a67-f113-450a-bf5c-2b5a5ad8ae2d"
      unitRef="Unit1">1200000</silk:AdditionalCommonStockCapitalSharesReservedForFutureIssuance>
    <silk:PercentOfOutstandingShares
      contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="INF"
      id="ct-nonFraction-a18a3fe8-de69-4c82-a16a-3a756d2b3682"
      unitRef="Unit13">0.010</silk:PercentOfOutstandingShares>
    <silk:FairMarketValueOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member"
      decimals="INF"
      id="ct-nonFraction-b9afd7ed-5924-49c7-abc8-cbfb12f61d51"
      unitRef="Unit13">0.85</silk:FairMarketValueOfCommonStock>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member"
      decimals="INF"
      id="ct-nonFraction-a63717dc-4521-4bfc-af58-bf39337f3af4"
      unitRef="Unit1">465952</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssued>
    <silk:CommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_silk_Espp2019Member"
      decimals="INF"
      id="ct-nonFraction-0d41904a-40d2-4908-b24e-b69dc3671292"
      unitRef="Unit1">1356463</silk:CommonStockCapitalSharesAvailableForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonNumeric-e958400c-9962-4181-aad6-78ec626e78ed">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 39.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.25&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.25&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;45.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.94&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.60&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.84&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.41&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.08&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonNumeric-ae2835f6-96b7-422c-a55e-25437198e76b">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonNumeric-68a1bfbb-9384-4cef-8a7f-f7bb689c0ee5">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonNumeric-fecae585-67c7-45a9-84a9-dccdd280bfc1">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonNumeric-98a52ed4-b79a-4c5a-ae36-a10831e3d747">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonNumeric-03fb3fde-8e8d-4808-9ae1-2a6afe03dcf3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="ct-nonFraction-5da287dd-3ddd-4fc3-89b1-c78196d564b0"
      unitRef="Unit13">0.551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="ct-nonFraction-bf533f60-0cfd-4faa-97a0-77d7f3ec98e9"
      unitRef="Unit13">0.482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="ct-nonFraction-8cc45432-9971-4b82-bff9-136d0f41e51e"
      unitRef="Unit13">0.514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="ct-nonFraction-da15d3a2-af60-4df2-b0df-8b816de55f70"
      unitRef="Unit13">0.450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="ct-nonFraction-eefb147e-8d57-4ea0-93d5-a9f0d0f2c454"
      unitRef="Unit13">0.504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="ct-nonFraction-85cfebad-fcdd-476b-9921-fa71b6883ae0"
      unitRef="Unit13">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="ct-nonFraction-9a2f176e-5d22-4291-8a79-e95289c8ba77"
      unitRef="Unit13">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="ct-nonFraction-e5a900b4-0aaa-4842-a8c7-c7d70f9b6ae6"
      unitRef="Unit13">0.0384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="ct-nonFraction-bf4f7585-01c9-45bb-935c-4a0a88821633"
      unitRef="Unit13">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="ct-nonFraction-baab46b0-7c80-4b08-93e9-83b3ecaca0eb"
      unitRef="Unit13">0.0108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-56c3b2be-c5c9-4e81-a8ec-41fb9bff7930"
      unitRef="Unit1">207468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      id="ct-nonNumeric-552e4818-2ff0-4241-a26b-651184e38dca">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="3"
      id="ct-nonFraction-5e653dab-80f3-4359-92a5-d15c132cafc2"
      unitRef="Unit13">0.594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="3"
      id="ct-nonFraction-a0f96b74-2ef0-4f7f-8c7b-a4f01a4623d8"
      unitRef="Unit13">0.606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="4"
      id="ct-nonFraction-06a271ed-3bdf-4fd1-bebf-41d1c98e285d"
      unitRef="Unit13">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="4"
      id="ct-nonFraction-e8da16ab-202f-4548-b1a4-5d9a2ba257fd"
      unitRef="Unit13">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="4"
      id="ct-nonFraction-168645dd-46e6-4039-82eb-66717bcba427"
      unitRef="Unit13">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-52f10938-c687-437a-9ba2-78bad6547f1c"
      unitRef="Unit13">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-8329c4d6-04c4-467a-a5cb-8862559c4b2d"
      unitRef="Unit1">99350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance
      contextRef="Duration_3_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="2"
      id="ct-nonFraction-4267dae5-3bd2-42ae-b316-8a9b24c1846d"
      unitRef="Unit13">2</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      id="ct-nonNumeric-912ca1ee-b3b4-42e4-9578-f52ea1746562">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="3"
      id="ct-nonFraction-bca93028-2549-46c3-840f-f4c4374af8cb"
      unitRef="Unit13">0.623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="3"
      id="ct-nonFraction-65e24219-2fdd-44a3-81ba-9e8f277324fb"
      unitRef="Unit13">0.612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="4"
      id="ct-nonFraction-4be54b55-b2a3-44f6-86a0-4246dbe1c4e8"
      unitRef="Unit13">0.0458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="4"
      id="ct-nonFraction-13aefb6c-4163-4526-8d4a-37baa3caaeb4"
      unitRef="Unit13">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateOneMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-54691960-7ccf-454b-bb0a-12a1c9bf4afd"
      unitRef="Unit13">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-2c4d83dd-7397-41cf-8f73-b1974d394f0f"
      unitRef="Unit1">612083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance
      contextRef="Duration_11_1_2023_To_11_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      decimals="2"
      id="ct-nonFraction-e4fa9f55-d040-42a5-9ab6-7ebda7a30dfe"
      unitRef="Unit13">2</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_silk_TwoThousandNineteenStockOptionPlanMember"
      id="ct-nonNumeric-d5a3b8b5-f486-49f5-95a6-4c8753454a2c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="3"
      id="ct-nonFraction-8754e4a2-81d1-4983-bbba-04d5f624055f"
      unitRef="Unit13">0.569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="3"
      id="ct-nonFraction-2f26a118-ec50-4251-9cee-142c15f1f7f3"
      unitRef="Unit13">0.711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_silk_BenchmarkMember_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="4"
      id="ct-nonFraction-3f2a913a-fada-4ac7-b2e1-36dd8df3be75"
      unitRef="Unit13">0.0472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="4"
      id="ct-nonFraction-e58b9383-b652-4d6a-92d4-1865634e44dc"
      unitRef="Unit13">0.0035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardDateAxis_silk_AwardDateTwoMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="ct-nonFraction-bdaa3806-d270-4b4a-bc5c-844130d5fecc"
      unitRef="Unit13">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-6b763ced-cfc2-4209-8361-1ed429299f76">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;47.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;119.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.6&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;46.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;51.6&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.64&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.43&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.07&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.64&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.03&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% - &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.10&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 55.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-9b4e6280-1402-4995-b527-ad690cbb67c8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-4f0c321f-8b8f-45a0-abb9-51681150ec60">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      id="ct-nonNumeric-cf845e55-51c0-4a6f-bd36-ec5471937e1e">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="3"
      id="ct-nonFraction-85ad4f56-4ba6-424f-a215-354ea95eb701"
      unitRef="Unit13">0.474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="3"
      id="ct-nonFraction-d1aead01-ce3f-431b-a483-8b02b41eab7c"
      unitRef="Unit13">1.195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="3"
      id="ct-nonFraction-ca1d35a4-2644-43cb-9c52-9a08b5bc2455"
      unitRef="Unit13">0.516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="3"
      id="ct-nonFraction-a79bd967-ce28-468e-8715-2bfb8aa15525"
      unitRef="Unit13">0.745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="3"
      id="ct-nonFraction-12896de1-0888-448a-b608-a3c549b2162c"
      unitRef="Unit13">0.469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="3"
      id="ct-nonFraction-f2a2ee58-06ee-4c57-a79d-fbe935a843ff"
      unitRef="Unit13">0.516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="4"
      id="ct-nonFraction-40336891-aab4-4c52-aad6-a4f218ba4b4e"
      unitRef="Unit13">0.0464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="4"
      id="ct-nonFraction-162c2fcf-4c71-4dc6-b7db-0a4b83acb59b"
      unitRef="Unit13">0.0543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="4"
      id="ct-nonFraction-3ac1227d-83f2-4eef-b632-f89a6e0b5fad"
      unitRef="Unit13">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="4"
      id="ct-nonFraction-66e5167f-6c80-4a7a-909b-b6017beb2ca7"
      unitRef="Unit13">0.0464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="4"
      id="ct-nonFraction-05ffc660-ed02-479d-b6f8-e56353b05c23"
      unitRef="Unit13">0.0003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_silk_EmployeeStockPurchasePlanMember"
      decimals="4"
      id="ct-nonFraction-8f4886a6-45f1-4402-bd57-6b5fd319b283"
      unitRef="Unit13">0.0010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-873d581e-e0f0-43b4-8fb8-221e9b3c8e09">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cost of goods sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;38,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="ct-nonFraction-f68f586d-e6c3-4f5f-bcb6-e33135f71c5c"
      unitRef="Unit12">1671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="ct-nonFraction-bbd0db54-538a-4898-8d04-32ef04d03c9c"
      unitRef="Unit12">1138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="ct-nonFraction-666d25b0-7a91-4e1e-b424-ac42e2f525e7"
      unitRef="Unit12">635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-374a86b9-0b1e-4ccf-bf2c-5e61114eabbf"
      unitRef="Unit12">7589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-8c8928dc-9b84-4078-baa5-10505b986a33"
      unitRef="Unit12">5240000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-f943a6c4-be4e-4088-8b42-f17ba1f11370"
      unitRef="Unit12">2909000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="ct-nonFraction-70ad5bef-cac8-4d96-841d-fe26cd6acf4d"
      unitRef="Unit12">29633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="ct-nonFraction-cdfba206-9108-4cbf-8de9-c77ddebdffc5"
      unitRef="Unit12">18645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="ct-nonFraction-6843e5d6-1b00-4a45-bdd0-e6d35d7d2bf5"
      unitRef="Unit12">11068000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-61630d9b-0b76-4546-9a72-921e00ac1d1f"
      unitRef="Unit12">38893000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4812b2a6-60f7-4c50-bfd6-90ff8b187fdc"
      unitRef="Unit12">25023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4292f2b0-9a38-4413-84dc-28d6732cff63"
      unitRef="Unit12">14612000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="ct-nonFraction-84358a81-5d36-43fe-aa09-8367e6a561b5"
      unitRef="Unit12">5645000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonNumeric-f479b8ef-5f59-48e6-b78c-f06afa38051e">P1Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="ct-nonFraction-851c3023-dd7b-412f-be8b-38fd12c274ee"
      unitRef="Unit12">73195000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="ct-nonNumeric-61173ca4-e355-47fd-9ba0-ce1ea0a01b99">P2Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-3"
      id="ct-nonFraction-81fbc471-a556-4543-a013-bbe4a70d3023"
      unitRef="Unit12">679000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="ct-nonNumeric-3f9fe6e3-6f4b-4732-91a2-df69a813b94d">P0Y4M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-fcb50848-08c1-4a62-87f2-7f7b0764ef59">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;10.&#160;&#160;&#160;&#160;Income Taxes&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The components of income before taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;United States &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,743&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,010&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,811&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;International &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,743&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,010&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,811&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;A reconciliation of the statutory U.S. federal rate to the Company&#x2019;s effective tax rate is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tax at federal statutory rate &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,706&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,552&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,460&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;State taxes, net of federal benefit &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,311&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,206&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,852&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Permanent differences &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;392&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,893&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,224&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Change in valuation allowance &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;18,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Limitation of compensation deduction under IRS Sec.162(m)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;General business credits &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,536&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,166&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;852&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;401&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Provision for income taxes &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company's provision for income taxes amounts are not significant and are included within other income (expense) on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Significant components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2023 and 2022 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Net operating loss carryforwards &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;85,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;82,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Research and development credits &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Capitalized start-up costs/Intangibles &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Accruals and reserves &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Stock-based compensation &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Operating lease liability &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Interest limitation &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax assets &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;126,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;114,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Valuation allowance &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;122,993&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;111,444&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax liabilities: &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Operating lease asset &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,636&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,278&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Property and equipment &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,475&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,776&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax liabilities &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,111&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,054&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net deferred tax assets &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-75d41ec1-bd07-4439-8d82-3e992d798b22;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-3bf04cf1-1a9a-405d-aa3f-bedeb093e2ab;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management believes it is more likely than not that the deferred tax assets will not be realized; accordingly, a valuation allowance has been established on U.S. net deferred tax assets. The valuation allowance increased $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,549,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;18,237,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,918,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2023, the Company had net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;331,957,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;288,608,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards begin to expire in 2027 and 2024, respectively. Federal NOL carryforwards generated in tax years beginning in 2018 are not subject to expiration. Federal NOLs that arose on or after January 1, 2018 can be carried forward indefinitely against future income, but can only be used to offset a maximum of 80% of the Company's federal taxable income in any year.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law. Federal tax legislation enacted in December 2017, commonly known as the Tax Cuts and Jobs Act, contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. A Section 382 &#x201c;ownership change&#x201d; generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company&#x2019;s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The Company may have previously experienced, and may in the future experience, one or more Section 382 &#x201c;ownership changes,&#x201d; including in connection with the Company&#x2019;s initial public offering. If so, the Company may lose some or all of the tax benefits of its NOLs and tax credits. The extent of such limitations for prior years, if any, has not yet been formally determined.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Under the Tax Cuts and Jobs Act, research and development expenditures are no longer fully deductible and are required to be capitalized and amortized under Section 174 of the Internal Revenue Code in tax years beginning on or after January 1, 2022. The capitalized research expenses must be amortized over five years for research performed in the U.S. and 15 years for research performed outside the U.S. The mandatory capitalization requirement increased the Company&#x2019;s deferred tax assets, which were fully offset by a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;At December&#160;31, 2023, the Company had $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,122,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,869,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; of federal and state research and development credit carryforwards, respectively, on a tax return basis. If not utilized, the federal credits will expire beginning in 2027. The California research and development credits can be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2023, the Company had $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,364,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; of unrecognized tax benefits. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits would increase or decrease within twelve months of the year ended December&#160;31, 2023. If recognized, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; would affect the effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. There was &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; such expense recorded during the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;A reconciliation of the unrecognized tax benefits from January 1, 2021 to December&#160;31, 2023 is as follows (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Balance at the beginning of year &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Increases related to current years&#x2019; tax positions &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Increases related to prior years&#x2019; tax positions &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Balance at end of year &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception. As a result of the Company&#x2019;s net operating loss carryforwards, all of its tax years are subject to federal and state tax examination.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-66e5eabf-e185-4576-9d59-a894c7328464">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;United States &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,743&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,010&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,811&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;International &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,743&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;55,010&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49,811&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-01e16cad-8b1f-4417-8cdc-c6b259a66f87"
      unitRef="Unit12">-55743000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c5e68650-31ba-4ad4-9992-cb3d16494be3"
      unitRef="Unit12">-55010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-8f021c01-0d30-4309-b0ca-0ada393502fb"
      unitRef="Unit12">-49811000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-231cf901-c33b-4996-ba57-676a18bba2cd"
      unitRef="Unit12">-55743000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-997a0b23-cd56-4217-bd7a-60253593e89a"
      unitRef="Unit12">-55010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-81c28fbd-5888-4410-b33b-c8c3825c908c"
      unitRef="Unit12">-49811000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-e5ae3f1a-f9be-40af-bee9-d7360ab0e9da">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tax at federal statutory rate &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,706&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,552&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,460&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;State taxes, net of federal benefit &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,311&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,206&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,852&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Permanent differences &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;392&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,893&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,224&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Change in valuation allowance &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;18,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Limitation of compensation deduction under IRS Sec.162(m)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;General business credits &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,536&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,166&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;852&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;401&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 53.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Provision for income taxes &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d315302f-6884-49a7-af9c-9a4ac136b146"
      unitRef="Unit12">-11706000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-db83de5e-d35f-40fc-bac7-989fba463d67"
      unitRef="Unit12">-11552000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f545a44a-bf37-4be4-a7a6-1fce956e1e1b"
      unitRef="Unit12">-10460000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-893d4447-74c0-4d8e-ac9c-55f9ae93f737"
      unitRef="Unit12">-2311000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-838a73ee-9c09-4563-a5f9-c718b2e444f0"
      unitRef="Unit12">-2206000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6bc3b6e2-c98a-47dd-a37f-381b1b49c3da"
      unitRef="Unit12">-1852000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-03bb1f3e-5baf-4ab0-b823-3e161b036a26"
      unitRef="Unit12">-392000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d78fa115-3132-4f9c-8ba7-733d01df52bd"
      unitRef="Unit12">-2893000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c6b2afbb-071a-4673-968a-5f4bf40fd6a2"
      unitRef="Unit12">-5224000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-c65c2025-d0db-419c-a54d-56693dddcb4a"
      unitRef="Unit12">11549000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-855c6856-bc5b-42b7-ad78-c9ca43c37500"
      unitRef="Unit12">18237000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6c0e3341-c976-4f2a-8074-02fca0a95e22"
      unitRef="Unit12">17918000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <silk:LimitationOfCompensationDeduction
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-fff19dd7-dff4-4404-9604-e48f0381ba35"
      unitRef="Unit12">4320000</silk:LimitationOfCompensationDeduction>
    <silk:LimitationOfCompensationDeduction
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-720c5e15-7646-4b88-83c6-92d5dc4ff445"
      unitRef="Unit12">10000</silk:LimitationOfCompensationDeduction>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-1cd0a5e3-829b-46e9-b4f5-549d1cdb2bf1"
      unitRef="Unit12">1536000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c798ec07-9966-4bb3-9646-fe733bcc6e6e"
      unitRef="Unit12">1166000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c9f0a262-d358-4466-954c-67288a3512e8"
      unitRef="Unit12">852000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-ecb71f8a-5f23-412b-ba5a-e74252543a72"
      unitRef="Unit12">119000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4e02f9f0-32cb-4df8-8354-7452398f71da"
      unitRef="Unit12">-401000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-efd7c533-6a2c-4055-8e27-33e04a019a74"
      unitRef="Unit12">490000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-3279cba1-b010-4140-b485-69389b649730"
      unitRef="Unit12">43000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-51918975-8188-48bd-8c5b-deae49401dc5"
      unitRef="Unit12">29000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1ba9cf39-abb2-459a-817c-36feb1774b9d"
      unitRef="Unit12">20000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-affee236-bb91-4fcc-9314-38de9561f8e8">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Net operating loss carryforwards &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;85,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;82,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Research and development credits &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Capitalized start-up costs/Intangibles &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Accruals and reserves &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Stock-based compensation &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Operating lease liability &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Interest limitation &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax assets &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;126,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;114,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less:  Valuation allowance &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;122,993&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;111,444&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax liabilities: &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Operating lease asset &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,636&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,278&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Property and equipment &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,475&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,776&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax liabilities &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,111&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,054&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net deferred tax assets &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-75d41ec1-bd07-4439-8d82-3e992d798b22;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-3bf04cf1-1a9a-405d-aa3f-bedeb093e2ab;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-8f5167d6-4a71-4809-b329-0cd2c00ebc3c"
      unitRef="Unit12">85945000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8abd7878-7608-4c95-bfa6-382a30ded928"
      unitRef="Unit12">82768000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-85d7ce7d-d441-42e4-bb72-a4399e098879"
      unitRef="Unit12">10753000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-df23db9f-59ef-47ab-9c88-54ae9be0e5e8"
      unitRef="Unit12">8898000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-600631cc-e871-4622-a6b8-9b29019237e5"
      unitRef="Unit12">1000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <silk:DeferredTaxAssetsSection174
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-e479d294-e7b7-44be-bb52-db5745843af2"
      unitRef="Unit12">12892000</silk:DeferredTaxAssetsSection174>
    <silk:DeferredTaxAssetsSection174
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-767377cf-59fa-4435-8203-487e9e5cc5cc"
      unitRef="Unit12">7816000</silk:DeferredTaxAssetsSection174>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-247d489d-68ac-48aa-a5dd-5f8f53e676fe"
      unitRef="Unit12">2775000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-204cfa65-fe88-4196-a488-a3b424cf98c4"
      unitRef="Unit12">2820000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-930aed77-b8b3-42d0-90be-a10c48bc4086"
      unitRef="Unit12">10353000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-1e6ef399-3753-4e51-a20c-c45533350e69"
      unitRef="Unit12">8209000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <silk:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-8ba3bfeb-20e8-4b10-8371-d4d2e4ebd63b"
      unitRef="Unit12">2272000</silk:DeferredTaxAssetsOperatingLeaseLiability>
    <silk:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-08d218a3-1d7e-4eb0-a049-765c02458925"
      unitRef="Unit12">1973000</silk:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-bd394c60-fa2f-489e-91db-8d457479e7a1"
      unitRef="Unit12">1114000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-777b5501-14b7-4cab-bbf8-0b0994faf9bd"
      unitRef="Unit12">2013000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-6879d677-9a17-4a27-8de6-5723b2dc0081"
      unitRef="Unit12">126104000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2105bd1c-9473-4a89-bc4d-835c1ed954c8"
      unitRef="Unit12">114498000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-141deb45-0cee-453c-a430-0e0e34cad4c4"
      unitRef="Unit12">122993000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-fe490476-eb43-4686-a6ac-5e9f5ef3a959"
      unitRef="Unit12">111444000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-d3bc2e6b-e8b3-495b-98ea-e934442df85f"
      unitRef="Unit12">1636000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b787baed-2c54-4eb8-b0af-f861cf884e91"
      unitRef="Unit12">1278000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-22ea8f1d-c9e7-4b40-b32e-85b55b28a915"
      unitRef="Unit12">1475000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c16e98af-d62d-4e2e-a312-6c1b5d260237"
      unitRef="Unit12">1776000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-f149c42a-0be7-44d3-940b-8ff0d418c58f"
      unitRef="Unit12">3111000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-448e3bbf-038c-48ac-9159-8e5c99c90fbf"
      unitRef="Unit12">3054000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-3c8d4005-f525-4901-9abd-4164cf1d6822"
      unitRef="Unit12">11549000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-37cc7d52-b53a-4f37-ad53-dd9b375de808"
      unitRef="Unit12">18237000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3d27c22d-f0cf-4335-8788-883045857a09"
      unitRef="Unit12">17918000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="ct-nonFraction-ce528388-ff49-464d-91d2-aa08e9eca24b"
      unitRef="Unit12">331957000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-3"
      id="ct-nonFraction-12ad4383-8807-4a41-a555-fedf38ac03a9"
      unitRef="Unit12">288608000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      decimals="-3"
      id="ct-nonFraction-6276304f-2300-4535-9ea1-422139ac1039"
      unitRef="Unit12">10122000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      decimals="-3"
      id="ct-nonFraction-750e09da-a75f-4978-86b1-c90a509cdc6e"
      unitRef="Unit12">5869000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-f30c4aef-698d-422a-8c7c-300c676eab4c"
      unitRef="Unit12">4364000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_12_31_2023"
      decimals="INF"
      id="ct-nonFraction-ba9c6171-dc5b-487e-83aa-83ce585ec02e"
      unitRef="Unit12">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1a0c8f96-2f4d-46de-ba37-981f4b35015e"
      unitRef="Unit12">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-bcf21559-cc0b-435c-8787-08e0093da94a"
      unitRef="Unit12">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-0af40b03-7029-432f-ba51-393d27acbee9"
      unitRef="Unit12">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-4acfcaad-cc73-452a-b848-104b40183fd9">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Balance at the beginning of year &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Increases related to current years&#x2019; tax positions &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Increases related to prior years&#x2019; tax positions &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 53.0%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Balance at end of year &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double windowtext 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-3914a14b-42f9-4d0c-b58e-c293302db994"
      unitRef="Unit12">3788000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7a2fbc9f-bbe8-40f3-b4d6-08b074397059"
      unitRef="Unit12">3314000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-1dafb477-1021-4cb7-886f-6ce7ce3cfd6f"
      unitRef="Unit12">2019000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-216c4b0a-d597-47ca-bc12-5b5613bb2042"
      unitRef="Unit12">571000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-424f2b8a-0d20-4344-a247-402914793532"
      unitRef="Unit12">474000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2d7d8ac3-dc37-403b-99d2-c8d8526c5153"
      unitRef="Unit12">704000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-406b53db-5b21-434c-9faa-2ff2cb5d631e"
      unitRef="Unit12">5000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-10e503fa-8d48-4e27-874e-61ff2c5d797a"
      unitRef="Unit12">591000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-4661f511-cab4-4aae-94d9-9fe65b19324e"
      unitRef="Unit12">4364000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d365ebd3-2346-48a3-af5f-57c35b333167"
      unitRef="Unit12">3788000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-bbdb82c8-740a-4f7c-ac30-45553c39d9d6"
      unitRef="Unit12">3314000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-aed51992-1837-4cda-9a1a-bc3f5d7b3fdd">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;11.&#160;&#160;&#160;&#160;401(k) Plan&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code, or the IRC, under which participants may contribute up to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;90&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of their eligible compensation, subject to maximum deferral limits specified by the IRC. The Company may make a discretionary matching contribution to the 401(k)&#160;plan and may make a discretionary employer contribution to each eligible employee each year. Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the first &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of compensation deferred to the 401(k) plan and at 50% of the first 6% of compensation deferred effective January 1, 2022. The Company's matching contributions were $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,256,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,872,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,313,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-56391d84-562a-4dd5-bea9-fa2d4415ff1f"
      unitRef="Unit13">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-e470a5a3-313f-44bb-b642-4d6c7303c79f"
      unitRef="Unit13">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="2"
      id="ct-nonFraction-6ace74cf-0482-4b50-9373-a14fc8e4f807"
      unitRef="Unit13">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023"
      decimals="-3"
      id="ct-nonFraction-26aac1b3-99d5-4d35-90a7-7ae909910eba"
      unitRef="Unit12">2256000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-84b05dad-2e5e-4a51-a291-6e8474e084fb"
      unitRef="Unit12">1872000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-dd7702fb-d3fb-4d94-a235-813465344709"
      unitRef="Unit12">1313000</us-gaap:DefinedContributionPlanCostRecognized>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-301e8bb2-2ac1-4d1f-b2dc-fd54d93e0022">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-57a2aa29-727b-40db-aaa3-8a9cd9730321">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-73972a75-54e2-470f-afff-ba00a20dbe30">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-a318069e-b1ed-4dd5-91ff-72fdd038f6ae">false</ecd:NonRule10b51ArrTrmntdFlag>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023"
      id="ct-nonNumeric-9cdb6fe6-9e2f-4e22-a769-6ab3a2c3d2ab">&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. The table below presents Schedule II, Valuation and Qualifying Accounts, detailing the activity of the allowance for credit losses for the years ended December 31, 2023, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Charged to Expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Write Offs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Balance at &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;End of Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Allowance for credit losses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 31.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-f41c4c8a-9ca5-4197-b5a5-d379dd3eab3c"
      unitRef="Unit12">3000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-5314f935-e015-488e-8a85-03f80a868e12"
      unitRef="Unit12">45000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-2e52c219-5ef5-4c28-b99d-3fa73364dabf"
      unitRef="Unit12">22000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-cb934ea4-9375-4174-94a4-e51d30a06d89"
      unitRef="Unit12">26000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-d0f55797-ac7c-4b74-ba0e-25d556d2d78a"
      unitRef="Unit12">6000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-a108508c-f617-4841-9f9d-7b44f41ce2d1"
      unitRef="Unit12">-3000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-2f8f8578-8a31-48af-9ff1-a00ca69165e3"
      unitRef="Unit12">3000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2020_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-2e224e05-3dbf-42b9-8a47-5717052f59f7"
      unitRef="Unit12">13000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-85395378-d5f2-48d4-b240-bd46af6eb990"
      unitRef="Unit12">6000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-b39fbe87-9505-4e05-8633-5ccf825113a9"
      unitRef="Unit12">13000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember"
      decimals="-3"
      id="ct-nonFraction-8910146a-22d5-473b-bcaa-9a4fb8c01dbf"
      unitRef="Unit12">6000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
